Dezapelisib
     RDKit          2D

 30 34  0  0  0  0  0  0  0  0999 V2000
    6.4901    0.2200    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3958    1.2459    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5826    2.7342    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2249    3.3718    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    3.1989    2.2775    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9226    0.9636    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.1466   -0.3201    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8703   -1.6339    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.6469   -0.2899    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9232    1.0240    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6992    2.3077    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5765    1.0542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3002    2.3681    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3525   -0.2295    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8522   -0.1993    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5759    1.1146    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0755    1.1448    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5103    2.5804    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2792    3.4375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0837    2.5315    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8515   -0.1389    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1278   -1.4528    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6281   -1.4830    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.8709   -1.5735    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6288   -1.5434    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4048   -2.8270    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6811   -4.1409    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8186   -4.1711    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5946   -2.8874    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5423   -5.4850    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  7  9  1  0
  9 10  2  0
 10 11  1  0
 10 12  1  0
 12 13  1  1
 12 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  1  0
 19 20  2  0
 17 21  1  0
 21 22  2  0
 22 23  1  0
  9 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 28 30  1  0
  6  2  1  0
 11  5  2  0
 23 15  2  0
 20 16  1  0
 29 24  1  0
M  END
>  <BrandName>  (1) 


>  <Applicants>  (1) 
Incyte Corporation

>  <CHEMBL_ID>  (1) 
CHEMBL2216863

>  <Canonical_Smiles>  (1) 
Cc1csc2n1c(=O)c(c(n2)[C@H](C)Nc3c4c([nH]cn4)ncn3)c5cccc(c5)F

>  <Chirality>  (1) 
Single Stereoisomer

>  <First_Approval>  (1) 
nan

>  <Phase>  (1) 
0.0

>  <SC_Patent>  (1) 
None

>  <Synonyms>  (1) 
DEZAPELISIB | INCB040093

>  <Withdrawn>  (1) 


>  <Indications>  (1) 
nan

>  <Type>  (1) 
nan

>  <targets_id>  (1) 
nan

>  <inchi>  (1) 
InChI=1S/C20H16FN7OS/c1-10-7-30-20-27-15(11(2)26-18-16-17(23-8-22-16)24-9-25-18)14(19(29)28(10)20)12-4-3-5-13(21)6-12/h3-9,11H,1-2H3,(H2,22,23,24,25,26)/t11-/m0/s1

>  <stdInchikey>  (1) 
RSIWALKZYXPAGW-NSHDSACASA-N

>  <csid>  (1) 
28651137

>  <Links>  (1) 
|http://www.chemspider.com/Chemical-Structure.28651137.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2216863|http://pubchem.ncbi.nlm.nih.gov/compound/58111426|http://www.drugbank.ca/drugs/DB16137|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9728|http://zinc15.docking.org/substances/ZINC000095564453|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=2K59L7G59M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50004547

>  <LinkName>  (1) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (1) 


>  <pdbID>  (1) 


>  <indicationG2P>  (1) 
None

>  <indicationDB>  (1) 


>  <uniprotId>  (1) 


>  <MW>  (1) 
421.1

>  <HBA>  (1) 
8.0

>  <HBD>  (1) 
2.0

>  <NRB>  (1) 
4.0

>  <TPSA>  (1) 
100.9

>  <LogP>  (1) 
3.7

>  <RoF>  (1) 
0.0

>  <Melting point>  (1) 


>  <Targets>  (1) 
nan

>  <Kinase families>  (1) 


>  <FDA_approved>  (1) 


$$$$
Toceranib
     RDKit          2D

 29 32  0  0  0  0  0  0  0  0999 V2000
    0.0418   -2.6982    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0439   -1.1982    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2587   -0.3183    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7972    1.1090    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7028    1.1111    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1684   -0.3148    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5956   -0.7763    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9096   -2.2431    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7089    0.2290    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1361   -0.2325    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2494    0.7728    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6767    0.3113    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.1422   -1.1146    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.6422   -1.1125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.1037    0.3147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.8889    1.1947    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5828    2.3259    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6846   -0.7838    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8008    0.2183    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2675   -0.0957    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0157   -1.3958    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5157   -1.3979    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2675   -0.1000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5194    1.2001    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0194    1.2023    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0173    2.3184    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.6461    1.7103    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3481    2.4621    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.2638   -2.6980    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  7  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
  5 17  1  0
  3 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  1  0
 27 28  2  0
 22 29  1  0
  6  2  1  0
 16 12  1  0
 19 27  1  0
 25 20  1  0
M  END
>  <BrandName>  (2) 


>  <Applicants>  (2) 
Pfizer

>  <CHEMBL_ID>  (2) 
CHEMBL13608

>  <Canonical_Smiles>  (2) 
Cc1c([nH]c(c1C(=O)NCCN2CCCC2)C)/C=C\3/c4cc(ccc4NC3=O)F

>  <Chirality>  (2) 
Achiral Molecule

>  <First_Approval>  (2) 
nan

>  <Phase>  (2) 
0.0

>  <SC_Patent>  (2) 
None

>  <Synonyms>  (2) 
PHA-291639 | TOCERANIB

>  <Withdrawn>  (2) 


>  <Indications>  (2) 
nan

>  <Type>  (2) 
nan

>  <targets_id>  (2) 
O97799

>  <inchi>  (2) 
InChI=1S/C22H25FN4O2/c1-13-19(12-17-16-11-15(23)5-6-18(16)26-21(17)28)25-14(2)20(13)22(29)24-7-10-27-8-3-4-9-27/h5-6,11-12,25H,3-4,7-10H2,1-2H3,(H,24,29)(H,26,28)/b17-12-

>  <stdInchikey>  (2) 
SRSGVKWWVXWSJT-ATVHPVEESA-N

>  <csid>  (2) 
4486268

>  <Links>  (2) 
|http://www.chemspider.com/Chemical-Structure.4486268.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL13608|http://pubchem.ncbi.nlm.nih.gov/compound/5329106| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=BWC|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/BWC|http://zinc15.docking.org/substances/ZINC000003989258|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=59L7Y0530C|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=4818

>  <LinkName>  (2) 
|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (2) 
'BWC'

>  <pdbID>  (2) 
6m13

>  <indicationG2P>  (2) 


>  <indicationDB>  (2) 


>  <uniprotId>  (2) 


>  <MW>  (2) 
396.2

>  <HBA>  (2) 
3.0

>  <HBD>  (2) 
3.0

>  <NRB>  (2) 
5.0

>  <TPSA>  (2) 
77.2

>  <LogP>  (2) 
3.1

>  <RoF>  (2) 
0.0

>  <Melting point>  (2) 


>  <Targets>  (2) 
KIT

>  <Kinase families>  (2) 
KIT

>  <FDA_approved>  (2) 


$$$$
Oclacitinib
     RDKit          2D

 23 25  0  0  0  0  0  0  0  0999 V2000
   -4.1363    2.8709    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0543    1.6845    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4859    0.2964    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8741   -0.2720    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0978    0.8648    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9175   -1.0917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4312   -1.2936    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5132   -0.1073    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0268   -0.3091    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5416   -1.6972    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3764   -2.8835    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8628   -2.6817    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0279   -1.8991    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.9459   -0.7127    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4322   -0.9146    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.3502    0.2717    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7818    1.6599    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.2955    1.8617    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3775    0.6754    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9656    1.1818    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0109    2.6812    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4509    3.1013    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.5963   -3.2872    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  3  5  2  0
  3  6  1  0
  7  6  1  1
  7  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 10 13  1  6
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 13 23  1  0
 12  7  1  0
 19 14  1  0
 22 18  1  0
M  END
>  <BrandName>  (3) 


>  <Applicants>  (3) 
Pfizer

>  <CHEMBL_ID>  (3) 
CHEMBL2103874

>  <Canonical_Smiles>  (3) 
CNS(=O)(=O)C[C@H]1CC[C@@H](CC1)N(c2ncnc3c2cc[nH]3)C

>  <Chirality>  (3) 
Single Stereoisomer

>  <First_Approval>  (3) 
nan

>  <Phase>  (3) 
0.0

>  <SC_Patent>  (3) 
None

>  <Synonyms>  (3) 
JAKI | OCLACITINIB | PF-03394197

>  <Withdrawn>  (3) 


>  <Indications>  (3) 
nan

>  <Type>  (3) 
nan

>  <targets_id>  (3) 
P23458|O60674|P52333

>  <inchi>  (3) 
InChI=1S/C15H23N5O2S/c1-16-23(21,22)9-11-3-5-12(6-4-11)20(2)15-13-7-8-17-14(13)18-10-19-15/h7-8,10-12,16H,3-6,9H2,1-2H3,(H,17,18,19)/t11-,12-

>  <stdInchikey>  (3) 
HJWLJNBZVZDLAQ-HAQNSBGRSA-N

>  <csid>  (3) 
28528036

>  <Links>  (3) 
|http://www.chemspider.com/Chemical-Structure.28528036.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103874|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9696|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=99GS5XTB51|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=185700

>  <LinkName>  (3) 
|ChemSpider|ChEMBL|Guide to Pharmacology|FDA SRS|BindingDB

>  <lig_pdbID>  (3) 


>  <pdbID>  (3) 


>  <indicationG2P>  (3) 
None

>  <indicationDB>  (3) 


>  <uniprotId>  (3) 


>  <MW>  (3) 
337.2

>  <HBA>  (3) 
5.0

>  <HBD>  (3) 
2.0

>  <NRB>  (3) 
5.0

>  <TPSA>  (3) 
91.0

>  <LogP>  (3) 
1.5

>  <RoF>  (3) 
0.0

>  <Melting point>  (3) 


>  <Targets>  (3) 
JAK1; JAK2; JAK3

>  <Kinase families>  (3) 
Tyr

>  <FDA_approved>  (3) 


$$$$
Tafetinib
     RDKit          2D

 31 34  0  0  0  0  0  0  0  0999 V2000
  -10.4357    0.6696    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.0343    1.2044    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.8704    0.2582    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.1079   -1.2229    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.5093   -1.7577    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4690    0.7931    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3051   -0.1531    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9037    0.3817    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7398   -0.5645    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9773   -2.0456    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3384   -0.0296    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9474    1.4185    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5507    1.4942    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0855    0.0928    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0820   -0.8490    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1498   -2.3310    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5492   -2.8712    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7167   -1.9295    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4849   -0.4475    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6524    0.4943    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1006    0.1032    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7790   -1.2346    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2768   -1.3160    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0961   -0.0595    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4177    1.2783    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9199    1.3597    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9782    2.5272    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.5768    1.9923    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3203    2.8117    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.9552   -2.6538    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8892    2.5861    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  3  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
  9 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  1  0
 28 29  2  0
 23 30  1  0
 12 31  1  0
 15 11  1  0
 14 19  1  0
 20 28  1  0
 26 21  1  0
M  END
>  <BrandName>  (4) 


>  <Applicants>  (4) 
Nanjing Yoko Biomedical

>  <CHEMBL_ID>  (4) 
CHEMBL2180602

>  <Canonical_Smiles>  (4) 
CCN(CC)CCNC(=O)c1c([nH]c\2c1CCC/C2=C/3\c4cc(ccc4NC3=O)F)C

>  <Chirality>  (4) 
Achiral Molecule

>  <First_Approval>  (4) 
nan

>  <Phase>  (4) 
1.0

>  <SC_Patent>  (4) 
None

>  <Synonyms>  (4) 
SIM 010603 | SIM-010603 | TAFETINIB

>  <Withdrawn>  (4) 


>  <Indications>  (4) 
nan

>  <Type>  (4) 
nan

>  <targets_id>  (4) 
P35968|P35916|P17948

>  <inchi>  (4) 
InChI=1S/C24H29FN4O2/c1-4-29(5-2)12-11-26-23(30)20-14(3)27-22-16(20)7-6-8-17(22)21-18-13-15(25)9-10-19(18)28-24(21)31/h9-10,13,27H,4-8,11-12H2,1-3H3,(H,26,30)(H,28,31)/b21-17-

>  <stdInchikey>  (4) 
KGSRYTUWXUESJK-FXBPSFAMSA-N

>  <csid>  (4) 
28664989

>  <Links>  (4) 
|http://www.chemspider.com/Chemical-Structure.28664989.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2180602|http://pubchem.ncbi.nlm.nih.gov/compound/56935577|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9921|http://zinc15.docking.org/substances/ZINC000095575309|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=H4X2M2NN5N|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50399535

>  <LinkName>  (4) 
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (4) 


>  <pdbID>  (4) 


>  <indicationG2P>  (4) 
None

>  <indicationDB>  (4) 


>  <uniprotId>  (4) 


>  <MW>  (4) 
424.2

>  <HBA>  (4) 
3.0

>  <HBD>  (4) 
3.0

>  <NRB>  (4) 
6.0

>  <TPSA>  (4) 
77.2

>  <LogP>  (4) 
3.7

>  <RoF>  (4) 
0.0

>  <Melting point>  (4) 


>  <Targets>  (4) 
KDR; FLT4; FLT1

>  <Kinase families>  (4) 
Tyr

>  <FDA_approved>  (4) 


$$$$
Repotrectinib
     RDKit          2D

 26 29  0  0  0  0  0  0  0  0999 V2000
    1.5498   -4.5860    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9084   -3.2301    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5616   -3.5282    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0019   -3.1091    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0824   -2.0686    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3512   -2.8687    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5556   -0.6452    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9083    0.7079    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4695    1.1323    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1177    2.5904    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2046    3.6242    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6433    3.1998    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9951    1.7417    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3142    1.0274    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0425   -0.4478    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4442    2.6121    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.7423    1.8605    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5424    0.5917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6612   -0.9036    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0715   -2.2829    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.0156   -1.5484    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2512   -0.6978    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1323    0.7974    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7780    1.4422    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3679    1.6480    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    2.7828    2.9409    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  2  0
  5  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  1  0
 14 15  2  0
 10 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 19 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 23 25  1  0
 17 26  1  0
 20  2  1  0
 15  7  1  0
 13  8  1  0
 24 18  1  0
M  END
>  <BrandName>  (5) 


>  <Applicants>  (5) 
TP Therapeutics

>  <CHEMBL_ID>  (5) 
CHEMBL4298138

>  <Canonical_Smiles>  (5) 
CC1CNC(=O)C2=C3N=C(C=CN3N=C2)NC(C4=C(O1)C=CC(=C4)F)C

>  <Chirality>  (5) 
Single Stereoisomer

>  <First_Approval>  (5) 
nan

>  <Phase>  (5) 
1.0

>  <SC_Patent>  (5) 
None

>  <Synonyms>  (5) 
REPOTRECTINIB | TPX-0005 | TRX-0005

>  <Withdrawn>  (5) 


>  <Indications>  (5) 
nan

>  <Type>  (5) 
nan

>  <targets_id>  (5) 
nan

>  <inchi>  (5) 
InChI=1S/C18H18FN5O2/c1-10-8-20-18(25)14-9-21-24-6-5-16(23-17(14)24)22-11(2)13-7-12(19)3-4-15(13)26-10/h3-7,9-11,21H,8H2,1-2H3,(H,20,25)/b22-16-

>  <stdInchikey>  (5) 
FIKPXCOQUIZNHB-WDEREUQCSA-N

>  <csid>  (5) 
71084199

>  <Links>  (5) 
|http://www.chemspider.com/Chemical-Structure.71084199.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4298138|http://pubchem.ncbi.nlm.nih.gov/compound/135565923|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10316|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=08O3FQ4UNP

>  <LinkName>  (5) 
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|FDA SRS

>  <lig_pdbID>  (5) 


>  <pdbID>  (5) 


>  <indicationG2P>  (5) 
None

>  <indicationDB>  (5) 


>  <uniprotId>  (5) 


>  <MW>  (5) 
355.1

>  <HBA>  (5) 
6.0

>  <HBD>  (5) 
2.0

>  <NRB>  (5) 
0.0

>  <TPSA>  (5) 
80.6

>  <LogP>  (5) 
2.6

>  <RoF>  (5) 
0.0

>  <Melting point>  (5) 


>  <Targets>  (5) 
nan

>  <Kinase families>  (5) 


>  <FDA_approved>  (5) 


$$$$
Vecabrutinib
     RDKit          2D

 36 39  0  0  0  0  0  0  0  0999 V2000
   -4.4899    0.3104    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9844    0.4378    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6214    1.7959    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7637    3.0265    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2691    2.8991    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6322    1.5410    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1376    1.4136    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5007    0.0555    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3584   -1.1751    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7214   -2.5332    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2268   -2.6606    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6308   -1.4300    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0061   -0.0719    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8515    1.1587    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.1254   -1.5574    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9830   -0.3268    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4776   -0.4542    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.1145   -1.8123    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2569   -3.0429    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7623   -2.9155    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9047   -4.1461    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4101   -4.0186    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.5416   -5.5041    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.3352    0.7764    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6983    2.1345    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5560    3.3651    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0505    3.2377    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.6875    1.8796    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8298    0.6490    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.9190    4.7232    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.2037    2.2619    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4007    4.3846    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -6.8421   -0.7928    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6997   -2.0234    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -8.0727    0.0648    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6115   -1.6505    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  8  7  1  1
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  2  0
 15 12  1  1
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  1  6
 21 22  2  0
 21 23  1  0
 17 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 26 30  1  0
 25 31  1  0
  4 32  1  0
  2 33  1  0
 33 34  1  0
 33 35  1  0
 33 36  1  0
  6  1  1  0
 13  8  1  0
 20 15  1  0
 29 24  1  0
M  END
>  <BrandName>  (6) 


>  <Applicants>  (6) 
Sunesis Pharmaceuticals

>  <CHEMBL_ID>  (6) 
CHEMBL4297640

>  <Canonical_Smiles>  (6) 
c1c(cc(cc1N[C@@H]2CCCN(C2=O)[C@H]3CN(CC[C@@H]3C(=O)N)c4c(c(ncn4)N)F)Cl)C(F)(F)F

>  <Chirality>  (6) 
Single Stereoisomer

>  <First_Approval>  (6) 
nan

>  <Phase>  (6) 
1.0

>  <SC_Patent>  (6) 
None

>  <Synonyms>  (6) 
BIIB-062 | BSK-4841 | FP-0182 | FP0182 | SNS-062 | VECABRUTINIB

>  <Withdrawn>  (6) 


>  <Indications>  (6) 
nan

>  <Type>  (6) 
nan

>  <targets_id>  (6) 
nan

>  <inchi>  (6) 
InChI=1S/C22H24ClF4N7O2/c23-12-6-11(22(25,26)27)7-13(8-12)32-15-2-1-4-34(21(15)36)16-9-33(5-3-14(16)19(29)35)20-17(24)18(28)30-10-31-20/h6-8,10,14-16,32H,1-5,9H2,(H2,29,35)(H2,28,30,31)/t14-,15+,16-/m0/s1

>  <stdInchikey>  (6) 
QLRRJMOBVVGXEJ-XHSDSOJGSA-N

>  <csid>  (6) 
64835225

>  <Links>  (6) 
|http://www.chemspider.com/Chemical-Structure.64835225.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297640|http://pubchem.ncbi.nlm.nih.gov/compound/72547837|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10231|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=PQ7O0OB5GU

>  <LinkName>  (6) 
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|FDA SRS

>  <lig_pdbID>  (6) 


>  <pdbID>  (6) 


>  <indicationG2P>  (6) 
None

>  <indicationDB>  (6) 


>  <uniprotId>  (6) 


>  <MW>  (6) 
529.2

>  <HBA>  (6) 
7.0

>  <HBD>  (6) 
3.0

>  <NRB>  (6) 
5.0

>  <TPSA>  (6) 
130.5

>  <LogP>  (6) 
2.7

>  <RoF>  (6) 
1.0

>  <Melting point>  (6) 


>  <Targets>  (6) 
nan

>  <Kinase families>  (6) 


>  <FDA_approved>  (6) 


$$$$
Peposertib
     RDKit          2D

 24 25  0  0  0  0  0  0  0  0999 V2000
   -8.4741   -0.4658    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1088    0.1553    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8881   -0.7165    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5228   -0.0953    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3022   -0.9672    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9368   -0.3460    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7921    1.1470    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4268    1.7682    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7938    0.8963    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6491   -0.5967    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7162   -1.2178    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8609   -2.7108    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2263   -3.3320    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1592    1.5175    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3798    0.6457    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2351   -0.8473    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4557   -1.7192    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.8210   -1.0980    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9657    0.3950    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.7451    1.2669    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8898    2.7599    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.0416   -1.9698    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0127    2.0188    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8680    3.5118    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  1  0
  9 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 18 22  1  0
  7 23  1  0
 23 24  1  0
 11  6  1  0
 20 15  1  0
M  END
>  <BrandName>  (7) 


>  <Applicants>  (7) 
Merck

>  <CHEMBL_ID>  (7) 
nan

>  <Canonical_Smiles>  (7) 
COCCOc1c(cc(cc1OC)Cc2cnc(nc2N)N)OC

>  <Chirality>  (7) 
nan

>  <First_Approval>  (7) 
nan

>  <Phase>  (7) 
1.0

>  <SC_Patent>  (7) 
nan

>  <Synonyms>  (7) 
TETROXOPRIM

>  <Withdrawn>  (7) 


>  <Indications>  (7) 
nan

>  <Type>  (7) 
nan

>  <targets_id>  (7) 
nan

>  <inchi>  (7) 
InChI=1S/C16H22N4O4/c1-21-4-5-24-14-12(22-2)7-10(8-13(14)23-3)6-11-9-19-16(18)20-15(11)17/h7-9H,4-6H2,1-3H3,(H4,17,18,19,20)

>  <stdInchikey>  (7) 
WSWJIZXMAUYHOE-UHFFFAOYSA-N

>  <csid>  (7) 
58910

>  <Links>  (7) 
|http://www.chemspider.com/Chemical-Structure.58910.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL32039|http://pubchem.ncbi.nlm.nih.gov/compound/65450|http://www.drugbank.ca/drugs/DB15976|http://zinc15.docking.org/substances/ZINC000002020087|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=5R6712AY0K|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50029760

>  <LinkName>  (7) 
|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (7) 


>  <pdbID>  (7) 


>  <indicationG2P>  (7) 


>  <indicationDB>  (7) 


>  <uniprotId>  (7) 


>  <MW>  (7) 
334.2

>  <HBA>  (7) 
8.0

>  <HBD>  (7) 
2.0

>  <NRB>  (7) 
8.0

>  <TPSA>  (7) 
114.7

>  <LogP>  (7) 
1.3

>  <RoF>  (7) 
0.0

>  <Melting point>  (7) 
154.0 Â°C

>  <Targets>  (7) 
nan

>  <Kinase families>  (7) 


>  <FDA_approved>  (7) 


$$$$
Omipalisib
     RDKit          2D

 36 40  0  0  0  0  0  0  0  0999 V2000
   -4.6358   -4.0183    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4090   -4.8814    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0481   -4.2506    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9140   -2.7566    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5531   -2.1257    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6737   -2.9889    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5396   -4.4829    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8213   -5.1137    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0346   -2.3580    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2614   -3.2211    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6222   -2.5903    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7563   -1.0963    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5296   -0.2332    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1687   -0.8640    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6637    1.2608    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0246    1.8917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2513    1.0286    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1172   -0.4654    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.4369    2.1240    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5710    3.6180    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3442    4.4811    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0167    3.8502    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1508    2.3562    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0760    1.4931    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1408   -1.8935    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0067   -0.3995    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5127   -0.5336    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5007   -0.2654    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8726    1.0945    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5117    1.7254    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3776    3.2194    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6044    4.0825    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9653    3.4517    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0994    1.9577    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4602    1.3268    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4703    5.5765    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  6  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 13 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 15 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
  4 25  1  0
 25 26  1  0
 26 27  2  0
 26 28  2  0
 26 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  2  0
 32 33  1  0
 33 34  2  0
 34 35  1  0
 32 36  1  0
  8  3  1  0
 14  9  1  0
 18 12  1  0
 24 19  1  0
 34 29  1  0
M  END
>  <BrandName>  (8) 


>  <Applicants>  (8) 
GlaxosmithKline

>  <CHEMBL_ID>  (8) 
CHEMBL1236962

>  <Canonical_Smiles>  (8) 
COc1c(cc(cn1)c2ccc3c(c2)c(ccn3)c4ccnnc4)NS(=O)(=O)c5ccc(cc5F)F

>  <Chirality>  (8) 
Achiral Molecule

>  <First_Approval>  (8) 
nan

>  <Phase>  (8) 
1.0

>  <SC_Patent>  (8) 
None

>  <Synonyms>  (8) 
GSK-2126458 | GSK2126458 | OMIPALISIB

>  <Withdrawn>  (8) 


>  <Indications>  (8) 
nan

>  <Type>  (8) 
1

>  <targets_id>  (8) 
P42336|P42345

>  <inchi>  (8) 
InChI=1S/C25H17F2N5O3S/c1-35-25-23(32-36(33,34)24-5-3-18(26)12-21(24)27)11-17(13-29-25)15-2-4-22-20(10-15)19(7-8-28-22)16-6-9-30-31-14-16/h2-14,32H,1H3

>  <stdInchikey>  (8) 
CGBJSGAELGCMKE-UHFFFAOYSA-N

>  <csid>  (8) 
25027388

>  <Links>  (8) 
|http://www.chemspider.com/Chemical-Structure.25027388.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1236962|http://pubchem.ncbi.nlm.nih.gov/compound/25167777|http://www.drugbank.ca/drugs/DB12703| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=ZIG|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/ZIG|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8974|http://zinc15.docking.org/substances/ZINC43208634|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=1X8F5A3NA0|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50145416

>  <LinkName>  (8) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (8) 
'ZIG'

>  <pdbID>  (8) 
3l08

>  <indicationG2P>  (8) 
None

>  <indicationDB>  (8) 


>  <uniprotId>  (8) 


>  <MW>  (8) 
505.1

>  <HBA>  (8) 
7.0

>  <HBD>  (8) 
1.0

>  <NRB>  (8) 
6.0

>  <TPSA>  (8) 
107.0

>  <LogP>  (8) 
4.8

>  <RoF>  (8) 
1.0

>  <Melting point>  (8) 


>  <Targets>  (8) 
PIK3CA; MTOR

>  <Kinase families>  (8) 
Atypical

>  <FDA_approved>  (8) 


$$$$
Recilisib
     RDKit          2D

 22 23  0  0  0  0  0  0  0  0999 V2000
   -3.8172   -0.8558    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0051   -1.7717    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3923   -1.2010    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5916    0.2857    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4038    1.2017    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0166    0.6309    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8287    1.5469    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4415    0.9762    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8708    2.3634    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0123   -0.4110    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0544    0.4055    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1335    1.3214    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5207    0.7507    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7200   -0.7360    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1072   -1.3067    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2950   -0.3907    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0957    1.0960    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7085    1.6667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6822   -0.9615    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8701   -0.0455    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.8815   -2.4482    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5801   -2.1170    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  8 10  2  0
  8 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 16 19  1  0
 19 20  2  0
 19 21  1  0
  3 22  1  0
  6  1  1  0
 18 13  1  0
M  END
>  <BrandName>  (9) 
Ex-RAD;Ex-rad

>  <Applicants>  (9) 
Onconova Therapeutics

>  <CHEMBL_ID>  (9) 
CHEMBL2219421

>  <Canonical_Smiles>  (9) 
c1cc(ccc1CS(=O)(=O)/C=C/c2ccc(cc2)C(=O)O)Cl

>  <Chirality>  (9) 
Achiral Molecule

>  <First_Approval>  (9) 
nan

>  <Phase>  (9) 
1.0

>  <SC_Patent>  (9) 
None

>  <Synonyms>  (9) 
EX-RAD | ON 01210 | ON 01210.NA | ON-01210 | RECILISIB

>  <Withdrawn>  (9) 


>  <Indications>  (9) 
nan

>  <Type>  (9) 
nan

>  <targets_id>  (9) 
nan

>  <inchi>  (9) 
InChI=1S/C16H13ClO4S/c17-15-7-3-13(4-8-15)11-22(20,21)10-9-12-1-5-14(6-2-12)16(18)19/h1-10H,11H2,(H,18,19)/b10-9+

>  <stdInchikey>  (9) 
KBEKQQJUNVQLDZ-MDZDMXLPSA-N

>  <csid>  (9) 
8059894

>  <Links>  (9) 
|http://www.chemspider.com/Chemical-Structure.8059894.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2219421|http://pubchem.ncbi.nlm.nih.gov/compound/9884220|http://zinc15.docking.org/substances/ZINC000034007613|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=F5V4K11SYV

>  <LinkName>  (9) 
|ChemSpider|ChEMBL|PubChem|ZINC|FDA SRS

>  <lig_pdbID>  (9) 


>  <pdbID>  (9) 


>  <indicationG2P>  (9) 


>  <indicationDB>  (9) 


>  <uniprotId>  (9) 


>  <MW>  (9) 
336.0

>  <HBA>  (9) 
3.0

>  <HBD>  (9) 
1.0

>  <NRB>  (9) 
5.0

>  <TPSA>  (9) 
71.4

>  <LogP>  (9) 
3.6

>  <RoF>  (9) 
0.0

>  <Melting point>  (9) 


>  <Targets>  (9) 
nan

>  <Kinase families>  (9) 


>  <FDA_approved>  (9) 


$$$$
Nedisertib
     RDKit          2D

 34 38  0  0  0  0  0  0  0  0999 V2000
   -9.3526   -1.2937    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3211   -2.3826    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8622   -2.0338    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4349   -0.5959    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9760   -0.2471    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9445   -1.3361    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3718   -2.7739    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8307   -3.1228    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4856   -0.9872    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0583    0.4506    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5994    0.7995    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1721    2.2373    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2037    3.3263    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6625    2.9775    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0899    1.5396    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5487    1.1908    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -0.7764    4.7642    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    1.2868    2.5862    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3183    1.4972    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8910    0.0593    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9225   -1.0296    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3814   -0.6808    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8087    0.7571    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7772    1.8460    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2045    3.2839    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.1729    4.3729    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7141    4.0240    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.4130   -1.7698    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.9856   -3.2076    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0172   -4.2966    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4761   -3.9478    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.9034   -2.5099    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8718   -1.4209    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4541   -2.0762    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  6  9  1  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 13 17  1  0
 12 18  1  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 22 28  1  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 32 33  1  0
  9 34  1  0
  8  3  1  0
 15 10  1  0
 27 18  2  0
 24 19  1  0
 33 28  1  0
M  END
>  <BrandName>  (10) 


>  <Applicants>  (10) 
Merck

>  <CHEMBL_ID>  (10) 
CHEMBL4297629

>  <Canonical_Smiles>  (10) 
COc1ccc(nn1)C(c2cc(c(cc2Cl)F)c3c4ccc(cc4ncn3)N5CCOCC5)O

>  <Chirality>  (10) 
Single Stereoisomer

>  <First_Approval>  (10) 
nan

>  <Phase>  (10) 
1.0

>  <SC_Patent>  (10) 
None

>  <Synonyms>  (10) 
|MSC2490484A|MSC-2490484A|MSC 2490484A|M3814|M-3814

>  <Withdrawn>  (10) 


>  <Indications>  (10) 
nan

>  <Type>  (10) 
nan

>  <targets_id>  (10) 
nan

>  <inchi>  (10) 
InChI=1S/C24H21ClFN5O3/c1-33-22-5-4-20(29-30-22)24(32)16-11-17(19(26)12-18(16)25)23-15-3-2-14(10-21(15)27-13-28-23)31-6-8-34-9-7-31/h2-5,10-13,24,32H,6-9H2,1H3

>  <stdInchikey>  (10) 
MOWXJLUYGFNTAL-UHFFFAOYSA-N

>  <csid>  (10) 
68007068

>  <Links>  (10) 
|http://www.chemspider.com/Chemical-Structure.68007068.html|http://pubchem.ncbi.nlm.nih.gov/compound/117696445|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=315705

>  <LinkName>  (10) 
|ChemSpider|PubChem|BindingDB

>  <lig_pdbID>  (10) 


>  <pdbID>  (10) 


>  <indicationG2P>  (10) 


>  <indicationDB>  (10) 


>  <uniprotId>  (10) 


>  <MW>  (10) 
481.1

>  <HBA>  (10) 
8.0

>  <HBD>  (10) 
1.0

>  <NRB>  (10) 
5.0

>  <TPSA>  (10) 
93.5

>  <LogP>  (10) 
3.8

>  <RoF>  (10) 
0.0

>  <Melting point>  (10) 


>  <Targets>  (10) 
nan

>  <Kinase families>  (10) 


>  <FDA_approved>  (10) 


$$$$
Lifirafenib
     RDKit          2D

 35 41  0  0  0  0  0  0  0  0999 V2000
   -7.9046   -0.2890    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1460    1.0050    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6460    0.9951    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9046   -0.3089    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6633   -1.6030    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1632   -1.5930    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9219   -2.8870    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.6805   -4.1810    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -9.2159   -2.1284    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6278   -3.6456    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4354   -0.0068    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2687    1.4839    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6349    2.1031    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9647    2.2252    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4647    2.2152    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2061    3.5192    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1950    4.6273    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.1713    4.0081    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0046    2.5173    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2122    1.6276    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5865    2.2286    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7532    3.7193    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5456    4.6090    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7942    1.3389    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.6275   -0.1518    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2531   -0.7528    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0864   -2.2435    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2940   -3.1333    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.6684   -2.5323    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8351   -1.0416    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2094   -0.4406    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4171   -1.3303    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2504   -2.8210    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4580   -3.7107    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.8760   -3.4220    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  1  0
  7  9  1  0
  7 10  1  0
  4 11  1  0
 11 12  1  0
 12 13  2  0
 14 12  1  6
 14 15  1  0
 15 16  1  0
 16 17  1  1
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 21 24  1  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  1  0
 32 33  1  0
 33 34  2  0
 33 35  1  0
  6  1  1  0
 13  3  1  0
 16 14  1  0
 15 19  1  1
 23 18  1  0
 30 25  1  0
 35 29  1  0
M  END
>  <BrandName>  (11) 


>  <Applicants>  (11) 
BeiGene

>  <CHEMBL_ID>  (11) 
CHEMBL4209157

>  <Canonical_Smiles>  (11) 
c1cc2c(cc1C(F)(F)F)[nH]c(n2)[C@H]3[C@H]4[C@@H]3Oc5c4cc(cc5)Oc6ccnc7c6CCC(=O)N7

>  <Chirality>  (11) 
Single Stereoisomer

>  <First_Approval>  (11) 
nan

>  <Phase>  (11) 
1.0

>  <SC_Patent>  (11) 
None

>  <Synonyms>  (11) 
BGB 283 | BGB-283 | LIFIRAFENIB

>  <Withdrawn>  (11) 


>  <Indications>  (11) 
nan

>  <Type>  (11) 
nan

>  <targets_id>  (11) 
nan

>  <inchi>  (11) 
InChI=1S/C25H17F3N4O3/c26-25(27,28)11-1-4-15-16(9-11)31-24(30-15)21-20-14-10-12(2-5-17(14)35-22(20)21)34-18-7-8-29-23-13(18)3-6-19(33)32-23/h1-2,4-5,7-10,20-22H,3,6H2,(H,30,31)(H,29,32,33)/t20-,21-,22-/m0/s1

>  <stdInchikey>  (11) 
NGFFVZQXSRKHBM-FKBYEOEOSA-N

>  <csid>  (11) 
58145118

>  <Links>  (11) 
|http://www.chemspider.com/Chemical-Structure.58145118.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4209157|http://pubchem.ncbi.nlm.nih.gov/compound/89670174|http://www.drugbank.ca/drugs/DB14773| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=3K3|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/3K3|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8958|http://zinc15.docking.org/substances/ZINC000068764621|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=8762XZS5ZF

>  <LinkName>  (11) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (11) 
'3K3'

>  <pdbID>  (11) 
4r5y

>  <indicationG2P>  (11) 
None

>  <indicationDB>  (11) 


>  <uniprotId>  (11) 


>  <MW>  (11) 
478.1

>  <HBA>  (11) 
5.0

>  <HBD>  (11) 
2.0

>  <NRB>  (11) 
3.0

>  <TPSA>  (11) 
89.1

>  <LogP>  (11) 
5.3

>  <RoF>  (11) 
1.0

>  <Melting point>  (11) 


>  <Targets>  (11) 
nan

>  <Kinase families>  (11) 


>  <FDA_approved>  (11) 


$$$$
Ravoxertinib
     RDKit          2D

 31 34  0  0  0  0  0  0  0  0999 V2000
   -8.6136    1.0548    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1789    1.4927    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9814    0.5895    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7523    1.4493    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1902    2.8839    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6900    2.9108    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0082   -0.9103    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7228   -1.6834    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7497   -3.1832    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4643   -3.9563    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1520   -3.2297    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1252   -1.7299    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4106   -0.9568    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8129   -1.0033    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4725   -1.7764    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7847   -1.0498    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8116    0.4500    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.5262    1.2231    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5530    2.7229    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7861    0.4965    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1238    1.1766    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1507    2.6764    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4629    3.4030    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.4093    0.4035    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3824   -1.0963    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6678   -1.8694    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9801   -1.1428    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0069    0.3570    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7215    1.1301    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3192    1.0836    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    8.2655   -1.9159    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  3  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  1  0
 18 19  2  0
 18 20  1  0
 17 21  1  0
 21 22  1  6
 22 23  1  0
 21 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 28 30  1  0
 27 31  1  0
  6  2  1  0
 13  8  1  0
 20 14  2  0
 29 24  1  0
M  END
>  <BrandName>  (12) 


>  <Applicants>  (12) 
Genentech

>  <CHEMBL_ID>  (12) 
CHEMBL3544964

>  <Canonical_Smiles>  (12) 
Cn1c(ccn1)Nc2nccc(n2)c3ccn(c(=O)c3)[C@H](CO)c4ccc(c(c4)F)Cl

>  <Chirality>  (12) 
Single Stereoisomer

>  <First_Approval>  (12) 
nan

>  <Phase>  (12) 
1.0

>  <SC_Patent>  (12) 
None

>  <Synonyms>  (12) 
GDC-0994 | GDC0994 | RAVOXERTINIB | RG-7842

>  <Withdrawn>  (12) 


>  <Indications>  (12) 
nan

>  <Type>  (12) 
nan

>  <targets_id>  (12) 
nan

>  <inchi>  (12) 
InChI=1S/C21H18ClFN6O2/c1-28-19(5-8-25-28)27-21-24-7-4-17(26-21)13-6-9-29(20(31)11-13)18(12-30)14-2-3-15(22)16(23)10-14/h2-11,18,30H,12H2,1H3,(H,24,26,27)/t18-/m1/s1

>  <stdInchikey>  (12) 
RZUOCXOYPYGSKL-GOSISDBHSA-N

>  <csid>  (12) 
32501977

>  <Links>  (12) 
|http://www.chemspider.com/Chemical-Structure.32501977.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3544964|http://pubchem.ncbi.nlm.nih.gov/compound/71727581|http://www.drugbank.ca/drugs/DB15281| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=6QB|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6QB|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9229|http://zinc15.docking.org/substances/ZINC000144904566|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=R6AXV96CRH|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=120095

>  <LinkName>  (12) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (12) 
'6QB'

>  <pdbID>  (12) 
5k4i 5k4j 6oph

>  <indicationG2P>  (12) 
None

>  <indicationDB>  (12) 


>  <uniprotId>  (12) 


>  <MW>  (12) 
440.1

>  <HBA>  (12) 
8.0

>  <HBD>  (12) 
2.0

>  <NRB>  (12) 
6.0

>  <TPSA>  (12) 
97.9

>  <LogP>  (12) 
3.2

>  <RoF>  (12) 
0.0

>  <Melting point>  (12) 


>  <Targets>  (12) 
nan

>  <Kinase families>  (12) 


>  <FDA_approved>  (12) 


$$$$
Selatinib
     RDKit          2D

 39 43  0  0  0  0  0  0  0  0999 V2000
   -4.8068    7.6802    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8776    6.6298    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3227    7.0319    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5033    5.1773    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5741    4.1268    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1998    2.6743    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2706    1.6238    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8963    0.1713    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.8514   -0.9853    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0465   -2.2511    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5940   -1.8768    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5011   -0.3797    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4374   -2.8319    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6862   -4.3111    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5296   -5.2663    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1242   -4.7422    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8753   -3.2630    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0319   -2.3078    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4698   -2.7389    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6868   -3.6940    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.4379   -5.1732    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9676   -5.6973    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2210   -1.2597    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.1845   -0.7356    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3411   -1.6907    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7466   -1.1666    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9954    0.3126    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8388    1.2677    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4333    0.7436    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0877    2.7469    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    5.4009    0.8367    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.5575   -0.1184    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9630    0.4056    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1196   -0.5495    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.5250   -0.0254    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.7739    1.4538    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.6173    2.4089    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2118    1.8848    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8661    3.8881    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  2  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 11 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 17 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 19 23  1  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 28 30  1  0
 27 31  1  0
 31 32  1  0
 32 33  1  0
 33 34  2  0
 34 35  1  0
 35 36  2  0
 36 37  1  0
 37 38  2  0
 37 39  1  0
 12  8  1  0
 18 13  1  0
 22 16  1  0
 29 24  1  0
 38 33  1  0
M  END
>  <BrandName>  (13) 


>  <Applicants>  (13) 
Qilu Pharmaceutical

>  <CHEMBL_ID>  (13) 
nan

>  <Canonical_Smiles>  (13) 
CS(=O)CCNCc1ccc(o1)c2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5cccc(c5)F

>  <Chirality>  (13) 
nan

>  <First_Approval>  (13) 
nan

>  <Phase>  (13) 
1.0

>  <SC_Patent>  (13) 
nan

>  <Synonyms>  (13) 


>  <Withdrawn>  (13) 


>  <Indications>  (13) 
nan

>  <Type>  (13) 
nan

>  <targets_id>  (13) 
P00533|P04626

>  <inchi>  (13) 
InChI=1S/C29H26ClFN4O3S/c1-39(36)12-11-32-16-23-7-10-27(38-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)37-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)

>  <stdInchikey>  (13) 
OAMVGUFHZPRXOM-UHFFFAOYSA-N

>  <csid>  (13) 
30841488

>  <Links>  (13) 
|http://www.chemspider.com/Chemical-Structure.30841488.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3040548|http://pubchem.ncbi.nlm.nih.gov/compound/51348455|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9919|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=140985

>  <LinkName>  (13) 
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|BindingDB

>  <lig_pdbID>  (13) 


>  <pdbID>  (13) 


>  <indicationG2P>  (13) 
None

>  <indicationDB>  (13) 


>  <uniprotId>  (13) 


>  <MW>  (13) 
564.1

>  <HBA>  (13) 
7.0

>  <HBD>  (13) 
2.0

>  <NRB>  (13) 
11.0

>  <TPSA>  (13) 
89.3

>  <LogP>  (13) 
6.5

>  <RoF>  (13) 
2.0

>  <Melting point>  (13) 


>  <Targets>  (13) 
EGFR; ERBB2

>  <Kinase families>  (13) 
Tyr

>  <FDA_approved>  (13) 


$$$$
Theliatinib
     RDKit          2D

 33 37  0  0  0  0  0  0  0  0999 V2000
   -6.4669    4.5457    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6285    3.0544    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9299    2.3087    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6228    0.8404    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1316    0.6788    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5170    2.0471    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0258    1.8855    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7187    0.4173    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0201   -0.3285    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3503   -0.1973    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1339    0.6805    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1984   -1.6895    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8300   -2.3041    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3863   -1.4263    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7547   -2.0409    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9066   -3.5332    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6903   -4.4109    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6781   -3.7964    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8944   -4.6741    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7425   -6.1664    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2750   -4.1477    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.4914   -3.2700    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3394   -1.7777    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.9711   -1.1631    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8191    0.3291    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.0355    1.2069    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4038    0.5923    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6202    1.4701    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4682    2.9624    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0999    3.5769    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8835    2.6992    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9479    5.0692    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7960    6.5615    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  5  4  1  1
  5  6  1  0
  6  7  1  1
  7  8  1  0
  8  9  1  0
  8 10  1  0
 10 11  2  0
 10 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  1  0
 16 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 30 32  1  0
 32 33  3  0
  6  2  1  0
  9  5  1  0
 18 13  1  0
 24 15  1  0
 31 26  1  0
M  END
>  <BrandName>  (14) 


>  <Applicants>  (14) 
Hutchison MediPharma

>  <CHEMBL_ID>  (14) 
nan

>  <Canonical_Smiles>  (14) 
CN1CC[C@H]2[C@@H]1CN(C2)C(=O)Nc3cc4c(cc3OC)ncnc4Nc5cccc(c5)C#C

>  <Chirality>  (14) 
nan

>  <First_Approval>  (14) 
nan

>  <Phase>  (14) 
1.0

>  <SC_Patent>  (14) 
nan

>  <Synonyms>  (14) 


>  <Withdrawn>  (14) 


>  <Indications>  (14) 
nan

>  <Type>  (14) 
nan

>  <targets_id>  (14) 
nan

>  <inchi>  (14) 
InChI=1S/C25H26N6O2/c1-4-16-6-5-7-18(10-16)28-24-19-11-21(23(33-3)12-20(19)26-15-27-24)29-25(32)31-13-17-8-9-30(2)22(17)14-31/h1,5-7,10-12,15,17,22H,8-9,13-14H2,2-3H3,(H,29,32)(H,26,27,28)/t17-,22+/m1/s1

>  <stdInchikey>  (14) 
FSXCKIBROURMFT-VGSWGCGISA-N

>  <csid>  (14) 
68025614

>  <Links>  (14) 
|http://www.chemspider.com/Chemical-Structure.68025614.html|http://pubchem.ncbi.nlm.nih.gov/compound/54759275|http://zinc15.docking.org/substances/ZINC000113384840|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6ZZ3B7NZ0B

>  <LinkName>  (14) 
|ChemSpider|PubChem|ZINC|FDA SRS

>  <lig_pdbID>  (14) 


>  <pdbID>  (14) 


>  <indicationG2P>  (14) 


>  <indicationDB>  (14) 


>  <uniprotId>  (14) 


>  <MW>  (14) 
442.2

>  <HBA>  (14) 
6.0

>  <HBD>  (14) 
2.0

>  <NRB>  (14) 
4.0

>  <TPSA>  (14) 
82.6

>  <LogP>  (14) 
3.5

>  <RoF>  (14) 
0.0

>  <Melting point>  (14) 


>  <Targets>  (14) 
nan

>  <Kinase families>  (14) 


>  <FDA_approved>  (14) 


$$$$
Balamapimod
     RDKit          2D

 40 45  0  0  0  0  0  0  0  0999 V2000
   -6.9295   -2.6378    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3413   -2.1310    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -9.5811   -2.9752    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.7672   -2.0570    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.2604   -0.6452    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7611   -0.6909    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.8428    0.4951    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3565    0.2929    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7885   -1.0954    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3022   -1.2976    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3839   -0.1116    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9519    1.2767    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4382    1.4790    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0062    2.8672    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -1.8976   -0.3138    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9793    0.8723    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5070    0.6700    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0750   -0.7183    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5614   -0.9205    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4796    0.2656    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9116    1.6539    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4253    1.8561    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8573    3.2444    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6290    3.4466    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5473    2.2606    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0336    2.4628    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5199    2.6650    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.9659    0.0633    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.5340   -1.3249    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0203   -1.5272    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9386   -0.3411    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3705    1.0472    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8842    1.2494    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4249   -0.5433    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.4621    0.5402    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.8132   -0.1114    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.6109   -1.5977    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1349   -1.8647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1294   -2.3088    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.2111   -3.4948    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 11 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  1  0
 26 27  3  0
 20 28  1  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 32 33  1  0
 31 34  1  0
 34 35  1  0
 35 36  1  0
 36 37  1  0
 37 38  1  0
 19 39  1  0
 39 40  1  0
  6  2  1  0
 13  8  1  0
 25 16  2  0
 22 17  1  0
 33 28  1  0
 38 34  1  0
M  END
>  <BrandName>  (15) 


>  <Applicants>  (15) 
Wyeth

>  <CHEMBL_ID>  (15) 
CHEMBL2104954

>  <Canonical_Smiles>  (15) 
Cn1ccnc1Sc2ccc(cc2Cl)Nc3c4cc(c(cc4ncc3C#N)N5CCC(CC5)N6CCCC6)OC

>  <Chirality>  (15) 
Achiral Molecule

>  <First_Approval>  (15) 
nan

>  <Phase>  (15) 
1.0

>  <SC_Patent>  (15) 
None

>  <Synonyms>  (15) 
BALAMAPIMOD | MKI-833

>  <Withdrawn>  (15) 


>  <Indications>  (15) 
nan

>  <Type>  (15) 
nan

>  <targets_id>  (15) 
P04049|Q02750|P36507

>  <inchi>  (15) 
InChI=1S/C30H32ClN7OS/c1-36-14-9-33-30(36)40-28-6-5-21(15-24(28)31)35-29-20(18-32)19-34-25-17-26(27(39-2)16-23(25)29)38-12-7-22(8-13-38)37-10-3-4-11-37/h5-6,9,14-17,19,22H,3-4,7-8,10-13H2,1-2H3,(H,34,35)

>  <stdInchikey>  (15) 
CVAKNHIXTWLGJO-UHFFFAOYSA-N

>  <csid>  (15) 
9653509

>  <Links>  (15) 
|http://www.chemspider.com/Chemical-Structure.9653509.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2104954|http://pubchem.ncbi.nlm.nih.gov/compound/11478684|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9925|http://zinc15.docking.org/substances/ZINC000011726212|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=7Y0IV7N95Q

>  <LinkName>  (15) 
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (15) 


>  <pdbID>  (15) 


>  <indicationG2P>  (15) 
None

>  <indicationDB>  (15) 


>  <uniprotId>  (15) 


>  <MW>  (15) 
573.2

>  <HBA>  (15) 
9.0

>  <HBD>  (15) 
1.0

>  <NRB>  (15) 
7.0

>  <TPSA>  (15) 
82.2

>  <LogP>  (15) 
6.5

>  <RoF>  (15) 
2.0

>  <Melting point>  (15) 


>  <Targets>  (15) 
RAF1; MAP2K1; MAP2K2

>  <Kinase families>  (15) 
TKL<br>STE

>  <FDA_approved>  (15) 


$$$$
Zotiraciclib
     RDKit          2D

 28 31  0  0  0  0  0  0  0  0999 V2000
   -5.7736   -2.6673    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3450   -2.2098    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6465   -3.5372    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5360   -4.5457    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1477   -5.1135    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3512   -5.1722    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7797   -4.7148    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9657   -3.7963    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.7799   -2.1715    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2787   -2.2303    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0790   -0.9616    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3805    0.3658    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8816    0.4245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0813   -0.8441    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1830    1.7520    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6819    3.2107    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9834    4.5382    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4845    4.5969    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.6842    3.3282    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0726    2.7604    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8146    3.3869    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2432    2.9295    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5932    3.6741    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0217    3.2166    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3398    1.7507    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2294    0.7423    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4291    2.0110    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5475   -0.7236    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 13 15  1  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 19 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 26 28  1  0
 28  2  1  0
 14  9  2  0
 20 15  2  0
 27 22  2  0
M  END
>  <BrandName>  (16) 


>  <Applicants>  (16) 
S*BIO

>  <CHEMBL_ID>  (16) 
CHEMBL1944698

>  <Canonical_Smiles>  (16) 
CN1C/C=C/CCOc2cccc(c2)-c3ccnc(n3)Nc4cccc(c4)C1

>  <Chirality>  (16) 
Achiral Molecule

>  <First_Approval>  (16) 
nan

>  <Phase>  (16) 
1.0

>  <SC_Patent>  (16) 
None

>  <Synonyms>  (16) 
EX45 | SB-1317 | SB1317 | TG-02 | TG02 | ZOTIRACICLIB

>  <Withdrawn>  (16) 


>  <Indications>  (16) 
nan

>  <Type>  (16) 
nan

>  <targets_id>  (16) 
nan

>  <inchi>  (16) 
InChI=1S/C23H24N4O/c1-27-13-3-2-4-14-28-21-10-6-8-19(16-21)22-11-12-24-23(26-22)25-20-9-5-7-18(15-20)17-27/h2-3,5-12,15-16H,4,13-14,17H2,1H3,(H,24,25,26)/b3-2+

>  <stdInchikey>  (16) 
VXBAJLGYBMTJCY-NSCUHMNNSA-N

>  <csid>  (16) 
20571045

>  <Links>  (16) 
|http://www.chemspider.com/Chemical-Structure.20571045.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1944698|http://pubchem.ncbi.nlm.nih.gov/compound/16739650|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9095|http://zinc15.docking.org/substances/ZINC000068251500|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=40D08182TT|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50363196

>  <LinkName>  (16) 
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (16) 


>  <pdbID>  (16) 


>  <indicationG2P>  (16) 
None

>  <indicationDB>  (16) 


>  <uniprotId>  (16) 


>  <MW>  (16) 
372.2

>  <HBA>  (16) 
5.0

>  <HBD>  (16) 
1.0

>  <NRB>  (16) 
0.0

>  <TPSA>  (16) 
50.3

>  <LogP>  (16) 
4.7

>  <RoF>  (16) 
0.0

>  <Melting point>  (16) 


>  <Targets>  (16) 
nan

>  <Kinase families>  (16) 


>  <FDA_approved>  (16) 


$$$$
Empesertib
     RDKit          2D

 40 44  0  0  0  0  0  0  0  0999 V2000
   -9.2328    3.0446    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.6026    1.6834    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.4663    0.4570    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.9602    0.5918    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.8239   -0.6345    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.1937   -1.9957    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.6998   -2.1306    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.8361   -0.9042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -12.0575   -3.2221    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1086    1.5485    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2449    2.7749    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4784    0.1873    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9845    0.0525    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3543   -1.3087    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8604   -1.4435    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9966   -0.2171    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6268    1.1440    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1208    1.2789    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5027   -0.3520    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1275   -1.7132    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6214   -1.8480    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4851   -0.6216    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9745   -0.4429    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.2647    1.0287    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9548    1.7595    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.8549    0.7396    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.3610    0.8744    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6259    1.6589    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.8523    0.7952    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7174   -0.6987    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9438   -1.5625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3050   -0.9323    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4398    0.5617    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2135    1.4254    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3483    2.9193    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.7095    3.5495    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.5314   -1.7960    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   11.3951   -0.5696    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.6676   -3.0223    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   11.7577   -2.6597    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  1
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  6  9  1  0
  2 10  1  0
 10 11  2  0
 10 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 16 19  1  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  1  0
 24 28  1  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  2  0
 32 33  1  0
 33 34  2  0
 34 35  1  0
 35 36  1  0
 32 37  1  0
 37 38  2  0
 37 39  2  0
 37 40  1  0
  8  3  1  0
 18 13  1  0
 27 19  2  0
 26 22  1  0
 34 29  1  0
M  END
>  <BrandName>  (17) 


>  <Applicants>  (17) 
Bayer

>  <CHEMBL_ID>  (17) 
CHEMBL3545425

>  <Canonical_Smiles>  (17) 
C[C@H](c1ccc(cc1)F)C(=O)Nc2ccc(cc2)c3ccc4nc(nn4c3)Nc5ccc(cc5OC)S(=O)(=O)C

>  <Chirality>  (17) 
Single Stereoisomer

>  <First_Approval>  (17) 
nan

>  <Phase>  (17) 
1.0

>  <SC_Patent>  (17) 
None

>  <Synonyms>  (17) 


>  <Withdrawn>  (17) 


>  <Indications>  (17) 
nan

>  <Type>  (17) 
nan

>  <targets_id>  (17) 
nan

>  <inchi>  (17) 
InChI=1S/C29H26FN5O4S/c1-18(19-4-9-22(30)10-5-19)28(36)31-23-11-6-20(7-12-23)21-8-15-27-33-29(34-35(27)17-21)32-25-14-13-24(40(3,37)38)16-26(25)39-2/h4-18H,1-3H3,(H,31,36)(H,32,34)/t18-/m1/s1

>  <stdInchikey>  (17) 
NRJKIOCCERLIDG-GOSISDBHSA-N

>  <csid>  (17) 
35308224

>  <Links>  (17) 
|http://www.chemspider.com/Chemical-Structure.35308224.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4303241|http://pubchem.ncbi.nlm.nih.gov/compound/71599640| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=8QW|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/8QW|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9427|http://zinc15.docking.org/substances/ZINC000206769279|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=02Y3Z2756M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=329334

>  <LinkName>  (17) 
|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (17) 
'8QW'

>  <pdbID>  (17) 
5n9s 6tnb

>  <indicationG2P>  (17) 
None

>  <indicationDB>  (17) 


>  <uniprotId>  (17) 


>  <MW>  (17) 
559.2

>  <HBA>  (17) 
8.0

>  <HBD>  (17) 
2.0

>  <NRB>  (17) 
8.0

>  <TPSA>  (17) 
114.7

>  <LogP>  (17) 
5.4

>  <RoF>  (17) 
2.0

>  <Melting point>  (17) 


>  <Targets>  (17) 
nan

>  <Kinase families>  (17) 


>  <FDA_approved>  (17) 


$$$$
Pexmetinib
     RDKit          2D

 41 45  0  0  0  0  0  0  0  0999 V2000
   -7.3682    4.2931    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4826    3.0825    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9913    3.2442    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1057    2.0335    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7114    0.6612    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2026    0.4996    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0882    1.7102    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8257   -0.5494    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3257   -0.5446    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8576   -1.9696    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0682   -2.8552    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2846   -1.9775    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0633   -4.3552    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5633   -4.3601    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5633   -4.3504    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0584   -5.8552    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4480    0.6718    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0443    0.5199    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9220    1.7363    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.6588   -0.8484    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.1511   -1.0004    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7657   -2.3687    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8880   -3.5851    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5025   -4.9534    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9948   -5.1053    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8725   -3.8889    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2580   -2.5206    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1357   -1.3042    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.5211    0.0641    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0288    0.2160    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4143    1.5844    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2920    2.8008    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7843    2.6488    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3988    1.2805    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3899    4.0211    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2719    5.0212    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.9754    4.2670    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.6031    4.8726    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4414    6.3639    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0691    6.9695    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.6248   -6.1698    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  5  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 11 13  1  0
 13 14  1  0
 13 15  1  0
 13 16  1  0
  9 17  1  0
 17 18  1  0
 18 19  2  0
 18 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  2  0
 32 33  1  0
 33 34  2  0
 33 35  1  0
 35 36  2  0
 36 37  1  0
 37 38  1  0
 38 39  1  0
 39 40  1  0
 24 41  1  0
  7  2  1  0
 12  8  1  0
 27 22  1  0
 34 29  1  0
 37 32  1  0
M  END
>  <BrandName>  (18) 


>  <Applicants>  (18) 
Array BioPharma

>  <CHEMBL_ID>  (18) 
CHEMBL3545297

>  <Canonical_Smiles>  (18) 
Cc1ccc(cc1)n2c(cc(n2)C(C)(C)C)NC(=O)NCc3cc(ccc3Oc4ccc5c(c4)cnn5CCO)F

>  <Chirality>  (18) 
Single Stereoisomer

>  <First_Approval>  (18) 
nan

>  <Phase>  (18) 
1.0

>  <SC_Patent>  (18) 
None

>  <Synonyms>  (18) 


>  <Withdrawn>  (18) 


>  <Indications>  (18) 
nan

>  <Type>  (18) 
nan

>  <targets_id>  (18) 
Q16539|Q02763

>  <inchi>  (18) 
InChI=1S/C31H33FN6O3/c1-20-5-8-24(9-6-20)38-29(17-28(36-38)31(2,3)4)35-30(40)33-18-22-15-23(32)7-12-27(22)41-25-10-11-26-21(16-25)19-34-37(26)13-14-39/h5-12,15-17,19,39H,13-14,18H2,1-4H3,(H2,33,35,40)

>  <stdInchikey>  (18) 
LNMRSSIMGCDUTP-UHFFFAOYSA-N

>  <csid>  (18) 
32702049

>  <Links>  (18) 
|http://www.chemspider.com/Chemical-Structure.32702049.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3991932|http://pubchem.ncbi.nlm.nih.gov/compound/24765037|http://www.drugbank.ca/drugs/DB16294|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9917|http://zinc15.docking.org/substances/ZINC000041747181|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=3750D0U8B5

>  <LinkName>  (18) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (18) 


>  <pdbID>  (18) 


>  <indicationG2P>  (18) 
None

>  <indicationDB>  (18) 


>  <uniprotId>  (18) 


>  <MW>  (18) 
556.3

>  <HBA>  (18) 
7.0

>  <HBD>  (18) 
3.0

>  <NRB>  (18) 
8.0

>  <TPSA>  (18) 
106.2

>  <LogP>  (18) 
6.1

>  <RoF>  (18) 
2.0

>  <Melting point>  (18) 


>  <Targets>  (18) 
MAPK14; TEK

>  <Kinase families>  (18) 
CMGC<br>Tyr

>  <FDA_approved>  (18) 


$$$$
Altiratinib
     RDKit          2D

 37 41  0  0  0  0  0  0  0  0999 V2000
   -5.4916    1.7164    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9257    3.1523    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8993    4.2461    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4388    3.9042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0047    2.4684    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0311    1.3745    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5969   -0.0613    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6233   -1.1552    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0838   -0.8132    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1892   -2.5910    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2723   -4.0887    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5278   -3.2678    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6998   -2.4128    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1095   -1.0338    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8008   -3.6135    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3114   -3.4353    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5876   -4.6360    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0770   -4.4578    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6673   -3.0789    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7683   -1.8781    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2789   -2.0563    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6201   -0.8556    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    4.1567   -2.9006    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.7471   -1.5217    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2364   -1.3435    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8268    0.0354    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9278    1.2362    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.4384    1.0580    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8480   -0.3210    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5394    2.2587    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.1297    3.6376    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6191    3.8159    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.2307    4.8384    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8518    5.4287    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0525    6.3278    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9760   -5.6585    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3335    5.6819    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  8 10  1  0
 10 11  1  0
 11 12  1  0
 10 13  1  0
 13 14  2  0
 13 15  1  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 19 23  1  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 28 30  1  0
 30 31  1  0
 31 32  2  0
 31 33  1  0
 33 34  1  0
 34 35  1  0
 18 36  1  0
  3 37  1  0
  6  1  1  0
 12 10  1  0
 21 16  1  0
 29 24  1  0
 35 33  1  0
M  END
>  <BrandName>  (19) 


>  <Applicants>  (19) 
Deciphera Pharmaceuticals

>  <CHEMBL_ID>  (19) 
CHEMBL3545365

>  <Canonical_Smiles>  (19) 
c1cc(ccc1NC(=O)C2(CC2)C(=O)Nc3cc(c(cc3F)Oc4ccnc(c4)NC(=O)C5CC5)F)F

>  <Chirality>  (19) 
Achiral Molecule

>  <First_Approval>  (19) 
nan

>  <Phase>  (19) 
1.0

>  <SC_Patent>  (19) 
None

>  <Synonyms>  (19) 
ALTIRATINIB | DCC-2701 | DP-5164

>  <Withdrawn>  (19) 


>  <Indications>  (19) 
nan

>  <Type>  (19) 
nan

>  <targets_id>  (19) 
P08581|Q02763|P35968|P04629

>  <inchi>  (19) 
InChI=1S/C26H21F3N4O4/c27-15-3-5-16(6-4-15)31-24(35)26(8-9-26)25(36)32-20-12-19(29)21(13-18(20)28)37-17-7-10-30-22(11-17)33-23(34)14-1-2-14/h3-7,10-14H,1-2,8-9H2,(H,31,35)(H,32,36)(H,30,33,34)

>  <stdInchikey>  (19) 
GNNDEPIMDAZHRQ-UHFFFAOYSA-N

>  <csid>  (19) 
33427355

>  <Links>  (19) 
|http://www.chemspider.com/Chemical-Structure.33427355.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545365|http://pubchem.ncbi.nlm.nih.gov/compound/54576299|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9174|http://zinc15.docking.org/substances/ZINC000113198271|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=T678746713|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50193395

>  <LinkName>  (19) 
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (19) 


>  <pdbID>  (19) 


>  <indicationG2P>  (19) 
None

>  <indicationDB>  (19) 


>  <uniprotId>  (19) 


>  <MW>  (19) 
510.2

>  <HBA>  (19) 
5.0

>  <HBD>  (19) 
3.0

>  <NRB>  (19) 
8.0

>  <TPSA>  (19) 
109.4

>  <LogP>  (19) 
5.0

>  <RoF>  (19) 
1.0

>  <Melting point>  (19) 


>  <Targets>  (19) 
MET; TEK; KDR; NTRK1

>  <Kinase families>  (19) 
Tyr

>  <FDA_approved>  (19) 


$$$$
Panulisib
     RDKit          2D

 39 43  0  0  0  0  0  0  0  0999 V2000
    3.2049   -1.9866    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5148   -3.3184    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8247   -4.6502    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8466   -4.0085    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1784   -4.6987    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.1830   -2.6283    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0806   -3.4366    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4124   -2.7465    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4806   -1.2481    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2171   -0.4397    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1147   -1.1298    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8125   -0.5579    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0370    0.9252    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0850    2.0844    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6051    1.8396    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3468    2.9988    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1811    4.4029    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6610    4.6476    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6130    3.4884    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0929    3.7332    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0448    2.5740    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5169    1.1700    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2070   -0.1619    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1536   -1.2298    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3984   -2.7096    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8024   -3.2376    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2064   -3.7656    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6901   -0.3864    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8267    2.7540    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3546    1.3500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8345    1.1052    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7865    2.2645    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2585    3.6685    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.7786    3.9133    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2664    2.0197    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.3625   -0.2988    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8904   -1.7028    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    5.7665    0.2292    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    2.9585   -0.8267    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  4  5  3  0
  2  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
  9 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  2  3
 25 26  1  0
 26 27  3  0
 23 28  1  0
 16 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  2  0
 32 33  1  0
 33 34  2  0
 32 35  1  0
 31 36  1  0
 36 37  1  0
 36 38  1  0
 36 39  1  0
 11  6  1  0
 24 12  1  0
 22 13  2  0
 19 14  1  0
 34 29  1  0
M  END
>  <BrandName>  (20) 


>  <Applicants>  (20) 
Piramal Enterprises

>  <CHEMBL_ID>  (20) 
CHEMBL3545322

>  <Canonical_Smiles>  (20) 
CC(C)(C#N)c1ccc(cn1)n2c3c4cc(ccc4ncc3n(c2=NC#N)C)c5cc(c(nc5)N)C(F)(F)F

>  <Chirality>  (20) 
Single Stereoisomer

>  <First_Approval>  (20) 
nan

>  <Phase>  (20) 
1.0

>  <SC_Patent>  (20) 
None

>  <Synonyms>  (20) 


>  <Withdrawn>  (20) 


>  <Indications>  (20) 
nan

>  <Type>  (20) 
nan

>  <targets_id>  (20) 
P42336|P42345

>  <inchi>  (20) 
InChI=1S/C27H20F3N9/c1-26(2,13-31)22-7-5-17(11-35-22)39-23-18-8-15(16-9-19(27(28,29)30)24(33)36-10-16)4-6-20(18)34-12-21(23)38(3)25(39)37-14-32/h4-12H,1-3H3,(H2,33,36)

>  <stdInchikey>  (20) 
VJLRLTSXTLICIR-UHFFFAOYSA-N

>  <csid>  (20) 
29165869

>  <Links>  (20) 
|http://www.chemspider.com/Chemical-Structure.29165869.html|http://pubchem.ncbi.nlm.nih.gov/compound/56947515|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9916|http://zinc15.docking.org/substances/ZINC000301055099

>  <LinkName>  (20) 
|ChemSpider|PubChem|Guide to Pharmacology|ZINC

>  <lig_pdbID>  (20) 


>  <pdbID>  (20) 


>  <indicationG2P>  (20) 
None

>  <indicationDB>  (20) 


>  <uniprotId>  (20) 


>  <MW>  (20) 
527.2

>  <HBA>  (20) 
9.0

>  <HBD>  (20) 
1.0

>  <NRB>  (20) 
3.0

>  <TPSA>  (20) 
134.5

>  <LogP>  (20) 
4.8

>  <RoF>  (20) 
1.0

>  <Melting point>  (20) 


>  <Targets>  (20) 
PIK3CA; MTOR

>  <Kinase families>  (20) 
Atypical

>  <FDA_approved>  (20) 


$$$$
Elimusertib
     RDKit          2D

 28 32  0  0  0  0  0  0  0  0999 V2000
   -2.3227    3.1447    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9165    3.6667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6654    5.1455    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7409    5.6675    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.8961    4.7106    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6450    3.2318    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2387    2.7098    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0124    1.2310    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4187    0.7090    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6698   -0.7698    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5146   -1.7267    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7657   -3.2055    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3895   -4.1624    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7957   -3.6404    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0468   -2.1616    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8917   -1.2047    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1428    0.2741    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.4531   -1.6397    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8574   -0.1952    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3561   -0.1333    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8781   -1.5396    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.7019   -2.4705    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0760   -1.2918    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4803   -2.7363    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9790   -2.7981    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5010   -1.3919    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3249   -0.4609    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3867    1.0378    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 15 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 10 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  1  0
  7  2  1  0
 17  8  1  0
 16 11  1  0
 22 18  1  0
 27 23  1  0
M  END
>  <BrandName>  (21) 


>  <Applicants>  (21) 
Bayer

>  <CHEMBL_ID>  (21) 
nan

>  <Canonical_Smiles>  (21) 
CC1COCCN1c2cc(c3ccnc(c3n2)c4ccn[nH]4)c5ccnn5C

>  <Chirality>  (21) 
nan

>  <First_Approval>  (21) 
nan

>  <Phase>  (21) 
1.0

>  <SC_Patent>  (21) 
nan

>  <Synonyms>  (21) 
BAY 1895344||BAY1895344|BAY-1895344

>  <Withdrawn>  (21) 


>  <Indications>  (21) 
nan

>  <Type>  (21) 
nan

>  <targets_id>  (21) 
nan

>  <inchi>  (21) 
InChI=1S/C20H21N7O/c1-13-12-28-10-9-27(13)18-11-15(17-5-8-23-26(17)2)14-3-6-21-20(19(14)24-18)16-4-7-22-25-16/h3-8,11,13H,9-10,12H2,1-2H3,(H,22,25)

>  <stdInchikey>  (21) 
YBXRSCXGRPSTMW-UHFFFAOYSA-N

>  <csid>  (21) 
64879752

>  <Links>  (21) 
|http://www.chemspider.com/Chemical-Structure.64879752.html|http://pubchem.ncbi.nlm.nih.gov/compound/134446438

>  <LinkName>  (21) 
|ChemSpider|PubChem

>  <lig_pdbID>  (21) 


>  <pdbID>  (21) 


>  <indicationG2P>  (21) 


>  <indicationDB>  (21) 


>  <uniprotId>  (21) 


>  <MW>  (21) 
375.2

>  <HBA>  (21) 
7.0

>  <HBD>  (21) 
1.0

>  <NRB>  (21) 
3.0

>  <TPSA>  (21) 
84.8

>  <LogP>  (21) 
2.6

>  <RoF>  (21) 
0.0

>  <Melting point>  (21) 


>  <Targets>  (21) 
nan

>  <Kinase families>  (21) 


>  <FDA_approved>  (21) 


$$$$
Cenisertib
     RDKit          2D

 33 37  0  0  0  0  0  0  0  0999 V2000
    2.4709   -1.2306    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7372    0.2456    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5919    1.2143    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8582    2.6904    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2697    3.1979    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4150    2.2292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1487    0.7531    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2940   -0.2156    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.0277   -1.6918    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1730   -2.6605    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5845   -2.1530    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.8508   -0.6768    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7056    0.2919    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7298   -3.1217    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7129    3.6591    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6986    3.1516    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8439    4.1203    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2554    3.6128    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5217    2.1367    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3764    1.1680    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9649    1.6755    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6427   -0.3082    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0543   -0.8157    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2945    0.0280    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7870   -1.3836    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9727   -2.3024    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4734   -2.2559    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5545   -3.4416    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0683   -3.2387    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1219   -4.8301    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2129   -1.4587    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7938   -0.0185    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9332    1.6292    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 11 14  1  0
  4 15  1  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 20 22  1  0
 23 22  1  1
 23 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  1
 28 29  2  0
 28 30  1  0
 26 31  1  6
 31 32  2  0
 19 33  1  0
  7  2  1  0
 13  8  1  0
 21 16  1  0
 27 23  1  0
 24 32  1  6
M  END
>  <BrandName>  (22) 


>  <Applicants>  (22) 
EMD Serono

>  <CHEMBL_ID>  (22) 
CHEMBL1967878

>  <Canonical_Smiles>  (22) 
Cc1cc(ccc1N2CCN(CC2)C)Nc3ncc(c(n3)N[C@@H]4[C@@H]5C[C@H]([C@@H]4C(=O)N)C=C5)F

>  <Chirality>  (22) 
Racemic Mixture

>  <First_Approval>  (22) 
nan

>  <Phase>  (22) 
1.0

>  <SC_Patent>  (22) 
None

>  <Synonyms>  (22) 
AS-703569 | R-763

>  <Withdrawn>  (22) 


>  <Indications>  (22) 
nan

>  <Type>  (22) 
nan

>  <targets_id>  (22) 
O14965|Q96GD4|Q9UQB9

>  <inchi>  (22) 
InChI=1S/C24H30FN7O/c1-14-11-17(5-6-19(14)32-9-7-31(2)8-10-32)28-24-27-13-18(25)23(30-24)29-21-16-4-3-15(12-16)20(21)22(26)33/h3-6,11,13,15-16,20-21H,7-10,12H2,1-2H3,(H2,26,33)(H2,27,28,29,30)/t15-,16+,20+,21-/m1/s1

>  <stdInchikey>  (22) 
KSOVGRCOLZZTPF-QMKUDKLTSA-N

>  <csid>  (22) 
9744737

>  <Links>  (22) 
|http://www.chemspider.com/Chemical-Structure.9744737.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1614709|http://pubchem.ncbi.nlm.nih.gov/compound/11569967|http://www.drugbank.ca/drugs/DB06347|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9927|http://zinc15.docking.org/substances/ZINC000063298059|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=5277GPA358|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50389967

>  <LinkName>  (22) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (22) 


>  <pdbID>  (22) 


>  <indicationG2P>  (22) 
None

>  <indicationDB>  (22) 
Cenisertib is an aurora kinase inhibitor.

>  <uniprotId>  (22) 
O14965

>  <MW>  (22) 
451.2

>  <HBA>  (22) 
7.0

>  <HBD>  (22) 
3.0

>  <NRB>  (22) 
6.0

>  <TPSA>  (22) 
99.4

>  <LogP>  (22) 
2.5

>  <RoF>  (22) 
0.0

>  <Melting point>  (22) 


>  <Targets>  (22) 
AURKA; AURKB; AURKC

>  <Kinase families>  (22) 
Other

>  <FDA_approved>  (22) 


$$$$
Mubritinib
     RDKit          2D

 34 37  0  0  0  0  0  0  0  0999 V2000
    5.2394   -0.9781    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8161   -1.4517    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6944   -0.4560    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9958    1.0134    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4191    1.4871    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5409    0.4913    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9642    0.9649    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0860   -0.0309    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.5092    0.4427    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.6310   -0.5531    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.0543   -0.0795    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.5077    1.3504    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.0077    1.3610    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.4813   -0.0623    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   13.2740   -0.9525    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.2711   -0.9296    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.1493    0.0662    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2740   -0.4074    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7274   -1.8372    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2274   -1.8478    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7010   -0.4246    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4937    0.4657    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1308    0.0288    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2384   -0.9827    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6682   -0.5293    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9905    0.9357    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.4203    1.3891    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.5279    0.3775    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.2056   -1.0874    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7758   -1.5409    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.9577    0.8309    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -13.3875    1.2844    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  -11.5043    2.2608    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  -12.4111   -0.5989    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
  3 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  1  0
 21 22  2  0
 21 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 28 31  1  0
 31 32  1  0
 31 33  1  0
 31 34  1  0
  6  1  1  0
 15 11  1  0
 22 18  1  0
 30 25  1  0
M  END
>  <BrandName>  (23) 


>  <Applicants>  (23) 
Takeda

>  <CHEMBL_ID>  (23) 
CHEMBL1614707

>  <Canonical_Smiles>  (23) 
c1cc(ccc1CCCCn2ccnn2)OCc3coc(n3)/C=C/c4ccc(cc4)C(F)(F)F

>  <Chirality>  (23) 
Achiral Molecule

>  <First_Approval>  (23) 
nan

>  <Phase>  (23) 
1.0

>  <SC_Patent>  (23) 
None

>  <Synonyms>  (23) 
MUBRITINIB | TAK-165

>  <Withdrawn>  (23) 


>  <Indications>  (23) 
nan

>  <Type>  (23) 
nan

>  <targets_id>  (23) 
P00533|P04626

>  <inchi>  (23) 
InChI=1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+

>  <stdInchikey>  (23) 
ZTFBIUXIQYRUNT-MDWZMJQESA-N

>  <csid>  (23) 
4948554

>  <Links>  (23) 
|http://www.chemspider.com/Chemical-Structure.4948554.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1614707|http://pubchem.ncbi.nlm.nih.gov/compound/6444692|http://www.drugbank.ca/drugs/DB12682|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6011|http://zinc15.docking.org/substances/ZINC11679877|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=V734AZP9BR

>  <LinkName>  (23) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (23) 


>  <pdbID>  (23) 


>  <indicationG2P>  (23) 
None

>  <indicationDB>  (23) 


>  <uniprotId>  (23) 


>  <MW>  (23) 
468.2

>  <HBA>  (23) 
6.0

>  <HBD>  (23) 
0.0

>  <NRB>  (23) 
10.0

>  <TPSA>  (23) 
66.0

>  <LogP>  (23) 
6.1

>  <RoF>  (23) 
1.0

>  <Melting point>  (23) 


>  <Targets>  (23) 
EGFR; ERBB2

>  <Kinase families>  (23) 
Tyr

>  <FDA_approved>  (23) 


$$$$
Glumetinib
     RDKit          2D

 33 38  0  0  0  0  0  0  0  0999 V2000
   -9.5576    1.1752    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.0638    1.0387    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2961   -0.2499    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8333    0.0819    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7050   -0.9065    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9968   -2.3778    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8685   -3.3662    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4484   -2.8832    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1392   -3.6154    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0383   -2.5966    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6670   -1.2348    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0652    0.0744    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2440    0.8066    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.3743   -0.6578    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.7974    1.3835    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1686    2.7454    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2695    3.7642    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.5787    3.0320    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9988    3.5150    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1271    2.5266    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8353    1.0552    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9636    0.0668    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4264    0.3987    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1941   -0.8900    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.2057   -2.0183    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.5376   -3.4811    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8272   -1.4269    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4152    0.5723    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2869    1.5607    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1565   -1.4119    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2849   -0.4235    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6969    1.5757    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0754    2.1671    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  1  0
 12 13  2  0
 12 14  2  0
 12 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  1  0
 25 27  1  0
 21 28  2  0
 28 29  1  0
 11 30  1  0
 30 31  2  0
  4 32  1  0
 32 33  2  0
 33  2  1  0
 31  5  1  0
 30  8  1  0
 29 15  1  0
 29 18  1  0
 27 22  2  0
M  END
>  <BrandName>  (24) 


>  <Applicants>  (24) 
HaiHe Phaemaceutical

>  <CHEMBL_ID>  (24) 
CHEMBL4594400

>  <Canonical_Smiles>  (24) 
Cn1cc(-c2cnc3cnn(S(=O)(=O)c4cnc5ccc(-c6cnn(C)c6)cn45)c3c2)cn1

>  <Chirality>  (24) 
Achiral Molecule

>  <First_Approval>  (24) 
nan

>  <Phase>  (24) 
1.0

>  <SC_Patent>  (24) 
None

>  <Synonyms>  (24) 
GLUMETINIB

>  <Withdrawn>  (24) 


>  <Indications>  (24) 
nan

>  <Type>  (24) 
nan

>  <targets_id>  (24) 
nan

>  <inchi>  (24) 
InChI=1S/C21H17N9O2S/c1-27-11-16(7-24-27)14-3-4-20-23-10-21(29(20)13-14)33(31,32)30-19-5-15(6-22-18(19)9-26-30)17-8-25-28(2)12-17/h3-13H,1-2H3

>  <stdInchikey>  (24) 
RYBLECYFLJXEJX-UHFFFAOYSA-N

>  <csid>  (24) 
68006902

>  <Links>  (24) 
|http://www.chemspider.com/Chemical-Structure.68006902.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4594400|http://pubchem.ncbi.nlm.nih.gov/compound/117797905|http://www.drugbank.ca/drugs/DB15630|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=7JTT036WGX

>  <LinkName>  (24) 
|ChemSpider|ChEMBL|PubChem|DrugBank|FDA SRS

>  <lig_pdbID>  (24) 


>  <pdbID>  (24) 


>  <indicationG2P>  (24) 


>  <indicationDB>  (24) 


>  <uniprotId>  (24) 


>  <MW>  (24) 
459.1

>  <HBA>  (24) 
11.0

>  <HBD>  (24) 
0.0

>  <NRB>  (24) 
4.0

>  <TPSA>  (24) 
117.8

>  <LogP>  (24) 
2.1

>  <RoF>  (24) 
1.0

>  <Melting point>  (24) 


>  <Targets>  (24) 
nan

>  <Kinase families>  (24) 


>  <FDA_approved>  (24) 


$$$$
Alofanib
     RDKit          2D

 29 31  0  0  0  0  0  0  0  0999 V2000
   -5.3958    0.4642    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9463    0.8500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5557    2.2983    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1062    2.6841    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7156    4.1324    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7745    5.1948    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2660    4.5183    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0472    1.6218    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4023    2.0076    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.4612    0.9452    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.3988   -0.1137    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.5236    2.0041    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.5201   -0.1172    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1295   -1.5654    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1884   -2.6278    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6380   -2.2420    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0286   -0.7937    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4781   -0.4079    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8687    1.0404    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.5370   -1.4703    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.9696    0.2687    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4378    0.1735    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8874   -0.2124    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2780   -1.6606    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7275   -2.0465    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1181   -3.4947    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0592   -4.5571    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6096   -4.1713    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2190   -2.7230    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  1  0
  5  6  2  0
  5  7  1  0
  4  8  2  0
  8  9  1  0
  9 10  1  0
 10 11  2  0
 10 12  2  0
 10 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  1  0
 18 19  2  0
 18 20  1  0
 17 21  2  0
  8 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 23  2  1  0
 29 24  1  0
 21 13  1  0
M  CHG  2   5   1   7  -1
M  END
>  <BrandName>  (25) 


>  <Applicants>  (25) 
Russian Pharmaceutical Technologies

>  <CHEMBL_ID>  (25) 
CHEMBL4594436

>  <Canonical_Smiles>  (25) 
Cc1cc([N+](=O)[O-])c(NS(=O)(=O)c2cccc(C(=O)O)c2)cc1-c1cccnc1

>  <Chirality>  (25) 
Achiral Molecule

>  <First_Approval>  (25) 
nan

>  <Phase>  (25) 
1.0

>  <SC_Patent>  (25) 
None

>  <Synonyms>  (25) 
ALOFANIB

>  <Withdrawn>  (25) 


>  <Indications>  (25) 
nan

>  <Type>  (25) 
nan

>  <targets_id>  (25) 
nan

>  <inchi>  (25) 
InChI=1S/C19H15N3O6S/c1-12-8-18(22(25)26)17(10-16(12)14-5-3-7-20-11-14)21-29(27,28)15-6-2-4-13(9-15)19(23)24/h2-11,21H,1H3,(H,23,24)

>  <stdInchikey>  (25) 
QUQGQIASFYWKAB-UHFFFAOYSA-N

>  <csid>  (25) 
44208820

>  <Links>  (25) 
|http://www.chemspider.com/Chemical-Structure.44208820.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4594436|http://pubchem.ncbi.nlm.nih.gov/compound/86280646|http://zinc15.docking.org/substances/ZINC000219244618|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=LQX7RFK8MZ

>  <LinkName>  (25) 
|ChemSpider|ChEMBL|PubChem|ZINC|FDA SRS

>  <lig_pdbID>  (25) 


>  <pdbID>  (25) 


>  <indicationG2P>  (25) 


>  <indicationDB>  (25) 


>  <uniprotId>  (25) 


>  <MW>  (25) 
413.1

>  <HBA>  (25) 
6.0

>  <HBD>  (25) 
2.0

>  <NRB>  (25) 
6.0

>  <TPSA>  (25) 
139.5

>  <LogP>  (25) 
3.5

>  <RoF>  (25) 
0.0

>  <Melting point>  (25) 


>  <Targets>  (25) 
nan

>  <Kinase families>  (25) 


>  <FDA_approved>  (25) 


$$$$
Henatinib
     RDKit          2D

 34 38  0  0  0  0  0  0  0  0999 V2000
    1.2445   -2.8037    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2210   -1.3039    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4206   -0.4033    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9347    1.0159    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.4349    0.9924    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0062   -0.4413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4021   -0.9903    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5131   -2.4862    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7017   -0.2412    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9263    1.2418    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9068    2.3421    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4109    2.2311    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9404   -1.0871    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2924   -0.4373    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5311   -1.2831    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.8830   -0.6333    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9962    0.8625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.3481    1.5123    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.5869    0.6665    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  -10.4737   -0.8293    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.1218   -1.4791    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4055    1.0585    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.8542   -0.8444    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9531    0.1767    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4250   -0.1122    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1953   -1.3993    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6951   -1.3758    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4247   -0.0651    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6544    1.2220    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1546    1.1985    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1335    2.2973    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.7729    1.6658    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4623    2.3954    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.4654   -2.6629    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  7  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
  9 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  1  0
 14 22  1  1
  3 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  1  0
 32 33  2  0
 27 34  1  0
  6  2  1  0
 12  5  1  0
 21 16  1  0
 24 32  1  0
 30 25  1  0
M  END
>  <BrandName>  (26) 


>  <Applicants>  (26) 
Jiangsu Hengrui Medicine

>  <CHEMBL_ID>  (26) 
CHEMBL3545416

>  <Canonical_Smiles>  (26) 
Cc1c([nH]c2c1C(=O)N(CCC2)C[C@@H](CN3CCOCC3)O)/C=C\4/c5cc(ccc5NC4=O)F

>  <Chirality>  (26) 
Single Stereoisomer

>  <First_Approval>  (26) 
nan

>  <Phase>  (26) 
1.0

>  <SC_Patent>  (26) 
None

>  <Synonyms>  (26) 


>  <Withdrawn>  (26) 


>  <Indications>  (26) 
nan

>  <Type>  (26) 
nan

>  <targets_id>  (26) 
P35968

>  <inchi>  (26) 
InChI=1S/C25H29FN4O4/c1-15-22(12-19-18-11-16(26)4-5-20(18)28-24(19)32)27-21-3-2-6-30(25(33)23(15)21)14-17(31)13-29-7-9-34-10-8-29/h4-5,11-12,17,27,31H,2-3,6-10,13-14H2,1H3,(H,28,32)/b19-12-/t17-/m1/s1

>  <stdInchikey>  (26) 
MCTXSDCWFQAGFS-UEXNTNOUSA-N

>  <csid>  (26) 
26354883

>  <Links>  (26) 
|http://www.chemspider.com/Chemical-Structure.26354883.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1277072|http://pubchem.ncbi.nlm.nih.gov/compound/25116064|http://www.drugbank.ca/drugs/DB13019|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9930|http://zinc15.docking.org/substances/ZINC000064454147|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=TE20GB753F|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50331032

>  <LinkName>  (26) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (26) 


>  <pdbID>  (26) 


>  <indicationG2P>  (26) 
None

>  <indicationDB>  (26) 


>  <uniprotId>  (26) 


>  <MW>  (26) 
468.2

>  <HBA>  (26) 
5.0

>  <HBD>  (26) 
3.0

>  <NRB>  (26) 
5.0

>  <TPSA>  (26) 
97.9

>  <LogP>  (26) 
2.0

>  <RoF>  (26) 
0.0

>  <Melting point>  (26) 


>  <Targets>  (26) 
KDR

>  <Kinase families>  (26) 
Tyr

>  <FDA_approved>  (26) 


$$$$
Allitinib
     RDKit          2D

 32 35  0  0  0  0  0  0  0  0999 V2000
  -10.1922   -3.2857    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.6939   -3.2149    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.0061   -1.8819    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.8165   -0.6197    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5077   -1.8111    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8199   -0.4781    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6303    0.7841    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9425    2.1170    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4441    2.1878    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6337    0.9256    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3215   -0.4074    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1353    0.9964    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4475    2.3294    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2579    3.5916    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7563    3.5208    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3249   -0.2658    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.1735   -0.1950    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9839   -1.4572    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4823   -1.3864    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1701   -0.0534    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3597    1.2088    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8613    1.1380    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0475    2.5417    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    4.6684    0.0173    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.4789   -1.2449    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9772   -1.1741    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7877   -2.4363    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2860   -2.3655    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9739   -1.0325    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1634    0.2297    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6651    0.1589    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8513    1.5627    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  3  5  1  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 10 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 12 16  1  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 21 23  1  0
 20 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 30 32  1  0
 11  6  1  0
 15  9  1  0
 22 17  1  0
 31 26  1  0
M  END
>  <BrandName>  (27) 


>  <Applicants>  (27) 
Allist Pharmaceuticals

>  <CHEMBL_ID>  (27) 
CHEMBL3545244

>  <Canonical_Smiles>  (27) 
C=CC(=O)Nc1ccc2c(c1)c(ncn2)Nc3ccc(c(c3)Cl)OCc4cccc(c4)F

>  <Chirality>  (27) 
Single Stereoisomer

>  <First_Approval>  (27) 
nan

>  <Phase>  (27) 
1.0

>  <SC_Patent>  (27) 
None

>  <Synonyms>  (27) 
ALL-3 | AST-1306

>  <Withdrawn>  (27) 


>  <Indications>  (27) 
nan

>  <Type>  (27) 
nan

>  <targets_id>  (27) 
P04626|P00533

>  <inchi>  (27) 
InChI=1S/C24H18ClFN4O2/c1-2-23(31)29-17-6-8-21-19(11-17)24(28-14-27-21)30-18-7-9-22(20(25)12-18)32-13-15-4-3-5-16(26)10-15/h2-12,14H,1,13H2,(H,29,31)(H,27,28,30)

>  <stdInchikey>  (27) 
MVZGYPSXNDCANY-UHFFFAOYSA-N

>  <csid>  (27) 
25027184

>  <Links>  (27) 
|http://www.chemspider.com/Chemical-Structure.25027184.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1947204|http://pubchem.ncbi.nlm.nih.gov/compound/24739943|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9912|http://zinc15.docking.org/substances/ZINC000052509434|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=CX0M5RO7CY

>  <LinkName>  (27) 
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (27) 


>  <pdbID>  (27) 


>  <indicationG2P>  (27) 
None

>  <indicationDB>  (27) 


>  <uniprotId>  (27) 


>  <MW>  (27) 
448.1

>  <HBA>  (27) 
5.0

>  <HBD>  (27) 
2.0

>  <NRB>  (27) 
7.0

>  <TPSA>  (27) 
76.1

>  <LogP>  (27) 
5.9

>  <RoF>  (27) 
1.0

>  <Melting point>  (27) 


>  <Targets>  (27) 
ERBB2; EGFR

>  <Kinase families>  (27) 
Tyr

>  <FDA_approved>  (27) 


$$$$
Agerafenib
     RDKit          2D

 37 40  0  0  0  0  0  0  0  0999 V2000
    7.4221    0.0068    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6923   -1.3036    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9624   -2.6141    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3818   -0.5738    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2019    0.9154    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7301    1.2045    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0002   -0.1060    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.0211   -1.2051    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.0988    2.5652    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.6048    2.6989    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7420    1.4719    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.9736    4.0596    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5204    4.1933    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1517    5.5540    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6457    5.6878    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5085    4.4607    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8773    3.1000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3832    2.9663    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7401    1.8730    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1089    0.5123    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9717   -0.7147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4657   -0.5810    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3285   -1.8080    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6973   -3.1688    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2032   -3.3025    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3404   -2.0755    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8464   -2.2092    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9836   -0.9821    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6148    0.3786    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5601   -4.3958    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9288   -5.7565    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.8225   -1.6743    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4537   -0.3136    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0027   -2.0335    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3132   -2.7633    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    8.7326   -0.7230    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    7.2729   -3.3439    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  6  9  1  0
  9 10  1  0
 10 11  2  0
 10 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 17 19  1  0
 19 20  1  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 24 30  1  0
 30 31  1  0
 23 32  1  0
 32 33  1  0
  2 34  1  0
 34 35  1  0
 34 36  1  0
 34 37  1  0
  8  4  1  0
 18 13  1  0
 29 20  2  0
 26 21  1  0
M  END
>  <BrandName>  (28) 


>  <Applicants>  (28) 
Ignyta

>  <CHEMBL_ID>  (28) 
CHEMBL2029988

>  <Canonical_Smiles>  (28) 
CC(C)(c1cc(no1)NC(=O)Nc2cccc(c2)Oc3c4cc(c(cc4ncn3)OC)OC)C(F)(F)F

>  <Chirality>  (28) 
Achiral Molecule

>  <First_Approval>  (28) 
nan

>  <Phase>  (28) 
1.0

>  <SC_Patent>  (28) 
None

>  <Synonyms>  (28) 
AB-024 | AC-013773 | AGERAFENIB | CEP-32496 | RXDX 105 | RXDX-105

>  <Withdrawn>  (28) 


>  <Indications>  (28) 
nan

>  <Type>  (28) 
nan

>  <targets_id>  (28) 
nan

>  <inchi>  (28) 
InChI=1S/C24H22F3N5O5/c1-23(2,24(25,26)27)19-11-20(32-37-19)31-22(33)30-13-6-5-7-14(8-13)36-21-15-9-17(34-3)18(35-4)10-16(15)28-12-29-21/h5-12H,1-4H3,(H2,30,31,32,33)

>  <stdInchikey>  (28) 
DKNUPRMJNUQNHR-UHFFFAOYSA-N

>  <csid>  (28) 
28506650

>  <Links>  (28) 
|http://www.chemspider.com/Chemical-Structure.28506650.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2029988|http://pubchem.ncbi.nlm.nih.gov/compound/56846693|http://www.drugbank.ca/drugs/DB15068|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7880|http://zinc15.docking.org/substances/ZINC000043207440|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=78I4VEX88N|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50382959

>  <LinkName>  (28) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (28) 


>  <pdbID>  (28) 


>  <indicationG2P>  (28) 
None

>  <indicationDB>  (28) 


>  <uniprotId>  (28) 


>  <MW>  (28) 
517.2

>  <HBA>  (28) 
8.0

>  <HBD>  (28) 
2.0

>  <NRB>  (28) 
7.0

>  <TPSA>  (28) 
120.6

>  <LogP>  (28) 
5.9

>  <RoF>  (28) 
2.0

>  <Melting point>  (28) 


>  <Targets>  (28) 
nan

>  <Kinase families>  (28) 


>  <FDA_approved>  (28) 


$$$$
Dubermatinib
     RDKit          2D

 35 38  0  0  0  0  0  0  0  0999 V2000
   -9.6076   -3.4404    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.8712   -2.1337    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -9.6346   -0.8425    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.8982    0.4643    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3982    0.4799    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6348   -0.8113    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3712   -2.1181    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6618    1.7866    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1619    1.8022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3984    0.5110    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8985    0.5266    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1620    1.8334    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9255    3.1246    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4254    3.1090    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6621    1.8490    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.1014    0.5578    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6351   -0.7489    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.1284   -2.0401    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6283   -2.0245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3647   -0.7178    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6013    0.5734    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.8646   -0.7022    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.6011    0.6046    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8376    1.8958    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5741    3.2025    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0740    3.2181    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8375    1.9269    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1010    0.6202    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8645   -0.6710    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    8.1557    0.0925    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.5733   -1.4345    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.6279   -1.9622    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.1279   -1.9466    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8915   -3.2689    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3917   -3.3157    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  5  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 12 15  1  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 20 22  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 29 31  2  0
 29 32  1  0
 32 33  1  0
 32 34  1  0
 19 35  1  0
  7  2  1  0
 14  9  1  0
 21 16  1  0
 28 23  1  0
M  END
>  <BrandName>  (29) 


>  <Applicants>  (29) 
Tolero Pharmaceuticals

>  <CHEMBL_ID>  (29) 
CHEMBL2022968

>  <Canonical_Smiles>  (29) 
CN1CCN(CC1)Cc2ccc(cc2)Nc3ncc(c(n3)Nc4ccccc4S(=O)(=O)N(C)C)Cl

>  <Chirality>  (29) 
Achiral Molecule

>  <First_Approval>  (29) 
nan

>  <Phase>  (29) 
1.5

>  <SC_Patent>  (29) 
None

>  <Synonyms>  (29) 
DUBERMATINIB | HCL-2084 | TP 0903 | TP-0903 | TP0903

>  <Withdrawn>  (29) 


>  <Indications>  (29) 
nan

>  <Type>  (29) 
nan

>  <targets_id>  (29) 
nan

>  <inchi>  (29) 
InChI=1S/C24H30ClN7O2S/c1-30(2)35(33,34)22-7-5-4-6-21(22)28-23-20(25)16-26-24(29-23)27-19-10-8-18(9-11-19)17-32-14-12-31(3)13-15-32/h4-11,16H,12-15,17H2,1-3H3,(H2,26,27,28,29)

>  <stdInchikey>  (29) 
YUAALFPUEOYPNX-UHFFFAOYSA-N

>  <csid>  (29) 
28516684

>  <Links>  (29) 
|http://www.chemspider.com/Chemical-Structure.28516684.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2022968|http://pubchem.ncbi.nlm.nih.gov/compound/56839178|http://www.drugbank.ca/drugs/DB15187|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8863|http://zinc15.docking.org/substances/ZINC000084617535|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=14D65TV20J|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50382425

>  <LinkName>  (29) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (29) 


>  <pdbID>  (29) 


>  <indicationG2P>  (29) 
None

>  <indicationDB>  (29) 


>  <uniprotId>  (29) 


>  <MW>  (29) 
515.2

>  <HBA>  (29) 
8.0

>  <HBD>  (29) 
2.0

>  <NRB>  (29) 
8.0

>  <TPSA>  (29) 
93.7

>  <LogP>  (29) 
3.6

>  <RoF>  (29) 
1.0

>  <Melting point>  (29) 


>  <Targets>  (29) 
nan

>  <Kinase families>  (29) 


>  <FDA_approved>  (29) 


$$$$
Selitrectinib
     RDKit          2D

 28 32  0  0  0  0  0  0  0  0999 V2000
    1.2118   -5.1741    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9538   -3.6964    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5426   -3.5933    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8197   -2.8065    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5849   -1.5163    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6629   -0.0184    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9991    0.6631    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2574   -0.1534    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1795   -1.6514    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8432   -2.3328    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5937    0.5281    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0358    1.3443    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2733    2.1918    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8497    3.6308    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3503    3.6725    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8472    2.2594    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.6304    2.5173    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3588    3.5248    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8349    3.2579    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3417    1.8461    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.1104    0.9895    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0587    2.0590    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.5446   -0.4463    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0443   -0.4771    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5369    0.9397    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.2618   -1.9194    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6244   -2.5465    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.3268   -3.0924    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  6
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
  8 11  1  0
  6 12  1  0
 12 13  1  1
 13 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 21 23  2  0
 23 24  1  0
 24 25  2  0
 23 26  1  0
 26 27  2  0
 26 28  1  0
 28  2  1  0
 10  5  1  0
 16 12  1  0
 22 17  2  0
 25 20  1  0
M  END
>  <BrandName>  (30) 


>  <Applicants>  (30) 
Bayer

>  <CHEMBL_ID>  (30) 
CHEMBL4297627

>  <Canonical_Smiles>  (30) 
C[C@@H]1CCc2c(cc(cn2)F)[C@H]3CCCN3c4ccn5c(n4)c(cn5)C(=O)N1

>  <Chirality>  (30) 
Single Stereoisomer

>  <First_Approval>  (30) 
nan

>  <Phase>  (30) 
1.5

>  <SC_Patent>  (30) 
None

>  <Synonyms>  (30) 
LOXO-195 | SELITRECTINIB

>  <Withdrawn>  (30) 


>  <Indications>  (30) 
nan

>  <Type>  (30) 
nan

>  <targets_id>  (30) 
nan

>  <inchi>  (30) 
InChI=1S/C20H21FN6O/c1-12-4-5-16-14(9-13(21)10-22-16)17-3-2-7-26(17)18-6-8-27-19(25-18)15(11-23-27)20(28)24-12/h6,8-12,17H,2-5,7H2,1H3,(H,24,28)/t12-,17-/m1/s1

>  <stdInchikey>  (30) 
OEBIHOVSAMBXIB-SJKOYZFVSA-N

>  <csid>  (30) 
64853862

>  <Links>  (30) 
|http://www.chemspider.com/Chemical-Structure.64853862.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297627|http://pubchem.ncbi.nlm.nih.gov/compound/129103609|http://www.drugbank.ca/drugs/DB14896|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10314|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=0J45910S3X

>  <LinkName>  (30) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS

>  <lig_pdbID>  (30) 


>  <pdbID>  (30) 


>  <indicationG2P>  (30) 
None

>  <indicationDB>  (30) 


>  <uniprotId>  (30) 


>  <MW>  (30) 
380.2

>  <HBA>  (30) 
6.0

>  <HBD>  (30) 
1.0

>  <NRB>  (30) 
0.0

>  <TPSA>  (30) 
75.4

>  <LogP>  (30) 
2.7

>  <RoF>  (30) 
0.0

>  <Melting point>  (30) 


>  <Targets>  (30) 
nan

>  <Kinase families>  (30) 


>  <FDA_approved>  (30) 


$$$$
Ningetinib
     RDKit          2D

 41 45  0  0  0  0  0  0  0  0999 V2000
   -5.2884   -2.9213    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1066   -1.6641    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5704   -0.2632    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7371    0.6796    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6600    2.1776    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9943   -0.1386    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6046   -1.5871    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.5474   -2.7537    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.3952    0.3976    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.6313    1.8789    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.0322    2.4151    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -12.1970    1.4700    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.9608   -0.0113    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.5599   -0.5475    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1219    0.1264    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7351    1.5757    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0602   -0.9332    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6117   -0.5435    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5500   -1.6032    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8985   -1.2135    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2853    0.2358    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2236    1.2954    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2249    0.9057    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6104    2.7446    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    2.7338    0.6254    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.7955   -0.4342    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4087   -1.8835    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4704   -2.9431    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9189   -2.5535    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.3057   -1.1042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2440   -0.0446    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6308    1.4047    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0793    1.7943    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1410    0.7347    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7542   -0.7145    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.5896    1.1244    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.6513    0.0648    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.0998    0.4544    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.7101    1.9029    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.4894   -0.9941    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.5483    0.8441    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  4  6  1  0
  6  7  1  0
  7  8  1  0
  6  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
  3 15  1  0
 15 16  2  0
 15 17  1  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 22 24  1  0
 21 25  1  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 32 33  2  0
 33 34  1  0
 34 35  2  0
 34 36  1  0
 36 37  1  0
 37 38  1  0
 38 39  1  0
 38 40  1  0
 38 41  1  0
  7  2  1  0
 14  9  1  0
 23 18  1  0
 31 26  1  0
 35 30  1  0
M  END
>  <BrandName>  (31) 


>  <Applicants>  (31) 
HEC Pharm

>  <CHEMBL_ID>  (31) 
nan

>  <Canonical_Smiles>  (31) 
Cc1c(c(=O)n(n1C)c2ccccc2)C(=O)Nc3ccc(c(c3)F)Oc4ccnc5c4ccc(c5)OCC(C)(C)O

>  <Chirality>  (31) 
nan

>  <First_Approval>  (31) 
nan

>  <Phase>  (31) 
1.5

>  <SC_Patent>  (31) 
nan

>  <Synonyms>  (31) 


>  <Withdrawn>  (31) 


>  <Indications>  (31) 
Ningetinib, also known as CT-053 or DE-120, is a VEGF and PDGF inhibitor potentially for the treatment of wet age-related macular degeneration.

>  <Type>  (31) 
nan

>  <targets_id>  (31) 
nan

>  <inchi>  (31) 
InChI=1S/C31H29FN4O5/c1-19-28(30(38)36(35(19)4)21-8-6-5-7-9-21)29(37)34-20-10-13-27(24(32)16-20)41-26-14-15-33-25-17-22(11-12-23(25)26)40-18-31(2,3)39/h5-17,39H,18H2,1-4H3,(H,34,37)

>  <stdInchikey>  (31) 
VQYYQSZNRVQLIS-UHFFFAOYSA-N

>  <csid>  (31) 
61719564

>  <Links>  (31) 
|http://www.chemspider.com/Chemical-Structure.61719564.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3984441|http://pubchem.ncbi.nlm.nih.gov/compound/60165029|http://www.drugbank.ca/drugs/DB16256|http://zinc15.docking.org/substances/ZINC000143426755|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=PW3Q92Z6A4|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=180270

>  <LinkName>  (31) 
|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (31) 


>  <pdbID>  (31) 


>  <indicationG2P>  (31) 


>  <indicationDB>  (31) 


>  <uniprotId>  (31) 


>  <MW>  (31) 
556.2

>  <HBA>  (31) 
8.0

>  <HBD>  (31) 
2.0

>  <NRB>  (31) 
8.0

>  <TPSA>  (31) 
107.6

>  <LogP>  (31) 
5.4

>  <RoF>  (31) 
2.0

>  <Melting point>  (31) 


>  <Targets>  (31) 
nan

>  <Kinase families>  (31) 


>  <FDA_approved>  (31) 


$$$$
Lerociclib
     RDKit          2D

 35 40  0  0  0  0  0  0  0  0999 V2000
   10.6116   -2.1083    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1439   -0.6830    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1444    0.4346    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6758   -0.3754    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.6753   -1.4930    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2072   -1.1854    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7396    0.2399    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.7400    1.3575    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2081    1.0498    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2714    0.5475    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8038    1.9727    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3357    2.2803    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3352    1.1627    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8029   -0.2625    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.2710   -0.5701    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1329    1.4704    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1334    0.3527    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6657   -1.0725    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6662   -2.1901    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1343   -1.8825    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3453   -2.7677    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5614   -1.8895    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1020   -0.4616    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6020   -0.4572    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6015    0.6604    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1089    0.6502    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6426    0.9663    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1832    2.3943    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1901    3.5061    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6564    3.1900    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1158    1.7621    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5752    0.3341    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.0346   -1.0938    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0277   -2.2056    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4871   -3.6335    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  7 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 13 16  1  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  1  0
 24 25  2  0
 23 26  1  0
 26 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
 26 32  1  0
 32 33  1  0
 33 34  1  0
 34 35  2  0
  9  4  1  0
 15 10  1  0
 25 17  1  0
 24 20  1  0
 34 22  1  0
 31 26  1  0
M  END
>  <BrandName>  (32) 


>  <Applicants>  (32) 
G1 Therapeutics

>  <CHEMBL_ID>  (32) 
CHEMBL3904602

>  <Canonical_Smiles>  (32) 
CC(C)N1CCN(CC1)c2ccc(nc2)Nc3ncc4cc5n(c4n3)C6(CCCCC6)CNC5=O

>  <Chirality>  (32) 
Achiral Molecule

>  <First_Approval>  (32) 
nan

>  <Phase>  (32) 
1.5

>  <SC_Patent>  (32) 
None

>  <Synonyms>  (32) 
G1T38 | G1T38 FREE BASE | LEROCICLIB

>  <Withdrawn>  (32) 


>  <Indications>  (32) 
nan

>  <Type>  (32) 
nan

>  <targets_id>  (32) 
nan

>  <inchi>  (32) 
InChI=1S/C26H34N8O/c1-18(2)32-10-12-33(13-11-32)20-6-7-22(27-16-20)30-25-28-15-19-14-21-24(35)29-17-26(8-4-3-5-9-26)34(21)23(19)31-25/h6-7,14-16,18H,3-5,8-13,17H2,1-2H3,(H,29,35)(H,27,28,30,31)

>  <stdInchikey>  (32) 
YPJRHEKCFKOVRT-UHFFFAOYSA-N

>  <csid>  (32) 
68007293

>  <Links>  (32) 
|http://www.chemspider.com/Chemical-Structure.68007293.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3904602|http://pubchem.ncbi.nlm.nih.gov/compound/86269224|http://www.drugbank.ca/drugs/DB16218|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10313|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=WBH8AY6ENB|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=253941

>  <LinkName>  (32) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB

>  <lig_pdbID>  (32) 


>  <pdbID>  (32) 


>  <indicationG2P>  (32) 
None

>  <indicationDB>  (32) 


>  <uniprotId>  (32) 


>  <MW>  (32) 
474.3

>  <HBA>  (32) 
8.0

>  <HBD>  (32) 
2.0

>  <NRB>  (32) 
4.0

>  <TPSA>  (32) 
91.2

>  <LogP>  (32) 
3.5

>  <RoF>  (32) 
0.0

>  <Melting point>  (32) 


>  <Targets>  (32) 
nan

>  <Kinase families>  (32) 


>  <FDA_approved>  (32) 


$$$$
Decernotinib
     RDKit          2D

 28 30  0  0  0  0  0  0  0  0999 V2000
   -3.4226    0.6104    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1004   -0.0980    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0527   -1.5972    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0050   -3.0964    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5520   -1.6449    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2603   -2.9671    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3429   -0.3704    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8421   -0.4181    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6331    0.8565    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4240    2.1310    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9076    0.0656    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3585    1.6474    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5535   -1.5495    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.1548   -0.2273    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6361    1.0472    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0722    2.3695    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5715    2.4172    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.3624    1.1426    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6541   -0.1796    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.8616    1.1903    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7043    2.4313    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1449    2.0133    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.1926    0.5141    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7814    0.0054    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5164   -1.4709    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6625   -2.4387    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0736   -1.9300    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3386   -0.4537    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  6
  3  5  1  0
  5  6  2  0
  5  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
  9 11  1  0
  9 12  1  0
  3 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 18 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 19 14  1  0
 24 20  1  0
 28 23  1  0
M  END
>  <BrandName>  (33) 


>  <Applicants>  (33) 
Vertex Pharmaceuticals

>  <CHEMBL_ID>  (33) 
CHEMBL3039513

>  <Canonical_Smiles>  (33) 
CC[C@](C)(C(=O)NCC(F)(F)F)Nc1ccnc(n1)c2c[nH]c3c2cccn3

>  <Chirality>  (33) 
Single Stereoisomer

>  <First_Approval>  (33) 
nan

>  <Phase>  (33) 
2.0

>  <SC_Patent>  (33) 
None

>  <Synonyms>  (33) 
ADELATINIB | DECERNOTINIB | VRT-831509 | VX-509

>  <Withdrawn>  (33) 


>  <Indications>  (33) 
nan

>  <Type>  (33) 
1

>  <targets_id>  (33) 
P52333

>  <inchi>  (33) 
InChI=1S/C18H19F3N6O/c1-3-17(2,16(28)25-10-18(19,20)21)27-13-6-8-23-15(26-13)12-9-24-14-11(12)5-4-7-22-14/h4-9H,3,10H2,1-2H3,(H,22,24)(H,25,28)(H,23,26,27)/t17-/m1/s1

>  <stdInchikey>  (33) 
ASUGUQWIHMTFJL-QGZVFWFLSA-N

>  <csid>  (33) 
30843790

>  <Links>  (33) 
|http://www.chemspider.com/Chemical-Structure.30843790.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3039513|http://pubchem.ncbi.nlm.nih.gov/compound/59422203|http://www.drugbank.ca/drugs/DB12566| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=VJK|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/VJK|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8309|http://zinc15.docking.org/substances/ZINC000096941867|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=MZK2GP0RHK|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50021655

>  <LinkName>  (33) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (33) 
'VJK'

>  <pdbID>  (33) 
4yti

>  <indicationG2P>  (33) 
None

>  <indicationDB>  (33) 


>  <uniprotId>  (33) 


>  <MW>  (33) 
392.2

>  <HBA>  (33) 
5.0

>  <HBD>  (33) 
3.0

>  <NRB>  (33) 
6.0

>  <TPSA>  (33) 
95.6

>  <LogP>  (33) 
3.3

>  <RoF>  (33) 
0.0

>  <Melting point>  (33) 


>  <Targets>  (33) 
JAK3

>  <Kinase families>  (33) 
Tyr

>  <FDA_approved>  (33) 


$$$$
Seletalisib
     RDKit          2D

 34 38  0  0  0  0  0  0  0  0999 V2000
    6.7285   -1.3616    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3533   -1.9606    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1470   -1.0692    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7718   -1.6682    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5654   -0.7767    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7343    0.7137    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1095    1.3127    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.3158    0.4213    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6910    1.0203    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8974    0.1288    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8599    2.5108    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    0.5279    1.6052    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8473    1.0062    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0537    1.8976    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8848    3.3881    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5096    3.9871    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.6968    3.0957    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3408    5.4776    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.1902   -1.3757    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0214   -2.8662    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1475   -4.3567    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4691   -2.6974    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    1.5118   -3.0351    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0161   -0.4843    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3914   -1.0833    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5977   -0.1918    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9729   -0.7908    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1793    0.1006    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0104    1.5911    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6352    2.1901    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4289    1.2986    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1418   -2.2813    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9354   -3.1728    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5602   -2.5738    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
  9 11  1  0
  6 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 16 18  1  0
  5 19  1  0
 19 20  1  0
 20 21  1  0
 20 22  1  0
 20 23  1  0
 19 24  1  6
 24 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 27 32  1  0
 32 33  2  0
 33 34  1  0
 10  1  1  0
  8  3  1  0
 17 12  1  0
 34 25  2  0
 31 26  2  0
M  CHG  2  16   1  18  -1
M  END
>  <BrandName>  (34) 


>  <Applicants>  (34) 
UCB

>  <CHEMBL_ID>  (34) 
CHEMBL4297648

>  <Canonical_Smiles>  (34) 
c1cc2cc(c(nc2c(c1)Cl)c3ccc[n+](c3)[O-])[C@H](C(F)(F)F)Nc4c5c(cccn5)ncn4

>  <Chirality>  (34) 
Single Stereoisomer

>  <First_Approval>  (34) 
nan

>  <Phase>  (34) 
2.0

>  <SC_Patent>  (34) 
None

>  <Synonyms>  (34) 
SELETALISIB | UCB-5857 | UCB5857

>  <Withdrawn>  (34) 


>  <Indications>  (34) 
nan

>  <Type>  (34) 
nan

>  <targets_id>  (34) 
nan

>  <inchi>  (34) 
InChI=1S/C23H14ClF3N6O/c24-16-6-1-4-13-10-15(18(31-19(13)16)14-5-3-9-33(34)11-14)21(23(25,26)27)32-22-20-17(29-12-30-22)7-2-8-28-20/h1-12,21H,(H,29,30,32)/t21-/m1/s1

>  <stdInchikey>  (34) 
LNLJHGXOFYUARS-OAQYLSRUSA-N

>  <csid>  (34) 
34985875

>  <Links>  (34) 
|http://www.chemspider.com/Chemical-Structure.34985875.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297648|http://pubchem.ncbi.nlm.nih.gov/compound/56928390|http://www.drugbank.ca/drugs/DB12706|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9800|http://zinc15.docking.org/substances/ZINC000144763934|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=64CW205BDD

>  <LinkName>  (34) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (34) 


>  <pdbID>  (34) 


>  <indicationG2P>  (34) 
None

>  <indicationDB>  (34) 


>  <uniprotId>  (34) 


>  <MW>  (34) 
482.1

>  <HBA>  (34) 
6.0

>  <HBD>  (34) 
1.0

>  <NRB>  (34) 
4.0

>  <TPSA>  (34) 
90.5

>  <LogP>  (34) 
5.2

>  <RoF>  (34) 
1.0

>  <Melting point>  (34) 


>  <Targets>  (34) 
nan

>  <Kinase families>  (34) 


>  <FDA_approved>  (34) 


$$$$
Foslinanib
     RDKit          2D

 25 27  0  0  0  0  0  0  0  0999 V2000
    5.1788   -2.7093    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4959   -1.3738    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.9978   -1.2974    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1827   -2.5566    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6846   -2.4803    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0017   -1.1447    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8169    0.1144    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3149    0.0381    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1301    1.2973    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.6282    1.2209    0.0000 P   0  0  0  0  0  0  0  0  0  0  0  0
    4.7045    2.7190    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.5518   -0.2772    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.1262    1.1445    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.1340    1.4500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9491    2.7092    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3641    1.5263    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1792    0.2672    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4963   -1.0684    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6773    0.3435    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3602    1.6791    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8582    1.7554    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6734    0.4962    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9905   -0.8393    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4924   -0.9156    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8056   -2.0985    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  1  0
 10 11  2  0
 10 12  1  0
 10 13  1  0
  7 14  1  0
 14 15  2  0
 14 16  1  0
 16 17  2  0
 17 18  1  0
 17 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 23 25  1  0
  8  3  1  0
 18  6  1  0
 24 19  1  0
M  END
>  <BrandName>  (35) 


>  <Applicants>  (35) 
TaiRx

>  <CHEMBL_ID>  (35) 
CHEMBL1615993

>  <Canonical_Smiles>  (35) 
COc1ccc2c(c1OP(=O)(O)O)c(=O)cc([nH]2)c3cccc(c3)F

>  <Chirality>  (35) 
Achiral Molecule

>  <First_Approval>  (35) 
nan

>  <Phase>  (35) 
2.0

>  <SC_Patent>  (35) 
None

>  <Synonyms>  (35) 
CVM-1118 | CVM-1118 FREE ACID | FOSLINANIB | TRX 818 | TRX-818 | TRX-818 FREE ACID

>  <Withdrawn>  (35) 


>  <Indications>  (35) 
nan

>  <Type>  (35) 
nan

>  <targets_id>  (35) 
nan

>  <inchi>  (35) 
InChI=1S/C16H13FNO6P/c1-23-14-6-5-11-15(16(14)24-25(20,21)22)13(19)8-12(18-11)9-3-2-4-10(17)7-9/h2-8H,1H3,(H,18,19)(H2,20,21,22)

>  <stdInchikey>  (35) 
ZDWFMAHQGDEALT-UHFFFAOYSA-N

>  <csid>  (35) 
26374637

>  <Links>  (35) 
|http://www.chemspider.com/Chemical-Structure.26374637.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1615993|http://pubchem.ncbi.nlm.nih.gov/compound/49840582|http://www.drugbank.ca/drugs/DB16172|http://zinc15.docking.org/substances/ZINC000064447756|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=2X2DNM7NGX

>  <LinkName>  (35) 
|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS

>  <lig_pdbID>  (35) 


>  <pdbID>  (35) 


>  <indicationG2P>  (35) 


>  <indicationDB>  (35) 


>  <uniprotId>  (35) 


>  <MW>  (35) 
365.0

>  <HBA>  (35) 
4.0

>  <HBD>  (35) 
3.0

>  <NRB>  (35) 
4.0

>  <TPSA>  (35) 
108.8

>  <LogP>  (35) 
2.8

>  <RoF>  (35) 
0.0

>  <Melting point>  (35) 


>  <Targets>  (35) 
nan

>  <Kinase families>  (35) 


>  <FDA_approved>  (35) 


$$$$
Pamapimod
     RDKit          2D

 29 31  0  0  0  0  0  0  0  0999 V2000
   -0.8153    2.9326    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8337    1.4327    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.4561    0.6669    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4378   -0.8330    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8703   -1.5671    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1601   -0.8013    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1418    0.6986    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4315    1.4644    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4682   -1.5353    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7580   -0.7695    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7396    0.7304    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0294    1.4962    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3375    0.7621    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3558   -0.7378    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0661   -1.5036    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0844   -3.0035    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -8.6273    1.5279    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    1.7276   -1.5988    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0357   -0.8647    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.0540    0.6352    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7642    1.4010    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.3621    1.3692    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.6519    0.6034    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9600    1.3375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2498    0.5717    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.5579    1.3058    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.6336   -0.8965    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9233   -1.6623    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9050   -3.1622    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  6  9  1  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 13 17  1  0
  4 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 20 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 23 27  1  0
 27 28  1  0
 28 29  1  0
  7  2  1  0
 21  3  1  0
 15 10  1  0
M  END
>  <BrandName>  (36) 


>  <Applicants>  (36) 
Hoffmann-La Roche

>  <CHEMBL_ID>  (36) 
CHEMBL1090089

>  <Canonical_Smiles>  (36) 
Cn1c2c(cc(c1=O)Oc3ccc(cc3F)F)cnc(n2)NC(CCO)CCO

>  <Chirality>  (36) 
Achiral Molecule

>  <First_Approval>  (36) 
nan

>  <Phase>  (36) 
2.0

>  <SC_Patent>  (36) 
None

>  <Synonyms>  (36) 
PAMAPIMOD | R-1503 | R1503 | RO 4402257 | RO-4402257

>  <Withdrawn>  (36) 


>  <Indications>  (36) 
nan

>  <Type>  (36) 
1

>  <targets_id>  (36) 
Q16539|Q15759

>  <inchi>  (36) 
InChI=1S/C19H20F2N4O4/c1-25-17-11(10-22-19(24-17)23-13(4-6-26)5-7-27)8-16(18(25)28)29-15-3-2-12(20)9-14(15)21/h2-3,8-10,13,26-27H,4-7H2,1H3,(H,22,23,24)

>  <stdInchikey>  (36) 
JYYLVUFNAHSSFE-UHFFFAOYSA-N

>  <csid>  (36) 
17347490

>  <Links>  (36) 
|http://www.chemspider.com/Chemical-Structure.17347490.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1090089|http://pubchem.ncbi.nlm.nih.gov/compound/16220188| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=FLW|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/FLW|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9915|http://zinc15.docking.org/substances/ZINC30691792|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=8S2C9V11K4|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50314070

>  <LinkName>  (36) 
|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (36) 
'FLW'

>  <pdbID>  (36) 
3flw

>  <indicationG2P>  (36) 
None

>  <indicationDB>  (36) 


>  <uniprotId>  (36) 


>  <MW>  (36) 
406.1

>  <HBA>  (36) 
8.0

>  <HBD>  (36) 
3.0

>  <NRB>  (36) 
8.0

>  <TPSA>  (36) 
109.5

>  <LogP>  (36) 
1.9

>  <RoF>  (36) 
0.0

>  <Melting point>  (36) 


>  <Targets>  (36) 
MAPK14; MAPK11

>  <Kinase families>  (36) 
CMGC

>  <FDA_approved>  (36) 


$$$$
Branebrutinib
     RDKit          2D

 27 29  0  0  0  0  0  0  0  0999 V2000
    9.2550    2.1525    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9853    1.3538    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7157    0.5551    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4460   -0.2437    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5029   -1.7426    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.1195    0.4565    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.8498   -0.3422    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9067   -1.8411    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6370   -2.6398    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3105   -1.9396    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2536   -0.4407    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.5233    0.3580    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0729    0.2595    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1298    1.7584    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4564    2.4586    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7260    1.6599    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6692    0.1610    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3426   -0.5392    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5986   -2.0172    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0834   -2.2305    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7450   -0.8843    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7836   -3.5570    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5534   -3.0931    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0526    2.3601    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3222    1.5614    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1095    3.8590    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.1398    2.5571    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  3  0
  3  4  1  0
  4  5  2  0
  4  6  1  0
  7  6  1  1
  7  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 11 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 20 22  1  0
 19 23  1  0
 16 24  1  0
 24 25  2  0
 24 26  1  0
 14 27  1  0
 12  7  1  0
 18 13  1  0
 21 17  1  0
M  END
>  <BrandName>  (37) 


>  <Applicants>  (37) 
Bristol Myers Squibb

>  <CHEMBL_ID>  (37) 
CHEMBL4297674

>  <Canonical_Smiles>  (37) 
CC#CC(=O)N[C@H]1CCCN(C1)c2c(cc(c3c2c(c([nH]3)C)C)C(=O)N)F

>  <Chirality>  (37) 
Single Stereoisomer

>  <First_Approval>  (37) 
nan

>  <Phase>  (37) 
2.0

>  <SC_Patent>  (37) 
None

>  <Synonyms>  (37) 
BMS-986195 | BRANEBRUTINIB

>  <Withdrawn>  (37) 


>  <Indications>  (37) 
nan

>  <Type>  (37) 
nan

>  <targets_id>  (37) 
nan

>  <inchi>  (37) 
InChI=1S/C20H23FN4O2/c1-4-6-16(26)24-13-7-5-8-25(10-13)19-15(21)9-14(20(22)27)18-17(19)11(2)12(3)23-18/h9,13,23H,5,7-8,10H2,1-3H3,(H2,22,27)(H,24,26)/t13-/m0/s1

>  <stdInchikey>  (37) 
VJPPLCNBDLZIFG-ZDUSSCGKSA-N

>  <csid>  (37) 
64835069

>  <Links>  (37) 
|http://www.chemspider.com/Chemical-Structure.64835069.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297674|http://pubchem.ncbi.nlm.nih.gov/compound/121293929|http://www.drugbank.ca/drugs/DB15347|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9869|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=7LBRZUYSHU|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=164638

>  <LinkName>  (37) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB

>  <lig_pdbID>  (37) 


>  <pdbID>  (37) 


>  <indicationG2P>  (37) 
None

>  <indicationDB>  (37) 


>  <uniprotId>  (37) 


>  <MW>  (37) 
370.2

>  <HBA>  (37) 
3.0

>  <HBD>  (37) 
3.0

>  <NRB>  (37) 
3.0

>  <TPSA>  (37) 
91.2

>  <LogP>  (37) 
2.1

>  <RoF>  (37) 
0.0

>  <Melting point>  (37) 


>  <Targets>  (37) 
nan

>  <Kinase families>  (37) 


>  <FDA_approved>  (37) 


$$$$
Spebrutinib
     RDKit          2D

 31 33  0  0  0  0  0  0  0  0999 V2000
  -11.1890    2.2147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.6892    2.2381    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -8.9191    0.9508    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4193    0.9742    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6492   -0.3130    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1493   -0.2897    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4196    1.0209    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9198    1.0442    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1497   -0.2430    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8794   -1.5536    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3792   -1.5769    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6499   -0.2197    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.1202   -1.5069    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6095   -2.8174    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.1607   -4.1046    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6605   -4.0813    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3902   -2.7707    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6201   -1.4835    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.8900   -2.7474    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.6197   -1.4368    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1195   -1.4135    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8492   -0.1030    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0791    1.1843    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5793    1.1609    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8496   -0.1496    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8091    2.4481    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.5388    3.7587    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0387    3.7820    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.7687    5.0459    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4984    6.3564    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4306   -5.3685    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
  9 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 17 19  1  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 24 26  1  0
 26 27  1  0
 27 28  2  0
 27 29  1  0
 29 30  2  0
 16 31  1  0
 11  6  1  0
 18 13  1  0
 25 20  1  0
M  END
>  <BrandName>  (38) 


>  <Applicants>  (38) 
Celgene

>  <CHEMBL_ID>  (38) 
CHEMBL3301625

>  <Canonical_Smiles>  (38) 
COCCOc1ccc(cc1)Nc2ncc(c(n2)Nc3cccc(c3)NC(=O)C=C)F

>  <Chirality>  (38) 
Achiral Molecule

>  <First_Approval>  (38) 
nan

>  <Phase>  (38) 
2.0

>  <SC_Patent>  (38) 
None

>  <Synonyms>  (38) 
AVL-292 | CC-292 | SPEBRUTINIB

>  <Withdrawn>  (38) 


>  <Indications>  (38) 
nan

>  <Type>  (38) 
nan

>  <targets_id>  (38) 
Q06187

>  <inchi>  (38) 
InChI=1S/C22H22FN5O3/c1-3-20(29)25-16-5-4-6-17(13-16)26-21-19(23)14-24-22(28-21)27-15-7-9-18(10-8-15)31-12-11-30-2/h3-10,13-14H,1,11-12H2,2H3,(H,25,29)(H2,24,26,27,28)

>  <stdInchikey>  (38) 
KXBDTLQSDKGAEB-UHFFFAOYSA-N

>  <csid>  (38) 
29361342

>  <Links>  (38) 
|http://www.chemspider.com/Chemical-Structure.29361342.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3301625|http://pubchem.ncbi.nlm.nih.gov/compound/59174488|http://www.drugbank.ca/drugs/DB11764|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7837|http://zinc15.docking.org/substances/ZINC000072319585|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=DRU6NG543J|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50161162

>  <LinkName>  (38) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (38) 


>  <pdbID>  (38) 


>  <indicationG2P>  (38) 
None

>  <indicationDB>  (38) 


>  <uniprotId>  (38) 


>  <MW>  (38) 
423.2

>  <HBA>  (38) 
7.0

>  <HBD>  (38) 
3.0

>  <NRB>  (38) 
10.0

>  <TPSA>  (38) 
97.4

>  <LogP>  (38) 
4.3

>  <RoF>  (38) 
0.0

>  <Melting point>  (38) 


>  <Targets>  (38) 
BTK

>  <Kinase families>  (38) 
Tyr

>  <FDA_approved>  (38) 


$$$$
Pictilisib
     RDKit          2D

 35 40  0  0  0  0  0  0  0  0999 V2000
    8.7595   -2.1866    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5676   -1.2760    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    8.4782   -0.0840    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.6569   -2.4679    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.3756   -0.3653    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.9910   -0.9423    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7990   -0.0316    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9917    1.4559    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.3763    2.0329    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5683    1.1222    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7997    2.3666    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4151    1.7896    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0680    0.3303    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4271    0.2095    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0040    1.5941    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1345    2.5707    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4916    1.7867    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4022    0.5948    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8253   -0.7898    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3377   -0.9825    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7359   -1.9818    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2235   -1.7891    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1341   -2.9811    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5572   -4.3657    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0696   -4.5583    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1590   -3.3664    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7439   -3.8641    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7801   -5.3637    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2174   -5.7927    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0685    3.1713    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1579    4.3633    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7349    5.7479    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2224    5.9405    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1331    4.7486    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5561    3.3640    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  2  4  2  0
  2  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
  8 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 15 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 19 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 17 30  1  0
 30 31  1  0
 31 32  1  0
 32 33  1  0
 33 34  1  0
 34 35  1  0
 10  5  1  0
 16 12  1  0
 20 14  1  0
 26 21  1  0
 29 25  1  0
 35 30  1  0
M  END
>  <BrandName>  (39) 


>  <Applicants>  (39) 
Hoffmann-La Roche

>  <CHEMBL_ID>  (39) 
CHEMBL521851

>  <Canonical_Smiles>  (39) 
CS(=O)(=O)N1CCN(CC1)Cc2cc3c(s2)c(nc(n3)c4cccc5c4cn[nH]5)N6CCOCC6

>  <Chirality>  (39) 
Achiral Molecule

>  <First_Approval>  (39) 
nan

>  <Phase>  (39) 
2.0

>  <SC_Patent>  (39) 
None

>  <Synonyms>  (39) 
CDC-0941 | GDC 0941 | GDC-0941 | PICTILISIB | RG-7321

>  <Withdrawn>  (39) 


>  <Indications>  (39) 
nan

>  <Type>  (39) 
1

>  <targets_id>  (39) 
P42336|P42338|O00329|P48736

>  <inchi>  (39) 
InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)

>  <stdInchikey>  (39) 
LHNIIDJUOCFXAP-UHFFFAOYSA-N

>  <csid>  (39) 
21437049

>  <Links>  (39) 
|http://www.chemspider.com/Chemical-Structure.21437049.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL521851|http://pubchem.ncbi.nlm.nih.gov/compound/17755052|http://www.drugbank.ca/drugs/DB11663| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=GD9|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/GD9|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682|http://zinc15.docking.org/substances/ZINC16052714|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=ICY00EMP8P|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=25028

>  <LinkName>  (39) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (39) 
'GD9'

>  <pdbID>  (39) 
2wxp 2y3a 3dbs

>  <indicationG2P>  (39) 
None

>  <indicationDB>  (39) 


>  <uniprotId>  (39) 


>  <MW>  (39) 
513.2

>  <HBA>  (39) 
9.0

>  <HBD>  (39) 
1.0

>  <NRB>  (39) 
5.0

>  <TPSA>  (39) 
107.6

>  <LogP>  (39) 
2.1

>  <RoF>  (39) 
1.0

>  <Melting point>  (39) 


>  <Targets>  (39) 
PIK3CA; PIK3CB; PIK3CD; PIK3CG

>  <Kinase families>  (39) 
Atypical

>  <FDA_approved>  (39) 


$$$$
Fenebrutinib
     RDKit          2D

 49 56  0  0  0  0  0  0  0  0999 V2000
    9.6038    2.2700    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7480    0.7769    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1131    0.1553    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.2574   -1.3377    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.0365   -2.2092    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6713   -1.5876    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5271   -0.0945    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.1620    0.5271    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0177    2.0202    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6526    2.6418    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4317    1.7703    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5759    0.2773    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.9411   -0.3443    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0665    2.3919    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.8456    1.5205    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4805    2.1421    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7404    1.2707    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5962   -0.2224    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7690   -0.8440    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.9899    0.0274    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3550   -0.5942    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.9132   -2.3370    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1055    1.8923    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2498    3.3853    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6149    4.0069    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8358    3.1355    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6916    1.6425    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3264    1.0208    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1822   -0.4722    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4031   -1.3436    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9125    0.7710    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7682   -0.7220    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9891   -1.5935    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3543   -0.9719    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4985    0.5212    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.9630    0.8454    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.7239   -0.4473    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.7297   -1.5704    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.4906   -2.8631    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.9551   -2.5389    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -12.0994   -1.0459    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -12.1244   -4.0293    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -13.4551   -2.5263    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2776    1.3926    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4218    2.8857    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   12.6225   -1.9593    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.1483   -3.3642    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.5531   -2.8384    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   14.0273   -1.4336    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  1
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 11 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  1  0
 20 21  2  0
 19 22  1  0
 17 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  1  0
 27 31  1  0
 31 32  1  0
 32 33  1  0
 33 34  1  0
 34 35  1  0
 35 36  2  0
 36 37  1  0
 37 38  2  0
 38 39  1  0
 39 40  1  0
 40 41  1  0
 40 42  1  0
 40 43  1  0
 35 44  1  0
 44 45  2  0
  4 46  1  0
 46 47  1  0
 47 48  1  0
 48 49  1  0
  7  2  1  0
 13  8  1  0
 20 15  1  0
 28 23  1  0
 44 31  1  0
 38 34  1  0
 41 37  1  0
 49 46  1  0
M  END
>  <BrandName>  (40) 


>  <Applicants>  (40) 
Genentech

>  <CHEMBL_ID>  (40) 
CHEMBL4065122

>  <Canonical_Smiles>  (40) 
C[C@H]1CN(CCN1c2ccc(nc2)Nc3cc(cn(c3=O)C)c4ccnc(c4CO)N5CCn6c(cc7c6CC(C7)(C)C)C5=O)C8COC8

>  <Chirality>  (40) 
Single Stereoisomer

>  <First_Approval>  (40) 
nan

>  <Phase>  (40) 
2.0

>  <SC_Patent>  (40) 
None

>  <Synonyms>  (40) 
FENEBRUTINIB | G-02599853 | G02599853 | GDC-0853 | RG-7845 | RG7845 | RO-7010939 | RO7010939

>  <Withdrawn>  (40) 


>  <Indications>  (40) 
nan

>  <Type>  (40) 
nan

>  <targets_id>  (40) 
nan

>  <inchi>  (40) 
InChI=1S/C37H44N8O4/c1-23-18-42(27-21-49-22-27)9-10-43(23)26-5-6-33(39-17-26)40-30-13-25(19-41(4)35(30)47)28-7-8-38-34(29(28)20-46)45-12-11-44-31(36(45)48)14-24-15-37(2,3)16-32(24)44/h5-8,13-14,17,19,23,27,46H,9-12,15-16,18,20-22H2,1-4H3,(H,39,40)/t23-/m0/s1

>  <stdInchikey>  (40) 
WNEODWDFDXWOLU-QHCPKHFHSA-N

>  <csid>  (40) 
58145210

>  <Links>  (40) 
|http://www.chemspider.com/Chemical-Structure.58145210.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4065122|http://pubchem.ncbi.nlm.nih.gov/compound/86567195|http://www.drugbank.ca/drugs/DB14785| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=9AJ|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/9AJ|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9299|http://zinc15.docking.org/substances/ZINC000220197997|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=E9L2885WUL|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50244440

>  <LinkName>  (40) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (40) 
'9AJ'

>  <pdbID>  (40) 
5vfi

>  <indicationG2P>  (40) 
None

>  <indicationDB>  (40) 


>  <uniprotId>  (40) 


>  <MW>  (40) 
664.3

>  <HBA>  (40) 
11.0

>  <HBD>  (40) 
2.0

>  <NRB>  (40) 
7.0

>  <TPSA>  (40) 
121.0

>  <LogP>  (40) 
3.6

>  <RoF>  (40) 
2.0

>  <Melting point>  (40) 


>  <Targets>  (40) 
nan

>  <Kinase families>  (40) 


>  <FDA_approved>  (40) 


$$$$
Mavelertinib
     RDKit          2D

 30 33  0  0  0  0  0  0  0  0999 V2000
   -3.1480    6.2495    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8429    4.7808    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8516    3.6707    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1076    2.3683    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6389    2.6734    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4753    4.1645    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5288    1.6647    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.8999    2.1217    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7239    1.0007    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8478   -0.2168    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4641   -1.5843    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5880   -2.8018    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0955   -2.6519    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4791   -1.2843    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3553   -0.0668    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0133   -1.1343    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.7692    0.1613    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2350   -0.1573    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3850   -1.6498    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0119   -2.2536    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6806   -2.4057    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    4.3543    0.8413    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.7788    0.3713    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0839   -1.0973    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.8980    1.3699    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3225    0.8999    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4752   -4.0113    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8996   -3.5413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8928   -2.0413    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0182   -5.4400    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  5  7  1  0
  7  8  1  0
  4  9  1  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 14 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 19 21  1  6
 18 22  1  1
 22 23  1  0
 23 24  2  0
 23 25  1  0
 25 26  2  0
 12 27  1  0
 27 28  1  0
 28 29  2  0
 27 30  1  0
  6  2  1  0
 15 10  1  0
 29 11  1  0
 20 16  1  0
M  END
>  <BrandName>  (41) 


>  <Applicants>  (41) 
Pfizer

>  <CHEMBL_ID>  (41) 
CHEMBL3989970

>  <Canonical_Smiles>  (41) 
Cn1cc(c(n1)OC)Nc2c3c(nc(n2)N4C[C@H]([C@@H](C4)F)NC(=O)C=C)n(cn3)C

>  <Chirality>  (41) 
Single Stereoisomer

>  <First_Approval>  (41) 
nan

>  <Phase>  (41) 
2.0

>  <SC_Patent>  (41) 
None

>  <Synonyms>  (41) 
MAVELERTINIB | PF-06747775

>  <Withdrawn>  (41) 


>  <Indications>  (41) 
nan

>  <Type>  (41) 
nan

>  <targets_id>  (41) 
nan

>  <inchi>  (41) 
InChI=1S/C18H22FN9O2/c1-5-13(29)21-11-8-28(6-10(11)19)18-23-15(14-16(24-18)26(2)9-20-14)22-12-7-27(3)25-17(12)30-4/h5,7,9-11H,1,6,8H2,2-4H3,(H,21,29)(H,22,23,24)/t10-,11-/m1/s1

>  <stdInchikey>  (41) 
JYIUNVOCEFIUIU-GHMZBOCLSA-N

>  <csid>  (41) 
49070873

>  <Links>  (41) 
|http://www.chemspider.com/Chemical-Structure.49070873.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3989970|http://pubchem.ncbi.nlm.nih.gov/compound/91668194|http://www.drugbank.ca/drugs/DB16228|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9765|http://zinc15.docking.org/substances/ZINC000231225813|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=YXX2180047|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50450870

>  <LinkName>  (41) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (41) 


>  <pdbID>  (41) 


>  <indicationG2P>  (41) 
None

>  <indicationDB>  (41) 


>  <uniprotId>  (41) 


>  <MW>  (41) 
415.2

>  <HBA>  (41) 
10.0

>  <HBD>  (41) 
2.0

>  <NRB>  (41) 
6.0

>  <TPSA>  (41) 
115.0

>  <LogP>  (41) 
0.7

>  <RoF>  (41) 
0.0

>  <Melting point>  (41) 


>  <Targets>  (41) 
nan

>  <Kinase families>  (41) 


>  <FDA_approved>  (41) 


$$$$
Vorolanib
     RDKit          2D

 32 35  0  0  0  0  0  0  0  0999 V2000
    0.8589   -2.7586    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8114   -1.2593    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9964   -0.3396    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4879    1.0716    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0113    1.0240    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4294   -0.4165    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8406   -0.9250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1059   -2.4013    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9866    0.0429    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3977   -0.4656    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8159   -1.9061    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3151   -1.9536    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8236   -0.5424    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6386    0.3772    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.2641   -0.1243    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.3465   -1.1628    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -8.6223    1.3323    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  -10.0629    1.7504    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5399    2.3708    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9310    2.2090    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4370   -0.7578    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5193    0.2807    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9957    0.0155    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7865   -1.2591    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2857   -1.2116    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.9942    0.1105    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2034    1.3851    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7042    1.3376    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6657    2.4200    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.3154    1.7668    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9932    2.4753    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.0765   -2.4863    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  7  9  1  0
 10  9  1  1
 10 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 13 15  1  0
 15 16  2  0
 15 17  1  0
 17 18  1  0
 17 19  1  0
  5 20  1  0
  3 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  1  0
 30 31  2  0
 25 32  1  0
  6  2  1  0
 14 10  1  0
 22 30  1  0
 28 23  1  0
M  END
>  <BrandName>  (42) 


>  <Applicants>  (42) 
Tyrogenex

>  <CHEMBL_ID>  (42) 
CHEMBL4297587

>  <Canonical_Smiles>  (42) 
Cc1c([nH]c(c1C(=O)N[C@H]2CCN(C2)C(=O)N(C)C)C)/C=C\3/c4cc(ccc4NC3=O)F

>  <Chirality>  (42) 
Single Stereoisomer

>  <First_Approval>  (42) 
nan

>  <Phase>  (42) 
2.0

>  <SC_Patent>  (42) 
None

>  <Synonyms>  (42) 
VOROLANIB

>  <Withdrawn>  (42) 


>  <Indications>  (42) 
nan

>  <Type>  (42) 
nan

>  <targets_id>  (42) 
nan

>  <inchi>  (42) 
InChI=1S/C23H26FN5O3/c1-12-19(10-17-16-9-14(24)5-6-18(16)27-21(17)30)25-13(2)20(12)22(31)26-15-7-8-29(11-15)23(32)28(3)4/h5-6,9-10,15,25H,7-8,11H2,1-4H3,(H,26,31)(H,27,30)/b17-10-/t15-/m0/s1

>  <stdInchikey>  (42) 
KMIOJWCYOHBUJS-HAKPAVFJSA-N

>  <csid>  (42) 
58827733

>  <Links>  (42) 
|http://www.chemspider.com/Chemical-Structure.58827733.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297587|http://pubchem.ncbi.nlm.nih.gov/compound/59215954|http://www.drugbank.ca/drugs/DB15247|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=YP8G3I74EL

>  <LinkName>  (42) 
|ChemSpider|ChEMBL|PubChem|DrugBank|FDA SRS

>  <lig_pdbID>  (42) 


>  <pdbID>  (42) 


>  <indicationG2P>  (42) 


>  <indicationDB>  (42) 


>  <uniprotId>  (42) 


>  <MW>  (42) 
439.2

>  <HBA>  (42) 
3.0

>  <HBD>  (42) 
3.0

>  <NRB>  (42) 
3.0

>  <TPSA>  (42) 
97.5

>  <LogP>  (42) 
2.7

>  <RoF>  (42) 
0.0

>  <Melting point>  (42) 


>  <Targets>  (42) 
nan

>  <Kinase families>  (42) 


>  <FDA_approved>  (42) 


$$$$
Edicotinib
     RDKit          2D

 34 37  0  0  0  0  0  0  0  0999 V2000
    3.0545   -5.4261    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6911   -4.8007    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1960   -4.6794    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4465   -3.3240    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4062   -2.0898    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9012   -2.2112    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5437   -3.5666    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2363   -0.7344    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6163    0.4997    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0261    1.8552    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5212    1.9765    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3738    0.7424    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7314   -0.6131    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8689    0.8637    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5114    2.2192    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0065    2.3405    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8591    1.1064    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2166   -0.2490    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7215   -0.3704    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0765   -1.7425    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6631   -0.6464    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3699    2.9659    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6273    3.7918    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1114    0.3784    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.9640    1.6125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3216    2.9679    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.4591    1.4911    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4361    2.6294    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.8205    2.0520    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6992    0.5569    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2397    0.2103    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.1014    2.8326    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3822    3.6132    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.3120   -6.2520    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  5  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 12 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 18 20  1  0
 18 21  1  0
 16 22  1  0
 16 23  1  0
  9 24  1  0
 24 25  1  0
 25 26  2  0
 25 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 29 32  1  0
 32 33  3  0
  2 34  1  0
  7  2  1  0
 13  8  2  0
 19 14  1  0
 31 27  2  0
M  END
>  <BrandName>  (43) 


>  <Applicants>  (43) 
Janssen

>  <CHEMBL_ID>  (43) 
CHEMBL3674570

>  <Canonical_Smiles>  (43) 
CC1(CCC(=CC1)c2c(ccc(n2)C3CC(OC(C3)(C)C)(C)C)NC(=O)c4[nH]c(cn4)C#N)C

>  <Chirality>  (43) 
Achiral Molecule

>  <First_Approval>  (43) 
nan

>  <Phase>  (43) 
2.0

>  <SC_Patent>  (43) 
None

>  <Synonyms>  (43) 
EDICOTINIB | JNJ-40346527

>  <Withdrawn>  (43) 


>  <Indications>  (43) 
nan

>  <Type>  (43) 
nan

>  <targets_id>  (43) 
nan

>  <inchi>  (43) 
InChI=1S/C27H35N5O2/c1-25(2)11-9-17(10-12-25)22-21(32-24(33)23-29-16-19(15-28)30-23)8-7-20(31-22)18-13-26(3,4)34-27(5,6)14-18/h7-9,16,18H,10-14H2,1-6H3,(H,29,30)(H,32,33)

>  <stdInchikey>  (43) 
BNVPFDRNGHMRJS-UHFFFAOYSA-N

>  <csid>  (43) 
34951020

>  <Links>  (43) 
|http://www.chemspider.com/Chemical-Structure.34951020.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3674570|http://pubchem.ncbi.nlm.nih.gov/compound/25230468|http://www.drugbank.ca/drugs/DB12504|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8942|http://zinc15.docking.org/substances/ZINC000043208574|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=3NU609VYNF|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=98634

>  <LinkName>  (43) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (43) 


>  <pdbID>  (43) 


>  <indicationG2P>  (43) 
None

>  <indicationDB>  (43) 


>  <uniprotId>  (43) 


>  <MW>  (43) 
461.3

>  <HBA>  (43) 
5.0

>  <HBD>  (43) 
2.0

>  <NRB>  (43) 
4.0

>  <TPSA>  (43) 
103.7

>  <LogP>  (43) 
6.0

>  <RoF>  (43) 
1.0

>  <Melting point>  (43) 


>  <Targets>  (43) 
nan

>  <Kinase families>  (43) 


>  <FDA_approved>  (43) 


$$$$
Poseltinib
     RDKit          2D

 35 39  0  0  0  0  0  0  0  0999 V2000
   11.3586    1.2439    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8599    1.1826    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.1636   -0.1460    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6649   -0.2074    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8624    1.0599    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.5587    2.3885    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0574    2.4499    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3637    0.9986    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5612    2.2659    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0624    2.2045    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3662    0.8759    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1687   -0.3914    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6674   -0.3300    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8674    0.8146    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.1712   -0.5140    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9736   -1.7813    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.2774   -3.1099    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7989   -4.5164    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3776   -5.4469    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6262   -4.6156    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2214   -3.1713    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0238   -1.9040    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3276   -0.5754    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5226   -1.9653    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3251   -0.6980    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6288    0.6306    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4313    1.8979    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9301    1.8365    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6263    0.5079    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8238   -0.7594    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.1251    0.4466    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.9275    1.7139    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.2313    3.0425    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  -10.4263    1.6525    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.2288    2.9198    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  5  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 11 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  2  0
 22 24  1  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 29 31  1  0
 31 32  1  0
 32 33  2  0
 32 34  1  0
 34 35  2  0
  7  2  1  0
 13  8  1  0
 23 15  1  0
 21 17  2  0
 30 25  1  0
M  END
>  <BrandName>  (44) 


>  <Applicants>  (44) 
Hanmi Pharmaceutical

>  <CHEMBL_ID>  (44) 
CHEMBL4163691

>  <Canonical_Smiles>  (44) 
CN1CCN(CC1)c2ccc(cc2)Nc3nc4ccoc4c(n3)Oc5cccc(c5)NC(=O)C=C

>  <Chirality>  (44) 
Achiral Molecule

>  <First_Approval>  (44) 
nan

>  <Phase>  (44) 
2.0

>  <SC_Patent>  (44) 
None

>  <Synonyms>  (44) 
HM71224 | LY3337641 | POSELTINIB

>  <Withdrawn>  (44) 


>  <Indications>  (44) 
nan

>  <Type>  (44) 
nan

>  <targets_id>  (44) 
nan

>  <inchi>  (44) 
InChI=1S/C26H26N6O3/c1-3-23(33)27-19-5-4-6-21(17-19)35-25-24-22(11-16-34-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)

>  <stdInchikey>  (44) 
LZMJNVRJMFMYQS-UHFFFAOYSA-N

>  <csid>  (44) 
58826582

>  <Links>  (44) 
|http://www.chemspider.com/Chemical-Structure.58826582.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4163691|http://pubchem.ncbi.nlm.nih.gov/compound/56644522|http://www.drugbank.ca/drugs/DB16299|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9862|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=D01E4B1U35|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50369724

>  <LinkName>  (44) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB

>  <lig_pdbID>  (44) 


>  <pdbID>  (44) 


>  <indicationG2P>  (44) 
None

>  <indicationDB>  (44) 


>  <uniprotId>  (44) 


>  <MW>  (44) 
470.2

>  <HBA>  (44) 
8.0

>  <HBD>  (44) 
2.0

>  <NRB>  (44) 
7.0

>  <TPSA>  (44) 
95.8

>  <LogP>  (44) 
4.6

>  <RoF>  (44) 
0.0

>  <Melting point>  (44) 


>  <Targets>  (44) 
nan

>  <Kinase families>  (44) 


>  <FDA_approved>  (44) 


$$$$
Apitolisib
     RDKit          2D

 35 39  0  0  0  0  0  0  0  0999 V2000
    1.0836   -4.2403    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7309   -2.7824    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6559   -2.2108    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5408   -0.7152    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.9171   -0.3625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7031   -1.6401    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2025   -1.5982    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.9159   -0.2787    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1299    0.9989    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.6305    0.9570    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8446    2.2346    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.5580    3.5540    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7720    4.8316    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7274    4.7897    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4408    3.4703    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6549    2.1927    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4153   -0.2368    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2013   -1.5144    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7007   -1.4726    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.4142   -0.1531    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6282    1.1245    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.1288    1.0826    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9136   -0.1112    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9335   -2.9968    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2530   -2.2833    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2949   -0.7839    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6143   -0.0705    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8919   -0.8565    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8500   -2.3559    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5306   -3.0693    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2114   -0.1430    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4890   -0.9290    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2533    1.3564    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.5728    2.0698    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9757    2.1424    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
  8 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 20 23  1  0
  3 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  1  0
 28 31  1  0
 31 32  2  0
 31 33  1  0
 33 34  1  6
 33 35  1  0
  6  2  1  0
 10  5  1  0
 16 11  1  0
 22 17  1  0
 30 25  1  0
M  END
>  <BrandName>  (45) 


>  <Applicants>  (45) 
Hoffmann-La Roche

>  <CHEMBL_ID>  (45) 
CHEMBL1922094

>  <Canonical_Smiles>  (45) 
Cc1c(sc2c1nc(nc2N3CCOCC3)c4cnc(nc4)N)CN5CCN(CC5)C(=O)[C@H](C)O

>  <Chirality>  (45) 
Single Stereoisomer

>  <First_Approval>  (45) 
nan

>  <Phase>  (45) 
2.0

>  <SC_Patent>  (45) 
None

>  <Synonyms>  (45) 
APITOLISIB | G-038390 | G-038390.1 | GDC-0980 | GDC-0980.1 | RG-7422 | RG7422

>  <Withdrawn>  (45) 


>  <Indications>  (45) 
nan

>  <Type>  (45) 
nan

>  <targets_id>  (45) 
P42336|P42345

>  <inchi>  (45) 
InChI=1S/C23H30N8O3S/c1-14-17(13-29-3-5-31(6-4-29)22(33)15(2)32)35-19-18(14)27-20(16-11-25-23(24)26-12-16)28-21(19)30-7-9-34-10-8-30/h11-12,15,32H,3-10,13H2,1-2H3,(H2,24,25,26)/t15-/m0/s1

>  <stdInchikey>  (45) 
YOVVNQKCSKSHKT-HNNXBMFYSA-N

>  <csid>  (45) 
26325996

>  <Links>  (45) 
|http://www.chemspider.com/Chemical-Structure.26325996.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1922094|http://pubchem.ncbi.nlm.nih.gov/compound/25254071|http://www.drugbank.ca/drugs/DB12180| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=980|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/980|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888|http://zinc15.docking.org/substances/ZINC000059224388|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=1C854K1MIJ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50358204

>  <LinkName>  (45) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (45) 
'980'

>  <pdbID>  (45) 
3tl5

>  <indicationG2P>  (45) 
None

>  <indicationDB>  (45) 


>  <uniprotId>  (45) 


>  <MW>  (45) 
498.2

>  <HBA>  (45) 
11.0

>  <HBD>  (45) 
2.0

>  <NRB>  (45) 
5.0

>  <TPSA>  (45) 
133.8

>  <LogP>  (45) 
0.9

>  <RoF>  (45) 
1.0

>  <Melting point>  (45) 


>  <Targets>  (45) 
PIK3CA; MTOR

>  <Kinase families>  (45) 
Atypical

>  <FDA_approved>  (45) 


$$$$
Gusacitinib
     RDKit          2D

 34 38  0  0  0  0  0  0  0  0999 V2000
    5.2761    7.4534    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.9767    6.7040    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6773    5.9546    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6766    4.4546    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9753    3.7040    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9746    2.2040    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6752    1.4546    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6745   -0.0454    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3751   -0.7948    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.3744   -2.2948    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0750   -3.0442    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2237   -2.2935    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2230   -0.7935    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5217   -0.0429    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8211   -0.7923    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1198   -0.0417    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1191    1.4583    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4177    2.2089    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.7171    1.4595    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.0158    2.2101    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.7178   -0.0405    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4192   -0.7911    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8218   -2.2923    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5231   -3.0429    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6731   -3.0454    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6723   -4.5454    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3730   -5.2948    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.9710   -5.2960    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.2704   -4.5466    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.2711   -3.0466    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9724   -2.2960    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9732   -0.7960    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.3765    2.2052    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3772    3.7052    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  3  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 19 21  1  0
 21 22  1  0
 15 23  1  0
 23 24  2  0
 10 25  2  0
 25 26  1  0
 26 27  2  0
 26 28  1  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  2  0
  7 33  1  0
 33 34  1  0
 34  4  1  0
 32  8  1  0
 24 12  1  0
 31 25  1  0
 22 16  1  0
M  END
>  <BrandName>  (46) 


>  <Applicants>  (46) 
Asana BioSciences

>  <CHEMBL_ID>  (46) 
CHEMBL4594275

>  <Canonical_Smiles>  (46) 
N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1

>  <Chirality>  (46) 
Achiral Molecule

>  <First_Approval>  (46) 
nan

>  <Phase>  (46) 
2.0

>  <SC_Patent>  (46) 
None

>  <Synonyms>  (46) 
ASN-002 | ASN002 | EN-3351 | EN3351 | GUSACITINIB

>  <Withdrawn>  (46) 


>  <Indications>  (46) 
nan

>  <Type>  (46) 
nan

>  <targets_id>  (46) 
nan

>  <inchi>  (46) 
InChI=1S/C24H28N8O2/c25-10-5-16-6-11-32(12-7-16)24-28-20-15-26-30-23(34)21(20)22(29-24)27-17-1-3-18(4-2-17)31-13-8-19(33)9-14-31/h1-4,15-16,19,33H,5-9,11-14H2,(H,30,34)(H,27,28,29)

>  <stdInchikey>  (46) 
NLFLXLJXEIUQDL-UHFFFAOYSA-N

>  <csid>  (46) 
71117451

>  <Links>  (46) 
|http://www.chemspider.com/Chemical-Structure.71117451.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4594275|http://pubchem.ncbi.nlm.nih.gov/compound/71269142|http://www.drugbank.ca/drugs/DB15670|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10000|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=4801QYW816

>  <LinkName>  (46) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS

>  <lig_pdbID>  (46) 


>  <pdbID>  (46) 


>  <indicationG2P>  (46) 
None

>  <indicationDB>  (46) 


>  <uniprotId>  (46) 


>  <MW>  (46) 
460.2

>  <HBA>  (46) 
9.0

>  <HBD>  (46) 
3.0

>  <NRB>  (46) 
5.0

>  <TPSA>  (46) 
134.1

>  <LogP>  (46) 
2.5

>  <RoF>  (46) 
0.0

>  <Melting point>  (46) 


>  <Targets>  (46) 
nan

>  <Kinase families>  (46) 
(*)

>  <FDA_approved>  (46) 


$$$$
Onvansertib
     RDKit          2D

 38 42  0  0  0  0  0  0  0  0999 V2000
    2.3628    5.7948    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2767    4.7603    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.6295    3.3024    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5433    2.2679    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8957    2.6913    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2485    4.1492    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1623    5.1837    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9819    1.6568    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4209    2.0802    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5071    1.0457    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1543   -0.4123    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7153   -0.8357    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6291    0.1988    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3625   -2.2936    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9235   -2.7170    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5706   -4.1749    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.8684   -4.5983    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9545   -3.5638    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6017   -2.1059    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1627   -1.6825    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6879   -1.0714    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1269   -1.4948    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9743   -0.2571    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0590    0.9313    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6459    0.4280    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.4082    1.2754    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0555    0.6272    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1822    1.4745    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.4737   -0.2151    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2598   -1.4926    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.1870    1.1044    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.4797   -2.9527    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3935   -3.9872    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2405   -1.4468    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6795   -1.0233    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.1185   -0.5999    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1029   -2.4623    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2560    0.4157    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  5  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 19 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
 23 29  1  0
 29 30  2  0
 29 31  1  0
 22 32  1  0
 32 33  1  0
 11 34  1  0
 34 35  1  0
 35 36  1  0
 35 37  1  0
 35 38  1  0
  7  2  1  0
 13  8  1  0
 20 15  1  0
 33 18  1  0
 25 21  1  0
M  END
>  <BrandName>  (47) 


>  <Applicants>  (47) 
Cardiff Oncology

>  <CHEMBL_ID>  (47) 
CHEMBL1738758

>  <Canonical_Smiles>  (47) 
CN1CCN(CC1)c2ccc(c(c2)Nc3ncc4c(n3)-c5c(c(nn5CCO)C(=O)N)CC4)OC(F)(F)F

>  <Chirality>  (47) 
Achiral Molecule

>  <First_Approval>  (47) 
nan

>  <Phase>  (47) 
2.0

>  <SC_Patent>  (47) 
None

>  <Synonyms>  (47) 
NMS-1286937 | NMS-P937 | ONVANSERTIB | PCM-075

>  <Withdrawn>  (47) 


>  <Indications>  (47) 
nan

>  <Type>  (47) 
nan

>  <targets_id>  (47) 
nan

>  <inchi>  (47) 
InChI=1S/C24H27F3N8O3/c1-33-6-8-34(9-7-33)15-3-5-18(38-24(25,26)27)17(12-15)30-23-29-13-14-2-4-16-20(22(28)37)32-35(10-11-36)21(16)19(14)31-23/h3,5,12-13,36H,2,4,6-11H2,1H3,(H2,28,37)(H,29,30,31)

>  <stdInchikey>  (47) 
QHLVBNKYJGBCQJ-UHFFFAOYSA-N

>  <csid>  (47) 
26325993

>  <Links>  (47) 
|http://www.chemspider.com/Chemical-Structure.26325993.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1738758|http://pubchem.ncbi.nlm.nih.gov/compound/49792852|http://www.drugbank.ca/drugs/DB15110| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=937|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/937|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7918|http://zinc15.docking.org/substances/ZINC000043196885|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=67RM91WDHQ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50343559

>  <LinkName>  (47) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (47) 
'937'

>  <pdbID>  (47) 
2yac

>  <indicationG2P>  (47) 
None

>  <indicationDB>  (47) 


>  <uniprotId>  (47) 


>  <MW>  (47) 
532.2

>  <HBA>  (47) 
10.0

>  <HBD>  (47) 
3.0

>  <NRB>  (47) 
7.0

>  <TPSA>  (47) 
134.7

>  <LogP>  (47) 
1.9

>  <RoF>  (47) 
1.0

>  <Melting point>  (47) 


>  <Targets>  (47) 
nan

>  <Kinase families>  (47) 


>  <FDA_approved>  (47) 


$$$$
Mivavotinib
     RDKit          2D

 25 28  0  0  0  0  0  0  0  0999 V2000
   -2.1318   -5.2023    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3572   -3.7193    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2899   -2.6654    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9625   -1.3246    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2731    0.0076    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2253    0.0767    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.9147    1.4089    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4131    1.4780    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.2221    0.2149    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5327   -1.1173    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3418   -2.3804    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8402   -2.3113    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5296   -0.9791    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7205    0.2840    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4099    1.6162    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.1056    2.6720    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7950    4.0042    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3928    2.6029    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0822    1.2707    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5622    1.5147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6295    0.4607    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7875    2.9976    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4468    3.6702    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4455   -1.5499    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6894   -3.0300    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  1  0
  9  8  1  1
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  1
  7 16  2  0
 16 17  1  0
 16 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 20 22  1  0
 22 23  1  0
  4 24  1  0
 24 25  2  0
 25  2  1  0
 19  5  1  0
 14  9  1  0
 23 18  1  0
M  END
>  <BrandName>  (48) 


>  <Applicants>  (48) 
Takeda

>  <CHEMBL_ID>  (48) 
CHEMBL3979920

>  <Canonical_Smiles>  (48) 
Cn1cc(-c2nc(N[C@@H]3CCCC[C@@H]3N)c(F)c3c2C(=O)NC3)cn1

>  <Chirality>  (48) 
Single Stereoisomer

>  <First_Approval>  (48) 
nan

>  <Phase>  (48) 
2.0

>  <SC_Patent>  (48) 
None

>  <Synonyms>  (48) 
MIVAVOTINIB | TAK-659F

>  <Withdrawn>  (48) 


>  <Indications>  (48) 
nan

>  <Type>  (48) 
nan

>  <targets_id>  (48) 
nan

>  <inchi>  (48) 
InChI=1S/C17H21FN6O/c1-24-8-9(6-21-24)15-13-10(7-20-17(13)25)14(18)16(23-15)22-12-5-3-2-4-11(12)19/h6,8,11-12H,2-5,7,19H2,1H3,(H,20,25)(H,22,23)/t11-,12+/m0/s1

>  <stdInchikey>  (48) 
MJHOMTRKVMKCNE-NWDGAFQWSA-N

>  <csid>  (48) 
57583808

>  <Links>  (48) 
|http://www.chemspider.com/Chemical-Structure.57583808.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3979920|http://pubchem.ncbi.nlm.nih.gov/compound/53252276| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=7KG|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/7KG|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9600|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=8QR88H79VX|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50204290

>  <LinkName>  (48) 
|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|Guide to Pharmacology|FDA SRS|BindingDB

>  <lig_pdbID>  (48) 
'7KG'

>  <pdbID>  (48) 
5tr6

>  <indicationG2P>  (48) 
None

>  <indicationDB>  (48) 


>  <uniprotId>  (48) 


>  <MW>  (48) 
344.2

>  <HBA>  (48) 
6.0

>  <HBD>  (48) 
3.0

>  <NRB>  (48) 
3.0

>  <TPSA>  (48) 
97.9

>  <LogP>  (48) 
1.5

>  <RoF>  (48) 
0.0

>  <Melting point>  (48) 


>  <Targets>  (48) 
nan

>  <Kinase families>  (48) 


>  <FDA_approved>  (48) 


$$$$
Acalisib
     RDKit          2D

 30 34  0  0  0  0  0  0  0  0999 V2000
   -1.1075    1.7366    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7253    0.2861    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7220   -0.1081    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1042   -1.5586    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.5515   -1.9528    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9337   -3.4033    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3810   -3.7975    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4460   -2.7413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0638   -1.2908    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6165   -0.8965    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2343    0.5539    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2993    1.6102    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.7870    0.9482    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.4048    2.3986    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4698    3.4549    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0876    4.9054    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6403    5.2996    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4247    4.2434    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0425    2.7929    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8933   -3.1355    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7903   -0.7701    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2376   -0.3759    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3027   -1.4322    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7499   -1.0380    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5721   -2.2926    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6329   -3.4622    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2303   -2.9304    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1321    0.4125    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0671    1.4688    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6198    1.0746    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  1
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 11 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
  8 20  1  0
  2 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 24 28  1  0
 28 29  2  0
 29 30  1  0
 13  3  1  0
 10  5  1  0
 19 14  1  0
 30 22  2  0
 27 23  1  0
M  END
>  <BrandName>  (49) 


>  <Applicants>  (49) 
Gilead Sciences

>  <CHEMBL_ID>  (49) 
CHEMBL3545397

>  <Canonical_Smiles>  (49) 
C[C@@H](c1nc2ccc(cc2c(=O)n1c3ccccc3)F)Nc4c5c(nc[nH]5)ncn4

>  <Chirality>  (49) 
Single Stereoisomer

>  <First_Approval>  (49) 
nan

>  <Phase>  (49) 
2.0

>  <SC_Patent>  (49) 
None

>  <Synonyms>  (49) 


>  <Withdrawn>  (49) 


>  <Indications>  (49) 
nan

>  <Type>  (49) 
nan

>  <targets_id>  (49) 
P42336

>  <inchi>  (49) 
InChI=1S/C21H16FN7O/c1-12(27-19-17-18(24-10-23-17)25-11-26-19)20-28-16-8-7-13(22)9-15(16)21(30)29(20)14-5-3-2-4-6-14/h2-12H,1H3,(H2,23,24,25,26,27)/t12-/m0/s1

>  <stdInchikey>  (49) 
DOCINCLJNAXZQF-LBPRGKRZSA-N

>  <csid>  (49) 
9793017

>  <Links>  (49) 
|http://www.chemspider.com/Chemical-Structure.9793017.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4303323|http://pubchem.ncbi.nlm.nih.gov/compound/11618268|http://www.drugbank.ca/drugs/DB15407|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10096|http://zinc15.docking.org/substances/ZINC000035943170|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=OVW60IDW1D|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=217352

>  <LinkName>  (49) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (49) 


>  <pdbID>  (49) 


>  <indicationG2P>  (49) 
None

>  <indicationDB>  (49) 


>  <uniprotId>  (49) 


>  <MW>  (49) 
401.1

>  <HBA>  (49) 
7.0

>  <HBD>  (49) 
2.0

>  <NRB>  (49) 
4.0

>  <TPSA>  (49) 
101.4

>  <LogP>  (49) 
3.4

>  <RoF>  (49) 
0.0

>  <Melting point>  (49) 


>  <Targets>  (49) 
PIK3CA

>  <Kinase families>  (49) 
Atypical

>  <FDA_approved>  (49) 


$$$$
Brepocitinib
     RDKit          2D

 28 32  0  0  0  0  0  0  0  0999 V2000
    5.9758   -2.3830    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7643   -1.4986    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.7677    0.0014    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3422    0.4683    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4578   -0.7432    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3366   -1.9588    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.8820    1.8959    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.4155    2.2112    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9553    3.6388    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5112    3.9541    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5175    2.8417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0573    1.4140    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4092    1.0988    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0635    0.3016    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6033   -1.1260    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6096   -2.2384    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9103   -2.9854    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0227   -1.9792    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4095   -0.6102    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5300    0.6169    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9180   -0.7705    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9118    0.3419    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3720    1.7696    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4453    0.0267    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9824    0.4869    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6671   -0.9796    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0566   -1.5447    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1307   -2.2498    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  4  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  1  0
 16 15  1  1
 16 17  1  0
 17 18  1  0
 19 18  1  1
 19 20  1  0
 19 21  1  0
 21 22  1  0
 22 23  2  0
 24 22  1  6
 24 25  1  0
 25 26  1  0
 26 27  1  0
 26 28  1  0
  6  2  1  0
 13  8  1  0
 20 14  1  0
 21 16  1  0
 26 24  1  0
M  END
>  <BrandName>  (50) 


>  <Applicants>  (50) 
Pfizer

>  <CHEMBL_ID>  (50) 
CHEMBL4297477

>  <Canonical_Smiles>  (50) 
Cn1cc(cn1)Nc2nccc(n2)N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]5CC5(F)F

>  <Chirality>  (50) 
Single Stereoisomer

>  <First_Approval>  (50) 
nan

>  <Phase>  (50) 
2.0

>  <SC_Patent>  (50) 
None

>  <Synonyms>  (50) 
BREPOCITINIB | PF-06700841

>  <Withdrawn>  (50) 


>  <Indications>  (50) 
nan

>  <Type>  (50) 
nan

>  <targets_id>  (50) 
nan

>  <inchi>  (50) 
InChI=1S/C18H21F2N7O/c1-25-8-11(7-22-25)23-17-21-5-4-15(24-17)26-9-12-2-3-13(10-26)27(12)16(28)14-6-18(14,19)20/h4-5,7-8,12-14H,2-3,6,9-10H2,1H3,(H,21,23,24)/t12-,13+,14-/m0/s1

>  <stdInchikey>  (50) 
BUWBRTXGQRBBHG-MJBXVCDLSA-N

>  <csid>  (50) 
71107316

>  <Links>  (50) 
|http://www.chemspider.com/Chemical-Structure.71107316.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297477|http://pubchem.ncbi.nlm.nih.gov/compound/118878093|http://www.drugbank.ca/drugs/DB15003| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=G4J|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/G4J|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10459|http://zinc15.docking.org/substances/ZINC000526061580|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=3X8387Q25N|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=329924

>  <LinkName>  (50) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (50) 
'G4J'

>  <pdbID>  (50) 
6dbm 6dbn

>  <indicationG2P>  (50) 
None

>  <indicationDB>  (50) 


>  <uniprotId>  (50) 


>  <MW>  (50) 
389.2

>  <HBA>  (50) 
7.0

>  <HBD>  (50) 
1.0

>  <NRB>  (50) 
4.0

>  <TPSA>  (50) 
79.2

>  <LogP>  (50) 
1.8

>  <RoF>  (50) 
0.0

>  <Melting point>  (50) 


>  <Targets>  (50) 
nan

>  <Kinase families>  (50) 


>  <FDA_approved>  (50) 


$$$$
Ripasudil
     RDKit          2D

 22 24  0  0  0  0  0  0  0  0999 V2000
   -1.0610    2.0019    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2429    1.0783    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5878    1.7424    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9457    1.1050    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2939   -0.3540    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3703   -1.5360    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8704   -1.5508    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9236   -0.3873    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4646   -0.7356    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8128   -2.1946    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1163    0.7235    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.9945   -1.0838    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4224   -2.5214    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8814   -2.8696    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9125   -1.7802    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4846   -0.3425    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0255    0.0057    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5976    1.4433    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6287    2.5328    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0877    2.1846    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.5156    0.7469    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1386    1.7915    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  6
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
  9 11  2  0
  9 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 18 22  1  0
  8  2  1  0
 17 12  1  0
 21 16  1  0
M  END
>  <BrandName>  (51) 


>  <Applicants>  (51) 
Kowa Pharmaceutical

>  <CHEMBL_ID>  (51) 
CHEMBL3426621

>  <Canonical_Smiles>  (51) 
C[C@H]1CNCCCN1S(=O)(=O)c2cccc3c2c(cnc3)F

>  <Chirality>  (51) 
Single Stereoisomer

>  <First_Approval>  (51) 
nan

>  <Phase>  (51) 
2.0

>  <SC_Patent>  (51) 
None

>  <Synonyms>  (51) 
RIPASUDIL

>  <Withdrawn>  (51) 


>  <Indications>  (51) 
nan

>  <Type>  (51) 
nan

>  <targets_id>  (51) 
nan

>  <inchi>  (51) 
InChI=1S/C15H18FN3O2S/c1-11-8-17-6-3-7-19(11)22(20,21)14-5-2-4-12-9-18-10-13(16)15(12)14/h2,4-5,9-11,17H,3,6-8H2,1H3/t11-/m0/s1

>  <stdInchikey>  (51) 
QSKQVZWVLOIIEV-NSHDSACASA-N

>  <csid>  (51) 
8039366

>  <Links>  (51) 
|http://www.chemspider.com/Chemical-Structure.8039366.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3426621|http://pubchem.ncbi.nlm.nih.gov/compound/9863672|http://www.drugbank.ca/drugs/DB13165|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10423|http://zinc15.docking.org/substances/ZINC000003940873|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=11978226XX|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50087135

>  <LinkName>  (51) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (51) 


>  <pdbID>  (51) 


>  <indicationG2P>  (51) 
None

>  <indicationDB>  (51) 
Ripasudil, as hydrochloride hydrate (K-115), is a specifc Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor used for the treatment of glaucoma and ocular hypertension. It was first approved for treatment in Japan in September 2014. This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec. Ripasudil is a well tolerated medication that is used when other drugs have been proven to be non-effective or cannot be administered.

>  <uniprotId>  (51) 
Q13464|O75116

>  <MW>  (51) 
323.1

>  <HBA>  (51) 
4.0

>  <HBD>  (51) 
1.0

>  <NRB>  (51) 
2.0

>  <TPSA>  (51) 
62.3

>  <LogP>  (51) 
1.7

>  <RoF>  (51) 
0.0

>  <Melting point>  (51) 


>  <Targets>  (51) 
nan

>  <Kinase families>  (51) 


>  <FDA_approved>  (51) 


$$$$
Danusertib
     RDKit          2D

 35 39  0  0  0  0  0  0  0  0999 V2000
  -11.4022    2.1642    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.9775    1.6948    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.8587    2.6939    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4340    2.2246    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1282    0.7561    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.2470   -0.2430    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.6717    0.2263    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7035    0.2867    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3977   -1.1818    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9730   -1.6512    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8542   -0.6521    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1600    0.8164    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5847    1.2858    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4295   -1.1214    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3107   -0.1223    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1237   -2.5899    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.3010   -3.0593    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5181   -2.1826    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7280   -3.0693    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2587   -4.4939    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.7587   -4.4878    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.9452   -2.1926    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4875   -0.7641    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.9875   -0.7580    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3742    0.4458    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7697    1.8186    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.8653    0.2829    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7519    1.4928    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2431    1.3298    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1297    2.5397    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5253    3.9126    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0341    4.0755    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1475    2.8656    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4698   -1.0899    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.9609   -1.2529    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  5  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 11 14  1  0
 14 15  2  0
 14 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  1  0
 19 22  1  0
 22 23  1  0
 23 24  1  0
 23 25  1  0
 25 26  2  0
 25 27  1  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 32 33  2  0
 27 34  1  1
 34 35  1  0
  7  2  1  0
 13  8  1  0
 21 17  2  0
 24 18  1  0
 33 28  1  0
M  END
>  <BrandName>  (52) 


>  <Applicants>  (52) 
Nerviano Medical Sciences

>  <CHEMBL_ID>  (52) 
CHEMBL402548

>  <Canonical_Smiles>  (52) 
CN1CCN(CC1)c2ccc(cc2)C(=O)Nc3c4c([nH]n3)CN(C4)C(=O)[C@@H](c5ccccc5)OC

>  <Chirality>  (52) 
Single Stereoisomer

>  <First_Approval>  (52) 
nan

>  <Phase>  (52) 
2.0

>  <SC_Patent>  (52) 
None

>  <Synonyms>  (52) 
DANUSERTIB | PHA-739358

>  <Withdrawn>  (52) 


>  <Indications>  (52) 
nan

>  <Type>  (52) 
1

>  <targets_id>  (52) 
O14965|Q96GD4|Q9UQB9

>  <inchi>  (52) 
InChI=1S/C26H30N6O3/c1-30-12-14-31(15-13-30)20-10-8-19(9-11-20)25(33)27-24-21-16-32(17-22(21)28-29-24)26(34)23(35-2)18-6-4-3-5-7-18/h3-11,23H,12-17H2,1-2H3,(H2,27,28,29,33)/t23-/m1/s1

>  <stdInchikey>  (52) 
XKFTZKGMDDZMJI-HSZRJFAPSA-N

>  <csid>  (52) 
9617754

>  <Links>  (52) 
|http://www.chemspider.com/Chemical-Structure.9617754.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL402548|http://pubchem.ncbi.nlm.nih.gov/compound/11442891|http://www.drugbank.ca/drugs/DB11778| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=627|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/627|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7937|http://zinc15.docking.org/substances/ZINC000006718723|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=M3X659D0FY|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=209858

>  <LinkName>  (52) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (52) 
'627'

>  <pdbID>  (52) 
2j50 2v7a 4qo9 5i9z

>  <indicationG2P>  (52) 
None

>  <indicationDB>  (52) 


>  <uniprotId>  (52) 


>  <MW>  (52) 
474.2

>  <HBA>  (52) 
6.0

>  <HBD>  (52) 
2.0

>  <NRB>  (52) 
6.0

>  <TPSA>  (52) 
93.8

>  <LogP>  (52) 
2.6

>  <RoF>  (52) 
0.0

>  <Melting point>  (52) 


>  <Targets>  (52) 
AURKA; AURKB; AURKC

>  <Kinase families>  (52) 
Other

>  <FDA_approved>  (52) 


$$$$
Adavosertib
     RDKit          2D

 37 41  0  0  0  0  0  0  0  0999 V2000
   -7.8781    0.1129    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.0496    1.6030    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.2212    3.0932    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5595    1.7746    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9629    3.1509    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4728    3.3224    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5791    2.1177    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1757    0.7414    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6658    0.5698    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2820   -0.4633    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7821   -0.4485    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3045   -1.8704    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1658   -2.1678    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1584   -1.0432    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.6808    0.3788    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7895    0.6761    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.6734    1.5034    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.1436    1.2060    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6212   -0.2159    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0915   -0.5132    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0841    0.6114    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6065    2.0333    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1362    2.3306    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5543    0.3140    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.0319   -1.1079    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.5022   -1.4052    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.4948   -0.2806    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.0172    1.1413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5469    1.4386    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.9650   -0.5780    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5092   -2.7641    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4944   -4.2640    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7314   -1.8944    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1533   -2.3721    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4507   -3.8423    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8726   -4.3199    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.5398    1.4315    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  8 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 15 17  1  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 21 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
 28 29  1  0
 27 30  1  0
 12 31  1  0
 31 32  2  0
 31 33  1  0
 33 34  1  0
 34 35  1  0
 35 36  2  0
  2 37  1  0
  9  4  1  0
 33 10  1  0
 16 11  2  0
 23 18  1  0
 29 24  1  0
M  END
>  <BrandName>  (53) 


>  <Applicants>  (53) 
Astrazeneca

>  <CHEMBL_ID>  (53) 
CHEMBL1976040

>  <Canonical_Smiles>  (53) 
CC(C)(c1cccc(n1)n2c3c(cnc(n3)Nc4ccc(cc4)N5CCN(CC5)C)c(=O)n2CC=C)O

>  <Chirality>  (53) 
Achiral Molecule

>  <First_Approval>  (53) 
nan

>  <Phase>  (53) 
2.0

>  <SC_Patent>  (53) 
None

>  <Synonyms>  (53) 
ADAVOSERTIB | AZD 1775 | AZD-1775 | AZD1775 | MK-1775 | MK1775

>  <Withdrawn>  (53) 


>  <Indications>  (53) 
nan

>  <Type>  (53) 
1

>  <targets_id>  (53) 
P30291

>  <inchi>  (53) 
InChI=1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31)

>  <stdInchikey>  (53) 
BKWJAKQVGHWELA-UHFFFAOYSA-N

>  <csid>  (53) 
24808590

>  <Links>  (53) 
|http://www.chemspider.com/Chemical-Structure.24808590.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1976040|http://pubchem.ncbi.nlm.nih.gov/compound/24856436|http://www.drugbank.ca/drugs/DB11740| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=8X7|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/8X7|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7702|http://zinc15.docking.org/substances/ZINC000063539231|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=K2T6HJX3I3|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50240826

>  <LinkName>  (53) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (53) 
'8X7'

>  <pdbID>  (53) 
5v5y 5vd0 5vdk

>  <indicationG2P>  (53) 
None

>  <indicationDB>  (53) 
MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.

>  <uniprotId>  (53) 
P30291

>  <MW>  (53) 
500.3

>  <HBA>  (53) 
10.0

>  <HBD>  (53) 
2.0

>  <NRB>  (53) 
7.0

>  <TPSA>  (53) 
104.3

>  <LogP>  (53) 
2.9

>  <RoF>  (53) 
1.0

>  <Melting point>  (53) 


>  <Targets>  (53) 
WEE1

>  <Kinase families>  (53) 
Other

>  <FDA_approved>  (53) 


$$$$
Belvarafenib
     RDKit          2D

 33 37  0  0  0  0  0  0  0  0999 V2000
    1.0964    4.9550    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1460    3.7945    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6758    2.3912    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2746    1.2307    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7548    1.4736    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2846    2.8769    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3342    4.0374    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7052    0.3131    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1754   -1.0902    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6952   -1.3331    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2552   -0.1726    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1855    0.5559    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1359   -0.6046    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6161   -0.3617    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5665   -1.5222    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0367   -2.9255    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5565   -3.1684    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6061   -2.0079    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.0467   -1.2794    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -7.1459    1.0416    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    2.1560    2.1484    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6858    0.7450    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7354   -0.4154    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.1660    0.5022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2325    1.5570    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5653    0.8686    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    6.3224   -0.6116    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8396   -0.8381    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2943   -2.2354    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.2318   -3.4064    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7147   -3.1799    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.2599   -1.7825    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7427   -1.5561    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  5  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
  8 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 15 19  1  0
 14 20  1  0
  3 21  1  0
 21 22  1  0
 22 23  2  0
 22 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  2  0
 32 33  1  0
  7  2  1  0
 11  4  1  0
 18 13  1  0
 28 24  1  0
 32 27  1  0
M  END
>  <BrandName>  (54) 


>  <Applicants>  (54) 
Hanmi Pharmaceutical

>  <CHEMBL_ID>  (54) 
nan

>  <Canonical_Smiles>  (54) 
CC1=C(C2=C(C=C1)C(=NC=C2)NC3=C(C(=CC=C3)Cl)F)NC(=O)C4=CSC5=C4N=CN=C5N

>  <Chirality>  (54) 
nan

>  <First_Approval>  (54) 
nan

>  <Phase>  (54) 
2.0

>  <SC_Patent>  (54) 
nan

>  <Synonyms>  (54) 


>  <Withdrawn>  (54) 


>  <Indications>  (54) 
nan

>  <Type>  (54) 
nan

>  <targets_id>  (54) 
nan

>  <inchi>  (54) 
InChI=1S/C23H16ClFN6OS/c1-11-5-6-13-12(7-8-27-22(13)30-16-4-2-3-15(24)17(16)25)18(11)31-23(32)14-9-33-20-19(14)28-10-29-21(20)26/h2-10H,1H3,(H,27,30)(H,31,32)(H2,26,28,29)

>  <stdInchikey>  (54) 
KVCQTKNUUQOELD-UHFFFAOYSA-N

>  <csid>  (54) 
64878400

>  <Links>  (54) 
|http://www.chemspider.com/Chemical-Structure.64878400.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3977543|http://pubchem.ncbi.nlm.nih.gov/compound/89655386| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=V1Y|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/V1Y|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=31M3WLJ3KG|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=185591

>  <LinkName>  (54) 
|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|FDA SRS|BindingDB

>  <lig_pdbID>  (54) 
'V1Y'

>  <pdbID>  (54) 
6xfp

>  <indicationG2P>  (54) 


>  <indicationDB>  (54) 


>  <uniprotId>  (54) 


>  <MW>  (54) 
478.1

>  <HBA>  (54) 
7.0

>  <HBD>  (54) 
3.0

>  <NRB>  (54) 
4.0

>  <TPSA>  (54) 
105.8

>  <LogP>  (54) 
5.9

>  <RoF>  (54) 
1.0

>  <Melting point>  (54) 


>  <Targets>  (54) 
nan

>  <Kinase families>  (54) 
(*)

>  <FDA_approved>  (54) 


$$$$
Ceralasertib
     RDKit          2D

 29 33  0  0  0  0  0  0  0  0999 V2000
    4.3137   -0.8773    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5841   -2.1879    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3543   -3.4751    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6246   -4.7857    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.1248   -4.8091    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3546   -3.5219    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0843   -2.2113    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.3141   -0.9241    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0438    0.3865    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2736    1.6736    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2262    1.6503    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9559    0.3397    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1857   -0.9475    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4557    0.3163    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2259    1.6035    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7257    1.5801    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4553    0.2695    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6852   -1.0177    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1853   -0.9943    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6996   -2.4135    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8993   -3.3140    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1264   -2.4513    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0032    2.9842    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1371    3.9662    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4206    2.4932    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8393    3.9304    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1069    2.7664    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.7854    5.0943    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3247    4.8765    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 10 23  1  0
 23 24  1  0
 24 25  1  0
 23 26  1  0
 26 27  2  0
 26 28  2  0
 26 29  1  0
  7  2  1  0
 13  8  1  0
 19 14  1  0
 22 18  1  0
 25 23  1  0
M  END
>  <BrandName>  (55) 


>  <Applicants>  (55) 
Astrazeneca

>  <CHEMBL_ID>  (55) 
CHEMBL4285417

>  <Canonical_Smiles>  (55) 
CC1COCCN1c2cc(nc(n2)c3cncc4c3cc[nH]4)C5(CC5)S(=N)(=O)C

>  <Chirality>  (55) 
Single Stereoisomer

>  <First_Approval>  (55) 
nan

>  <Phase>  (55) 
2.0

>  <SC_Patent>  (55) 
None

>  <Synonyms>  (55) 
AZD6738

>  <Withdrawn>  (55) 


>  <Indications>  (55) 
Ceralasertib, also known as AZD6738, is an orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, ATR kinase inhibitor Ceralasertib selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis.

>  <Type>  (55) 
nan

>  <targets_id>  (55) 
nan

>  <inchi>  (55) 
InChI=1S/C20H24N6O2S/c1-13-12-28-8-7-26(13)18-9-17(20(4-5-20)29(2,21)27)24-19(25-18)15-10-22-11-16-14(15)3-6-23-16/h3,6,9-11,13,21,23H,4-5,7-8,12H2,1-2H3

>  <stdInchikey>  (55) 
DTTJKLNXNZAVSM-UHFFFAOYSA-N

>  <csid>  (55) 
64879993

>  <Links>  (55) 
|http://www.chemspider.com/Chemical-Structure.64879993.html|http://pubchem.ncbi.nlm.nih.gov/compound/76189946

>  <LinkName>  (55) 
|ChemSpider|PubChem

>  <lig_pdbID>  (55) 


>  <pdbID>  (55) 


>  <indicationG2P>  (55) 


>  <indicationDB>  (55) 


>  <uniprotId>  (55) 


>  <MW>  (55) 
412.2

>  <HBA>  (55) 
7.0

>  <HBD>  (55) 
2.0

>  <NRB>  (55) 
4.0

>  <TPSA>  (55) 
107.8

>  <LogP>  (55) 
2.9

>  <RoF>  (55) 
0.0

>  <Melting point>  (55) 


>  <Targets>  (55) 
nan

>  <Kinase families>  (55) 


>  <FDA_approved>  (55) 


$$$$
Afuresertib
     RDKit          2D

 27 29  0  0  0  0  0  0  0  0999 V2000
   -5.8253   -0.5770    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9725    0.6570    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4730    0.6924    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0433    2.1296    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2773    2.9823    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4697    2.0722    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6281    2.6267    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -2.5628   -0.4999    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0633   -0.4644    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5661   -1.8797    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7585   -2.7898    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9925   -1.9370    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4077   -2.4342    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    0.8710   -2.3093    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2175   -3.7688    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.9617   -1.2796    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.3988   -1.7092    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4895   -0.6795    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1430    0.7800    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2337    1.8097    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8872    3.2692    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4501    3.6988    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3594    2.6691    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7059    1.2096    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9223    3.0988    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    3.7453   -3.1687    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6546   -4.1984    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  4  7  1  0
  3  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 10 14  1  0
 14 15  2  0
 14 16  1  0
 16 17  1  0
 17 18  1  1
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 23 25  1  0
 17 26  1  0
 26 27  1  0
  6  2  1  0
 12  8  2  0
 24 19  1  0
M  END
>  <BrandName>  (56) 


>  <Applicants>  (56) 
GlaxoSmithKline

>  <CHEMBL_ID>  (56) 
CHEMBL2219422

>  <Canonical_Smiles>  (56) 
Cn1c(c(cn1)Cl)c2cc(sc2Cl)C(=O)N[C@@H](Cc3cccc(c3)F)CN

>  <Chirality>  (56) 
Single Stereoisomer

>  <First_Approval>  (56) 
nan

>  <Phase>  (56) 
2.0

>  <SC_Patent>  (56) 
None

>  <Synonyms>  (56) 
AFURESERTIB | ASB-183 | ASB183 | GSK-2110183 | GSK-2110183C | GSK2110183 | GSK2110183C

>  <Withdrawn>  (56) 


>  <Indications>  (56) 
nan

>  <Type>  (56) 
nan

>  <targets_id>  (56) 
P31749|P31751|Q9Y243

>  <inchi>  (56) 
InChI=1S/C18H17Cl2FN4OS/c1-25-16(14(19)9-23-25)13-7-15(27-17(13)20)18(26)24-12(8-22)6-10-3-2-4-11(21)5-10/h2-5,7,9,12H,6,8,22H2,1H3,(H,24,26)/t12-/m0/s1

>  <stdInchikey>  (56) 
AFJRDFWMXUECEW-LBPRGKRZSA-N

>  <csid>  (56) 
28651809

>  <Links>  (56) 
|http://www.chemspider.com/Chemical-Structure.28651809.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2219422|http://pubchem.ncbi.nlm.nih.gov/compound/46843057|http://www.drugbank.ca/drugs/DB11648|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7890|http://zinc15.docking.org/substances/ZINC000043197674|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=8739X25QI3

>  <LinkName>  (56) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (56) 


>  <pdbID>  (56) 


>  <indicationG2P>  (56) 
None

>  <indicationDB>  (56) 


>  <uniprotId>  (56) 


>  <MW>  (56) 
426.0

>  <HBA>  (56) 
5.0

>  <HBD>  (56) 
2.0

>  <NRB>  (56) 
6.0

>  <TPSA>  (56) 
72.9

>  <LogP>  (56) 
3.9

>  <RoF>  (56) 
0.0

>  <Melting point>  (56) 


>  <Targets>  (56) 
AKT1; AKT2; AKT3

>  <Kinase families>  (56) 
AGC

>  <FDA_approved>  (56) 


$$$$
Olmutinib
     RDKit          2D

 35 39  0  0  0  0  0  0  0  0999 V2000
   11.3586    1.2439    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8599    1.1826    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.1636   -0.1460    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6649   -0.2074    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8624    1.0599    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.5587    2.3885    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0574    2.4499    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3637    0.9986    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5612    2.2659    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0624    2.2045    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3662    0.8759    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1687   -0.3914    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6674   -0.3300    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8674    0.8146    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.1712   -0.5140    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9736   -1.7813    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.2774   -3.1099    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7989   -4.5164    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3776   -5.4469    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6262   -4.6156    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2214   -3.1713    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0238   -1.9040    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3276   -0.5754    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5226   -1.9653    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3251   -0.6980    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6288    0.6306    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4313    1.8979    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9301    1.8365    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6263    0.5079    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8238   -0.7594    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.1251    0.4466    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.9275    1.7139    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.2313    3.0425    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  -10.4263    1.6525    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.2288    2.9198    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  5  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 11 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  2  0
 22 24  1  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 29 31  1  0
 31 32  1  0
 32 33  2  0
 32 34  1  0
 34 35  2  0
  7  2  1  0
 13  8  1  0
 23 15  1  0
 21 17  2  0
 30 25  1  0
M  END
>  <BrandName>  (57) 


>  <Applicants>  (57) 
Hanmi Pharmaceutical

>  <CHEMBL_ID>  (57) 
CHEMBL3786343

>  <Canonical_Smiles>  (57) 
CN1CCN(CC1)c2ccc(cc2)Nc3nc4ccsc4c(n3)Oc5cccc(c5)NC(=O)C=C

>  <Chirality>  (57) 
Achiral Molecule

>  <First_Approval>  (57) 
nan

>  <Phase>  (57) 
2.0

>  <SC_Patent>  (57) 
None

>  <Synonyms>  (57) 
BI 1482694 | BI-1482694 | HM-61713 | HM61713 | OLMUTINIB

>  <Withdrawn>  (57) 


>  <Indications>  (57) 
For use in treatment of metastatic T790M mutation positive non-small cell lung cancer

>  <Type>  (57) 
nan

>  <targets_id>  (57) 
P00533

>  <inchi>  (57) 
InChI=1S/C26H26N6O2S/c1-3-23(33)27-19-5-4-6-21(17-19)34-25-24-22(11-16-35-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)

>  <stdInchikey>  (57) 
FDMQDKQUTRLUBU-UHFFFAOYSA-N

>  <csid>  (57) 
45743494

>  <Links>  (57) 
|http://www.chemspider.com/Chemical-Structure.45743494.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3786343|http://pubchem.ncbi.nlm.nih.gov/compound/54758501|http://www.drugbank.ca/drugs/DB13164|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9196|http://zinc15.docking.org/substances/ZINC000198970879|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=CHL9B67L95|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50160871

>  <LinkName>  (57) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (57) 


>  <pdbID>  (57) 


>  <indicationG2P>  (57) 
None

>  <indicationDB>  (57) 
Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer. It is available under the brand name Olita made by Hanmi Pharmaceuticals <sup class="text-reference-group"><a class="reference-popover-link" data-content="Kim ES: Olmutinib: First Global Approval. Drugs. 2016 Jul;76(11):1153-7. doi: 10.1007/s40265-016-0606-z. (PubMed ID 27357069)" href="#reference-A19196">4</a></sup>. Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim. Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016.

>  <uniprotId>  (57) 
P00533

>  <MW>  (57) 
486.2

>  <HBA>  (57) 
8.0

>  <HBD>  (57) 
2.0

>  <NRB>  (57) 
7.0

>  <TPSA>  (57) 
82.6

>  <LogP>  (57) 
5.1

>  <RoF>  (57) 
1.0

>  <Melting point>  (57) 


>  <Targets>  (57) 
EGFR

>  <Kinase families>  (57) 
Tyr

>  <FDA_approved>  (57) 


$$$$
Derazantinib
     RDKit          2D

 35 39  0  0  0  0  0  0  0  0999 V2000
  -14.4304    0.1382    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -13.0591    0.7462    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  -11.8469   -0.1373    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.4757    0.4707    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.2635   -0.4128    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.8923    0.1952    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6801   -0.6883    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3088   -0.0803    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1498    1.4112    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7785    2.0192    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5663    1.1357    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7254   -0.3558    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0967   -0.9639    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5132   -1.2394    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1420   -0.6314    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0171    0.8602    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.3883    1.4682    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6005    0.5847    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4414   -0.9069    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0702   -1.5149    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.6536   -1.7904    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4946   -3.2819    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7067   -4.1655    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0780   -3.5575    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2370   -2.0659    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0249   -1.1824    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1839    0.3092    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9718    1.1927    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5552    0.9172    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7674    0.0336    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1386    0.6417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2977    2.1332    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0855    3.0167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7143    2.4087    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5021    3.2922    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 19 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  1  0
 27 29  1  1
 29 30  2  0
 30 31  1  0
 31 32  2  0
 32 33  1  0
 33 34  2  0
 34 35  1  0
 13  8  1  0
 20 15  1  0
 28 18  1  0
 26 21  1  0
 34 29  1  0
M  END
>  <BrandName>  (58) 


>  <Applicants>  (58) 
ArQule

>  <CHEMBL_ID>  (58) 
CHEMBL4297187

>  <Canonical_Smiles>  (58) 
COCCNCCc1cccc(c1)Nc2ncc3c(n2)-c4ccccc4[C@@H](C3)c5ccccc5F

>  <Chirality>  (58) 
Single Stereoisomer

>  <First_Approval>  (58) 
nan

>  <Phase>  (58) 
2.0

>  <SC_Patent>  (58) 
None

>  <Synonyms>  (58) 
ARQ 087 | ARQ-087 | ARQ087 | DERAZANTINIB

>  <Withdrawn>  (58) 


>  <Indications>  (58) 
Derazantinib (ARQ087) is an orally bioavailable, non-selective FGFR inhibitor being investigated for antineoplastic activity.

>  <Type>  (58) 
nan

>  <targets_id>  (58) 
nan

>  <inchi>  (58) 
InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1

>  <stdInchikey>  (58) 
KPJDVVCDVBFRMU-AREMUKBSSA-N

>  <csid>  (58) 
59718644

>  <Links>  (58) 
|http://www.chemspider.com/Chemical-Structure.59718644.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297187|http://pubchem.ncbi.nlm.nih.gov/compound/46834118|http://www.drugbank.ca/drugs/DB14889|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9785|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=N9B0H171MJ

>  <LinkName>  (58) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS

>  <lig_pdbID>  (58) 


>  <pdbID>  (58) 


>  <indicationG2P>  (58) 
None

>  <indicationDB>  (58) 


>  <uniprotId>  (58) 


>  <MW>  (58) 
468.2

>  <HBA>  (58) 
5.0

>  <HBD>  (58) 
2.0

>  <NRB>  (58) 
9.0

>  <TPSA>  (58) 
59.1

>  <LogP>  (58) 
5.5

>  <RoF>  (58) 
1.0

>  <Melting point>  (58) 


>  <Targets>  (58) 
nan

>  <Kinase families>  (58) 


>  <FDA_approved>  (58) 


$$$$
Sonolisib
     RDKit          2D

 38 41  0  0  0  0  0  0  0  0999 V2000
   -5.1358    2.9700    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5258    1.5997    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4075    0.3862    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0340    1.4429    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4239    0.0725    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3056   -1.1410    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6955   -2.5113    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2037   -2.6681    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8919   -4.1353    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1909   -4.8853    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3056   -3.8816    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7729   -4.1934    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3220   -1.4546    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9321   -0.0843    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0504    1.1292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6605    2.4996    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2212    3.7131    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.7130    3.5562    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5947    4.7698    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.3231    2.1859    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8148    2.0291    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4249    0.6588    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.9167    0.5020    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5268   -0.8684    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0186   -1.0252    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5432   -0.5547    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1533   -1.9251    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2716   -3.1386    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4414    0.9724    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0514   -0.3979    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1697   -1.6114    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7798   -2.9818    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.8005   -0.6706    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1523    2.6564    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7624    4.0267    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2541    4.1835    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5422    1.2860    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1955   -2.5113    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  2  4  1  0
  5  4  1  1
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  6
  9 10  1  0
 10 11  1  0
 11 12  2  0
  8 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  2  0
 18 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  2  0
 22 26  1  0
 26 27  1  0
 27 28  2  0
 20 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  2  0
 30 33  1  0
 16 34  1  1
 34 35  1  0
 35 36  1  0
 15 37  1  6
  7 38  1  6
 14  5  1  0
 11  7  1  0
 31 13  1  0
 29 15  1  0
M  END
>  <BrandName>  (59) 


>  <Applicants>  (59) 
Cascadian Therapeutics

>  <CHEMBL_ID>  (59) 
CHEMBL411907

>  <Canonical_Smiles>  (59) 
CC(=O)O[C@@H]1C[C@]2([C@@H](CCC2=O)C3=C1[C@]4([C@H](OC(=O)/C(=C/N(CC=C)CC=C)/C4=C(C3=O)O)COC)C)C

>  <Chirality>  (59) 
Single Stereoisomer

>  <First_Approval>  (59) 
nan

>  <Phase>  (59) 
2.0

>  <SC_Patent>  (59) 
None

>  <Synonyms>  (59) 
PX-866 | SONOLISIB

>  <Withdrawn>  (59) 


>  <Indications>  (59) 
nan

>  <Type>  (59) 
nan

>  <targets_id>  (59) 
P42336|P42338|P48736

>  <inchi>  (59) 
InChI=1S/C29H35NO8/c1-7-11-30(12-8-2)14-17-23-26(34)25(33)22-18-9-10-20(32)28(18,4)13-19(37-16(3)31)24(22)29(23,5)21(15-36-6)38-27(17)35/h7-8,14,18-19,21,34H,1-2,9-13,15H2,3-6H3/b17-14+/t18-,19+,21+,28-,29-/m0/s1

>  <stdInchikey>  (59) 
QIUASFSNWYMDFS-NILGECQDSA-N

>  <csid>  (59) 
8025448

>  <Links>  (59) 
|http://www.chemspider.com/Chemical-Structure.8025448.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL411907|http://pubchem.ncbi.nlm.nih.gov/compound/9849735|http://www.drugbank.ca/drugs/DB12601|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7941|http://zinc15.docking.org/substances/ZINC000029134545|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=987796874T

>  <LinkName>  (59) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (59) 


>  <pdbID>  (59) 


>  <indicationG2P>  (59) 
None

>  <indicationDB>  (59) 


>  <uniprotId>  (59) 


>  <MW>  (59) 
525.2

>  <HBA>  (59) 
9.0

>  <HBD>  (59) 
1.0

>  <NRB>  (59) 
8.0

>  <TPSA>  (59) 
119.4

>  <LogP>  (59) 
3.1

>  <RoF>  (59) 
1.0

>  <Melting point>  (59) 


>  <Targets>  (59) 
PIK3CA; PIK3CB; PIK3CG

>  <Kinase families>  (59) 
Atypical

>  <FDA_approved>  (59) 


$$$$
Parsaclisib
     RDKit          2D

 30 33  0  0  0  0  0  0  0  0999 V2000
    0.1849   -3.1918    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9704   -1.9139    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2564   -0.5948    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.0419    0.6832    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3279    2.0023    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1134    3.2802    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6128    3.2390    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3268    1.9198    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5413    0.6419    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2553   -0.6773    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7422   -0.8751    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0136   -2.3504    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3666   -2.9979    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.6944   -3.0643    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6077   -2.0303    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8262    1.8785    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    3.3983    4.5169    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -1.1715    2.0436    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8855    3.3628    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9570    0.7657    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4525    0.6500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8046   -0.8080    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5267   -1.5935    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3848   -0.6209    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4111   -3.0890    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2434   -1.2321    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3301   -0.1981    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9780    1.2599    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5392    1.6840    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5956   -2.6902    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
 10  9  1  1
 10 11  1  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  1  0
  8 16  1  0
  7 17  1  0
  5 18  1  0
 18 19  1  1
 18 20  1  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 23 25  1  0
 22 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 26 30  1  0
  9  4  1  0
 15 10  1  0
 24 20  1  0
 29 21  1  0
M  END
>  <BrandName>  (60) 


>  <Applicants>  (60) 
Incyte Corporation

>  <CHEMBL_ID>  (60) 
CHEMBL4297615

>  <Canonical_Smiles>  (60) 
CCOc1c(cc(c(c1[C@H]2CC(=O)NC2)F)Cl)[C@H](C)n3c4c(c(n3)C)c(ncn4)N

>  <Chirality>  (60) 
Single Stereoisomer

>  <First_Approval>  (60) 
nan

>  <Phase>  (60) 
2.0

>  <SC_Patent>  (60) 
None

>  <Synonyms>  (60) 
INCB-050465 | INCB050465 | PARSACLISIB

>  <Withdrawn>  (60) 


>  <Indications>  (60) 
Parsaclisib (INCB050465) is a PI3K&delta; inhibitor that was developed by Incyte Corporation as an antineoplastic and immunomodulatory agent, as claimed in their patent WO2014134426A1 [<a href='javascript:callRef("ReferenceDisplayForward?referenceId=36232&displayId=1", 960, 600)' title="1. Li Y-L, Yao W, Combs AP, Yue EW, Mei S, Zhu W, Glenn J Jr, Maduskuie TP, Sparks RB, Douty B, He C. (2014) USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3KÎ´ RELATED DISORDERS. Patent no. WO2014134426A1.">1</a>]. The chemical structure is one of those claimed in patent WO2013033569A1, but it is not clear which example it is from a mixture of diastereoisomers 345-348 (although 347 and 348 had the highest inhibitory potency <i>vs</i>. PI3K&delta; and 347 was tested <i>in vivo</i> [<a href='javascript:callRef("ReferenceDisplayForward?referenceId=36233&displayId=2", 960, 600)' title="2. Li Y-L, Yao W, Combs AP, Yue EW, Mei S, Zhu W, Glenn J, Maduskuie TP Jr, Sparks RB, Douty B. (2013) Heterocyclylamines as pi3k inhibitors. Patent no. WO2013033569A1.">2</a>].

>  <Type>  (60) 
nan

>  <targets_id>  (60) 
nan

>  <inchi>  (60) 
InChI=1S/C20H22ClFN6O2/c1-4-30-18-12(6-13(21)17(22)16(18)11-5-14(29)24-7-11)10(3)28-20-15(9(2)27-28)19(23)25-8-26-20/h6,8,10-11H,4-5,7H2,1-3H3,(H,24,29)(H2,23,25,26)/t10-,11-/m0/s1

>  <stdInchikey>  (60) 
ZQPDJCIXJHUERQ-QWRGUYRKSA-N

>  <csid>  (60) 
64835232

>  <Links>  (60) 
|http://www.chemspider.com/Chemical-Structure.64835232.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297615|http://pubchem.ncbi.nlm.nih.gov/compound/86677874|http://www.drugbank.ca/drugs/DB14867|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10098|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=OS7097575K|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=272573

>  <LinkName>  (60) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB

>  <lig_pdbID>  (60) 


>  <pdbID>  (60) 


>  <indicationG2P>  (60) 
None

>  <indicationDB>  (60) 


>  <uniprotId>  (60) 


>  <MW>  (60) 
432.1

>  <HBA>  (60) 
7.0

>  <HBD>  (60) 
2.0

>  <NRB>  (60) 
5.0

>  <TPSA>  (60) 
107.9

>  <LogP>  (60) 
3.1

>  <RoF>  (60) 
0.0

>  <Melting point>  (60) 


>  <Targets>  (60) 
nan

>  <Kinase families>  (60) 


>  <FDA_approved>  (60) 


$$$$
Entospletinib
     RDKit          2D

 31 36  0  0  0  0  0  0  0  0999 V2000
    0.9908   -1.0030    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3314   -0.3300    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5845   -1.1545    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4970   -2.6519    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1565   -3.3249    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9034   -2.5005    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4372   -3.1735    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6903   -2.3490    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0308   -3.0220    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4277   -4.4686    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9261   -4.5381    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4553   -3.1346    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2839   -2.1976    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1965   -0.7001    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8559   -0.0271    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6028   -0.8516    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7685    1.4703    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0216    2.2948    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9342    3.7922    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5936    4.4652    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1967    5.9118    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6984    5.9813    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1692    4.5778    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3405    3.6408    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4279    2.1433    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9250   -0.4815    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.1781   -1.3059    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5187   -0.6329    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6061    0.8645    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.3530    1.6890    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0125    1.0160    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 15 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  1  0
 24 25  2  0
  3 26  1  0
 26 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
  6  1  1  0
 16  8  2  0
 13  9  1  0
 25 17  1  0
 24 20  1  0
 31 26  1  0
M  END
>  <BrandName>  (61) 


>  <Applicants>  (61) 
Gilead Sciences

>  <CHEMBL_ID>  (61) 
CHEMBL3265032

>  <Canonical_Smiles>  (61) 
c1cc(ccc1Nc2c3nccn3cc(n2)c4ccc5cn[nH]c5c4)N6CCOCC6

>  <Chirality>  (61) 
Achiral Molecule

>  <First_Approval>  (61) 
nan

>  <Phase>  (61) 
2.0

>  <SC_Patent>  (61) 
None

>  <Synonyms>  (61) 
ENTOSPLETINIB | GS-9973 | SYK INHIBITOR GS-9973

>  <Withdrawn>  (61) 


>  <Indications>  (61) 
nan

>  <Type>  (61) 
1

>  <targets_id>  (61) 
P43405

>  <inchi>  (61) 
InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27)

>  <stdInchikey>  (61) 
XSMSNFMDVXXHGJ-UHFFFAOYSA-N

>  <csid>  (61) 
31042596

>  <Links>  (61) 
|http://www.chemspider.com/Chemical-Structure.31042596.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3265032|http://pubchem.ncbi.nlm.nih.gov/compound/59473233|http://www.drugbank.ca/drugs/DB12121| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=CG9|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/CG9|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7889|http://zinc15.docking.org/substances/ZINC000098208742|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6I3O3W6O3B|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50015448

>  <LinkName>  (61) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (61) 
'CG9'

>  <pdbID>  (61) 
4puz

>  <indicationG2P>  (61) 
None

>  <indicationDB>  (61) 


>  <uniprotId>  (61) 


>  <MW>  (61) 
411.2

>  <HBA>  (61) 
7.0

>  <HBD>  (61) 
2.0

>  <NRB>  (61) 
4.0

>  <TPSA>  (61) 
83.4

>  <LogP>  (61) 
3.9

>  <RoF>  (61) 
0.0

>  <Melting point>  (61) 


>  <Targets>  (61) 
SYK

>  <Kinase families>  (61) 
Tyr

>  <FDA_approved>  (61) 


$$$$
Defactinib
     RDKit          2D

 35 37  0  0  0  0  0  0  0  0999 V2000
  -11.0438    0.5161    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.6014    0.9276    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.5238   -0.1158    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.8887   -1.5708    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0813    0.2957    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7165    1.7506    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2740    2.1621    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1964    1.1186    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5613   -0.3363    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0038   -0.7478    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7540    1.5301    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6764    0.4867    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0413   -0.9683    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9637   -2.0117    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4788   -1.6002    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8437   -0.1453    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2339    0.8982    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.2861    0.2662    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6510    1.7211    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0934    2.1326    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1710    1.0892    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6135    1.5007    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.9783    2.9556    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9007    3.9991    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4583    3.5876    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.8061   -0.3658    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.3637   -0.7773    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8837   -1.4092    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    6.9272   -0.3316    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.8403   -2.4868    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.9613   -2.4527    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5564   -2.6437    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6340   -3.6872    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    0.5129   -3.7213    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    2.5998   -1.5661    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  3  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
  8 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 16 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 21 26  1  0
 26 27  1  0
 26 28  1  0
 28 29  2  0
 28 30  2  0
 28 31  1  0
 15 32  1  0
 32 33  1  0
 32 34  1  0
 32 35  1  0
 10  5  1  0
 17 12  1  0
 25 20  1  0
M  END
>  <BrandName>  (62) 


>  <Applicants>  (62) 
Verastem

>  <CHEMBL_ID>  (62) 
CHEMBL3137331

>  <Canonical_Smiles>  (62) 
CNC(=O)c1ccc(cc1)Nc2ncc(c(n2)NCc3c(nccn3)N(C)S(=O)(=O)C)C(F)(F)F

>  <Chirality>  (62) 
Achiral Molecule

>  <First_Approval>  (62) 
nan

>  <Phase>  (62) 
2.0

>  <SC_Patent>  (62) 
None

>  <Synonyms>  (62) 
DEFACTINIB | PF-04554878 | VS-6063

>  <Withdrawn>  (62) 


>  <Indications>  (62) 
nan

>  <Type>  (62) 
1

>  <targets_id>  (62) 
Q05397|Q14289

>  <inchi>  (62) 
InChI=1S/C20H21F3N8O3S/c1-24-18(32)12-4-6-13(7-5-12)29-19-28-10-14(20(21,22)23)16(30-19)27-11-15-17(26-9-8-25-15)31(2)35(3,33)34/h4-10H,11H2,1-3H3,(H,24,32)(H2,27,28,29,30)

>  <stdInchikey>  (62) 
FWLMVFUGMHIOAA-UHFFFAOYSA-N

>  <csid>  (62) 
32695161

>  <Links>  (62) 
|http://www.chemspider.com/Chemical-Structure.32695161.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3137331|http://pubchem.ncbi.nlm.nih.gov/compound/25117126|http://www.drugbank.ca/drugs/DB12282| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=7KD|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/7KD|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7910|http://zinc15.docking.org/substances/ZINC000103297739|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=53O87HA2QU|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=418817

>  <LinkName>  (62) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (62) 
'7KD'

>  <pdbID>  (62) 
5mah

>  <indicationG2P>  (62) 
None

>  <indicationDB>  (62) 


>  <uniprotId>  (62) 


>  <MW>  (62) 
510.1

>  <HBA>  (62) 
9.0

>  <HBD>  (62) 
3.0

>  <NRB>  (62) 
8.0

>  <TPSA>  (62) 
142.1

>  <LogP>  (62) 
2.4

>  <RoF>  (62) 
1.0

>  <Melting point>  (62) 


>  <Targets>  (62) 
PTK2; PTK2B

>  <Kinase families>  (62) 
Tyr

>  <FDA_approved>  (62) 


$$$$
Bafetinib
     RDKit          2D

 42 46  0  0  0  0  0  0  0  0999 V2000
   -8.0934    1.8219    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6012    1.9751    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9879    3.3440    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4957    3.4972    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6169    2.2816    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2303    0.9127    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7225    0.7595    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3358   -0.6094    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4570   -1.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0704   -3.1938    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1916   -4.4095    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6994   -4.2562    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0861   -2.8874    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9649   -1.6717    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5939   -2.7341    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7151   -3.9497    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7770   -3.7965    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.3904   -2.4276    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5116   -1.2120    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9806   -1.3652    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1248    2.4349    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2460    1.2192    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8594   -0.1496    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.2462    1.3725    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1249    0.1569    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6171    0.3101    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2305    1.6790    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3517    2.8946    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8595    2.7413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9650    4.2635    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5784    5.6323    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    1.5962    4.8768    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    4.3339    3.6501    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    4.7226    1.8322    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6014    0.6166    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.1014    0.6130    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5615   -0.8147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3459   -1.6934    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1345   -0.8089    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3423   -3.1934    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.0415   -3.9403    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6396   -3.9465    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 13 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
  5 21  1  0
 21 22  1  0
 22 23  2  0
 22 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 28 30  1  0
 30 31  1  0
 30 32  1  0
 30 33  1  0
 27 34  1  0
 34 35  1  0
 35 36  1  0
 36 37  1  0
 37 38  1  0
 38 39  1  0
 38 40  1  6
 40 41  1  0
 40 42  1  0
  7  2  1  0
 14  9  1  0
 20 15  1  0
 29 24  1  0
 39 35  1  0
M  END
>  <BrandName>  (63) 


>  <Applicants>  (63) 
Innovive Pharmaceuticals

>  <CHEMBL_ID>  (63) 
CHEMBL206834

>  <Canonical_Smiles>  (63) 
Cc1ccc(cc1Nc2nccc(n2)c3cncnc3)NC(=O)c4ccc(c(c4)C(F)(F)F)CN5CC[C@@H](C5)N(C)C

>  <Chirality>  (63) 
Single Stereoisomer

>  <First_Approval>  (63) 
nan

>  <Phase>  (63) 
2.0

>  <SC_Patent>  (63) 
None

>  <Synonyms>  (63) 
BAFETINIB | CNS-9 | INNO-406 | NS-187

>  <Withdrawn>  (63) 


>  <Indications>  (63) 
nan

>  <Type>  (63) 
2

>  <targets_id>  (63) 
P07948|P00519

>  <inchi>  (63) 
InChI=1S/C30H31F3N8O/c1-19-4-7-23(13-27(19)39-29-36-10-8-26(38-29)22-14-34-18-35-15-22)37-28(42)20-5-6-21(25(12-20)30(31,32)33)16-41-11-9-24(17-41)40(2)3/h4-8,10,12-15,18,24H,9,11,16-17H2,1-3H3,(H,37,42)(H,36,38,39)/t24-/m0/s1

>  <stdInchikey>  (63) 
ZGBAJMQHJDFTQJ-DEOSSOPVSA-N

>  <csid>  (63) 
9562515

>  <Links>  (63) 
|http://www.chemspider.com/Chemical-Structure.9562515.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL206834|http://pubchem.ncbi.nlm.nih.gov/compound/11387605|http://www.drugbank.ca/drugs/DB11851| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=406|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/406|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7906|http://zinc15.docking.org/substances/ZINC000022940637|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=NVW4Z03I9B|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50178612

>  <LinkName>  (63) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (63) 
'406'

>  <pdbID>  (63) 
2e2b

>  <indicationG2P>  (63) 
None

>  <indicationDB>  (63) 


>  <uniprotId>  (63) 


>  <MW>  (63) 
576.3

>  <HBA>  (63) 
8.0

>  <HBD>  (63) 
2.0

>  <NRB>  (63) 
8.0

>  <TPSA>  (63) 
99.2

>  <LogP>  (63) 
5.4

>  <RoF>  (63) 
2.0

>  <Melting point>  (63) 


>  <Targets>  (63) 
LYN; ABL1

>  <Kinase families>  (63) 
Tyr

>  <FDA_approved>  (63) 


$$$$
Amcasertib
     RDKit          2D

 39 43  0  0  0  0  0  0  0  0999 V2000
  -12.5966   -1.6608    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.3958   -0.7617    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.0169   -1.3521    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -9.8387   -2.8415    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.0395   -3.7405    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.8162   -0.4531    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4372   -1.0435    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2365   -0.1445    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8575   -0.7348    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6793   -2.2242    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6568    0.1642    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2237   -0.2788    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3595    0.9472    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2585    2.1480    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6783    1.6640    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9044    2.5282    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1403    0.9688    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8716    2.2784    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3610    2.4566    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4900    1.4690    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9098    1.9530    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2005    3.4245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0715    4.4121    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6517    3.9282    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3421    4.6594    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.2419    3.6398    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2297    3.9306    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.0388    0.9654    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5014    1.2983    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2699    0.0101    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    7.2823   -1.1189    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9034   -0.5285    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.6152   -2.5815    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5150   -3.6011    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8479   -5.0636    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2810   -5.5066    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3812   -4.4870    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0483   -3.0245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7397   -1.6986    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  3  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
  9 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 13 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  1  0
 26 27  2  0
 21 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  1  0
 31 32  2  0
 31 33  1  0
 33 34  2  0
 34 35  1  0
 35 36  2  0
 36 37  1  0
 37 38  2  0
 12 39  1  0
 15 11  2  0
 18 26  1  0
 24 19  1  0
 32 28  1  0
 38 33  1  0
M  END
>  <BrandName>  (64) 


>  <Applicants>  (64) 
Boston Biomedical

>  <CHEMBL_ID>  (64) 
CHEMBL3707349

>  <Canonical_Smiles>  (64) 
CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)c4csc(n4)c5ccccc5)C

>  <Chirality>  (64) 
Achiral Molecule

>  <First_Approval>  (64) 
nan

>  <Phase>  (64) 
2.0

>  <SC_Patent>  (64) 
None

>  <Synonyms>  (64) 
AMCASERTIB | BBI-503 | BBI503

>  <Withdrawn>  (64) 


>  <Indications>  (64) 
nan

>  <Type>  (64) 
nan

>  <targets_id>  (64) 
P16234

>  <inchi>  (64) 
InChI=1S/C31H33N5O2S/c1-5-36(6-2)15-14-32-30(38)28-19(3)26(33-20(28)4)17-24-23-16-22(12-13-25(23)34-29(24)37)27-18-39-31(35-27)21-10-8-7-9-11-21/h7-13,16-18,33H,5-6,14-15H2,1-4H3,(H,32,38)(H,34,37)/b24-17-

>  <stdInchikey>  (64) 
QDWKGEFGLQMDAM-ULJHMMPZSA-N

>  <csid>  (64) 
44208821

>  <Links>  (64) 
|http://www.chemspider.com/Chemical-Structure.44208821.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3707349|http://pubchem.ncbi.nlm.nih.gov/compound/25190990|http://www.drugbank.ca/drugs/DB14866|http://zinc15.docking.org/substances/ZINC000059029686|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=GLY8ABW25V

>  <LinkName>  (64) 
|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS

>  <lig_pdbID>  (64) 


>  <pdbID>  (64) 


>  <indicationG2P>  (64) 


>  <indicationDB>  (64) 


>  <uniprotId>  (64) 


>  <MW>  (64) 
539.2

>  <HBA>  (64) 
5.0

>  <HBD>  (64) 
3.0

>  <NRB>  (64) 
9.0

>  <TPSA>  (64) 
90.1

>  <LogP>  (64) 
6.0

>  <RoF>  (64) 
2.0

>  <Melting point>  (64) 


>  <Targets>  (64) 
PDGFRA

>  <Kinase families>  (64) 
Tyr

>  <FDA_approved>  (64) 


$$$$
Galunisertib
     RDKit          2D

 28 32  0  0  0  0  0  0  0  0999 V2000
   -7.0093   -0.8762    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6737   -0.1933    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5973    1.3047    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2618    1.9876    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0026    1.1724    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0790   -0.3257    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4146   -1.0085    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8199   -1.1409    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4203   -0.6014    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5253   -1.7658    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2899   -3.0249    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7393   -2.6387    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.6558   -4.1893    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0554   -3.6498    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9748   -2.1520    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0341    0.8481    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0962    1.9072    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7100    3.3567    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7383    3.7469    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.8005    2.6877    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4143    1.2383    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4764    0.1791    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9248    0.5694    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3110    2.0188    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2488    3.0780    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9869   -0.4898    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6007   -1.9392    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.4352   -0.0995    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  6  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  1  0
 11 13  1  0
 13 14  1  0
 14 15  1  0
  9 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 23 26  1  0
 26 27  2  0
 26 28  1  0
  7  2  1  0
 12  8  2  0
 15 10  1  0
 21 16  1  0
 25 20  1  0
M  END
>  <BrandName>  (65) 


>  <Applicants>  (65) 
Eli Lilly

>  <CHEMBL_ID>  (65) 
CHEMBL2364611

>  <Canonical_Smiles>  (65) 
Cc1cccc(n1)c2c(c3n(n2)CCC3)c4ccnc5c4cc(cc5)C(=O)N

>  <Chirality>  (65) 
Achiral Molecule

>  <First_Approval>  (65) 
nan

>  <Phase>  (65) 
2.0

>  <SC_Patent>  (65) 
None

>  <Synonyms>  (65) 
GALUNISERTIB | LY-2157299 | LY2157299

>  <Withdrawn>  (65) 


>  <Indications>  (65) 
nan

>  <Type>  (65) 
nan

>  <targets_id>  (65) 
P36897

>  <inchi>  (65) 
InChI=1S/C22H19N5O/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12H,3,6,11H2,1H3,(H2,23,28)

>  <stdInchikey>  (65) 
IVRXNBXKWIJUQB-UHFFFAOYSA-N

>  <csid>  (65) 
8266022

>  <Links>  (65) 
|http://www.chemspider.com/Chemical-Structure.8266022.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2364611|http://pubchem.ncbi.nlm.nih.gov/compound/10090485|http://www.drugbank.ca/drugs/DB11911|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7797|http://zinc15.docking.org/substances/ZINC03959536|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=3OKH1W5LZE|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50015640

>  <LinkName>  (65) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (65) 


>  <pdbID>  (65) 


>  <indicationG2P>  (65) 
None

>  <indicationDB>  (65) 


>  <uniprotId>  (65) 


>  <MW>  (65) 
369.2

>  <HBA>  (65) 
5.0

>  <HBD>  (65) 
1.0

>  <NRB>  (65) 
3.0

>  <TPSA>  (65) 
86.7

>  <LogP>  (65) 
3.5

>  <RoF>  (65) 
0.0

>  <Melting point>  (65) 


>  <Targets>  (65) 
TGFBR1

>  <Kinase families>  (65) 
TKL

>  <FDA_approved>  (65) 


$$$$
Gedatolisib
     RDKit          2D

 45 50  0  0  0  0  0  0  0  0999 V2000
  -10.2676   -5.1102    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.9116   -4.4690    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6783   -5.3228    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7888   -2.9740    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.0221   -2.1202    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.8993   -0.6253    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.5433    0.0159    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3100   -0.8379    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4327   -2.3329    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4205    1.5109    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.6538    2.3647    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0644    2.1521    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8312    1.2983    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4751    1.9394    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3523    3.4344    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5856    4.2882    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9417    3.6470    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9963    4.0756    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7630    3.2218    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8857    1.7268    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4069    3.8629    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.8264    3.0091    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7036    1.5142    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9369    0.6604    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2930    1.3015    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4158    2.7965    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1825    3.6503    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5263    0.4477    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4035   -1.0472    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.6368   -1.9010    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9929   -1.2599    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.1157    0.2351    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8824    1.0889    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.4717    0.8763    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.7050    0.0225    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.0611    0.6636    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1838    2.1586    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.9505    3.0124    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5945    2.3712    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5141   -3.3960    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.1580   -4.0372    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0352   -5.5321    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2685   -6.3859    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.6246   -5.7448    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7474   -4.2498    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  7 10  1  0
 10 11  2  0
 10 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 15 18  1  0
 18 19  1  0
 19 20  2  0
 19 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 25 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 32 33  2  0
 32 34  1  0
 34 35  1  0
 35 36  1  0
 36 37  1  0
 37 38  1  0
 38 39  1  0
 30 40  1  0
 40 41  1  0
 41 42  1  0
 42 43  1  0
 43 44  1  0
 44 45  1  0
  9  4  1  0
 17 12  1  0
 27 22  1  0
 33 28  1  0
 39 34  1  0
 45 40  1  0
M  END
>  <BrandName>  (66) 


>  <Applicants>  (66) 
Pfizer

>  <CHEMBL_ID>  (66) 
CHEMBL592445

>  <Canonical_Smiles>  (66) 
CN(C)C1CCN(CC1)C(=O)c2ccc(cc2)NC(=O)Nc3ccc(cc3)c4nc(nc(n4)N5CCOCC5)N6CCOCC6

>  <Chirality>  (66) 
Achiral Molecule

>  <First_Approval>  (66) 
nan

>  <Phase>  (66) 
2.0

>  <SC_Patent>  (66) 
None

>  <Synonyms>  (66) 
GEDATOLISIB | PF-05212384 | PKI-587

>  <Withdrawn>  (66) 
|Study NCT03400254 in United States was Withdrawn during Phase 1/Phase 2 because due to business decision regarding the study drug

>  <Indications>  (66) 
nan

>  <Type>  (66) 
nan

>  <targets_id>  (66) 
P42336|P42338|P48736|O00329|P42345

>  <inchi>  (66) 
InChI=1S/C32H41N9O4/c1-38(2)27-11-13-39(14-12-27)29(42)24-5-9-26(10-6-24)34-32(43)33-25-7-3-23(4-8-25)28-35-30(40-15-19-44-20-16-40)37-31(36-28)41-17-21-45-22-18-41/h3-10,27H,11-22H2,1-2H3,(H2,33,34,43)

>  <stdInchikey>  (66) 
DWZAEMINVBZMHQ-UHFFFAOYSA-N

>  <csid>  (66) 
24644946

>  <Links>  (66) 
|http://www.chemspider.com/Chemical-Structure.24644946.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL592445|http://pubchem.ncbi.nlm.nih.gov/compound/44516953|http://www.drugbank.ca/drugs/DB11896| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=VL1|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/VL1|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7940|http://zinc15.docking.org/substances/ZINC000049757175|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=96265TNH2R|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50308135

>  <LinkName>  (66) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (66) 
'VL1'

>  <pdbID>  (66) 
7jwe

>  <indicationG2P>  (66) 
None

>  <indicationDB>  (66) 


>  <uniprotId>  (66) 


>  <MW>  (66) 
615.3

>  <HBA>  (66) 
10.0

>  <HBD>  (66) 
2.0

>  <NRB>  (66) 
7.0

>  <TPSA>  (66) 
128.3

>  <LogP>  (66) 
3.0

>  <RoF>  (66) 
1.0

>  <Melting point>  (66) 


>  <Targets>  (66) 
PIK3CA; PIK3CB; PIK3CG; PIK3CD; MTOR

>  <Kinase families>  (66) 
Atypical

>  <FDA_approved>  (66) 


$$$$
Glesatinib
     RDKit          2D

 43 47  0  0  0  0  0  0  0  0999 V2000
   16.4367    2.9921    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.0357    3.5278    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   13.8712    2.5823    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.4701    3.1180    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.3056    2.1725    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.9046    2.7082    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7401    1.7627    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.9767    0.2814    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8122   -0.6641    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4111   -0.1284    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1745    1.3528    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.3390    2.2984    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2467   -1.0739    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3272   -2.5717    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9275   -3.1111    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9820   -1.9467    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7973   -0.6876    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    1.5008   -2.1833    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9651   -3.5844    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9106   -4.7488    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3918   -4.5122    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.5552   -1.0188    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9260   -1.2554    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8715   -0.0909    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3527   -0.3275    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8884   -1.7286    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9429   -2.8931    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4617   -2.6565    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5162   -3.8210    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3697   -1.9652    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3152   -0.8008    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7795    0.6003    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -7.7964   -1.0374    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7419    0.1271    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.2062    1.5282    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  -10.2231   -0.1095    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.1687    1.0550    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.6329    2.4560    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.5785    3.6205    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -13.0597    3.3839    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -13.5954    1.9828    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -12.6499    0.8184    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -14.0052    4.5484    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 10 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 16 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 18 22  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 26 30  1  0
 30 31  1  0
 31 32  2  0
 31 33  1  0
 33 34  1  0
 34 35  2  0
 34 36  1  0
 36 37  1  0
 37 38  2  0
 38 39  1  0
 39 40  2  0
 40 41  1  0
 41 42  2  0
 40 43  1  0
 12  7  1  0
 17 13  1  0
 21 15  1  0
 28 23  1  0
 42 37  1  0
M  END
>  <BrandName>  (67) 


>  <Applicants>  (67) 
Mirati Therapeutics

>  <CHEMBL_ID>  (67) 
CHEMBL3989914

>  <Canonical_Smiles>  (67) 
COCCNCc1ccc(nc1)c2cc3c(s2)c(ccn3)Oc4ccc(cc4F)NC(=S)NC(=O)Cc5ccc(cc5)F

>  <Chirality>  (67) 
Achiral Molecule

>  <First_Approval>  (67) 
nan

>  <Phase>  (67) 
2.0

>  <SC_Patent>  (67) 
None

>  <Synonyms>  (67) 
GLESATINIB | MG-90265 | MG-90265X | MG90265 | MG90265GLY | MG90265H9 | MG90265X | MGCD-265 | MGCD265

>  <Withdrawn>  (67) 


>  <Indications>  (67) 
nan

>  <Type>  (67) 
nan

>  <targets_id>  (67) 
P08581|Q02763|P17948|P35968|P35916|Q04912

>  <inchi>  (67) 
InChI=1S/C31H27F2N5O3S2/c1-40-13-12-34-17-20-4-8-24(36-18-20)28-16-25-30(43-28)27(10-11-35-25)41-26-9-7-22(15-23(26)33)37-31(42)38-29(39)14-19-2-5-21(32)6-3-19/h2-11,15-16,18,34H,12-14,17H2,1H3,(H2,37,38,39,42)

>  <stdInchikey>  (67) 
YRCHYHRCBXNYNU-UHFFFAOYSA-N

>  <csid>  (67) 
52084900

>  <Links>  (67) 
|http://www.chemspider.com/Chemical-Structure.52084900.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3989914|http://pubchem.ncbi.nlm.nih.gov/compound/25181472|http://www.drugbank.ca/drugs/DB06302|http://zinc15.docking.org/substances/ZINC000113139653|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=7Q29OXD98N

>  <LinkName>  (67) 
|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS

>  <lig_pdbID>  (67) 


>  <pdbID>  (67) 


>  <indicationG2P>  (67) 


>  <indicationDB>  (67) 


>  <uniprotId>  (67) 


>  <MW>  (67) 
619.2

>  <HBA>  (67) 
8.0

>  <HBD>  (67) 
3.0

>  <NRB>  (67) 
11.0

>  <TPSA>  (67) 
97.4

>  <LogP>  (67) 
6.2

>  <RoF>  (67) 
2.0

>  <Melting point>  (67) 


>  <Targets>  (67) 
MET; TEK; FLT1; KDR; FLT4; MST1R

>  <Kinase families>  (67) 
Tyr

>  <FDA_approved>  (67) 


$$$$
Nemiralisib
     RDKit          2D

 33 38  0  0  0  0  0  0  0  0999 V2000
    9.3898   -1.0894    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8880    0.3241    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8613    1.4655    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4129    0.5963    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.4396   -0.5451    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9645   -0.2729    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4627    1.1407    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.4360    2.2821    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9111    2.0099    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9876    1.4129    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0143    0.2715    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3656   -1.1868    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0873   -1.9715    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0541   -0.9983    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5189    0.3880    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5124   -1.3496    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5457   -0.2624    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0040   -0.6137    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4289   -2.0523    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3955   -3.1395    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9372   -2.7882    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1525   -4.0665    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1257   -5.2079    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5120   -4.6350    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0374    0.4736    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4957    0.1222    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5291    1.2095    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1042    2.6480    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6459    2.9994    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6125    1.9121    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2592    2.5590    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4561    4.0460    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9312    4.3182    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  7 10  1  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 14 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 18 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  2  0
 32 33  1  0
  9  4  1  0
 15 11  1  0
 21 16  1  0
 24 20  1  0
 30 25  1  0
 33 29  1  0
M  END
>  <BrandName>  (68) 


>  <Applicants>  (68) 
GlaxosmithKline

>  <CHEMBL_ID>  (68) 
CHEMBL2216859

>  <Canonical_Smiles>  (68) 
CC(C)N1CCN(CC1)Cc2cnc(o2)c3cc(cc4c3cn[nH]4)c5cccc6c5cc[nH]6

>  <Chirality>  (68) 
Achiral Molecule

>  <First_Approval>  (68) 
nan

>  <Phase>  (68) 
2.0

>  <SC_Patent>  (68) 
None

>  <Synonyms>  (68) 
GSK-2269557 | GSK-2269557 FREE BASE | GSK-2269557A | GSK2269557A | NEMIRALISIB

>  <Withdrawn>  (68) 


>  <Indications>  (68) 
nan

>  <Type>  (68) 
nan

>  <targets_id>  (68) 
nan

>  <inchi>  (68) 
InChI=1S/C26H28N6O/c1-17(2)32-10-8-31(9-11-32)16-19-14-28-26(33-19)22-12-18(13-25-23(22)15-29-30-25)20-4-3-5-24-21(20)6-7-27-24/h3-7,12-15,17,27H,8-11,16H2,1-2H3,(H,29,30)

>  <stdInchikey>  (68) 
MCIDWGZGWVSZMK-UHFFFAOYSA-N

>  <csid>  (68) 
28651123

>  <Links>  (68) 
|http://www.chemspider.com/Chemical-Structure.28651123.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2216859|http://pubchem.ncbi.nlm.nih.gov/compound/49784002|http://www.drugbank.ca/drugs/DB16253| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=VVX|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/VVX|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9425|http://zinc15.docking.org/substances/ZINC000095564436|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=OEP8JJ3OZR|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50004529

>  <LinkName>  (68) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (68) 
'VVX'

>  <pdbID>  (68) 
5ae8

>  <indicationG2P>  (68) 
None

>  <indicationDB>  (68) 


>  <uniprotId>  (68) 


>  <MW>  (68) 
440.2

>  <HBA>  (68) 
5.0

>  <HBD>  (68) 
2.0

>  <NRB>  (68) 
5.0

>  <TPSA>  (68) 
77.0

>  <LogP>  (68) 
4.9

>  <RoF>  (68) 
0.0

>  <Melting point>  (68) 


>  <Targets>  (68) 
nan

>  <Kinase families>  (68) 


>  <FDA_approved>  (68) 


$$$$
Neflamapimod
     RDKit          2D

 28 31  0  0  0  0  0  0  0  0999 V2000
   -4.3541   -3.6169    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3234   -2.4722    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8167   -1.0603    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3407   -0.7932    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3714   -1.9379    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8780   -3.3497    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8953   -1.6708    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -2.8340    0.6186    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3580    0.8858    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3887   -0.2589    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0874    0.0082    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5940    1.4200    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6247    2.5647    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8514    2.2976    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8207    3.4423    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2967    3.1752    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8034    1.7633    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2794    1.4962    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.0700    1.6872    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    4.0394    0.5425    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5327   -0.8694    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5021   -2.0141    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9781   -1.7470    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4848   -0.3351    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5154    0.8096    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0221    2.2214    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    6.9475   -2.8917    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7861    0.0844    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  5  7  1  0
  4  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 12 19  1  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 23 27  1  0
  3 28  1  0
  6  1  1  0
 17  8  1  0
 14  9  1  0
 25 20  1  0
M  END
>  <BrandName>  (69) 


>  <Applicants>  (69) 
EIP Pharma

>  <CHEMBL_ID>  (69) 
CHEMBL119385

>  <Canonical_Smiles>  (69) 
c1cc(c(c(c1)Cl)c2c3ccc(nn3cnc2=O)Sc4ccc(cc4F)F)Cl

>  <Chirality>  (69) 
Achiral Molecule

>  <First_Approval>  (69) 
nan

>  <Phase>  (69) 
2.0

>  <SC_Patent>  (69) 
None

>  <Synonyms>  (69) 
745 | NEFLAMAPIMOD | VD-31 | VD-31,745 | VD-31745 | VRT-031745 | VX-745

>  <Withdrawn>  (69) 


>  <Indications>  (69) 
nan

>  <Type>  (69) 
nan

>  <targets_id>  (69) 
Q16539

>  <inchi>  (69) 
InChI=1S/C19H9Cl2F2N3OS/c20-11-2-1-3-12(21)17(11)18-14-5-7-16(25-26(14)9-24-19(18)27)28-15-6-4-10(22)8-13(15)23/h1-9H

>  <stdInchikey>  (69) 
VEPKQEUBKLEPRA-UHFFFAOYSA-N

>  <csid>  (69) 
2302086

>  <Links>  (69) 
|http://www.chemspider.com/Chemical-Structure.2302086.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL119385|http://pubchem.ncbi.nlm.nih.gov/compound/3038525|http://www.drugbank.ca/drugs/DB07138| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=52P|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/52P|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5719|http://zinc15.docking.org/substances/ZINC13493055|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=TYL52QM320|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15244

>  <LinkName>  (69) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (69) 
'52P'

>  <pdbID>  (69) 
3fc1 3hp5 3zsi

>  <indicationG2P>  (69) 
None

>  <indicationDB>  (69) 
Neflamapimod has been used in trials studying the treatment of Alzheimer&#39;s Disease and Mild Cognitive Impairment.

>  <uniprotId>  (69) 
Q16539

>  <MW>  (69) 
435.0

>  <HBA>  (69) 
5.0

>  <HBD>  (69) 
0.0

>  <NRB>  (69) 
3.0

>  <TPSA>  (69) 
47.3

>  <LogP>  (69) 
5.5

>  <RoF>  (69) 
1.0

>  <Melting point>  (69) 


>  <Targets>  (69) 
MAPK14

>  <Kinase families>  (69) 
CMGC

>  <FDA_approved>  (69) 


$$$$
Ilorasertib
     RDKit          2D

 35 39  0  0  0  0  0  0  0  0999 V2000
    8.9384   -2.4232    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8249   -1.4182    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1385    0.0487    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.5657    0.5105    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.6792   -0.4945    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.3656   -1.9614    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.1063   -0.0327    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    7.0250    1.0537    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.5979    0.5919    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2843   -0.8750    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.4844    1.5969    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.0572    1.1351    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9437    2.1401    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5166    1.6783    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2030    0.2114    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3165   -0.7936    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7436   -0.3318    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2242   -0.2504    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6894   -1.6764    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1894   -1.6746    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6512   -0.2475    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4366    0.6327    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5917    2.1247    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9613    2.7364    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1758    1.8562    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0208    0.3642    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2354   -0.5160    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2372   -2.0160    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6643   -2.4778    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.5445   -1.2632    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6614   -0.0508    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.0445   -1.2615    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.7930    0.0385    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -12.2930    0.0403    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3771    3.0049    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  5  7  1  0
  3  8  1  0
  8  9  1  0
  9 10  2  0
  9 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 15 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  1  0
 30 32  1  0
 32 33  1  0
 33 34  1  0
 23 35  1  0
  6  1  1  0
 17 12  1  0
 22 18  1  0
 26 21  1  0
 31 27  2  0
M  END
>  <BrandName>  (70) 
ABT-348, A-968660;Abt-348, a-968660

>  <Applicants>  (70) 
Abbott Laboratories

>  <CHEMBL_ID>  (70) 
CHEMBL1980297

>  <Canonical_Smiles>  (70) 
c1cc(cc(c1)F)NC(=O)Nc2ccc(cc2)c3csc4c3c(ncc4c5cnn(c5)CCO)N

>  <Chirality>  (70) 
Achiral Molecule

>  <First_Approval>  (70) 
nan

>  <Phase>  (70) 
2.0

>  <SC_Patent>  (70) 
None

>  <Synonyms>  (70) 
A-968660 | A-968660.0 | ABBOTT-968660 | ABT-348 | ABT-348, A-968660 | ILORASERTIB

>  <Withdrawn>  (70) 


>  <Indications>  (70) 
nan

>  <Type>  (70) 
nan

>  <targets_id>  (70) 
O14965|Q96GD4|Q9UQB9|P17948|P16234|P09619

>  <inchi>  (70) 
InChI=1S/C25H21FN6O2S/c26-17-2-1-3-19(10-17)31-25(34)30-18-6-4-15(5-7-18)21-14-35-23-20(12-28-24(27)22(21)23)16-11-29-32(13-16)8-9-33/h1-7,10-14,33H,8-9H2,(H2,27,28)(H2,30,31,34)

>  <stdInchikey>  (70) 
WPHKIQPVPYJNAX-UHFFFAOYSA-N

>  <csid>  (70) 
24809095

>  <Links>  (70) 
|http://www.chemspider.com/Chemical-Structure.24809095.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1980297|http://pubchem.ncbi.nlm.nih.gov/compound/46207586|http://www.drugbank.ca/drugs/DB11694|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9914|http://zinc15.docking.org/substances/ZINC000063298074|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6L5D03D975|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50381716

>  <LinkName>  (70) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (70) 


>  <pdbID>  (70) 


>  <indicationG2P>  (70) 
None

>  <indicationDB>  (70) 


>  <uniprotId>  (70) 


>  <MW>  (70) 
488.1

>  <HBA>  (70) 
7.0

>  <HBD>  (70) 
4.0

>  <NRB>  (70) 
6.0

>  <TPSA>  (70) 
118.1

>  <LogP>  (70) 
5.2

>  <RoF>  (70) 
1.0

>  <Melting point>  (70) 


>  <Targets>  (70) 
AURKA; AURKB; AURKC; FLT1; PDGFRA; PDGFRB

>  <Kinase families>  (70) 
Tyr<br>Other

>  <FDA_approved>  (70) 


$$$$
Amuvatinib
     RDKit          2D

 32 37  0  0  0  0  0  0  0  0999 V2000
   -9.3655    0.9668    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7044    2.3132    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2078    2.4139    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3723    1.1681    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0334   -0.1783    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.5300   -0.2790    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9572   -1.2232    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6309   -0.5225    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8875    0.9554    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3609   -1.3207    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4173   -2.8196    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7435   -3.5203    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0135   -2.7221    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0347   -0.6200    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7647   -1.4182    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5616   -0.7175    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6179    0.7814    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6521    1.5796    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9783    0.8789    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9442    1.4821    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0005    2.9810    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    3.2141    0.6839    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.5404    1.3846    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8104    0.5863    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7541   -0.9126    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0240   -1.7109    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3503   -1.0102    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4066    0.4888    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1367    1.2870    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8496    0.8984    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.6851   -0.3474    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7585   -1.5269    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  5  7  1  0
  7  8  2  0
  8  9  1  0
  8 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 10 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 17 20  1  0
 20 21  2  0
 20 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 28 30  1  0
 30 31  1  0
 31 32  1  0
  6  1  1  0
  9  4  1  0
 13  7  1  0
 19 14  1  0
 29 24  1  0
 32 27  1  0
M  END
>  <BrandName>  (71) 


>  <Applicants>  (71) 
Supergen

>  <CHEMBL_ID>  (71) 
CHEMBL2103851

>  <Canonical_Smiles>  (71) 
c1ccc2c(c1)c3c(o2)c(ncn3)N4CCN(CC4)C(=S)NCc5ccc6c(c5)OCO6

>  <Chirality>  (71) 
Achiral Molecule

>  <First_Approval>  (71) 
nan

>  <Phase>  (71) 
2.0

>  <SC_Patent>  (71) 
None

>  <Synonyms>  (71) 
AMUVATINIB | HPK 56 | HPK-56 | HPK56 | MP 470 | MP-470 | MP470

>  <Withdrawn>  (71) 


>  <Indications>  (71) 
Amuvatinib is a selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical comp
onent of double-stranded DNA repair in cancer cells.

>  <Type>  (71) 
nan

>  <targets_id>  (71) 
P10721|P08581|P07949|P36888|P09619

>  <inchi>  (71) 
InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)

>  <stdInchikey>  (71) 
FOFDIMHVKGYHRU-UHFFFAOYSA-N

>  <csid>  (71) 
9457280

>  <Links>  (71) 
|http://www.chemspider.com/Chemical-Structure.9457280.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103851|http://pubchem.ncbi.nlm.nih.gov/compound/11282283|http://www.drugbank.ca/drugs/DB12742|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7932|http://zinc15.docking.org/substances/ZINC34951302|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=SO9S6QZB4R|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50172081

>  <LinkName>  (71) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (71) 


>  <pdbID>  (71) 


>  <indicationG2P>  (71) 
None

>  <indicationDB>  (71) 
Amuvatinib has been used in trials studying the treatment of Solid Tumors and Small Cell Lung Carcinoma. Amuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer cells.

>  <uniprotId>  (71) 
P10721|P08581|P07949|P16234|P36888|Q06609

>  <MW>  (71) 
447.1

>  <HBA>  (71) 
7.0

>  <HBD>  (71) 
1.0

>  <NRB>  (71) 
3.0

>  <TPSA>  (71) 
75.9

>  <LogP>  (71) 
3.3

>  <RoF>  (71) 
0.0

>  <Melting point>  (71) 


>  <Targets>  (71) 
KIT; MET; RET; FLT3; PDGFRB

>  <Kinase families>  (71) 
Tyr

>  <FDA_approved>  (71) 


$$$$
Bimiralisib
     RDKit          2D

 29 32  0  0  0  0  0  0  0  0999 V2000
    4.5694    1.0558    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1993    0.4452    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9855    1.3263    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1416    2.8182    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5117    3.4289    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.7256    2.5477    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0957    3.1584    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.6154    0.7157    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5985    1.5969    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9686    0.9862    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1247   -0.5057    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9109   -1.3868    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4592   -0.7762    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0670   -2.8787    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4371   -3.4894    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5933   -4.9812    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3794   -5.8624    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0093   -5.2517    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1469   -3.7599    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1825    1.8674    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0263    3.3592    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2402    4.2404    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6102    3.6297    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7664    2.1379    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5525    1.2567    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0432   -1.0467    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8870   -2.5385    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    4.5350   -1.2029    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    1.5513   -0.8905    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  1  0
  6  7  2  0
  3  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 10 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
  2 26  1  0
 26 27  1  0
 26 28  1  0
 26 29  1  0
  6  1  1  0
 13  8  1  0
 19 14  1  0
 25 20  1  0
M  END
>  <BrandName>  (72) 


>  <Applicants>  (72) 
Piqur Therapeutics

>  <CHEMBL_ID>  (72) 
CHEMBL4084907

>  <Canonical_Smiles>  (72) 
c1c(c(c[nH]c1=N)c2nc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F

>  <Chirality>  (72) 
Achiral Molecule

>  <First_Approval>  (72) 
nan

>  <Phase>  (72) 
2.0

>  <SC_Patent>  (72) 
None

>  <Synonyms>  (72) 
BIMIRALISIB | NC-B5 | NCB5 | PI3K-IN-2 | PQR-309 | PQR309

>  <Withdrawn>  (72) 


>  <Indications>  (72) 
Bimiralisib (PQR309) is a novel dual inhibitor of phosphoinositol 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR) kinases, with expected utility as an anti-cancer agent.

>  <Type>  (72) 
nan

>  <targets_id>  (72) 
nan

>  <inchi>  (72) 
InChI=1S/C17H20F3N7O2/c18-17(19,20)12-9-13(21)22-10-11(12)14-23-15(26-1-5-28-6-2-26)25-16(24-14)27-3-7-29-8-4-27/h9-10H,1-8H2,(H2,21,22)

>  <stdInchikey>  (72) 
ADGGYDAFIHSYFI-UHFFFAOYSA-N

>  <csid>  (72) 
35033288

>  <Links>  (72) 
|http://www.chemspider.com/Chemical-Structure.35033288.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4084907|http://pubchem.ncbi.nlm.nih.gov/compound/58507717|http://www.drugbank.ca/drugs/DB14846| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=A3W|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/A3W|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8383|http://zinc15.docking.org/substances/ZINC000068203488|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6Z3QHB00LB|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50240975

>  <LinkName>  (72) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (72) 
'A3W'

>  <pdbID>  (72) 
5oq4

>  <indicationG2P>  (72) 
None

>  <indicationDB>  (72) 


>  <uniprotId>  (72) 


>  <MW>  (72) 
411.2

>  <HBA>  (72) 
8.0

>  <HBD>  (72) 
2.0

>  <NRB>  (72) 
3.0

>  <TPSA>  (72) 
103.2

>  <LogP>  (72) 
1.0

>  <RoF>  (72) 
0.0

>  <Melting point>  (72) 


>  <Targets>  (72) 
nan

>  <Kinase families>  (72) 


>  <FDA_approved>  (72) 


$$$$
Berzosertib
     RDKit          2D

 33 36  0  0  0  0  0  0  0  0999 V2000
    8.9417   -2.8875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4874   -3.2551    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0786   -4.6983    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4420   -2.1794    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    7.5177   -1.1340    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.3663   -3.2248    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.3966   -1.1037    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9423   -1.4713    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8969   -0.3956    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3057    1.0476    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7600    1.4151    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8054    0.3395    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2603    2.1233    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6691    3.5665    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6236    4.6421    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.1694    4.2746    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2395    2.8314    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8060    1.7557    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6937    2.4638    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2512    1.0713    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7479    1.1711    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1154    2.6254    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8459    3.4243    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7084    0.0190    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1864    0.2747    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1469   -0.8774    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6294   -2.2853    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1513   -2.5411    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1908   -1.3889    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5898   -3.4375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.0679   -3.1817    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  -10.0284   -4.3339    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8761    5.3503    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  4  5  2  0
  4  6  2  0
  4  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 10 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 17 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 21 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 27 30  1  0
 30 31  1  0
 31 32  1  0
 16 33  1  0
 12  7  1  0
 18 13  1  0
 23 19  1  0
 29 24  1  0
M  END
>  <BrandName>  (73) 


>  <Applicants>  (73) 
Vertex Pharmaceuticals

>  <CHEMBL_ID>  (73) 
CHEMBL3989870

>  <Canonical_Smiles>  (73) 
CC(C)S(=O)(=O)c1ccc(cc1)c2cnc(c(n2)c3cc(no3)c4ccc(cc4)CNC)N

>  <Chirality>  (73) 
Achiral Molecule

>  <First_Approval>  (73) 
nan

>  <Phase>  (73) 
2.0

>  <SC_Patent>  (73) 
None

>  <Synonyms>  (73) 
BERZOSERTIB | M-6620 | M6620 | VE-822 | VX-970 | VX970

>  <Withdrawn>  (73) 


>  <Indications>  (73) 
nan

>  <Type>  (73) 
nan

>  <targets_id>  (73) 
nan

>  <inchi>  (73) 
InChI=1S/C24H25N5O3S/c1-15(2)33(30,31)19-10-8-18(9-11-19)21-14-27-24(25)23(28-21)22-12-20(29-32-22)17-6-4-16(5-7-17)13-26-3/h4-12,14-15,26H,13H2,1-3H3,(H2,25,27)

>  <stdInchikey>  (73) 
JZCWLJDSIRUGIN-UHFFFAOYSA-N

>  <csid>  (73) 
30773968

>  <Links>  (73) 
|http://www.chemspider.com/Chemical-Structure.30773968.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3989870|http://pubchem.ncbi.nlm.nih.gov/compound/59472121|http://www.drugbank.ca/drugs/DB11794|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8003|http://zinc15.docking.org/substances/ZINC000096170459|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=L423PRV3V3|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50226746

>  <LinkName>  (73) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (73) 


>  <pdbID>  (73) 


>  <indicationG2P>  (73) 
None

>  <indicationDB>  (73) 


>  <uniprotId>  (73) 


>  <MW>  (73) 
463.2

>  <HBA>  (73) 
8.0

>  <HBD>  (73) 
2.0

>  <NRB>  (73) 
7.0

>  <TPSA>  (73) 
124.0

>  <LogP>  (73) 
3.9

>  <RoF>  (73) 
0.0

>  <Melting point>  (73) 


>  <Targets>  (73) 
nan

>  <Kinase families>  (73) 


>  <FDA_approved>  (73) 


$$$$
Lucitanib
     RDKit          2D

 33 37  0  0  0  0  0  0  0  0999 V2000
   -9.3171   -2.7471    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7300   -1.3668    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2410   -1.1851    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3392   -2.3837    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6539    0.1952    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5557    1.3939    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9685    2.7742    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4796    2.9558    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5778    1.7572    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1649    0.3769    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2631   -0.8217    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7741   -0.6401    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1870    0.7402    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0888    1.9389    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6980    0.9219    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.2038   -0.2767    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3834   -1.6570    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5185   -2.8557    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0074   -2.6740    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.5946   -1.2937    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6927   -0.0951    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2799    1.2853    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7688    1.4669    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6707    0.2683    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0835   -1.1120    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1596    0.4500    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.0614   -0.7487    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5504   -0.5670    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.0117   -0.9055    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.9879   -2.0018    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6300    0.9309    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.3560    2.8472    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.8450    3.0289    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  3  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 13 15  1  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 24 26  1  0
 26 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  1  0
 28 31  1  0
 23 32  1  0
 32 33  1  0
 10  5  1  0
 14  9  1  0
 21 16  1  0
 25 20  1  0
 30 28  1  0
M  END
>  <BrandName>  (74) 


>  <Applicants>  (74) 
Clovis Oncology

>  <CHEMBL_ID>  (74) 
CHEMBL2220486

>  <Canonical_Smiles>  (74) 
CNC(=O)c1cccc2c1ccc(c2)Oc3ccnc4c3cc(c(c4)OCC5(CC5)N)OC

>  <Chirality>  (74) 
Achiral Molecule

>  <First_Approval>  (74) 
nan

>  <Phase>  (74) 
2.0

>  <SC_Patent>  (74) 
None

>  <Synonyms>  (74) 
AL-3810 | CO-3810 | E-3810 | LUCITANIB | S 80881 | S-80881

>  <Withdrawn>  (74) 
|Study NCT02747797 in United States was Withdrawn during Phase 2 because Drug Supply No Longer Available

>  <Indications>  (74) 
nan

>  <Type>  (74) 
1

>  <targets_id>  (74) 
P17948|P35968|P35916|P11362|P21802

>  <inchi>  (74) 
InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)

>  <stdInchikey>  (74) 
CUDVHEFYRIWYQD-UHFFFAOYSA-N

>  <csid>  (74) 
28189586

>  <Links>  (74) 
|http://www.chemspider.com/Chemical-Structure.28189586.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2220486|http://pubchem.ncbi.nlm.nih.gov/compound/25031915|http://www.drugbank.ca/drugs/DB11845| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=3ZC|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/3ZC|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7649|http://zinc15.docking.org/substances/ZINC000077024213|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=PP449XA4BH|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50399539

>  <LinkName>  (74) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (74) 
'3ZC'

>  <pdbID>  (74) 
4rwl

>  <indicationG2P>  (74) 
None

>  <indicationDB>  (74) 


>  <uniprotId>  (74) 


>  <MW>  (74) 
443.2

>  <HBA>  (74) 
6.0

>  <HBD>  (74) 
2.0

>  <NRB>  (74) 
7.0

>  <TPSA>  (74) 
95.7

>  <LogP>  (74) 
4.4

>  <RoF>  (74) 
0.0

>  <Melting point>  (74) 


>  <Targets>  (74) 
FLT1; KDR; FLT4; FGFR1; FGFR2

>  <Kinase families>  (74) 
Tyr

>  <FDA_approved>  (74) 


$$$$
Bemcentinib
     RDKit          2D

 38 44  0  0  0  0  0  0  0  0999 V2000
   -9.6875   -2.4743    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.5183   -0.9839    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.1430   -0.3852    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9368   -1.2769    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1060   -2.7673    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4813   -3.3660    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0462   -3.8288    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5555   -3.6621    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7564   -2.3926    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2507   -0.9764    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6661   -0.4798    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9438    0.9942    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8060    1.9717    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3906    1.4752    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1129    0.0011    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2529    2.4527    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3749    3.9477    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9908    4.5258    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0133    3.3880    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7933    2.1068    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.4817    3.5101    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.3350    2.2764    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6932    0.9206    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5464   -0.3131    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0414   -0.1910    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6832    1.1648    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8300    2.3985    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1433    1.5083    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3223    0.5809    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3323   -0.9191    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1658   -1.8621    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7012   -1.5381    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6881   -1.5609    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.0042   -0.8413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.0953   -1.8706    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.4535   -3.2264    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.9657   -3.0349    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6562    4.7277    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  5  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 14 16  1  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 19 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 26 28  1  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 30 33  1  1
 33 34  1  0
 34 35  1  0
 35 36  1  0
 36 37  1  0
 17 38  1  0
  6  1  1  0
  4 11  1  0
 15 10  1  0
 20 16  1  0
 27 22  1  0
 32 25  1  0
 37 33  1  0
M  END
>  <BrandName>  (75) 


>  <Applicants>  (75) 
BerGenBio

>  <CHEMBL_ID>  (75) 
CHEMBL3809489

>  <Canonical_Smiles>  (75) 
c1ccc-2c(c1)CCCc3c2nnc(c3)n4c(nc(n4)Nc5ccc6c(c5)CC[C@H](CC6)N7CCCC7)N

>  <Chirality>  (75) 
Single Stereoisomer

>  <First_Approval>  (75) 
nan

>  <Phase>  (75) 
2.0

>  <SC_Patent>  (75) 
None

>  <Synonyms>  (75) 
BEMCENTINIB | BGB 324 | BGB-324 | BGB324 | CS-1046 | HY-15150 | KB-80319 | QC-11751 | R 428 | R-428 | R428 | SYN-1131 | SYN1131 | W-5845

>  <Withdrawn>  (75) 


>  <Indications>  (75) 
nan

>  <Type>  (75) 
nan

>  <targets_id>  (75) 
P30530

>  <inchi>  (75) 
InChI=1S/C30H34N8/c31-29-33-30(32-24-13-10-20-11-14-25(15-12-22(20)18-24)37-16-3-4-17-37)36-38(29)27-19-23-8-5-7-21-6-1-2-9-26(21)28(23)35-34-27/h1-2,6,9-10,13,18-19,25H,3-5,7-8,11-12,14-17H2,(H3,31,32,33,36)/t25-/m0/s1

>  <stdInchikey>  (75) 
KXMZDGSRSGHMMK-VWLOTQADSA-N

>  <csid>  (75) 
28637805

>  <Links>  (75) 
|http://www.chemspider.com/Chemical-Structure.28637805.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3809489|http://pubchem.ncbi.nlm.nih.gov/compound/46215462|http://www.drugbank.ca/drugs/DB12411|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10478|http://zinc15.docking.org/substances/ZINC000051951669|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=0ICW2LX8AS|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50172079

>  <LinkName>  (75) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (75) 


>  <pdbID>  (75) 


>  <indicationG2P>  (75) 
None

>  <indicationDB>  (75) 


>  <uniprotId>  (75) 


>  <MW>  (75) 
506.3

>  <HBA>  (75) 
8.0

>  <HBD>  (75) 
2.0

>  <NRB>  (75) 
4.0

>  <TPSA>  (75) 
97.8

>  <LogP>  (75) 
4.9

>  <RoF>  (75) 
1.0

>  <Melting point>  (75) 


>  <Targets>  (75) 
AXL

>  <Kinase families>  (75) 
Tyr

>  <FDA_approved>  (75) 


$$$$
Pelitinib
     RDKit          2D

 33 35  0  0  0  0  0  0  0  0999 V2000
    3.4050   -4.6409    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0006   -4.1140    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7547   -2.6343    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.3503   -2.1075    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8082   -3.0603    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2127   -2.5334    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4586   -1.0537    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3001   -0.1009    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1043   -0.6278    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2628    0.3251    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6673   -0.2018    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9132   -1.6815    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.8258    0.7510    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2302    0.2242    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3887    1.1770    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7931    0.6501    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.9516    1.6029    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0390   -0.8296    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8630   -0.5268    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0215   -1.4797    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7756   -2.9594    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3712   -3.4862    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4259   -0.9528    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.8304   -0.4259    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1089    0.9529    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9504    1.9057    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5460    1.3788    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3875    2.3317    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6334    3.8114    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0379    4.3382    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1964    3.3854    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2838    5.8179    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    0.5251    4.7642    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  1  0
 11 12  2  0
 11 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 16 18  1  0
  7 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 20 23  1  0
 23 24  3  0
 19 25  1  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 30 32  1  0
 29 33  1  0
  9  4  1  0
 22  6  1  0
 31 26  1  0
M  END
>  <BrandName>  (76) 


>  <Applicants>  (76) 
Wyeth

>  <CHEMBL_ID>  (76) 
CHEMBL607707

>  <Canonical_Smiles>  (76) 
CCOc1cc2c(cc1NC(=O)/C=C/CN(C)C)c(c(cn2)C#N)Nc3ccc(c(c3)Cl)F

>  <Chirality>  (76) 
Achiral Molecule

>  <First_Approval>  (76) 
nan

>  <Phase>  (76) 
2.0

>  <SC_Patent>  (76) 
None

>  <Synonyms>  (76) 
EKB-569 | PELITINIB | WAY-EKB-569

>  <Withdrawn>  (76) 


>  <Indications>  (76) 
nan

>  <Type>  (76) 
1

>  <targets_id>  (76) 
P00533|P04626

>  <inchi>  (76) 
InChI=1S/C24H23ClFN5O2/c1-4-33-22-12-20-17(11-21(22)30-23(32)6-5-9-31(2)3)24(15(13-27)14-28-20)29-16-7-8-19(26)18(25)10-16/h5-8,10-12,14H,4,9H2,1-3H3,(H,28,29)(H,30,32)/b6-5+

>  <stdInchikey>  (76) 
WVUNYSQLFKLYNI-AATRIKPKSA-N

>  <csid>  (76) 
4949255

>  <Links>  (76) 
|http://www.chemspider.com/Chemical-Structure.4949255.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL607707|http://pubchem.ncbi.nlm.nih.gov/compound/6445562|http://www.drugbank.ca/drugs/DB05524| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=93J|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/93J|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7644|http://zinc15.docking.org/substances/ZINC000000602803|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=X5DWL380Z6|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=31090

>  <LinkName>  (76) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (76) 
'93J'

>  <pdbID>  (76) 
5vcw 7axm

>  <indicationG2P>  (76) 
None

>  <indicationDB>  (76) 
Pelitinib (EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent.

>  <uniprotId>  (76) 
P00533

>  <MW>  (76) 
467.2

>  <HBA>  (76) 
6.0

>  <HBD>  (76) 
2.0

>  <NRB>  (76) 
8.0

>  <TPSA>  (76) 
90.3

>  <LogP>  (76) 
5.1

>  <RoF>  (76) 
1.0

>  <Melting point>  (76) 


>  <Targets>  (76) 
EGFR; ERBB2

>  <Kinase families>  (76) 
Tyr

>  <FDA_approved>  (76) 


$$$$
Dilmapimod
     RDKit          2D

 33 36  0  0  0  0  0  0  0  0999 V2000
   -3.4989   -1.9827    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3110   -0.7216    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8092   -0.7943    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6213    0.4669    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9352    1.8007    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4369    1.8735    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6249    0.6123    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1266    0.6850    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3145   -0.5761    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0007   -1.9100    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1886   -3.1712    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3097   -3.0985    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1217   -4.3596    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.9958   -1.7646    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.1837   -0.5034    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8699    0.8304    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0578    2.0916    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4405    2.0189    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.7439    3.4255    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.2421    3.4982    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9283    4.8320    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4265    4.9048    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.0542    2.2370    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5525    2.3097    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.4940   -1.6919    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3061   -2.9530    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8044   -2.8803    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4905   -1.5464    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6784   -0.2853    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1802   -0.3580    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3681    0.9032    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    2.6200   -4.2869    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -8.1196    0.3942    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 17 19  1  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 20 23  1  0
 23 24  1  0
 14 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 26 32  1  0
  4 33  1  0
  7  2  1  0
 18  8  1  0
 15  9  1  0
 30 25  1  0
M  END
>  <BrandName>  (77) 


>  <Applicants>  (77) 
GlaxoSmithKline

>  <CHEMBL_ID>  (77) 
CHEMBL2103838

>  <Canonical_Smiles>  (77) 
Cc1cc(ccc1c2c3ccc(=O)n(c3nc(n2)NC(CO)CO)c4c(cccc4F)F)F

>  <Chirality>  (77) 
Achiral Molecule

>  <First_Approval>  (77) 
nan

>  <Phase>  (77) 
2.0

>  <SC_Patent>  (77) 
None

>  <Synonyms>  (77) 
DILMAPIMOD | GW-681323 | SB-681323 | SB681323

>  <Withdrawn>  (77) 


>  <Indications>  (77) 
Dilmapimod has been used in trials studying the treatment and diagnostic of Nerve Trauma, Inflammation, Pain, Neuropathic, Arthritis, Rheumatoid, and Coronary Heart Disease, among others.

>  <Type>  (77) 
nan

>  <targets_id>  (77) 
Q16539|Q15759|O15264|P53778

>  <inchi>  (77) 
InChI=1S/C23H19F3N4O3/c1-12-9-13(24)5-6-15(12)20-16-7-8-19(33)30(21-17(25)3-2-4-18(21)26)22(16)29-23(28-20)27-14(10-31)11-32/h2-9,14,31-32H,10-11H2,1H3,(H,27,28,29)

>  <stdInchikey>  (77) 
ORVNHOYNEHYKJG-UHFFFAOYSA-N

>  <csid>  (77) 
8473450

>  <Links>  (77) 
|http://www.chemspider.com/Chemical-Structure.8473450.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103838|http://pubchem.ncbi.nlm.nih.gov/compound/10297982|http://www.drugbank.ca/drugs/DB12140|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7815|http://zinc15.docking.org/substances/ZINC000034997404|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=Q3238VQW0N

>  <LinkName>  (77) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (77) 


>  <pdbID>  (77) 


>  <indicationG2P>  (77) 
None

>  <indicationDB>  (77) 
Dilmapimod has been used in trials studying the treatment and diagnostic of Nerve Trauma, Inflammation, Pain, Neuropathic, Arthritis, Rheumatoid, and Coronary Heart Disease, among others. Dilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis). Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.}

>  <uniprotId>  (77) 
P01375|P01584|P05231

>  <MW>  (77) 
456.1

>  <HBA>  (77) 
7.0

>  <HBD>  (77) 
3.0

>  <NRB>  (77) 
6.0

>  <TPSA>  (77) 
100.3

>  <LogP>  (77) 
2.9

>  <RoF>  (77) 
0.0

>  <Melting point>  (77) 


>  <Targets>  (77) 
MAPK14; MAPK11; MAPK13; MAPK12

>  <Kinase families>  (77) 
CMGC

>  <FDA_approved>  (77) 


$$$$
Foretinib
     RDKit          2D

 46 51  0  0  0  0  0  0  0  0999 V2000
    6.8697    3.4256    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3739    3.3144    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.7222    1.9633    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2264    1.8521    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5747    0.5011    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0788    0.3899    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4272   -0.9612    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2714   -2.2011    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7673   -2.0899    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.4189   -0.7388    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9148   -0.6276    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5665    0.7235    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0623    0.8346    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.9066   -0.4052    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4024   -0.2940    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.2467   -1.5339    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.7425   -1.4227    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.5868   -2.6626    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.0827   -2.5514    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.7343   -1.2003    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   13.8901    0.0396    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.3942   -0.0716    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2346    1.6297    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2613    1.5185    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1055    2.7584    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6014    2.6472    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2530    1.2962    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4088    0.0563    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9129    0.1675    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0687   -1.0724    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7489    1.1850    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5931    2.4248    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9415    3.7759    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -8.0890    2.3136    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.5327    2.7208    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4583    3.7675    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.2392    0.8212    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0219   -0.0552    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -9.6069    0.2051    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -9.7571   -1.2874    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.1248   -1.9035    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.2750   -3.3960    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.0576   -4.2723    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.6900   -3.6562    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.5397   -2.1637    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.2079   -5.7648    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
  6 23  1  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 27 31  1  0
 31 32  1  0
 32 33  2  0
 32 34  1  0
 34 35  1  0
 35 36  1  0
 34 37  1  0
 37 38  2  0
 37 39  1  0
 39 40  1  0
 40 41  2  0
 41 42  1  0
 42 43  2  0
 43 44  1  0
 44 45  2  0
 43 46  1  0
 12  3  1  0
 10  5  1  0
 22 17  1  0
 29 24  1  0
 36 34  1  0
 45 40  1  0
M  END
>  <BrandName>  (78) 


>  <Applicants>  (78) 
GlaxoSmithKline

>  <CHEMBL_ID>  (78) 
CHEMBL1230609

>  <Canonical_Smiles>  (78) 
COc1cc2c(ccnc2cc1OCCCN3CCOCC3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F

>  <Chirality>  (78) 
Achiral Molecule

>  <First_Approval>  (78) 
nan

>  <Phase>  (78) 
2.0

>  <SC_Patent>  (78) 
None

>  <Synonyms>  (78) 
EXEL-2880 | FORETINIB | GSK-089 | GSK-1363089 | GSK-1363089G | GSK089 | GSK1363089G | XL-880 | XL880

>  <Withdrawn>  (78) 
|Study NCT02034097 in nan was Withdrawn during Phase 2 because GSK has decided to terminate the Product Development of foretinib and conclude our Development    Agreement with Exelixis

>  <Indications>  (78) 
nan

>  <Type>  (78) 
2

>  <targets_id>  (78) 
P08581|P35968

>  <inchi>  (78) 
InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)

>  <stdInchikey>  (78) 
CXQHYVUVSFXTMY-UHFFFAOYSA-N

>  <csid>  (78) 
24608641

>  <Links>  (78) 
|http://www.chemspider.com/Chemical-Structure.24608641.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1230609|http://pubchem.ncbi.nlm.nih.gov/compound/42642645|http://www.drugbank.ca/drugs/DB12307| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=88Z|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/88Z|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5679|http://zinc15.docking.org/substances/ZINC43204048|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=81FH7VK1C4|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50399540

>  <LinkName>  (78) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (78) 
'88Z'

>  <pdbID>  (78) 
3lq8 5ia4 6i2y 6sd9 6sdc

>  <indicationG2P>  (78) 
None

>  <indicationDB>  (78) 
Foretinib has been used in trials studying the treatment of Cancer, Breast Cancer, Carcinoma, Renal Cell, Recurrent Breast Cancer, and Neoplasms, Head and Neck, among others. Foretinib is an orally available small molecule compound designed to target multiple RTKs implicated in the development, progression and spread of cancer. It inhibits the activation of MET, RON, ERK and AKT, decreased proliferation and increased apoptosis.

>  <uniprotId>  (78) 
P14210|P35968

>  <MW>  (78) 
632.2

>  <HBA>  (78) 
8.0

>  <HBD>  (78) 
2.0

>  <NRB>  (78) 
12.0

>  <TPSA>  (78) 
111.2

>  <LogP>  (78) 
5.8

>  <RoF>  (78) 
2.0

>  <Melting point>  (78) 


>  <Targets>  (78) 
MET; KDR

>  <Kinase families>  (78) 
Tyr

>  <FDA_approved>  (78) 


$$$$
Tozasertib
     RDKit          2D

 33 37  0  0  0  0  0  0  0  0999 V2000
   -9.2158    2.5379    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.8059    2.0257    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3916    0.5841    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8925    0.5326    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3803    1.9425    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5629    2.8652    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0530   -0.7104    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5567   -0.6049    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7172   -1.8480    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2209   -1.7425    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5641   -0.3939    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4036    0.8492    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8999    0.7437    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7469    2.1978    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.7494    2.3033    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5889    1.0602    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0852    1.1657    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7420    2.5143    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9024    3.7574    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4062    3.6519    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2382    2.6198    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.0778    1.3768    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4210    0.0282    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.5741    1.4823    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8171    2.3218    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.9226    0.8255    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3813   -2.9855    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0381   -4.3341    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1986   -5.5772    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2977   -5.4716    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.9545   -4.1231    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1149   -2.8800    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1372   -6.7147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  4  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 18 21  1  0
 21 22  1  0
 22 23  2  0
 22 24  1  0
 24 25  1  0
 25 26  1  0
 10 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 30 33  1  0
  6  2  1  0
 13  8  1  0
 20 15  1  0
 26 24  1  0
 32 27  1  0
M  END
>  <BrandName>  (79) 


>  <Applicants>  (79) 
Merck

>  <CHEMBL_ID>  (79) 
CHEMBL572878

>  <Canonical_Smiles>  (79) 
Cc1cc(n[nH]1)Nc2cc(nc(n2)Sc3ccc(cc3)NC(=O)C4CC4)N5CCN(CC5)C

>  <Chirality>  (79) 
Achiral Molecule

>  <First_Approval>  (79) 
nan

>  <Phase>  (79) 
2.0

>  <SC_Patent>  (79) 
None

>  <Synonyms>  (79) 
MK-045 | MK-0457 | TOZASERTIB | VX-68 | VX-680

>  <Withdrawn>  (79) 


>  <Indications>  (79) 
nan

>  <Type>  (79) 
1

>  <targets_id>  (79) 
O14965|Q96GD4|Q9UQB9

>  <inchi>  (79) 
InChI=1S/C23H28N8OS/c1-15-13-20(29-28-15)25-19-14-21(31-11-9-30(2)10-12-31)27-23(26-19)33-18-7-5-17(6-8-18)24-22(32)16-3-4-16/h5-8,13-14,16H,3-4,9-12H2,1-2H3,(H,24,32)(H2,25,26,27,28,29)

>  <stdInchikey>  (79) 
GCIKSSRWRFVXBI-UHFFFAOYSA-N

>  <csid>  (79) 
4591897

>  <Links>  (79) 
|http://www.chemspider.com/Chemical-Structure.4591897.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL572878|http://pubchem.ncbi.nlm.nih.gov/compound/5494449| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=VX6|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/VX6|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5718|http://zinc15.docking.org/substances/ZINC13125756|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=234335M86K|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50004205

>  <LinkName>  (79) 
|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (79) 
'VX6'

>  <pdbID>  (79) 
2f4j 2xyn 3amb 3e5a 4af3 4b8m 4jbq 4zog 5wnm 6brj 6gr9

>  <indicationG2P>  (79) 
None

>  <indicationDB>  (79) 


>  <uniprotId>  (79) 


>  <MW>  (79) 
464.2

>  <HBA>  (79) 
8.0

>  <HBD>  (79) 
3.0

>  <NRB>  (79) 
7.0

>  <TPSA>  (79) 
102.1

>  <LogP>  (79) 
3.5

>  <RoF>  (79) 
0.0

>  <Melting point>  (79) 


>  <Targets>  (79) 
AURKA; AURKB; AURKC

>  <Kinase families>  (79) 
Other

>  <FDA_approved>  (79) 


$$$$
Refametinib
     RDKit          2D

 31 33  0  0  0  0  0  0  0  0999 V2000
   -3.2633    2.0696    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9883    1.2795    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6665    1.9887    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6198    3.4880    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7020    4.1972    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9770    3.4071    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9303    1.9078    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6085    1.1986    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5618   -0.3006    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7600   -1.0098    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4691    0.3119    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0508   -2.3316    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0817   -1.7190    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0812   -2.8375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6129   -3.1438    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0097   -0.5405    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4943   -0.7548    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4222    0.4237    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9068    0.2094    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0510   -2.1477    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.2053    1.1177    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.1586   -0.3816    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8368   -1.0907    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7901   -2.5900    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0652   -3.3801    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3869   -2.6709    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4337   -1.1717    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7554   -0.4625    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    3.0185   -4.8794    0.0000 I   0  0  0  0  0  0  0  0  0  0  0  0
    3.2988    4.1163    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    0.7487    5.6964    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  1  0
 10 11  2  0
 10 12  2  0
 10 13  1  0
 13 14  1  0
 14 15  1  0
 13 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 17 20  1  6
  7 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 25 29  1  0
  6 30  1  0
  5 31  1  0
  8  3  1  0
 15 13  1  0
 27 22  1  0
M  END
>  <BrandName>  (80) 


>  <Applicants>  (80) 
Bayer

>  <CHEMBL_ID>  (80) 
CHEMBL1236682

>  <Canonical_Smiles>  (80) 
COc1cc(c(c(c1NS(=O)(=O)C2(CC2)C[C@@H](CO)O)Nc3ccc(cc3F)I)F)F

>  <Chirality>  (80) 
Single Stereoisomer

>  <First_Approval>  (80) 
nan

>  <Phase>  (80) 
2.0

>  <SC_Patent>  (80) 
None

>  <Synonyms>  (80) 
BAY 869766 | BAY 8697661 | BAY-86-9766 | BAY-869766 | BAY-8697661 | BAY86-9766 | RDEA 119 | RDEA-119 | REFAMETINIB

>  <Withdrawn>  (80) 


>  <Indications>  (80) 
nan

>  <Type>  (80) 
nan

>  <targets_id>  (80) 
Q02750

>  <inchi>  (80) 
InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24-27H,4-5,8-9H2,1H3/t11-/m0/s1

>  <stdInchikey>  (80) 
RDSACQWTXKSHJT-NSHDSACASA-N

>  <csid>  (80) 
25058723

>  <Links>  (80) 
|http://www.chemspider.com/Chemical-Structure.25058723.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1236682|http://pubchem.ncbi.nlm.nih.gov/compound/44182295|http://www.drugbank.ca/drugs/DB06309| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=VRA|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/VRA|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7942|http://zinc15.docking.org/substances/ZINC39187987|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=JPX07AFM0N

>  <LinkName>  (80) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (80) 
'VRA'

>  <pdbID>  (80) 
3e8n

>  <indicationG2P>  (80) 
None

>  <indicationDB>  (80) 


>  <uniprotId>  (80) 


>  <MW>  (80) 
572.0

>  <HBA>  (80) 
6.0

>  <HBD>  (80) 
4.0

>  <NRB>  (80) 
9.0

>  <TPSA>  (80) 
107.9

>  <LogP>  (80) 
3.5

>  <RoF>  (80) 
1.0

>  <Melting point>  (80) 


>  <Targets>  (80) 
MAP2K1

>  <Kinase families>  (80) 
STE

>  <FDA_approved>  (80) 


$$$$
Rebastinib
     RDKit          2D

 41 45  0  0  0  0  0  0  0  0999 V2000
    4.7071    5.4105    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2360    5.1173    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7650    4.8241    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9428    6.5883    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5292    3.6462    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5114    2.5443    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2449    1.2359    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7159    1.5291    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.8917    3.0187    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.8178    0.5113    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2502    0.9567    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3520   -0.0611    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0216   -1.5243    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5892   -1.9696    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4873   -0.9518    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2587   -3.4328    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3606   -4.4505    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7929   -4.0052    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1234   -2.5420    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6174   -0.1266    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.1238   -0.2644    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2576    0.9602    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.4963   -1.6269    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9974   -1.7647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8636   -0.5400    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3572   -0.6779    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9847   -2.0403    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1185   -3.2650    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6248   -3.1271    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7587   -4.3518    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4783   -2.1781    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3445   -0.9535    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7171    0.4089    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5832    1.6336    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.0769    1.4957    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7044    0.1333    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.8382   -1.0913    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.1980   -0.0045    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.8255   -1.3670    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  -11.0642    1.2201    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  -12.5579    1.0823    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  2  5  1  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  1  0
  8 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 14 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
  7 20  1  0
 20 21  1  0
 21 22  2  0
 21 23  1  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 27 31  1  0
 31 32  1  0
 32 33  2  0
 33 34  1  0
 34 35  2  0
 35 36  1  0
 36 37  2  0
 36 38  1  0
 38 39  2  0
 38 40  1  0
 40 41  1  0
  9  5  2  0
 15 10  1  0
 19 13  1  0
 29 24  1  0
 37 32  1  0
M  END
>  <BrandName>  (81) 
DP-1919;Dp-1919

>  <Applicants>  (81) 
Deciphera Pharmaceuticals

>  <CHEMBL_ID>  (81) 
CHEMBL1738757

>  <Canonical_Smiles>  (81) 
CC(C)(C)c1cc(n(n1)c2ccc3c(c2)cccn3)NC(=O)Nc4ccc(cc4F)Oc5ccnc(c5)C(=O)NC

>  <Chirality>  (81) 
Achiral Molecule

>  <First_Approval>  (81) 
nan

>  <Phase>  (81) 
2.0

>  <SC_Patent>  (81) 
None

>  <Synonyms>  (81) 
DCC-2036 | DCC-2036 FREE BASE | DP-1919 | REBASTINIB

>  <Withdrawn>  (81) 


>  <Indications>  (81) 
nan

>  <Type>  (81) 
2

>  <targets_id>  (81) 
P36888|Q02763|P35968|P07948|P11274|P00519|P04629

>  <inchi>  (81) 
InChI=1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17H,1-4H3,(H,32,39)(H2,35,36,40)

>  <stdInchikey>  (81) 
WVXNSAVVKYZVOE-UHFFFAOYSA-N

>  <csid>  (81) 
26325986

>  <Links>  (81) 
|http://www.chemspider.com/Chemical-Structure.26325986.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1738757|http://pubchem.ncbi.nlm.nih.gov/compound/25066467|http://www.drugbank.ca/drugs/DB13005| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=919|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/919|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9173|http://zinc15.docking.org/substances/ZINC63933734|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=75017Q6I97|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=185674

>  <LinkName>  (81) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (81) 
'919'

>  <pdbID>  (81) 
3qri 3qrj 5g6v 6cnh 6mwe

>  <indicationG2P>  (81) 
None

>  <indicationDB>  (81) 


>  <uniprotId>  (81) 


>  <MW>  (81) 
553.2

>  <HBA>  (81) 
7.0

>  <HBD>  (81) 
3.0

>  <NRB>  (81) 
6.0

>  <TPSA>  (81) 
123.1

>  <LogP>  (81) 
6.0

>  <RoF>  (81) 
2.0

>  <Melting point>  (81) 


>  <Targets>  (81) 
FLT3; TEK; KDR; LYN; BCR; ABL1; NTRK1

>  <Kinase families>  (81) 
Tyr<br>Atypical

>  <FDA_approved>  (81) 


$$$$
Ralimetinib
     RDKit          2D

 31 34  0  0  0  0  0  0  0  0999 V2000
   -5.5614   -2.4115    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2323   -1.7161    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9032   -1.0207    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5369   -3.0451    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9277   -0.3870    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1244    0.8798    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6274    0.9745    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2549    2.4275    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8103    2.8314    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2618    1.7822    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1107    0.3292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5553   -0.0747    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.9613   -0.7199    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4403   -0.4692    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1357   -1.7983    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0865   -2.8704    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7427   -2.2039    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.3372   -4.3493    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8583   -4.5999    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8161   -4.0986    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5879   -5.8282    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1067    0.8746    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2762    2.1237    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9427    3.4675    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4397    3.5622    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2702    2.3131    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6037    0.9693    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1062    4.9060    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5217    3.2308    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6771    2.2742    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1301    2.6468    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  2  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 11 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 16 18  1  0
 18 19  1  0
 18 20  1  0
 18 21  1  0
 14 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 25 28  1  0
  8 29  1  0
 29 30  2  0
 30 31  1  0
 30  6  1  0
 12  7  1  0
 17 13  1  0
 27 22  1  0
M  END
>  <BrandName>  (82) 


>  <Applicants>  (82) 
Eli Lilly

>  <CHEMBL_ID>  (82) 
CHEMBL2364626

>  <Canonical_Smiles>  (82) 
CC(C)(C)Cn1c2c(ccc(n2)c3c(nc([nH]3)C(C)(C)C)c4ccc(cc4)F)nc1N

>  <Chirality>  (82) 
Achiral Molecule

>  <First_Approval>  (82) 
nan

>  <Phase>  (82) 
2.0

>  <SC_Patent>  (82) 
None

>  <Synonyms>  (82) 
LSN-2322600 FREE BASE | LSN2322600 FREE BASE | LY-2228820 | LY2228820 | LY22288220 | RALIMETINIB

>  <Withdrawn>  (82) 


>  <Indications>  (82) 
nan

>  <Type>  (82) 
nan

>  <targets_id>  (82) 
Q16539|Q15759

>  <inchi>  (82) 
InChI=1S/C24H29FN6/c1-23(2,3)13-31-20-17(28-22(31)26)12-11-16(27-20)19-18(14-7-9-15(25)10-8-14)29-21(30-19)24(4,5)6/h7-12H,13H2,1-6H3,(H2,26,28)(H,29,30)

>  <stdInchikey>  (82) 
XPPBBJCBDOEXDN-UHFFFAOYSA-N

>  <csid>  (82) 
9713805

>  <Links>  (82) 
|http://www.chemspider.com/Chemical-Structure.9713805.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2364626|http://pubchem.ncbi.nlm.nih.gov/compound/11539025|http://www.drugbank.ca/drugs/DB11787|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7959|http://zinc15.docking.org/substances/ZINC34630490|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=73I34XW4HD

>  <LinkName>  (82) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (82) 


>  <pdbID>  (82) 


>  <indicationG2P>  (82) 
None

>  <indicationDB>  (82) 


>  <uniprotId>  (82) 


>  <MW>  (82) 
420.2

>  <HBA>  (82) 
5.0

>  <HBD>  (82) 
2.0

>  <NRB>  (82) 
3.0

>  <TPSA>  (82) 
85.4

>  <LogP>  (82) 
5.6

>  <RoF>  (82) 
1.0

>  <Melting point>  (82) 


>  <Targets>  (82) 
MAPK14; MAPK11

>  <Kinase families>  (82) 
CMGC

>  <FDA_approved>  (82) 


$$$$
Prexasertib
     RDKit          2D

 27 29  0  0  0  0  0  0  0  0999 V2000
   -2.6180   -5.2908    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1320   -3.8717    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1179   -2.7412    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5899   -3.0299    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5759   -1.8994    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0898   -0.4803    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6178   -0.1917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6319   -1.3222    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1599   -1.0336    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5282    0.3269    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9609    0.1466    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2495   -1.3254    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0612   -2.0548    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.9821    1.2453    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.4442    0.9102    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8851   -0.5235    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3472   -0.8585    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.3684    0.2401    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9275    1.6739    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4654    2.0089    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.8305   -0.0949    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2926   -0.4299    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1318    1.2274    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1177    2.3578    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6317    3.7769    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6176    4.9073    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1316    6.3264    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 11 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 18 21  1  0
 21 22  3  0
  7 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
  8  3  1  0
 13  9  1  0
 20 15  1  0
M  END
>  <BrandName>  (83) 


>  <Applicants>  (83) 
Eli Lilly

>  <CHEMBL_ID>  (83) 
CHEMBL3544911

>  <Canonical_Smiles>  (83) 
COc1cccc(c1c2cc(n[nH]2)Nc3cnc(cn3)C#N)OCCCN

>  <Chirality>  (83) 
Achiral Molecule

>  <First_Approval>  (83) 
nan

>  <Phase>  (83) 
2.0

>  <SC_Patent>  (83) 
None

>  <Synonyms>  (83) 
LY2606368 | PREXASERTIB

>  <Withdrawn>  (83) 


>  <Indications>  (83) 
nan

>  <Type>  (83) 
nan

>  <targets_id>  (83) 
O14757|O96017

>  <inchi>  (83) 
InChI=1S/C18H19N7O2/c1-26-14-4-2-5-15(27-7-3-6-19)18(14)13-8-16(25-24-13)23-17-11-21-12(9-20)10-22-17/h2,4-5,8,10-11H,3,6-7,19H2,1H3,(H2,22,23,24,25)

>  <stdInchikey>  (83) 
DOTGPNHGTYJDEP-UHFFFAOYSA-N

>  <csid>  (83) 
32738771

>  <Links>  (83) 
|http://www.chemspider.com/Chemical-Structure.32738771.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3544911|http://pubchem.ncbi.nlm.nih.gov/compound/46700756|http://www.drugbank.ca/drugs/DB12008|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9549|http://zinc15.docking.org/substances/ZINC000095837013|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=820NH671E6

>  <LinkName>  (83) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (83) 


>  <pdbID>  (83) 


>  <indicationG2P>  (83) 
None

>  <indicationDB>  (83) 


>  <uniprotId>  (83) 


>  <MW>  (83) 
365.2

>  <HBA>  (83) 
8.0

>  <HBD>  (83) 
3.0

>  <NRB>  (83) 
8.0

>  <TPSA>  (83) 
134.8

>  <LogP>  (83) 
2.2

>  <RoF>  (83) 
0.0

>  <Melting point>  (83) 


>  <Targets>  (83) 
CHEK1; CHEK2

>  <Kinase families>  (83) 
CAMK

>  <FDA_approved>  (83) 


$$$$
Poziotinib
     RDKit          2D

 33 36  0  0  0  0  0  0  0  0999 V2000
   -1.9114    6.7012    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3000    5.2524    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2396    4.1915    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2094    4.5794    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2698    3.5184    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8812    2.0696    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5678    1.6818    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6282    2.7427    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0772    2.3549    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4658    0.9061    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9148    0.5182    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3034   -0.9306    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2430   -1.9915    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7940   -1.6036    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4054   -0.1549    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6316   -3.4403    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5712   -4.5012    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0806   -3.8282    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4692   -5.2769    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9416    1.0087    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3906    1.3966    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.7792    2.8454    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7188    3.9063    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.5530   -0.4401    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6134   -1.5010    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2248   -2.9498    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2851   -4.0107    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7341   -3.6229    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1227   -2.1741    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0623   -1.1131    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4509    0.3356    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    6.5717   -1.7862    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    5.7945   -4.6838    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 13 16  1  0
 16 17  2  0
 16 18  1  0
 18 19  2  0
  6 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 20 24  1  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 29 32  1  0
 28 33  1  0
  8  3  1  0
 23  5  1  0
 15 10  1  0
 30 25  1  0
M  END
>  <BrandName>  (84) 


>  <Applicants>  (84) 
Hanmi Pharmaceutical

>  <CHEMBL_ID>  (84) 
CHEMBL3545154

>  <Canonical_Smiles>  (84) 
COc1cc2c(cc1OC3CCN(CC3)C(=O)C=C)c(ncn2)Nc4ccc(c(c4F)Cl)Cl

>  <Chirality>  (84) 
Achiral Molecule

>  <First_Approval>  (84) 
nan

>  <Phase>  (84) 
2.0

>  <SC_Patent>  (84) 
None

>  <Synonyms>  (84) 
HM 781-36 | HM 781-36B | HM-781-36 | HM-781-36B | NOV-120101 | POZIOTINIB

>  <Withdrawn>  (84) 


>  <Indications>  (84) 
nan

>  <Type>  (84) 
nan

>  <targets_id>  (84) 
P00533

>  <inchi>  (84) 
InChI=1S/C23H21Cl2FN4O3/c1-3-20(31)30-8-6-13(7-9-30)33-19-10-14-17(11-18(19)32-2)27-12-28-23(14)29-16-5-4-15(24)21(25)22(16)26/h3-5,10-13H,1,6-9H2,2H3,(H,27,28,29)

>  <stdInchikey>  (84) 
LPFWVDIFUFFKJU-UHFFFAOYSA-N

>  <csid>  (84) 
30687714

>  <Links>  (84) 
|http://www.chemspider.com/Chemical-Structure.30687714.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545154|http://pubchem.ncbi.nlm.nih.gov/compound/25127713|http://www.drugbank.ca/drugs/DB12114|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7903|http://zinc15.docking.org/substances/ZINC000095930125|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=OEI6OOU6IK|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50468247

>  <LinkName>  (84) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (84) 


>  <pdbID>  (84) 


>  <indicationG2P>  (84) 
None

>  <indicationDB>  (84) 


>  <uniprotId>  (84) 


>  <MW>  (84) 
490.1

>  <HBA>  (84) 
6.0

>  <HBD>  (84) 
1.0

>  <NRB>  (84) 
6.0

>  <TPSA>  (84) 
76.6

>  <LogP>  (84) 
5.4

>  <RoF>  (84) 
1.0

>  <Melting point>  (84) 


>  <Targets>  (84) 
EGFR

>  <Kinase families>  (84) 
Tyr

>  <FDA_approved>  (84) 


$$$$
Pimasertib
     RDKit          2D

 23 24  0  0  0  0  0  0  0  0999 V2000
    4.6692   -2.5075    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1901   -2.2576    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6671   -0.8517    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6231    0.3042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1021    0.0542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6251   -1.3517    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1042   -1.6016    0.0000 I   0  0  0  0  0  0  0  0  0  0  0  0
    3.1001    1.7100    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    1.1881   -0.6018    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.6650    0.8041    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6210    1.9600    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0980    3.3658    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3810    3.6158    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3370    2.4599    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8140    1.0541    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7700   -0.1018    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2469   -1.5077    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2490    0.1481    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2050   -1.0077    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6840   -0.7578    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6400   -1.9137    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.1190   -1.6637    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2071    0.6481    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  4  8  1  0
  3  9  1  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 16 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 20 23  1  1
  6  1  1  0
 15 10  1  0
M  END
>  <BrandName>  (85) 
 EMD 1036239; as703026; emd 1036239;AS703026;MSC1936369A;Msc1936369a;Msc1936369a; as703026; emd 1036239

>  <Applicants>  (85) 
Merck

>  <CHEMBL_ID>  (85) 
CHEMBL2107832

>  <Canonical_Smiles>  (85) 
c1cc(c(cc1I)F)Nc2cnccc2C(=O)NC[C@@H](CO)O

>  <Chirality>  (85) 
Single Stereoisomer

>  <First_Approval>  (85) 
nan

>  <Phase>  (85) 
2.0

>  <SC_Patent>  (85) 
None

>  <Synonyms>  (85) 
AS 703026 | AS-703026 | AS703026 | EMD 1036239 | EMD-1036239 | G-02443714 | MSC-1936369A | MSC-1936369B | MSC1936369A | MSC1936369A; AS703026; EMD 1036239 | PIMASERTIB

>  <Withdrawn>  (85) 


>  <Indications>  (85) 
nan

>  <Type>  (85) 
nan

>  <targets_id>  (85) 
Q02750|P36507

>  <inchi>  (85) 
InChI=1S/C15H15FIN3O3/c16-12-5-9(17)1-2-13(12)20-14-7-18-4-3-11(14)15(23)19-6-10(22)8-21/h1-5,7,10,20-22H,6,8H2,(H,19,23)/t10-/m0/s1

>  <stdInchikey>  (85) 
VIUAUNHCRHHYNE-JTQLQIEISA-N

>  <csid>  (85) 
24747378

>  <Links>  (85) 
|http://www.chemspider.com/Chemical-Structure.24747378.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2107832|http://pubchem.ncbi.nlm.nih.gov/compound/44187362|http://www.drugbank.ca/drugs/DB14904| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=QOA|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/QOA|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7872|http://zinc15.docking.org/substances/ZINC38226009|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6ON9RK82AL|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50014412

>  <LinkName>  (85) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (85) 
'QOA'

>  <pdbID>  (85) 
6v30

>  <indicationG2P>  (85) 
None

>  <indicationDB>  (85) 


>  <uniprotId>  (85) 


>  <MW>  (85) 
431.0

>  <HBA>  (85) 
5.0

>  <HBD>  (85) 
4.0

>  <NRB>  (85) 
6.0

>  <TPSA>  (85) 
94.5

>  <LogP>  (85) 
1.7

>  <RoF>  (85) 
0.0

>  <Melting point>  (85) 


>  <Targets>  (85) 
MAP2K1; MAP2K2

>  <Kinase families>  (85) 
STE

>  <FDA_approved>  (85) 


$$$$
Tenalisib
     RDKit          2D

 31 35  0  0  0  0  0  0  0  0999 V2000
   -1.5190    3.5791    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1251    3.0248    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0919    1.5406    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4857    0.9864    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7027   -0.4978    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0965   -1.0520    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3135   -2.5363    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.2734   -0.1220    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6673   -0.6763    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8442    0.2538    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6272    1.7380    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2334    2.2922    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0565    1.3622    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6626    1.9164    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.5258   -1.4278    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8681   -0.8736    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0450   -1.8036    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8280   -3.2879    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4342   -3.8421    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7427   -2.9121    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2172   -5.3263    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0850    0.6106    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4789    1.1648    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6558    0.2348    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0497    0.7890    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0075   -0.3653    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2056   -1.6330    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7522   -1.2621    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2666    2.2733    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0897    3.2033    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6959    2.6490    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  3  2  1  1
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  6  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
  5 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 19 21  1  0
  3 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  1  0
 27 28  2  0
 25 29  1  0
 29 30  2  0
 30 31  1  0
 14  4  1  0
 13  8  1  0
 20 15  1  0
 31 23  2  0
 28 24  1  0
M  END
>  <BrandName>  (86) 


>  <Applicants>  (86) 
Rhizen Pharmaceuticals

>  <CHEMBL_ID>  (86) 
CHEMBL4297584

>  <Canonical_Smiles>  (86) 
CC[C@@H](c1c(c(=O)c2ccccc2o1)c3cccc(c3)F)Nc4c5c([nH]cn5)ncn4

>  <Chirality>  (86) 
Single Stereoisomer

>  <First_Approval>  (86) 
nan

>  <Phase>  (86) 
2.0

>  <SC_Patent>  (86) 
None

>  <Synonyms>  (86) 
TENALISIB

>  <Withdrawn>  (86) 


>  <Indications>  (86) 
nan

>  <Type>  (86) 
nan

>  <targets_id>  (86) 
nan

>  <inchi>  (86) 
InChI=1S/C23H18FN5O2/c1-2-16(29-23-19-22(26-11-25-19)27-12-28-23)21-18(13-6-5-7-14(24)10-13)20(30)15-8-3-4-9-17(15)31-21/h3-12,16H,2H2,1H3,(H2,25,26,27,28,29)/t16-/m0/s1

>  <stdInchikey>  (86) 
HDXDQPRPFRKGKZ-INIZCTEOSA-N

>  <csid>  (86) 
52083673

>  <Links>  (86) 
|http://www.chemspider.com/Chemical-Structure.52083673.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297584|http://pubchem.ncbi.nlm.nih.gov/compound/86291103|http://www.drugbank.ca/drugs/DB15295|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9907|http://zinc15.docking.org/substances/ZINC000220062787|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=2261HH611H

>  <LinkName>  (86) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (86) 


>  <pdbID>  (86) 


>  <indicationG2P>  (86) 
None

>  <indicationDB>  (86) 


>  <uniprotId>  (86) 


>  <MW>  (86) 
415.1

>  <HBA>  (86) 
6.0

>  <HBD>  (86) 
2.0

>  <NRB>  (86) 
5.0

>  <TPSA>  (86) 
96.7

>  <LogP>  (86) 
4.8

>  <RoF>  (86) 
0.0

>  <Melting point>  (86) 


>  <Targets>  (86) 
nan

>  <Kinase families>  (86) 


>  <FDA_approved>  (86) 


$$$$
Bentamapimod
     RDKit          2D

 33 37  0  0  0  0  0  0  0  0999 V2000
   -8.1455    0.4356    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6456    0.4177    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1457    0.3999    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4112   -0.9079    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0376   -2.2709    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9349   -3.2878    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9527   -4.7877    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6626   -5.5531    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3548   -4.8186    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3370   -3.3187    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6270   -2.5533    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9214   -1.0825    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3803    1.6899    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8804    1.6721    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1151    2.9621    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6152    2.9443    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.1193    1.6365    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6192    1.6186    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3538    0.3108    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8536    0.2929    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6190    1.5830    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8845    2.8908    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3846    2.9087    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1189    1.5651    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8534    0.2573    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.0880   -1.0327    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8226   -2.3406    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3224   -2.3584    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.0878   -1.0684    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3533    0.2395    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8496    4.2700    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3495    4.2878    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1148    2.9978    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  3  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
  3 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 21 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  1  0
 15 31  2  0
 31 32  1  0
 32 33  2  0
 12  4  1  0
 11  6  1  0
 23 18  1  0
 30 25  1  0
 33 13  1  0
M  END
>  <BrandName>  (87) 


>  <Applicants>  (87) 
PregLem

>  <CHEMBL_ID>  (87) 
CHEMBL3545213

>  <Canonical_Smiles>  (87) 
N#CC(c1nc2ccccc2s1)c5nc(OCc3ccc(cc3)CN4CCOCC4)ncc5

>  <Chirality>  (87) 
Racemic Mixture

>  <First_Approval>  (87) 
nan

>  <Phase>  (87) 
2.0

>  <SC_Patent>  (87) 
None

>  <Synonyms>  (87) 
AS-602801 | BENTAMAPIMOD | PGL-5001

>  <Withdrawn>  (87) 


>  <Indications>  (87) 
nan

>  <Type>  (87) 
nan

>  <targets_id>  (87) 
P45983|P45984

>  <inchi>  (87) 
InChI=1S/C25H23N5O2S/c26-15-20(24-28-22-3-1-2-4-23(22)33-24)21-9-10-27-25(29-21)32-17-19-7-5-18(6-8-19)16-30-11-13-31-14-12-30/h1-10,20H,11-14,16-17H2

>  <stdInchikey>  (87) 
XCPPIJCBCWUBNT-UHFFFAOYSA-N

>  <csid>  (87) 
8370750

>  <Links>  (87) 
|http://www.chemspider.com/Chemical-Structure.8370750.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545213|http://pubchem.ncbi.nlm.nih.gov/compound/10195250|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9926

>  <LinkName>  (87) 
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology

>  <lig_pdbID>  (87) 


>  <pdbID>  (87) 


>  <indicationG2P>  (87) 
None

>  <indicationDB>  (87) 


>  <uniprotId>  (87) 


>  <MW>  (87) 
457.2

>  <HBA>  (87) 
8.0

>  <HBD>  (87) 
0.0

>  <NRB>  (87) 
7.0

>  <TPSA>  (87) 
84.2

>  <LogP>  (87) 
4.2

>  <RoF>  (87) 
0.0

>  <Melting point>  (87) 


>  <Targets>  (87) 
MAPK8; MAPK9

>  <Kinase families>  (87) 
CMGC

>  <FDA_approved>  (87) 


$$$$
Tomivosertib
     RDKit          2D

 25 28  0  0  0  0  0  0  0  0999 V2000
   -0.4206    3.4185    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0604    1.9624    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1414    0.9224    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7812   -0.5337    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6600   -0.9498    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0201   -2.4060    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.7409    0.0901    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.3807    1.5463    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6542    2.3388    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7617    3.8349    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.8015    1.3725    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.2370   -0.0173    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5304   -1.3404    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3229   -2.6139    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8221   -2.5643    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5287   -1.2412    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7362    0.0323    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8621   -1.5737    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3032   -1.1576    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6634    0.2985    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1045    0.7147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1855   -0.3253    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8253   -1.7814    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3842   -2.1976    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4647    2.1708    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  5  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
  9 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
  4 18  1  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 21 25  1  0
  8  2  2  0
 12  7  1  0
 17 12  1  0
 24 19  1  0
M  END
>  <BrandName>  (88) 


>  <Applicants>  (88) 
Effector Therapeutics

>  <CHEMBL_ID>  (88) 
CHEMBL4073443

>  <Canonical_Smiles>  (88) 
Cc1cc(c(=O)n2c1C(=O)NC23CCCCC3)Nc4cc(ncn4)N

>  <Chirality>  (88) 
Achiral Molecule

>  <First_Approval>  (88) 
nan

>  <Phase>  (88) 
2.0

>  <SC_Patent>  (88) 
None

>  <Synonyms>  (88) 
EFT 508 | EFT-508 | EFT508 | TOMIVOSERTIB

>  <Withdrawn>  (88) 


>  <Indications>  (88) 
Tomivosertib, also known as eFT508 is a MNK1/2 inhibitor. Tomivosertib binds to and inhibits the activity of MNK1 and 2. This prevents MNK1/2-mediated signaling, and inhibits the phosphorylation of certain regulatory proteins, including eukaryotic translation initiation factor 4E (eIF4E), that regulate the translation of messenger RNAs (mRNAs) involved in tumor cell proliferation, angiogenesis, survival and immune signaling

>  <Type>  (88) 
nan

>  <targets_id>  (88) 
nan

>  <inchi>  (88) 
InChI=1S/C17H20N6O2/c1-10-7-11(21-13-8-12(18)19-9-20-13)16(25)23-14(10)15(24)22-17(23)5-3-2-4-6-17/h7-9H,2-6H2,1H3,(H,22,24)(H3,18,19,20,21)

>  <stdInchikey>  (88) 
HKTBYUWLRDZAJK-UHFFFAOYSA-N

>  <csid>  (88) 
57617704

>  <Links>  (88) 
|http://www.chemspider.com/Chemical-Structure.57617704.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4073443|http://pubchem.ncbi.nlm.nih.gov/compound/118598754|http://www.drugbank.ca/drugs/DB15219| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=N45|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/N45|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10167|http://zinc15.docking.org/substances/ZINC000575623807|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=U2H19X4WBV|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50263263

>  <LinkName>  (88) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (88) 
'N45'

>  <pdbID>  (88) 
6ck6

>  <indicationG2P>  (88) 
None

>  <indicationDB>  (88) 


>  <uniprotId>  (88) 


>  <MW>  (88) 
340.2

>  <HBA>  (88) 
7.0

>  <HBD>  (88) 
3.0

>  <NRB>  (88) 
2.0

>  <TPSA>  (88) 
114.9

>  <LogP>  (88) 
1.6

>  <RoF>  (88) 
0.0

>  <Melting point>  (88) 


>  <Targets>  (88) 
nan

>  <Kinase families>  (88) 


>  <FDA_approved>  (88) 


$$$$
Voruciclib
     RDKit          2D

 32 35  0  0  0  0  0  0  0  0999 V2000
   -4.1207   -4.8903    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3075   -3.6298    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8098   -3.5469    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4259   -2.0968    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6863   -1.2836    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8492   -2.2311    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2993   -1.8471    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3568   -2.9110    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7693    0.2141    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1078    0.8911    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1908    2.3888    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9352    3.2095    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5967    2.5325    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5137    1.0348    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1752    0.3578    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.0804    1.1785    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9974    2.6762    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3411    3.3532    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4241    4.8509    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.4189    0.5015    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5019   -0.9962    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8404   -1.6732    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0960   -0.8525    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0130    0.6452    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6745    1.3222    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5915    2.8199    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    6.4345   -1.5295    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7730   -2.2065    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    5.7575   -2.8681    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    7.1115   -0.1910    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0182    4.7072    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3634    0.0704    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  1
  7  8  1  0
  5  9  1  6
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 16 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 23 27  1  0
 27 28  1  0
 27 29  1  0
 27 30  1  0
 12 31  1  0
 10 32  1  0
  6  2  1  0
 14  9  1  0
 18 13  1  0
 25 20  1  0
M  END
>  <BrandName>  (89) 


>  <Applicants>  (89) 
Piramal Enterprises

>  <CHEMBL_ID>  (89) 
CHEMBL3545218

>  <Canonical_Smiles>  (89) 
CN1CC[C@H]([C@@H]1CO)c2c(cc(c3c2oc(cc3=O)c4ccc(cc4Cl)C(F)(F)F)O)O

>  <Chirality>  (89) 
Single Stereoisomer

>  <First_Approval>  (89) 
nan

>  <Phase>  (89) 
2.0

>  <SC_Patent>  (89) 
None

>  <Synonyms>  (89) 


>  <Withdrawn>  (89) 


>  <Indications>  (89) 
nan

>  <Type>  (89) 
nan

>  <targets_id>  (89) 
P11802

>  <inchi>  (89) 
InChI=1S/C22H19ClF3NO5/c1-27-5-4-12(14(27)9-28)19-15(29)7-16(30)20-17(31)8-18(32-21(19)20)11-3-2-10(6-13(11)23)22(24,25)26/h2-3,6-8,12,14,28-30H,4-5,9H2,1H3/t12-,14+/m1/s1

>  <stdInchikey>  (89) 
MRPGRAKIAJJGMM-OCCSQVGLSA-N

>  <csid>  (89) 
29165867

>  <Links>  (89) 
|http://www.chemspider.com/Chemical-Structure.29165867.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3905910|http://pubchem.ncbi.nlm.nih.gov/compound/67409219|http://www.drugbank.ca/drugs/DB15157|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9923|http://zinc15.docking.org/substances/ZINC000118905502|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=W66XP666AM|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50193104

>  <LinkName>  (89) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (89) 


>  <pdbID>  (89) 


>  <indicationG2P>  (89) 
None

>  <indicationDB>  (89) 


>  <uniprotId>  (89) 


>  <MW>  (89) 
469.1

>  <HBA>  (89) 
6.0

>  <HBD>  (89) 
3.0

>  <NRB>  (89) 
3.0

>  <TPSA>  (89) 
94.1

>  <LogP>  (89) 
4.3

>  <RoF>  (89) 
0.0

>  <Melting point>  (89) 


>  <Targets>  (89) 
CDK4

>  <Kinase families>  (89) 
CMGC

>  <FDA_approved>  (89) 


$$$$
Miransertib
     RDKit          2D

 33 38  0  0  0  0  0  0  0  0999 V2000
   -7.2537    1.6240    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8759    2.2171    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6734    1.3205    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8486   -0.1693    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2264   -0.7624    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4289    0.1342    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6461   -1.0659    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8213   -2.5556    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6188   -3.4522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2410   -2.8591    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0658   -1.3693    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2683   -0.4727    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.4052   -1.0756    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.1391   -2.3838    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1217   -3.4861    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6288   -2.5590    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5254   -1.3565    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0151   -1.5317    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6083   -2.9095    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7116   -4.1120    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.2219   -3.9368    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3253   -5.1393    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0322    0.2870    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5258    0.4254    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1528    1.7881    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2861    3.0124    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7925    2.8741    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1655    1.5114    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9131    4.3751    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5505    5.0021    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1775    6.3647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5401    5.7377    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1298    4.5231    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  4  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 11 13  1  0
 13 14  1  0
 14 15  2  0
 14 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 13 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 26 29  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 29 33  1  0
  6  1  1  0
 12  7  1  0
 15 10  1  0
 21 16  1  0
 28 23  1  0
 32 29  1  0
M  END
>  <BrandName>  (90) 


>  <Applicants>  (90) 
Merck

>  <CHEMBL_ID>  (90) 
CHEMBL4297188

>  <Canonical_Smiles>  (90) 
c1ccc(cc1)c2ccc3c(n2)n(c(n3)c4cccnc4N)c5ccc(cc5)C6(CCC6)N

>  <Chirality>  (90) 
Achiral Molecule

>  <First_Approval>  (90) 
nan

>  <Phase>  (90) 
2.0

>  <SC_Patent>  (90) 
None

>  <Synonyms>  (90) 
ARQ 092 | ARQ 092 FREE BASE | ARQ-092 | MIRANSERTIB

>  <Withdrawn>  (90) 


>  <Indications>  (90) 
nan

>  <Type>  (90) 
nan

>  <targets_id>  (90) 
nan

>  <inchi>  (90) 
InChI=1S/C27H24N6/c28-24-21(8-4-17-30-24)25-32-23-14-13-22(18-6-2-1-3-7-18)31-26(23)33(25)20-11-9-19(10-12-20)27(29)15-5-16-27/h1-4,6-14,17H,5,15-16,29H2,(H2,28,30)

>  <stdInchikey>  (90) 
HNFMVVHMKGFCMB-UHFFFAOYSA-N

>  <csid>  (90) 
57251282

>  <Links>  (90) 
|http://www.chemspider.com/Chemical-Structure.57251282.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297188|http://pubchem.ncbi.nlm.nih.gov/compound/53262401|http://www.drugbank.ca/drugs/DB14982| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=6S1|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6S1|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9429|http://zinc15.docking.org/substances/ZINC000072315647|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=T1DQI1B52Y

>  <LinkName>  (90) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (90) 
'6S1'

>  <pdbID>  (90) 
5kcv

>  <indicationG2P>  (90) 
None

>  <indicationDB>  (90) 


>  <uniprotId>  (90) 


>  <MW>  (90) 
432.2

>  <HBA>  (90) 
6.0

>  <HBD>  (90) 
2.0

>  <NRB>  (90) 
4.0

>  <TPSA>  (90) 
95.6

>  <LogP>  (90) 
5.1

>  <RoF>  (90) 
1.0

>  <Melting point>  (90) 


>  <Targets>  (90) 
nan

>  <Kinase families>  (90) 


>  <FDA_approved>  (90) 


$$$$
Sapitinib
     RDKit          2D

 33 36  0  0  0  0  0  0  0  0999 V2000
    6.8433    1.9203    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8865    3.0755    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.4077    2.8244    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8856    1.4182    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.4508    3.9796    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9720    3.7286    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.4500    2.3224    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0289    2.0713    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9857    3.2266    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4637    4.6328    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0152    4.8838    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4645    2.9755    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9866    1.5693    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0297    0.4141    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5518   -0.9921    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0306   -1.2432    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9874   -0.0880    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4654    1.3183    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4222    2.4735    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9002    3.8797    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5526   -2.6494    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5958   -3.8046    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1170   -3.5536    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5949   -2.1473    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1161   -1.8963    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.8407   -3.0515    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3187   -4.4578    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2755   -5.6130    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7544   -5.3619    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2764   -3.9557    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3196   -2.8005    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8416   -1.3943    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    4.7552   -3.7047    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  3  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
  9 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  1  0
 16 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 30 33  1  0
 11  6  1  0
 18 13  1  0
 24 15  1  0
 31 26  1  0
M  END
>  <BrandName>  (91) 


>  <Applicants>  (91) 
Astrazeneca

>  <CHEMBL_ID>  (91) 
CHEMBL2408045

>  <Canonical_Smiles>  (91) 
CNC(=O)CN1CCC(CC1)Oc2cc3c(cc2OC)ncnc3Nc4cccc(c4F)Cl

>  <Chirality>  (91) 
Achiral Molecule

>  <First_Approval>  (91) 
nan

>  <Phase>  (91) 
2.0

>  <SC_Patent>  (91) 
None

>  <Synonyms>  (91) 
AZD-8931 | AZD8931 | SAPITINIB

>  <Withdrawn>  (91) 


>  <Indications>  (91) 
nan

>  <Type>  (91) 
nan

>  <targets_id>  (91) 
P00533|P04626|Q15303|P21860

>  <inchi>  (91) 
InChI=1S/C23H25ClFN5O3/c1-26-21(31)12-30-8-6-14(7-9-30)33-20-10-15-18(11-19(20)32-2)27-13-28-23(15)29-17-5-3-4-16(24)22(17)25/h3-5,10-11,13-14H,6-9,12H2,1-2H3,(H,26,31)(H,27,28,29)

>  <stdInchikey>  (91) 
DFJSJLGUIXFDJP-UHFFFAOYSA-N

>  <csid>  (91) 
9663133

>  <Links>  (91) 
|http://www.chemspider.com/Chemical-Structure.9663133.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2408045|http://pubchem.ncbi.nlm.nih.gov/compound/11488320|http://www.drugbank.ca/drugs/DB12183|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7717|http://zinc15.docking.org/substances/ZINC000034587071|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=3499328002|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50437353

>  <LinkName>  (91) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (91) 


>  <pdbID>  (91) 


>  <indicationG2P>  (91) 
None

>  <indicationDB>  (91) 


>  <uniprotId>  (91) 


>  <MW>  (91) 
473.2

>  <HBA>  (91) 
7.0

>  <HBD>  (91) 
2.0

>  <NRB>  (91) 
7.0

>  <TPSA>  (91) 
88.6

>  <LogP>  (91) 
3.8

>  <RoF>  (91) 
0.0

>  <Melting point>  (91) 


>  <Targets>  (91) 
EGFR; ERBB2; ERBB4; ERBB3

>  <Kinase families>  (91) 
Tyr

>  <FDA_approved>  (91) 


$$$$
Tanzisertib
     RDKit          2D

 32 36  0  0  0  0  0  0  0  0999 V2000
   -5.8888    1.6004    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4970    1.0411    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2854   -0.4439    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4657   -1.3696    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8575   -0.8104    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0691    0.6746    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4609    1.2339    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2541   -2.8547    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8936   -1.0032    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7133   -0.0775    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2706   -0.4882    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.5658    0.7569    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0508    0.9685    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6101    2.3604    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6843    3.5406    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.1993    3.3291    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3599    1.9372    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7685    1.4215    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.0951    2.5719    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.0208    1.3917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4615   -0.0002    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3873   -1.1804    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8723   -0.9689    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4315    0.4230    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5058    1.6032    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7980   -2.1491    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.2451   -1.8968    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6877   -2.3075    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7429   -3.8065    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.3344   -4.3222    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5914   -3.1419    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3167    1.9668    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  4  8  1  0
  3  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 14 19  1  0
 20 19  1  6
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 23 26  1  1
 27 11  1  6
 27 28  1  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
  2 32  1  0
  6  1  1  0
 18 10  2  0
 17 12  1  0
 25 20  1  0
 31 27  1  0
M  END
>  <BrandName>  (92) 


>  <Applicants>  (92) 
Celgene

>  <CHEMBL_ID>  (92) 
CHEMBL1950289

>  <Canonical_Smiles>  (92) 
c1c(c(c(cc1F)F)Nc2n(c3nc(ncc3n2)N[C@H]4CC[C@@H](CC4)O)[C@@H]5COCC5)F

>  <Chirality>  (92) 
Single Stereoisomer

>  <First_Approval>  (92) 
nan

>  <Phase>  (92) 
2.0

>  <SC_Patent>  (92) 
None

>  <Synonyms>  (92) 
CC-930 | JNK 930 | JNK-930 | TANZISERTIB

>  <Withdrawn>  (92) 


>  <Indications>  (92) 
nan

>  <Type>  (92) 
1

>  <targets_id>  (92) 
P45983

>  <inchi>  (92) 
InChI=1S/C21H23F3N6O2/c22-11-7-15(23)18(16(24)8-11)28-21-27-17-9-25-20(26-12-1-3-14(31)4-2-12)29-19(17)30(21)13-5-6-32-10-13/h7-9,12-14,31H,1-6,10H2,(H,27,28)(H,25,26,29)/t12-,13-,14-/m0/s1

>  <stdInchikey>  (92) 
IBGLGMOPHJQDJB-IHRRRGAJSA-N

>  <csid>  (92) 
28492361

>  <Links>  (92) 
|http://www.chemspider.com/Chemical-Structure.28492361.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1950289|http://www.drugbank.ca/drugs/DB11798| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=KBI|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/KBI|http://zinc15.docking.org/substances/ZINC000102930548|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=M5O06306UO|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50364378

>  <LinkName>  (92) 
|ChemSpider|ChEMBL|DrugBank|RCSB|PDBe|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (92) 
'KBI'

>  <pdbID>  (92) 
3tti

>  <indicationG2P>  (92) 


>  <indicationDB>  (92) 


>  <uniprotId>  (92) 


>  <MW>  (92) 
448.2

>  <HBA>  (92) 
8.0

>  <HBD>  (92) 
3.0

>  <NRB>  (92) 
5.0

>  <TPSA>  (92) 
97.1

>  <LogP>  (92) 
3.7

>  <RoF>  (92) 
0.0

>  <Melting point>  (92) 


>  <Targets>  (92) 
MAPK8

>  <Kinase families>  (92) 
CMGC

>  <FDA_approved>  (92) 


$$$$
Delgocitinib
     RDKit          2D

 23 26  0  0  0  0  0  0  0  0999 V2000
    0.8311    3.8127    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6825    2.5777    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1578    2.3065    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8866    0.8313    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.4113    1.1025    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3743   -0.3971    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0633   -0.8252    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9148    0.4097    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0034    1.6011    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4143    0.4468    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1962   -0.8333    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7681   -2.2709    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0030   -3.1223    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1944   -2.2109    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6957   -0.7962    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4134    0.5210    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6315    1.8011    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1320    1.7640    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.7380   -0.4037    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0942   -1.7585    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.2332   -0.2838    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0846   -1.5188    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9361   -2.7537    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  8 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
  4 19  1  0
 19 20  2  0
 19 21  1  0
 21 22  1  0
 22 23  3  0
  5  2  1  0
  9  5  1  0
 18 10  1  0
 15 11  1  0
M  END
>  <BrandName>  (93) 


>  <Applicants>  (93) 
Japan Tobacco

>  <CHEMBL_ID>  (93) 
CHEMBL4297507

>  <Canonical_Smiles>  (93) 
CC1CN(C12CCN(C2)c3c4cc[nH]c4ncn3)C(=O)CC#N

>  <Chirality>  (93) 
Single Stereoisomer

>  <First_Approval>  (93) 
nan

>  <Phase>  (93) 
2.0

>  <SC_Patent>  (93) 
None

>  <Synonyms>  (93) 


>  <Withdrawn>  (93) 


>  <Indications>  (93) 
nan

>  <Type>  (93) 
nan

>  <targets_id>  (93) 
nan

>  <inchi>  (93) 
InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)

>  <stdInchikey>  (93) 
LOWWYYZBZNSPDT-UHFFFAOYSA-N

>  <csid>  (93) 
34960249

>  <Links>  (93) 
|http://www.chemspider.com/Chemical-Structure.34960249.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3689518|http://pubchem.ncbi.nlm.nih.gov/compound/50913622|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=109868

>  <LinkName>  (93) 
|ChemSpider|ChEMBL|PubChem|BindingDB

>  <lig_pdbID>  (93) 


>  <pdbID>  (93) 


>  <indicationG2P>  (93) 


>  <indicationDB>  (93) 


>  <uniprotId>  (93) 


>  <MW>  (93) 
310.2

>  <HBA>  (93) 
5.0

>  <HBD>  (93) 
1.0

>  <NRB>  (93) 
2.0

>  <TPSA>  (93) 
88.9

>  <LogP>  (93) 
1.3

>  <RoF>  (93) 
0.0

>  <Melting point>  (93) 


>  <Targets>  (93) 
nan

>  <Kinase families>  (93) 


>  <FDA_approved>  (93) 


$$$$
Ilginatinib
     RDKit          2D

 29 32  0  0  0  0  0  0  0  0999 V2000
    2.7063    1.3605    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1562   -0.0705    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6204   -0.3964    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0702   -1.8273    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5344   -2.1532    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5487   -1.0481    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0988    0.3828    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6347    0.7087    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0129   -1.3740    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    2.1419   -1.1756    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.6777   -0.8497    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2278    0.5812    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2363    0.9071    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2506   -0.1980    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8008   -1.6289    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3366   -1.9548    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8151   -2.7340    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2792   -2.4081    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7291   -0.9772    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1933   -0.6513    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2076   -1.7564    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7577   -3.1873    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2935   -3.5132    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6862    2.3381    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1083    2.8152    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0940    4.3151    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6630    4.7650    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7930    3.5431    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1859    6.1871    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  6  9  1  0
  2 10  1  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 15 17  1  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 13 24  1  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  1  0
 27 29  1  0
  8  3  1  0
 16 11  1  0
 23 18  1  0
 28 24  2  0
M  END
>  <BrandName>  (94) 


>  <Applicants>  (94) 
Nippon Shinyaku

>  <CHEMBL_ID>  (94) 
CHEMBL3545217

>  <Canonical_Smiles>  (94) 
CC(c1ccc(cc1)F)Nc2cc(cc(n2)Nc3cnccn3)c4cnn(c4)C

>  <Chirality>  (94) 
Single Stereoisomer

>  <First_Approval>  (94) 
nan

>  <Phase>  (94) 
2.0

>  <SC_Patent>  (94) 
None

>  <Synonyms>  (94) 
|NS-018

>  <Withdrawn>  (94) 


>  <Indications>  (94) 
nan

>  <Type>  (94) 
nan

>  <targets_id>  (94) 
nan

>  <inchi>  (94) 
InChI=1S/C21H20FN7/c1-14(15-3-5-18(22)6-4-15)26-19-9-16(17-11-25-29(2)13-17)10-20(27-19)28-21-12-23-7-8-24-21/h3-14H,1-2H3,(H2,24,26,27,28)

>  <stdInchikey>  (94) 
UQTPDWDAYHAZNT-UHFFFAOYSA-N

>  <csid>  (94) 
64880076

>  <Links>  (94) 
|http://www.chemspider.com/Chemical-Structure.64880076.html|http://pubchem.ncbi.nlm.nih.gov/compound/75236651

>  <LinkName>  (94) 
|ChemSpider|PubChem

>  <lig_pdbID>  (94) 


>  <pdbID>  (94) 


>  <indicationG2P>  (94) 


>  <indicationDB>  (94) 


>  <uniprotId>  (94) 


>  <MW>  (94) 
389.2

>  <HBA>  (94) 
7.0

>  <HBD>  (94) 
2.0

>  <NRB>  (94) 
6.0

>  <TPSA>  (94) 
80.6

>  <LogP>  (94) 
4.3

>  <RoF>  (94) 
0.0

>  <Melting point>  (94) 


>  <Targets>  (94) 
nan

>  <Kinase families>  (94) 


>  <FDA_approved>  (94) 


$$$$
Tirabrutinib
     RDKit          2D

 34 38  0  0  0  0  0  0  0  0999 V2000
    9.3898   -1.5495    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5598   -0.3000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7298    0.9495    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8999    2.1989    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5670    3.5424    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.4028    2.1049    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.4468    3.2608    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0521    2.7087    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1461    1.2117    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5990    0.8385    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9903    0.2557    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0843   -1.2414    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6896   -1.7934    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4703   -3.2773    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6457   -4.2091    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.0405   -3.6571    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2597   -2.1732    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9244   -3.8293    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2665   -0.6375    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.5374    0.6289    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0146    2.0236    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7635   -0.7316    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5935    0.5179    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0905    0.4239    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7576   -0.9196    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9276   -2.1691    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4306   -2.0751    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2546   -1.0137    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0846    0.2358    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4175    1.5793    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2475    2.8288    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7445    2.7347    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.4116    1.3912    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.5817    0.1418    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  3  0
  3  4  1  0
  4  5  2  0
  4  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
  9 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 14 18  1  0
 13 19  1  0
 19 20  1  0
 20 21  2  0
 19 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 25 28  1  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  2  0
 32 33  1  0
 33 34  2  0
 10  6  1  0
 20 11  1  0
 17 12  2  0
 27 22  1  0
 34 29  1  0
M  END
>  <BrandName>  (95) 


>  <Applicants>  (95) 
Ono Pharmaceutical

>  <CHEMBL_ID>  (95) 
CHEMBL4071161

>  <Canonical_Smiles>  (95) 
CC#CC(=O)N1CCC(C1)n2c3c(c(ncn3)N)n(c2=O)c4ccc(cc4)Oc5ccccc5

>  <Chirality>  (95) 
Single Stereoisomer

>  <First_Approval>  (95) 
nan

>  <Phase>  (95) 
2.0

>  <SC_Patent>  (95) 
None

>  <Synonyms>  (95) 
|ONO-4059(FREE BASE)|GS-4059|ONO-4059

>  <Withdrawn>  (95) 


>  <Indications>  (95) 
nan

>  <Type>  (95) 
nan

>  <targets_id>  (95) 
nan

>  <inchi>  (95) 
InChI=1S/C25H22N6O3/c1-2-6-21(32)29-14-13-18(15-29)31-24-22(23(26)27-16-28-24)30(25(31)33)17-9-11-20(12-10-17)34-19-7-4-3-5-8-19/h3-5,7-12,16,18H,13-15H2,1H3,(H2,26,27,28)

>  <stdInchikey>  (95) 
SEJLPXCPMNSRAM-UHFFFAOYSA-N

>  <csid>  (95) 
34979967

>  <Links>  (95) 
|http://www.chemspider.com/Chemical-Structure.34979967.html|http://pubchem.ncbi.nlm.nih.gov/compound/54755435

>  <LinkName>  (95) 
|ChemSpider|PubChem

>  <lig_pdbID>  (95) 


>  <pdbID>  (95) 


>  <indicationG2P>  (95) 


>  <indicationDB>  (95) 


>  <uniprotId>  (95) 


>  <MW>  (95) 
454.2

>  <HBA>  (95) 
8.0

>  <HBD>  (95) 
1.0

>  <NRB>  (95) 
4.0

>  <TPSA>  (95) 
108.3

>  <LogP>  (95) 
2.8

>  <RoF>  (95) 
0.0

>  <Melting point>  (95) 


>  <Targets>  (95) 
nan

>  <Kinase families>  (95) 


>  <FDA_approved>  (95) 


$$$$
Ulixertinib
     RDKit          2D

 29 31  0  0  0  0  0  0  0  0999 V2000
    6.7429   -4.1190    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0171   -2.8063    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5174   -2.7784    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7911   -1.5214    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.0653   -0.2086    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5656   -0.1808    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8398    1.1319    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6138    2.4168    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1135    2.3890    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8393    1.0762    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.8880    3.7296    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    2.3401    1.1598    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4360   -0.0372    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0183    0.4527    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0461    1.9525    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.4811    2.3894    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2114   -0.4063    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0823   -1.9007    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5701    0.2292    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7998   -0.6298    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6707   -2.1243    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9004   -2.9833    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1586    0.0056    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2877    1.5000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6464    2.1355    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.8761    1.2764    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.7470   -0.2180    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3883   -0.8534    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.9767   -1.0770    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
  8 11  1  0
  7 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  1  0
 14 17  1  0
 17 18  2  0
 17 19  1  0
 19 20  1  0
 20 21  1  6
 21 22  1  0
 20 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 27 29  1  0
 10  5  1  0
 16 12  2  0
 28 23  1  0
M  END
>  <BrandName>  (96) 


>  <Applicants>  (96) 
BioMed Valley Discoveries

>  <CHEMBL_ID>  (96) 
CHEMBL3545022

>  <Canonical_Smiles>  (96) 
CC(C)Nc1cc(c(cn1)Cl)c2cc([nH]c2)C(=O)N[C@H](CO)c3cccc(c3)Cl

>  <Chirality>  (96) 
Single Stereoisomer

>  <First_Approval>  (96) 
nan

>  <Phase>  (96) 
2.0

>  <SC_Patent>  (96) 
None

>  <Synonyms>  (96) 


>  <Withdrawn>  (96) 


>  <Indications>  (96) 
nan

>  <Type>  (96) 
nan

>  <targets_id>  (96) 
P28482|P27361

>  <inchi>  (96) 
InChI=1S/C21H22Cl2N4O2/c1-12(2)26-20-8-16(17(23)10-25-20)14-7-18(24-9-14)21(29)27-19(11-28)13-4-3-5-15(22)6-13/h3-10,12,19,24,28H,11H2,1-2H3,(H,25,26)(H,27,29)/t19-/m1/s1

>  <stdInchikey>  (96) 
KSERXGMCDHOLSS-LJQANCHMSA-N

>  <csid>  (96) 
9893722

>  <Links>  (96) 
|http://www.chemspider.com/Chemical-Structure.9893722.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3590106|http://pubchem.ncbi.nlm.nih.gov/compound/11719003|http://www.drugbank.ca/drugs/DB13930| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=EVK|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/EVK|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9210|http://zinc15.docking.org/substances/ZINC000034642570|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=16ZDH50O1U

>  <LinkName>  (96) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (96) 
'EVK'

>  <pdbID>  (96) 
6gdq

>  <indicationG2P>  (96) 
None

>  <indicationDB>  (96) 
Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity <sup class="text-reference-group"><a class="reference-popover-link" data-content="Germann UA, Furey BF, Markland W, Hoover RR, Aronov AM, Roix JJ, Hale M, Boucher DM, Sorrell DA, Martinez-Botella G, Fitzgibbon M, Shapiro P, Wick MJ, Samadani R, Meshaw K, Groover A, DeCrescenzo G, Namchuk M, Emery CM, Saha S, Welsch DJ: Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib). Mol Cancer Ther. 2017 Nov;16(11):2351-2363. doi: 10.1158/1535-7163.MCT-17-0456. Epub 2017 Sep 22. (PubMed ID 28939558)" href="#reference-A31474">1</a></sup>. It is currently in clinical trials for the treatment of a wide range of tumors.

>  <uniprotId>  (96) 
P27361|P28482

>  <MW>  (96) 
432.1

>  <HBA>  (96) 
4.0

>  <HBD>  (96) 
4.0

>  <NRB>  (96) 
7.0

>  <TPSA>  (96) 
90.0

>  <LogP>  (96) 
4.7

>  <RoF>  (96) 
0.0

>  <Melting point>  (96) 


>  <Targets>  (96) 
MAPK1; MAPK3

>  <Kinase families>  (96) 
CMGC

>  <FDA_approved>  (96) 


$$$$
Rabusertib
     RDKit          2D

 27 29  0  0  0  0  0  0  0  0999 V2000
   -2.5903   -5.1727    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8525   -3.8666    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6147   -2.5747    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8770   -1.2687    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3771   -1.2545    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3851   -2.5464    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3526   -3.8525    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4096   -5.1444    0.0000 Br  0  0  0  0  0  0  0  0  0  0  0  0
    0.3606    0.0515    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.8606    0.0656    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6228   -1.2263    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.5983    1.3717    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.0982    1.3858    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8604    0.0939    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3604    0.1081    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.0981    1.4141    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3359    2.7060    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8360    2.6919    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.5980    1.4282    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6392    0.0232    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1392    0.0091    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9014    1.3010    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1636    2.6071    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9258    3.8990    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4258    3.8848    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1635    2.5788    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4013    1.2869    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  5  9  1  0
  9 10  1  0
 10 11  2  0
 10 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 16 19  1  0
  4 20  1  0
 20 21  1  0
 22 21  1  1
 22 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
  7  2  1  0
 18 13  1  0
 27 22  1  0
M  END
>  <BrandName>  (97) 


>  <Applicants>  (97) 
Eli Lilly

>  <CHEMBL_ID>  (97) 
CHEMBL3039517

>  <Canonical_Smiles>  (97) 
Cc1cc(c(cc1Br)NC(=O)Nc2cnc(cn2)C)OC[C@@H]3CNCCO3

>  <Chirality>  (97) 
Single Stereoisomer

>  <First_Approval>  (97) 
nan

>  <Phase>  (97) 
2.0

>  <SC_Patent>  (97) 
None

>  <Synonyms>  (97) 
IC-83 | LY-2603618 | LY2603618 | RABUSERTIB

>  <Withdrawn>  (97) 


>  <Indications>  (97) 
nan

>  <Type>  (97) 
nan

>  <targets_id>  (97) 
O14757

>  <inchi>  (97) 
InChI=1S/C18H22BrN5O3/c1-11-5-16(27-10-13-8-20-3-4-26-13)15(6-14(11)19)23-18(25)24-17-9-21-12(2)7-22-17/h5-7,9,13,20H,3-4,8,10H2,1-2H3,(H2,22,23,24,25)/t13-/m0/s1

>  <stdInchikey>  (97) 
SYYBDNPGDKKJDU-ZDUSSCGKSA-N

>  <csid>  (97) 
10130131

>  <Links>  (97) 
|http://www.chemspider.com/Chemical-Structure.10130131.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3039517|http://pubchem.ncbi.nlm.nih.gov/compound/11955855|http://www.drugbank.ca/drugs/DB11662|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7960|http://zinc15.docking.org/substances/ZINC000070466463|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=3S9L1NU6U7

>  <LinkName>  (97) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (97) 


>  <pdbID>  (97) 


>  <indicationG2P>  (97) 
None

>  <indicationDB>  (97) 


>  <uniprotId>  (97) 


>  <MW>  (97) 
435.1

>  <HBA>  (97) 
6.0

>  <HBD>  (97) 
3.0

>  <NRB>  (97) 
5.0

>  <TPSA>  (97) 
97.4

>  <LogP>  (97) 
2.9

>  <RoF>  (97) 
0.0

>  <Melting point>  (97) 


>  <Targets>  (97) 
CHEK1

>  <Kinase families>  (97) 
CAMK

>  <FDA_approved>  (97) 


$$$$
Uprosertib
     RDKit          2D

 28 30  0  0  0  0  0  0  0  0999 V2000
   -5.9815   -0.1961    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0158    0.9517    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5196    0.8451    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9559    2.2351    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1037    3.2008    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3768    2.4076    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5000    2.5961    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -2.7264   -0.4280    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2302   -0.5346    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8693   -1.9906    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1424   -2.7838    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2902   -1.8181    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7461   -2.1790    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    0.5208   -2.5543    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7276   -4.0400    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.7040   -1.6324    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.0940   -2.1961    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2773   -1.2742    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0705    0.2115    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2537    1.1334    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0469    2.6191    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6569    3.1829    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4736    2.2609    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6804    0.7752    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0836    2.8247    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    3.4501    4.6685    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    3.3008   -3.6818    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1176   -4.6037    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  4  7  1  0
  3  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 10 14  1  0
 14 15  2  0
 14 16  1  0
 16 17  1  0
 17 18  1  1
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 23 25  1  0
 22 26  1  0
 17 27  1  0
 27 28  1  0
  6  2  1  0
 12  8  2  0
 24 19  1  0
M  END
>  <BrandName>  (98) 


>  <Applicants>  (98) 
GlaxoSmithKline

>  <CHEMBL_ID>  (98) 
CHEMBL3137336

>  <Canonical_Smiles>  (98) 
Cn1c(c(cn1)Cl)c2cc(oc2Cl)C(=O)N[C@@H](Cc3ccc(c(c3)F)F)CN

>  <Chirality>  (98) 
Single Stereoisomer

>  <First_Approval>  (98) 
nan

>  <Phase>  (98) 
2.0

>  <SC_Patent>  (98) 
None

>  <Synonyms>  (98) 
GSK-2141795 | GSK-2141795C | GSK2141795 | GSK2141795C | UPROSERTIB

>  <Withdrawn>  (98) 


>  <Indications>  (98) 
nan

>  <Type>  (98) 
nan

>  <targets_id>  (98) 
P31749|P31751|Q9Y243

>  <inchi>  (98) 
InChI=1S/C18H16Cl2F2N4O2/c1-26-16(12(19)8-24-26)11-6-15(28-17(11)20)18(27)25-10(7-23)4-9-2-3-13(21)14(22)5-9/h2-3,5-6,8,10H,4,7,23H2,1H3,(H,25,27)/t10-/m0/s1

>  <stdInchikey>  (98) 
AXTAPYRUEKNRBA-JTQLQIEISA-N

>  <csid>  (98) 
32701836

>  <Links>  (98) 
|http://www.chemspider.com/Chemical-Structure.32701836.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3137336|http://pubchem.ncbi.nlm.nih.gov/compound/51042438|http://www.drugbank.ca/drugs/DB11969|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7902|http://zinc15.docking.org/substances/ZINC000043197676|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=ZXM835LQ5E|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50170284

>  <LinkName>  (98) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (98) 


>  <pdbID>  (98) 


>  <indicationG2P>  (98) 
None

>  <indicationDB>  (98) 


>  <uniprotId>  (98) 


>  <MW>  (98) 
428.1

>  <HBA>  (98) 
5.0

>  <HBD>  (98) 
2.0

>  <NRB>  (98) 
6.0

>  <TPSA>  (98) 
86.1

>  <LogP>  (98) 
3.6

>  <RoF>  (98) 
0.0

>  <Melting point>  (98) 


>  <Targets>  (98) 
AKT1; AKT2; AKT3

>  <Kinase families>  (98) 
AGC

>  <FDA_approved>  (98) 


$$$$
Vistusertib
     RDKit          2D

 34 38  0  0  0  0  0  0  0  0999 V2000
   -1.0315   -3.6070    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5311   -3.5725    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3107   -4.8540    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8104   -4.8196    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5304   -3.5037    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7508   -2.2222    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2511   -2.2566    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4715   -0.9752    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9719   -1.0096    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2519   -2.3255    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2477   -2.3599    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0273   -1.0784    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3073    0.2375    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1923    0.2719    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9123    1.5878    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4120    1.6222    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1916    0.3407    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1320    2.9381    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3524    4.2196    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0724    5.5355    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5720    5.5699    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3516    4.2884    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6316    2.9725    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4112    1.6911    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5269   -1.1128    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2469   -2.4287    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7465   -2.4631    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5261   -1.1816    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8061    0.1343    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3065    0.1687    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5857    1.4158    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8657    2.7317    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.0853    1.3814    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.8649    2.6629    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  1
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 16 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  1
 12 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 29 31  1  0
 31 32  2  0
 31 33  1  0
 33 34  1  0
  7  2  1  0
 17  8  2  0
 14  9  1  0
 23 18  1  0
 30 25  1  0
M  END
>  <BrandName>  (99) 


>  <Applicants>  (99) 
Astrazeneca

>  <CHEMBL_ID>  (99) 
CHEMBL2336325

>  <Canonical_Smiles>  (99) 
C[C@H]1COCCN1c2c3ccc(nc3nc(n2)N4CCOC[C@@H]4C)c5cccc(c5)C(=O)NC

>  <Chirality>  (99) 
Single Stereoisomer

>  <First_Approval>  (99) 
nan

>  <Phase>  (99) 
2.0

>  <SC_Patent>  (99) 
None

>  <Synonyms>  (99) 
AZD-2014 | AZD2014 | VISTUSERTIB

>  <Withdrawn>  (99) 
|Study NCT03166904 in Korea, Republic of was Withdrawn during Phase 2 because Lack of efficacy|Study NCT03166176 in Korea, Republic of was Withdrawn during Phase 2 because lack of efficacy

>  <Indications>  (99) 
nan

>  <Type>  (99) 
nan

>  <targets_id>  (99) 
P42345

>  <inchi>  (99) 
InChI=1S/C25H30N6O3/c1-16-14-33-11-9-30(16)23-20-7-8-21(18-5-4-6-19(13-18)24(32)26-3)27-22(20)28-25(29-23)31-10-12-34-15-17(31)2/h4-8,13,16-17H,9-12,14-15H2,1-3H3,(H,26,32)/t16-,17-/m0/s1

>  <stdInchikey>  (99) 
JUSFANSTBFGBAF-IRXDYDNUSA-N

>  <csid>  (99) 
28294977

>  <Links>  (99) 
|http://www.chemspider.com/Chemical-Structure.28294977.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2336325|http://pubchem.ncbi.nlm.nih.gov/compound/25262792|http://www.drugbank.ca/drugs/DB11925|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7699|http://zinc15.docking.org/substances/ZINC000059258964|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=0BSC3P4H5X|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50429701

>  <LinkName>  (99) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (99) 


>  <pdbID>  (99) 


>  <indicationG2P>  (99) 
None

>  <indicationDB>  (99) 


>  <uniprotId>  (99) 


>  <MW>  (99) 
462.2

>  <HBA>  (99) 
8.0

>  <HBD>  (99) 
1.0

>  <NRB>  (99) 
4.0

>  <TPSA>  (99) 
92.7

>  <LogP>  (99) 
2.5

>  <RoF>  (99) 
0.0

>  <Melting point>  (99) 


>  <Targets>  (99) 
MTOR

>  <Kinase families>  (99) 
Atypical

>  <FDA_approved>  (99) 


$$$$
Vactosertib
     RDKit          2D

 30 34  0  0  0  0  0  0  0  0999 V2000
   -1.1512   -6.1698    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7289   -4.7856    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2166   -4.5938    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7944   -3.2096    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8845   -2.0171    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3968   -2.2088    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8190   -3.5931    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4869   -1.0163    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9168    0.4207    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3171    1.2737    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.5096    0.3638    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0127   -1.0515    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.9467    0.7937    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0375   -0.2359    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.4746    0.1940    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5654   -0.8355    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0025   -0.4056    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3487    1.0539    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2579    2.0834    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8208    1.6535    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7300    2.6831    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3321    0.9176    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4701   -0.0596    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8854    0.4372    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1627    1.9114    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4438    2.6917    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0976    4.1512    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6025    4.2729    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0248    2.8886    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6094    2.3918    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  6  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 11 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
  9 22  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  1  0
  7  2  1  0
 12  8  1  0
 20 15  1  0
 30 22  2  0
 29 25  1  0
M  END
>  <BrandName>  (100) 


>  <Applicants>  (100) 
MedPacto

>  <CHEMBL_ID>  (100) 
CHEMBL3260567

>  <Canonical_Smiles>  (100) 
Cc1cccc(n1)c2c(nc([nH]2)CNc3ccccc3F)c4ccc5ncnn5c4

>  <Chirality>  (100) 
Achiral Molecule

>  <First_Approval>  (100) 
nan

>  <Phase>  (100) 
2.0

>  <SC_Patent>  (100) 
None

>  <Synonyms>  (100) 
TEW 7197 | TEW-7197 | VACTOSERTIB

>  <Withdrawn>  (100) 


>  <Indications>  (100) 
Vactosertib (EW-7197) acts as in inhibitor of transforming growth factor beta receptor 1B (ALK5) and activin A receptor type IB (ALK4). The compound is potent, selective, and orally bioavailable, and exhibits experimental anti-tumour activity.

>  <Type>  (100) 
nan

>  <targets_id>  (100) 
nan

>  <inchi>  (100) 
InChI=1S/C22H18FN7/c1-14-5-4-8-18(27-14)22-21(15-9-10-20-25-13-26-30(20)12-15)28-19(29-22)11-24-17-7-3-2-6-16(17)23/h2-10,12-13,24H,11H2,1H3,(H,28,29)

>  <stdInchikey>  (100) 
FJCDSQATIJKQKA-UHFFFAOYSA-N

>  <csid>  (100) 
32813335

>  <Links>  (100) 
|http://www.chemspider.com/Chemical-Structure.32813335.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3260567|http://pubchem.ncbi.nlm.nih.gov/compound/54766013|http://www.drugbank.ca/drugs/DB15310|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8107|http://zinc15.docking.org/substances/ZINC000113391423|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6T4O391P5Y|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50015639

>  <LinkName>  (100) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (100) 


>  <pdbID>  (100) 


>  <indicationG2P>  (100) 
None

>  <indicationDB>  (100) 


>  <uniprotId>  (100) 


>  <MW>  (100) 
399.2

>  <HBA>  (100) 
6.0

>  <HBD>  (100) 
2.0

>  <NRB>  (100) 
5.0

>  <TPSA>  (100) 
83.8

>  <LogP>  (100) 
4.2

>  <RoF>  (100) 
0.0

>  <Melting point>  (100) 


>  <Targets>  (100) 
nan

>  <Kinase families>  (100) 


>  <FDA_approved>  (100) 


$$$$
Golvatinib
     RDKit          2D

 46 51  0  0  0  0  0  0  0  0999 V2000
  -10.3280   -6.4061    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.5612   -5.1169    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  -10.2942   -3.8082    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.5274   -2.5191    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.0275   -2.5386    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2945   -3.8473    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.0613   -5.1365    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2606   -1.2494    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7608   -1.2690    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9939    0.0202    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7269    1.3289    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2268    1.3484    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9937    0.0593    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9601    2.6180    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6931    3.9267    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4602    2.5985    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6933    3.8877    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1935    3.8681    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4266    5.1573    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1596    6.4660    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6595    6.4855    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4264    5.1964    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0732    5.1378    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.8063    3.8291    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0394    2.5399    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7724    1.2312    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2723    1.2117    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0392    2.5008    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3061    3.8095    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5390    2.4813    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    4.0053   -0.0970    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.2385   -1.3862    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7386   -1.3666    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.9715   -2.6949    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2127   -4.1754    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8100   -3.6440    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3876   -2.2002    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6673   -0.7265    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.5240   -3.1793    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.9401   -2.6847    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0765   -3.6637    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.4926   -3.1691    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.7723   -1.6954    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.6359   -0.7163    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2198   -1.2110    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.1884   -1.2008    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  5  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 11 14  1  0
 14 15  2  0
 14 16  1  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 19 23  1  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 28 30  1  0
 27 31  1  0
 31 32  1  0
 32 33  2  0
 32 34  1  0
 34 35  1  0
 35 36  1  0
 34 37  1  0
 37 38  2  0
 37 39  1  0
 39 40  1  0
 40 41  2  0
 41 42  1  0
 42 43  2  0
 43 44  1  0
 44 45  2  0
 43 46  1  0
  7  2  1  0
 13  8  1  0
 22 17  1  0
 29 24  1  0
 36 34  1  0
 45 40  1  0
M  END
>  <BrandName>  (101) 


>  <Applicants>  (101) 
Eisai

>  <CHEMBL_ID>  (101) 
CHEMBL3039525

>  <Canonical_Smiles>  (101) 
CN1CCN(CC1)C2CCN(CC2)C(=O)Nc3cc(ccn3)Oc4ccc(c(c4)F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F

>  <Chirality>  (101) 
Achiral Molecule

>  <First_Approval>  (101) 
nan

>  <Phase>  (101) 
2.0

>  <SC_Patent>  (101) 
None

>  <Synonyms>  (101) 
E-7050 | E7050 | GOLVATINIB

>  <Withdrawn>  (101) 


>  <Indications>  (101) 
nan

>  <Type>  (101) 
2

>  <targets_id>  (101) 
P08581|P35968

>  <inchi>  (101) 
InChI=1S/C33H37F2N7O4/c1-40-16-18-41(19-17-40)24-9-14-42(15-10-24)32(45)39-29-21-26(8-13-36-29)46-25-6-7-28(27(35)20-25)38-31(44)33(11-12-33)30(43)37-23-4-2-22(34)3-5-23/h2-8,13,20-21,24H,9-12,14-19H2,1H3,(H,37,43)(H,38,44)(H,36,39,45)

>  <stdInchikey>  (101) 
UQRCJCNVNUFYDX-UHFFFAOYSA-N

>  <csid>  (101) 
17275597

>  <Links>  (101) 
|http://www.chemspider.com/Chemical-Structure.17275597.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3039525|http://pubchem.ncbi.nlm.nih.gov/compound/16118392|http://www.drugbank.ca/drugs/DB11977| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=GV0|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/GV0|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7956|http://zinc15.docking.org/substances/ZINC000043195317|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=516Z3YP58E|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50100615

>  <LinkName>  (101) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (101) 
'GV0'

>  <pdbID>  (101) 
5ia5

>  <indicationG2P>  (101) 
None

>  <indicationDB>  (101) 


>  <uniprotId>  (101) 


>  <MW>  (101) 
633.3

>  <HBA>  (101) 
7.0

>  <HBD>  (101) 
3.0

>  <NRB>  (101) 
8.0

>  <TPSA>  (101) 
119.1

>  <LogP>  (101) 
4.8

>  <RoF>  (101) 
1.0

>  <Melting point>  (101) 


>  <Targets>  (101) 
MET; KDR

>  <Kinase families>  (101) 
Tyr

>  <FDA_approved>  (101) 


$$$$
Tamatinib
     RDKit          2D

 34 37  0  0  0  0  0  0  0  0999 V2000
   -8.8557   -2.0564    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3456   -0.6458    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3488    0.8542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.6495    1.6014    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0514    1.6070    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7508    0.8598    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7476   -0.6402    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4469   -1.3875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1495   -0.6347    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1527    0.8653    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4533    1.6125    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8553    1.6181    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5546    0.8708    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5514   -0.6291    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7492   -1.3764    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0466   -0.6236    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0434    0.8764    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7428    1.6236    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.3409    1.6292    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.6415    0.8819    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6447   -0.6181    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9453   -1.3653    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2428   -0.6125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2396    0.8875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9389    1.6347    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5370    1.6403    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.5338    3.1402    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5434   -1.3597    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.8408   -0.6070    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9485   -2.8653    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.6511   -3.6181    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8489   -1.3819    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0450   -1.3930    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -9.8234   -0.3885    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  3  5  1  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 10 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 17 19  1  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 24 26  1  0
 26 27  1  0
 23 28  1  0
 28 29  1  0
 22 30  1  0
 30 31  1  0
 14 32  1  0
  7 33  1  0
  2 34  1  0
 33  2  1  0
 11  6  1  0
 18 13  1  0
 25 20  1  0
M  END
>  <BrandName>  (102) 


>  <Applicants>  (102) 
Rigel Pharmaceuticals

>  <CHEMBL_ID>  (102) 
nan

>  <Canonical_Smiles>  (102) 
CC1(C(=O)Nc2c(ccc(n2)Nc3c(cnc(n3)Nc4cc(c(c(c4)OC)OC)OC)F)O1)C

>  <Chirality>  (102) 
nan

>  <First_Approval>  (102) 
nan

>  <Phase>  (102) 
2.0

>  <SC_Patent>  (102) 
nan

>  <Synonyms>  (102) 
R-406

>  <Withdrawn>  (102) 


>  <Indications>  (102) 
nan

>  <Type>  (102) 
1

>  <targets_id>  (102) 
P43405

>  <inchi>  (102) 
InChI=1S/C22H23FN6O5/c1-22(2)20(30)28-19-13(34-22)6-7-16(27-19)26-18-12(23)10-24-21(29-18)25-11-8-14(31-3)17(33-5)15(9-11)32-4/h6-10H,1-5H3,(H3,24,25,26,27,28,29,30)

>  <stdInchikey>  (102) 
NHHQJBCNYHBUSI-UHFFFAOYSA-N

>  <csid>  (102) 
9388620

>  <Links>  (102) 
|http://www.chemspider.com/Chemical-Structure.9388620.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL475251|http://pubchem.ncbi.nlm.nih.gov/compound/11213558|http://www.drugbank.ca/drugs/DB07159| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=585|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/585|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7425|http://zinc15.docking.org/substances/ZINC06745792|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=RC3A285J2G|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=60665

>  <LinkName>  (102) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (102) 
'585'

>  <pdbID>  (102) 
3fqs 3piy

>  <indicationG2P>  (102) 
None

>  <indicationDB>  (102) 


>  <uniprotId>  (102) 
P43405

>  <MW>  (102) 
470.2

>  <HBA>  (102) 
10.0

>  <HBD>  (102) 
3.0

>  <NRB>  (102) 
7.0

>  <TPSA>  (102) 
128.8

>  <LogP>  (102) 
3.6

>  <RoF>  (102) 
0.0

>  <Melting point>  (102) 


>  <Targets>  (102) 
SYK

>  <Kinase families>  (102) 
Tyr

>  <FDA_approved>  (102) 


$$$$
Leniolisib
     RDKit          2D

 32 35  0  0  0  0  0  0  0  0999 V2000
    9.1778    0.0144    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6857    0.1681    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0728    1.5372    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9520    2.7525    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.5807    1.6910    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.8281    2.9885    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3615    2.6737    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2077    1.1816    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5793    0.5742    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9102    0.4289    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.9132   -1.0710    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6157   -1.8237    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6188   -3.3237    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9193   -4.0710    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.2168   -3.3184    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2138   -1.8184    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6788   -4.0763    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9793   -3.3289    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9823   -1.8289    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6848   -1.0763    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2829   -1.0816    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2859    0.4184    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5865    1.1658    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8840    0.4132    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8810   -1.0868    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5804   -1.8342    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1846    1.1606    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4821    0.4079    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5895    2.6658    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5925    4.1658    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0895    2.6688    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0895    2.6628    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  3  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  8 10  1  1
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 13 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 19 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 24 27  1  0
 27 28  1  0
 23 29  1  0
 29 30  1  0
 29 31  1  0
 29 32  1  0
  9  5  1  0
 16 11  1  0
 20 12  1  0
 26 21  1  0
M  END
>  <BrandName>  (103) 


>  <Applicants>  (103) 
Novartis

>  <CHEMBL_ID>  (103) 
CHEMBL3643413

>  <Canonical_Smiles>  (103) 
CCC(=O)N1CC[C@@H](C1)Nc2c3c(ncn2)CCN(C3)c4cc(c(nc4)OC)C(F)(F)F

>  <Chirality>  (103) 
Single Stereoisomer

>  <First_Approval>  (103) 
nan

>  <Phase>  (103) 
2.0

>  <SC_Patent>  (103) 
None

>  <Synonyms>  (103) 
CDZ173-NX | LENIOLISIB

>  <Withdrawn>  (103) 


>  <Indications>  (103) 
nan

>  <Type>  (103) 
nan

>  <targets_id>  (103) 
nan

>  <inchi>  (103) 
InChI=1S/C21H25F3N6O2/c1-3-18(31)30-6-4-13(10-30)28-19-15-11-29(7-5-17(15)26-12-27-19)14-8-16(21(22,23)24)20(32-2)25-9-14/h8-9,12-13H,3-7,10-11H2,1-2H3,(H,26,27,28)/t13-/m0/s1

>  <stdInchikey>  (103) 
MWKYMZXCGYXLPL-ZDUSSCGKSA-N

>  <csid>  (103) 
52083264

>  <Links>  (103) 
|http://www.chemspider.com/Chemical-Structure.52083264.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3643413|http://pubchem.ncbi.nlm.nih.gov/compound/57495353|http://www.drugbank.ca/drugs/DB16217| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=9NQ|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/9NQ|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9424|http://zinc15.docking.org/substances/ZINC000113570569|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=L22772Z9CP|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=118299

>  <LinkName>  (103) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (103) 
'9NQ'

>  <pdbID>  (103) 
5o83

>  <indicationG2P>  (103) 
None

>  <indicationDB>  (103) 


>  <uniprotId>  (103) 


>  <MW>  (103) 
450.2

>  <HBA>  (103) 
7.0

>  <HBD>  (103) 
1.0

>  <NRB>  (103) 
5.0

>  <TPSA>  (103) 
83.5

>  <LogP>  (103) 
2.9

>  <RoF>  (103) 
0.0

>  <Melting point>  (103) 


>  <Targets>  (103) 
nan

>  <Kinase families>  (103) 


>  <FDA_approved>  (103) 


$$$$
Voxtalisib
     RDKit          2D

 20 22  0  0  0  0  0  0  0  0999 V2000
    2.5838    3.2352    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1021    3.0014    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5638    1.6013    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.5071    0.4351    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9688   -0.9650    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5129   -1.1988    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4562   -0.0325    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9179    1.3675    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8612    2.5338    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9379   -0.2664    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6196   -1.6025    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1010   -1.3670    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3349    0.1147    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9980    0.7949    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.9121   -2.1312    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3937   -1.8974    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.9321   -0.4973    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9888    0.6689    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.4137   -0.2635    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.3737   -3.5313    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  7 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
  5 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 17 19  1  0
 15 20  1  0
  8  3  1  0
 18  4  1  0
 14 10  1  0
M  END
>  <BrandName>  (104) 


>  <Applicants>  (104) 
Sanofi

>  <CHEMBL_ID>  (104) 
CHEMBL3545366

>  <Canonical_Smiles>  (104) 
CCn1c2c(cc(c1=O)c3ccn[nH]3)c(nc(n2)N)C

>  <Chirality>  (104) 
Achiral Molecule

>  <First_Approval>  (104) 
nan

>  <Phase>  (104) 
2.0

>  <SC_Patent>  (104) 
None

>  <Synonyms>  (104) 
SAR-245409 | SAR245409 | VOXTALISIB | XL-765 | XL765

>  <Withdrawn>  (104) 


>  <Indications>  (104) 
nan

>  <Type>  (104) 
nan

>  <targets_id>  (104) 
P42336|P42345

>  <inchi>  (104) 
InChI=1S/C13H14N6O/c1-3-19-11-8(7(2)16-13(14)17-11)6-9(12(19)20)10-4-5-15-18-10/h4-6H,3H2,1-2H3,(H,15,18)(H2,14,16,17)

>  <stdInchikey>  (104) 
RGHYDLZMTYDBDT-UHFFFAOYSA-N

>  <csid>  (104) 
17279963

>  <Links>  (104) 
|http://www.chemspider.com/Chemical-Structure.17279963.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545366|http://pubchem.ncbi.nlm.nih.gov/compound/16123056|http://www.drugbank.ca/drugs/DB12400|http://zinc15.docking.org/substances/ZINC000035308805|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=CVL1685GPH

>  <LinkName>  (104) 
|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS

>  <lig_pdbID>  (104) 


>  <pdbID>  (104) 


>  <indicationG2P>  (104) 


>  <indicationDB>  (104) 


>  <uniprotId>  (104) 


>  <MW>  (104) 
270.1

>  <HBA>  (104) 
6.0

>  <HBD>  (104) 
2.0

>  <NRB>  (104) 
2.0

>  <TPSA>  (104) 
102.5

>  <LogP>  (104) 
1.1

>  <RoF>  (104) 
0.0

>  <Melting point>  (104) 


>  <Targets>  (104) 
PIK3CA; MTOR

>  <Kinase families>  (104) 
Atypical

>  <FDA_approved>  (104) 


$$$$
Roniciclib
     RDKit          2D

 29 31  0  0  0  0  0  0  0  0999 V2000
    0.9989   -2.4021    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3274   -1.7015    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5973   -2.4998    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5410   -3.9987    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9237   -1.7991    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9800   -0.3002    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3064    0.4004    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3627    1.8994    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0928    2.6977    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7665    1.9970    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7101    0.4981    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4966    2.7953    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.8297    2.0947    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8861    0.5958    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2124   -0.1049    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4824    0.6934    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4260    2.1924    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0997    2.8930    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8087   -0.0072    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    5.5093    1.3191    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.1080   -1.3335    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.1350   -0.7079    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6339   -0.6515    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9333   -1.9778    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5763   -0.3979    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8462   -1.1962    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3746    0.8721    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7780   -1.6678    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3838   -0.2025    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  6
  2  3  1  0
  3  4  1  1
  3  5  1  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 10 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 19 16  1  1
 19 20  2  0
 19 21  2  0
 19 22  1  0
 22 23  1  0
 23 24  1  0
  7 25  1  0
 25 26  1  0
 25 27  1  0
 25 28  1  0
  2 29  1  0
 11  6  1  0
 18 13  1  0
 24 22  1  0
M  END
>  <BrandName>  (105) 


>  <Applicants>  (105) 
Bayer

>  <CHEMBL_ID>  (105) 
CHEMBL3544942

>  <Canonical_Smiles>  (105) 
C[C@H]([C@@H](C)Oc1c(cnc(n1)Nc2ccc(cc2)[S@](=N)(=O)C3CC3)C(F)(F)F)O

>  <Chirality>  (105) 
Single Stereoisomer

>  <First_Approval>  (105) 
nan

>  <Phase>  (105) 
2.0

>  <SC_Patent>  (105) 
None

>  <Synonyms>  (105) 


>  <Withdrawn>  (105) 


>  <Indications>  (105) 
nan

>  <Type>  (105) 
nan

>  <targets_id>  (105) 
P06493|P24941|P11802|P50750

>  <inchi>  (105) 
InChI=1S/C18H21F3N4O3S/c1-10(26)11(2)28-16-15(18(19,20)21)9-23-17(25-16)24-12-3-5-13(6-4-12)29(22,27)14-7-8-14/h3-6,9-11,14,22,26H,7-8H2,1-2H3,(H,23,24,25)/t10-,11-,29+/m1/s1

>  <stdInchikey>  (105) 
UELYDGOOJPRWGF-SRQXXRKNSA-N

>  <csid>  (105) 
32697590

>  <Links>  (105) 
|http://www.chemspider.com/Chemical-Structure.32697590.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4282338|http://pubchem.ncbi.nlm.nih.gov/compound/71494949|http://www.drugbank.ca/drugs/DB12974|http://zinc15.docking.org/substances/ZINC000095616570|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=0W9Q8U337A|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50468265

>  <LinkName>  (105) 
|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (105) 


>  <pdbID>  (105) 


>  <indicationG2P>  (105) 


>  <indicationDB>  (105) 


>  <uniprotId>  (105) 


>  <MW>  (105) 
430.1

>  <HBA>  (105) 
7.0

>  <HBD>  (105) 
3.0

>  <NRB>  (105) 
7.0

>  <TPSA>  (105) 
108.2

>  <LogP>  (105) 
4.0

>  <RoF>  (105) 
0.0

>  <Melting point>  (105) 


>  <Targets>  (105) 
CDK1; CDK2; CDK4; CDK9

>  <Kinase families>  (105) 
CMGC

>  <FDA_approved>  (105) 


$$$$
Merestinib
     RDKit          2D

 41 46  0  0  0  0  0  0  0  0999 V2000
    8.2665   -2.6851    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8088   -2.3313    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7736   -3.4169    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3159   -3.0631    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8935   -1.6238    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9287   -0.5383    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5062    0.9010    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.3863   -0.8921    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.4215    0.1935    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8792   -0.1603    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9144    0.9252    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4920    2.3645    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0343    2.7183    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9991    1.6327    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.5272    3.4500    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    2.4358   -1.2701    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4006   -2.3556    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.0133    0.1692    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.5556    0.5229    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1331    1.9622    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3246    2.3160    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3598    1.2304    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9373   -0.2088    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4796   -0.5626    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9725   -1.2943    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8175    1.5842    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8527    0.4987    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4302   -0.9406    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4654   -2.0261    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3514   -3.5218    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7386   -4.0924    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.7100   -2.9494    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9231   -1.6724    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3456   -0.2331    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3104    0.8524    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7329    2.2917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.1456    2.7959    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.1026    4.2953    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6634    4.7178    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8168    3.4795    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.2056   -3.0634    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  6  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 12 15  1  0
  5 16  1  0
 16 17  2  0
 16 18  1  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 23 25  1  0
 22 26  1  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 32 33  1  0
 33 34  1  0
 34 35  2  0
 35 36  1  0
 36 37  2  0
 37 38  1  0
 38 39  1  0
 39 40  2  0
 32 41  1  0
  8  2  1  0
 14  9  1  0
 24 19  1  0
 35 27  1  0
 33 29  2  0
 40 36  1  0
M  END
>  <BrandName>  (106) 


>  <Applicants>  (106) 
Eli Lilly

>  <CHEMBL_ID>  (106) 
CHEMBL3545307

>  <Canonical_Smiles>  (106) 
Cc1ccc(c(=O)n1c2ccc(cc2)F)C(=O)Nc3ccc(c(c3)F)Oc4cc5cnn(c5cc4c6c[nH]nc6)C

>  <Chirality>  (106) 
Achiral Molecule

>  <First_Approval>  (106) 
nan

>  <Phase>  (106) 
2.0

>  <SC_Patent>  (106) 
None

>  <Synonyms>  (106) 
LY-2801653 | LY2801653 | MERESTINIB

>  <Withdrawn>  (106) 


>  <Indications>  (106) 
nan

>  <Type>  (106) 
2

>  <targets_id>  (106) 
P08581

>  <inchi>  (106) 
InChI=1S/C30H22F2N6O3/c1-17-3-9-23(30(40)38(17)22-7-4-20(31)5-8-22)29(39)36-21-6-10-27(25(32)12-21)41-28-11-18-16-35-37(2)26(18)13-24(28)19-14-33-34-15-19/h3-16H,1-2H3,(H,33,34)(H,36,39)

>  <stdInchikey>  (106) 
QHADVLVFMKEIIP-UHFFFAOYSA-N

>  <csid>  (106) 
29361338

>  <Links>  (106) 
|http://www.chemspider.com/Chemical-Structure.29361338.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545307|http://pubchem.ncbi.nlm.nih.gov/compound/44603533|http://www.drugbank.ca/drugs/DB12381| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=L1X|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/L1X|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9841|http://zinc15.docking.org/substances/ZINC000095926668|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=5OGS5K699E|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50172078

>  <LinkName>  (106) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (106) 
'L1X'

>  <pdbID>  (106) 
4eev 7aay

>  <indicationG2P>  (106) 
None

>  <indicationDB>  (106) 


>  <uniprotId>  (106) 


>  <MW>  (106) 
552.2

>  <HBA>  (106) 
7.0

>  <HBD>  (106) 
2.0

>  <NRB>  (106) 
6.0

>  <TPSA>  (106) 
106.8

>  <LogP>  (106) 
5.7

>  <RoF>  (106) 
2.0

>  <Melting point>  (106) 


>  <Targets>  (106) 
MET

>  <Kinase families>  (106) 
Tyr

>  <FDA_approved>  (106) 


$$$$
Milciclib
     RDKit          2D

 34 38  0  0  0  0  0  0  0  0999 V2000
   -6.0997   -1.8298    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6009   -1.7684    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1716   -2.2233    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0629   -1.2128    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6336   -1.6677    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4751   -0.6573    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.1543    0.8080    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2750    1.2629    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3836    0.2525    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8130    0.7074    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9216   -0.3030    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2252    0.4391    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9222    1.9082    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4314    2.0740    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6892    3.3775    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5918   -0.1793    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.7396   -1.6720    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -8.8106    0.6951    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  -10.1772    0.0767    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2630    1.8184    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6923    1.3635    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0131   -0.1018    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4424   -0.5567    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5511    0.4537    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2303    1.9190    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8010    2.3739    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9804   -0.0012    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.3011   -1.4665    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7305   -1.9214    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8391   -0.9110    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.5184    0.5543    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0891    1.0092    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.2685   -1.3659    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8007   -3.2550    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  1  0
 12 16  1  0
 16 17  2  0
 16 18  1  0
 18 19  1  0
  7 20  1  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 24 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 30 33  1  0
  2 34  1  0
 11  2  1  0
  9  4  1  0
 14 10  1  0
 26 21  1  0
 32 27  1  0
M  END
>  <BrandName>  (107) 


>  <Applicants>  (107) 
Nerviano Medical Sciences

>  <CHEMBL_ID>  (107) 
CHEMBL564829

>  <Canonical_Smiles>  (107) 
CC1(Cc2cnc(nc2-c3c1c(nn3C)C(=O)NC)Nc4ccc(cc4)N5CCN(CC5)C)C

>  <Chirality>  (107) 
Achiral Molecule

>  <First_Approval>  (107) 
nan

>  <Phase>  (107) 
2.0

>  <SC_Patent>  (107) 
None

>  <Synonyms>  (107) 
MILCICLIB | PHA 848125 | PHA-848125

>  <Withdrawn>  (107) 


>  <Indications>  (107) 
nan

>  <Type>  (107) 
1

>  <targets_id>  (107) 
P06493|P04629

>  <inchi>  (107) 
InChI=1S/C25H32N8O/c1-25(2)14-16-15-27-24(29-20(16)22-19(25)21(23(34)26-3)30-32(22)5)28-17-6-8-18(9-7-17)33-12-10-31(4)11-13-33/h6-9,15H,10-14H2,1-5H3,(H,26,34)(H,27,28,29)

>  <stdInchikey>  (107) 
RXZMYLDMFYNEIM-UHFFFAOYSA-N

>  <csid>  (107) 
16788113

>  <Links>  (107) 
|http://www.chemspider.com/Chemical-Structure.16788113.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL564829|http://pubchem.ncbi.nlm.nih.gov/compound/16718576|http://www.drugbank.ca/drugs/DB16232| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=P48|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/P48|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7938|http://zinc15.docking.org/substances/ZINC000053119602|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=688000M8S8|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=31545

>  <LinkName>  (107) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (107) 
'P48'

>  <pdbID>  (107) 
2wih 5vc6 5vd1

>  <indicationG2P>  (107) 
None

>  <indicationDB>  (107) 


>  <uniprotId>  (107) 


>  <MW>  (107) 
460.3

>  <HBA>  (107) 
8.0

>  <HBD>  (107) 
2.0

>  <NRB>  (107) 
4.0

>  <TPSA>  (107) 
91.2

>  <LogP>  (107) 
2.6

>  <RoF>  (107) 
0.0

>  <Melting point>  (107) 


>  <Targets>  (107) 
CDK1; NTRK1

>  <Kinase families>  (107) 
CMGC<br>Tyr

>  <FDA_approved>  (107) 


$$$$
Selonsertib
     RDKit          2D

 33 37  0  0  0  0  0  0  0  0999 V2000
    5.4893   -3.3903    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1043   -2.8144    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9130   -3.7259    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5280   -3.1500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3342   -1.6626    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5254   -0.7511    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9105   -1.3269    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1017   -0.4154    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.0645    1.0841    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4791    1.5830    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3907    0.3917    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.5394   -0.8433    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9071    3.0206    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5589    4.4796    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9965    4.0517    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0509   -1.0867    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2421   -1.9983    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2447    0.4007    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6297    0.9766    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8235    2.4640    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2086    3.0399    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3998    2.1283    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2060    0.6409    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8210    0.0650    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3973   -0.2706    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3600   -1.7702    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7746   -2.2690    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6862   -1.0777    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8349    0.1573    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3337    1.5720    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.8083    1.8473    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3580    2.7113    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3367   -4.0616    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 10 13  1  0
 13 14  1  0
 14 15  1  0
  5 16  1  0
 16 17  2  0
 16 18  1  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 23 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
 30 32  1  0
  4 33  1  0
  7  2  1  0
 12  8  1  0
 15 13  1  0
 24 19  1  0
 29 25  1  0
M  END
>  <BrandName>  (108) 


>  <Applicants>  (108) 
Gilead Sciences

>  <CHEMBL_ID>  (108) 
CHEMBL3916717

>  <Canonical_Smiles>  (108) 
Cc1cc(c(cc1n2cc(nc2)C3CC3)C(=O)Nc4cccc(n4)c5nncn5C(C)C)F

>  <Chirality>  (108) 
Achiral Molecule

>  <First_Approval>  (108) 
nan

>  <Phase>  (108) 
2.0

>  <SC_Patent>  (108) 
None

>  <Synonyms>  (108) 
GS-4997 | SELONSERTIB

>  <Withdrawn>  (108) 


>  <Indications>  (108) 
nan

>  <Type>  (108) 
nan

>  <targets_id>  (108) 
Q99683

>  <inchi>  (108) 
InChI=1S/C24H24FN7O/c1-14(2)32-13-27-30-23(32)19-5-4-6-22(28-19)29-24(33)17-10-21(15(3)9-18(17)25)31-11-20(26-12-31)16-7-8-16/h4-6,9-14,16H,7-8H2,1-3H3,(H,28,29,33)

>  <stdInchikey>  (108) 
YIDDLAAKOYYGJG-UHFFFAOYSA-N

>  <csid>  (108) 
44209497

>  <Links>  (108) 
|http://www.chemspider.com/Chemical-Structure.44209497.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3916717|http://pubchem.ncbi.nlm.nih.gov/compound/71245288|http://www.drugbank.ca/drugs/DB14916| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=NJV|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/NJV|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9040|http://zinc15.docking.org/substances/ZINC000149387856|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=NS3988A2TC|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50212258

>  <LinkName>  (108) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (108) 
'NJV'

>  <pdbID>  (108) 
6oyt

>  <indicationG2P>  (108) 
None

>  <indicationDB>  (108) 


>  <uniprotId>  (108) 


>  <MW>  (108) 
445.2

>  <HBA>  (108) 
7.0

>  <HBD>  (108) 
1.0

>  <NRB>  (108) 
6.0

>  <TPSA>  (108) 
90.5

>  <LogP>  (108) 
4.7

>  <RoF>  (108) 
0.0

>  <Melting point>  (108) 


>  <Targets>  (108) 
MAP3K5

>  <Kinase families>  (108) 
STE

>  <FDA_approved>  (108) 


$$$$
Doramapimod
     RDKit          2D

 39 43  0  0  0  0  0  0  0  0999 V2000
   -9.1924   -3.4405    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.1957   -2.3196    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7265   -2.6223    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7298   -1.5014    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2021   -0.0777    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6713    0.2250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.6680   -0.8959    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2054    1.0432    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7126    0.8956    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1110    2.2697    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2320    3.2665    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5263    2.5084    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0844    4.7592    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5772    4.9068    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5917    4.6117    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9369    6.2519    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9546   -0.3987    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4546   -0.3894    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7127    0.9142    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6966   -1.6838    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.8034   -1.6745    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5453   -0.3708    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0453   -0.3615    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8033   -1.6559    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0614   -2.9596    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5614   -2.9689    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8195   -4.2725    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5775   -5.5669    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0775   -5.5576    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8194   -4.2539    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3033   -1.6466    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.0452   -0.3429    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5452   -0.3336    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2871    0.9700    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.7871    0.9793    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.5290    2.2830    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7710    3.5774    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.2710    3.5681    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5291    2.2644    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  5  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 11 13  1  0
 13 14  1  0
 13 15  1  0
 13 16  1  0
  9 17  1  0
 17 18  1  0
 18 19  2  0
 18 20  1  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 24 31  1  0
 31 32  1  0
 32 33  1  0
 33 34  1  0
 34 35  1  0
 35 36  1  0
 36 37  1  0
 37 38  1  0
 38 39  1  0
  7  2  1  0
 12  8  1  0
 26 21  1  0
 30 25  1  0
 39 34  1  0
M  END
>  <BrandName>  (109) 


>  <Applicants>  (109) 
Boehringer Ingelheim

>  <CHEMBL_ID>  (109) 
CHEMBL103667

>  <Canonical_Smiles>  (109) 
Cc1ccc(cc1)n2c(cc(n2)C(C)(C)C)NC(=O)Nc3ccc(c4c3cccc4)OCCN5CCOCC5

>  <Chirality>  (109) 
Achiral Molecule

>  <First_Approval>  (109) 
nan

>  <Phase>  (109) 
2.0

>  <SC_Patent>  (109) 
None

>  <Synonyms>  (109) 
BIRB 796 BS | BIRB-796 | BIRB-796 BS | DORAMAPIMOD

>  <Withdrawn>  (109) 


>  <Indications>  (109) 
nan

>  <Type>  (109) 
2

>  <targets_id>  (109) 
Q16539

>  <inchi>  (109) 
InChI=1S/C31H37N5O3/c1-22-9-11-23(12-10-22)36-29(21-28(34-36)31(2,3)4)33-30(37)32-26-13-14-27(25-8-6-5-7-24(25)26)39-20-17-35-15-18-38-19-16-35/h5-14,21H,15-20H2,1-4H3,(H2,32,33,37)

>  <stdInchikey>  (109) 
MVCOAUNKQVWQHZ-UHFFFAOYSA-N

>  <csid>  (109) 
137746

>  <Links>  (109) 
|http://www.chemspider.com/Chemical-Structure.137746.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL103667|http://pubchem.ncbi.nlm.nih.gov/compound/156422|http://www.drugbank.ca/drugs/DB03044| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=B96|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/B96|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5668|http://zinc15.docking.org/substances/ZINC24044436|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=HO1A8B3YVV|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13533

>  <LinkName>  (109) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (109) 
'B96'

>  <pdbID>  (109) 
1kv2 3fzs 3npc 4jvg 4twn 5n66 6gtt

>  <indicationG2P>  (109) 
None

>  <indicationDB>  (109) 
Doramapimod is a P38 MAP kinase inhibitor.

>  <uniprotId>  (109) 
Q16539

>  <MW>  (109) 
527.3

>  <HBA>  (109) 
6.0

>  <HBD>  (109) 
2.0

>  <NRB>  (109) 
7.0

>  <TPSA>  (109) 
80.7

>  <LogP>  (109) 
6.0

>  <RoF>  (109) 
2.0

>  <Melting point>  (109) 


>  <Targets>  (109) 
MAPK14

>  <Kinase families>  (109) 
CMGC

>  <FDA_approved>  (109) 


$$$$
Simurosertib
     RDKit          2D

 24 28  0  0  0  0  0  0  0  0999 V2000
    5.5301    1.7920    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6119    0.2943    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4483   -0.6523    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9890   -2.0515    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4867   -1.9696    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.8718   -0.5199    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.9986   -0.2673    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8350   -1.2138    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5751   -0.3997    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9602    1.0501    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4579    1.1319    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1029    2.1084    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2822    3.5581    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5509    1.7170    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9359    0.2672    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8729   -0.7911    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3158   -0.9584    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2769   -0.0015    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8949    0.5426    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2800   -0.9071    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2170   -1.9654    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7689   -1.5740    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3839   -0.1242    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4469    0.9341    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  1  0
  3  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 10 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  1  0
 15 16  2  0
 15 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
  6  2  2  0
 11  7  1  0
 16  9  1  0
 22 17  1  0
 24 19  1  0
M  END
>  <BrandName>  (110) 


>  <Applicants>  (110) 
Takeda

>  <CHEMBL_ID>  (110) 
CHEMBL4297644

>  <Canonical_Smiles>  (110) 
Cc1c(c[nH]n1)c2cc3c(s2)c(=O)[nH]c(n3)C4CC5CCN4CC5

>  <Chirality>  (110) 
Single Stereoisomer

>  <First_Approval>  (110) 
nan

>  <Phase>  (110) 
2.0

>  <SC_Patent>  (110) 
None

>  <Synonyms>  (110) 
|TAK-931

>  <Withdrawn>  (110) 


>  <Indications>  (110) 
nan

>  <Type>  (110) 
nan

>  <targets_id>  (110) 
nan

>  <inchi>  (110) 
InChI=1S/C17H19N5OS/c1-9-11(8-18-21-9)14-7-12-15(24-14)17(23)20-16(19-12)13-6-10-2-4-22(13)5-3-10/h7-8,10,13H,2-6H2,1H3,(H,18,21)(H,19,20,23)

>  <stdInchikey>  (110) 
XGVXKJKTISMIOW-UHFFFAOYSA-N

>  <csid>  (110) 
64879789

>  <Links>  (110) 
|http://www.chemspider.com/Chemical-Structure.64879789.html|http://pubchem.ncbi.nlm.nih.gov/compound/71147529

>  <LinkName>  (110) 
|ChemSpider|PubChem

>  <lig_pdbID>  (110) 


>  <pdbID>  (110) 


>  <indicationG2P>  (110) 


>  <indicationDB>  (110) 


>  <uniprotId>  (110) 


>  <MW>  (110) 
341.1

>  <HBA>  (110) 
5.0

>  <HBD>  (110) 
2.0

>  <NRB>  (110) 
2.0

>  <TPSA>  (110) 
77.7

>  <LogP>  (110) 
2.8

>  <RoF>  (110) 
0.0

>  <Melting point>  (110) 


>  <Targets>  (110) 
nan

>  <Kinase families>  (110) 


>  <FDA_approved>  (110) 


$$$$
Solcitinib
     RDKit          2D

 29 33  0  0  0  0  0  0  0  0999 V2000
   -6.7790    3.7937    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5480    2.9365    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3171    2.0794    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1742    0.8484    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4052    1.7056    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9099   -0.6281    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0564   -1.5953    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4990   -1.1375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2346   -2.6140    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8238   -3.1233    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6772   -2.1561    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9416   -0.6796    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3524   -0.1703    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7337   -2.6655    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9980   -4.1420    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4089   -4.6513    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5554   -3.6841    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2911   -2.2076    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8802   -1.6983    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.9286   -0.1991    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.3694    0.2182    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2115   -1.0232    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.8788    1.6291    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.3553    1.8934    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3225    0.7469    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.8646    3.3043    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6003    4.7808    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0111    4.2715    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6909    4.1675    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  4  6  1  0
  6  7  2  0
  6  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 11 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 21 23  1  0
 23 24  1  0
 24 25  2  0
 24 26  1  0
 26 27  1  0
 27 28  1  0
  2 29  1  0
  5  2  1  0
 13  8  1  0
 19 14  1  0
 22 18  2  0
 28 26  1  0
M  END
>  <BrandName>  (111) 


>  <Applicants>  (111) 
GlaxoSmithKline

>  <CHEMBL_ID>  (111) 
CHEMBL3301606

>  <Canonical_Smiles>  (111) 
CC1(CN(C1)C(=O)c2ccc(cc2)c3cccc4n3nc(n4)NC(=O)C5CC5)C

>  <Chirality>  (111) 
Achiral Molecule

>  <First_Approval>  (111) 
nan

>  <Phase>  (111) 
2.0

>  <SC_Patent>  (111) 
None

>  <Synonyms>  (111) 
G-154578 | G154578 | GLPG-0778 | GLPG-0788 | GLPG0778 | GSK-2586184 | GSK-2586184A | GSK2586184A | SOLCITINIB

>  <Withdrawn>  (111) 


>  <Indications>  (111) 
nan

>  <Type>  (111) 
nan

>  <targets_id>  (111) 
P23458

>  <inchi>  (111) 
InChI=1S/C22H23N5O2/c1-22(2)12-26(13-22)20(29)16-10-6-14(7-11-16)17-4-3-5-18-23-21(25-27(17)18)24-19(28)15-8-9-15/h3-7,10-11,15H,8-9,12-13H2,1-2H3,(H,24,25,28)

>  <stdInchikey>  (111) 
MPYACSQFXVMWNO-UHFFFAOYSA-N

>  <csid>  (111) 
31389944

>  <Links>  (111) 
|http://www.chemspider.com/Chemical-Structure.31389944.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3301606|http://pubchem.ncbi.nlm.nih.gov/compound/44603362|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9697|http://zinc15.docking.org/substances/ZINC000118401631|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=3V7GQ1260K|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=128101

>  <LinkName>  (111) 
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (111) 


>  <pdbID>  (111) 


>  <indicationG2P>  (111) 
None

>  <indicationDB>  (111) 


>  <uniprotId>  (111) 


>  <MW>  (111) 
389.2

>  <HBA>  (111) 
5.0

>  <HBD>  (111) 
1.0

>  <NRB>  (111) 
4.0

>  <TPSA>  (111) 
79.6

>  <LogP>  (111) 
3.2

>  <RoF>  (111) 
0.0

>  <Melting point>  (111) 


>  <Targets>  (111) 
JAK1

>  <Kinase families>  (111) 
Tyr

>  <FDA_approved>  (111) 


$$$$
Riviciclib
     RDKit          2D

 28 31  0  0  0  0  0  0  0  0999 V2000
   -4.7229   -3.7399    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5267   -2.8349    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0914   -3.2706    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2334   -2.0402    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1385   -0.8440    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5558   -1.3352    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7862   -0.4772    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1444   -1.1138    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7027    0.5913    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7279    1.6863    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2921    3.1216    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8312    3.4619    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1939    2.3669    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2418    0.9316    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7833   -0.1635    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.2442    0.1768    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6799    1.6121    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6548    2.7072    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0906    4.1425    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.2693   -0.9182    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8336   -2.3535    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8587   -3.4486    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3196   -3.1083    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7554   -1.6730    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7302   -0.5779    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1660    0.8574    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -0.3955    4.8972    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1888    1.3460    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  1
  7  8  1  0
  5  9  1  6
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 16 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 12 27  1  0
 10 28  1  0
  6  2  1  0
 14  9  1  0
 18 13  1  0
 25 20  1  0
M  END
>  <BrandName>  (112) 


>  <Applicants>  (112) 
Piramal Enterprises

>  <CHEMBL_ID>  (112) 
CHEMBL3545283

>  <Canonical_Smiles>  (112) 
CN1CC[C@H]([C@@H]1CO)c2c(cc(c3c2oc(cc3=O)c4ccccc4Cl)O)O

>  <Chirality>  (112) 
Racemic Mixture

>  <First_Approval>  (112) 
nan

>  <Phase>  (112) 
2.0

>  <SC_Patent>  (112) 
None

>  <Synonyms>  (112) 


>  <Withdrawn>  (112) 


>  <Indications>  (112) 
nan

>  <Type>  (112) 
nan

>  <targets_id>  (112) 
P06493|P11802|P50750

>  <inchi>  (112) 
InChI=1S/C21H20ClNO5/c1-23-7-6-12(14(23)10-24)19-15(25)8-16(26)20-17(27)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,14,24-26H,6-7,10H2,1H3/t12-,14+/m1/s1

>  <stdInchikey>  (112) 
QLUYMIVVAYRECT-OCCSQVGLSA-N

>  <csid>  (112) 
29165868

>  <Links>  (112) 
|http://www.chemspider.com/Chemical-Structure.29165868.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3969723|http://pubchem.ncbi.nlm.nih.gov/compound/23643976|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7934|http://zinc15.docking.org/substances/ZINC000003937395|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=9EK26WE8QN|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50193086

>  <LinkName>  (112) 
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (112) 


>  <pdbID>  (112) 


>  <indicationG2P>  (112) 
None

>  <indicationDB>  (112) 


>  <uniprotId>  (112) 


>  <MW>  (112) 
401.1

>  <HBA>  (112) 
6.0

>  <HBD>  (112) 
3.0

>  <NRB>  (112) 
3.0

>  <TPSA>  (112) 
94.1

>  <LogP>  (112) 
3.3

>  <RoF>  (112) 
0.0

>  <Melting point>  (112) 


>  <Targets>  (112) 
CDK1; CDK4; CDK9

>  <Kinase families>  (112) 
CMGC

>  <FDA_approved>  (112) 


$$$$
Acumapimod
     RDKit          2D

 29 32  0  0  0  0  0  0  0  0999 V2000
   -1.6548   -4.2330    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5803   -3.0526    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0654   -3.2639    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9909   -2.0834    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4313   -0.6917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9463   -0.4804    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0208   -1.6608    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5357   -1.4495    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.1662   -0.1239    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6439   -0.3819    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8552   -1.8669    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5081   -2.5268    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.7211    0.6620    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3557    2.1168    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.1637    0.2510    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5291   -1.2039    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9717   -1.6148    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0489   -0.5710    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6835    0.8838    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2409    1.2948    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7607    1.9276    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8380    2.9715    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4936    1.2231    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3568    0.4887    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8419    0.2774    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7973    1.8805    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7228    3.0609    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1145    3.6204    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9341    4.5460    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 10 13  1  0
 13 14  2  0
 13 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 19 21  1  0
 21 22  3  0
  9 23  1  0
  5 24  1  0
 24 25  2  0
 24 26  1  0
 26 27  1  0
 27 28  1  0
 28 29  1  0
  7  2  1  0
 12  8  1  0
 20 15  1  0
 29 27  1  0
M  END
>  <BrandName>  (113) 


>  <Applicants>  (113) 
Mereo BioPharma

>  <CHEMBL_ID>  (113) 
CHEMBL3545226

>  <Canonical_Smiles>  (113) 
Cc1ccc(cc1n2c(c(cn2)C(=O)c3cccc(c3)C#N)N)C(=O)NC4CC4

>  <Chirality>  (113) 
Single Stereoisomer

>  <First_Approval>  (113) 
nan

>  <Phase>  (113) 
2.0

>  <SC_Patent>  (113) 
None

>  <Synonyms>  (113) 


>  <Withdrawn>  (113) 


>  <Indications>  (113) 
nan

>  <Type>  (113) 
nan

>  <targets_id>  (113) 
Q16539|Q15759|O15264|P53778

>  <inchi>  (113) 
InChI=1S/C22H19N5O2/c1-13-5-6-16(22(29)26-17-7-8-17)10-19(13)27-21(24)18(12-25-27)20(28)15-4-2-3-14(9-15)11-23/h2-6,9-10,12,17H,7-8,24H2,1H3,(H,26,29)

>  <stdInchikey>  (113) 
VGUSQKZDZHAAEE-UHFFFAOYSA-N

>  <csid>  (113) 
9513071

>  <Links>  (113) 
|http://www.chemspider.com/Chemical-Structure.9513071.html|http://pubchem.ncbi.nlm.nih.gov/compound/11338127|http://www.drugbank.ca/drugs/DB15448|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9203|http://zinc15.docking.org/substances/ZINC000116024237|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=2F16KW647L

>  <LinkName>  (113) 
|ChemSpider|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (113) 


>  <pdbID>  (113) 


>  <indicationG2P>  (113) 
None

>  <indicationDB>  (113) 


>  <uniprotId>  (113) 


>  <MW>  (113) 
385.2

>  <HBA>  (113) 
6.0

>  <HBD>  (113) 
2.0

>  <NRB>  (113) 
5.0

>  <TPSA>  (113) 
113.8

>  <LogP>  (113) 
2.8

>  <RoF>  (113) 
0.0

>  <Melting point>  (113) 


>  <Targets>  (113) 
MAPK14; MAPK11; MAPK13; MAPK12

>  <Kinase families>  (113) 
CMGC

>  <FDA_approved>  (113) 


$$$$
Silmitasertib
     RDKit          2D

 25 28  0  0  0  0  0  0  0  0999 V2000
   -3.3592    2.7010    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5279    1.4524    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1934    0.1082    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6904    0.0124    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5217    1.2610    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8562    2.6052    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0187    1.1652    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -2.3620   -1.1403    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8651   -1.0446    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0337   -2.2931    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6993   -3.6374    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1321   -4.8859    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6290   -4.7902    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.2946   -3.4459    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4632   -2.1974    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1288   -0.8531    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6257   -0.7574    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2913    0.5869    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4599    1.8354    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9630    1.7396    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2974    0.3954    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1995    0.2996    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.1255    3.1796    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2941    4.4282    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.6224    3.2754    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  5  7  1  0
  3  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 19 23  1  0
 23 24  2  0
 23 25  1  0
  6  1  1  0
 22  9  2  0
 15 10  1  0
 21 16  1  0
M  END
>  <BrandName>  (114) 


>  <Applicants>  (114) 
Senhwa Biosciences

>  <CHEMBL_ID>  (114) 
CHEMBL1230165

>  <Canonical_Smiles>  (114) 
c1cc(cc(c1)Cl)Nc2c3ccncc3c4ccc(cc4n2)C(=O)O

>  <Chirality>  (114) 
Achiral Molecule

>  <First_Approval>  (114) 
nan

>  <Phase>  (114) 
2.0

>  <SC_Patent>  (114) 
None

>  <Synonyms>  (114) 
CX 4945 | CX-4945 | CX4945 | SILMITASERTIB

>  <Withdrawn>  (114) 


>  <Indications>  (114) 
nan

>  <Type>  (114) 
1

>  <targets_id>  (114) 
P68400|P19784

>  <inchi>  (114) 
InChI=1S/C19H12ClN3O2/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18/h1-10H,(H,22,23)(H,24,25)

>  <stdInchikey>  (114) 
MUOKSQABCJCOPU-UHFFFAOYSA-N

>  <csid>  (114) 
25057795

>  <Links>  (114) 
|http://www.chemspider.com/Chemical-Structure.25057795.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1230165|http://pubchem.ncbi.nlm.nih.gov/compound/24748573|http://www.drugbank.ca/drugs/DB15408| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=3NG|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/3NG|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8126|http://zinc15.docking.org/substances/ZINC000058638454|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=C6RWP0N0L2|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50335638

>  <LinkName>  (114) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (114) 
'3NG'

>  <pdbID>  (114) 
3nga 3pe1 5o11 6fyl 6fyp 6fyv 6hmb 6isj 6k3l 6khd 6khe 6khf 6p5s

>  <indicationG2P>  (114) 
None

>  <indicationDB>  (114) 


>  <uniprotId>  (114) 


>  <MW>  (114) 
349.1

>  <HBA>  (114) 
4.0

>  <HBD>  (114) 
2.0

>  <NRB>  (114) 
3.0

>  <TPSA>  (114) 
75.1

>  <LogP>  (114) 
4.9

>  <RoF>  (114) 
0.0

>  <Melting point>  (114) 


>  <Targets>  (114) 
CSNK2A1; CSNK2A2

>  <Kinase families>  (114) 
Other

>  <FDA_approved>  (114) 


$$$$
Verosudil
     RDKit          2D

 23 25  0  0  0  0  0  0  0  0999 V2000
   -4.8623   -2.2966    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3972   -1.9749    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3861   -3.0829    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9433   -0.5453    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9544    0.5627    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4451    0.3959    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0644    1.7621    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9565    2.7732    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6524    2.0320    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4782   -0.2236    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0242    1.2061    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4670   -1.3315    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.9981   -1.0098    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0092   -2.1178    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4743   -1.7961    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9283   -0.3664    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9171    0.7415    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4520    0.4198    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3711    2.1712    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8361    2.4929    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8473    1.3849    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.3933   -0.0447    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4045   -1.1527    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  1  0
  4 10  1  0
 10 11  2  0
 10 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 17 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  1  0
 22 23  2  0
  9  5  2  0
 18 13  1  0
 22 16  1  0
M  END
>  <BrandName>  (115) 


>  <Applicants>  (115) 
Aerie Pharmaceutical

>  <CHEMBL_ID>  (115) 
CHEMBL3545065

>  <Canonical_Smiles>  (115) 
CN(C)C(c1ccsc1)C(=O)Nc2ccc3c(c2)cc[nH]c3=O

>  <Chirality>  (115) 
Racemic Mixture

>  <First_Approval>  (115) 
nan

>  <Phase>  (115) 
2.0

>  <SC_Patent>  (115) 
None

>  <Synonyms>  (115) 
AR-12286 | AR-12286 FREE BASE | VEROSUDIL

>  <Withdrawn>  (115) 


>  <Indications>  (115) 
nan

>  <Type>  (115) 
nan

>  <targets_id>  (115) 
nan

>  <inchi>  (115) 
InChI=1S/C17H17N3O2S/c1-20(2)15(12-6-8-23-10-12)17(22)19-13-3-4-14-11(9-13)5-7-18-16(14)21/h3-10,15H,1-2H3,(H,18,21)(H,19,22)

>  <stdInchikey>  (115) 
VDYRZXYYQMMFJW-UHFFFAOYSA-N

>  <csid>  (115) 
32742441

>  <Links>  (115) 
|http://www.chemspider.com/Chemical-Structure.32742441.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545065|http://pubchem.ncbi.nlm.nih.gov/compound/66906051|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8911

>  <LinkName>  (115) 
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology

>  <lig_pdbID>  (115) 


>  <pdbID>  (115) 


>  <indicationG2P>  (115) 
None

>  <indicationDB>  (115) 


>  <uniprotId>  (115) 


>  <MW>  (115) 
327.1

>  <HBA>  (115) 
4.0

>  <HBD>  (115) 
2.0

>  <NRB>  (115) 
4.0

>  <TPSA>  (115) 
65.2

>  <LogP>  (115) 
2.8

>  <RoF>  (115) 
0.0

>  <Melting point>  (115) 


>  <Targets>  (115) 
nan

>  <Kinase families>  (115) 


>  <FDA_approved>  (115) 


$$$$
Serabelisib
     RDKit          2D

 27 31  0  0  0  0  0  0  0  0999 V2000
   -2.4770   -1.3012    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7460   -2.1009    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0731   -1.4016    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1311    0.0972    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8620    0.8969    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5349    0.1977    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2659    0.9973    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3238    2.4962    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0547    3.2958    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2723    2.5966    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6799    3.1149    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.6078    1.9364    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7737    0.6897    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3303    1.0977    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0612    0.2981    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2920   -0.7179    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3322   -1.8706    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.7702   -0.9729    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.2885   -2.3805    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7667   -2.6354    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7266   -1.4827    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.2083   -0.0751    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7301    0.1798    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5745    0.5053    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4086   -0.7414    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4807   -1.9200    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -8.9075   -0.7994    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  1  0
 13 16  1  0
 16 17  2  0
 16 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
  4 24  1  0
 24 25  2  0
 25 26  1  0
 25 27  1  0
  6  1  1  0
 26  3  1  0
 15  7  2  0
 14 10  1  0
 23 18  1  0
M  END
>  <BrandName>  (116) 


>  <Applicants>  (116) 
Takeda

>  <CHEMBL_ID>  (116) 
CHEMBL3935857

>  <Canonical_Smiles>  (116) 
c1cc2c(cc1c3ccc4ncc(n4c3)C(=O)N5CCOCC5)nc(o2)N

>  <Chirality>  (116) 
Achiral Molecule

>  <First_Approval>  (116) 
nan

>  <Phase>  (116) 
2.0

>  <SC_Patent>  (116) 
None

>  <Synonyms>  (116) 
AGN-PC-0DB6FL | INK1117 | MLN-1117 | MLN1117 | SERABELISIB | TAK-117

>  <Withdrawn>  (116) 


>  <Indications>  (116) 
nan

>  <Type>  (116) 
nan

>  <targets_id>  (116) 
nan

>  <inchi>  (116) 
InChI=1S/C19H17N5O3/c20-19-22-14-9-12(1-3-16(14)27-19)13-2-4-17-21-10-15(24(17)11-13)18(25)23-5-7-26-8-6-23/h1-4,9-11H,5-8H2,(H2,20,22)

>  <stdInchikey>  (116) 
BLGWHBSBBJNKJO-UHFFFAOYSA-N

>  <csid>  (116) 
35143228

>  <Links>  (116) 
|http://www.chemspider.com/Chemical-Structure.35143228.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3935857|http://pubchem.ncbi.nlm.nih.gov/compound/70798655|http://www.drugbank.ca/drugs/DB14935|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8969|http://zinc15.docking.org/substances/ZINC000146965425|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=43J9Q56T3W|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=119531

>  <LinkName>  (116) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (116) 


>  <pdbID>  (116) 


>  <indicationG2P>  (116) 
None

>  <indicationDB>  (116) 


>  <uniprotId>  (116) 


>  <MW>  (116) 
363.1

>  <HBA>  (116) 
7.0

>  <HBD>  (116) 
1.0

>  <NRB>  (116) 
2.0

>  <TPSA>  (116) 
98.9

>  <LogP>  (116) 
2.2

>  <RoF>  (116) 
0.0

>  <Melting point>  (116) 


>  <Targets>  (116) 
nan

>  <Kinase families>  (116) 


>  <FDA_approved>  (116) 


$$$$
Telatinib
     RDKit          2D

 29 32  0  0  0  0  0  0  0  0999 V2000
   -7.1929    4.3811    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3118    3.1671    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9227    1.7971    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4146    1.6412    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0417    0.5831    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5498    0.7391    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6688   -0.4749    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2796   -1.8449    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7715   -2.0009    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6525   -0.7868    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1769   -0.3189    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2959   -1.5329    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.1960   -1.3769    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0770   -2.5909    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5689   -2.4349    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1782   -3.8056    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0630   -4.8087    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7643   -4.0580    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.1797   -1.0649    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2987    0.1491    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.8068   -0.0069    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.6716   -0.9090    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.2824    0.4610    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7743    0.6170    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3851    1.9870    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5041    3.2010    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0122    3.0450    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4014    1.6750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1150    4.5710    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  3  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
  7 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 15 19  1  0
 19 20  2  0
 20 21  1  0
 19 22  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 26 29  1  0
 10  5  1  0
 21 13  2  0
 18 14  1  0
 28 23  1  0
M  END
>  <BrandName>  (117) 


>  <Applicants>  (117) 
Bayer

>  <CHEMBL_ID>  (117) 
CHEMBL2079588

>  <Canonical_Smiles>  (117) 
CNC(=O)c1cc(ccn1)COc2c3c(cco3)c(nn2)Nc4ccc(cc4)Cl

>  <Chirality>  (117) 
Achiral Molecule

>  <First_Approval>  (117) 
nan

>  <Phase>  (117) 
2.0

>  <SC_Patent>  (117) 
None

>  <Synonyms>  (117) 
BAY 57-9352 | BAY-57-9352 | BAY-579352 | TELATINIB

>  <Withdrawn>  (117) 


>  <Indications>  (117) 
nan

>  <Type>  (117) 
nan

>  <targets_id>  (117) 
P35968|P35916

>  <inchi>  (117) 
InChI=1S/C20H16ClN5O3/c1-22-19(27)16-10-12(6-8-23-16)11-29-20-17-15(7-9-28-17)18(25-26-20)24-14-4-2-13(21)3-5-14/h2-10H,11H2,1H3,(H,22,27)(H,24,25)

>  <stdInchikey>  (117) 
QFCXANHHBCGMAS-UHFFFAOYSA-N

>  <csid>  (117) 
7984603

>  <Links>  (117) 
|http://www.chemspider.com/Chemical-Structure.7984603.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2079588|http://pubchem.ncbi.nlm.nih.gov/compound/9808844|http://www.drugbank.ca/drugs/DB15393|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10476|http://zinc15.docking.org/substances/ZINC00590964|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=18P7197Q7J|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50399538

>  <LinkName>  (117) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (117) 


>  <pdbID>  (117) 


>  <indicationG2P>  (117) 
None

>  <indicationDB>  (117) 


>  <uniprotId>  (117) 


>  <MW>  (117) 
409.1

>  <HBA>  (117) 
7.0

>  <HBD>  (117) 
2.0

>  <NRB>  (117) 
6.0

>  <TPSA>  (117) 
102.2

>  <LogP>  (117) 
4.0

>  <RoF>  (117) 
0.0

>  <Melting point>  (117) 


>  <Targets>  (117) 
KDR; FLT4

>  <Kinase families>  (117) 
Tyr

>  <FDA_approved>  (117) 


$$$$
Tandutinib
     RDKit          2D

 41 45  0  0  0  0  0  0  0  0999 V2000
   13.9813    2.0599    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.6506    1.3675    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.5848   -0.1310    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.3857    2.1738    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.0550    1.4814    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9893   -0.0171    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6586   -0.7095    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3937    0.0967    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4594    1.5953    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7901    2.2876    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0630   -0.5956    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.7981    0.2106    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8639    1.7092    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.4674   -0.4817    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.2025    0.3245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8719   -0.3678    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8061   -1.8664    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0710   -2.6726    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4017   -1.9803    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5245   -2.5587    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7895   -1.7525    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7237   -0.2540    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9886    0.5523    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3193   -0.1401    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3850   -1.6386    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1201   -2.4449    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1859   -3.9434    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9210   -4.7496    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5903   -4.0573    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5842    0.6661    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9149   -0.0262    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.1798    0.7800    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.5105    0.0877    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.7754    0.8939    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  -10.7096    2.3925    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.9745    3.1987    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -13.3052    2.5063    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -13.3709    1.0078    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -12.1060    0.2016    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9229    2.0508    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5922    2.7432    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
  8 11  1  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 17 20  1  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 24 30  1  0
 30 31  1  0
 31 32  1  0
 32 33  1  0
 33 34  1  0
 34 35  1  0
 35 36  1  0
 36 37  1  0
 37 38  1  0
 38 39  1  0
 23 40  1  0
 40 41  1  0
 10  5  1  0
 19 14  1  0
 29 20  2  0
 26 21  1  0
 39 34  1  0
M  END
>  <BrandName>  (118) 


>  <Applicants>  (118) 
Takeda

>  <CHEMBL_ID>  (118) 
CHEMBL124660

>  <Canonical_Smiles>  (118) 
CC(C)Oc1ccc(cc1)NC(=O)N2CCN(CC2)c3c4cc(c(cc4ncn3)OCCCN5CCCCC5)OC

>  <Chirality>  (118) 
Achiral Molecule

>  <First_Approval>  (118) 
nan

>  <Phase>  (118) 
2.0

>  <SC_Patent>  (118) 
None

>  <Synonyms>  (118) 
CT 53518 | CT-53518 | CT53518 | MLN-0518 | MLN-518 | TANDUTINIB

>  <Withdrawn>  (118) 


>  <Indications>  (118) 
Investigated for use/treatment in leukemia (myeloid).

>  <Type>  (118) 
nan

>  <targets_id>  (118) 
P36888|Q9GZP0

>  <inchi>  (118) 
InChI=1S/C31H42N6O4/c1-23(2)41-25-10-8-24(9-11-25)34-31(38)37-17-15-36(16-18-37)30-26-20-28(39-3)29(21-27(26)32-22-33-30)40-19-7-14-35-12-5-4-6-13-35/h8-11,20-23H,4-7,12-19H2,1-3H3,(H,34,38)

>  <stdInchikey>  (118) 
UXXQOJXBIDBUAC-UHFFFAOYSA-N

>  <csid>  (118) 
2302085

>  <Links>  (118) 
|http://www.chemspider.com/Chemical-Structure.2302085.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL124660|http://pubchem.ncbi.nlm.nih.gov/compound/3038522|http://www.drugbank.ca/drugs/DB05465|http://zinc15.docking.org/substances/ZINC000003966243|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=E1IO3ICJ9A|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13535

>  <LinkName>  (118) 
|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (118) 


>  <pdbID>  (118) 


>  <indicationG2P>  (118) 


>  <indicationDB>  (118) 
MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT. Tyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth. AML patients with FLT3 mutations experience earlier disease relapse and shorter survival rates compared to patients without these mutations. Approximately 25 to 30 percent of all adult AML patients have a mutation of the FLT3 gene. The use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration. Phase I/II trials are underway.

>  <uniprotId>  (118) 
P36888|Q9GZP0

>  <MW>  (118) 
562.3

>  <HBA>  (118) 
8.0

>  <HBD>  (118) 
1.0

>  <NRB>  (118) 
10.0

>  <TPSA>  (118) 
92.3

>  <LogP>  (118) 
5.0

>  <RoF>  (118) 
2.0

>  <Melting point>  (118) 


>  <Targets>  (118) 
FLT3; PDGFD

>  <Kinase families>  (118) 
Tyr<br>(*)

>  <FDA_approved>  (118) 


$$$$
Samotolisib
     RDKit          2D

 30 33  0  0  0  0  0  0  0  0999 V2000
   -0.4488   -4.0828    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5886   -3.1076    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3139   -1.6330    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4536   -0.6578    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3346    0.8375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1437    1.7495    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2416    1.1743    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4325    2.0863    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2380    3.5737    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1473    4.1489    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3381    3.2369    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7234    3.8122    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9143    2.9001    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7199    1.4128    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6951    0.2730    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9125   -1.0066    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4878   -2.3919    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1903    0.3921    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8177    1.5110    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0122    0.0237    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3975   -0.5516    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5883    0.3605    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3939    1.8478    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.0086    2.4231    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5919   -2.0389    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0793   -1.8445    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1046   -2.2334    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7864   -3.5263    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0030   -3.6071    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2777   -5.0817    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  6
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  1  0
 16 17  2  0
 15 18  1  0
  8 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 21 25  1  0
 25 26  1  0
 25 27  1  0
 25 28  1  0
  2 29  1  0
 29 30  1  0
 16  4  1  0
 14  5  1  0
 11  6  1  0
 24 19  1  0
M  END
>  <BrandName>  (119) 


>  <Applicants>  (119) 
Eli Lilly

>  <CHEMBL_ID>  (119) 
CHEMBL4297181

>  <Canonical_Smiles>  (119) 
C[C@@H](Cn1c2c3cc(ccc3ncc2n(c1=O)C)c4cc(cnc4)C(C)(C)O)OC

>  <Chirality>  (119) 
Single Stereoisomer

>  <First_Approval>  (119) 
nan

>  <Phase>  (119) 
2.0

>  <SC_Patent>  (119) 
None

>  <Synonyms>  (119) 
LY 3023414 | LY-3023414 | LY3023414 | SAMOTOLISIB

>  <Withdrawn>  (119) 


>  <Indications>  (119) 
LY3023414 is a dual inhibitor of phosphoinositide 3-kinase &alpha; (PI3K&alpha;) and the serine/threonine kinase mTOR (mechanistic target of rapamycin), with potential antineoplastic activity.

>  <Type>  (119) 
nan

>  <targets_id>  (119) 
nan

>  <inchi>  (119) 
InChI=1S/C23H26N4O3/c1-14(30-5)13-27-21-18-9-15(16-8-17(11-24-10-16)23(2,3)29)6-7-19(18)25-12-20(21)26(4)22(27)28/h6-12,14,29H,13H2,1-5H3/t14-/m0/s1

>  <stdInchikey>  (119) 
ACCFLVVUVBJNGT-AWEZNQCLSA-N

>  <csid>  (119) 
35142771

>  <Links>  (119) 
|http://www.chemspider.com/Chemical-Structure.35142771.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297181|http://pubchem.ncbi.nlm.nih.gov/compound/57519748|http://www.drugbank.ca/drugs/DB12167|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8918|http://zinc15.docking.org/substances/ZINC000143116580|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=C88817F47Y

>  <LinkName>  (119) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (119) 


>  <pdbID>  (119) 


>  <indicationG2P>  (119) 
None

>  <indicationDB>  (119) 


>  <uniprotId>  (119) 


>  <MW>  (119) 
406.2

>  <HBA>  (119) 
7.0

>  <HBD>  (119) 
1.0

>  <NRB>  (119) 
5.0

>  <TPSA>  (119) 
82.2

>  <LogP>  (119) 
3.2

>  <RoF>  (119) 
0.0

>  <Melting point>  (119) 


>  <Targets>  (119) 
nan

>  <Kinase families>  (119) 


>  <FDA_approved>  (119) 


$$$$
Rogaratinib
     RDKit          2D

 33 37  0  0  0  0  0  0  0  0999 V2000
    7.6853    0.2232    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2020    0.4459    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2674   -0.7274    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7840   -0.5047    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6259   -1.4580    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3614   -0.6512    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7379    0.8007    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    3.2352    0.8913    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1698    2.0646    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6531    1.8419    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6209    3.4606    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.5555    4.6339    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0346   -1.2001    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2991   -0.3933    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4572   -1.3466    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9084   -2.7426    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4111   -2.6520    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4159   -3.9034    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2543   -5.2454    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7515   -5.3359    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5786   -4.0846    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.9132   -3.8128    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9092   -0.9701    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3091    0.4757    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2570    1.5448    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6569    2.9905    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1089    3.3671    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1609    2.2979    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6129    2.6744    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7610    0.8522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3897    1.1040    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1383    1.9311    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2289    3.4283    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
  9 11  1  0
 11 12  1  0
  6 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 18 22  1  0
 15 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
 28 29  2  0
 28 30  1  0
 14 31  1  0
 31 32  1  0
 32 33  1  0
 10  2  1  0
  8  4  2  0
 17 13  2  0
 21 16  1  0
 30 24  1  0
M  END
>  <BrandName>  (120) 


>  <Applicants>  (120) 
Bayer

>  <CHEMBL_ID>  (120) 
CHEMBL3963485

>  <Canonical_Smiles>  (120) 
Cc1cc2cc(sc2c(c1)OC)c3c(c(n4c3c(ncn4)N)CN5CCNC(=O)C5)COC

>  <Chirality>  (120) 
Achiral Molecule

>  <First_Approval>  (120) 
nan

>  <Phase>  (120) 
2.0

>  <SC_Patent>  (120) 
None

>  <Synonyms>  (120) 
BAY-1163877 | ROGARATINIB

>  <Withdrawn>  (120) 


>  <Indications>  (120) 
Rogaratinib (BAY-1163877) is a FGFR-selective kinase inhibitor that is being investigated for antineoplastic activity.

>  <Type>  (120) 
nan

>  <targets_id>  (120) 
nan

>  <inchi>  (120) 
InChI=1S/C23H26N6O3S/c1-13-6-14-8-18(33-22(14)17(7-13)32-3)20-15(11-31-2)16(9-28-5-4-25-19(30)10-28)29-21(20)23(24)26-12-27-29/h6-8,12H,4-5,9-11H2,1-3H3,(H,25,30)(H2,24,26,27)

>  <stdInchikey>  (120) 
HNLRRJSKGXOYNO-UHFFFAOYSA-N

>  <csid>  (120) 
58828032

>  <Links>  (120) 
|http://www.chemspider.com/Chemical-Structure.58828032.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3963485|http://pubchem.ncbi.nlm.nih.gov/compound/71611869|http://www.drugbank.ca/drugs/DB15078|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9789|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=98BSN6N516|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=194820

>  <LinkName>  (120) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB

>  <lig_pdbID>  (120) 


>  <pdbID>  (120) 


>  <indicationG2P>  (120) 
None

>  <indicationDB>  (120) 


>  <uniprotId>  (120) 


>  <MW>  (120) 
466.2

>  <HBA>  (120) 
9.0

>  <HBD>  (120) 
2.0

>  <NRB>  (120) 
6.0

>  <TPSA>  (120) 
107.0

>  <LogP>  (120) 
2.6

>  <RoF>  (120) 
0.0

>  <Melting point>  (120) 


>  <Targets>  (120) 
nan

>  <Kinase families>  (120) 


>  <FDA_approved>  (120) 


$$$$
Tarloxotinib
     RDKit          2D

 39 41  0  0  0  0  0  0  0  0999 V2000
   -5.5014    1.0971    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0006    1.1446    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.8434    2.3855    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.2839    1.9675    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -9.3315    0.4682    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9203   -0.0403    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5023   -1.4809    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0457   -1.8391    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6874   -0.3825    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4039   -3.2957    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5891   -2.1973    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5505   -1.1150    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0939   -1.4733    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0554   -0.3909    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4735    1.0496    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.4012   -0.7492    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.4397    0.3332    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8963   -0.0251    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9349    1.0573    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5168    2.4978    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0602    2.8561    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0217    1.7737    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.5553    3.5802    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.0119    3.2219    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4300    1.7814    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.3915    0.6990    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8095   -0.7415    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.2661   -1.0998    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6842   -2.5403    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1408   -2.8986    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1793   -1.8162    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7612   -0.3757    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3046   -0.0174    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.7998    0.7066    0.0000 Br  0  0  0  0  0  0  0  0  0  0  0  0
   11.6359   -2.1745    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  -10.5724   -0.3745    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  -10.4630   -1.8705    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  -11.9227    0.2787    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    4.5802    0.0000 Br  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  8 10  1  0
  8 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 14 16  1  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 20 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 32 33  2  0
 32 34  1  0
 31 35  1  0
  5 36  1  0
 36 37  2  0
 36 38  1  0
  6  2  1  0
 22 17  1  0
 26 19  1  0
 33 28  1  0
M  CHG  4   8   1  36   1  38  -1  39  -1
M  END
>  <BrandName>  (121) 


>  <Applicants>  (121) 
Threshold Pharmaceuticals

>  <CHEMBL_ID>  (121) 
CHEMBL4297661

>  <Canonical_Smiles>  (121) 
Cn1cnc(c1C[N+](C)(C)C/C=C/C(=O)Nc2cc3c(cn2)ncnc3Nc4ccc(c(c4)Br)Cl)[N+](=O)[O-].[Br-]

>  <Chirality>  (121) 
Achiral Molecule

>  <First_Approval>  (121) 
nan

>  <Phase>  (121) 
2.0

>  <SC_Patent>  (121) 
None

>  <Synonyms>  (121) 
TARLOXOTINIB BROMIDE

>  <Withdrawn>  (121) 


>  <Indications>  (121) 
nan

>  <Type>  (121) 
nan

>  <targets_id>  (121) 
P00533

>  <inchi>  (121) 
InChI=1S/C24H23BrClN9O3.BrH/c1-33-14-30-24(34(37)38)20(33)12-35(2,3)8-4-5-22(36)32-21-10-16-19(11-27-21)28-13-29-23(16)31-15-6-7-18(26)17(25)9-15;/h4-7,9-11,13-14H,8,12H2,1-3H3,(H-,27,28,29,31,32,36);1H/b5-4+;

>  <stdInchikey>  (121) 
WAKIMVYUBWMMHJ-FXRZFVDSSA-N

>  <csid>  (121) 
46518771

>  <Links>  (121) 
|http://www.chemspider.com/Chemical-Structure.46518771.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297662|http://pubchem.ncbi.nlm.nih.gov/compound/51038315|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=3Y31FJ8K50

>  <LinkName>  (121) 
|ChemSpider|ChEMBL|PubChem|FDA SRS

>  <lig_pdbID>  (121) 


>  <pdbID>  (121) 


>  <indicationG2P>  (121) 


>  <indicationDB>  (121) 


>  <uniprotId>  (121) 


>  <MW>  (121) 
679.0

>  <HBA>  (121) 
9.0

>  <HBD>  (121) 
2.0

>  <NRB>  (121) 
9.0

>  <TPSA>  (121) 
140.8

>  <LogP>  (121) 
1.6

>  <RoF>  (121) 
1.0

>  <Melting point>  (121) 


>  <Targets>  (121) 
EGFR

>  <Kinase families>  (121) 
Tyr

>  <FDA_approved>  (121) 


$$$$
Gandotinib
     RDKit          2D

 33 37  0  0  0  0  0  0  0  0999 V2000
    1.0312   -7.5557    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0095   -6.0559    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2102   -5.1568    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7261   -3.7371    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2263   -3.7587    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2166   -5.1918    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.5902   -2.5109    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.9603   -1.1496    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8244    0.0766    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1946    1.4379    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7007    1.5732    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1984    2.7738    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6182    2.2898    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5965    0.7899    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1634    0.3470    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.4665   -1.0143    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7972   -0.1092    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1762    0.4811    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3545    1.9704    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7335    2.5607    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9341    1.6616    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7558    0.1722    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3768   -0.4181    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1985   -1.9074    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3131    2.2518    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -2.8443    3.1538    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0586    2.6641    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5525    2.5288    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.1824    1.1675    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6762    1.0322    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5403    2.2584    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.9105    3.6197    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4166    3.7550    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  4  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  1  0
 14 17  1  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 21 25  1  0
 13 26  1  0
 10 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 32 33  1  0
  6  2  1  0
 16  8  2  0
 15 11  1  0
 23 18  1  0
 33 28  1  0
M  END
>  <BrandName>  (122) 


>  <Applicants>  (122) 
Eli Lilly

>  <CHEMBL_ID>  (122) 
CHEMBL2107823

>  <Canonical_Smiles>  (122) 
Cc1cc(n[nH]1)Nc2cc(c3nc(c(n3n2)Cc4ccc(cc4F)Cl)C)CN5CCOCC5

>  <Chirality>  (122) 
Achiral Molecule

>  <First_Approval>  (122) 
nan

>  <Phase>  (122) 
2.0

>  <SC_Patent>  (122) 
None

>  <Synonyms>  (122) 
GANDOTINIB | LY-2784544 | LY2784544

>  <Withdrawn>  (122) 


>  <Indications>  (122) 
nan

>  <Type>  (122) 
nan

>  <targets_id>  (122) 
O60674

>  <inchi>  (122) 
InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)

>  <stdInchikey>  (122) 
SQSZANZGUXWJEA-UHFFFAOYSA-N

>  <csid>  (122) 
25027412

>  <Links>  (122) 
|http://www.chemspider.com/Chemical-Structure.25027412.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2107823|http://pubchem.ncbi.nlm.nih.gov/compound/46213929|http://www.drugbank.ca/drugs/DB13040|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7909|http://zinc15.docking.org/substances/ZINC68245097|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=ANC71R916O

>  <LinkName>  (122) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (122) 


>  <pdbID>  (122) 


>  <indicationG2P>  (122) 
None

>  <indicationDB>  (122) 


>  <uniprotId>  (122) 


>  <MW>  (122) 
469.2

>  <HBA>  (122) 
7.0

>  <HBD>  (122) 
2.0

>  <NRB>  (122) 
6.0

>  <TPSA>  (122) 
83.4

>  <LogP>  (122) 
4.0

>  <RoF>  (122) 
0.0

>  <Melting point>  (122) 


>  <Targets>  (122) 
JAK2

>  <Kinase families>  (122) 
Tyr

>  <FDA_approved>  (122) 


$$$$
Sapanisertib
     RDKit          2D

 23 26  0  0  0  0  0  0  0  0999 V2000
    3.3243    3.9627    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7846    2.5351    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2511    2.2199    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7784    1.4226    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.0870   -0.0453    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7863   -0.7924    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6738    0.2138    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2870    1.5828    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7941   -0.0948    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2609   -1.5203    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7288   -1.8289    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7300   -0.7119    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2632    0.7136    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7953    1.0222    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4748    1.5981    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6903    0.7191    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2300   -0.7085    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1158    1.1858    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.7829   -2.2924    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0802   -3.0453    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.3810   -2.2982    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3843   -0.7982    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.4822   -3.0395    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  7  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 13 15  1  0
 15 16  2  0
 16 17  1  0
 16 18  1  0
  6 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 19 23  1  0
  8  4  1  0
 22  5  1  0
 14  9  1  0
 17 12  1  0
M  END
>  <BrandName>  (123) 


>  <Applicants>  (123) 
Takeda

>  <CHEMBL_ID>  (123) 
CHEMBL3545097

>  <Canonical_Smiles>  (123) 
CC(C)n1c2c(c(n1)c3ccc4c(c3)nc(o4)N)c(ncn2)N

>  <Chirality>  (123) 
Achiral Molecule

>  <First_Approval>  (123) 
nan

>  <Phase>  (123) 
2.0

>  <SC_Patent>  (123) 
None

>  <Synonyms>  (123) 
INK-128 | INK128 | MLN-0128 | MLN0128 | SAPANISERTIB | TAK-228

>  <Withdrawn>  (123) 


>  <Indications>  (123) 
nan

>  <Type>  (123) 
nan

>  <targets_id>  (123) 
P42345

>  <inchi>  (123) 
InChI=1S/C15H15N7O/c1-7(2)22-14-11(13(16)18-6-19-14)12(21-22)8-3-4-10-9(5-8)20-15(17)23-10/h3-7H,1-2H3,(H2,17,20)(H2,16,18,19)

>  <stdInchikey>  (123) 
GYLDXIAOMVERTK-UHFFFAOYSA-N

>  <csid>  (123) 
28189069

>  <Links>  (123) 
|http://www.chemspider.com/Chemical-Structure.28189069.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545097|http://pubchem.ncbi.nlm.nih.gov/compound/45375953|http://www.drugbank.ca/drugs/DB11836| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=FE5|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/FE5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7933|http://zinc15.docking.org/substances/ZINC000073069271|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=JGH0DF1U03|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=315477

>  <LinkName>  (123) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (123) 
'FE5'

>  <pdbID>  (123) 
6gvf

>  <indicationG2P>  (123) 
None

>  <indicationDB>  (123) 


>  <uniprotId>  (123) 


>  <MW>  (123) 
309.1

>  <HBA>  (123) 
8.0

>  <HBD>  (123) 
2.0

>  <NRB>  (123) 
2.0

>  <TPSA>  (123) 
121.7

>  <LogP>  (123) 
2.4

>  <RoF>  (123) 
0.0

>  <Melting point>  (123) 


>  <Targets>  (123) 
MTOR

>  <Kinase families>  (123) 
Atypical

>  <FDA_approved>  (123) 


$$$$
Talmapimod
     RDKit          2D

 36 39  0  0  0  0  0  0  0  0999 V2000
   -1.3305   -4.4610    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0505   -3.1451    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5501   -3.1107    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2701   -1.7948    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4905   -0.5133    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9909   -0.5477    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2709   -1.8636    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.2287   -1.8980    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9487   -3.2139    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.0083   -0.6165    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5079   -0.6509    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2875    0.6306    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5675    1.9465    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0679    1.9809    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2883    0.6994    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2113    0.7338    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    3.5965    3.0379    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.9524    2.3965    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7615    0.9087    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8529   -0.1203    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5075   -1.5799    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.2897    0.3104    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6352    1.7701    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.3811   -0.7186    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.8180   -0.2879    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0357   -2.1782    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3183    4.5119    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2105    0.8026    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7697   -1.7604    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4897   -0.4445    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7101    0.8370    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4302    2.1529    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9298    2.1873    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7094    0.9058    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9893   -0.4101    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.6498    3.5032    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  6
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  8 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 13 17  1  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 20 22  1  0
 22 23  2  0
 22 24  1  0
 24 25  1  0
 24 26  1  0
 17 27  1  0
  5 28  1  1
  4 29  1  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 32 33  2  0
 33 34  1  0
 34 35  2  0
 33 36  1  0
  7  2  1  0
 15 10  1  0
 19 12  1  0
 35 30  1  0
M  END
>  <BrandName>  (124) 


>  <Applicants>  (124) 
Scios inc

>  <CHEMBL_ID>  (124) 
CHEMBL514201

>  <Canonical_Smiles>  (124) 
C[C@@H]1CN([C@H](CN1C(=O)c2cc3c(cc2Cl)n(cc3C(=O)C(=O)N(C)C)C)C)Cc4ccc(cc4)F

>  <Chirality>  (124) 
Single Stereoisomer

>  <First_Approval>  (124) 
nan

>  <Phase>  (124) 
2.0

>  <SC_Patent>  (124) 
None

>  <Synonyms>  (124) 
SCIO 469 | SCIO-469 | TALMAPIMOD

>  <Withdrawn>  (124) 


>  <Indications>  (124) 
Investigated for use/treatment in pain (acute or chronic) and rheumatoid arthritis.

>  <Type>  (124) 
1

>  <targets_id>  (124) 
Q16539

>  <inchi>  (124) 
InChI=1S/C27H30ClFN4O3/c1-16-13-33(17(2)12-32(16)14-18-6-8-19(29)9-7-18)26(35)21-10-20-22(25(34)27(36)30(3)4)15-31(5)24(20)11-23(21)28/h6-11,15-17H,12-14H2,1-5H3/t16-,17+/m0/s1

>  <stdInchikey>  (124) 
ZMELOYOKMZBMRB-DLBZAZTESA-N

>  <csid>  (124) 
8046764

>  <Links>  (124) 
|http://www.chemspider.com/Chemical-Structure.8046764.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL514201|http://pubchem.ncbi.nlm.nih.gov/compound/9871074|http://www.drugbank.ca/drugs/DB05412| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=469|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/469|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7817|http://zinc15.docking.org/substances/ZINC000034001955|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=B1E00KQ6NT|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50266947

>  <LinkName>  (124) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (124) 
'469'

>  <pdbID>  (124) 
3hub 3zsh

>  <indicationG2P>  (124) 
None

>  <indicationDB>  (124) 
Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.

>  <uniprotId>  (124) 
Q16539|P01375|P01584|P00403

>  <MW>  (124) 
512.2

>  <HBA>  (124) 
5.0

>  <HBD>  (124) 
0.0

>  <NRB>  (124) 
5.0

>  <TPSA>  (124) 
65.9

>  <LogP>  (124) 
4.0

>  <RoF>  (124) 
1.0

>  <Melting point>  (124) 


>  <Targets>  (124) 
MAPK14

>  <Kinase families>  (124) 
CMGC

>  <FDA_approved>  (124) 


$$$$
Sotrastaurin
     RDKit          2D

 33 38  0  0  0  0  0  0  0  0999 V2000
   -0.4308   -7.0995    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1205   -5.7045    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8119   -4.5295    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2606   -3.1345    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2232   -2.9145    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.1556   -4.0895    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6043   -5.4845    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7746   -1.5195    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2583   -1.2995    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.8097    0.0955    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2935    0.3155    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8448    1.7105    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9124    2.8855    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4286    2.6655    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8773    1.2705    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3935    1.0505    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8421   -0.3445    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.4611    2.2255    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0376    2.1618    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5613    3.5674    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0063    3.9699    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3863    4.4998    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.8636    3.6704    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2692    4.1941    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8669    0.9119    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3432   -0.4937    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5182   -1.4262    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7681   -0.5968    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3656    0.8482    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4157    1.9192    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8684    1.5453    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2709    0.1004    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2207   -0.9707    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  5  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 16 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 20 22  1  0
 22 23  1  0
 23 24  2  0
 19 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 32 33  2  0
  7  2  1  0
 17  8  1  0
 15 10  1  0
 23 18  1  0
 29 25  1  0
 33 28  1  0
M  END
>  <BrandName>  (125) 


>  <Applicants>  (125) 
Novartis

>  <CHEMBL_ID>  (125) 
CHEMBL565612

>  <Canonical_Smiles>  (125) 
CN1CCN(CC1)c2nc3ccccc3c(n2)C4=C(C(=O)NC4=O)c5c[nH]c6c5cccc6

>  <Chirality>  (125) 
Achiral Molecule

>  <First_Approval>  (125) 
nan

>  <Phase>  (125) 
2.0

>  <SC_Patent>  (125) 
None

>  <Synonyms>  (125) 
AEB-071 | AEB071 | NVP-AEB071 | SOTRASTAURIN

>  <Withdrawn>  (125) 


>  <Indications>  (125) 
nan

>  <Type>  (125) 
nan

>  <targets_id>  (125) 
nan

>  <inchi>  (125) 
InChI=1S/C25H22N6O2/c1-30-10-12-31(13-11-30)25-27-19-9-5-3-7-16(19)22(28-25)21-20(23(32)29-24(21)33)17-14-26-18-8-4-2-6-15(17)18/h2-9,14,26H,10-13H2,1H3,(H,29,32,33)

>  <stdInchikey>  (125) 
OAVGBZOFDPFGPJ-UHFFFAOYSA-N

>  <csid>  (125) 
8472351

>  <Links>  (125) 
|http://www.chemspider.com/Chemical-Structure.8472351.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL565612|http://pubchem.ncbi.nlm.nih.gov/compound/10296883|http://www.drugbank.ca/drugs/DB12369| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=LW4|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/LW4|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7946|http://zinc15.docking.org/substances/ZINC000003973984|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=7I279E1NZ8|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=33971

>  <LinkName>  (125) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (125) 
'LW4'

>  <pdbID>  (125) 
3iw4

>  <indicationG2P>  (125) 
None

>  <indicationDB>  (125) 


>  <uniprotId>  (125) 


>  <MW>  (125) 
438.2

>  <HBA>  (125) 
6.0

>  <HBD>  (125) 
2.0

>  <NRB>  (125) 
3.0

>  <TPSA>  (125) 
94.2

>  <LogP>  (125) 
2.4

>  <RoF>  (125) 
0.0

>  <Melting point>  (125) 


>  <Targets>  (125) 
nan

>  <Kinase families>  (125) 


>  <FDA_approved>  (125) 


$$$$
Pilaralisib
     RDKit          2D

 37 40  0  0  0  0  0  0  0  0999 V2000
   -6.8529   -1.0140    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5794    0.2983    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3060    1.6106    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2671    1.0249    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2402    2.5247    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9818    0.2517    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6695    0.9782    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6425    2.4780    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3302    3.2045    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0449    2.4313    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0718    0.9316    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3841    0.2050    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2135    0.1584    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.9867    1.4437    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5597   -1.1270    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.4989   -0.6149    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.8112    0.1117    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0965   -0.6615    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4088    0.0650    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.4358    1.5648    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7481    2.2913    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7750    3.7911    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4897    4.5643    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1774    3.8377    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1504    2.3380    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8381    1.6114    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.0696   -2.1613    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.7573   -2.8878    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4719   -2.1146    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1596   -2.8412    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1327   -4.3409    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4181   -5.1141    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7304   -4.3876    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0157   -5.1608    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -1.1257   -2.0680    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4380   -2.7945    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.8917   -0.4282    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  4  5  2  0
  4  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 11 13  1  0
 13 14  2  0
 13 15  2  0
 13 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 18 27  1  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 32 33  2  0
 33 34  1  0
 30 35  1  0
 35 36  1  0
  2 37  1  0
 12  7  1  0
 26 17  2  0
 25 20  1  0
 33 28  1  0
M  END
>  <BrandName>  (126) 


>  <Applicants>  (126) 
Sanofi

>  <CHEMBL_ID>  (126) 
CHEMBL3360203

>  <Canonical_Smiles>  (126) 
CC(C)(C(=O)Nc1cccc(c1)S(=O)(=O)Nc2c(nc3ccccc3n2)Nc4cc(ccc4Cl)OC)N

>  <Chirality>  (126) 
Achiral Molecule

>  <First_Approval>  (126) 
nan

>  <Phase>  (126) 
2.0

>  <SC_Patent>  (126) 
None

>  <Synonyms>  (126) 
PILARALISIB | SAR-245408 | SAR245408 | XL-147 | XL147

>  <Withdrawn>  (126) 


>  <Indications>  (126) 
nan

>  <Type>  (126) 
nan

>  <targets_id>  (126) 
P42336|P42338|O00329|P48736

>  <inchi>  (126) 
InChI=1S/C25H25ClN6O4S/c1-25(2,27)24(33)28-15-7-6-8-17(13-15)37(34,35)32-23-22(29-19-9-4-5-10-20(19)30-23)31-21-14-16(36-3)11-12-18(21)26/h4-14H,27H2,1-3H3,(H,28,33)(H,29,31)(H,30,32)

>  <stdInchikey>  (126) 
QINPEPAQOBZPOF-UHFFFAOYSA-N

>  <csid>  (126) 
29340997

>  <Links>  (126) 
|http://www.chemspider.com/Chemical-Structure.29340997.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3360203|http://pubchem.ncbi.nlm.nih.gov/compound/56599306|http://www.drugbank.ca/drugs/DB11772|http://zinc15.docking.org/substances/ZINC000100472223|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=60ES45KTMK|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50197062

>  <LinkName>  (126) 
|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (126) 


>  <pdbID>  (126) 


>  <indicationG2P>  (126) 


>  <indicationDB>  (126) 
Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.

>  <uniprotId>  (126) 
P42336

>  <MW>  (126) 
540.1

>  <HBA>  (126) 
8.0

>  <HBD>  (126) 
4.0

>  <NRB>  (126) 
8.0

>  <TPSA>  (126) 
148.3

>  <LogP>  (126) 
4.5

>  <RoF>  (126) 
1.0

>  <Melting point>  (126) 


>  <Targets>  (126) 
PIK3CA; PIK3CB; PIK3CD; PIK3CG

>  <Kinase families>  (126) 
Atypical

>  <FDA_approved>  (126) 


$$$$
Seliciclib
     RDKit          2D

 26 28  0  0  0  0  0  0  0  0999 V2000
    0.5807    6.1771    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6535    5.3245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5322    3.8295    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8232    3.1869    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0574    4.0395    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7664    2.9769    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6451    1.4818    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2897    0.8393    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1684   -0.6558    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1870   -1.2984    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.4211   -0.4458    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7766   -1.0883    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8978   -2.5834    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2532   -3.2260    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4874   -2.3734    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3661   -0.8783    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0107   -0.2358    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4026   -1.5084    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5948   -2.9960    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0691   -3.2729    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7879   -1.9564    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2756   -1.7641    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1859   -2.9563    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8529   -0.3797    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7580   -0.8658    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8793    0.6292    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  3  2  1  6
  3  4  1  0
  4  5  1  0
  3  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
  9 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 22 24  1  0
 21 25  1  0
 25 26  2  0
 26  7  1  0
 17 12  1  0
 25 18  1  0
M  END
>  <BrandName>  (127) 


>  <Applicants>  (127) 
Cyclacel pharmaceuticals

>  <CHEMBL_ID>  (127) 
CHEMBL14762

>  <Canonical_Smiles>  (127) 
CC[C@H](CO)Nc1nc(NCc2ccccc2)c3ncn(C(C)C)c3n1

>  <Chirality>  (127) 
Single Stereoisomer

>  <First_Approval>  (127) 
nan

>  <Phase>  (127) 
2.0

>  <SC_Patent>  (127) 
None

>  <Synonyms>  (127) 
AL-39256 | CYC-202 | NSC-701554 | SELICICLIB

>  <Withdrawn>  (127) 


>  <Indications>  (127) 
nan

>  <Type>  (127) 
1

>  <targets_id>  (127) 
P24941|P50613|P50750

>  <inchi>  (127) 
InChI=1S/C19H26N6O/c1-4-15(11-26)22-19-23-17(20-10-14-8-6-5-7-9-14)16-18(24-19)25(12-21-16)13(2)3/h5-9,12-13,15,26H,4,10-11H2,1-3H3,(H2,20,22,23,24)/t15-/m1/s1

>  <stdInchikey>  (127) 
BTIHMVBBUGXLCJ-OAHLLOKOSA-N

>  <csid>  (127) 
140922

>  <Links>  (127) 
|http://www.chemspider.com/Chemical-Structure.140922.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL14762|http://pubchem.ncbi.nlm.nih.gov/compound/160355|http://www.drugbank.ca/drugs/DB06195| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=RRC|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/RRC|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6035|http://zinc15.docking.org/substances/ZINC01649340|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=0ES1C2KQ94|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=7533

>  <LinkName>  (127) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (127) 
'RRC'

>  <pdbID>  (127) 
1unl 1ygk 2a4l 3ddq

>  <indicationG2P>  (127) 
None

>  <indicationDB>  (127) 
R-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase of treated cells. Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation disorders.

>  <uniprotId>  (127) 
P06493|P24941|P27361|P28482|P50613|P50750|P49674|P35354

>  <MW>  (127) 
354.2

>  <HBA>  (127) 
7.0

>  <HBD>  (127) 
3.0

>  <NRB>  (127) 
8.0

>  <TPSA>  (127) 
87.9

>  <LogP>  (127) 
3.2

>  <RoF>  (127) 
0.0

>  <Melting point>  (127) 


>  <Targets>  (127) 
CDK2; CDK7; CDK9

>  <Kinase families>  (127) 
CMGC

>  <FDA_approved>  (127) 


$$$$
Opaganib
     RDKit          2D

 27 31  0  0  0  0  0  0  0  0999 V2000
   -2.0968   -1.2807    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4597   -2.7362    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9016   -3.1496    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9806   -2.1075    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6177   -0.6521    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1758   -0.2387    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8128    1.2167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3709    1.6301    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0080    3.0856    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0870    4.1276    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5289    3.7142    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8918    2.2588    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7474    0.9510    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2919    0.5881    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0710    2.0435    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7339    0.1747    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7870   -0.4539    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4241   -1.9093    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.2289   -0.0405    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.3079   -1.0825    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7498   -0.6691    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8288   -1.7111    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2707   -1.2977    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6336    0.1577    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.5547    1.1997    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1127    0.7863    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2646   -4.6050    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 11 13  1  0
 13 14  1  0
 14 15  1  0
 14 16  1  0
 14 17  1  0
 17 18  2  0
 17 19  1  0
 19 20  1  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
  3 27  1  0
  6  1  1  0
 12  7  1  0
 16  7  1  0
 15  9  1  0
 26 21  1  0
M  END
>  <BrandName>  (128) 


>  <Applicants>  (128) 
RedHill Biopharma

>  <CHEMBL_ID>  (128) 
CHEMBL2158685

>  <Canonical_Smiles>  (128) 
c1cc(ccc1C23CC4CC(C2)CC(C4)(C3)C(=O)NCc5ccncc5)Cl

>  <Chirality>  (128) 
Achiral Molecule

>  <First_Approval>  (128) 
nan

>  <Phase>  (128) 
2.5

>  <SC_Patent>  (128) 
None

>  <Synonyms>  (128) 
ABC 294640 | ABC-294640 | OPAGANIB

>  <Withdrawn>  (128) 


>  <Indications>  (128) 
nan

>  <Type>  (128) 
nan

>  <targets_id>  (128) 
nan

>  <inchi>  (128) 
InChI=1S/C23H25ClN2O/c24-20-3-1-19(2-4-20)22-10-17-9-18(11-22)13-23(12-17,15-22)21(27)26-14-16-5-7-25-8-6-16/h1-8,17-18H,9-15H2,(H,26,27)

>  <stdInchikey>  (128) 
CAOTVXGYTWCKQE-UHFFFAOYSA-N

>  <csid>  (128) 
13079494

>  <Links>  (128) 
|http://www.chemspider.com/Chemical-Structure.13079494.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2158685|http://pubchem.ncbi.nlm.nih.gov/compound/15604015|http://www.drugbank.ca/drugs/DB12764|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=DRG21OQ517|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50393642

>  <LinkName>  (128) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB

>  <lig_pdbID>  (128) 


>  <pdbID>  (128) 


>  <indicationG2P>  (128) 
None

>  <indicationDB>  (128) 
Opaganib, also known as ABC294640, is a selective <a href="https://go.drugbank.com/polypeptides/Q9NRA0">sphingosine kinase-2 (SK2)</a> inhibitor that is orally administered.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Opaganib (YelivaÂ®, ABC294640)" href="#reference-L27436">2</a></sup> This drug has potential anticancer, anti-inflammatory, and antiviral activities, with potential applications in oncology, inflammation, the gastrointestinal system, and COVID-19.

>  <uniprotId>  (128) 
Q9NRA0

>  <MW>  (128) 
380.2

>  <HBA>  (128) 
2.0

>  <HBD>  (128) 
1.0

>  <NRB>  (128) 
4.0

>  <TPSA>  (128) 
42.0

>  <LogP>  (128) 
4.9

>  <RoF>  (128) 
0.0

>  <Melting point>  (128) 


>  <Targets>  (128) 
nan

>  <Kinase families>  (128) 


>  <FDA_approved>  (128) 


$$$$
Varlitinib
     RDKit          2D

 32 36  0  0  0  0  0  0  0  0999 V2000
   -3.0266    4.4079    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2824    3.5876    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6842    4.1213    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6251    2.9531    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8047    1.6973    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3569    2.0894    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3385    0.2954    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3914   -0.8677    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9251   -2.2695    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9780   -3.4327    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4971   -3.1941    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9633   -1.7922    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9105   -0.6291    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4825   -1.5536    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5353   -2.7168    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0691   -4.1186    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5500   -4.3572    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9487   -0.1518    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.5322    0.0869    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4793   -1.0763    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9602   -0.8376    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4940    0.5642    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5469    1.7273    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0660    1.4887    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0807    3.1292    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    4.9749    0.8028    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.9220   -0.3603    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4029   -0.1217    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0803    1.2166    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.5624    0.9860    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8011   -0.4949    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4664   -1.1795    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  1
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  2  0
  5  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 14 18  1  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 23 25  1  0
 22 26  1  0
 26 27  1  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
  6  2  1  0
 13  8  1  0
 17 11  1  0
 24 19  1  0
 32 28  1  0
M  END
>  <BrandName>  (129) 


>  <Applicants>  (129) 
Array Biopharma

>  <CHEMBL_ID>  (129) 
CHEMBL2103842

>  <Canonical_Smiles>  (129) 
C[C@@H]1COC(=N1)Nc2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5nccs5

>  <Chirality>  (129) 
Single Stereoisomer

>  <First_Approval>  (129) 
nan

>  <Phase>  (129) 
2.5

>  <SC_Patent>  (129) 
None

>  <Synonyms>  (129) 
AR-00334543 | ARRY-334543 | ARRY-543 | ASLAN-001 | ASLAN001 | VARLITINIB

>  <Withdrawn>  (129) 


>  <Indications>  (129) 
Investigated for use/treatment in cancer/tumors (unspecified).

>  <Type>  (129) 
nan

>  <targets_id>  (129) 
P00533|P04626

>  <inchi>  (129) 
InChI=1S/C22H19ClN6O2S/c1-13-10-31-22(27-13)29-14-2-4-18-16(8-14)21(26-12-25-18)28-15-3-5-19(17(23)9-15)30-11-20-24-6-7-32-20/h2-9,12-13H,10-11H2,1H3,(H,27,29)(H,25,26,28)/t13-/m1/s1

>  <stdInchikey>  (129) 
UWXSAYUXVSFDBQ-CYBMUJFWSA-N

>  <csid>  (129) 
25027380

>  <Links>  (129) 
|http://www.chemspider.com/Chemical-Structure.25027380.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103842|http://pubchem.ncbi.nlm.nih.gov/compound/42642648|http://www.drugbank.ca/drugs/DB05944|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7645|http://zinc15.docking.org/substances/ZINC000013980035|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=846Y8197W1|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50205268

>  <LinkName>  (129) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (129) 


>  <pdbID>  (129) 


>  <indicationG2P>  (129) 
None

>  <indicationDB>  (129) 
Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and epidermal carcinoma tumors.

>  <uniprotId>  (129) 
P04626|P00533

>  <MW>  (129) 
466.1

>  <HBA>  (129) 
9.0

>  <HBD>  (129) 
2.0

>  <NRB>  (129) 
6.0

>  <TPSA>  (129) 
93.5

>  <LogP>  (129) 
5.2

>  <RoF>  (129) 
1.0

>  <Melting point>  (129) 


>  <Targets>  (129) 
EGFR; ERBB2

>  <Kinase families>  (129) 
Tyr

>  <FDA_approved>  (129) 


$$$$
Inavolisib
     RDKit          2D

 29 32  0  0  0  0  0  0  0  0999 V2000
    7.3451   -1.3420    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8706   -1.0662    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8946   -2.2051    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3929   -3.6199    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.4201   -1.9293    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.3723    0.3486    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.8979    0.6245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9218   -0.5145    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4474   -0.2387    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9491    1.1761    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9251    2.3151    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3996    2.0393    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6432    3.7884    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.3156    4.4866    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0580    3.8839    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4432    2.4342    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5500    1.2291    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4201    0.0073    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8510    0.4572    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8653    1.9571    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0561   -0.4361    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0418   -1.9360    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4639   -2.4131    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3571   -1.2080    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4870    0.0138    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9641    1.4359    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8199   -2.8060    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9624   -4.2993    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4555   -2.1829    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  1
  2  3  1  0
  3  4  2  0
  3  5  1  0
  2  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 11 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 19 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  2  0
 22 27  1  6
 27 28  1  0
 27 29  1  0
 12  7  1  0
 10 17  1  0
 20 16  1  0
 25 21  1  0
M  END
>  <BrandName>  (130) 


>  <Applicants>  (130) 
Genentech

>  <CHEMBL_ID>  (130) 
CHEMBL4297757

>  <Canonical_Smiles>  (130) 
C[C@@H](C(=N)O)Nc1ccc-2c(c1)OCCn3c2nc(c3)N4[C@@H](COC4=O)C(F)F

>  <Chirality>  (130) 
Unknown

>  <First_Approval>  (130) 
nan

>  <Phase>  (130) 
2.5

>  <SC_Patent>  (130) 
None

>  <Synonyms>  (130) 
INAVOLISIB|GDC-0077|GDC0077|RO7113755|RG6114|RO7113755, GDC-0077

>  <Withdrawn>  (130) 


>  <Indications>  (130) 
nan

>  <Type>  (130) 
nan

>  <targets_id>  (130) 
nan

>  <inchi>  (130) 
InChI=1S/C18H19F2N5O4/c1-9(16(21)26)22-10-2-3-11-13(6-10)28-5-4-24-7-14(23-17(11)24)25-12(15(19)20)8-29-18(25)27/h2-3,6-7,9,12,15,22H,4-5,8H2,1H3,(H2,21,26)/t9-,12-/m0/s1

>  <stdInchikey>  (130) 
SGEUNORSOZVTOL-CABZTGNLSA-N

>  <csid>  (130) 
59718498

>  <Links>  (130) 
|http://www.chemspider.com/Chemical-Structure.59718498.html|http://pubchem.ncbi.nlm.nih.gov/compound/124173720|http://www.drugbank.ca/drugs/DB15275|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9636|http://zinc15.docking.org/substances/ZINC000669678973|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=L4C1UY2NYH|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=295665

>  <LinkName>  (130) 
|ChemSpider|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (130) 


>  <pdbID>  (130) 


>  <indicationG2P>  (130) 
None

>  <indicationDB>  (130) 


>  <uniprotId>  (130) 


>  <MW>  (130) 
407.1

>  <HBA>  (130) 
7.0

>  <HBD>  (130) 
3.0

>  <NRB>  (130) 
5.0

>  <TPSA>  (130) 
112.7

>  <LogP>  (130) 
2.9

>  <RoF>  (130) 
0.0

>  <Melting point>  (130) 


>  <Targets>  (130) 
nan

>  <Kinase families>  (130) 


>  <FDA_approved>  (130) 


$$$$
Cerdulatinib
     RDKit          2D

 31 34  0  0  0  0  0  0  0  0999 V2000
  -10.0043   -2.0059    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.5143   -0.5882    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.0415   -0.3038    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -7.7571   -1.7766    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3259    1.1690    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5687   -0.0194    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0786    1.3983    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6058    1.6827    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6231    0.5494    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1132   -0.8682    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5860   -1.1527    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1503    0.8339    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1676   -0.2994    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3052   -0.0150    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7953    1.4027    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1874    2.5360    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6602    2.2515    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2681    1.6871    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.2508    0.5538    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7607   -0.8638    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.7434   -1.9971    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2162   -1.7127    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7063   -0.2950    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7236    0.8383    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.1790   -0.0106    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.6691    1.4071    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3847    2.8799    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8024    2.3898    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1989   -2.8459    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6717   -2.5615    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.7088   -4.2636    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  3  5  2  0
  3  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
  9 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 15 18  1  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 23 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
 22 29  1  0
 29 30  2  0
 29 31  1  0
 11  6  1  0
 17 12  1  0
 24 19  1  0
 28 26  1  0
M  END
>  <BrandName>  (131) 


>  <Applicants>  (131) 
Portola pharmaceuticals

>  <CHEMBL_ID>  (131) 
CHEMBL3545284

>  <Canonical_Smiles>  (131) 
CCS(=O)(=O)N1CCN(CC1)c2ccc(cc2)Nc3ncc(c(n3)NC4CC4)C(=O)N

>  <Chirality>  (131) 
Single Stereoisomer

>  <First_Approval>  (131) 
nan

>  <Phase>  (131) 
2.5

>  <SC_Patent>  (131) 
None

>  <Synonyms>  (131) 


>  <Withdrawn>  (131) 
Study NCT04021082 in nan was Withdrawn during Phase 2/Phase 3 because Sponsor decision to not initiate the trial

>  <Indications>  (131) 
nan

>  <Type>  (131) 
nan

>  <targets_id>  (131) 
P23458|P43405

>  <inchi>  (131) 
InChI=1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25)

>  <stdInchikey>  (131) 
BGLPECHZZQDNCD-UHFFFAOYSA-N

>  <csid>  (131) 
32822046

>  <Links>  (131) 
|http://www.chemspider.com/Chemical-Structure.32822046.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4116008|http://pubchem.ncbi.nlm.nih.gov/compound/44595079|http://www.drugbank.ca/drugs/DB15499|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8957|http://zinc15.docking.org/substances/ZINC000114483165|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=D1LXQ45S1O|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50468574

>  <LinkName>  (131) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (131) 


>  <pdbID>  (131) 


>  <indicationG2P>  (131) 
None

>  <indicationDB>  (131) 


>  <uniprotId>  (131) 


>  <MW>  (131) 
445.2

>  <HBA>  (131) 
8.0

>  <HBD>  (131) 
3.0

>  <NRB>  (131) 
8.0

>  <TPSA>  (131) 
133.6

>  <LogP>  (131) 
1.4

>  <RoF>  (131) 
0.0

>  <Melting point>  (131) 


>  <Targets>  (131) 
JAK1; SYK

>  <Kinase families>  (131) 
Tyr

>  <FDA_approved>  (131) 


$$$$
Savolitinib
     RDKit          2D

 26 30  0  0  0  0  0  0  0  0999 V2000
   -0.2359   -1.8827    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1426   -0.6877    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6308   -0.8755    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2123   -2.2582    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7005   -2.4459    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6072   -1.2510    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1020   -1.1252    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4443    0.3352    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1611    1.1120    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0257    0.1317    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5375    0.3195    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5611    0.6950    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.8993    1.0373    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0250    2.5320    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3824    3.1704    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.6140    2.3142    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4882    0.8194    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1309    0.1810    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.7198   -0.0368    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1364    0.4562    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0431   -0.7387    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.1869   -1.9703    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.7510   -1.5365    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6799   -3.3869    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3577    3.1135    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3380    1.9781    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  1
  2  3  1  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  1  0
  2 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 17 19  1  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  1  0
 22 24  1  0
 14 25  1  0
 25 26  2  0
 11  3  2  0
 10  6  1  0
 26 12  1  0
 18 13  2  0
 23 19  2  0
M  END
>  <BrandName>  (132) 


>  <Applicants>  (132) 
Astrazeneca

>  <CHEMBL_ID>  (132) 
CHEMBL3334567

>  <Canonical_Smiles>  (132) 
C[C@@H](c1ccc2nccn2c1)n3c4c(ncc(n4)c5cnn(c5)C)nn3

>  <Chirality>  (132) 
Single Stereoisomer

>  <First_Approval>  (132) 
nan

>  <Phase>  (132) 
3.0

>  <SC_Patent>  (132) 
None

>  <Synonyms>  (132) 
AZD-6094 | AZD6094 | HMPL-504 | SAVOLITINIB | VOLITINIB

>  <Withdrawn>  (132) 


>  <Indications>  (132) 
nan

>  <Type>  (132) 
nan

>  <targets_id>  (132) 
P08581

>  <inchi>  (132) 
InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1

>  <stdInchikey>  (132) 
XYDNMOZJKOGZLS-NSHDSACASA-N

>  <csid>  (132) 
34501055

>  <Links>  (132) 
|http://www.chemspider.com/Chemical-Structure.34501055.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3334567|http://pubchem.ncbi.nlm.nih.gov/compound/68289010|http://www.drugbank.ca/drugs/DB12048| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=V0L|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/V0L|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9918|http://zinc15.docking.org/substances/ZINC000149738712|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=2A2DA6857R|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50023342

>  <LinkName>  (132) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (132) 
'V0L'

>  <pdbID>  (132) 
5lbw 6sde

>  <indicationG2P>  (132) 
None

>  <indicationDB>  (132) 


>  <uniprotId>  (132) 


>  <MW>  (132) 
345.1

>  <HBA>  (132) 
9.0

>  <HBD>  (132) 
0.0

>  <NRB>  (132) 
3.0

>  <TPSA>  (132) 
91.6

>  <LogP>  (132) 
1.9

>  <RoF>  (132) 
0.0

>  <Melting point>  (132) 


>  <Targets>  (132) 
MET

>  <Kinase families>  (132) 
Tyr

>  <FDA_approved>  (132) 


$$$$
Enzastaurin
     RDKit          2D

 39 45  0  0  0  0  0  0  0  0999 V2000
    0.8574   -3.6589    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1018   -2.8214    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.1557   -1.3224    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5981   -0.9104    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4356   -2.1548    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5108   -3.3359    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0713   -4.7273    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5565   -4.9376    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4812   -3.7565    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9207   -2.3652    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1126    0.4986    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2751    1.7430    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1998    2.9241    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7878    4.3664    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.6088    2.4096    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.5549    0.9105    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7359   -0.0142    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.7760    1.7969    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8513    0.6159    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5577    1.1304    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5038    2.6294    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9385    3.0414    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3029    4.4964    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2250    5.5395    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2173    5.1276    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5817    3.6725    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8021    0.2929    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1496    0.9518    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3941    0.1143    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2910   -1.3821    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9435   -2.0411    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6990   -1.2036    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5354   -2.2196    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8829   -1.5607    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9860   -0.0642    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3335    0.5948    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.5779   -0.2427    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.4748   -1.7392    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.1273   -2.3982    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
  4 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 13 15  1  0
 15 16  1  0
 16 17  2  0
 12 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 20 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 30 33  1  0
 33 34  1  0
 34 35  2  0
 35 36  1  0
 36 37  2  0
 37 38  1  0
 38 39  2  0
  6  2  1  0
 10  5  1  0
 16 11  1  0
 22 18  1  0
 26 21  1  0
 32 27  1  0
 39 34  1  0
M  END
>  <BrandName>  (133) 


>  <Applicants>  (133) 
Eli Lilly

>  <CHEMBL_ID>  (133) 
CHEMBL300138

>  <Canonical_Smiles>  (133) 
Cn1cc(c2c1cccc2)C3=C(C(=O)NC3=O)c4cn(c5c4cccc5)C6CCN(CC6)Cc7ccccn7

>  <Chirality>  (133) 
Achiral Molecule

>  <First_Approval>  (133) 
nan

>  <Phase>  (133) 
3.0

>  <SC_Patent>  (133) 
None

>  <Synonyms>  (133) 
ENZASTAURIN | LY-317615 | LY317615

>  <Withdrawn>  (133) 


>  <Indications>  (133) 
nan

>  <Type>  (133) 
nan

>  <targets_id>  (133) 
nan

>  <inchi>  (133) 
InChI=1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)

>  <stdInchikey>  (133) 
AXRCEOKUDYDWLF-UHFFFAOYSA-N

>  <csid>  (133) 
153463

>  <Links>  (133) 
|http://www.chemspider.com/Chemical-Structure.153463.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL300138|http://pubchem.ncbi.nlm.nih.gov/compound/176167|http://www.drugbank.ca/drugs/DB06486|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5693|http://zinc15.docking.org/substances/ZINC000001494900|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=UC96G28EQF|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50128285

>  <LinkName>  (133) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (133) 


>  <pdbID>  (133) 


>  <indicationG2P>  (133) 
None

>  <indicationDB>  (133) 
Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.

>  <uniprotId>  (133) 
P05771|Q96GD4|O14965|Q96Q40|O14757|O96017|P31749|P27986

>  <MW>  (133) 
515.2

>  <HBA>  (133) 
6.0

>  <HBD>  (133) 
1.0

>  <NRB>  (133) 
5.0

>  <TPSA>  (133) 
72.2

>  <LogP>  (133) 
4.9

>  <RoF>  (133) 
1.0

>  <Melting point>  (133) 


>  <Targets>  (133) 
nan

>  <Kinase families>  (133) 


>  <FDA_approved>  (133) 


$$$$
Futibatinib
     RDKit          2D

 31 34  0  0  0  0  0  0  0  0999 V2000
   -6.1995    4.4880    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1069    3.2936    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5262    1.9105    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0381    1.7219    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4573    0.3389    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3647   -0.8555    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8528   -0.6669    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4335    0.7161    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.7602   -1.8614    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -9.2483   -1.6728    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9693    0.1503    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4812   -0.0383    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0069   -0.2269    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7290   -1.5417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2352   -2.9580    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2148   -4.0939    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6884   -3.8134    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1823   -2.3971    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.2026   -1.2612    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3912    0.2269    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0342    0.8661    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.7059    0.9490    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8945    2.4371    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3681    2.7176    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0902    1.4029    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.0629    0.3098    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5783    1.2143    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4857    2.4087    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.1590   -0.1688    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.6471   -0.3574    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2384   -3.2385    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  7  9  1  0
  9 10  1  0
  5 11  1  0
 11 12  3  0
 12 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  1  0
 20 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 25 27  1  0
 27 28  2  0
 27 29  1  0
 29 30  2  0
 15 31  1  0
  8  3  1  0
 21 13  2  0
 19 14  1  0
 26 22  1  0
M  END
>  <BrandName>  (134) 


>  <Applicants>  (134) 
Taiho Pharmaceutical

>  <CHEMBL_ID>  (134) 
CHEMBL3701238

>  <Canonical_Smiles>  (134) 
COc1cc(cc(c1)OC)C#Cc2c3c(ncnc3n(n2)C4CCN(C4)C(=O)C=C)N

>  <Chirality>  (134) 
Single Stereoisomer

>  <First_Approval>  (134) 
nan

>  <Phase>  (134) 
3.0

>  <SC_Patent>  (134) 
None

>  <Synonyms>  (134) 


>  <Withdrawn>  (134) 


>  <Indications>  (134) 
nan

>  <Type>  (134) 
nan

>  <targets_id>  (134) 
nan

>  <inchi>  (134) 
InChI=1S/C22H22N6O3/c1-4-19(29)27-8-7-15(12-27)28-22-20(21(23)24-13-25-22)18(26-28)6-5-14-9-16(30-2)11-17(10-14)31-3/h4,9-11,13,15H,1,7-8,12H2,2-3H3,(H2,23,24,25)

>  <stdInchikey>  (134) 
KEIPNCCJPRMIAX-UHFFFAOYSA-N

>  <csid>  (134) 
58877815

>  <Links>  (134) 
|http://www.chemspider.com/Chemical-Structure.58877815.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3701237|http://pubchem.ncbi.nlm.nih.gov/compound/78137072|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=161388

>  <LinkName>  (134) 
|ChemSpider|ChEMBL|PubChem|BindingDB

>  <lig_pdbID>  (134) 


>  <pdbID>  (134) 


>  <indicationG2P>  (134) 


>  <indicationDB>  (134) 


>  <uniprotId>  (134) 


>  <MW>  (134) 
418.2

>  <HBA>  (134) 
8.0

>  <HBD>  (134) 
1.0

>  <NRB>  (134) 
4.0

>  <TPSA>  (134) 
108.4

>  <LogP>  (134) 
1.8

>  <RoF>  (134) 
0.0

>  <Melting point>  (134) 


>  <Targets>  (134) 
nan

>  <Kinase families>  (134) 


>  <FDA_approved>  (134) 


$$$$
Losmapimod
     RDKit          2D

 28 30  0  0  0  0  0  0  0  0999 V2000
    1.3558   -3.7790    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1758   -2.5230    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4981   -1.1849    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3181    0.0711    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8159   -0.0110    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4936   -1.3492    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6736   -2.6052    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3513   -3.9434    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    4.6359    1.2450    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9582    2.5832    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.1336    1.1628    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.9537    2.4189    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0358    3.9166    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2918    3.0966    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0004   -1.1027    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6774    0.2355    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1751    0.3176    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9951   -0.9384    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3174   -2.2766    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8197   -2.3587    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4929   -0.8562    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3129   -2.1122    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1706    0.4819    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6684    0.5641    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3461    1.9023    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.6843    1.2245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0079    2.5800    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.0238    3.2404    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  5  9  1  0
  9 10  2  0
  9 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
  3 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 18 21  1  0
 21 22  2  0
 21 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 25 27  1  0
 25 28  1  0
  7  2  1  0
 14 12  1  0
 20 15  1  0
M  END
>  <BrandName>  (135) 


>  <Applicants>  (135) 
GlaxoSmithKline

>  <CHEMBL_ID>  (135) 
CHEMBL1088752

>  <Canonical_Smiles>  (135) 
Cc1c(cc(cc1F)C(=O)NC2CC2)c3ccc(cn3)C(=O)NCC(C)(C)C

>  <Chirality>  (135) 
Achiral Molecule

>  <First_Approval>  (135) 
nan

>  <Phase>  (135) 
3.0

>  <SC_Patent>  (135) 
None

>  <Synonyms>  (135) 
FTX-1821 | FTX1821 | GSK-AHAB | GSKAHAB | GW-856553 | GW-856553X | GW856553X | LOSMAPIMOD

>  <Withdrawn>  (135) 


>  <Indications>  (135) 
nan

>  <Type>  (135) 
nan

>  <targets_id>  (135) 
Q16539|Q15759|O15264|P53778

>  <inchi>  (135) 
InChI=1S/C22H26FN3O2/c1-13-17(9-15(10-18(13)23)21(28)26-16-6-7-16)19-8-5-14(11-24-19)20(27)25-12-22(2,3)4/h5,8-11,16H,6-7,12H2,1-4H3,(H,25,27)(H,26,28)

>  <stdInchikey>  (135) 
KKYABQBFGDZVNQ-UHFFFAOYSA-N

>  <csid>  (135) 
9727484

>  <Links>  (135) 
|http://www.chemspider.com/Chemical-Structure.9727484.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1088752|http://pubchem.ncbi.nlm.nih.gov/compound/11552706|http://www.drugbank.ca/drugs/DB12270|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7835|http://zinc15.docking.org/substances/ZINC000035793138|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=F2DQF16BXE|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50418610

>  <LinkName>  (135) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (135) 


>  <pdbID>  (135) 


>  <indicationG2P>  (135) 
None

>  <indicationDB>  (135) 


>  <uniprotId>  (135) 


>  <MW>  (135) 
383.2

>  <HBA>  (135) 
3.0

>  <HBD>  (135) 
2.0

>  <NRB>  (135) 
5.0

>  <TPSA>  (135) 
71.1

>  <LogP>  (135) 
3.9

>  <RoF>  (135) 
0.0

>  <Melting point>  (135) 


>  <Targets>  (135) 
MAPK14; MAPK11; MAPK13; MAPK12

>  <Kinase families>  (135) 
CMGC

>  <FDA_approved>  (135) 


$$$$
Pacritinib
     RDKit          2D

 35 39  0  0  0  0  0  0  0  0999 V2000
   -8.4443   -0.4155    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.0406    1.0291    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5876    1.4018    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5384    0.3298    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9422   -1.1149    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3951   -1.4875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8044   -2.5320    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8650   -4.0726    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8158   -5.1446    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3628   -4.7719    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9590   -3.3273    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4518   -3.1805    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5061   -2.9546    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.7318   -2.1075    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2385   -2.4347    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4764   -1.5876    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3617   -0.0920    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0091    0.5565    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6053   -0.8881    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8944    2.0521    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2751    3.4183    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.2259    4.4903    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1267    5.1388    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6195    5.2856    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0724    4.9129    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3103    4.0658    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1838    2.8464    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5996    0.7552    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.9521    0.1067    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1900    0.9538    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5426    0.3053    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.8623    1.0184    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.9483   -0.0163    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.2998   -1.3689    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8130   -1.1701    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  5  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 11 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 18 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 17 28  1  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 32 33  1  0
 33 34  1  0
 34 35  1  0
  6  1  1  0
 27  3  1  0
 12  7  1  0
 19 14  1  0
 35 31  1  0
M  END
>  <BrandName>  (136) 


>  <Applicants>  (136) 
Cell Therapeutics

>  <CHEMBL_ID>  (136) 
CHEMBL2035187

>  <Canonical_Smiles>  (136) 
c1cc2cc(c1)-c3ccnc(n3)Nc4ccc(c(c4)COC/C=C/COC2)OCCN5CCCC5

>  <Chirality>  (136) 
Achiral Molecule

>  <First_Approval>  (136) 
nan

>  <Phase>  (136) 
3.0

>  <SC_Patent>  (136) 
None

>  <Synonyms>  (136) 
ONX-0803 | PACRITINIB | SB-1518 | SB1518

>  <Withdrawn>  (136) 
|Study NCT02677948 in United States was Withdrawn during Phase 1/Phase 2 because FDA has placed all trials involving Pacritinib on Full Clinical Hold

>  <Indications>  (136) 
nan

>  <Type>  (136) 
nan

>  <targets_id>  (136) 
O60674

>  <inchi>  (136) 
InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+

>  <stdInchikey>  (136) 
HWXVIOGONBBTBY-ONEGZZNKSA-N

>  <csid>  (136) 
28518965

>  <Links>  (136) 
|http://www.chemspider.com/Chemical-Structure.28518965.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2035187|http://pubchem.ncbi.nlm.nih.gov/compound/46216796|http://www.drugbank.ca/drugs/DB11697| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=6T3|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6T3|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7793|http://zinc15.docking.org/substances/ZINC000043153645|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=G22N65IL3O|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50400312

>  <LinkName>  (136) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (136) 
'6T3'

>  <pdbID>  (136) 
5lbz

>  <indicationG2P>  (136) 
None

>  <indicationDB>  (136) 


>  <uniprotId>  (136) 


>  <MW>  (136) 
472.2

>  <HBA>  (136) 
7.0

>  <HBD>  (136) 
1.0

>  <NRB>  (136) 
4.0

>  <TPSA>  (136) 
68.7

>  <LogP>  (136) 
5.0

>  <RoF>  (136) 
0.0

>  <Melting point>  (136) 


>  <Targets>  (136) 
JAK2

>  <Kinase families>  (136) 
Tyr

>  <FDA_approved>  (136) 


$$$$
Pyrotinib
     RDKit          2D

 42 46  0  0  0  0  0  0  0  0999 V2000
   -0.0741   -6.2644    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1543   -5.2237    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7930   -3.7678    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8732   -2.7271    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3146   -3.1422    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3948   -2.1014    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0336   -0.6455    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5922   -0.2304    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5120   -1.2712    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0706   -0.8561    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0096   -1.8969    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6484   -3.3527    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.4511   -1.4818    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5312   -2.5226    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9727   -2.1075    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4841   -0.6974    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9832   -0.7480    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3983   -2.1894    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1557   -3.0296    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.1051   -4.5288    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1138    0.3952    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5552   -0.0199    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9164   -1.4757    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8363   -2.5165    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6354    1.0209    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7156    2.0617    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7525    1.8511    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3111    2.2662    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2309    1.2254    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7895    1.6405    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4283    3.0963    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5085    4.1371    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9499    3.7220    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1472    5.5930    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    1.0131    3.5114    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.0933    2.4707    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5348    2.8858    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6149    1.8450    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0564    2.2601    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4176    3.7159    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3374    4.7567    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8960    4.3416    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  1  0
 11 12  2  0
 11 13  1  0
 13 14  2  0
 15 14  1  1
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
  7 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 22 25  1  0
 25 26  3  0
 21 27  1  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 32 33  2  0
 32 34  1  0
 31 35  1  0
 35 36  1  0
 36 37  1  0
 37 38  2  0
 38 39  1  0
 39 40  2  0
 40 41  1  0
 41 42  2  0
  9  4  1  0
 24  6  1  0
 19 15  1  0
 33 28  1  0
 42 37  1  0
M  END
>  <BrandName>  (137) 


>  <Applicants>  (137) 
Hengrui Therapeutics

>  <CHEMBL_ID>  (137) 
CHEMBL3544956

>  <Canonical_Smiles>  (137) 
CCOc1cc2c(cc1NC(=O)/C=C/[C@H]3CCCN3C)c(c(cn2)C#N)Nc4ccc(c(c4)Cl)OCc5ccccn5

>  <Chirality>  (137) 
Single Stereoisomer

>  <First_Approval>  (137) 
nan

>  <Phase>  (137) 
3.0

>  <SC_Patent>  (137) 
None

>  <Synonyms>  (137) 


>  <Withdrawn>  (137) 


>  <Indications>  (137) 
nan

>  <Type>  (137) 
nan

>  <targets_id>  (137) 
P00533|P04626

>  <inchi>  (137) 
InChI=1S/C32H31ClN6O3/c1-3-41-30-17-27-25(16-28(30)38-31(40)12-10-24-8-6-14-39(24)2)32(21(18-34)19-36-27)37-22-9-11-29(26(33)15-22)42-20-23-7-4-5-13-35-23/h4-5,7,9-13,15-17,19,24H,3,6,8,14,20H2,1-2H3,(H,36,37)(H,38,40)/b12-10+/t24-/m1/s1

>  <stdInchikey>  (137) 
SADXACCFNXBCFY-IYNHSRRRSA-N

>  <csid>  (137) 
52083721

>  <Links>  (137) 
|http://www.chemspider.com/Chemical-Structure.52083721.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3647420|http://pubchem.ncbi.nlm.nih.gov/compound/51039030|http://www.drugbank.ca/drugs/DB14993|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9662|http://zinc15.docking.org/substances/ZINC000068250550|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=CJN36EQM0H|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=139991

>  <LinkName>  (137) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (137) 


>  <pdbID>  (137) 


>  <indicationG2P>  (137) 
None

>  <indicationDB>  (137) 


>  <uniprotId>  (137) 


>  <MW>  (137) 
582.2

>  <HBA>  (137) 
8.0

>  <HBD>  (137) 
2.0

>  <NRB>  (137) 
10.0

>  <TPSA>  (137) 
112.4

>  <LogP>  (137) 
6.5

>  <RoF>  (137) 
2.0

>  <Melting point>  (137) 


>  <Targets>  (137) 
EGFR; ERBB2

>  <Kinase families>  (137) 
Tyr

>  <FDA_approved>  (137) 


$$$$
Quizartinib
     RDKit          2D

 40 45  0  0  0  0  0  0  0  0999 V2000
  -12.9702    1.7775    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -13.0395    0.2791    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -13.1088   -1.2193    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -14.5379    0.3484    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.5411    0.2098    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.7164   -1.0432    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.2699   -0.6461    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.2006    0.8523    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  -10.6043    1.3813    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -8.0984   -1.5828    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7014   -1.0367    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4759    0.4463    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5299   -1.9735    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1329   -1.4273    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9614   -2.3641    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5643   -1.8180    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3388   -0.3350    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5103    0.6018    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9073    0.0556    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0583    0.2111    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3213   -0.5981    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4812    0.3531    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.9786    0.4408    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0458   -0.6134    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4922   -0.2162    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8715    1.2350    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8044    2.2891    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3579    1.8920    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0949    2.7012    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    1.9350    1.7501    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4376    1.6624    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.3180    1.6322    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.3852    0.5780    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.8316    0.9752    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.8988   -0.0789    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.5195   -1.5302    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.5867   -2.5843    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.0331   -2.1872    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   14.4124   -0.7359    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.3453    0.3182    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  2  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  7 10  1  0
 10 11  1  0
 11 12  2  0
 11 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 17 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  1  0
 30 31  2  0
 26 32  1  0
 32 33  1  0
 33 34  1  0
 34 35  1  0
 35 36  1  0
 36 37  1  0
 37 38  1  0
 38 39  1  0
 39 40  1  0
  9  5  1  0
 19 14  1  0
 31 20  1  0
 30 22  1  0
 28 23  1  0
 40 35  1  0
M  END
>  <BrandName>  (138) 


>  <Applicants>  (138) 
Ambit Biosciences

>  <CHEMBL_ID>  (138) 
CHEMBL576982

>  <Canonical_Smiles>  (138) 
CC(C)(C)c1cc(no1)NC(=O)Nc2ccc(cc2)c3cn4c5ccc(cc5sc4n3)OCCN6CCOCC6

>  <Chirality>  (138) 
Achiral Molecule

>  <First_Approval>  (138) 
nan

>  <Phase>  (138) 
3.0

>  <SC_Patent>  (138) 
None

>  <Synonyms>  (138) 
AC-010220 | AC-220 | AC010220 | AC220 | ASP-2689 | QUIZARTINIB

>  <Withdrawn>  (138) 


>  <Indications>  (138) 
nan

>  <Type>  (138) 
2

>  <targets_id>  (138) 
P36888|P07333|P10721

>  <inchi>  (138) 
InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)

>  <stdInchikey>  (138) 
CVWXJKQAOSCOAB-UHFFFAOYSA-N

>  <csid>  (138) 
24640357

>  <Links>  (138) 
|http://www.chemspider.com/Chemical-Structure.24640357.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL576982|http://pubchem.ncbi.nlm.nih.gov/compound/24889392|http://www.drugbank.ca/drugs/DB12874| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=P30|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/P30|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5658|http://zinc15.docking.org/substances/ZINC43204002|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=7LA4O6Q0D3|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50300690

>  <LinkName>  (138) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (138) 
'P30'

>  <pdbID>  (138) 
4rt7 4xuf

>  <indicationG2P>  (138) 
None

>  <indicationDB>  (138) 
Quizartinib is under investigation in Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies. It is a potent inhibitor of FLT3.

>  <uniprotId>  (138) 
P36888

>  <MW>  (138) 
560.2

>  <HBA>  (138) 
9.0

>  <HBD>  (138) 
2.0

>  <NRB>  (138) 
7.0

>  <TPSA>  (138) 
106.2

>  <LogP>  (138) 
5.9

>  <RoF>  (138) 
2.0

>  <Melting point>  (138) 


>  <Targets>  (138) 
FLT3; CSF1R; KIT

>  <Kinase families>  (138) 
Tyr

>  <FDA_approved>  (138) 


$$$$
Radotinib
     RDKit          2D

 39 43  0  0  0  0  0  0  0  0999 V2000
    5.6804   -4.6621    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3180   -4.0345    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0933   -4.9006    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7309   -4.2729    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5932   -2.7793    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8180   -1.9132    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1803   -2.5408    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4051   -1.6748    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.2674   -0.1811    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4921    0.6849    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.3545    2.1786    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9921    2.8062    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7674    1.9402    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9050    0.4465    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.4050    2.5678    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2673    4.0615    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9050    4.6891    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3198    3.8230    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1821    2.3294    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1803    1.7017    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.2308   -2.1516    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9939   -3.0177    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0932   -0.6580    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2692   -0.0303    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4069    1.4633    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7692    2.0909    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9940    1.2249    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8563   -0.2688    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4939   -0.8964    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0810   -1.1348    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1003   -2.6347    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5327   -3.0799    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3987   -1.8552    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5016   -0.6530    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0145   -4.5004    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9069    3.5846    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0445    5.0783    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4006    3.4470    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4132    3.7223    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 13 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
  5 21  1  0
 21 22  2  0
 21 23  1  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 28 30  1  0
 30 31  1  0
 31 32  2  0
 32 33  1  0
 33 34  2  0
 32 35  1  0
 26 36  1  0
 36 37  1  0
 36 38  1  0
 36 39  1  0
  7  2  1  0
 14  9  1  0
 20 15  1  0
 29 24  1  0
 34 30  1  0
M  END
>  <BrandName>  (139) 


>  <Applicants>  (139) 
Il-Yang Pharmaceutical

>  <CHEMBL_ID>  (139) 
CHEMBL4297524

>  <Canonical_Smiles>  (139) 
Cc1ccc(cc1Nc2nccc(n2)c3cnccn3)C(=O)Nc4cc(cc(c4)n5cc(nc5)C)C(F)(F)F

>  <Chirality>  (139) 
Achiral Molecule

>  <First_Approval>  (139) 
nan

>  <Phase>  (139) 
3.0

>  <SC_Patent>  (139) 
None

>  <Synonyms>  (139) 
IY5511 | RADOTINIB

>  <Withdrawn>  (139) 


>  <Indications>  (139) 
Radotinib is indicated for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib.

>  <Type>  (139) 
nan

>  <targets_id>  (139) 
P00519|P09619

>  <inchi>  (139) 
InChI=1S/C27H21F3N8O/c1-16-3-4-18(9-23(16)37-26-33-6-5-22(36-26)24-13-31-7-8-32-24)25(39)35-20-10-19(27(28,29)30)11-21(12-20)38-14-17(2)34-15-38/h3-15H,1-2H3,(H,35,39)(H,33,36,37)

>  <stdInchikey>  (139) 
DUPWHXBITIZIKZ-UHFFFAOYSA-N

>  <csid>  (139) 
17222861

>  <Links>  (139) 
|http://www.chemspider.com/Chemical-Structure.17222861.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297524|http://pubchem.ncbi.nlm.nih.gov/compound/16063245|http://www.drugbank.ca/drugs/DB12323|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7814|http://zinc15.docking.org/substances/ZINC000059749972|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=I284LJY110

>  <LinkName>  (139) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (139) 


>  <pdbID>  (139) 


>  <indicationG2P>  (139) 
None

>  <indicationDB>  (139) 
Radotinib is under investigation for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

>  <uniprotId>  (139) 
P00519

>  <MW>  (139) 
530.2

>  <HBA>  (139) 
8.0

>  <HBD>  (139) 
2.0

>  <NRB>  (139) 
6.0

>  <TPSA>  (139) 
110.5

>  <LogP>  (139) 
5.8

>  <RoF>  (139) 
2.0

>  <Melting point>  (139) 


>  <Targets>  (139) 
ABL1; PDGFRB

>  <Kinase families>  (139) 
Tyr

>  <FDA_approved>  (139) 


$$$$
Abivertinib
     RDKit          2D

 36 40  0  0  0  0  0  0  0  0999 V2000
    7.7865    2.2220    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2937    2.3694    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.4197    1.1504    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9270    1.2978    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3083    2.6643    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.1823    3.8833    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6750    3.7359    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8155    2.8117    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1968    4.1781    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2959    4.3255    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1700    3.1065    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5513    1.7400    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9415    1.5926    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5602    0.2262    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6627    3.2539    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5367    2.0349    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0295    2.1823    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9035    0.9632    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2848   -0.4032    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3932   -1.4139    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6969   -0.6721    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3943    0.7971    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7921   -0.5506    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9180    0.6684    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1733   -1.9171    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6806   -2.0645    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8066   -0.8455    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6862   -0.9929    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3049   -2.3593    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4308   -3.5784    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0619   -3.4310    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0495   -4.9448    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.5423   -5.0922    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4163   -3.8732    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.1610   -6.4587    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6537   -6.6061    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  5  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 11 15  1  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 19 23  1  0
 23 24  2  0
 23 25  1  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 30 32  1  0
 32 33  1  0
 33 34  2  0
 33 35  1  0
 35 36  2  0
  7  2  1  0
 13  8  1  0
 24 16  1  0
 22 18  1  0
 31 26  1  0
M  END
>  <BrandName>  (140) 


>  <Applicants>  (140) 
ACEA Biosciences

>  <CHEMBL_ID>  (140) 
CHEMBL4297865

>  <Canonical_Smiles>  (140) 
CN1CCN(CC1)c2ccc(cc2F)Nc3nc4c(cc[nH]4)c(n3)Oc5cccc(c5)NC(=O)C=C

>  <Chirality>  (140) 
Achiral Molecule

>  <First_Approval>  (140) 
nan

>  <Phase>  (140) 
3.0

>  <SC_Patent>  (140) 
None

>  <Synonyms>  (140) 
A610 | ABIVERTINIB | AC-0010 | AC0010 | ACEA100610 | AVITINIB | EX-ACEA0010

>  <Withdrawn>  (140) 


>  <Indications>  (140) 
AC0010 is an orally active, irreversible EGFR inhibitor that selectively targets mutated EGFRs, and was designed to overcome T790M-induced resistance in tumours [<a href='javascript:callRef("ReferenceDisplayForward?referenceId=35960&displayId=2", 960, 600)' title="2. Xu X, Mao L, Xu W, Tang W, Zhang X, Xi B, Xu R, Fang X, Liu J, Fang C et al.. (2016) Mol. Cancer Ther. 15 (11): 2586-2597">2</a>]. It may also inhibit BTK, thus offering extended clinical utility [<a href='javascript:callRef("ReferenceDisplayForward?referenceId=35961&displayId=3", 960, 600)' title="3. Yan X, Zhou Y, Huang S, Li X, Yu M, Huang J, Wang J, Ma Z, Jin J, Pan J et al.. (2018) J. Cancer Res. Clin. Oncol. 144 (4): 697-706">3</a>]. We show the structure for the free base form of the compound.

>  <Type>  (140) 
nan

>  <targets_id>  (140) 
nan

>  <inchi>  (140) 
InChI=1S/C26H26FN7O2/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32)

>  <stdInchikey>  (140) 
UOFYSRZSLXWIQB-UHFFFAOYSA-N

>  <csid>  (140) 
57490375

>  <Links>  (140) 
|http://www.chemspider.com/Chemical-Structure.57490375.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297865|http://pubchem.ncbi.nlm.nih.gov/compound/72734520|http://www.drugbank.ca/drugs/DB15327|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10044|http://zinc15.docking.org/substances/ZINC000142081723|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=CER0OPG92L|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=294480

>  <LinkName>  (140) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (140) 


>  <pdbID>  (140) 


>  <indicationG2P>  (140) 
None

>  <indicationDB>  (140) 
Abivertinib is a tyrosine kinase inhibitor targeted against mutant forms of both human epidermal growth factor receptor (EGFR) and Bruton&#39;s tyrosine kinase (BTK).<sup class="text-reference-group"><a class="reference-popover-link" data-content="Sorrento Therapeutics: Abivertinib" href="#reference-L17383">1</a></sup> It has been investigated for use in the treatment of non-small cell lung cancer (NSCLC) and B-cell malignancies. In binding to and inhibiting EGFR and BTK receptors, abivertinib exerts immunomodulatory effects by preventing the production and release of pro-inflammatory cytokines (e.g. TNF-alpha, interleukins).<sup class="text-reference-group"><a class="reference-popover-link" data-content="Sorrento Therapeutics: Abivertinib COVID-19 Trial" href="#reference-L17388">2</a></sup></p><p>Abivertinib&#39;s potential to depress cytokine production has led to its investigation in the treatment of hospitalized patients with moderate-to-severe COVID-19.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Sorrento Therapeutics: Abivertinib COVID-19 Trial" href="#reference-L17388">2</a>,<a class="reference-popover-link" data-content="NCT04440007: Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With SOC Versus SOC in Subjects With COVID-19 (SOC)" href="#reference-L17393">3</a></sup> The cytokine storm associated with COVID-19 is thought to contribute to disease progression and is associated with poor outcomes in patients - as abivertinib inhibits the release of multiple cytokines at once, it may provide more pronounced clinical benefits as compared to agents targeting single pathways (e.g. interleukin-6 inhibitors). The study is expected to be completed in March 2021.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Targeted Oncology: FDA Clears Phase 2 Study of Abivertinib in Hospitalized Patients With COVID-19" href="#reference-L17398">4</a></sup>

>  <uniprotId>  (140) 
P00533|Q06187

>  <MW>  (140) 
487.2

>  <HBA>  (140) 
7.0

>  <HBD>  (140) 
3.0

>  <NRB>  (140) 
7.0

>  <TPSA>  (140) 
98.4

>  <LogP>  (140) 
4.5

>  <RoF>  (140) 
0.0

>  <Melting point>  (140) 


>  <Targets>  (140) 
nan

>  <Kinase families>  (140) 


>  <FDA_approved>  (140) 


$$$$
Surufatinib
     RDKit          2D

 34 37  0  0  0  0  0  0  0  0999 V2000
   -9.8837   -3.9420    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.1556   -2.6306    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6667   -2.4487    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3795   -0.9765    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0933   -0.2048    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1184    1.2950    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4299    2.0231    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7162    1.2514    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.6910   -0.2484    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.7887   -1.2707    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8322    2.0667    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5207    1.3386    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4955   -0.1611    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1841   -0.8892    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8978   -0.1175    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9230    1.3823    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2345    2.1104    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.3632    2.1540    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.6747    1.4259    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6999   -0.0739    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0113   -0.8020    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2976   -0.0302    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2724    1.4695    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9609    2.1976    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5587    2.2413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8701    1.5132    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    7.5982    2.8246    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.1420    0.2017    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.1816    0.7851    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.2067   -0.7147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.5182   -1.4428    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.5434   -2.9425    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.8548   -3.6706    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2571   -3.7143    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
  6 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 16 18  1  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 23 25  1  0
 25 26  1  0
 26 27  2  0
 26 28  2  0
 26 29  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 32 33  1  0
 32 34  1  0
 10  2  1  0
  9  4  1  0
 17 12  1  0
 24 19  1  0
M  END
>  <BrandName>  (141) 


>  <Applicants>  (141) 
Hutchison MediPharma

>  <CHEMBL_ID>  (141) 
CHEMBL4297190

>  <Canonical_Smiles>  (141) 
Cc1cc2cc(ccc2[nH]1)Oc3ccnc(n3)Nc4cccc(c4)CS(=O)(=O)NCCN(C)C

>  <Chirality>  (141) 
Achiral Molecule

>  <First_Approval>  (141) 
nan

>  <Phase>  (141) 
3.0

>  <SC_Patent>  (141) 
None

>  <Synonyms>  (141) 
HMPL-012 | SULFATINIB | SURUFATINIB

>  <Withdrawn>  (141) 


>  <Indications>  (141) 
nan

>  <Type>  (141) 
nan

>  <targets_id>  (141) 
nan

>  <inchi>  (141) 
InChI=1S/C24H28N6O3S/c1-17-13-19-15-21(7-8-22(19)27-17)33-23-9-10-25-24(29-23)28-20-6-4-5-18(14-20)16-34(31,32)26-11-12-30(2)3/h4-10,13-15,26-27H,11-12,16H2,1-3H3,(H,25,28,29)

>  <stdInchikey>  (141) 
TTZSNFLLYPYKIL-UHFFFAOYSA-N

>  <csid>  (141) 
57583328

>  <Links>  (141) 
|http://www.chemspider.com/Chemical-Structure.57583328.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297190|http://pubchem.ncbi.nlm.nih.gov/compound/52920501|http://www.drugbank.ca/drugs/DB15106|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9769|http://zinc15.docking.org/substances/ZINC000117218067|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=B2K5L1L8S9

>  <LinkName>  (141) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (141) 


>  <pdbID>  (141) 


>  <indicationG2P>  (141) 
None

>  <indicationDB>  (141) 


>  <uniprotId>  (141) 


>  <MW>  (141) 
480.2

>  <HBA>  (141) 
7.0

>  <HBD>  (141) 
3.0

>  <NRB>  (141) 
10.0

>  <TPSA>  (141) 
112.2

>  <LogP>  (141) 
3.8

>  <RoF>  (141) 
0.0

>  <Melting point>  (141) 


>  <Targets>  (141) 
nan

>  <Kinase families>  (141) 


>  <FDA_approved>  (141) 


$$$$
Asciminib
     RDKit          2D

 31 34  0  0  0  0  0  0  0  0999 V2000
   -3.7501   -1.0934    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1923   -1.5057    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2705   -0.4629    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9064    0.9923    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4642    1.4046    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3860    0.3617    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9438    0.7740    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8656   -0.2688    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2297   -1.7240    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.5766    0.1434    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6548   -0.8994    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0970   -0.4871    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4610    0.9680    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3829    2.0109    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.9407    1.5986    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9033    1.3803    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.4174    2.7895    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9165    2.7359    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3288    1.2937    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0845    0.4559    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7379    0.7795    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.1752   -1.5300    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6526   -1.2707    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3557   -2.5957    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3129   -3.6738    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.9652   -3.0152    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.7127   -0.8752    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7909    0.1677    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.8690    1.2106    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -9.8337   -0.9105    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -7.7480    1.2459    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  8 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 13 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 19 21  1  1
 12 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
  3 27  1  0
 27 28  1  0
 28 29  1  0
 28 30  1  0
 28 31  1  0
  6  1  1  0
 15 10  1  0
 20 16  1  0
 26 22  1  0
M  END
>  <BrandName>  (142) 


>  <Applicants>  (142) 
Novartis

>  <CHEMBL_ID>  (142) 
CHEMBL4208229

>  <Canonical_Smiles>  (142) 
c1cc(ccc1NC(=O)c2cc(c(nc2)N3CC[C@H](C3)O)c4ccn[nH]4)OC(F)(F)Cl

>  <Chirality>  (142) 
Single Stereoisomer

>  <First_Approval>  (142) 
nan

>  <Phase>  (142) 
3.0

>  <SC_Patent>  (142) 
None

>  <Synonyms>  (142) 
ABL-001 | ABL001 | ABL001-NX | ASCIMINIB | NVP-ABL001

>  <Withdrawn>  (142) 


>  <Indications>  (142) 
nan

>  <Type>  (142) 
nan

>  <targets_id>  (142) 
nan

>  <inchi>  (142) 
InChI=1S/C20H18ClF2N5O3/c21-20(22,23)31-15-3-1-13(2-4-15)26-19(30)12-9-16(17-5-7-25-27-17)18(24-10-12)28-8-6-14(29)11-28/h1-5,7,9-10,14,29H,6,8,11H2,(H,25,27)(H,26,30)/t14-/m1/s1

>  <stdInchikey>  (142) 
VOVZXURTCKPRDQ-CQSZACIVSA-N

>  <csid>  (142) 
52085218

>  <Links>  (142) 
|http://www.chemspider.com/Chemical-Structure.52085218.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4208229|http://pubchem.ncbi.nlm.nih.gov/compound/72165228|http://www.drugbank.ca/drugs/DB12597| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=AY7|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/AY7|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8962|http://zinc15.docking.org/substances/ZINC000150275965|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=L1F3R18W77

>  <LinkName>  (142) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (142) 
'AY7'

>  <pdbID>  (142) 
5mo4

>  <indicationG2P>  (142) 
None

>  <indicationDB>  (142) 


>  <uniprotId>  (142) 


>  <MW>  (142) 
449.1

>  <HBA>  (142) 
6.0

>  <HBD>  (142) 
3.0

>  <NRB>  (142) 
6.0

>  <TPSA>  (142) 
103.4

>  <LogP>  (142) 
3.5

>  <RoF>  (142) 
0.0

>  <Melting point>  (142) 


>  <Targets>  (142) 
nan

>  <Kinase families>  (142) 


>  <FDA_approved>  (142) 


$$$$
Tesevatinib
     RDKit          2D

 33 37  0  0  0  0  0  0  0  0999 V2000
   11.2883    0.1438    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7974   -0.0217    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.7873    1.0872    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4205    0.4691    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9515    0.7725    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2090   -0.5309    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2192   -1.6398    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5860   -1.0217    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0550   -1.3251    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7182   -0.6963    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8295    0.5120    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.3386    0.3466    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7365   -1.0272    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7543   -1.1927    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6430    0.0157    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0409    1.3895    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4499    1.5550    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0521    2.9288    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.5429    3.0943    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1339   -0.1498    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7360   -1.5236    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8473   -2.7320    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3565   -2.5665    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0226    1.0586    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5135    0.8932    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4022    2.1016    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.8930    1.9361    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4951    0.5623    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6064   -0.6461    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1156   -0.4807    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2269   -1.6890    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -8.2086   -2.0199    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -9.9860    0.3968    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  4  3  1  6
  4  5  1  0
  5  6  1  0
  6  7  1  0
  8  7  1  6
  8  9  1  0
  6 10  1  6
 10 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  1  0
 15 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 20 24  1  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 29 32  1  0
 28 33  1  0
  9  2  1  0
  8  4  1  0
 17 12  1  0
 23 14  1  0
 30 25  1  0
M  END
>  <BrandName>  (143) 


>  <Applicants>  (143) 
Kadmon Corporation

>  <CHEMBL_ID>  (143) 
CHEMBL3544983

>  <Canonical_Smiles>  (143) 
CN1C[C@H]2C[C@H](C[C@H]2C1)COc3cc4c(cc3OC)c(ncn4)Nc5ccc(c(c5F)Cl)Cl

>  <Chirality>  (143) 
Racemic Mixture

>  <First_Approval>  (143) 
nan

>  <Phase>  (143) 
3.0

>  <SC_Patent>  (143) 
None

>  <Synonyms>  (143) 
EXEL-7647 | KD-019 | KD-020 | KD019 | TESEVATINIB | XL-647 | XL647

>  <Withdrawn>  (143) 


>  <Indications>  (143) 
nan

>  <Type>  (143) 
nan

>  <targets_id>  (143) 
P00533|P04626|P35968|P35916|P54760

>  <inchi>  (143) 
InChI=1S/C24H25Cl2FN4O2/c1-31-9-14-5-13(6-15(14)10-31)11-33-21-8-19-16(7-20(21)32-2)24(29-12-28-19)30-18-4-3-17(25)22(26)23(18)27/h3-4,7-8,12-15H,5-6,9-11H2,1-2H3,(H,28,29,30)/t13-,14-,15+

>  <stdInchikey>  (143) 
HVXKQKFEHMGHSL-QKDCVEJESA-N

>  <csid>  (143) 
32699556

>  <Links>  (143) 
|http://www.chemspider.com/Chemical-Structure.32699556.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3544983|http://www.drugbank.ca/drugs/DB11973|http://zinc15.docking.org/substances/ZINC000114456300|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=F6XM2TN5A1

>  <LinkName>  (143) 
|ChemSpider|ChEMBL|DrugBank|ZINC|FDA SRS

>  <lig_pdbID>  (143) 


>  <pdbID>  (143) 


>  <indicationG2P>  (143) 


>  <indicationDB>  (143) 
Tesevatinib has been used in trials studying the treatment of Cancer, Stomach Cancer, Brain Metastases, Esophageal Cancer, and Leptomeningeal Metastases, among others.</p><p>Tesevatinib is a potent inhibitor of multiple RTKs implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation). Tesevatinib inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer therapies. In addition, tesevatinib inhibits EphB4, an RTK that is highly expressed in many human tumors and plays a role in promoting angiogenesis. In a broad array of preclinical tumor models including breast, lung, colon and prostate cancer, XL647 demonstrated potent inhibition of tumor growth and causes tumor regression. In cell culture models, tesevatinib retains significant potency against mutant EGFRs that are resistant to current EGFR inhibitors.

>  <uniprotId>  (143) 
P01133|P54760|P04626

>  <MW>  (143) 
490.1

>  <HBA>  (143) 
6.0

>  <HBD>  (143) 
1.0

>  <NRB>  (143) 
6.0

>  <TPSA>  (143) 
59.5

>  <LogP>  (143) 
5.8

>  <RoF>  (143) 
1.0

>  <Melting point>  (143) 


>  <Targets>  (143) 
EGFR; ERBB2; KDR; FLT4; EPHB4

>  <Kinase families>  (143) 
Tyr

>  <FDA_approved>  (143) 


$$$$
Canertinib
     RDKit          2D

 34 37  0  0  0  0  0  0  0  0999 V2000
    0.8839    6.2025    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1652    5.1304    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2388    3.6858    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6918    3.3134    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8102    2.6137    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4063    1.1691    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0468    0.7966    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4507   -0.6479    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4017   -1.7201    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0514   -1.3476    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4553    0.0969    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9084    0.4694    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9574   -0.6028    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4104   -0.2303    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4595   -1.3025    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9125   -0.9300    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3165    0.5146    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.7695    0.8870    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.8186   -0.1851    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  -10.4146   -1.6297    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.9616   -2.0022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8056   -3.1647    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.2587   -3.5371    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3077   -2.4650    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.9038   -1.0204    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9528    0.0518    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.4058   -0.3207    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8098   -1.7653    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2628   -2.1377    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3119   -1.0656    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9079    0.3790    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4549    0.7515    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.9570    1.4511    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    9.7649   -1.4380    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  3  5  1  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  1  0
  9 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  2  0
 31 33  1  0
 30 34  1  0
 11  6  1  0
 25  8  1  0
 21 16  1  0
 32 27  1  0
M  END
>  <BrandName>  (144) 


>  <Applicants>  (144) 
Pfizer

>  <CHEMBL_ID>  (144) 
CHEMBL31965

>  <Canonical_Smiles>  (144) 
C=CC(=O)Nc1cc2c(cc1OCCCN3CCOCC3)ncnc2Nc4ccc(c(c4)Cl)F

>  <Chirality>  (144) 
Achiral Molecule

>  <First_Approval>  (144) 
nan

>  <Phase>  (144) 
3.0

>  <SC_Patent>  (144) 
None

>  <Synonyms>  (144) 
CANERTINIB | CI-1033

>  <Withdrawn>  (144) 


>  <Indications>  (144) 
Investigated for use/treatment in breast cancer and lung cancer.

>  <Type>  (144) 
nan

>  <targets_id>  (144) 
P00533

>  <inchi>  (144) 
InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)

>  <stdInchikey>  (144) 
OMZCMEYTWSXEPZ-UHFFFAOYSA-N

>  <csid>  (144) 
137741

>  <Links>  (144) 
|http://www.chemspider.com/Chemical-Structure.137741.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL31965|http://pubchem.ncbi.nlm.nih.gov/compound/156414|http://www.drugbank.ca/drugs/DB05424|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5675|http://zinc15.docking.org/substances/ZINC27439698|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=C78W1K5ASF|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=4779

>  <LinkName>  (144) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (144) 


>  <pdbID>  (144) 


>  <indicationG2P>  (144) 
None

>  <indicationDB>  (144) 
Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.

>  <uniprotId>  (144) 
P00533

>  <MW>  (144) 
485.2

>  <HBA>  (144) 
7.0

>  <HBD>  (144) 
2.0

>  <NRB>  (144) 
9.0

>  <TPSA>  (144) 
88.6

>  <LogP>  (144) 
4.4

>  <RoF>  (144) 
0.0

>  <Melting point>  (144) 


>  <Targets>  (144) 
EGFR

>  <Kinase families>  (144) 
Tyr

>  <FDA_approved>  (144) 


$$$$
Taselisib
     RDKit          2D

 34 38  0  0  0  0  0  0  0  0999 V2000
   -6.6288   -4.9243    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3787   -3.4453    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0352   -2.7782    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2544   -1.2943    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7334   -1.0443    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4283   -2.3736    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4005    0.2993    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.8975    0.3934    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5705    1.5487    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1828   -0.2448    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4020    1.2391    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0585    1.9062    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0089    0.8345    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7038   -0.4948    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5167    0.9870    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1704   -0.3464    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6687   -0.4181    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4799    0.8436    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7928    2.1770    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2946    2.2487    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1861    3.6696    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5967    4.1797    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8750    3.3949    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9782    0.7719    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9169    1.9419    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3197    1.4107    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.2480   -0.0876    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.8009   -0.4824    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4180   -1.0262    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4793   -2.1962    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3566    0.1438    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5880   -1.9649    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3601   -3.4475    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.9859   -1.4210    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  1  0
  5  7  1  0
  7  8  1  0
  7  9  1  0
  4 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  1  0
 13 14  2  0
 13 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 18 24  1  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  1  0
 27 29  1  0
 29 30  1  0
 29 31  1  0
 29 32  1  0
 32 33  2  0
 32 34  1  0
  6  2  2  0
 14 10  1  0
 23 12  1  0
 20 15  1  0
 28 24  2  0
M  END
>  <BrandName>  (145) 


>  <Applicants>  (145) 
Hoffmann-La Roche

>  <CHEMBL_ID>  (145) 
CHEMBL2387080

>  <Canonical_Smiles>  (145) 
Cc1nc(n(n1)C(C)C)c2cn3c(n2)-c4ccc(cc4OCC3)c5cnn(c5)C(C)(C)C(=O)N

>  <Chirality>  (145) 
Racemic Mixture

>  <First_Approval>  (145) 
nan

>  <Phase>  (145) 
3.0

>  <SC_Patent>  (145) 
None

>  <Synonyms>  (145) 
GDC-0032 | RG-7604 | TASELISIB

>  <Withdrawn>  (145) 


>  <Indications>  (145) 
nan

>  <Type>  (145) 
1

>  <targets_id>  (145) 
P42336|O00329|P48736

>  <inchi>  (145) 
InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33)

>  <stdInchikey>  (145) 
BEUQXVWXFDOSAQ-UHFFFAOYSA-N

>  <csid>  (145) 
29315044

>  <Links>  (145) 
|http://www.chemspider.com/Chemical-Structure.29315044.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2387080|http://pubchem.ncbi.nlm.nih.gov/compound/51001932|http://www.drugbank.ca/drugs/DB12108| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=799|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/799|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7794|http://zinc15.docking.org/substances/ZINC000068267049|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=L08J2O299M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50434806

>  <LinkName>  (145) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (145) 
'799'

>  <pdbID>  (145) 
5t8f

>  <indicationG2P>  (145) 
None

>  <indicationDB>  (145) 


>  <uniprotId>  (145) 


>  <MW>  (145) 
460.2

>  <HBA>  (145) 
9.0

>  <HBD>  (145) 
1.0

>  <NRB>  (145) 
5.0

>  <TPSA>  (145) 
118.7

>  <LogP>  (145) 
3.2

>  <RoF>  (145) 
0.0

>  <Melting point>  (145) 


>  <Targets>  (145) 
PIK3CA; PIK3CD; PIK3CG

>  <Kinase families>  (145) 
Atypical

>  <FDA_approved>  (145) 


$$$$
Saracatinib
     RDKit          2D

 38 43  0  0  0  0  0  0  0  0999 V2000
   11.0025   -2.1096    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7418   -1.2969    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.4076   -1.9824    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1468   -1.1697    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2203    0.3285    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.5545    1.0140    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8152    0.2013    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9595    1.1413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6253    0.4558    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3646    1.2685    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.0304    0.5830    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9569   -0.9152    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6227   -1.6007    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6381   -0.7880    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5646    0.7102    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7696    1.3957    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8254    1.5229    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7519    3.0211    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4177    3.7066    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3442    5.2048    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6050    6.0175    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9392    5.3320    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0127    3.8338    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9723   -1.4735    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0457   -2.9717    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7850   -3.7844    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5493   -3.0989    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2330   -0.6608    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5672   -1.3463    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6407   -2.8445    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9749   -3.5299    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2356   -2.7172    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1622   -1.2190    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8280   -0.5335    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0676    0.9472    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5499    1.1768    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.2264   -0.1620    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3799   -3.6572    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  5  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 15 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 14 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 24 28  1  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  2  0
 32 33  1  0
 33 34  2  0
 34 35  1  0
 35 36  1  0
 36 37  1  0
 30 38  1  0
  7  2  1  0
 16 11  1  0
 27 13  1  0
 23 18  1  0
 34 29  1  0
 37 33  1  0
M  END
>  <BrandName>  (146) 


>  <Applicants>  (146) 
Astrazeneca

>  <CHEMBL_ID>  (146) 
CHEMBL217092

>  <Canonical_Smiles>  (146) 
CN1CCN(CC1)CCOc2cc3c(c(c2)OC4CCOCC4)c(ncn3)Nc5c(ccc6c5OCO6)Cl

>  <Chirality>  (146) 
Achiral Molecule

>  <First_Approval>  (146) 
nan

>  <Phase>  (146) 
3.0

>  <SC_Patent>  (146) 
None

>  <Synonyms>  (146) 
AZ-10353926 | AZD-0530 | AZD0530 | SARACATINIB

>  <Withdrawn>  (146) 


>  <Indications>  (146) 
nan

>  <Type>  (146) 
1

>  <targets_id>  (146) 
P12931|P00519

>  <inchi>  (146) 
InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)

>  <stdInchikey>  (146) 
OUKYUETWWIPKQR-UHFFFAOYSA-N

>  <csid>  (146) 
8477917

>  <Links>  (146) 
|http://www.chemspider.com/Chemical-Structure.8477917.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL217092|http://pubchem.ncbi.nlm.nih.gov/compound/10302451|http://www.drugbank.ca/drugs/DB11805| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=H8H|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/H8H|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7731|http://zinc15.docking.org/substances/ZINC24811973|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=9KD24QGH76|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=12255

>  <LinkName>  (146) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (146) 
'H8H'

>  <pdbID>  (146) 
2h8h 4qmx 5vcx 5vd3 6zgc

>  <indicationG2P>  (146) 
None

>  <indicationDB>  (146) 


>  <uniprotId>  (146) 


>  <MW>  (146) 
541.2

>  <HBA>  (146) 
10.0

>  <HBD>  (146) 
1.0

>  <NRB>  (146) 
8.0

>  <TPSA>  (146) 
90.4

>  <LogP>  (146) 
3.9

>  <RoF>  (146) 
1.0

>  <Melting point>  (146) 


>  <Targets>  (146) 
SRC; ABL1

>  <Kinase families>  (146) 
Tyr

>  <FDA_approved>  (146) 


$$$$
Masitinib
     RDKit          2D

 36 40  0  0  0  0  0  0  0  0999 V2000
   -7.7817    1.8752    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3006    2.1122    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7653    3.5134    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2841    3.7505    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3383    2.5863    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8736    1.1850    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3547    0.9480    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8900   -0.4532    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9442   -1.6174    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4464   -1.5365    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9066   -2.9360    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0708   -3.8819    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3301   -3.0669    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4571   -3.3220    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0665   -4.7702    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3830   -5.1561    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4419   -4.0938    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0514   -2.6455    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3981   -2.2596    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8571    2.8233    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9113    1.6591    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4466    0.2578    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.5699    1.8961    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5157    0.7319    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9969    0.9689    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5322    2.3701    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5864    3.5343    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1052    3.2973    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0134    2.6071    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9592    1.4429    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.4239    0.0417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3697   -1.1225    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8509   -0.8855    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.3862    0.5157    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4404    1.6800    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7967   -2.0497    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 11 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
  5 20  1  0
 20 21  1  0
 21 22  2  0
 21 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 26 29  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 32 33  1  0
 33 34  1  0
 34 35  1  0
 33 36  1  0
  7  2  1  0
 13  9  1  0
 19 14  1  0
 28 23  1  0
 35 30  1  0
M  END
>  <BrandName>  (147) 
Kinavet;Masivet

>  <Applicants>  (147) 
AB Science

>  <CHEMBL_ID>  (147) 
CHEMBL1908391

>  <Canonical_Smiles>  (147) 
Cc1ccc(cc1Nc2nc(cs2)c3cccnc3)NC(=O)c4ccc(cc4)CN5CCN(CC5)C

>  <Chirality>  (147) 
Achiral Molecule

>  <First_Approval>  (147) 
nan

>  <Phase>  (147) 
3.0

>  <SC_Patent>  (147) 
None

>  <Synonyms>  (147) 
AB-1010 | KINAVET | MASITINIB | MASIVET

>  <Withdrawn>  (147) 


>  <Indications>  (147) 
nan

>  <Type>  (147) 
nan

>  <targets_id>  (147) 
P10721|P16234|P09619|P11362|P21802|P22607

>  <inchi>  (147) 
InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32)

>  <stdInchikey>  (147) 
WJEOLQLKVOPQFV-UHFFFAOYSA-N

>  <csid>  (147) 
8250179

>  <Links>  (147) 
|http://www.chemspider.com/Chemical-Structure.8250179.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1908391|http://pubchem.ncbi.nlm.nih.gov/compound/10074640|http://www.drugbank.ca/drugs/DB11526| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=G65|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/G65|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5656|http://zinc15.docking.org/substances/ZINC34177219|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=M59NC4E26P|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50355495

>  <LinkName>  (147) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (147) 
'G65'

>  <pdbID>  (147) 
5mql 7ju7

>  <indicationG2P>  (147) 
None

>  <indicationDB>  (147) 


>  <uniprotId>  (147) 


>  <MW>  (147) 
498.2

>  <HBA>  (147) 
7.0

>  <HBD>  (147) 
2.0

>  <NRB>  (147) 
7.0

>  <TPSA>  (147) 
73.4

>  <LogP>  (147) 
5.3

>  <RoF>  (147) 
1.0

>  <Melting point>  (147) 


>  <Targets>  (147) 
KIT; PDGFRA; PDGFRB; FGFR1; FGFR2; FGFR3

>  <Kinase families>  (147) 
Tyr

>  <FDA_approved>  (147) 


$$$$
Peficitinib
     RDKit          2D

 24 28  0  0  0  0  0  0  0  0999 V2000
   -0.8062   -2.1234    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4706   -3.4682    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9549   -3.2519    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2079   -1.7734    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8799   -1.0759    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8199    0.4229    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0880    1.2242    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4159    0.5267    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4759   -0.9721    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0280    2.7230    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7000    3.4205    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2960    3.5243    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4920    1.1203    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.7761    0.3190    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1040    1.0164    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0441   -0.4824    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3121   -1.2837    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9841   -1.9812    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7161   -1.1798    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8987   -0.3555    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7000    0.9126    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6401   -0.5862    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4320    1.7139    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0280    1.6100    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  7 10  1  0
 10 11  2  0
 10 12  1  0
  6 13  1  0
 14 13  1  6
 14 15  1  0
 15 16  1  6
 17 16  1  6
 17 18  1  0
 19 18  1  6
 19 20  1  0
 20 21  1  0
 21 22  1  0
 21 23  1  0
 21 24  1  1
  5  1  1  0
  9  4  1  0
 19 14  1  0
 23 15  1  0
 22 17  1  0
M  END
>  <BrandName>  (148) 


>  <Applicants>  (148) 
Astellas Pharma

>  <CHEMBL_ID>  (148) 
CHEMBL3137308

>  <Canonical_Smiles>  (148) 
c1c[nH]c2c1c(c(cn2)C(=O)N)N[C@@H]3[C@@H]4C[C@@H]5C[C@H]3C[C@@](C5)(C4)O

>  <Chirality>  (148) 
Racemic Mixture

>  <First_Approval>  (148) 
nan

>  <Phase>  (148) 
3.0

>  <SC_Patent>  (148) 
None

>  <Synonyms>  (148) 


>  <Withdrawn>  (148) 


>  <Indications>  (148) 
nan

>  <Type>  (148) 
nan

>  <targets_id>  (148) 
P23458|O60674|P52333|P29597

>  <inchi>  (148) 
InChI=1S/C18H22N4O2/c19-16(23)13-8-21-17-12(1-2-20-17)15(13)22-14-10-3-9-4-11(14)7-18(24,5-9)6-10/h1-2,8-11,14,24H,3-7H2,(H2,19,23)(H2,20,21,22)/t9-,10-,11+,14-,18-

>  <stdInchikey>  (148) 
DREIJXJRTLTGJC-ZKVNVPQCSA-N

>  <csid>  (148) 
32742439

>  <Links>  (148) 
|http://www.chemspider.com/Chemical-Structure.32742439.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4536840| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=9T6|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/9T6|http://zinc15.docking.org/substances/ZINC000146784326

>  <LinkName>  (148) 
|ChemSpider|ChEMBL|RCSB|PDBe|ZINC

>  <lig_pdbID>  (148) 
'9T6'

>  <pdbID>  (148) 
6aah 6aaj 6aak 6aam

>  <indicationG2P>  (148) 


>  <indicationDB>  (148) 


>  <uniprotId>  (148) 


>  <MW>  (148) 
326.2

>  <HBA>  (148) 
4.0

>  <HBD>  (148) 
4.0

>  <NRB>  (148) 
3.0

>  <TPSA>  (148) 
104.0

>  <LogP>  (148) 
2.0

>  <RoF>  (148) 
0.0

>  <Melting point>  (148) 


>  <Targets>  (148) 
JAK1; JAK2; JAK3; TYK2

>  <Kinase families>  (148) 
Tyr

>  <FDA_approved>  (148) 


$$$$
Momelotinib
     RDKit          2D

 31 34  0  0  0  0  0  0  0  0999 V2000
   -4.0114   -2.2227    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5028   -2.0618    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1092   -0.6899    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2242    0.5213    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7329    0.3604    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1265   -1.0115    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6351   -1.1724    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0287   -2.5443    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4626   -2.7052    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3476   -1.4940    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.7412   -0.1221    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7502    0.0388    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.6261    1.0891    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.1175    0.9282    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7239   -0.4437    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2152   -0.6046    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1002    0.6066    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4938    1.9785    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0025    2.1394    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5916    0.4457    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.1979   -0.9262    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.6893   -1.0871    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.5743    0.1240    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.9679    1.4960    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4765    1.6568    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6005   -0.5290    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4855   -1.7402    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -8.2069    0.8429    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -9.6983    1.0038    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.3047    2.3757    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.9111    3.7477    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 11 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 17 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
  3 26  1  0
 26 27  2  0
 26 28  1  0
 28 29  1  0
 29 30  1  0
 30 31  3  0
  6  1  1  0
 12  7  1  0
 19 14  1  0
 25 20  1  0
M  END
>  <BrandName>  (149) 


>  <Applicants>  (149) 
Ym Biosciences Australia

>  <CHEMBL_ID>  (149) 
CHEMBL1078178

>  <Canonical_Smiles>  (149) 
c1cc(ccc1c2ccnc(n2)Nc3ccc(cc3)N4CCOCC4)C(=O)NCC#N

>  <Chirality>  (149) 
Achiral Molecule

>  <First_Approval>  (149) 
nan

>  <Phase>  (149) 
3.0

>  <SC_Patent>  (149) 
None

>  <Synonyms>  (149) 
CYT-0387 | CYT-11387 | CYT-387 | CYT387 | GS-0387 | MOMELOTINIB

>  <Withdrawn>  (149) 


>  <Indications>  (149) 
nan

>  <Type>  (149) 
nan

>  <targets_id>  (149) 
P23458|O60674|P52333

>  <inchi>  (149) 
InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)

>  <stdInchikey>  (149) 
ZVHNDZWQTBEVRY-UHFFFAOYSA-N

>  <csid>  (149) 
24676202

>  <Links>  (149) 
|http://www.chemspider.com/Chemical-Structure.24676202.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1078178|http://pubchem.ncbi.nlm.nih.gov/compound/25062766|http://www.drugbank.ca/drugs/DB11763| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=C87|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/C87|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7791|http://zinc15.docking.org/substances/ZINC43199890|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6O01GMS00P|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50311017

>  <LinkName>  (149) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (149) 
'C87'

>  <pdbID>  (149) 
6fdz 7nns

>  <indicationG2P>  (149) 
None

>  <indicationDB>  (149) 


>  <uniprotId>  (149) 


>  <MW>  (149) 
414.2

>  <HBA>  (149) 
7.0

>  <HBD>  (149) 
2.0

>  <NRB>  (149) 
6.0

>  <TPSA>  (149) 
103.2

>  <LogP>  (149) 
3.0

>  <RoF>  (149) 
0.0

>  <Melting point>  (149) 


>  <Targets>  (149) 
JAK1; JAK2; JAK3

>  <Kinase families>  (149) 
Tyr

>  <FDA_approved>  (149) 


$$$$
Sitravatinib
     RDKit          2D

 45 50  0  0  0  0  0  0  0  0999 V2000
  -16.9051    0.2503    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -15.7203   -0.6696    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  -14.3312   -0.1035    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -13.1464   -1.0234    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.7574   -0.4573    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  -10.5726   -1.3772    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.1835   -0.8111    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.9792    0.6749    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5901    1.2410    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4053    0.3211    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6096   -1.1649    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9987   -1.7310    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0163    0.8872    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6578    2.3438    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1618    2.4529    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5957    1.0639    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7418    0.0962    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1096    0.8596    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1897    2.0444    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7558    3.4335    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2418    3.6377    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5435   -0.5295    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.9425   -0.7338    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5086   -2.1228    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9947   -2.3271    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9146   -1.1423    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3485    0.2468    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8624    0.4510    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2963    1.8401    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    5.4006   -1.3466    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.9667   -2.7356    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0468   -3.9204    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.4527   -2.9399    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7793   -3.6401    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5096   -4.4388    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9119   -1.5119    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9049   -0.4002    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.3782   -1.1956    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.8374    0.2324    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.3037    0.5487    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.7629    1.9766    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.7558    3.0883    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2896    2.7720    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8304    1.3440    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.2151    4.5163    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 10 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 16 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 18 22  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 26 30  1  0
 30 31  1  0
 31 32  2  0
 31 33  1  0
 33 34  1  0
 34 35  1  0
 33 36  1  0
 36 37  2  0
 36 38  1  0
 38 39  1  0
 39 40  2  0
 40 41  1  0
 41 42  2  0
 42 43  1  0
 43 44  2  0
 42 45  1  0
 12  7  1  0
 17 13  1  0
 21 15  1  0
 28 23  1  0
 35 33  1  0
 44 39  1  0
M  END
>  <BrandName>  (150) 


>  <Applicants>  (150) 
Mirati Therapeutics

>  <CHEMBL_ID>  (150) 
CHEMBL3989926

>  <Canonical_Smiles>  (150) 
COCCNCc1ccc(nc1)c2cc3c(s2)c(ccn3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F

>  <Chirality>  (150) 
Achiral Molecule

>  <First_Approval>  (150) 
nan

>  <Phase>  (150) 
3.0

>  <SC_Patent>  (150) 
None

>  <Synonyms>  (150) 
MG-516 | MG-91516 | MGCD-516 | MGCD516 | SITRAVATINIB

>  <Withdrawn>  (150) 


>  <Indications>  (150) 
nan

>  <Type>  (150) 
nan

>  <targets_id>  (150) 
P07949|Q16832|P04629|Q16620|Q16288

>  <inchi>  (150) 
InChI=1S/C33H29F2N5O4S/c1-43-15-14-36-18-20-2-8-25(38-19-20)29-17-26-30(45-29)28(10-13-37-26)44-27-9-7-23(16-24(27)35)40-32(42)33(11-12-33)31(41)39-22-5-3-21(34)4-6-22/h2-10,13,16-17,19,36H,11-12,14-15,18H2,1H3,(H,39,41)(H,40,42)

>  <stdInchikey>  (150) 
WLAVZAAODLTUSW-UHFFFAOYSA-N

>  <csid>  (150) 
52083477

>  <Links>  (150) 
|http://www.chemspider.com/Chemical-Structure.52083477.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3989926|http://pubchem.ncbi.nlm.nih.gov/compound/25212148|http://www.drugbank.ca/drugs/DB15036|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9920|http://zinc15.docking.org/substances/ZINC000164334830|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=CWG62Q1VTB|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50467574

>  <LinkName>  (150) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (150) 


>  <pdbID>  (150) 


>  <indicationG2P>  (150) 
None

>  <indicationDB>  (150) 


>  <uniprotId>  (150) 


>  <MW>  (150) 
629.2

>  <HBA>  (150) 
8.0

>  <HBD>  (150) 
3.0

>  <NRB>  (150) 
12.0

>  <TPSA>  (150) 
114.5

>  <LogP>  (150) 
6.5

>  <RoF>  (150) 
2.0

>  <Melting point>  (150) 


>  <Targets>  (150) 
RET; DDR2; NTRK1; NTRK2; NTRK3

>  <Kinase families>  (150) 
Tyr

>  <FDA_approved>  (150) 


$$$$
Semaxanib
     RDKit          2D

 18 20  0  0  0  0  0  0  0  0999 V2000
   -3.0634   -3.0466    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0860   -1.5468    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3127   -0.6835    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8707    0.7499    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3708    0.7725    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8859   -0.6469    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4525   -1.0889    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6470   -0.0686    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1187   -0.3583    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8882   -1.6459    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3880   -1.6233    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1184   -0.3131    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3489    0.9745    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8491    0.9519    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8287    2.0514    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.4678    1.4207    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8424    2.1511    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7705    1.9501    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  1  0
 16 17  2  0
  4 18  1  0
  6  2  2  0
  8 16  1  0
 14  9  1  0
M  END
>  <BrandName>  (151) 


>  <Applicants>  (151) 
Sugen

>  <CHEMBL_ID>  (151) 
CHEMBL276711

>  <Canonical_Smiles>  (151) 
Cc1cc([nH]c1/C=C\2/c3ccccc3NC2=O)C

>  <Chirality>  (151) 
Achiral Molecule

>  <First_Approval>  (151) 
nan

>  <Phase>  (151) 
3.0

>  <SC_Patent>  (151) 
None

>  <Synonyms>  (151) 
NSC-696819 | SEMAXANIB | SEMAXINIB | SU-5416 | SU005416 | SU5416

>  <Withdrawn>  (151) 


>  <Indications>  (151) 
Investigated for use/treatment in colorectal cancer and lung cancer.

>  <Type>  (151) 
1

>  <targets_id>  (151) 
P35968

>  <inchi>  (151) 
InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-

>  <stdInchikey>  (151) 
WUWDLXZGHZSWQZ-WQLSENKSSA-N

>  <csid>  (151) 
4486260

>  <Links>  (151) 
|http://www.chemspider.com/Chemical-Structure.4486260.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL276711|http://pubchem.ncbi.nlm.nih.gov/compound/5329098|http://www.drugbank.ca/drugs/DB06436| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=X2M|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/X2M|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5056|http://zinc15.docking.org/substances/ZINC12410091|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=71IA9S35AJ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=4810

>  <LinkName>  (151) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (151) 
'X2M'

>  <pdbID>  (151) 
2x2m

>  <indicationG2P>  (151) 
None

>  <indicationDB>  (151) 


>  <uniprotId>  (151) 
P35968|P35354

>  <MW>  (151) 
238.1

>  <HBA>  (151) 
1.0

>  <HBD>  (151) 
2.0

>  <NRB>  (151) 
1.0

>  <TPSA>  (151) 
44.9

>  <LogP>  (151) 
3.1

>  <RoF>  (151) 
0.0

>  <Melting point>  (151) 


>  <Targets>  (151) 
KDR

>  <Kinase families>  (151) 
Tyr

>  <FDA_approved>  (151) 


$$$$
Dovitinib
     RDKit          2D

 29 33  0  0  0  0  0  0  0  0999 V2000
   -9.2698    1.9461    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9068    1.3197    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6829    2.1869    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3199    1.5605    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1809    0.0669    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4048   -0.8002    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.7678   -0.1738    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8180   -0.5594    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6789   -2.0530    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3160   -2.6794    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0920   -1.8122    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2311   -0.3186    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5940    0.3077    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1464    0.2751    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.1368   -0.8515    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3714   -2.1415    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6303   -0.7125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2567    0.6505    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7502    0.7895    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6174   -0.4344    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1110   -0.2954    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7373    1.0675    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8702    2.2915    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3766    2.1525    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5095    3.3764    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    4.9910   -1.7974    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.4975   -1.9364    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8711   -3.2994    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.3895    1.8744    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  5  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  1  0
 15 16  2  0
 15 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 20 26  1  0
 26 27  1  0
 27 28  2  0
 18 29  1  0
  7  2  1  0
 13  8  1  0
 16 11  1  0
 27 17  1  0
 24 19  1  0
M  END
>  <BrandName>  (152) 


>  <Applicants>  (152) 
Novartis

>  <CHEMBL_ID>  (152) 
CHEMBL522892

>  <Canonical_Smiles>  (152) 
CN1CCN(CC1)c2ccc3c(c2)[nH]c(n3)c4c(c5c(cccc5F)[nH]c4=O)N

>  <Chirality>  (152) 
Achiral Molecule

>  <First_Approval>  (152) 
nan

>  <Phase>  (152) 
3.0

>  <SC_Patent>  (152) 
None

>  <Synonyms>  (152) 
CHIR-258 | DOVITINIB | GFKI-258 | NVP-TKI258 | TKI-258

>  <Withdrawn>  (152) 
|Study NCT02048943 in United States was Withdrawn during Phase 1 because Lack of funding|Study NCT02268435 in nan was Withdrawn during Phase 1 because Dovitinib Production stopped|Study NCT02065323 in United States was Withdrawn during Phase 2 because Terminated due to budgetary considerations and length of development

>  <Indications>  (152) 
nan

>  <Type>  (152) 
1

>  <targets_id>  (152) 
P22607|P15692|P11362|P16234|P10721|P07333

>  <inchi>  (152) 
InChI=1S/C21H21FN6O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29)

>  <stdInchikey>  (152) 
PIQCTGMSNWUMAF-UHFFFAOYSA-N

>  <csid>  (152) 
11530944

>  <Links>  (152) 
|http://www.chemspider.com/Chemical-Structure.11530944.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL522892|http://pubchem.ncbi.nlm.nih.gov/compound/135398510|http://www.drugbank.ca/drugs/DB05928| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=38O|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/38O|http://zinc15.docking.org/substances/ZINC000003816310|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=I35H55G906|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=25118

>  <LinkName>  (152) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (152) 
'38O'

>  <pdbID>  (152) 
4tyi 5a46 5am6 5am7 5owq 7akg

>  <indicationG2P>  (152) 


>  <indicationDB>  (152) 
Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with different cancers, including acute myeloid leukemia (AML) and multiple myeloma. Chiron currently has three ongoing Phase I clinical trials for dovitinib.

>  <uniprotId>  (152) 
O75469|P04798|P05177|P35503|P16662|P33261|P08684|O15438|Q9UNQ0|Q9Y6L6|O94956|Q9NPD5|P08183

>  <MW>  (152) 
392.2

>  <HBA>  (152) 
5.0

>  <HBD>  (152) 
3.0

>  <NRB>  (152) 
2.0

>  <TPSA>  (152) 
94.0

>  <LogP>  (152) 
2.5

>  <RoF>  (152) 
0.0

>  <Melting point>  (152) 


>  <Targets>  (152) 
FGFR3; VEGFA; FGFR1; PDGFRA; KIT; CSF1R

>  <Kinase families>  (152) 
Tyr<br>(*)

>  <FDA_approved>  (152) 


$$$$
Motesanib
     RDKit          2D

 28 31  0  0  0  0  0  0  0  0999 V2000
   -7.1065    0.0693    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6142   -0.0833    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6185    1.4167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1932    1.8842    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3081    0.6732    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1864   -0.5428    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5724   -1.9114    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0802   -2.0640    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2019   -0.8480    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8159    0.5206    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2903   -1.0006    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.9043   -2.3692    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0260   -3.5852    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.3965   -2.5218    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0104   -3.8904    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5027   -4.0430    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3809   -2.8269    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7670   -1.4584    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.2747   -1.3058    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6608    0.0628    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.5390    1.2788    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9251    2.6474    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8033    3.8634    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1894    5.2320    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6972    5.3846    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.8189    4.1686    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4329    2.8000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9220   -1.5514    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
  9 11  1  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
  2 28  1  0
  6  2  1  0
 10  5  1  0
 19 14  1  0
 27 22  1  0
M  END
>  <BrandName>  (153) 


>  <Applicants>  (153) 
Amgen

>  <CHEMBL_ID>  (153) 
CHEMBL572881

>  <Canonical_Smiles>  (153) 
CC1(CNc2c1ccc(c2)NC(=O)c3cccnc3NCc4ccncc4)C

>  <Chirality>  (153) 
Achiral Molecule

>  <First_Approval>  (153) 
nan

>  <Phase>  (153) 
3.0

>  <SC_Patent>  (153) 
None

>  <Synonyms>  (153) 
AMG 706 | AMG-706 | MOTESANIB

>  <Withdrawn>  (153) 


>  <Indications>  (153) 
nan

>  <Type>  (153) 
2

>  <targets_id>  (153) 
P17948|P35968|P35916|P16234|P09619|P10721|P07949

>  <inchi>  (153) 
InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28)

>  <stdInchikey>  (153) 
RAHBGWKEPAQNFF-UHFFFAOYSA-N

>  <csid>  (153) 
9842625

>  <Links>  (153) 
|http://www.chemspider.com/Chemical-Structure.9842625.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL572881|http://pubchem.ncbi.nlm.nih.gov/compound/11667893|http://www.drugbank.ca/drugs/DB05575| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=706|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/706|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5660|http://zinc15.docking.org/substances/ZINC18710082|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=U1JK633AYI|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=24773

>  <LinkName>  (153) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (153) 
'706'

>  <pdbID>  (153) 
3efl

>  <indicationG2P>  (153) 
None

>  <indicationDB>  (153) 


>  <uniprotId>  (153) 


>  <MW>  (153) 
373.2

>  <HBA>  (153) 
5.0

>  <HBD>  (153) 
3.0

>  <NRB>  (153) 
5.0

>  <TPSA>  (153) 
78.9

>  <LogP>  (153) 
4.0

>  <RoF>  (153) 
0.0

>  <Melting point>  (153) 


>  <Targets>  (153) 
FLT1; KDR; FLT4; PDGFRA; PDGFRB; KIT; RET

>  <Kinase families>  (153) 
Tyr

>  <FDA_approved>  (153) 


$$$$
Naquotinib
     RDKit          2D

 41 45  0  0  0  0  0  0  0  0999 V2000
    7.0504   -3.4850    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5353   -2.0656    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5484   -0.9359    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0767   -1.2257    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0899   -0.0960    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.5748    1.3234    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0465    1.6132    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0333    0.4835    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.5314    3.0327    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5446    4.1623    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.0031    3.3225    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.5879    2.4531    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.1162    2.1633    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1293    3.2930    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3424    3.0032    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8273    1.5837    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1595    0.4541    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6313    0.7438    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2990    1.2939    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2859    2.4236    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7576    2.1338    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2425    0.7144    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2557   -0.4153    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7839   -0.1255    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7143    0.4246    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.7011    1.5542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.1728    1.2644    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.6577   -0.1550    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.6709   -1.2847    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1992   -0.9949    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.1295   -0.4448    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5918   -2.6452    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.1200   -2.9350    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4894   -4.2960    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0002   -4.1168    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7104   -2.6450    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0205   -1.9146    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6506   -2.0144    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7850   -0.5204    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8773   -2.8778    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2383   -2.2471    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  7  9  1  0
  9 10  2  0
  9 11  1  0
  6 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 16 19  1  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 22 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  1  0
 28 31  1  0
  4 32  1  0
 33 32  1  6
 33 34  1  0
 34 35  1  0
 35 36  1  0
 36 37  1  0
 36 38  1  0
 38 39  2  0
 38 40  1  0
 40 41  2  0
  8  3  1  0
 18 13  1  0
 24 19  1  0
 30 25  1  0
 37 33  1  0
M  END
>  <BrandName>  (154) 


>  <Applicants>  (154) 
Astellas Pharma

>  <CHEMBL_ID>  (154) 
CHEMBL3663929

>  <Canonical_Smiles>  (154) 
CCc1c(nc(c(n1)C(=O)N)Nc2ccc(cc2)N3CCC(CC3)N4CCN(CC4)C)O[C@@H]5CCN(C5)C(=O)C=C

>  <Chirality>  (154) 
Single Stereoisomer

>  <First_Approval>  (154) 
nan

>  <Phase>  (154) 
3.0

>  <SC_Patent>  (154) 
None

>  <Synonyms>  (154) 
ASP-8273 | ASP8273 | NAQUOTINIB

>  <Withdrawn>  (154) 
|Study NCT02674555 in nan was Withdrawn during Phase 1 because Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies

>  <Indications>  (154) 
nan

>  <Type>  (154) 
nan

>  <targets_id>  (154) 
P00533

>  <inchi>  (154) 
InChI=1S/C30H42N8O3/c1-4-25-30(41-24-12-15-38(20-24)26(39)5-2)34-29(27(33-25)28(31)40)32-21-6-8-22(9-7-21)36-13-10-23(11-14-36)37-18-16-35(3)17-19-37/h5-9,23-24H,2,4,10-20H2,1,3H3,(H2,31,40)(H,32,34)/t24-/m1/s1

>  <stdInchikey>  (154) 
QKDCLUARMDUUKN-XMMPIXPASA-N

>  <csid>  (154) 
44210447

>  <Links>  (154) 
|http://www.chemspider.com/Chemical-Structure.44210447.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3663929|http://pubchem.ncbi.nlm.nih.gov/compound/71667668|http://www.drugbank.ca/drugs/DB12036| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=8RC|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/8RC|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9248|http://zinc15.docking.org/substances/ZINC000205341959|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=47DD4548PB|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=170514

>  <LinkName>  (154) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (154) 
'8RC'

>  <pdbID>  (154) 
5y9t

>  <indicationG2P>  (154) 
None

>  <indicationDB>  (154) 


>  <uniprotId>  (154) 


>  <MW>  (154) 
562.3

>  <HBA>  (154) 
9.0

>  <HBD>  (154) 
2.0

>  <NRB>  (154) 
9.0

>  <TPSA>  (154) 
120.2

>  <LogP>  (154) 
2.3

>  <RoF>  (154) 
1.0

>  <Melting point>  (154) 


>  <Targets>  (154) 
EGFR

>  <Kinase families>  (154) 
Tyr

>  <FDA_approved>  (154) 


$$$$
Orantinib
     RDKit          2D

 23 25  0  0  0  0  0  0  0  0999 V2000
   -1.5412    2.7940    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4754    1.2954    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6491    0.3614    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1235   -1.0435    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6249   -0.9777    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2244    0.4678    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1805    0.9934    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3382    0.0396    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7903    0.4155    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4826    1.7462    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9812    1.8120    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7874    0.5471    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0951   -0.7836    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5965   -0.8494    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6427   -2.0070    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.2469   -1.4576    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9820   -2.2639    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9511   -2.2946    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0946    0.7619    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1643   -0.2898    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6098    0.1108    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9857    1.5629    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6794   -0.9409    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  1  0
 16 17  2  0
  4 18  1  0
  3 19  1  0
 19 20  1  0
 20 21  1  0
 21 22  2  0
 21 23  1  0
  6  2  2  0
  8 16  1  0
 14  9  1  0
M  END
>  <BrandName>  (155) 


>  <Applicants>  (155) 
Pfizer

>  <CHEMBL_ID>  (155) 
CHEMBL274654

>  <Canonical_Smiles>  (155) 
Cc1c(c([nH]c1/C=C\2/c3ccccc3NC2=O)C)CCC(=O)O

>  <Chirality>  (155) 
Achiral Molecule

>  <First_Approval>  (155) 
nan

>  <Phase>  (155) 
3.0

>  <SC_Patent>  (155) 
None

>  <Synonyms>  (155) 
NSC-702827 | ORANTINIB | SU-6668 | TSU-68

>  <Withdrawn>  (155) 


>  <Indications>  (155) 
nan

>  <Type>  (155) 
1

>  <targets_id>  (155) 
P35968|P09619|P11362

>  <inchi>  (155) 
InChI=1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19H,7-8H2,1-2H3,(H,20,23)(H,21,22)/b14-9-

>  <stdInchikey>  (155) 
NHFDRBXTEDBWCZ-ZROIWOOFSA-N

>  <csid>  (155) 
4486261

>  <Links>  (155) 
|http://www.chemspider.com/Chemical-Structure.4486261.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL274654|http://pubchem.ncbi.nlm.nih.gov/compound/5329099|http://www.drugbank.ca/drugs/DB12072| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=SU6|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/SU6|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7816|http://zinc15.docking.org/substances/ZINC000003834032|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=9RL37ZZ665|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=4811

>  <LinkName>  (155) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (155) 
'SU6'

>  <pdbID>  (155) 
4jlc 5yvc

>  <indicationG2P>  (155) 
None

>  <indicationDB>  (155) 


>  <uniprotId>  (155) 


>  <MW>  (155) 
310.1

>  <HBA>  (155) 
2.0

>  <HBD>  (155) 
3.0

>  <NRB>  (155) 
4.0

>  <TPSA>  (155) 
82.2

>  <LogP>  (155) 
3.1

>  <RoF>  (155) 
0.0

>  <Melting point>  (155) 


>  <Targets>  (155) 
KDR; PDGFRB; FGFR1

>  <Kinase families>  (155) 
Tyr

>  <FDA_approved>  (155) 


$$$$
Barasertib
     RDKit          2D

 41 44  0  0  0  0  0  0  0  0999 V2000
   11.2660   -3.3224    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7675   -3.2551    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0765   -1.9238    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.5780   -1.8566    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8870   -0.5252    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3885   -0.4580    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6975    0.8734    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.1990    0.9406    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3915   -0.3235    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8931   -0.2563    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2020    1.0751    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0095    2.3392    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5080    2.2720    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3185    3.6706    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1800    3.7378    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9875    2.4737    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2965    1.1423    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1039   -0.1218    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6024   -0.0545    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5376   -1.2273    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9420   -0.7003    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8747    0.7982    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4288    1.1973    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1938   -1.5267    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.5354   -0.8558    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.6252    0.6415    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -9.7872   -1.6822    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  -11.1288   -1.0113    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.2186    0.4860    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -12.5602    1.1569    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -13.8120    0.3306    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -13.7222   -1.1668    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -12.3807   -1.8377    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -14.9741   -1.9932    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    9.8840   -0.6597    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.3825   -0.7269    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.1900    0.5372    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   13.6885    0.4700    0.0000 P   0  0  0  0  0  0  0  0  0  0  0  0
   13.7557    1.9685    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   13.6212   -1.0285    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   15.1870    0.4027    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 21 24  1  0
 24 25  1  0
 25 26  2  0
 25 27  1  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 32 33  2  0
 32 34  1  0
  3 35  1  0
 35 36  1  0
 36 37  1  0
 37 38  1  0
 38 39  2  0
 38 40  1  0
 38 41  1  0
 13  8  1  0
 17 11  1  0
 23 19  1  0
 33 28  1  0
M  END
>  <BrandName>  (156) 


>  <Applicants>  (156) 
Astrazeneca

>  <CHEMBL_ID>  (156) 
CHEMBL415049

>  <Canonical_Smiles>  (156) 
CCN(CCCOc1ccc2c(c1)ncnc2Nc3cc(n[nH]3)CC(=O)Nc4cccc(c4)F)CCOP(=O)(O)O

>  <Chirality>  (156) 
Achiral Molecule

>  <First_Approval>  (156) 
nan

>  <Phase>  (156) 
3.0

>  <SC_Patent>  (156) 
None

>  <Synonyms>  (156) 
AZD 1152 | AZD-1152 | AZD1152 | BARASERTIB

>  <Withdrawn>  (156) 


>  <Indications>  (156) 
nan

>  <Type>  (156) 
nan

>  <targets_id>  (156) 
Q96GD4

>  <inchi>  (156) 
InChI=1S/C26H31FN7O6P/c1-2-34(10-12-40-41(36,37)38)9-4-11-39-21-7-8-22-23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(35)30-19-6-3-5-18(27)13-19/h3,5-8,13-14,16-17H,2,4,9-12,15H2,1H3,(H,30,35)(H2,36,37,38)(H2,28,29,31,32,33)

>  <stdInchikey>  (156) 
GBJVVSCPOBPEIT-UHFFFAOYSA-N

>  <csid>  (156) 
9672789

>  <Links>  (156) 
|http://www.chemspider.com/Chemical-Structure.9672789.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL415049|http://pubchem.ncbi.nlm.nih.gov/compound/11497983|http://www.drugbank.ca/drugs/DB11747|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7332|http://zinc15.docking.org/substances/ZINC000043129461|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=16XC2U7W8N|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50241089

>  <LinkName>  (156) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (156) 


>  <pdbID>  (156) 


>  <indicationG2P>  (156) 
None

>  <indicationDB>  (156) 


>  <uniprotId>  (156) 


>  <MW>  (156) 
587.2

>  <HBA>  (156) 
9.0

>  <HBD>  (156) 
5.0

>  <NRB>  (156) 
15.0

>  <TPSA>  (156) 
174.8

>  <LogP>  (156) 
3.6

>  <RoF>  (156) 
1.0

>  <Melting point>  (156) 


>  <Targets>  (156) 
AURKB

>  <Kinase families>  (156) 
Other

>  <FDA_approved>  (156) 


$$$$
Nazartinib
     RDKit          2D

 35 38  0  0  0  0  0  0  0  0999 V2000
   -9.5074    1.4920    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.0290    1.7457    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0701    0.5922    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5917    0.8458    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0722    2.2530    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0311    3.4065    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5095    3.1528    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6329   -0.3077    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1524   -1.7148    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1545   -0.0540    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1956   -1.2076    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5652   -2.6613    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2968   -3.4621    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0432   -4.9405    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3640   -5.4600    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5175   -4.5011    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2638   -3.0227    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1433   -2.5032    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6988   -1.1098    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.1020    0.1586    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6934    1.4303    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1950    2.8451    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2219    3.3375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4903    2.5368    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6551    1.0458    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.5922   -0.0126    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0698    0.5474    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3456   -0.9270    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.2089    1.5234    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6237    1.0250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7627    2.0010    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1775    1.5026    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.3165    2.4786    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4532    0.0281    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4174   -2.0639    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  4  8  1  0
  8  9  2  0
  8 10  1  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 20 19  1  6
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 25 27  1  0
 27 28  2  0
 27 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  1  0
 32 33  1  0
 32 34  1  0
 17 35  1  0
  7  2  1  0
 19 11  1  0
 18 13  1  0
 26 20  1  0
M  END
>  <BrandName>  (157) 


>  <Applicants>  (157) 
Novartis

>  <CHEMBL_ID>  (157) 
CHEMBL3787344

>  <Canonical_Smiles>  (157) 
Cc1cc(ccn1)C(=O)Nc2nc3cccc(c3n2[C@@H]4CCCCN(C4)C(=O)/C=C/CN(C)C)Cl

>  <Chirality>  (157) 
Single Stereoisomer

>  <First_Approval>  (157) 
nan

>  <Phase>  (157) 
3.0

>  <SC_Patent>  (157) 
None

>  <Synonyms>  (157) 
EGF-816 | EGF816 | NAZARTINIB | NVP-EGF816-NX

>  <Withdrawn>  (157) 
|Study NCT03529084 in nan was Withdrawn during Phase 3 because Decision by Sponsor not to continue with the trial

>  <Indications>  (157) 
nan

>  <Type>  (157) 
nan

>  <targets_id>  (157) 
nan

>  <inchi>  (157) 
InChI=1S/C26H31ClN6O2/c1-18-16-19(12-13-28-18)25(35)30-26-29-22-10-6-9-21(27)24(22)33(26)20-8-4-5-15-32(17-20)23(34)11-7-14-31(2)3/h6-7,9-13,16,20H,4-5,8,14-15,17H2,1-3H3,(H,29,30,35)/b11-7+/t20-/m1/s1

>  <stdInchikey>  (157) 
IOMMMLWIABWRKL-WUTDNEBXSA-N

>  <csid>  (157) 
35308229

>  <Links>  (157) 
|http://www.chemspider.com/Chemical-Structure.35308229.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3787344|http://pubchem.ncbi.nlm.nih.gov/compound/72703790|http://www.drugbank.ca/drugs/DB16250|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9204|http://zinc15.docking.org/substances/ZINC000210610738|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=KE7K32EME8|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50160870

>  <LinkName>  (157) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (157) 


>  <pdbID>  (157) 


>  <indicationG2P>  (157) 
None

>  <indicationDB>  (157) 


>  <uniprotId>  (157) 


>  <MW>  (157) 
494.2

>  <HBA>  (157) 
6.0

>  <HBD>  (157) 
1.0

>  <NRB>  (157) 
6.0

>  <TPSA>  (157) 
83.4

>  <LogP>  (157) 
4.3

>  <RoF>  (157) 
0.0

>  <Melting point>  (157) 


>  <Targets>  (157) 
nan

>  <Kinase families>  (157) 


>  <FDA_approved>  (157) 


$$$$
Rigosertib
     RDKit          2D

 31 32  0  0  0  0  0  0  0  0999 V2000
   -7.7742    1.5445    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6079    0.6013    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2079    1.1398    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9742    2.6214    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5742    3.1599    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4079    2.2167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6415    0.7350    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0416    0.1965    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2752   -1.2851    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6753   -1.8236    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9089   -3.3053    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7426   -4.2485    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3090   -3.8438    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0078    2.7552    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1585    1.8119    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    1.1017    2.9783    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7847    0.6456    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.3248    0.8687    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7249    1.4072    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8912    0.4640    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6575   -1.0177    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8238   -1.9609    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2239   -1.4225    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4575    0.0592    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2912    1.0024    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5249    2.4841    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.9249    3.0226    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3902   -2.3657    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.1565   -3.8474    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2575   -1.5562    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.0238   -3.0379    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  2  0
 11 13  1  0
  6 14  1  0
 14 15  1  0
 15 16  2  0
 15 17  2  0
 15 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  1  0
 23 28  1  0
 28 29  1  0
 21 30  1  0
 30 31  1  0
  8  3  1  0
 25 20  1  0
M  END
>  <BrandName>  (158) 


>  <Applicants>  (158) 
Onconova Therapeutics

>  <CHEMBL_ID>  (158) 
CHEMBL1241855

>  <Canonical_Smiles>  (158) 
COc1ccc(cc1NCC(=O)O)CS(=O)(=O)/C=C/c2c(cc(cc2OC)OC)OC

>  <Chirality>  (158) 
Achiral Molecule

>  <First_Approval>  (158) 
nan

>  <Phase>  (158) 
3.0

>  <SC_Patent>  (158) 
None

>  <Synonyms>  (158) 
ON 01910 | RIGOSERTIB

>  <Withdrawn>  (158) 


>  <Indications>  (158) 
nan

>  <Type>  (158) 
3

>  <targets_id>  (158) 
P42336|P53350

>  <inchi>  (158) 
InChI=1S/C21H25NO8S/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24/h5-11,22H,12-13H2,1-4H3,(H,23,24)/b8-7+

>  <stdInchikey>  (158) 
OWBFCJROIKNMGD-BQYQJAHWSA-N

>  <csid>  (158) 
5293927

>  <Links>  (158) 
|http://www.chemspider.com/Chemical-Structure.5293927.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1241855|http://pubchem.ncbi.nlm.nih.gov/compound/6918736|http://www.drugbank.ca/drugs/DB12146| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=6FS|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6FS|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7833|http://zinc15.docking.org/substances/ZINC000003942646|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=67DOW7F9GL|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50060917

>  <LinkName>  (158) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (158) 
'6FS'

>  <pdbID>  (158) 
5j18 5j2r 5ov7

>  <indicationG2P>  (158) 
None

>  <indicationDB>  (158) 


>  <uniprotId>  (158) 


>  <MW>  (158) 
451.1

>  <HBA>  (158) 
8.0

>  <HBD>  (158) 
2.0

>  <NRB>  (158) 
11.0

>  <TPSA>  (158) 
120.4

>  <LogP>  (158) 
2.8

>  <RoF>  (158) 
0.0

>  <Melting point>  (158) 


>  <Targets>  (158) 
PIK3CA; PLK1

>  <Kinase families>  (158) 
Atypical<br>Other

>  <FDA_approved>  (158) 


$$$$
Alisertib
     RDKit          2D

 37 41  0  0  0  0  0  0  0  0999 V2000
   -5.8907   -4.5708    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1966   -3.2411    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0012   -1.9751    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4998   -2.0389    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3044   -0.7729    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6103    0.5569    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1116    0.6206    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3071   -0.6454    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8084   -0.5816    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1007   -1.9042    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6255   -2.1755    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4936   -1.1912    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8362   -1.8853    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1022   -1.0808    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0384    0.4179    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7087    1.1120    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5573    0.3074    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7688    1.1920    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2156    0.7963    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2817    1.8515    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9009    3.3024    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4540    3.6980    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3880    2.6428    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9670    4.3576    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    3.3044    1.2224    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.6341    0.5283    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6979   -0.9703    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0276   -1.6644    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2936   -0.8599    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2299    0.6388    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9001    1.3329    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4958    1.4433    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.4321    2.9419    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6234   -1.5540    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8894   -0.7494    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.6871   -3.0526    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4175    1.9504    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 21 24  1  0
 15 25  1  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 30 32  1  0
 32 33  1  0
 29 34  1  0
 34 35  2  0
 34 36  1  0
  7 37  1  0
  8  3  1  0
 19  9  1  0
 17 12  1  0
 23 18  1  0
 31 26  1  0
M  END
>  <BrandName>  (159) 


>  <Applicants>  (159) 
Millennium Pharmaceuticals

>  <CHEMBL_ID>  (159) 
CHEMBL483158

>  <Canonical_Smiles>  (159) 
COc1cccc(c1C2=NCc3cnc(nc3-c4c2cc(cc4)Cl)Nc5ccc(c(c5)OC)C(=O)O)F

>  <Chirality>  (159) 
Achiral Molecule

>  <First_Approval>  (159) 
nan

>  <Phase>  (159) 
3.0

>  <SC_Patent>  (159) 
None

>  <Synonyms>  (159) 
ALISERTIB | MLN 8237 | MLN-8237 | MLN8237

>  <Withdrawn>  (159) 


>  <Indications>  (159) 
For the treatment of various forms of cancer.

>  <Type>  (159) 
1

>  <targets_id>  (159) 
O14965

>  <inchi>  (159) 
InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)

>  <stdInchikey>  (159) 
ZLHFILGSQDJULK-UHFFFAOYSA-N

>  <csid>  (159) 
24700147

>  <Links>  (159) 
|http://www.chemspider.com/Chemical-Structure.24700147.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL483158|http://pubchem.ncbi.nlm.nih.gov/compound/24771867|http://www.drugbank.ca/drugs/DB05220| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=A5B|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/A5B|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7790|http://zinc15.docking.org/substances/ZINC40939534|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=T66ES73M18|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50277545

>  <LinkName>  (159) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (159) 
'A5B'

>  <pdbID>  (159) 
5ia0

>  <indicationG2P>  (159) 
None

>  <indicationDB>  (159) 
Alisertib is a novel aurora A kinase inhibitor under investigation for the treatment of various forms of cancer.

>  <uniprotId>  (159) 
O14965

>  <MW>  (159) 
518.1

>  <HBA>  (159) 
7.0

>  <HBD>  (159) 
2.0

>  <NRB>  (159) 
6.0

>  <TPSA>  (159) 
105.9

>  <LogP>  (159) 
5.7

>  <RoF>  (159) 
2.0

>  <Melting point>  (159) 


>  <Targets>  (159) 
AURKA

>  <Kinase families>  (159) 
Other

>  <FDA_approved>  (159) 


$$$$
Crenolanib
     RDKit          2D

 33 38  0  0  0  0  0  0  0  0999 V2000
   -8.1628   -1.0900    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.2575    0.4070    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3522    1.9040    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.8492    1.8093    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -9.7545    0.3123    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7605    0.5017    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9300   -0.7474    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4330   -0.6527    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6025   -1.9018    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1055   -1.8072    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4390   -0.4634    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2695    0.7857    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7665    0.6911    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3381    1.9616    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0680    1.4392    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0056   -0.0595    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.1815   -0.9909    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9628   -2.4748    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1387   -3.4062    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5332   -2.8535    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7090   -3.7849    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1035   -3.2322    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3221   -1.7482    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1463   -0.8169    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7518   -1.3695    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5760   -0.4382    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.3649    0.6671    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.7594    1.2197    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9780    2.7037    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8022    3.6350    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4077    3.0824    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1891    1.5984    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0208    5.1190    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  2  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 24 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 30 33  1  0
  5  2  1  0
 13  8  1  0
 16 11  1  0
 26 17  1  0
 25 20  1  0
 32 27  1  0
M  END
>  <BrandName>  (160) 


>  <Applicants>  (160) 
Arog Pharmaceuticals

>  <CHEMBL_ID>  (160) 
CHEMBL2105728

>  <Canonical_Smiles>  (160) 
CC1(COC1)COc2ccc3c(c2)ncn3c4ccc5cccc(c5n4)N6CCC(CC6)N

>  <Chirality>  (160) 
Achiral Molecule

>  <First_Approval>  (160) 
nan

>  <Phase>  (160) 
3.0

>  <SC_Patent>  (160) 
None

>  <Synonyms>  (160) 
ARO 002 | ARO-002 | CP 868596 | CP-868,596 | CP-868596 | CRENOLANIB

>  <Withdrawn>  (160) 


>  <Indications>  (160) 
nan

>  <Type>  (160) 
1

>  <targets_id>  (160) 
P36888|P16234|P09619

>  <inchi>  (160) 
InChI=1S/C26H29N5O2/c1-26(14-32-15-26)16-33-20-6-7-22-21(13-20)28-17-31(22)24-8-5-18-3-2-4-23(25(18)29-24)30-11-9-19(27)10-12-30/h2-8,13,17,19H,9-12,14-16,27H2,1H3

>  <stdInchikey>  (160) 
DYNHJHQFHQTFTP-UHFFFAOYSA-N

>  <csid>  (160) 
8541584

>  <Links>  (160) 
|http://www.chemspider.com/Chemical-Structure.8541584.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2105728|http://pubchem.ncbi.nlm.nih.gov/compound/10366136|http://www.drugbank.ca/drugs/DB11832| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=6T2|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6T2|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7882|http://zinc15.docking.org/substances/ZINC000003820043|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=LQF7I567TQ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=185149

>  <LinkName>  (160) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (160) 
'6T2'

>  <pdbID>  (160) 
5lby 6bqp 6joi 6joj

>  <indicationG2P>  (160) 
None

>  <indicationDB>  (160) 


>  <uniprotId>  (160) 


>  <MW>  (160) 
443.2

>  <HBA>  (160) 
7.0

>  <HBD>  (160) 
1.0

>  <NRB>  (160) 
5.0

>  <TPSA>  (160) 
78.4

>  <LogP>  (160) 
3.9

>  <RoF>  (160) 
0.0

>  <Melting point>  (160) 


>  <Targets>  (160) 
FLT3; PDGFRA; PDGFRB

>  <Kinase families>  (160) 
Tyr

>  <FDA_approved>  (160) 


$$$$
Linifanib
     RDKit          2D

 28 31  0  0  0  0  0  0  0  0999 V2000
   -9.0600   -0.0141    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6038    0.3459    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1875    1.7869    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7313    2.1469    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6915    1.0659    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1078   -0.3752    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5640   -0.7352    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0680   -1.4563    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6118   -1.0963    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1955    0.3448    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5720   -2.1774    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1158   -1.8174    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9241   -2.8984    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3802   -2.5384    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7965   -1.0974    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7567   -0.0163    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3005   -0.3763    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2527   -0.7374    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2925   -1.8184    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7487   -1.4585    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1650   -0.0174    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1252    1.0637    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6690    0.7037    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8767    1.9773    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8431    3.1245    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.2328    2.5598    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.3805    2.0849    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2353    1.4259    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  6  8  1  0
  8  9  1  0
  9 10  2  0
  9 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 15 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 24 27  1  0
  5 28  1  0
  7  2  1  0
 17 12  1  0
 23 18  1  0
 26 22  1  0
M  END
>  <BrandName>  (161) 


>  <Applicants>  (161) 
Abbott Laboratories

>  <CHEMBL_ID>  (161) 
CHEMBL223360

>  <Canonical_Smiles>  (161) 
Cc1ccc(c(c1)NC(=O)Nc2ccc(cc2)c3cccc4c3c(n[nH]4)N)F

>  <Chirality>  (161) 
Achiral Molecule

>  <First_Approval>  (161) 
nan

>  <Phase>  (161) 
3.0

>  <SC_Patent>  (161) 
None

>  <Synonyms>  (161) 
A-741439 | ABT-869 | AL-39324 | LINIFANIB | RG-3635

>  <Withdrawn>  (161) 


>  <Indications>  (161) 
nan

>  <Type>  (161) 
nan

>  <targets_id>  (161) 
P36888|P07333|P35968

>  <inchi>  (161) 
InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28)

>  <stdInchikey>  (161) 
MPVGZUGXCQEXTM-UHFFFAOYSA-N

>  <csid>  (161) 
9660475

>  <Links>  (161) 
|http://www.chemspider.com/Chemical-Structure.9660475.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL223360|http://pubchem.ncbi.nlm.nih.gov/compound/11485656|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5657|http://zinc15.docking.org/substances/ZINC06718813|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=CO93X137CW|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=21079

>  <LinkName>  (161) 
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (161) 


>  <pdbID>  (161) 


>  <indicationG2P>  (161) 
None

>  <indicationDB>  (161) 


>  <uniprotId>  (161) 


>  <MW>  (161) 
375.1

>  <HBA>  (161) 
3.0

>  <HBD>  (161) 
4.0

>  <NRB>  (161) 
3.0

>  <TPSA>  (161) 
95.8

>  <LogP>  (161) 
4.9

>  <RoF>  (161) 
0.0

>  <Melting point>  (161) 


>  <Targets>  (161) 
FLT3; CSF1R; KDR

>  <Kinase families>  (161) 
Tyr

>  <FDA_approved>  (161) 


$$$$
Brivanib alaninate
     RDKit          2D

 32 35  0  0  0  0  0  0  0  0999 V2000
   -9.8881   -0.0343    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4562    0.4123    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2532   -0.4837    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0293    0.3835    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5659    0.0543    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1193   -1.3777    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5490    1.1571    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0856    0.8278    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6390   -0.6042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6559   -1.7069    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2093   -3.1389    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7458   -3.4681    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.2710   -2.3654    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.7709   -2.3831    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2513   -0.9622    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6833   -0.5156    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.7860   -1.5324    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2180   -1.0858    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3207   -2.1026    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5472    0.3776    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.9792    0.8242    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0819   -0.1926    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.3084    2.2876    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7404    2.7342    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2057    3.3045    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0483   -0.0662    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0661    1.4337    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1756   -0.9334    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9956    2.5890    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4590    2.9183    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4759    1.8155    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9758    1.8333    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  5  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  6
 18 20  1  0
 20 21  1  0
 21 22  2  0
 21 23  1  0
 23 24  1  1
 23 25  1  0
 15 26  1  0
 26 27  1  0
 26 28  2  0
  7 29  2  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 32  2  1  0
 31  4  1  0
 28  9  1  0
 28 13  1  0
M  END
>  <BrandName>  (162) 


>  <Applicants>  (162) 
Bristol Myers Squibb

>  <CHEMBL_ID>  (162) 
CHEMBL270995

>  <Canonical_Smiles>  (162) 
Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1

>  <Chirality>  (162) 
Single Stereoisomer

>  <First_Approval>  (162) 
nan

>  <Phase>  (162) 
3.0

>  <SC_Patent>  (162) 
None

>  <Synonyms>  (162) 
BMS-582664 | BMS-582664-02 | BRIVANIB ALANINATE | BRIVANIB L-ALANINE ESTER

>  <Withdrawn>  (162) 


>  <Indications>  (162) 
nan

>  <Type>  (162) 
nan

>  <targets_id>  (162) 
nan

>  <inchi>  (162) 
InChI=1S/C22H24FN5O4/c1-11-7-15-16(27-11)5-6-17(19(15)23)32-21-20-13(3)18(8-28(20)26-10-25-21)30-9-12(2)31-22(29)14(4)24/h5-8,10,12,14,27H,9,24H2,1-4H3/t12-,14+/m1/s1

>  <stdInchikey>  (162) 
LTEJRLHKIYCEOX-OCCSQVGLSA-N

>  <csid>  (162) 
9330033

>  <Links>  (162) 
|http://www.chemspider.com/Chemical-Structure.9330033.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL270995|http://pubchem.ncbi.nlm.nih.gov/compound/11154925|http://www.drugbank.ca/drugs/DB11865|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8097|http://zinc15.docking.org/substances/ZINC29134440|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=U2Y5OFN795

>  <LinkName>  (162) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (162) 


>  <pdbID>  (162) 


>  <indicationG2P>  (162) 
None

>  <indicationDB>  (162) 


>  <uniprotId>  (162) 


>  <MW>  (162) 
441.2

>  <HBA>  (162) 
8.0

>  <HBD>  (162) 
2.0

>  <NRB>  (162) 
7.0

>  <TPSA>  (162) 
116.8

>  <LogP>  (162) 
3.4

>  <RoF>  (162) 
0.0

>  <Melting point>  (162) 


>  <Targets>  (162) 
nan

>  <Kinase families>  (162) 


>  <FDA_approved>  (162) 


$$$$
Lestaurtinib
     RDKit          2D

 33 40  0  0  0  0  0  0  0  0999 V2000
   -3.8150   -1.1685    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3157   -1.1224    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7993   -2.5423    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5983   -3.4410    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1516   -2.7418    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6236   -2.4532    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.9918   -1.7709    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.4320   -2.1904    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0839   -3.5413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5798   -3.6521    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4238   -2.4120    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7718   -1.0611    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2759   -0.9503    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3573    0.2355    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9457   -0.2717    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2553    0.6271    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7067    0.2485    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5153    1.5118    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9953    1.7563    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5235    3.1602    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5718    4.3197    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0919    4.0752    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5636    2.6713    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1669    2.1245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3342    2.6237    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5352    1.7250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7610    2.5894    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1809    2.1058    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.3177    4.0224    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.8178    4.0436    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1609   -1.9129    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3867   -2.7774    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5675   -3.8306    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  6
  2  3  1  0
  3  4  1  0
  5  4  1  1
  5  6  1  0
  5  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 27 29  1  0
 29 30  1  0
  3 31  1  0
 31 32  1  0
  3 33  1  1
  6  2  1  0
 17  2  1  0
 15  7  1  0
 13  8  1  0
 26 14  1  0
 24 16  2  0
 23 18  1  0
 30 25  1  0
M  END
>  <BrandName>  (163) 


>  <Applicants>  (163) 
Cephalon

>  <CHEMBL_ID>  (163) 
CHEMBL603469

>  <Canonical_Smiles>  (163) 
C[C@@]12[C@](C[C@@H](O1)n3c4ccccc4c5c3c6n2c7ccccc7c6c8c5C(=O)NC8)(CO)O

>  <Chirality>  (163) 
Single Stereoisomer

>  <First_Approval>  (163) 
nan

>  <Phase>  (163) 
3.0

>  <SC_Patent>  (163) 
None

>  <Synonyms>  (163) 
A-154475 | A-154475.0 | CEP-701 | KT-555 | KT-5555 | KT5555 | LESTAURTINIB | SP-924 | SP924 | SPM-924

>  <Withdrawn>  (163) 


>  <Indications>  (163) 
nan

>  <Type>  (163) 
nan

>  <targets_id>  (163) 
P36888

>  <inchi>  (163) 
InChI=1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)/t18-,25+,26+/m1/s1

>  <stdInchikey>  (163) 
UIARLYUEJFELEN-LROUJFHJSA-N

>  <csid>  (163) 
112457

>  <Links>  (163) 
|http://www.chemspider.com/Chemical-Structure.112457.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL603469|http://pubchem.ncbi.nlm.nih.gov/compound/126565|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5672|http://zinc15.docking.org/substances/ZINC03781738|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=DO989GC5D1|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50308060

>  <LinkName>  (163) 
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (163) 


>  <pdbID>  (163) 


>  <indicationG2P>  (163) 
None

>  <indicationDB>  (163) 


>  <uniprotId>  (163) 


>  <MW>  (163) 
439.2

>  <HBA>  (163) 
6.0

>  <HBD>  (163) 
3.0

>  <NRB>  (163) 
1.0

>  <TPSA>  (163) 
88.7

>  <LogP>  (163) 
3.5

>  <RoF>  (163) 
0.0

>  <Melting point>  (163) 


>  <Targets>  (163) 
FLT3

>  <Kinase families>  (163) 
Tyr

>  <FDA_approved>  (163) 


$$$$
Simotinib
     RDKit          2D

 35 40  0  0  0  0  0  0  0  0999 V2000
   -2.1964   -3.6811    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7661   -2.2442    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3065   -1.8984    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7228   -2.9895    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1824   -2.6437    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6127   -1.2067    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5834   -0.1156    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1238   -0.4614    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9055    0.6297    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3651    0.2839    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3944    1.3750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8540    1.0292    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4321   -0.3549    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9271   -0.2327    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2049   -1.7068    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3426   -0.7292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2730    1.2269    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9917    2.0068    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.5542    0.4469    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -9.6919    1.4245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.1138    2.8086    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6188    2.6865    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.0723   -0.8609    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1015   -1.9520    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.6712   -3.3890    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2116   -3.7348    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.5026    0.5760    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.9622    0.9219    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9914   -0.1693    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4510    0.1765    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8813    1.6135    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8521    2.7046    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3925    2.3588    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2824    4.1416    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   10.3409    1.9593    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 14 17  1  0
 17 18  1  0
 17 19  1  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
  6 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 23 27  1  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 32 33  2  0
 32 34  1  0
 31 35  1  0
  8  3  1  0
 26  5  1  0
 18 12  1  0
 16 14  1  0
 22 17  1  0
 33 28  1  0
M  END
>  <BrandName>  (164) 


>  <Applicants>  (164) 
Advenchen Laboratories

>  <CHEMBL_ID>  (164) 
CHEMBL3545235

>  <Canonical_Smiles>  (164) 
COc1cc2c(cc1OCCN3CC4(CC4)C5(C3)OCCO5)c(ncn2)Nc6ccc(c(c6)Cl)F

>  <Chirality>  (164) 
Achiral Molecule

>  <First_Approval>  (164) 
nan

>  <Phase>  (164) 
3.0

>  <SC_Patent>  (164) 
None

>  <Synonyms>  (164) 
SIM-6802 | SIMOTINIB

>  <Withdrawn>  (164) 


>  <Indications>  (164) 
nan

>  <Type>  (164) 
nan

>  <targets_id>  (164) 
P00533

>  <inchi>  (164) 
InChI=1S/C25H26ClFN4O4/c1-32-21-12-20-17(23(29-15-28-20)30-16-2-3-19(27)18(26)10-16)11-22(21)33-7-6-31-13-24(4-5-24)25(14-31)34-8-9-35-25/h2-3,10-12,15H,4-9,13-14H2,1H3,(H,28,29,30)

>  <stdInchikey>  (164) 
OXWUWXCJDBRCCG-UHFFFAOYSA-N

>  <csid>  (164) 
20566604

>  <Links>  (164) 
|http://www.chemspider.com/Chemical-Structure.20566604.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545235|http://pubchem.ncbi.nlm.nih.gov/compound/16735117|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7640|http://zinc15.docking.org/substances/ZINC000137136675|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=58K797D5IK

>  <LinkName>  (164) 
|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (164) 


>  <pdbID>  (164) 


>  <indicationG2P>  (164) 
None

>  <indicationDB>  (164) 


>  <uniprotId>  (164) 


>  <MW>  (164) 
500.2

>  <HBA>  (164) 
8.0

>  <HBD>  (164) 
1.0

>  <NRB>  (164) 
7.0

>  <TPSA>  (164) 
78.0

>  <LogP>  (164) 
4.4

>  <RoF>  (164) 
1.0

>  <Melting point>  (164) 


>  <Targets>  (164) 
EGFR

>  <Kinase families>  (164) 
Tyr

>  <FDA_approved>  (164) 


$$$$
Filgotinib
     RDKit          2D

 30 34  0  0  0  0  0  0  0  0999 V2000
    3.3409   -4.5122    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8675   -4.2306    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3747   -2.8139    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3552   -1.6787    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.8286   -1.9603    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3214   -3.3770    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5517   -0.6461    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.5252    0.4477    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1678   -0.1905    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.8068    1.9211    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.2235    2.4139    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3587    1.4333    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.5051    3.8872    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0123    5.3039    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4856    5.0224    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0986   -2.5323    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5914   -1.1155    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0648   -0.8340    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0453   -1.9691    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5525   -3.3859    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0791   -3.6674    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5186   -1.6875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0114   -0.2708    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0309    0.8643    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5237    2.2811    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9971    2.5627    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2852    3.3312    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4639    3.9647    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9776    1.4275    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4848    0.0108    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  5  7  2  0
  7  8  1  0
  8  9  2  0
  8 10  1  0
 10 11  1  0
 11 12  2  0
 11 13  1  0
 13 14  1  0
 14 15  1  0
  3 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 19 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  2  0
 26 28  2  0
 26 29  1  0
 29 30  1  0
  6  1  2  0
  9  4  1  0
 15 13  1  0
 21 16  1  0
 30 23  1  0
M  END
>  <BrandName>  (165) 


>  <Applicants>  (165) 
Galapagos

>  <CHEMBL_ID>  (165) 
CHEMBL3301607

>  <Canonical_Smiles>  (165) 
c1cc(n2c(c1)nc(n2)NC(=O)C3CC3)c4ccc(cc4)CN5CCS(=O)(=O)CC5

>  <Chirality>  (165) 
Single Stereoisomer

>  <First_Approval>  (165) 
nan

>  <Phase>  (165) 
3.0

>  <SC_Patent>  (165) 
None

>  <Synonyms>  (165) 
FILGOTINIB | G-146034 | G146034 | GLPG-0634 | GLPG0634 | GS-6034 FREE BASE

>  <Withdrawn>  (165) 


>  <Indications>  (165) 
nan

>  <Type>  (165) 
1

>  <targets_id>  (165) 
P23458

>  <inchi>  (165) 
InChI=1S/C21H23N5O3S/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25/h1-7,17H,8-14H2,(H,23,24,27)

>  <stdInchikey>  (165) 
RIJLVEAXPNLDTC-UHFFFAOYSA-N

>  <csid>  (165) 
28189566

>  <Links>  (165) 
|http://www.chemspider.com/Chemical-Structure.28189566.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3301607|http://pubchem.ncbi.nlm.nih.gov/compound/49831257|http://www.drugbank.ca/drugs/DB14845| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=2HB|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/2HB|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7913|http://zinc15.docking.org/substances/ZINC000096174616|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=3XVL385Q0M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=103727

>  <LinkName>  (165) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (165) 
'2HB'

>  <pdbID>  (165) 
4p7e 5ut5

>  <indicationG2P>  (165) 
None

>  <indicationDB>  (165) 
Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Wasserman AM: Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2011 Dec 1;84(11):1245-52. (PubMed ID 22150658)" href="#reference-A221451">4</a>,<a class="reference-popover-link" data-content="Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J: Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018 Apr 27;6:15. doi: 10.1038/s41413-018-0016-9. eCollection 2018. (PubMed ID 29736302)" href="#reference-A221456">5</a></sup> The disease is associated with extra-articular manifestations, progressive disability, and comorbidities including cardiovascular disease and mental disorders.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019. (PubMed ID 31692920)" href="#reference-A189165">3</a></sup> 50-70% of patients with RA are unable to achieve sustained clinical remission despite the availability of several treatments including disease-modifying anti-rheumatic drugs (DMARDS) like <a href="https://go.drugbank.com/drugs/DB00563">methotrexate</a>, interleukin-6 (IL-6) blockers, and tumor necrosis factor (TNF) inhibitors.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019. (PubMed ID 31692920)" href="#reference-A189165">3</a></sup> New therapeutic developments target other inflammatory pathways implicated in RA including the Janus kinase (JAK) signaling pathway as seen with filgotinib.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J: Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018 Apr 27;6:15. doi: 10.1038/s41413-018-0016-9. eCollection 2018. (PubMed ID 29736302)" href="#reference-A221456">5</a></sup> </p><p>There are four JAK subtypes which include JAK1, JAK2, JAK3, and tyrosine kinase 2.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019. (PubMed ID 31692920)" href="#reference-A189165">3</a></sup> Non-selective JAK inhibitors like <a href="https://go.drugbank.com/drugs/DB08895">tofacitinib</a> target JAK1 and JAK3 subtypes with minimal activity at JAK2. In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019. (PubMed ID 31692920)" href="#reference-A189165">3</a></sup> JAK2 and JAK3 play important roles in both immune and hematologic functions; therefore, selectivity for JAK1 aims to improve the safety profile of filgotinib while maintaining clinical efficacy.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019. (PubMed ID 31692920)" href="#reference-A189165">3</a></sup> Filgotinib is currently reserved for patients who cannot tolerate DMARDs, or who have been unable to achieve remission in response to one or more DMARDs.<sup class="text-reference-group"><a class="reference-popover-link" data-content="EMA Label - Jyseleca (filgotinib)" href="#reference-L16616">10</a></sup>

>  <uniprotId>  (165) 
P23458|O00748|P23141|P08183

>  <MW>  (165) 
425.2

>  <HBA>  (165) 
7.0

>  <HBD>  (165) 
1.0

>  <NRB>  (165) 
5.0

>  <TPSA>  (165) 
96.7

>  <LogP>  (165) 
2.0

>  <RoF>  (165) 
0.0

>  <Melting point>  (165) 


>  <Targets>  (165) 
JAK1

>  <Kinase families>  (165) 
Tyr

>  <FDA_approved>  (165) 


$$$$
Capivasertib
     RDKit          2D

 30 33  0  0  0  0  0  0  0  0999 V2000
    3.1850    1.1141    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5450    2.5703    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9861    2.9866    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0672    1.9467    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7071    0.4906    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2661    0.0743    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9061   -1.3819    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9871   -2.4217    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4282   -2.0054    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5093   -3.0453    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.4650   -1.7982    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.3839   -0.7583    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7439    0.6978    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0572   -1.1746    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2169    0.3169    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5884    0.9243    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8002    0.0402    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6405   -1.4513    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2689   -2.0587    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1717    0.6476    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3835   -0.2365    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5373   -1.7286    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0039   -2.0433    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.7565   -0.7458    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7550    0.3709    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9147    1.8624    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7030    2.7465    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3314    2.1391    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.6031   -2.5215    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.3461    4.4427    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  1  6
  8  9  1  0
  9 10  1  0
  7 11  1  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 17 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 14 29  1  0
  3 30  1  0
  6  1  1  0
 19 14  1  0
 28 20  1  0
 25 21  1  0
M  END
>  <BrandName>  (166) 


>  <Applicants>  (166) 
Astrazeneca

>  <CHEMBL_ID>  (166) 
CHEMBL2325741

>  <Canonical_Smiles>  (166) 
c1cc(ccc1[C@H](CCO)NC(=O)C2(CCN(CC2)c3c4cc[nH]c4ncn3)N)Cl

>  <Chirality>  (166) 
Single Stereoisomer

>  <First_Approval>  (166) 
nan

>  <Phase>  (166) 
3.0

>  <SC_Patent>  (166) 
None

>  <Synonyms>  (166) 
AZC5363 | AZD 5363 | AZD-5363 | AZD5363 | CAPIVASERTIB

>  <Withdrawn>  (166) 


>  <Indications>  (166) 
nan

>  <Type>  (166) 
nan

>  <targets_id>  (166) 
P31749

>  <inchi>  (166) 
InChI=1S/C21H25ClN6O2/c22-15-3-1-14(2-4-15)17(6-12-29)27-20(30)21(23)7-10-28(11-8-21)19-16-5-9-24-18(16)25-13-26-19/h1-5,9,13,17,29H,6-8,10-12,23H2,(H,27,30)(H,24,25,26)/t17-/m0/s1

>  <stdInchikey>  (166) 
JDUBGYFRJFOXQC-KRWDZBQOSA-N

>  <csid>  (166) 
28189073

>  <Links>  (166) 
|http://www.chemspider.com/Chemical-Structure.28189073.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2325741|http://pubchem.ncbi.nlm.nih.gov/compound/25227436|http://www.drugbank.ca/drugs/DB12218| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=0XZ|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/0XZ|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7709|http://zinc15.docking.org/substances/ZINC000043204023|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=WFR23M21IE|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50427349

>  <LinkName>  (166) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (166) 
'0XZ'

>  <pdbID>  (166) 
4gv1

>  <indicationG2P>  (166) 
None

>  <indicationDB>  (166) 


>  <uniprotId>  (166) 


>  <MW>  (166) 
428.2

>  <HBA>  (166) 
6.0

>  <HBD>  (166) 
4.0

>  <NRB>  (166) 
6.0

>  <TPSA>  (166) 
120.2

>  <LogP>  (166) 
2.1

>  <RoF>  (166) 
0.0

>  <Melting point>  (166) 


>  <Targets>  (166) 
AKT1

>  <Kinase families>  (166) 
AGC

>  <FDA_approved>  (166) 


$$$$
Ensartinib
     RDKit          2D

 38 41  0  0  0  0  0  0  0  0999 V2000
  -10.0942   -3.0801    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.6841   -2.5686    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4221   -1.0917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0120   -0.5801    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8639   -1.5455    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1260   -3.0224    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5360   -3.5340    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9779   -3.9878    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7500    0.8968    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.8980    1.8622    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3399    1.4084    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1918    0.4430    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7818    0.9545    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5197    2.4315    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6678    3.3969    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0779    2.8853    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1097    2.9430    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0384    1.9776    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2236    0.5007    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.4485    2.4892    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5965    1.5238    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0066    2.0354    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2686    3.5123    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1206    4.4777    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.7105    3.9661    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.6787    4.0239    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.1546    1.0700    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.8926   -0.4070    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4825   -0.9185    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0407   -1.3723    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4508   -0.8608    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5988   -1.8262    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3368   -3.3031    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9267   -3.8147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7787   -2.8493    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3686   -3.3608    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    6.6647   -5.2916    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    7.7128    0.6161    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  6
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  6  8  1  6
  4  9  1  0
  9 10  2  0
  9 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 14 17  1  0
 17 18  1  0
 18 19  2  0
 18 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 23 26  1  0
 22 27  1  0
 27 28  1  0
 28 29  1  1
 28 30  1  0
 30 31  2  0
 31 32  1  0
 32 33  2  0
 33 34  1  0
 34 35  2  0
 35 36  1  0
 34 37  1  0
 31 38  1  0
  7  2  1  0
 16 11  1  0
 25 20  1  0
 35 30  1  0
M  END
>  <BrandName>  (167) 


>  <Applicants>  (167) 
Xcovery

>  <CHEMBL_ID>  (167) 
CHEMBL4113131

>  <Canonical_Smiles>  (167) 
C[C@@H]1CN(C[C@@H](N1)C)C(=O)c2ccc(cc2)NC(=O)c3cc(c(nn3)N)O[C@H](C)c4c(ccc(c4Cl)F)Cl

>  <Chirality>  (167) 
Single Stereoisomer

>  <First_Approval>  (167) 
nan

>  <Phase>  (167) 
3.0

>  <SC_Patent>  (167) 
None

>  <Synonyms>  (167) 
ENSARTINIB | X-396

>  <Withdrawn>  (167) 


>  <Indications>  (167) 
nan

>  <Type>  (167) 
nan

>  <targets_id>  (167) 
Q9UM73

>  <inchi>  (167) 
InChI=1S/C26H27Cl2FN6O3/c1-13-11-35(12-14(2)31-13)26(37)16-4-6-17(7-5-16)32-25(36)20-10-21(24(30)34-33-20)38-15(3)22-18(27)8-9-19(29)23(22)28/h4-10,13-15,31H,11-12H2,1-3H3,(H2,30,34)(H,32,36)/t13-,14+,15-/m1/s1

>  <stdInchikey>  (167) 
GLYMPHUVMRFTFV-QLFBSQMISA-N

>  <csid>  (167) 
58828042

>  <Links>  (167) 
|http://www.chemspider.com/Chemical-Structure.58828042.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4113131|http://pubchem.ncbi.nlm.nih.gov/compound/56960363|http://www.drugbank.ca/drugs/DB14860|http://zinc15.docking.org/substances/ZINC000199407645|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=SMA5ZS5B22|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=179297

>  <LinkName>  (167) 
|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (167) 


>  <pdbID>  (167) 


>  <indicationG2P>  (167) 


>  <indicationDB>  (167) 


>  <uniprotId>  (167) 


>  <MW>  (167) 
560.2

>  <HBA>  (167) 
7.0

>  <HBD>  (167) 
3.0

>  <NRB>  (167) 
6.0

>  <TPSA>  (167) 
122.5

>  <LogP>  (167) 
4.7

>  <RoF>  (167) 
1.0

>  <Melting point>  (167) 


>  <Targets>  (167) 
ALK

>  <Kinase families>  (167) 
Tyr

>  <FDA_approved>  (167) 


$$$$
Lazertinib
     RDKit          2D

 41 45  0  0  0  0  0  0  0  0999 V2000
    8.6793    3.8959    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3647    3.1737    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.0818    3.9511    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3328    1.6740    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0181    0.9518    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6611    1.5908    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6339    0.4977    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.3562   -0.8170    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.8297   -0.5364    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9229   -1.5635    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5799   -3.0238    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6731   -4.0509    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1092   -3.6178    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4521   -2.1575    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3590   -1.1304    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1458    0.6861    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5650    2.0691    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0768    2.2575    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8304    1.0630    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2495   -0.3200    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2386   -0.5084    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1568   -1.5145    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6449   -1.3261    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2258    0.0569    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7139    0.2453    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6211   -0.9492    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0403   -2.3322    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5521   -2.5206    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9713   -3.9036    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8785   -5.0981    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1092   -0.7608    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6901    0.6222    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.1782    0.8106    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.0855   -0.3839    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -9.5046   -1.7669    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.0165   -1.9553    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2948    1.6283    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3875    2.8228    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8994    2.6344    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9684    4.2058    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0611    5.4003    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
  7 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 20 22  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  1  0
 26 31  1  0
 31 32  1  0
 32 33  1  0
 33 34  1  0
 34 35  1  0
 35 36  1  0
 25 37  1  0
 37 38  1  0
 38 39  2  0
 38 40  1  0
 40 41  2  0
  9  5  1  0
 15 10  1  0
 21 16  1  0
 28 23  1  0
 36 31  1  0
M  END
>  <BrandName>  (168) 


>  <Applicants>  (168) 
Genosco

>  <CHEMBL_ID>  (168) 
CHEMBL4558324

>  <Canonical_Smiles>  (168) 
CN(C)Cc1cn(nc1c2ccccc2)c3ccnc(n3)Nc4cc(c(cc4OC)N5CCOCC5)NC(=O)C=C

>  <Chirality>  (168) 
Achiral Molecule

>  <First_Approval>  (168) 
nan

>  <Phase>  (168) 
3.0

>  <SC_Patent>  (168) 
None

>  <Synonyms>  (168) 
GNS-1480 | GNS1480 | LAZERTINIB | YH-25448 | YH25448

>  <Withdrawn>  (168) 


>  <Indications>  (168) 
Lazertinib (YH-25448, GNS-1480) is an inhibitor of the aberrant activity of EGFR mutant kinases, that was originally developed by Yuhan Corporation for antineoplastic potential in cancers with (acquired) resistance to existing EGFR tyrosine kinase inhibitors, in particular for EGFR mutation positive, advanced non-small cell lung cancer (NSCLC). In addition to predicted efficacy for the treatment of primary lung and extracranial lesions, lazertinib is expected to be beneficial for NSCLC brain metastases as it is able to cross the blood brain barrier.

>  <Type>  (168) 
nan

>  <targets_id>  (168) 
nan

>  <inchi>  (168) 
InChI=1S/C30H34N8O3/c1-5-28(39)32-23-17-24(26(40-4)18-25(23)37-13-15-41-16-14-37)33-30-31-12-11-27(34-30)38-20-22(19-36(2)3)29(35-38)21-9-7-6-8-10-21/h5-12,17-18,20H,1,13-16,19H2,2-4H3,(H,32,39)(H,31,33,34)

>  <stdInchikey>  (168) 
RRMJMHOQSALEJJ-UHFFFAOYSA-N

>  <csid>  (168) 
64835231

>  <Links>  (168) 
|http://www.chemspider.com/Chemical-Structure.64835231.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4558324|http://pubchem.ncbi.nlm.nih.gov/compound/121269225|http://www.drugbank.ca/drugs/DB16216|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10136|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=4A2Y23XK11

>  <LinkName>  (168) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS

>  <lig_pdbID>  (168) 


>  <pdbID>  (168) 


>  <indicationG2P>  (168) 
None

>  <indicationDB>  (168) 


>  <uniprotId>  (168) 


>  <MW>  (168) 
554.3

>  <HBA>  (168) 
10.0

>  <HBD>  (168) 
2.0

>  <NRB>  (168) 
10.0

>  <TPSA>  (168) 
109.7

>  <LogP>  (168) 
4.1

>  <RoF>  (168) 
1.0

>  <Melting point>  (168) 


>  <Targets>  (168) 
nan

>  <Kinase families>  (168) 


>  <FDA_approved>  (168) 


$$$$
Evobrutinib
     RDKit          2D

 32 35  0  0  0  0  0  0  0  0999 V2000
   -8.5569    0.9200    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1885    1.5343    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9723    0.6564    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1245   -0.8359    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6038    1.2707    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4516    2.7629    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0832    3.3772    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8669    2.4992    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0192    1.0070    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3876    0.3927    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4985    3.1135    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7177    2.2356    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0862    2.8499    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3024    1.9719    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6708    2.5862    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8231    4.0785    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.6069    4.9564    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2384    4.3421    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.8871    1.7082    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.1502    0.4797    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7817   -0.1346    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6295   -1.6269    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8457   -2.5049    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2141   -1.8906    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3664   -0.3983    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6935   -3.9971    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.3250   -4.6114    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1088   -3.7334    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2596   -4.3477    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4119   -5.8400    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1957   -6.7180    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1728   -6.1037    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  3  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
  8 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 15 19  1  0
 14 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 23 26  1  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  2  0
 10  5  1  0
 18 13  2  0
 25 20  1  0
 32 27  1  0
M  END
>  <BrandName>  (169) 


>  <Applicants>  (169) 
Merck

>  <CHEMBL_ID>  (169) 
CHEMBL4072833

>  <Canonical_Smiles>  (169) 
C=CC(=O)N1CCC(CC1)CNc2c(c(ncn2)N)c3ccc(cc3)Oc4ccccc4

>  <Chirality>  (169) 
Achiral Molecule

>  <First_Approval>  (169) 
nan

>  <Phase>  (169) 
3.0

>  <SC_Patent>  (169) 
None

>  <Synonyms>  (169) 
EVOBRUTINIB | M-2951

>  <Withdrawn>  (169) 


>  <Indications>  (169) 
nan

>  <Type>  (169) 
nan

>  <targets_id>  (169) 
Q06187

>  <inchi>  (169) 
InChI=1S/C25H27N5O2/c1-2-22(31)30-14-12-18(13-15-30)16-27-25-23(24(26)28-17-29-25)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-11,17-18H,1,12-16H2,(H3,26,27,28,29)

>  <stdInchikey>  (169) 
QUIWHXQETADMGN-UHFFFAOYSA-N

>  <csid>  (169) 
58827807

>  <Links>  (169) 
|http://www.chemspider.com/Chemical-Structure.58827807.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4072833|http://pubchem.ncbi.nlm.nih.gov/compound/71479709|http://www.drugbank.ca/drugs/DB15170| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=MZJ|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/MZJ|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9752|http://zinc15.docking.org/substances/ZINC000205623965|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=ZA45457L1K|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=291522

>  <LinkName>  (169) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (169) 
'MZJ'

>  <pdbID>  (169) 
6omu

>  <indicationG2P>  (169) 
None

>  <indicationDB>  (169) 


>  <uniprotId>  (169) 


>  <MW>  (169) 
429.2

>  <HBA>  (169) 
6.0

>  <HBD>  (169) 
2.0

>  <NRB>  (169) 
7.0

>  <TPSA>  (169) 
93.4

>  <LogP>  (169) 
4.4

>  <RoF>  (169) 
0.0

>  <Melting point>  (169) 


>  <Targets>  (169) 
BTK

>  <Kinase families>  (169) 
Tyr

>  <FDA_approved>  (169) 


$$$$
Volasertib
     RDKit          2D

 45 50  0  0  0  0  0  0  0  0999 V2000
  -12.0065   -2.2609    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.1582   -1.0238    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.6627   -1.1399    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.8144    0.0972    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3189   -0.0188    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4707    1.2183    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9752    1.1022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3279   -0.2510    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1762   -1.4881    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6717   -1.3720    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5200   -2.6091    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -9.0155   -2.4931    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.8637   -3.7302    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8727   -3.9623    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1269    2.3393    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6314    2.2233    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9842    0.8701    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4887    0.7540    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3596    1.9911    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2876    3.3443    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7831    3.4604    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8551    1.8751    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7034    3.1122    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.5024    0.5219    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.9979    0.4058    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6451   -0.9473    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1406   -1.0634    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9889    0.1737    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3416    1.5269    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8461    1.6429    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4844    0.0576    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.1316   -1.2955    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.6271   -1.4116    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.4754   -0.1745    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.8281    1.1787    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3326    1.2947    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.9709   -0.2906    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.6181   -1.6437    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.8552   -2.4920    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.5020   -3.1392    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8324   -0.3670    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1852   -1.7202    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.4617    1.4504    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.6134    2.6875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.9572    1.5665    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  3  2  1  1
  3  4  1  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  1  0
 12 13  2  0
 11 14  1  0
  7 15  1  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 19 22  1  0
 22 23  2  0
 22 24  1  0
 25 24  1  6
 25 26  1  0
 26 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  1  0
 28 31  1  1
 31 32  1  0
 32 33  1  0
 33 34  1  0
 34 35  1  0
 35 36  1  0
 34 37  1  0
 37 38  1  0
 38 39  1  0
 39 40  1  0
 17 41  1  0
 41 42  1  0
  4 43  1  0
 43 44  1  0
 43 45  1  0
 12  3  1  0
 10  5  1  0
 21 16  1  0
 30 25  1  0
 36 31  1  0
 40 38  1  0
M  END
>  <BrandName>  (170) 


>  <Applicants>  (170) 
Boehringer Ingelheim

>  <CHEMBL_ID>  (170) 
CHEMBL1233528

>  <Canonical_Smiles>  (170) 
CC[C@H]1N(c2nc(ncc2N(C1=O)C)Nc3c(cc(cc3)C(=O)N[C@H]4CC[C@@H](CC4)N5CCN(CC5)CC6CC6)OC)C(C)C

>  <Chirality>  (170) 
Single Stereoisomer

>  <First_Approval>  (170) 
nan

>  <Phase>  (170) 
3.0

>  <SC_Patent>  (170) 
None

>  <Synonyms>  (170) 
BI 6727 | BI-6727 | VOLASERTIB

>  <Withdrawn>  (170) 
|Study NCT02527174 in Canada was Withdrawn during Phase 1 because Volasertib no longer available|Study NCT02905994 in United States was Withdrawn during Phase 1 because Funding Withdrawn

>  <Indications>  (170) 
nan

>  <Type>  (170) 
1

>  <targets_id>  (170) 
P53350

>  <inchi>  (170) 
InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25-,26-,28-/m1/s1

>  <stdInchikey>  (170) 
SXNJFOWDRLKDSF-STROYTFGSA-N

>  <csid>  (170) 
26327706

>  <Links>  (170) 
|http://www.chemspider.com/Chemical-Structure.26327706.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1233528|http://www.drugbank.ca/drugs/DB12062| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=IBI|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/IBI|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7947|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6EM57086EA|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50402023

>  <LinkName>  (170) 
|ChemSpider|ChEMBL|DrugBank|RCSB|PDBe|Guide to Pharmacology|FDA SRS|BindingDB

>  <lig_pdbID>  (170) 
'IBI'

>  <pdbID>  (170) 
3fc2 5v67 5vbr

>  <indicationG2P>  (170) 
None

>  <indicationDB>  (170) 


>  <uniprotId>  (170) 


>  <MW>  (170) 
618.4

>  <HBA>  (170) 
9.0

>  <HBD>  (170) 
2.0

>  <NRB>  (170) 
10.0

>  <TPSA>  (170) 
106.2

>  <LogP>  (170) 
4.3

>  <RoF>  (170) 
1.0

>  <Melting point>  (170) 


>  <Targets>  (170) 
PLK1

>  <Kinase families>  (170) 
Other

>  <FDA_approved>  (170) 


$$$$
Buparlisib
     RDKit          2D

 29 32  0  0  0  0  0  0  0  0999 V2000
    4.5694    1.0558    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1993    0.4452    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9855    1.3263    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1416    2.8182    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5117    3.4289    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.7256    2.5477    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0957    3.1584    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.6154    0.7157    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5985    1.5969    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9686    0.9862    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1247   -0.5057    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9109   -1.3868    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4592   -0.7762    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0670   -2.8787    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4371   -3.4894    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5933   -4.9812    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3794   -5.8624    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0093   -5.2517    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1469   -3.7599    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1825    1.8674    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0263    3.3592    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2402    4.2404    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6102    3.6297    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7664    2.1379    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5525    1.2567    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0432   -1.0467    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8870   -2.5385    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    4.5350   -1.2029    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    1.5513   -0.8905    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  3  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 10 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
  2 26  1  0
 26 27  1  0
 26 28  1  0
 26 29  1  0
  6  1  1  0
 13  8  1  0
 19 14  1  0
 25 20  1  0
M  END
>  <BrandName>  (171) 


>  <Applicants>  (171) 
Novartis

>  <CHEMBL_ID>  (171) 
CHEMBL2017974

>  <Canonical_Smiles>  (171) 
c1c(c(cnc1N)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F

>  <Chirality>  (171) 
Achiral Molecule

>  <First_Approval>  (171) 
nan

>  <Phase>  (171) 
3.0

>  <SC_Patent>  (171) 
None

>  <Synonyms>  (171) 
BKM-120 | BKM-120NX | BKM120-NX | BUPARLISIB | NVP-BKM-120 | NVP-BKM120

>  <Withdrawn>  (171) 


>  <Indications>  (171) 
nan

>  <Type>  (171) 
1

>  <targets_id>  (171) 
P42336

>  <inchi>  (171) 
InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)

>  <stdInchikey>  (171) 
CWHUFRVAEUJCEF-UHFFFAOYSA-N

>  <csid>  (171) 
17588300

>  <Links>  (171) 
|http://www.chemspider.com/Chemical-Structure.17588300.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2017974|http://pubchem.ncbi.nlm.nih.gov/compound/16654980|http://www.drugbank.ca/drugs/DB11666| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=SD5|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/SD5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7878|http://zinc15.docking.org/substances/ZINC43154039|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=0ZM2Z182GD|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50380363

>  <LinkName>  (171) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (171) 
'SD5'

>  <pdbID>  (171) 
3sd5 5m7e

>  <indicationG2P>  (171) 
None

>  <indicationDB>  (171) 


>  <uniprotId>  (171) 


>  <MW>  (171) 
410.2

>  <HBA>  (171) 
8.0

>  <HBD>  (171) 
1.0

>  <NRB>  (171) 
3.0

>  <TPSA>  (171) 
89.6

>  <LogP>  (171) 
1.8

>  <RoF>  (171) 
0.0

>  <Melting point>  (171) 


>  <Targets>  (171) 
PIK3CA

>  <Kinase families>  (171) 
Atypical

>  <FDA_approved>  (171) 


$$$$
Famitinib
     RDKit          2D

 30 33  0  0  0  0  0  0  0  0999 V2000
  -10.0314    0.9734    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.5839    1.3666    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5196    0.3096    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9029   -1.1406    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.3504   -1.5338    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0720    0.7028    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0078   -0.3543    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5602    0.0389    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1769    1.4891    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7294    1.8823    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6651    0.8253    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0484   -0.6249    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2124   -1.4375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3749   -0.4896    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8326    0.9089    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.8251   -0.8728    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8821    0.1914    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3645   -0.0381    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1857   -1.2933    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6834   -1.2097    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3598    0.1291    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5385    1.3843    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0409    1.3007    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9766    2.3577    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.6424    1.6722    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3036    2.3486    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.5047   -2.4649    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    0.2961   -2.9352    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4959   -1.0181    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8792   -2.4683    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  3  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 14 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  1  0
 25 26  2  0
 20 27  1  0
 13 28  1  0
 12 29  1  0
 29 30  2  0
 29  8  1  0
 15 11  1  0
 17 25  1  0
 23 18  1  0
M  END
>  <BrandName>  (172) 


>  <Applicants>  (172) 
Jiangsu Hengrui Medicine

>  <CHEMBL_ID>  (172) 
CHEMBL3545026

>  <Canonical_Smiles>  (172) 
CCN(CC)CCN1CCc2c(c(c([nH]2)/C=C\3/c4cc(ccc4NC3=O)F)C)C1=O

>  <Chirality>  (172) 
Single Stereoisomer

>  <First_Approval>  (172) 
nan

>  <Phase>  (172) 
3.0

>  <SC_Patent>  (172) 
None

>  <Synonyms>  (172) 
SHR-1020

>  <Withdrawn>  (172) 
|Study NCT04044378 in China was Withdrawn during Phase 1/Phase 2 because toxicity

>  <Indications>  (172) 
nan

>  <Type>  (172) 
nan

>  <targets_id>  (172) 
P10721|P35968|P35916|P16234|P09619|P17948|P36888

>  <inchi>  (172) 
InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-

>  <stdInchikey>  (172) 
GKEYKDOLBLYGRB-LGMDPLHJSA-N

>  <csid>  (172) 
17595500

>  <Links>  (172) 
|http://www.chemspider.com/Chemical-Structure.17595500.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1278146|http://pubchem.ncbi.nlm.nih.gov/compound/16662431|http://www.drugbank.ca/drugs/DB11741|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7886|http://zinc15.docking.org/substances/ZINC000064453767|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=768FW21J3L|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50331023

>  <LinkName>  (172) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (172) 


>  <pdbID>  (172) 


>  <indicationG2P>  (172) 
None

>  <indicationDB>  (172) 


>  <uniprotId>  (172) 


>  <MW>  (172) 
410.2

>  <HBA>  (172) 
3.0

>  <HBD>  (172) 
2.0

>  <NRB>  (172) 
6.0

>  <TPSA>  (172) 
68.4

>  <LogP>  (172) 
3.3

>  <RoF>  (172) 
0.0

>  <Melting point>  (172) 


>  <Targets>  (172) 
KIT; KDR; FLT4; PDGFRA; PDGFRB; FLT1; FLT3

>  <Kinase families>  (172) 
Tyr

>  <FDA_approved>  (172) 


$$$$
Brivanib
     RDKit          2D

 27 30  0  0  0  0  0  0  0  0999 V2000
   -8.2591   -1.0548    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9184   -0.3821    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5862   -1.0713    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5190   -0.0172    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1917    1.3235    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6747    1.0980    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3670    2.5764    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8696    2.4887    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1968    1.1480    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0215   -0.1049    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3488   -1.4456    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6994    1.0603    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0267   -0.2804    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4708   -0.3681    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5379    0.6860    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8702   -0.0033    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6264   -1.4833    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1435   -1.7088    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.3188   -2.9618    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1786   -2.8740    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8514   -1.5334    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.2109    0.6695    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.4638   -0.1552    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8045    0.5175    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0575   -0.3072    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8923    2.0150    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.3124    2.1689    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  5  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
  9 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 16 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  6
 24 26  1  0
 15 27  1  0
  6  2  1  0
 10  4  1  0
 21 13  2  0
 18 14  1  0
M  END
>  <BrandName>  (173) 


>  <Applicants>  (173) 
Bristol Myers Squibb

>  <CHEMBL_ID>  (173) 
CHEMBL377300

>  <Canonical_Smiles>  (173) 
Cc1cc2c([nH]1)ccc(c2F)Oc3c4c(c(cn4ncn3)OC[C@@H](C)O)C

>  <Chirality>  (173) 
Single Stereoisomer

>  <First_Approval>  (173) 
nan

>  <Phase>  (173) 
3.0

>  <SC_Patent>  (173) 
None

>  <Synonyms>  (173) 
BMS-540215 | BRIVANIB

>  <Withdrawn>  (173) 


>  <Indications>  (173) 
nan

>  <Type>  (173) 
nan

>  <targets_id>  (173) 
P35968

>  <inchi>  (173) 
InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1

>  <stdInchikey>  (173) 
WCWUXEGQKLTGDX-LLVKDONJSA-N

>  <csid>  (173) 
9409099

>  <Links>  (173) 
|http://www.chemspider.com/Chemical-Structure.9409099.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL377300|http://pubchem.ncbi.nlm.nih.gov/compound/11234052|http://www.drugbank.ca/drugs/DB11958|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5671|http://zinc15.docking.org/substances/ZINC13684256|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=DDU33B674I|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50184807

>  <LinkName>  (173) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (173) 


>  <pdbID>  (173) 


>  <indicationG2P>  (173) 
None

>  <indicationDB>  (173) 


>  <uniprotId>  (173) 


>  <MW>  (173) 
370.1

>  <HBA>  (173) 
6.0

>  <HBD>  (173) 
2.0

>  <NRB>  (173) 
5.0

>  <TPSA>  (173) 
84.7

>  <LogP>  (173) 
3.5

>  <RoF>  (173) 
0.0

>  <Melting point>  (173) 


>  <Targets>  (173) 
KDR

>  <Kinase families>  (173) 
Tyr

>  <FDA_approved>  (173) 


$$$$
Vatalanib
     RDKit          2D

 25 28  0  0  0  0  0  0  0  0999 V2000
    1.6785   -4.6384    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1942   -4.8554    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7358   -3.6785    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1815   -2.2846    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3027   -2.0677    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2327   -3.2446    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8570   -0.6738    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9270    0.5031    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5572    0.2862    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1115   -1.1077    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5957   -1.3246    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5257   -0.1477    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9715    1.2461    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9014    2.4231    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3857    2.2061    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9399    0.8123    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0099   -0.3646    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3156    3.3830    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    3.3412   -0.4569    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8955    0.9369    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3797    1.1539    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9339    2.5477    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0040    3.7246    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.5197    3.5077    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9655    2.1139    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  5  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 15 18  1  0
  7 19  1  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
  6  1  1  0
 10  4  1  0
 17 12  1  0
 25 20  1  0
M  END
>  <BrandName>  (174) 


>  <Applicants>  (174) 
Novartis

>  <CHEMBL_ID>  (174) 
CHEMBL101253

>  <Canonical_Smiles>  (174) 
c1ccc2c(c1)c(nnc2Nc3ccc(cc3)Cl)Cc4ccncc4

>  <Chirality>  (174) 
Achiral Molecule

>  <First_Approval>  (174) 
nan

>  <Phase>  (174) 
3.0

>  <SC_Patent>  (174) 
None

>  <Synonyms>  (174) 
BAY-86-5127 | CGP-79787 | K-222584 | NVP-PTK787 | PTK-787 | PTK787 | VATALANIB | ZK-222584

>  <Withdrawn>  (174) 


>  <Indications>  (174) 
Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC).

>  <Type>  (174) 
nan

>  <targets_id>  (174) 
P17948|P35968|P35916

>  <inchi>  (174) 
InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)

>  <stdInchikey>  (174) 
YCOYDOIWSSHVCK-UHFFFAOYSA-N

>  <csid>  (174) 
133257

>  <Links>  (174) 
|http://www.chemspider.com/Chemical-Structure.133257.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL101253|http://pubchem.ncbi.nlm.nih.gov/compound/151194|http://www.drugbank.ca/drugs/DB04879|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5705|http://zinc15.docking.org/substances/ZINC00007460|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=5DX9U76296|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=4851

>  <LinkName>  (174) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (174) 


>  <pdbID>  (174) 


>  <indicationG2P>  (174) 
None

>  <indicationDB>  (174) 
Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.

>  <uniprotId>  (174) 
P17948|P35968|P35916

>  <MW>  (174) 
346.1

>  <HBA>  (174) 
4.0

>  <HBD>  (174) 
1.0

>  <NRB>  (174) 
4.0

>  <TPSA>  (174) 
50.7

>  <LogP>  (174) 
5.0

>  <RoF>  (174) 
1.0

>  <Melting point>  (174) 


>  <Targets>  (174) 
FLT1; KDR; FLT4

>  <Kinase families>  (174) 
Tyr

>  <FDA_approved>  (174) 


$$$$
Ipatasertib
     RDKit          2D

 32 35  0  0  0  0  0  0  0  0999 V2000
    2.5973    1.8166    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0442    1.4210    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2147    2.3591    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4685    1.5357    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0729    0.0888    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5746    0.0179    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8868   -1.3151    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6973   -2.5772    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.1957   -2.5064    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8834   -1.1733    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.3885   -1.3860    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.5779   -0.1238    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0796   -0.1947    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6082   -1.5277    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.2024   -2.7899    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7007   -2.7190    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1065   -1.5986    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7943   -2.9316    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9170   -0.3364    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2293    0.9966    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0398    2.2587    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3520    3.5918    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1626    4.8539    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8537    3.6626    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4154   -0.4073    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2259    0.8548    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7242    0.7840    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4120   -0.5491    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6015   -1.8112    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1032   -1.7403    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.9103   -0.6199    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    7.8716    2.0661    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  6
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
  7 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 14 17  1  0
 17 18  2  0
 17 19  1  0
 19 20  1  1
 20 21  1  0
 21 22  1  0
 22 23  1  0
 22 24  1  0
 19 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 28 31  1  0
  4 32  1  1
  6  2  1  0
 10  5  1  0
 16 11  1  0
 30 25  1  0
M  END
>  <BrandName>  (175) 


>  <Applicants>  (175) 
Hoffmann-La Roche

>  <CHEMBL_ID>  (175) 
CHEMBL2177390

>  <Canonical_Smiles>  (175) 
C[C@@H]1C[C@H](c2c1c(ncn2)N3CCN(CC3)C(=O)[C@H](CNC(C)C)c4ccc(cc4)Cl)O

>  <Chirality>  (175) 
Single Stereoisomer

>  <First_Approval>  (175) 
nan

>  <Phase>  (175) 
3.0

>  <SC_Patent>  (175) 
None

>  <Synonyms>  (175) 
GDC-0068 | IPATASERTIB | RG-7440 | RG7440

>  <Withdrawn>  (175) 


>  <Indications>  (175) 
nan

>  <Type>  (175) 
1

>  <targets_id>  (175) 
P31749|P31751|Q9Y243

>  <inchi>  (175) 
InChI=1S/C24H32ClN5O2/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3/t16-,19-,20-/m1/s1

>  <stdInchikey>  (175) 
GRZXWCHAXNAUHY-NSISKUIASA-N

>  <csid>  (175) 
28189084

>  <Links>  (175) 
|http://www.chemspider.com/Chemical-Structure.28189084.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2177390|http://pubchem.ncbi.nlm.nih.gov/compound/24788740|http://www.drugbank.ca/drugs/DB11743| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=0RF|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/0RF|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7887|http://zinc15.docking.org/substances/ZINC000068250459|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=524Y3IB4HQ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50398379

>  <LinkName>  (175) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (175) 
'0RF'

>  <pdbID>  (175) 
4ekl

>  <indicationG2P>  (175) 
None

>  <indicationDB>  (175) 


>  <uniprotId>  (175) 


>  <MW>  (175) 
457.2

>  <HBA>  (175) 
6.0

>  <HBD>  (175) 
2.0

>  <NRB>  (175) 
6.0

>  <TPSA>  (175) 
81.6

>  <LogP>  (175) 
3.1

>  <RoF>  (175) 
0.0

>  <Melting point>  (175) 


>  <Targets>  (175) 
AKT1; AKT2; AKT3

>  <Kinase families>  (175) 
AGC

>  <FDA_approved>  (175) 


$$$$
Itacitinib
     RDKit          2D

 40 45  0  0  0  0  0  0  0  0999 V2000
    8.5378   -2.0811    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8755   -2.7598    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.9343   -1.6973    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.2510   -0.3620    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.7862    1.0393    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.8402    2.2034    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3590    1.9662    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.8239    0.5649    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7699   -0.5992    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3428    0.3277    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6641   -1.0099    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1822   -0.7778    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.9450    0.7033    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.2803    1.3866    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6073    1.3820    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9286    0.0443    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5909    0.7230    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.2696    2.0607    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8349    0.2570    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9513    1.2588    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3771    0.7928    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6864   -0.6750    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5700   -1.6767    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1442   -1.2108    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1122   -1.1409    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4216   -2.6087    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2287   -0.1392    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9193    1.3286    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0358    2.3304    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4616    1.8644    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7709    0.3966    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6545   -0.6051    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9638   -2.0729    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  -10.1967   -0.0693    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.6225   -0.5353    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  -10.6627    1.3565    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -9.7307   -1.4951    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    1.9286    0.0443    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4308   -0.0368    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0029   -0.4779    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  8 10  1  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  1  0
 13 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 17 19  1  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 22 25  1  0
 25 26  2  0
 25 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  2  0
 32 33  1  0
 31 34  1  0
 34 35  1  0
 34 36  1  0
 34 37  1  0
 15 38  1  0
 38 39  1  0
 39 40  3  0
  9  1  1  0
  4  9  1  0
 14 10  2  0
 18 15  1  0
 24 19  1  0
 32 27  1  0
M  END
>  <BrandName>  (176) 


>  <Applicants>  (176) 
Incyte Corporation

>  <CHEMBL_ID>  (176) 
CHEMBL3622820

>  <Canonical_Smiles>  (176) 
c1cnc-2[nH]cnc(c12)c3cnn(c3)C4(CN(C4)C5CCN(CC5)C(=O)c6ccnc(c6F)C(F)(F)F)CC#N

>  <Chirality>  (176) 
Achiral Molecule

>  <First_Approval>  (176) 
nan

>  <Phase>  (176) 
3.0

>  <SC_Patent>  (176) 
None

>  <Synonyms>  (176) 
INCB-039110 | INCB-39110 | INCB039110 | ITACITINIB

>  <Withdrawn>  (176) 
|Study NCT02355431 in United States was Withdrawn during Phase 2 because Study withdrawn before enrolling first patient|Study NCT03627052 in nan was Withdrawn during Phase 2 because Study withdrawn due to lack of recruitment No patients enrolled No safety concerns

>  <Indications>  (176) 
nan

>  <Type>  (176) 
nan

>  <targets_id>  (176) 
P23458

>  <inchi>  (176) 
InChI=1S/C26H23F4N9O/c27-20-18(1-7-32-22(20)26(28,29)30)24(40)37-9-3-17(4-10-37)38-13-25(14-38,5-6-31)39-12-16(11-36-39)21-19-2-8-33-23(19)35-15-34-21/h1-2,7-8,11-12,15,17H,3-5,9-10,13-14H2,(H,33,34,35)

>  <stdInchikey>  (176) 
KTBSXLIQKWEBRB-UHFFFAOYSA-N

>  <csid>  (176) 
35033258

>  <Links>  (176) 
|http://www.chemspider.com/Chemical-Structure.35033258.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3622820|http://pubchem.ncbi.nlm.nih.gov/compound/53380437|http://www.drugbank.ca/drugs/DB12154|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8364|http://zinc15.docking.org/substances/ZINC000118795962|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=19J3781LPM|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=246868

>  <LinkName>  (176) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (176) 


>  <pdbID>  (176) 


>  <indicationG2P>  (176) 
None

>  <indicationDB>  (176) 


>  <uniprotId>  (176) 


>  <MW>  (176) 
553.2

>  <HBA>  (176) 
8.0

>  <HBD>  (176) 
1.0

>  <NRB>  (176) 
5.0

>  <TPSA>  (176) 
119.6

>  <LogP>  (176) 
3.6

>  <RoF>  (176) 
1.0

>  <Melting point>  (176) 


>  <Targets>  (176) 
JAK1

>  <Kinase families>  (176) 
Tyr

>  <FDA_approved>  (176) 


$$$$
Dactolisib
     RDKit          2D

 36 41  0  0  0  0  0  0  0  0999 V2000
    2.3510   -3.0258    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4534   -4.2276    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5559   -5.4294    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6553   -5.1251    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8571   -6.0227    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.2516   -3.3300    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1266   -3.9220    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3284   -3.0245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1520   -1.5349    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7738   -0.9429    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4280   -1.8404    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3539   -0.6373    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3341    0.8626    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2063    1.8515    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7859    1.3692    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3419    2.3582    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0494    3.8294    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3710    4.3116    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4988    3.3227    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9192    3.8049    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0470    2.8160    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7545    1.3448    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6520    0.1430    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7864   -1.0820    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2687   -2.5024    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1519    0.1627    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7623    1.8759    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8901    2.8649    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3104    2.3826    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4383    3.3716    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8586    2.8893    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1512    1.4181    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0233    0.4292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6030    0.9114    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4752   -0.0775    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0548    0.4047    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  4  5  3  0
  2  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
  9 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  2  0
 23 26  1  0
 16 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  2  0
 32 33  1  0
 33 34  2  0
 34 35  1  0
 35 36  2  0
 11  6  1  0
 24 12  1  0
 22 13  2  0
 19 14  1  0
 36 27  1  0
 34 29  1  0
M  END
>  <BrandName>  (177) 


>  <Applicants>  (177) 
Novartis

>  <CHEMBL_ID>  (177) 
CHEMBL1879463

>  <Canonical_Smiles>  (177) 
CC(C)(C#N)c1ccc(cc1)n2c3c4cc(ccc4ncc3n(c2=O)C)c5cc6ccccc6nc5

>  <Chirality>  (177) 
Achiral Molecule

>  <First_Approval>  (177) 
nan

>  <Phase>  (177) 
3.0

>  <SC_Patent>  (177) 
None

>  <Synonyms>  (177) 
BEZ-235 | BEZ235 | DACTOLISIB | NVP-BEZ235 | NVP-BEZ235-NX

>  <Withdrawn>  (177) 


>  <Indications>  (177) 
nan

>  <Type>  (177) 
nan

>  <targets_id>  (177) 
P42336|P42338|P48736|O00329|P42345

>  <inchi>  (177) 
InChI=1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3

>  <stdInchikey>  (177) 
JOGKUKXHTYWRGZ-UHFFFAOYSA-N

>  <csid>  (177) 
10151099

>  <Links>  (177) 
|http://www.chemspider.com/Chemical-Structure.10151099.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1879463|http://pubchem.ncbi.nlm.nih.gov/compound/11977753|http://www.drugbank.ca/drugs/DB11651|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950|http://zinc15.docking.org/substances/ZINC24760115|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=RUJ6Z9Y0DT|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=92862

>  <LinkName>  (177) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (177) 


>  <pdbID>  (177) 


>  <indicationG2P>  (177) 
None

>  <indicationDB>  (177) 


>  <uniprotId>  (177) 


>  <MW>  (177) 
469.2

>  <HBA>  (177) 
6.0

>  <HBD>  (177) 
0.0

>  <NRB>  (177) 
3.0

>  <TPSA>  (177) 
76.5

>  <LogP>  (177) 
5.9

>  <RoF>  (177) 
1.0

>  <Melting point>  (177) 


>  <Targets>  (177) 
PIK3CA; PIK3CB; PIK3CG; PIK3CD; MTOR

>  <Kinase families>  (177) 
Atypical

>  <FDA_approved>  (177) 


$$$$
Rociletinib
     RDKit          2D

 40 43  0  0  0  0  0  0  0  0999 V2000
  -10.9762    1.5390    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.2200    0.2436    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.9638   -1.0590    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7200    0.2507    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9762    1.5533    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4763    1.5605    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7201    0.2650    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4639   -1.0376    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9639   -1.0447    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2201    0.2722    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4639   -1.0233    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9639   -1.0161    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2201    0.2865    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9763    1.5819    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4763    1.5748    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2325    2.8845    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9887    4.1800    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2799    0.2936    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0360   -1.0018    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2922   -2.3044    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0484   -3.5999    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5484   -3.5927    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2922   -2.2901    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5360   -0.9947    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.7922   -2.2830    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.5360   -0.9804    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0360   -0.9732    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7798    0.3294    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0236    1.6248    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5236    1.6177    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7798    0.3151    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7674    2.9131    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.5112    4.2157    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0112    4.2228    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.7550    5.5112    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4988    6.8137    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3046   -4.8882    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0608   -6.1836    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    2.0091   -5.6444    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    4.6000   -4.1320    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  2  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  7 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 14 16  1  0
 16 17  1  0
 13 18  1  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 23 25  1  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 30 32  1  0
 32 33  1  0
 33 34  2  0
 33 35  1  0
 35 36  2  0
 22 37  1  0
 37 38  1  0
 37 39  1  0
 37 40  1  0
  9  4  1  0
 15 10  1  0
 24 19  1  0
 31 26  1  0
M  END
>  <BrandName>  (178) 


>  <Applicants>  (178) 
Clovis Oncology

>  <CHEMBL_ID>  (178) 
CHEMBL3545308

>  <Canonical_Smiles>  (178) 
CC(=O)N1CCN(CC1)c2ccc(c(c2)OC)Nc3ncc(c(n3)Nc4cccc(c4)NC(=O)C=C)C(F)(F)F

>  <Chirality>  (178) 
Achiral Molecule

>  <First_Approval>  (178) 
nan

>  <Phase>  (178) 
3.0

>  <SC_Patent>  (178) 
None

>  <Synonyms>  (178) 
AVL-301 | CNX-419 | CO-1686 | CS-1631 | ROCILETINIB

>  <Withdrawn>  (178) 


>  <Indications>  (178) 
nan

>  <Type>  (178) 
1

>  <targets_id>  (178) 
P00533

>  <inchi>  (178) 
InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35)

>  <stdInchikey>  (178) 
HUFOZJXAKZVRNJ-UHFFFAOYSA-N

>  <csid>  (178) 
30646712

>  <Links>  (178) 
|http://www.chemspider.com/Chemical-Structure.30646712.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545308|http://pubchem.ncbi.nlm.nih.gov/compound/57335384|http://www.drugbank.ca/drugs/DB11907| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=8JC|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/8JC|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7966|http://zinc15.docking.org/substances/ZINC000098043800|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=72AH61702G|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=149404

>  <LinkName>  (178) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (178) 
'8JC'

>  <pdbID>  (178) 
5xdk 5xdl

>  <indicationG2P>  (178) 
None

>  <indicationDB>  (178) 


>  <uniprotId>  (178) 


>  <MW>  (178) 
555.2

>  <HBA>  (178) 
8.0

>  <HBD>  (178) 
3.0

>  <NRB>  (178) 
8.0

>  <TPSA>  (178) 
111.7

>  <LogP>  (178) 
4.8

>  <RoF>  (178) 
1.0

>  <Melting point>  (178) 


>  <Targets>  (178) 
EGFR

>  <Kinase families>  (178) 
Tyr

>  <FDA_approved>  (178) 


$$$$
Dinaciclib
     RDKit          2D

 29 32  0  0  0  0  0  0  0  0999 V2000
   -4.2078   -5.0258    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7524   -3.5966    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2870   -3.2764    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1666   -4.2738    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1282   -3.5165    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1920   -2.0510    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6846   -1.9027    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3025   -0.5359    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4277    0.6826    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0650    0.5343    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6828   -0.8325    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1755   -0.9809    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.0502    0.2376    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5429    0.0893    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1607   -1.2776    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6534   -1.4259    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5282   -0.2074    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9103    1.1594    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.4177    1.3078    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7851    2.3779    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0455    2.0495    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1707    3.2680    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7886    4.6348    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2812    4.7832    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1560    3.5647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5382    2.1978    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4130    0.9793    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9056    1.1277    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7804   -0.0908    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 18 20  1  0
  9 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  6
 27 28  1  0
 28 29  1  0
  7  3  2  0
 11  6  1  0
 19 14  1  0
 26 21  1  0
M  CHG  2  18   1  20  -1
M  END
>  <BrandName>  (179) 


>  <Applicants>  (179) 
Schering-Plough

>  <CHEMBL_ID>  (179) 
CHEMBL2103840

>  <Canonical_Smiles>  (179) 
CCc1cnn2c1nc(cc2NCc3ccc[n+](c3)[O-])N4CCCC[C@H]4CCO

>  <Chirality>  (179) 
Single Stereoisomer

>  <First_Approval>  (179) 
nan

>  <Phase>  (179) 
3.0

>  <SC_Patent>  (179) 
None

>  <Synonyms>  (179) 
DINACICLIB | MK-7965 | SCH 727965 | SCH-727965

>  <Withdrawn>  (179) 


>  <Indications>  (179) 
nan

>  <Type>  (179) 
nan

>  <targets_id>  (179) 
P11802|Q00534|Q58F21

>  <inchi>  (179) 
InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1

>  <stdInchikey>  (179) 
PIMQWRZWLQKKBJ-SFHVURJKSA-N

>  <csid>  (179) 
25027387

>  <Links>  (179) 
|http://www.chemspider.com/Chemical-Structure.25027387.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103840|http://pubchem.ncbi.nlm.nih.gov/compound/46926350|http://www.drugbank.ca/drugs/DB12021|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7379|http://zinc15.docking.org/substances/ZINC000034894449|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=4V8ECV0NBQ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50139171

>  <LinkName>  (179) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (179) 


>  <pdbID>  (179) 


>  <indicationG2P>  (179) 
None

>  <indicationDB>  (179) 


>  <uniprotId>  (179) 


>  <MW>  (179) 
396.2

>  <HBA>  (179) 
7.0

>  <HBD>  (179) 
2.0

>  <NRB>  (179) 
7.0

>  <TPSA>  (179) 
92.6

>  <LogP>  (179) 
2.3

>  <RoF>  (179) 
0.0

>  <Melting point>  (179) 


>  <Targets>  (179) 
CDK4; CDK6; BRDT

>  <Kinase families>  (179) 
CMGC<br>(*)

>  <FDA_approved>  (179) 


$$$$
Alvocidib
     RDKit          2D

 28 31  0  0  0  0  0  0  0  0999 V2000
   -3.8841   -4.9071    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4213   -3.4803    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4255   -2.3661    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9627   -0.9392    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4956   -0.6266    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4914   -1.7409    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9542   -3.1677    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0243   -1.4283    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0328    0.8002    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0371    1.9144    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5743    3.3412    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1072    3.6538    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1029    2.5396    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5658    1.1128    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4385   -0.0014    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.9056    0.3112    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3684    1.7380    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3641    2.8522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8269    4.2790    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.9098   -0.8031    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4470   -2.2299    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4513   -3.3441    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9183   -3.0315    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3811   -1.6047    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3769   -0.4905    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8397    0.9364    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -0.6444    5.0806    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5041    1.6018    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  6  8  1  6
  5  9  1  6
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 16 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 12 27  1  0
 10 28  1  0
  7  2  1  0
 14  9  1  0
 18 13  1  0
 25 20  1  0
M  END
>  <BrandName>  (180) 


>  <Applicants>  (180) 
Sanofi

>  <CHEMBL_ID>  (180) 
CHEMBL428690

>  <Canonical_Smiles>  (180) 
CN1CC[C@@H]([C@@H](C1)O)c2c(cc(c3c2oc(cc3=O)c4ccccc4Cl)O)O

>  <Chirality>  (180) 
Single Stereoisomer

>  <First_Approval>  (180) 
nan

>  <Phase>  (180) 
3.0

>  <SC_Patent>  (180) 
None

>  <Synonyms>  (180) 
ALVOCIDIB | FLAVOPIRIDOL | HL 275 | HL-275 | HMR 1275 | HMR-1275 | L 86 8275 | L-868275 | L86-8275 | MDL 107,826A | MDL-107826A | NSC-649890

>  <Withdrawn>  (180) 
|Study NCT04493099 in United States was Withdrawn during Phase 1/Phase 2 because The original sponsor was acquired by a new company and has elected to end funding for all    Investigator Sponsored Trials (ISTs)

>  <Indications>  (180) 
Investigated for use/treatment in esophageal cancer, leukemia (lymphoid), lung cancer, liver cancer, and lymphoma (unspecified).

>  <Type>  (180) 
nan

>  <targets_id>  (180) 
nan

>  <inchi>  (180) 
InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m0/s1

>  <stdInchikey>  (180) 
BIIVYFLTOXDAOV-YVEFUNNKSA-N

>  <csid>  (180) 
4450222

>  <Links>  (180) 
|http://www.chemspider.com/Chemical-Structure.4450222.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL428690|http://pubchem.ncbi.nlm.nih.gov/compound/5287969|http://www.drugbank.ca/drugs/DB03496| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=CPB|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/CPB|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5680|http://zinc15.docking.org/substances/ZINC000021288966|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=45AD6X575G|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=5655

>  <LinkName>  (180) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (180) 
'CPB'

>  <pdbID>  (180) 
1c8k 1e1y 3blr 3ebp 4o71

>  <indicationG2P>  (180) 
None

>  <indicationDB>  (180) 
Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer. It works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.

>  <uniprotId>  (180) 
P24941|Q00535|P50750|P06493|Q00534|P00533|P11802|P49336|P50613|P11217|P11216|P06737|P22309|Q9UNQ0

>  <MW>  (180) 
401.1

>  <HBA>  (180) 
6.0

>  <HBD>  (180) 
3.0

>  <NRB>  (180) 
2.0

>  <TPSA>  (180) 
94.1

>  <LogP>  (180) 
3.3

>  <RoF>  (180) 
0.0

>  <Melting point>  (180) 


>  <Targets>  (180) 
nan

>  <Kinase families>  (180) 


>  <FDA_approved>  (180) 


$$$$
Ruboxistaurin
     RDKit          2D

 35 40  0  0  0  0  0  0  0  0999 V2000
   -2.7478   -7.6916    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4979   -6.2125    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6538   -5.2566    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0920   -5.6895    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8421   -4.2104    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6554   -4.1249    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9676   -3.3982    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8061   -1.6771    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.8567   -0.5158    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6678    0.7460    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1185    0.3645    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2040   -1.1330    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5436   -1.8078    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7978   -0.9850    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7124    0.5126    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3727    1.1873    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6673    1.8636    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2809    2.4363    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2166    2.3508    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5288    1.6241    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3957    0.3999    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0019    1.7720    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8844    2.7725    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1921    4.2406    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6174    4.7081    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7349    3.7076    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4272    2.2395    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6456   -1.0791    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2290   -2.5201    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2285   -3.6377    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.3972    3.9318    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7443    4.9049    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.8555    4.2833    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6404    3.0051    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1359    2.8887    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  5  4  1  1
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 10 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 21 28  1  0
 28 29  1  0
 29 30  1  0
 18 31  1  0
 31 32  2  0
 31 33  1  0
 33 34  1  0
 34 35  2  0
 30  5  1  0
 12  8  1  0
 16 11  1  0
 34 17  1  0
 23 19  1  0
 27 22  1  0
M  END
>  <BrandName>  (181) 
Arxxant

>  <Applicants>  (181) 
Eli Lilly

>  <CHEMBL_ID>  (181) 
CHEMBL91829

>  <Canonical_Smiles>  (181) 
CN(C)C[C@@H]1CCn2cc(c3c2cccc3)C4=C(c5cn(c6c5cccc6)CCO1)C(=O)NC4=O

>  <Chirality>  (181) 
Single Stereoisomer

>  <First_Approval>  (181) 
nan

>  <Phase>  (181) 
3.0

>  <SC_Patent>  (181) 
None

>  <Synonyms>  (181) 
ARXXANT | LY-333531 | RUBOXISTAURIN

>  <Withdrawn>  (181) 


>  <Indications>  (181) 
nan

>  <Type>  (181) 
nan

>  <targets_id>  (181) 
nan

>  <inchi>  (181) 
InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1

>  <stdInchikey>  (181) 
ZCBUQCWBWNUWSU-SFHVURJKSA-N

>  <csid>  (181) 
135727

>  <Links>  (181) 
|http://www.chemspider.com/Chemical-Structure.135727.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL91829|http://pubchem.ncbi.nlm.nih.gov/compound/153999|http://www.drugbank.ca/drugs/DB11829| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=LY4|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/LY4|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5263|http://zinc15.docking.org/substances/ZINC000003812168|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=721809WQCP|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50128281

>  <LinkName>  (181) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (181) 
'LY4'

>  <pdbID>  (181) 
1uu3 2j2i

>  <indicationG2P>  (181) 
None

>  <indicationDB>  (181) 


>  <uniprotId>  (181) 


>  <MW>  (181) 
468.2

>  <HBA>  (181) 
6.0

>  <HBD>  (181) 
1.0

>  <NRB>  (181) 
2.0

>  <TPSA>  (181) 
68.5

>  <LogP>  (181) 
3.5

>  <RoF>  (181) 
0.0

>  <Melting point>  (181) 


>  <Targets>  (181) 
nan

>  <Kinase families>  (181) 


>  <FDA_approved>  (181) 


$$$$
Almonertinib
     RDKit          2D

 39 43  0  0  0  0  0  0  0  0999 V2000
  -10.8243    0.9640    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.4388    0.3892    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -9.2438   -1.0981    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.2483    1.3017    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8628    0.7270    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6723    1.6395    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8673    3.1268    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2868    1.0648    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0963    1.9773    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7107    1.4025    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5202    2.3151    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7153    3.8023    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5157   -0.0847    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7062   -0.9973    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0917   -0.4225    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2823   -1.3350    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0872   -2.8223    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7017   -3.3970    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2777   -3.7348    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0827   -5.2221    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1302   -0.6595    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0603    0.2530    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4458   -0.3217    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.6363    0.5908    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4413    2.0781    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0558    2.6528    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8653    1.7403    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.0218    0.0161    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3713   -1.4427    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8666   -1.5611    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.6497   -2.8405    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.9675   -3.5569    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6881   -4.3400    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4413   -0.1756    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8555    0.3244    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1297    1.7991    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9896    2.7739    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5753    2.2739    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3012    0.7992    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  6  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 10 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  1  0
 17 18  2  0
 17 19  1  0
 19 20  2  0
 13 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 24 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 32 33  1  0
 30 34  1  0
 34 35  2  0
 35 36  1  0
 36 37  2  0
 37 38  1  0
 38 39  2  0
 15  8  1  0
 27 22  1  0
 39 28  1  0
 33 31  1  0
 39 34  1  0
M  END
>  <BrandName>  (182) 


>  <Applicants>  (182) 
Jiangsu Hansoh Pharmaceutical

>  <CHEMBL_ID>  (182) 
CHEMBL4594354

>  <Canonical_Smiles>  (182) 
CN(C)CCN(C)C1C=C(OC)C(=CC=1NC(=O)C=C)NC1N=C(C=CN=1)C1=CN(C2CC2)C2C=CC=CC=21

>  <Chirality>  (182) 
Unknown

>  <First_Approval>  (182) 
nan

>  <Phase>  (182) 
3.0

>  <SC_Patent>  (182) 
None

>  <Synonyms>  (182) 
|HS-10296|AMEILE

>  <Withdrawn>  (182) 


>  <Indications>  (182) 
nan

>  <Type>  (182) 
nan

>  <targets_id>  (182) 
nan

>  <inchi>  (182) 
InChI=1S/C30H35N7O2/c1-6-29(38)32-24-17-25(28(39-5)18-27(24)36(4)16-15-35(2)3)34-30-31-14-13-23(33-30)22-19-37(20-11-12-20)26-10-8-7-9-21(22)26/h6-10,13-14,17-20H,1,11-12,15-16H2,2-5H3,(H,32,38)(H,31,33,34)

>  <stdInchikey>  (182) 
DOEOECWDNSEFDN-UHFFFAOYSA-N

>  <csid>  (182) 
75535991

>  <Links>  (182) 
|http://www.chemspider.com/Chemical-Structure.75535991.html|http://pubchem.ncbi.nlm.nih.gov/compound/121280087|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11136|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=T4RS462G19

>  <LinkName>  (182) 
|ChemSpider|PubChem|Guide to Pharmacology|FDA SRS

>  <lig_pdbID>  (182) 


>  <pdbID>  (182) 


>  <indicationG2P>  (182) 
None

>  <indicationDB>  (182) 


>  <uniprotId>  (182) 


>  <MW>  (182) 
525.3

>  <HBA>  (182) 
8.0

>  <HBD>  (182) 
2.0

>  <NRB>  (182) 
11.0

>  <TPSA>  (182) 
87.6

>  <LogP>  (182) 
5.3

>  <RoF>  (182) 
2.0

>  <Melting point>  (182) 


>  <Targets>  (182) 
nan

>  <Kinase families>  (182) 


>  <FDA_approved>  (182) 


$$$$
Tivantinib
     RDKit          2D

 28 33  0  0  0  0  0  0  0  0999 V2000
   -6.1117    0.0870    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3188    1.5727    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1358    2.4948    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7456    1.9314    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5385    0.4457    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7216   -0.4764    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0616    0.1836    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3559    1.5072    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3967    2.5874    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4056   -1.1653    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0713   -1.4274    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2784   -2.9131    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6021   -3.6188    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0705   -3.5691    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1113   -2.4890    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5969   -2.6961    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.1515   -0.3867    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9444    1.0990    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2933    1.7550    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.3341    0.6748    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6284   -0.6488    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4219   -1.9217    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9210   -1.8711    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6267   -0.5474    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8333    0.7255    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2646    2.1692    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3424    3.3523    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8568    3.1452    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  5  7  1  0
  7  8  2  0
  8  9  1  0
 10  7  1  1
 10 11  1  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  1  0
 15 16  2  0
 11 17  1  6
 17 18  2  0
 18 19  1  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
  6  1  1  0
  9  4  1  0
 15 10  1  0
 21 17  1  0
 28 19  1  0
 25 20  1  0
M  END
>  <BrandName>  (183) 


>  <Applicants>  (183) 
Daiichi Sankyo

>  <CHEMBL_ID>  (183) 
CHEMBL2103882

>  <Canonical_Smiles>  (183) 
c1ccc2c(c1)c(c[nH]2)[C@H]3[C@@H](C(=O)NC3=O)c4cn5c6c4cccc6CCC5

>  <Chirality>  (183) 
Single Stereoisomer

>  <First_Approval>  (183) 
nan

>  <Phase>  (183) 
3.0

>  <SC_Patent>  (183) 
None

>  <Synonyms>  (183) 
ARQ 197 | ARQ-197 | TIVANTINIB

>  <Withdrawn>  (183) 


>  <Indications>  (183) 
nan

>  <Type>  (183) 
nan

>  <targets_id>  (183) 
P08581

>  <inchi>  (183) 
InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2,(H,25,27,28)/t19-,20-/m0/s1

>  <stdInchikey>  (183) 
UCEQXRCJXIVODC-PMACEKPBSA-N

>  <csid>  (183) 
9669218

>  <Links>  (183) 
|http://www.chemspider.com/Chemical-Structure.9669218.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103882|http://pubchem.ncbi.nlm.nih.gov/compound/11494412|http://www.drugbank.ca/drugs/DB12200| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=TIV|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/TIV|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7948|http://zinc15.docking.org/substances/ZINC000100016063|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=PJ4H73IL17|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50146168

>  <LinkName>  (183) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (183) 
'TIV'

>  <pdbID>  (183) 
5cb4

>  <indicationG2P>  (183) 
None

>  <indicationDB>  (183) 
Tivantinib has been investigated in Solid Tumors.

>  <uniprotId>  (183) 
P08581

>  <MW>  (183) 
369.1

>  <HBA>  (183) 
3.0

>  <HBD>  (183) 
2.0

>  <NRB>  (183) 
2.0

>  <TPSA>  (183) 
66.9

>  <LogP>  (183) 
3.6

>  <RoF>  (183) 
0.0

>  <Melting point>  (183) 


>  <Targets>  (183) 
MET

>  <Kinase families>  (183) 
Tyr

>  <FDA_approved>  (183) 


$$$$
Fruquintinib
     RDKit          2D

 29 32  0  0  0  0  0  0  0  0999 V2000
    6.9609    2.4612    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5887    1.8555    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2721    0.3893    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7798    0.2372    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8943   -0.9735    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4030   -0.8119    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7973    0.5603    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6828    1.7710    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1741    1.6095    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2920    2.6096    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6940    0.7219    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5795   -0.4889    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0708   -0.3273    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6765    1.0450    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1678    1.2065    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0534   -0.0042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4476   -1.3765    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9564   -1.5380    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3506   -2.9103    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8593   -3.0718    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9738   -1.8611    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5446    0.1573    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4302   -1.0534    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7736    2.5788    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8880    3.7895    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2722   -0.7287    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7405   -0.4215    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.8042   -2.1538    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.8043   -3.2717    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
  7 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 16 22  1  0
 22 23  1  0
 15 24  1  0
 24 25  1  0
  3 26  1  0
 26 27  2  0
 26 28  1  0
 28 29  1  0
 10  2  1  0
  9  4  1  0
 21 12  2  0
 18 13  1  0
M  END
>  <BrandName>  (184) 


>  <Applicants>  (184) 
Hutchison MediPharma

>  <CHEMBL_ID>  (184) 
CHEMBL3545339

>  <Canonical_Smiles>  (184) 
Cc1c(c2ccc(cc2o1)Oc3c4cc(c(cc4ncn3)OC)OC)C(=O)NC

>  <Chirality>  (184) 
Single Stereoisomer

>  <First_Approval>  (184) 
nan

>  <Phase>  (184) 
3.0

>  <SC_Patent>  (184) 
None

>  <Synonyms>  (184) 


>  <Withdrawn>  (184) 


>  <Indications>  (184) 
nan

>  <Type>  (184) 
nan

>  <targets_id>  (184) 
P17948|P35968|P35916

>  <inchi>  (184) 
InChI=1S/C21H19N3O5/c1-11-19(20(25)22-2)13-6-5-12(7-16(13)28-11)29-21-14-8-17(26-3)18(27-4)9-15(14)23-10-24-21/h5-10H,1-4H3,(H,22,25)

>  <stdInchikey>  (184) 
BALLNEJQLSTPIO-UHFFFAOYSA-N

>  <csid>  (184) 
39625837

>  <Links>  (184) 
|http://www.chemspider.com/Chemical-Structure.39625837.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4303214|http://pubchem.ncbi.nlm.nih.gov/compound/44480399|http://www.drugbank.ca/drugs/DB11679|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9428|http://zinc15.docking.org/substances/ZINC000114898570|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=49DXG3M5ZW

>  <LinkName>  (184) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (184) 


>  <pdbID>  (184) 


>  <indicationG2P>  (184) 
None

>  <indicationDB>  (184) 


>  <uniprotId>  (184) 


>  <MW>  (184) 
393.1

>  <HBA>  (184) 
7.0

>  <HBD>  (184) 
1.0

>  <NRB>  (184) 
5.0

>  <TPSA>  (184) 
95.7

>  <LogP>  (184) 
3.9

>  <RoF>  (184) 
0.0

>  <Melting point>  (184) 


>  <Targets>  (184) 
FLT1; KDR; FLT4

>  <Kinase families>  (184) 
Tyr

>  <FDA_approved>  (184) 


$$$$
Cediranib
     RDKit          2D

 33 37  0  0  0  0  0  0  0  0999 V2000
   10.6913    0.8056    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2389    0.4307    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0819    1.3853    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8165    0.5800    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1914   -0.8724    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6885   -0.9647    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.1210   -1.9233    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6758   -1.5218    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3009   -0.0694    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3712    0.9815    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9963    2.4339    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    2.8556    0.3321    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.7852   -0.7187    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3400   -0.3172    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0349    1.1352    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4802    1.5367    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5505    0.4858    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1756   -0.9666    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7304   -1.3681    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3555   -2.8205    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0898   -3.2220    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1601   -2.1711    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9958    0.8873    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0662   -0.1635    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5114    0.2380    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5818   -0.8129    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.0270   -0.4114    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  -10.2014   -1.3446    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.4518   -0.5161    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.0503    0.9291    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.5517    0.9939    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8551    2.9891    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7847    4.0400    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  5  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
  9 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 17 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
 16 32  1  0
 32 33  1  0
  6  2  1  0
 10  4  1  0
 22 13  2  0
 19 14  1  0
 31 27  1  0
M  END
>  <BrandName>  (185) 
Recentin

>  <Applicants>  (185) 
Astrazeneca

>  <CHEMBL_ID>  (185) 
CHEMBL491473

>  <Canonical_Smiles>  (185) 
Cc1cc2c([nH]1)ccc(c2F)Oc3c4cc(c(cc4ncn3)OCCCN5CCCC5)OC

>  <Chirality>  (185) 
Achiral Molecule

>  <First_Approval>  (185) 
nan

>  <Phase>  (185) 
3.0

>  <SC_Patent>  (185) 
None

>  <Synonyms>  (185) 
AZD-2171 | AZD2171 | CEDIRANIB | RECENTIN | ZD-2171

>  <Withdrawn>  (185) 
|Study NCT04184518 in Spain was Withdrawn during Phase 2 because The Cediranib producer laboratory decided to stop the development of this product

>  <Indications>  (185) 
For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.

>  <Type>  (185) 
nan

>  <targets_id>  (185) 
P35968

>  <inchi>  (185) 
InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3

>  <stdInchikey>  (185) 
XXJWYDDUDKYVKI-UHFFFAOYSA-N

>  <csid>  (185) 
8109103

>  <Links>  (185) 
|http://www.chemspider.com/Chemical-Structure.8109103.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL491473|http://pubchem.ncbi.nlm.nih.gov/compound/9933475|http://www.drugbank.ca/drugs/DB04849|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5664|http://zinc15.docking.org/substances/ZINC000003948085|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=NQU9IPY4K9|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50331096

>  <LinkName>  (185) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (185) 


>  <pdbID>  (185) 


>  <indicationG2P>  (185) 
None

>  <indicationDB>  (185) 
The novel indole-ether quinazoline Cediranib is a highly potent (IC<sub>50</sub> &lt; 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.

>  <uniprotId>  (185) 
P35968

>  <MW>  (185) 
450.2

>  <HBA>  (185) 
6.0

>  <HBD>  (185) 
1.0

>  <NRB>  (185) 
8.0

>  <TPSA>  (185) 
72.5

>  <LogP>  (185) 
5.2

>  <RoF>  (185) 
1.0

>  <Melting point>  (185) 


>  <Targets>  (185) 
KDR

>  <Kinase families>  (185) 
Tyr

>  <FDA_approved>  (185) 


$$$$
Abrocitinib
     RDKit          2D

 22 24  0  0  0  0  0  0  0  0999 V2000
   -4.4976    3.3422    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7661    2.0326    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5345    0.7444    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8031   -0.5652    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4935    0.1663    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1126   -1.2967    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0716   -1.8748    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5718   -1.8961    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4961   -0.8506    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5493   -1.9262    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5263   -2.9717    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0492   -1.9476    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.7807   -3.2571    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8176   -0.6593    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0861    0.6502    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6235    0.9829    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4879    2.4768    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8668    3.0674    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.8545    1.9385    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3544    1.9172    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.0858    0.6076    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3174   -0.6806    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  4  6  2  0
  4  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 10 12  1  0
 12 13  1  0
 12 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 11  8  1  0
 22 14  1  0
 19 15  1  0
M  END
>  <BrandName>  (186) 


>  <Applicants>  (186) 
Pfizer

>  <CHEMBL_ID>  (186) 
CHEMBL3655081

>  <Canonical_Smiles>  (186) 
CCCS(=O)(=O)NC1CC(C1)N(C)c2c3cc[nH]c3ncn2

>  <Chirality>  (186) 
Single Stereoisomer

>  <First_Approval>  (186) 
nan

>  <Phase>  (186) 
3.0

>  <SC_Patent>  (186) 
None

>  <Synonyms>  (186) 
|PF-04965842

>  <Withdrawn>  (186) 


>  <Indications>  (186) 
nan

>  <Type>  (186) 
nan

>  <targets_id>  (186) 
nan

>  <inchi>  (186) 
InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17)

>  <stdInchikey>  (186) 
IUEWXNHSKRWHDY-UHFFFAOYSA-N

>  <csid>  (186) 
68006894

>  <Links>  (186) 
|http://www.chemspider.com/Chemical-Structure.68006894.html|http://pubchem.ncbi.nlm.nih.gov/compound/78323835

>  <LinkName>  (186) 
|ChemSpider|PubChem

>  <lig_pdbID>  (186) 


>  <pdbID>  (186) 


>  <indicationG2P>  (186) 


>  <indicationDB>  (186) 


>  <uniprotId>  (186) 


>  <MW>  (186) 
323.1

>  <HBA>  (186) 
5.0

>  <HBD>  (186) 
2.0

>  <NRB>  (186) 
6.0

>  <TPSA>  (186) 
91.0

>  <LogP>  (186) 
1.3

>  <RoF>  (186) 
0.0

>  <Melting point>  (186) 


>  <Targets>  (186) 
nan

>  <Kinase families>  (186) 


>  <FDA_approved>  (186) 


$$$$
Infigratinib
     RDKit          2D

 38 41  0  0  0  0  0  0  0  0999 V2000
  -10.7959   -3.9268    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.3145   -4.1622    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3700   -2.9969    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.9069   -1.5963    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9623   -0.4310    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4809   -0.6664    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9440   -2.0670    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8886   -3.2323    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5364    0.4989    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0549    0.2635    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1104    1.4288    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6473    2.8294    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1287    3.0647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0732    1.8995    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7027    3.9946    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2213    3.7593    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6844    2.3587    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7970    2.1233    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7415    3.2885    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.2046    4.6892    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2768    4.9245    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.3339    0.7227    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.3893   -0.4426    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8153    0.4873    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7598    1.6526    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.3522   -0.9133    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.8336   -1.1487    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3705   -2.5493    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8519   -2.7847    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7964   -1.6194    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2595   -0.2188    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7781    0.0166    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2412    1.4172    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    8.2041    0.9465    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.6855    0.7111    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3888   -4.1853    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.8702   -4.4207    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4259   -3.7146    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  6  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 12 15  1  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 18 22  1  0
 22 23  1  0
 22 24  1  0
 24 25  2  0
 24 26  1  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  2  0
 32 33  1  0
 31 34  1  0
 34 35  1  0
 29 36  1  0
 36 37  1  0
 28 38  1  0
  8  3  1  0
 14  9  1  0
 21 16  1  0
 32 27  1  0
M  END
>  <BrandName>  (187) 


>  <Applicants>  (187) 
Novartis

>  <CHEMBL_ID>  (187) 
CHEMBL1852688

>  <Canonical_Smiles>  (187) 
CCN1CCN(CC1)c2ccc(cc2)Nc3cc(ncn3)N(C)C(=O)Nc4c(c(cc(c4Cl)OC)OC)Cl

>  <Chirality>  (187) 
Achiral Molecule

>  <First_Approval>  (187) 
nan

>  <Phase>  (187) 
3.0

>  <SC_Patent>  (187) 
None

>  <Synonyms>  (187) 
BGJ-398 | BGJ398 | INFIGRATINIB | MVP-BGJ398 | NVP-BGJ398

>  <Withdrawn>  (187) 


>  <Indications>  (187) 
nan

>  <Type>  (187) 
1

>  <targets_id>  (187) 
P11362|P21802|P22607

>  <inchi>  (187) 
InChI=1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31)

>  <stdInchikey>  (187) 
QADPYRIHXKWUSV-UHFFFAOYSA-N

>  <csid>  (187) 
26333103

>  <Links>  (187) 
|http://www.chemspider.com/Chemical-Structure.26333103.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1852688|http://pubchem.ncbi.nlm.nih.gov/compound/53235510|http://www.drugbank.ca/drugs/DB11886| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=07J|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/07J|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7877|http://zinc15.docking.org/substances/ZINC000072105034|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=A4055ME1VK|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50355393

>  <LinkName>  (187) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (187) 
'07J'

>  <pdbID>  (187) 
3tt0

>  <indicationG2P>  (187) 
None

>  <indicationDB>  (187) 


>  <uniprotId>  (187) 


>  <MW>  (187) 
559.2

>  <HBA>  (187) 
8.0

>  <HBD>  (187) 
2.0

>  <NRB>  (187) 
8.0

>  <TPSA>  (187) 
95.1

>  <LogP>  (187) 
5.4

>  <RoF>  (187) 
2.0

>  <Melting point>  (187) 


>  <Targets>  (187) 
FGFR1; FGFR2; FGFR3

>  <Kinase families>  (187) 
Tyr

>  <FDA_approved>  (187) 


$$$$
Linsitinib
     RDKit          2D

 32 37  0  0  0  0  0  0  0  0999 V2000
   -5.5026   -5.0677    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7339   -3.5856    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9652   -2.1036    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4831   -1.8723    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2518   -3.3544    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5987   -0.6608    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0590    0.7669    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8435    1.6458    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9969    3.1379    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3658    3.7511    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5813    2.8722    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4279    1.3801    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7813    4.0168    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6319    0.7613    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0987   -0.6642    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2043    1.2216    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9081    0.2154    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3358    0.6757    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4482   -0.3305    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.8758    0.1298    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1910    1.5963    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0786    2.6025    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6510    2.1422    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5385    3.1484    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1109    2.6881    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9883   -0.8765    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6731   -2.3430    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7855   -3.3492    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2131   -2.8889    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5283   -1.4224    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4159   -0.4162    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2160   -3.8169    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  1
  2  3  1  0
  3  4  1  0
  4  5  1  0
  4  6  1  6
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
  9 13  1  0
  8 14  2  0
 14 15  1  0
 14 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 20 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
  2 32  1  0
  5  2  1  0
 15  6  2  0
 12  7  1  0
 25 16  1  0
 23 18  1  0
 31 26  1  0
M  END
>  <BrandName>  (188) 


>  <Applicants>  (188) 
Osi Pharmaceuticals

>  <CHEMBL_ID>  (188) 
CHEMBL1091644

>  <Canonical_Smiles>  (188) 
C[C@]1(C[C@@H](C1)c2n3c(c(ncc3)N)c(n2)c4cc5nc(ccc5cc4)c6ccccc6)O

>  <Chirality>  (188) 
Single Stereoisomer

>  <First_Approval>  (188) 
nan

>  <Phase>  (188) 
3.0

>  <SC_Patent>  (188) 
None

>  <Synonyms>  (188) 
ASP-7487 | LINSITINIB | OSI-906 | OSI-906AA

>  <Withdrawn>  (188) 
|Study NCT01465815 in United States was Withdrawn during Phase 1/Phase 2 because Drug manufacturer, Astellas Pharma, informed us that safety and efficacy of Erlotinib and    OSI-906 in other oncology studies was determined to be unfavorable

>  <Indications>  (188) 
nan

>  <Type>  (188) 
nan

>  <targets_id>  (188) 
P08069

>  <inchi>  (188) 
InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)/t19-,26+

>  <stdInchikey>  (188) 
PKCDDUHJAFVJJB-VLZXCDOPSA-N

>  <csid>  (188) 
21391708

>  <Links>  (188) 
|http://www.chemspider.com/Chemical-Structure.21391708.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1091644|http://www.drugbank.ca/drugs/DB06075|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7423|http://zinc15.docking.org/substances/ZINC000100071817|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=15A52GPT8T|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50315887

>  <LinkName>  (188) 
|ChemSpider|ChEMBL|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (188) 


>  <pdbID>  (188) 


>  <indicationG2P>  (188) 
None

>  <indicationDB>  (188) 
An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis.

>  <uniprotId>  (188) 
P08069|P06213

>  <MW>  (188) 
421.2

>  <HBA>  (188) 
6.0

>  <HBD>  (188) 
2.0

>  <NRB>  (188) 
3.0

>  <TPSA>  (188) 
89.3

>  <LogP>  (188) 
4.8

>  <RoF>  (188) 
0.0

>  <Melting point>  (188) 


>  <Targets>  (188) 
IGF1R

>  <Kinase families>  (188) 
Tyr

>  <FDA_approved>  (188) 


$$$$
Fasudil
     RDKit          2D

 20 22  0  0  0  0  0  0  0  0999 V2000
    2.7967   -2.7203    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8432   -1.6457    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4359   -0.2021    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4825    0.8725    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0751    2.3161    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6213    2.6852    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5747    1.6106    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9820    0.1670    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9355   -0.9076    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3428   -2.3512    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5184   -0.5385    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8875   -1.9924    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1494    0.9154    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9723   -0.1695    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9357   -1.3192    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4352   -1.2829    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3418   -0.0879    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9727    1.3660    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6059    1.9839    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2706    1.3006    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
  9 11  1  0
 11 12  2  0
 11 13  2  0
 11 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 10  1  1  0
  8  3  1  0
 20 14  1  0
M  END
>  <BrandName>  (189) 


>  <Applicants>  (189) 
Asahi Kasei Pharma Corp

>  <CHEMBL_ID>  (189) 
CHEMBL38380

>  <Canonical_Smiles>  (189) 
c1cc2cnccc2c(c1)S(=O)(=O)N3CCCNCC3

>  <Chirality>  (189) 
Achiral Molecule

>  <First_Approval>  (189) 
nan

>  <Phase>  (189) 
4.0

>  <SC_Patent>  (189) 
None

>  <Synonyms>  (189) 
AT 877 | AT-877 | FASUDIL | HA 1077 | HA-1077 | ZK-258594

>  <Withdrawn>  (189) 


>  <Indications>  (189) 
Fasudil is a potent inhibitor of the Rho-kinases ROCK1 and ROCK2.

>  <Type>  (189) 
nan

>  <targets_id>  (189) 
nan

>  <inchi>  (189) 
InChI=1S/C14H17N3O2S/c18-20(19,17-9-2-6-15-8-10-17)14-4-1-3-12-11-16-7-5-13(12)14/h1,3-5,7,11,15H,2,6,8-10H2

>  <stdInchikey>  (189) 
NGOGFTYYXHNFQH-UHFFFAOYSA-N

>  <csid>  (189) 
3426

>  <Links>  (189) 
|http://www.chemspider.com/Chemical-Structure.3426.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL38380|http://pubchem.ncbi.nlm.nih.gov/compound/3547|http://www.drugbank.ca/drugs/DB08162| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=M77|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/M77|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5181|http://zinc15.docking.org/substances/ZINC000000006486|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=Q0CH43PGXS|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=14027

>  <LinkName>  (189) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (189) 
'M77'

>  <pdbID>  (189) 
1q8w 2esm 2f2u 2gni 3tku 5lcp 5nw8 5o0e 5ok3 5vef 6em2 6emb 6ers 6erw 6i2a 6i2c 6yna

>  <indicationG2P>  (189) 
None

>  <indicationDB>  (189) 
Fasudil has been investigated in Carotid Stenosis.

>  <uniprotId>  (189) 
P61925|P17612|Q13464|O75116

>  <MW>  (189) 
291.1

>  <HBA>  (189) 
4.0

>  <HBD>  (189) 
1.0

>  <NRB>  (189) 
2.0

>  <TPSA>  (189) 
62.3

>  <LogP>  (189) 
1.2

>  <RoF>  (189) 
0.0

>  <Melting point>  (189) 


>  <Targets>  (189) 
nan

>  <Kinase families>  (189) 


>  <FDA_approved>  (189) 
N

$$$$
Erlotinib
     RDKit          2D

 29 31  0  0  0  0  0  0  0  0999 V2000
   -1.2256    7.2656    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8069    5.8253    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8450    4.7425    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4263    3.3021    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4644    2.2193    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0457    0.7789    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5890    0.4213    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1703   -1.0191    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2083   -2.1018    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6651   -1.7442    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0838   -0.3038    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5405    0.0538    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5786   -1.0290    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0353   -0.6714    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.0734   -1.7542    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -9.5302   -1.3966    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7897   -3.5422    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.6671   -3.8998    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7052   -2.8171    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.2865   -1.3767    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3245   -0.2939    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.7813   -0.6515    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2000   -2.0919    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6567   -2.4495    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6948   -1.3667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2761    0.0737    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8194    0.4313    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3142    1.1565    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3523    2.2392    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
  9 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 26 28  1  0
 28 29  3  0
 11  6  1  0
 20  8  1  0
 27 22  1  0
M  END
>  <BrandName>  (190) 
Tarceva

>  <Applicants>  (190) 
Osi Pharmaceuticals

>  <CHEMBL_ID>  (190) 
CHEMBL553

>  <Canonical_Smiles>  (190) 
COCCOc1cc2c(cc1OCCOC)ncnc2Nc3cccc(c3)C#C

>  <Chirality>  (190) 
Achiral Molecule

>  <First_Approval>  (190) 
2004

>  <Phase>  (190) 
4.0

>  <SC_Patent>  (190) 
US-6900221-B1

>  <Synonyms>  (190) 
CP-358,774 | CP-358774 | CP-35877401 | ERLOTINIB | OSI-774 | R-1415 | RG-1415 | RO-508231 | TARCEVA

>  <Withdrawn>  (190) 
|Study NCT01006096 in United States was Withdrawn during Phase 2 because IND not obtained|Study NCT00570375 in United States was Withdrawn during Phase 2 because PI left institution|Study NCT00428194 in United States was Withdrawn during Phase 1 because Withdrawn due to lack of accrual|Study NCT03529084 in nan was Withdrawn during Phase 3 because Decision by Sponsor not to continue with the trial|Study NCT00728000 in United States was Withdrawn during Phase 2 because study withdrawn due to lack of enrollment|Study NCT02034097 in nan was Withdrawn during Phase 2 because GSK has decided to terminate the Product Development of foretinib and conclude our Development    Agreement with Exelixis|Study NCT02795884 in nan was Withdrawn during Phase 3 because Because of reconsideration of using erlotinib(EGFR Tyrosine kinase inhibitor) as adjuvant aim|Study NCT01013506 in nan was Withdrawn during Phase 2 because Study was abandoned before opening to accrual Replaced by another study|Study NCT01928160 in nan was Withdrawn during Phase 2 because study not accruing|Study NCT01332279 in United States was Withdrawn during Phase 1 because Pharmaceutical co withdrew support Study was never activated and did not accrue any patients|Study NCT01600807 in United States was Withdrawn during Phase 1/Phase 2 because Study was pending major changes and was on hold, pending activation; administratively    withdrawn; will be submitted as a new protocol if study is revised|Study NCT00385398 in nan was Withdrawn during Phase 2 because lack of funding and drug supply|Study NCT01728181 in nan was Withdrawn during Phase 1/Phase 2 because Stopped before approval due to ineffective drug|Study NCT01465815 in United States was Withdrawn during Phase 1/Phase 2 because Drug manufacturer, Astellas Pharma, informed us that safety and efficacy of Erlotinib and    OSI-906 in other oncology studies was determined to be unfavorable|Study NCT02355431 in United States was Withdrawn during Phase 2 because Study withdrawn before enrolling first patient

>  <Indications>  (190) 
For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

>  <Type>  (190) 
1.5

>  <targets_id>  (190) 
P00533|O75469

>  <inchi>  (190) 
InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)

>  <stdInchikey>  (190) 
AAKJLRGGTJKAMG-UHFFFAOYSA-N

>  <csid>  (190) 
154044

>  <Links>  (190) 
|http://www.chemspider.com/Chemical-Structure.154044.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL553|http://pubchem.ncbi.nlm.nih.gov/compound/176870|http://www.drugbank.ca/drugs/DB00530| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=AQ4|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/AQ4|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4920|http://zinc15.docking.org/substances/ZINC01546066|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=J4T82NDH7E|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=5446

>  <LinkName>  (190) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (190) 
'AQ4'

>  <pdbID>  (190) 
1m17 4hjo 6dwn

>  <indicationG2P>  (190) 
None

>  <indicationDB>  (190) 
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

>  <uniprotId>  (190) 
P00533|O75469|P08684|P20815|P05177|P04798|P10635|P10632|Q16678|P22309|P02768|P02763

>  <MW>  (190) 
393.2

>  <HBA>  (190) 
7.0

>  <HBD>  (190) 
1.0

>  <NRB>  (190) 
10.0

>  <TPSA>  (190) 
74.7

>  <LogP>  (190) 
3.4

>  <RoF>  (190) 
0.0

>  <Melting point>  (190) 


>  <Targets>  (190) 
EGFR; NR1I2

>  <Kinase families>  (190) 
Tyr<br>(*)

>  <FDA_approved>  (190) 
Y

$$$$
Erdafitinib
     RDKit          2D

 33 36  0  0  0  0  0  0  0  0999 V2000
   -4.3196    6.0890    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2763    4.5897    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5532    3.8025    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9562    3.8774    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9130    2.3780    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5929    1.6658    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5497    0.1664    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2296   -0.5459    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1864   -2.0452    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1338   -2.7575    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4106   -1.9704    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3674   -0.4710    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0473    0.2413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6443    0.3161    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.9644   -0.3961    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0076   -1.8955    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7307   -2.6826    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.2413    0.3910    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3551    1.8867    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8127    2.2407    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.5998    0.9638    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.6286   -0.1794    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.0955    0.8500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8266   -0.6207    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1467    0.0915    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4236   -0.6956    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3804   -2.1950    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0602   -2.9072    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7834   -2.1201    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0170   -4.4066    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2939   -5.1937    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7437    0.0167    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7869    1.5161    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 15 18  1  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  1  0
 21 23  1  0
  7 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 28 30  1  0
 30 31  1  0
 26 32  1  0
 32 33  1  0
 13  8  1  0
 17 11  1  0
 22 18  2  0
 29 24  1  0
M  END
>  <BrandName>  (191) 
Balversa

>  <Applicants>  (191) 
Janssen

>  <CHEMBL_ID>  (191) 
CHEMBL3545376

>  <Canonical_Smiles>  (191) 
CC(C)NCCN(c1ccc2c(c1)nc(cn2)c3cnn(c3)C)c4cc(cc(c4)OC)OC

>  <Chirality>  (191) 
Achiral Molecule

>  <First_Approval>  (191) 
2019

>  <Phase>  (191) 
4.0

>  <SC_Patent>  (191) 
US-8895601-B2

>  <Synonyms>  (191) 
BALVERSA | ERDAFITINIB | JNJ-42756493

>  <Withdrawn>  (191) 


>  <Indications>  (191) 
On april 2019, FDA approved erdafitinib to treat adult patients with locally advanced or metastatic bladder cancer

>  <Type>  (191) 
1

>  <targets_id>  (191) 
P11362

>  <inchi>  (191) 
InChI=1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3

>  <stdInchikey>  (191) 
OLAHOMJCDNXHFI-UHFFFAOYSA-N

>  <csid>  (191) 
35308353

>  <Links>  (191) 
|http://www.chemspider.com/Chemical-Structure.35308353.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545376|http://pubchem.ncbi.nlm.nih.gov/compound/67462786|http://www.drugbank.ca/drugs/DB12147| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=5SF|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/5SF|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9039|http://zinc15.docking.org/substances/ZINC000168520308|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=890E37NHMV

>  <LinkName>  (191) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (191) 
'5SF'

>  <pdbID>  (191) 
5ew8

>  <indicationG2P>  (191) 
None

>  <indicationDB>  (191) 
In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies&#39; brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy <sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma: Press Release" href="#reference-L5956">4</a>,<a class="reference-popover-link" data-content="First Targeted Therapy for Metastatic Bladder Cancer Receives FDA Approval" href="#reference-L5959">5</a></sup>. At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy <sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma: Press Release" href="#reference-L5956">4</a>,<a class="reference-popover-link" data-content="First Targeted Therapy for Metastatic Bladder Cancer Receives FDA Approval" href="#reference-L5959">5</a></sup>.</p><p>Erdafitinib&#39;s innovation lies in the fact that it is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the design of erdafitinib in developing more personalized and precision medicines with the capacity to target cancer treatment to a patient&#39;s specific genetic mutation <sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma: Press Release" href="#reference-L5956">4</a>,<a class="reference-popover-link" data-content="First Targeted Therapy for Metastatic Bladder Cancer Receives FDA Approval" href="#reference-L5959">5</a></sup>. Considering urothelial cancer is statistically the fourth most common kind of cancer in the world <sup class="text-reference-group"><a class="reference-popover-link" data-content="NHS Evidence Briefing On: Erdafitinib capsules for metastatic or surgically unresectable urothelial cancer with FGFR gene aberrations â second line therapy" href="#reference-F4372">7</a></sup>, the introduction of erdafitinib offers a welcome new option in the ever-expanding therapeutic tool kit to treat such prevalent medical conditions.</p><p>Nevertheless, although erdafitinib was granted Breakthrough Therapy designation and Accelerated Approval from the FDA so as to allow the agency to focus on and expedite the approval process for a medication indicated for a serious condition that fills an unmet medical need using clinical trial data that is believed to predict a genuine clinical benefit for patients with the given condition, such designations mean further ongoing clinical trials are necessary to confirm the clinical benefit of erdafitinib going forward <sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma: Press Release" href="#reference-L5956">4</a>,<a class="reference-popover-link" data-content="First Targeted Therapy for Metastatic Bladder Cancer Receives FDA Approval" href="#reference-L5959">5</a></sup>.

>  <uniprotId>  (191) 
P11362|P21802|P22607|P22455|O43519|P07333|P16234|P09619|P10721|P35968|P11712|P08684|P08183|O15244

>  <MW>  (191) 
446.2

>  <HBA>  (191) 
8.0

>  <HBD>  (191) 
1.0

>  <NRB>  (191) 
9.0

>  <TPSA>  (191) 
77.3

>  <LogP>  (191) 
4.2

>  <RoF>  (191) 
0.0

>  <Melting point>  (191) 


>  <Targets>  (191) 
FGFR1

>  <Kinase families>  (191) 
Tyr

>  <FDA_approved>  (191) 
Y

$$$$
Entrectinib
     RDKit          2D

 41 46  0  0  0  0  0  0  0  0999 V2000
   -7.4763   -5.6972    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4270   -4.6253    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8307   -3.1806    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7814   -2.1087    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3285   -2.4814    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9248   -3.9261    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9740   -4.9980    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2792   -1.4095    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8262   -1.7822    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7770   -0.7102    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1807    0.7344    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6336    1.1071    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6829    0.0352    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0373    2.5518    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4903    2.9245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8940    4.3692    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3469    4.7419    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3962    3.6699    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9925    2.2253    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5395    1.8526    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1314    1.8063    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5351    3.2510    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.3215    1.4336    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.3708    2.5056    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8548    2.2868    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6851    1.0376    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1821    1.1321    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8488    2.4758    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0184    3.7250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5214    3.6305    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4495    4.6797    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.1203    3.9845    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.0125   -0.1171    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3458   -1.4609    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8488   -1.5554    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1822   -2.8991    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0125   -4.1483    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5095   -4.0538    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1762   -2.7101    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3399   -5.3030    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    2.6851   -2.9936    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  5  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 11 21  1  0
 21 22  2  0
 21 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  1  0
 27 33  1  0
 33 34  1  0
 34 35  2  0
 35 36  1  0
 36 37  2  0
 37 38  1  0
 38 39  2  0
 38 40  1  0
 36 41  1  0
  7  2  1  0
 13  8  1  0
 20 15  1  0
 32 24  2  0
 30 25  1  0
 39 34  1  0
M  END
>  <BrandName>  (192) 
Rozlytrek

>  <Applicants>  (192) 
Ignyta

>  <CHEMBL_ID>  (192) 
CHEMBL1983268

>  <Canonical_Smiles>  (192) 
CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4c5cc(ccc5[nH]n4)Cc6cc(cc(c6)F)F

>  <Chirality>  (192) 
Achiral Molecule

>  <First_Approval>  (192) 
2019

>  <Phase>  (192) 
4.0

>  <SC_Patent>  (192) 
US-8299057-B2

>  <Synonyms>  (192) 
ENTRECTINIB | NMS-E628 | ROZLYTREK | RXDX-101

>  <Withdrawn>  (192) 


>  <Indications>  (192) 
On august 2019, FDA approved entrectinib to treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive and to treat adult and pediatric patients 12 years of age and older with solid tumors

>  <Type>  (192) 
1

>  <targets_id>  (192) 
P04629|Q16620|Q16288|P08922|Q9UM73

>  <inchi>  (192) 
InChI=1S/C31H34F2N6O2/c1-38-8-10-39(11-9-38)25-3-4-26(29(19-25)34-24-6-12-41-13-7-24)31(40)35-30-27-17-20(2-5-28(27)36-37-30)14-21-15-22(32)18-23(33)16-21/h2-5,15-19,24,34H,6-14H2,1H3,(H2,35,36,37,40)

>  <stdInchikey>  (192) 
HAYYBYPASCDWEQ-UHFFFAOYSA-N

>  <csid>  (192) 
24808589

>  <Links>  (192) 
|http://www.chemspider.com/Chemical-Structure.24808589.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1983268|http://pubchem.ncbi.nlm.nih.gov/compound/25141092|http://www.drugbank.ca/drugs/DB11986| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=YMX|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/YMX|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8290|http://zinc15.docking.org/substances/ZINC000043204146|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=L5ORF0AN1I|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=158154

>  <LinkName>  (192) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (192) 
'YMX'

>  <pdbID>  (192) 
5fto 5kvt

>  <indicationG2P>  (192) 
None

>  <indicationDB>  (192) 
Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Label: Rozlytrek" href="#reference-L8081">7</a></sup> It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Announcement: Entrectinib Approval" href="#reference-L8207">9</a></sup> Entrectinib&#39;s approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as <a href="https://go.drugbank.com/drugs/DB11363">alectinib</a>, <a href="https://go.drugbank.com/drugs/DB09063">ceritinib</a>, and <a href="https://go.drugbank.com/drugs/DB12130">lorlatinib</a> due to a wider range of targets.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Pacenta HL, Macy ME: Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma. Drug Des Devel Ther. 2018 Oct 23;12:3549-3561. doi: 10.2147/DDDT.S147384. eCollection 2018. (PubMed ID 30425456)" href="#reference-A183929">6</a></sup>

>  <uniprotId>  (192) 
P04629|Q16620|Q16288|P08922|O60674|Q07912|P08684|P08183

>  <MW>  (192) 
560.3

>  <HBA>  (192) 
6.0

>  <HBD>  (192) 
3.0

>  <NRB>  (192) 
7.0

>  <TPSA>  (192) 
85.5

>  <LogP>  (192) 
5.0

>  <RoF>  (192) 
2.0

>  <Melting point>  (192) 


>  <Targets>  (192) 
NTRK1; NTRK2; NTRK3; ROS1; ALK

>  <Kinase families>  (192) 
Tyr

>  <FDA_approved>  (192) 
Y

$$$$
Encorafenib
     RDKit          2D

 36 38  0  0  0  0  0  0  0  0999 V2000
   -5.9184    3.4437    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7118    2.5525    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3368    3.1519    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1302    2.2607    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7552    2.8600    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5867    4.3506    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.7884    4.9499    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9950    4.0587    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8265    2.5682    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4514    1.9689    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.0331    1.6771    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4632    2.1294    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3354    0.9090    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.4442   -0.2976    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.0213    0.1771    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8009   -0.6950    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4354   -0.0742    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7850   -0.9463    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6399   -2.4393    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7256   -3.0601    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9460   -2.1880    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3115   -2.8088    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    0.8707   -4.5531    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3497   -5.4252    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2219   -4.2048    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.5224   -6.6456    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5701   -6.2974    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1505   -0.3255    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    6.8353    0.8972    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5751   -0.4077    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5955    2.1903    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8803    1.0620    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2554    0.4627    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4620    1.3538    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4239   -1.0278    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.7989   -1.6272    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  1
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
  9 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 20 23  1  0
 23 24  1  0
 24 25  2  0
 24 26  2  0
 24 27  1  0
 18 28  1  0
 13 29  1  0
 29 30  1  0
 29 31  1  0
  2 32  1  0
 32 33  1  0
 33 34  2  0
 33 35  1  0
 35 36  1  0
 10  5  1  0
 15 11  1  0
 21 16  1  0
M  END
>  <BrandName>  (193) 
Braftovi

>  <Applicants>  (193) 
Novartis

>  <CHEMBL_ID>  (193) 
CHEMBL3301612

>  <Canonical_Smiles>  (193) 
C[C@@H](CNc1nccc(n1)c2cn(nc2c3cc(cc(c3F)NS(=O)(=O)C)Cl)C(C)C)NC(=O)OC

>  <Chirality>  (193) 
Single Stereoisomer

>  <First_Approval>  (193) 
2018

>  <Phase>  (193) 
4.0

>  <SC_Patent>  (193) 
US-8501758-B2

>  <Synonyms>  (193) 
BRAFTOVI | ENCORAFENIB | LGX-818 | NVP-LGX-818-NXA | NVP-LGX818 | NVP-LGX818-NXA

>  <Withdrawn>  (193) 


>  <Indications>  (193) 
On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

>  <Type>  (193) 
nan

>  <targets_id>  (193) 
P15056

>  <inchi>  (193) 
InChI=1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)/t13-/m0/s1

>  <stdInchikey>  (193) 
CMJCXYNUCSMDBY-ZDUSSCGKSA-N

>  <csid>  (193) 
28536139

>  <Links>  (193) 
|http://www.chemspider.com/Chemical-Structure.28536139.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3301612|http://pubchem.ncbi.nlm.nih.gov/compound/50922675|http://www.drugbank.ca/drugs/DB11718|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7908|http://zinc15.docking.org/substances/ZINC000068249103|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=8L7891MRB6|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=221688

>  <LinkName>  (193) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (193) 


>  <pdbID>  (193) 


>  <indicationG2P>  (193) 
None

>  <indicationDB>  (193) 
Encorafenib, also known as <em>BRAFTOVI</em>, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations <sup class="text-reference-group"><a class="reference-popover-link" data-content="Official drug label" href="#label-reference">Label</a></sup>. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung <sup class="text-reference-group"><a class="reference-popover-link" data-content="BRAF B-Raf proto-oncogene, serine/threonine kinase [ Homo sapiens (human) ]" href="#reference-L3344">6</a></sup>.</p><p>On June 27, 2018, the Food and Drug Administration approved encorafenib and <a href="https://go.drugbank.com/drugs/DB11967">Binimetinib</a> (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test <sup class="text-reference-group"><a class="reference-popover-link" data-content="Official drug label" href="#label-reference">Label</a></sup>.

>  <uniprotId>  (193) 
P15056|P24385|P08684|P33261|P10635

>  <MW>  (193) 
539.2

>  <HBA>  (193) 
9.0

>  <HBD>  (193) 
3.0

>  <NRB>  (193) 
9.0

>  <TPSA>  (193) 
140.1

>  <LogP>  (193) 
3.9

>  <RoF>  (193) 
1.0

>  <Melting point>  (193) 


>  <Targets>  (193) 
BRAF

>  <Kinase families>  (193) 
TKL

>  <FDA_approved>  (193) 
Y

$$$$
Duvelisib
     RDKit          2D

 30 34  0  0  0  0  0  0  0  0999 V2000
   -0.9446    1.7228    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6820    0.2459    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7282   -0.2651    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9908   -1.7420    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4011   -2.2530    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6636   -3.7298    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0739   -4.2409    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2216   -3.2751    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9590   -1.7982    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5488   -1.2872    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2862    0.1896    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4339    1.1555    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.8759    0.7007    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.6134    2.1775    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7611    3.1433    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4985    4.6202    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0883    5.1312    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0594    4.1654    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2031    2.6886    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1067   -0.8324    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -1.8297   -0.7199    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2400   -0.2089    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3877   -1.1747    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7980   -0.6636    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7198   -1.8470    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8792   -3.0893    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4379   -2.6738    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0605    0.8132    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9128    1.7790    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5025    1.2680    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  1
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 11 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
  9 20  1  0
  2 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  1  0
 26 27  2  0
 24 28  1  0
 28 29  2  0
 29 30  1  0
 13  3  1  0
 10  5  1  0
 19 14  1  0
 30 22  2  0
 27 23  1  0
M  END
>  <BrandName>  (194) 
Copiktra

>  <Applicants>  (194) 
Infinity Pharmacueticals

>  <CHEMBL_ID>  (194) 
CHEMBL3039502

>  <Canonical_Smiles>  (194) 
C[C@@H](c1cc2cccc(c2c(=O)n1c3ccccc3)Cl)Nc4c5c([nH]cn5)ncn4

>  <Chirality>  (194) 
Single Stereoisomer

>  <First_Approval>  (194) 
2018

>  <Phase>  (194) 
4.0

>  <SC_Patent>  (194) 
US-8193182-B2

>  <Synonyms>  (194) 
COPIKTRA | DUVELISIB | INK-1147 | INK-1197 | IPI-145

>  <Withdrawn>  (194) 
|Study NCT03370185 in United States was Withdrawn during Phase 2 because Reassessing corporate priorities|Study NCT02640833 in United States was Withdrawn during Phase 1 because Study Stopped

>  <Indications>  (194) 
On october 27, 2018, the FDA approved duvelisib to treat relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma

>  <Type>  (194) 
nan

>  <targets_id>  (194) 
O00329|P48736

>  <inchi>  (194) 
InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1

>  <stdInchikey>  (194) 
SJVQHLPISAIATJ-ZDUSSCGKSA-N

>  <csid>  (194) 
28637766

>  <Links>  (194) 
|http://www.chemspider.com/Chemical-Structure.28637766.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3039502|http://pubchem.ncbi.nlm.nih.gov/compound/50905713|http://www.drugbank.ca/drugs/DB11952|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7795|http://zinc15.docking.org/substances/ZINC000088346058|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=610V23S0JI|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50193013

>  <LinkName>  (194) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (194) 


>  <pdbID>  (194) 


>  <indicationG2P>  (194) 
None

>  <indicationDB>  (194) 
Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of both forms.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, Pink MM, Proctor JL, Lussier J, Martin CM, Hoyt JG, Tillotson B, Murphy EL, Lim AR, Thomas BD, Macdougall JR, Ren P, Liu Y, Li LS, Jessen KA, Fritz CC, Dunbar JL, Porter JR, Rommel C, Palombella VJ, Changelian PS, Kutok JL: PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74. doi: 10.1016/j.chembiol.2013.09.017. Epub 2013 Nov 7. (PubMed ID 24211136)" href="#reference-A39025">1</a></sup> Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA news" href="#reference-L4585">7</a></sup>

>  <uniprotId>  (194) 
P48736|O00329|P08684

>  <MW>  (194) 
416.1

>  <HBA>  (194) 
6.0

>  <HBD>  (194) 
2.0

>  <NRB>  (194) 
4.0

>  <TPSA>  (194) 
88.5

>  <LogP>  (194) 
4.5

>  <RoF>  (194) 
0.0

>  <Melting point>  (194) 
>190 ÂºC

>  <Targets>  (194) 
PIK3CD; PIK3CG

>  <Kinase families>  (194) 
Atypical

>  <FDA_approved>  (194) 
Y

$$$$
Dasatinib
     RDKit          2D

 33 36  0  0  0  0  0  0  0  0999 V2000
   -2.3701   -1.7411    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6146   -0.9038    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9621   -1.5628    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2066   -0.7255    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1037    0.7710    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7562    1.4301    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5117    0.5927    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1643    1.2518    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0613    2.7483    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3059    3.5856    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7139    3.4074    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4551    4.8849    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0301    5.0953    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.6891    3.7479    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6113    2.7047    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    3.1667    3.4891    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.6813    2.0801    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7184    0.9300    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2331   -0.4790    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7106   -0.7378    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.6734    0.4124    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1588    1.8214    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.1509    0.1536    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2702   -1.6291    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.7927   -1.3704    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1702   -2.5205    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3445   -3.9295    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.8220   -4.1883    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7848   -3.0381    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6184   -5.0796    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1038   -6.4886    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0667   -7.6388    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6533    2.9265    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
  9 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 14 16  1  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 21 23  1  0
 19 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
 28 29  1  0
 27 30  1  0
 30 31  1  0
 31 32  1  0
  6 33  1  0
  7  2  1  0
 15 11  1  0
 22 17  1  0
 29 24  1  0
M  END
>  <BrandName>  (195) 
Dasatinib;Sprycel

>  <Applicants>  (195) 
Bristol Myers Squibb

>  <CHEMBL_ID>  (195) 
CHEMBL1421

>  <Canonical_Smiles>  (195) 
Cc1cccc(c1NC(=O)c2cnc(s2)Nc3cc(nc(n3)C)N4CCN(CC4)CCO)Cl

>  <Chirality>  (195) 
Achiral Molecule

>  <First_Approval>  (195) 
2006

>  <Phase>  (195) 
4.0

>  <SC_Patent>  (195) 
US-6596746-B1

>  <Synonyms>  (195) 
BMS-354825 | BMS-354825 HYDRATE | BMS-354825-03 | DASATINIB | DASATINIB HYDRATE | DASATINIB MONOHYDRATE | SPRYCEL

>  <Withdrawn>  (195) 
|Study NCT02923986 in United States was Withdrawn during Phase 1/Phase 2 because No enrollment|Study NCT03414450 in United States was Withdrawn during Phase 1 because Withdrawal requested by D3|Study NCT01826838 in nan was Withdrawn during Phase 1 because Lack of patients|Study NCT04439305 in United States was Withdrawn during Phase 2 because zero accrual|Study NCT00324077 in United States was Withdrawn during Phase 1 because Insufficient Enrollment|Study NCT03560908 in China was Withdrawn during Phase 1 because No enough eligable participants enrolled|Study NCT02680951 in nan was Withdrawn during Phase 1 because Withdrawn due to lack of participants|Study NCT02815059 in United States was Withdrawn during Phase 1 because Termination of Investigator Initiated Studies using Ibrutinib|Study NCT02129166 in nan was Withdrawn during Phase 1 because PI resigned|Study NCT00872976 in United States was Withdrawn during Phase 1 because Business Objectives Changed|Study NCT00829647 in nan was Withdrawn during Phase 1/Phase 2 because Unable to enroll

>  <Indications>  (195) 
For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.

>  <Type>  (195) 
1

>  <targets_id>  (195) 
P00519|P12931|P29317|P06239|P07947|P10721|P09619|P42684|P06241

>  <inchi>  (195) 
InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)

>  <stdInchikey>  (195) 
ZBNZXTGUTAYRHI-UHFFFAOYSA-N

>  <csid>  (195) 
2323020

>  <Links>  (195) 
|http://www.chemspider.com/Chemical-Structure.2323020.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1421|http://pubchem.ncbi.nlm.nih.gov/compound/3062316|http://www.drugbank.ca/drugs/DB01254| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=1N1|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/1N1|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5678|http://zinc15.docking.org/substances/ZINC21982951|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=X78UG0A0RN|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13216

>  <LinkName>  (195) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (195) 
'1N1'

>  <pdbID>  (195) 
2gqg 2y6o 2zva 3g5d 3k54 3lfa 3oct 3oht 3qlg 3sxr 4qms 4xey 4xli 5bvw 5h2u 5i9y 5owr 5vcv 6bsd 6fnm

>  <indicationG2P>  (195) 
None

>  <indicationDB>  (195) 
Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.

>  <uniprotId>  (195) 
P00519|P12931|P29317|P06239|P07947|P10721|P09619|P51692|P42684|P06241|Q06187|Q92570|P11274|P41240|P54756|P54760|P09769|P42685|P11142|P07948|Q9NYL2|Q16539|Q06203|P08684|P04798|P05177|Q16678|P20815|P31513|P08183|Q9UNQ0

>  <MW>  (195) 
487.2

>  <HBA>  (195) 
9.0

>  <HBD>  (195) 
3.0

>  <NRB>  (195) 
7.0

>  <TPSA>  (195) 
106.5

>  <LogP>  (195) 
3.3

>  <RoF>  (195) 
0.0

>  <Melting point>  (195) 
280-286 Â°C

>  <Targets>  (195) 
ABL1; SRC; EPHA2; LCK; YES1; KIT; PDGFRB; ABL2; FYN

>  <Kinase families>  (195) 
Tyr

>  <FDA_approved>  (195) 
Y

$$$$
Pexidartinib
     RDKit          2D

 29 32  0  0  0  0  0  0  0  0999 V2000
    1.5474   -2.4840    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0478   -2.4510    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6735   -1.1358    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1049    0.1465    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.6045    0.1135    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3258   -1.2017    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8254   -1.2347    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6038    0.0475    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0240    1.4309    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1605    2.4099    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.4427    1.6315    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0987    0.1715    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1910   -0.8564    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6275   -0.4244    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.9715    1.0356    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8791    2.0636    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.7199   -1.4523    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -2.1731   -1.1028    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8944    0.2124    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3940    0.2454    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1153    1.5606    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6149    1.5936    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3933    0.3113    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6720   -1.0039    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1724   -1.0369    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.8929    0.3443    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.3926    0.3773    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -8.8600    1.8439    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -8.9259   -1.1554    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 14 17  1  0
  3 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 23 26  1  0
 26 27  1  0
 26 28  1  0
 26 29  1  0
  6  1  1  0
 12  8  1  0
 16 11  1  0
 25 20  1  0
M  END
>  <BrandName>  (196) 
Turalio

>  <Applicants>  (196) 
Daiichi Sankyo

>  <CHEMBL_ID>  (196) 
CHEMBL3813873

>  <Canonical_Smiles>  (196) 
c1cc(ncc1Cc2c[nH]c3c2cc(cn3)Cl)NCc4ccc(nc4)C(F)(F)F

>  <Chirality>  (196) 
Achiral Molecule

>  <First_Approval>  (196) 
2019

>  <Phase>  (196) 
4.0

>  <SC_Patent>  (196) 
US-7893075-B2

>  <Synonyms>  (196) 
CML-261 | PEXIDARTINIB | PLX-3397 | PLX3397

>  <Withdrawn>  (196) 


>  <Indications>  (196) 
On august 2019, FDA approved pexidartinib to treat adult patients with symptomatic tenosynovial giant cell tumor

>  <Type>  (196) 
2

>  <targets_id>  (196) 
P36888|P10721|P07333

>  <inchi>  (196) 
InChI=1S/C20H15ClF3N5/c21-15-6-16-14(10-28-19(16)29-11-15)5-12-2-4-18(26-7-12)27-9-13-1-3-17(25-8-13)20(22,23)24/h1-4,6-8,10-11H,5,9H2,(H,26,27)(H,28,29)

>  <stdInchikey>  (196) 
JGWRKYUXBBNENE-UHFFFAOYSA-N

>  <csid>  (196) 
35308322

>  <Links>  (196) 
|http://www.chemspider.com/Chemical-Structure.35308322.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3813873|http://pubchem.ncbi.nlm.nih.gov/compound/25151352|http://www.drugbank.ca/drugs/DB12978| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=P31|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/P31|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8710|http://zinc15.docking.org/substances/ZINC000115705166|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6783M2LV5X|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50177716

>  <LinkName>  (196) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (196) 
'P31'

>  <pdbID>  (196) 
4r7h

>  <indicationG2P>  (196) 
None

>  <indicationDB>  (196) 
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approves first therapy for rare joint tumor - FDA News Release" href="#reference-L7901">11</a></sup> Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Giustini N, Bernthal NM, Bukata SV, Singh AS: Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature. Clin Sarcoma Res. 2018 Jul 10;8:14. doi: 10.1186/s13569-018-0101-2. eCollection 2018. (PubMed ID 30002809)" href="#reference-A182240">1</a>,<a class="reference-popover-link" data-content="FDA approves first therapy for rare joint tumor - FDA News Release" href="#reference-L7901">11</a></sup> Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approves first therapy for rare joint tumor - FDA News Release" href="#reference-L7901">11</a></sup></p><p>While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence.<sup class="text-reference-group"><a class="reference-popover-link" data-content="TURALIO (PEXIDARTINIB) CAPSULES - Daiichi Sankyo, Inc. - FDA Oncologic Drugs Advisory Committee Briefing Document" href="#reference-L7895">10</a></sup> Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, Martin-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ: Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019 Jun 19. pii: S0140-6736(19)30764-0. doi: 10.1016/S0140-6736(19)30764-0. (PubMed ID 31229240)" href="#reference-A182243">2</a></sup> Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approves first therapy for rare joint tumor - FDA News Release" href="#reference-L7901">11</a></sup>

>  <uniprotId>  (196) 
P07333|P10721|P36888|P09619|P08684|P22310|P20813|P11712|P22309|P02768|P02763|Q96FL8|Q86VL8|Q9Y6L6|Q9NPD5|O94956

>  <MW>  (196) 
417.1

>  <HBA>  (196) 
4.0

>  <HBD>  (196) 
2.0

>  <NRB>  (196) 
5.0

>  <TPSA>  (196) 
66.5

>  <LogP>  (196) 
5.2

>  <RoF>  (196) 
1.0

>  <Melting point>  (196) 


>  <Targets>  (196) 
FLT3; KIT; CSF1R

>  <Kinase families>  (196) 
Tyr

>  <FDA_approved>  (196) 
Y

$$$$
Tucatinib
     RDKit          2D

 36 41  0  0  0  0  0  0  0  0999 V2000
   -2.7226    4.0612    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1584    2.6713    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6727    2.4651    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1084    1.0752    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0299   -0.1083    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5157    0.0980    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0799    1.4878    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5657    1.6941    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4872    0.5105    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9229   -0.8793    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8445   -2.0629    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3302   -1.8566    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.8944   -0.4668    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9729    0.7168    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.3906   -0.5739    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -9.7511   -2.0300    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4777   -2.8227    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.3773    0.8690    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.2988    2.0525    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7846    1.8463    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3488    0.4564    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8346    0.2502    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7561    1.4337    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1919    2.8235    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7061    3.0298    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1419    4.4197    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6561    4.6259    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7346    3.4424    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.3988   -1.1397    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.4773   -2.3232    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8932   -3.7644    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.6510   -4.6053    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4675   -3.6838    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9781   -2.2734    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.6171   -5.7528    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6108   -5.6861    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 13 15  2  0
 15 16  1  0
 16 17  2  0
  4 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 22 29  1  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 32 33  1  0
 33 34  1  0
 32 35  1  0
 32 36  1  0
  7  2  1  0
 14  9  2  0
 17 12  1  0
 28 19  2  0
 25 20  1  0
 34 30  1  0
M  END
>  <BrandName>  (197) 
Tukysa

>  <Applicants>  (197) 
Array BioPharma

>  <CHEMBL_ID>  (197) 
CHEMBL3989868

>  <Canonical_Smiles>  (197) 
Cc1cc(ccc1Oc2ccn3c(c2)ncn3)Nc4c5cc(ccc5ncn4)NC6=NC(CO6)(C)C

>  <Chirality>  (197) 
Achiral Molecule

>  <First_Approval>  (197) 
2020

>  <Phase>  (197) 
4.0

>  <SC_Patent>  (197) 
US-7452895-B2

>  <Synonyms>  (197) 
ARRY-380 | ONT-380 | TUCATINIB | TUKYSA

>  <Withdrawn>  (197) 
|Study NCT03846583 in nan was Withdrawn during Phase 1 because Study halted prematurely, prior to enrollment of first participant

>  <Indications>  (197) 
On April 2020, FDA approved tucatinib to treat advanced unresectable or metastatic HER2-positive breast cancer.

>  <Type>  (197) 
nan

>  <targets_id>  (197) 
P04626

>  <inchi>  (197) 
InChI=1S/C26H24N8O2/c1-16-10-17(5-7-22(16)36-19-8-9-34-23(12-19)28-15-30-34)31-24-20-11-18(4-6-21(20)27-14-29-24)32-25-33-26(2,3)13-35-25/h4-12,14-15H,13H2,1-3H3,(H,32,33)(H,27,29,31)

>  <stdInchikey>  (197) 
SDEAXTCZPQIFQM-UHFFFAOYSA-N

>  <csid>  (197) 
34995558

>  <Links>  (197) 
|http://www.chemspider.com/Chemical-Structure.34995558.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3989868|http://pubchem.ncbi.nlm.nih.gov/compound/51039094|http://www.drugbank.ca/drugs/DB11652|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9922|http://zinc15.docking.org/substances/ZINC000068250462|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=234248D0HH

>  <LinkName>  (197) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (197) 


>  <pdbID>  (197) 


>  <indicationG2P>  (197) 
None

>  <indicationDB>  (197) 
Tucatinbib is a kinase inhibitor drug used with <a href="https://go.drugbank.com/drugs/DB00072">trastuzumab</a> and <a href="https://go.drugbank.com/drugs/DB01101">capecitabine</a> in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA News Release: FDA Approves First New Drug Under International Collaboration, A Treatment Option for Patients with HER2-Positive Metastatic Breast Cancer" href="#reference-L12951">8</a></sup> Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approved products: Tukysa (tucatinib) oral tablets" href="#reference-L12945">7</a></sup>

>  <uniprotId>  (197) 
P04626|P21860|P10632|P08684|Q9HB55|P20815|P24462|P04626|Q9UNQ0|P08183|O15244|Q96FL8|Q86VL8

>  <MW>  (197) 
480.2

>  <HBA>  (197) 
10.0

>  <HBD>  (197) 
2.0

>  <NRB>  (197) 
5.0

>  <TPSA>  (197) 
110.9

>  <LogP>  (197) 
5.1

>  <RoF>  (197) 
1.0

>  <Melting point>  (197) 
230

>  <Targets>  (197) 
ERBB2

>  <Kinase families>  (197) 
Tyr

>  <FDA_approved>  (197) 
Y

$$$$
Trametinib
     RDKit          2D

 37 41  0  0  0  0  0  0  0  0999 V2000
   -2.2821   -1.6501    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8739   -1.1334    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6172    0.3445    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7910    0.8612    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9425   -0.1000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6859   -1.5779    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.2777   -2.0946    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0211   -3.5724    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.8375   -2.5391    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3507    0.4167    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.5023   -0.5445    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2457   -2.0224    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3972   -2.9835    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8054   -2.4669    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0621   -0.9890    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9105   -0.0278    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1671    1.4501    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    7.9570   -3.4280    0.0000 I   0  0  0  0  0  0  0  0  0  0  0  0
    1.0476    2.3391    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4558    2.8558    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1040    3.3003    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5122    2.7836    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6637    3.7448    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7688    1.3057    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1770    0.7890    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3286    1.7502    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7368    1.2335    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9934   -0.2444    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8418   -1.2056    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4336   -0.6889    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0985   -2.6835    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5067   -3.2001    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6582   -2.2390    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7633   -4.6780    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1527    4.7782    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3640    6.1864    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1138    5.9297    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  6  9  1  0
  5 10  1  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 14 18  1  0
  4 19  1  0
 19 20  2  0
 19 21  1  0
 21 22  1  0
 22 23  2  0
 22 24  1  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 29 31  1  0
 31 32  1  0
 32 33  2  0
 32 34  1  0
 21 35  1  0
 35 36  1  0
 36 37  1  0
  7  2  1  0
 24  3  1  0
 16 11  1  0
 30 25  1  0
 37 35  1  0
M  END
>  <BrandName>  (198) 
Mekinist

>  <Applicants>  (198) 
GlaxoSmithKline

>  <CHEMBL_ID>  (198) 
CHEMBL2103875

>  <Canonical_Smiles>  (198) 
Cc1c2c(c(n(c1=O)C)Nc3ccc(cc3F)I)c(=O)n(c(=O)n2c4cccc(c4)NC(=O)C)C5CC5

>  <Chirality>  (198) 
Achiral Molecule

>  <First_Approval>  (198) 
2013

>  <Phase>  (198) 
4.0

>  <SC_Patent>  (198) 
None

>  <Synonyms>  (198) 
GSK-1120212 | GSK1120212 | JTP 74057 | JTP-74057 | MEKINIST | TMT-212 | TMT212 | TRAMETINIB

>  <Withdrawn>  (198) 
|Study NCT02140840 in United States was Withdrawn during Phase 2 because PI left institution|Study NCT02300935 in United States was Withdrawn during Phase 1 because Study concept was terminated|Study NCT01938456 in nan was Withdrawn during Phase 1 because This study was Cancelled Before Active|Study NCT02357732 in nan was Withdrawn during Phase 1 because PI decided not to proceed|Study NCT02939846 in nan was Withdrawn during Phase 1 because Change in strategy|Study NCT03972046 in United States was Withdrawn during Phase 2 because Principal investigator leaving study site; no replacement PI will be sought|Study NCT02915666 in United States was Withdrawn during Phase 1 because No subjects consented for enrollment on this study|Study NCT03266159 in nan was Withdrawn during Phase 2 because Study withdrawn before active to fully evaluate impact of changing practice in target    population|Study NCT02342600 in nan was Withdrawn during Phase 2 because Supporting company withdrew interest|Study NCT02672358 in nan was Withdrawn during Phase 2 because Company Decision|Study NCT02447939 in nan was Withdrawn during Phase 1 because Change in strategy|Study NCT03794297 in United States was Withdrawn during Phase 2 because Inadequate accrual rate

>  <Indications>  (198) 
Trametinib is indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.

>  <Type>  (198) 
3

>  <targets_id>  (198) 
P15056|Q02750|P36507

>  <inchi>  (198) 
InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)

>  <stdInchikey>  (198) 
LIRYPHYGHXZJBZ-UHFFFAOYSA-N

>  <csid>  (198) 
9881833

>  <Links>  (198) 
|http://www.chemspider.com/Chemical-Structure.9881833.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103875|http://pubchem.ncbi.nlm.nih.gov/compound/11707110|http://www.drugbank.ca/drugs/DB08911| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=QOM|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/QOM|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6495|http://zinc15.docking.org/substances/ZINC43100709|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=33E86K87QN

>  <LinkName>  (198) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (198) 
'QOM'

>  <pdbID>  (198) 
6v2y 7jur 7jux

>  <indicationG2P>  (198) 
None

>  <indicationDB>  (198) 
Trametinib dimethyl sulfoxide is a kinase inhibitor. Each 1-mg tablet contains 1.127 mg trametinib dimethyl sulfoxide equivalent to 1 mg of trametinib non-solvated parent. FDA approved on May 29, 2013 <sup class="text-reference-group"><a class="reference-popover-link" data-content="Drugs@FDA: FDA Approved Drug Products" href="#reference-L2727">4</a></sup>.</p><p>The U.S. Food and Drug Administration approved <a href="https://go.drugbank.com/drugs/DB08912">Dabrafenib</a>(Tafilnar) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has a type of abnormal gene, BRAF V600E (BRAF V600E mutation-positive) <sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approves new uses for two drugs administered together for the treatment of BRAF-positive anaplastic thyroid cancer" href="#reference-L2726">3</a></sup>.</p><p>Thyroid cancer is a disease in which cancer cells form in the tissues of the thyroid. Anaplastic thyroid cancer is a rare, aggressive type of thyroid cancer. The National Institutes of Health (NIH) estimates there will be 53,990 new cases of thyroid cancer and an estimated 2,060 deaths from the disease in the United States in 2018. Anaplastic thyroid cancer accounts for approximately 1 to 2 percent of all thyroid cancers <sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approves new uses for two drugs administered together for the treatment of BRAF-positive anaplastic thyroid cancer" href="#reference-L2726">3</a></sup>.

>  <uniprotId>  (198) 
Q02750|P36507|P10632|P08684

>  <MW>  (198) 
615.1

>  <HBA>  (198) 
8.0

>  <HBD>  (198) 
2.0

>  <NRB>  (198) 
5.0

>  <TPSA>  (198) 
107.1

>  <LogP>  (198) 
3.9

>  <RoF>  (198) 
1.0

>  <Melting point>  (198) 
293-303

>  <Targets>  (198) 
BRAF; MAP2K1; MAP2K2

>  <Kinase families>  (198) 
TKL<br>STE

>  <FDA_approved>  (198) 
Y

$$$$
Pazopanib
     RDKit          2D

 31 34  0  0  0  0  0  0  0  0999 V2000
   -5.8587    3.1697    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1790    1.8325    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6812    1.7526    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0015    0.4154    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8197   -0.8418    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3175   -0.7619    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9972    0.5753    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4951    0.6553    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5750   -0.8426    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4151    2.1531    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -8.9929    0.7352    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1400   -2.1790    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6421   -2.2590    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9624   -3.5961    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.5354   -3.6761    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3536   -2.4189    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6739   -1.0817    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8239   -1.0018    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.4921    0.1755    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.8124    1.5127    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9900    0.0955    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6697   -1.2417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1675   -1.3216    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9857   -0.0644    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4675    0.1688    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7036    1.6501    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.3677    2.3324    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.3060    1.2728    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8082    1.3527    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0408    2.3298    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5271   -0.8929    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  8 10  2  0
  8 11  1  0
  5 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 17 19  1  0
 19 20  1  0
 19 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 26 30  1  0
 25 31  1  0
  7  2  1  0
 18 13  1  0
 29 21  2  0
 28 24  1  0
M  END
>  <BrandName>  (199) 
Votrient

>  <Applicants>  (199) 
GlaxoSmithKline

>  <CHEMBL_ID>  (199) 
CHEMBL477772

>  <Canonical_Smiles>  (199) 
Cc1ccc(cc1S(=O)(=O)N)Nc2nccc(n2)N(C)c3ccc4c(n(nc4c3)C)C

>  <Chirality>  (199) 
Achiral Molecule

>  <First_Approval>  (199) 
2009

>  <Phase>  (199) 
4.0

>  <SC_Patent>  (199) 
US-7105530-B2

>  <Synonyms>  (199) 
GW786034 | PAZOPANIB | VOTRIENT

>  <Withdrawn>  (199) 
|Study NCT02367651 in nan was Withdrawn during Phase 2 because Study cancelled: Withdrawn before enrollment of any participants|Study NCT02342600 in nan was Withdrawn during Phase 2 because Supporting company withdrew interest|Study NCT03275558 in Singapore was Withdrawn during Phase 1 because Study halted prior to enrollment of first participant (It has been determined on 2018 May 15    that the NCT03275558 study will be stopped by sponsor decision)

>  <Indications>  (199) 
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

>  <Type>  (199) 
1

>  <targets_id>  (199) 
P17948|P35968|P35916|P16234|P09619|P10721|P22607|Q08881|P11362

>  <inchi>  (199) 
InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)

>  <stdInchikey>  (199) 
CUIHSIWYWATEQL-UHFFFAOYSA-N

>  <csid>  (199) 
8289501

>  <Links>  (199) 
|http://www.chemspider.com/Chemical-Structure.8289501.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL477772|http://pubchem.ncbi.nlm.nih.gov/compound/10113978|http://www.drugbank.ca/drugs/DB06589|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5698|http://zinc15.docking.org/substances/ZINC000011617039|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=7RN5DR86CK|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=26474

>  <LinkName>  (199) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (199) 


>  <pdbID>  (199) 


>  <indicationG2P>  (199) 
None

>  <indicationDB>  (199) 
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

>  <uniprotId>  (199) 
P17948|P35968|P35916|P16234|P09619|P10721|P22607|Q08881|P05230|Q9UQQ2|P08684|P10635|P10632|P05177|P08183|Q9UNQ0|Q9Y6L6|P22309

>  <MW>  (199) 
437.2

>  <HBA>  (199) 
8.0

>  <HBD>  (199) 
2.0

>  <NRB>  (199) 
5.0

>  <TPSA>  (199) 
119.0

>  <LogP>  (199) 
3.1

>  <RoF>  (199) 
0.0

>  <Melting point>  (199) 


>  <Targets>  (199) 
FLT1; KDR; FLT4; PDGFRA; PDGFRB; KIT; FGFR3; ITK; FGFR1

>  <Kinase families>  (199) 
Tyr

>  <FDA_approved>  (199) 
Y

$$$$
Palbociclib
     RDKit          2D

 33 37  0  0  0  0  0  0  0  0999 V2000
   -3.0248   -3.7842    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3339   -2.3164    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2173   -1.3148    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7916   -1.7810    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3250   -0.7794    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0160    0.6884    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4097    1.1546    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5264    0.1530    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9521    0.6192    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0687   -0.3823    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4944    0.0839    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7596   -1.8502    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8762   -2.8517    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5671   -4.3196    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3019   -2.3855    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2612    2.0870    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6303    2.6997    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4707    4.1912    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0029    4.5003    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2554    3.1999    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1326    1.6900    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.5583    1.2237    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8674   -0.2441    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2931   -0.7103    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4097    0.2913    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1006    1.7591    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6749    2.2253    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.8354   -0.1750    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.1445   -1.6428    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5702   -2.1090    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.6868   -1.1074    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.3777    0.3604    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9520    0.8266    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  1  0
 10 11  2  0
 10 12  1  0
 12 13  1  0
 13 14  2  0
 13 15  1  0
  9 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
  6 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 25 28  1  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 32 33  1  0
 12  2  2  0
  8  3  1  0
 20 16  1  0
 27 22  1  0
 33 28  1  0
M  END
>  <BrandName>  (200) 
Ibrance

>  <Applicants>  (200) 
Pfizer

>  <CHEMBL_ID>  (200) 
CHEMBL189963

>  <Canonical_Smiles>  (200) 
Cc1c2cnc(nc2n(c(=O)c1C(=O)C)C3CCCC3)Nc4ccc(cn4)N5CCNCC5

>  <Chirality>  (200) 
Achiral Molecule

>  <First_Approval>  (200) 
2015

>  <Phase>  (200) 
4.0

>  <SC_Patent>  (200) 
US-6936612-B2

>  <Synonyms>  (200) 
IBRANCE | PALBOCICLIB | PD-0332991

>  <Withdrawn>  (200) 
|Study NCT03377101 in nan was Withdrawn during Phase 2 because change in study design|Study NCT03123744 in United States was Withdrawn during Phase 2 because No study funding available|Study NCT04220476 in nan was Withdrawn during Phase 2 because Initiating a new study with revised Statistics

>  <Indications>  (200) 
Palbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

>  <Type>  (200) 
1

>  <targets_id>  (200) 
P11802|Q00534

>  <inchi>  (200) 
InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)

>  <stdInchikey>  (200) 
AHJRHEGDXFFMBM-UHFFFAOYSA-N

>  <csid>  (200) 
4487437

>  <Links>  (200) 
|http://www.chemspider.com/Chemical-Structure.4487437.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL189963|http://pubchem.ncbi.nlm.nih.gov/compound/5330286|http://www.drugbank.ca/drugs/DB09073| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=LQQ|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/LQQ|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7380|http://zinc15.docking.org/substances/ZINC000003938686|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=G9ZF61LE7G|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=6309

>  <LinkName>  (200) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (200) 
'LQQ'

>  <pdbID>  (200) 
2euf 5l2i

>  <indicationG2P>  (200) 
None

>  <indicationDB>  (200) 
Palbociclib is a piperazine pyridopyrimidine<sup class="text-reference-group"><a class="reference-popover-link" data-content="Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, Zirkelbach JF, Yu J, Liu Q, Zhao L, Crich J, Chen XH, Hughes M, Bloomquist E, Tang S, Sridhara R, Kluetz PG, Kim G, Ibrahim A, Pazdur R, Cortazar P: FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clin Cancer Res. 2015 Nov 1;21(21):4760-6. doi: 10.1158/1078-0432.CCR-15-1185. Epub 2015 Aug 31. (PubMed ID 26324739)" href="#reference-A176792">3</a></sup> that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor<sup class="text-reference-group"><a class="reference-popover-link" data-content="Rocca A, Schirone A, Maltoni R, Bravaccini S, Cecconetto L, Farolfi A, Bronte G, Andreis D: Progress with palbociclib in breast cancer: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Feb;9(2):83-105. doi: 10.1177/1758834016677961. Epub 2016 Nov 21. (PubMed ID 28203301)" href="#reference-A176798">4</a></sup> selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Cadoo KA, Gucalp A, Traina TA: Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press). 2014 Aug 4;6:123-33. doi: 10.2147/BCTT.S46725. eCollection 2014. (PubMed ID 25177151)" href="#reference-A176810">5</a></sup></p><p>Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Pfizer history" href="#reference-L5867">8</a></sup> It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Apadaz (benzhydrocodone and acetaminophen) tablets" href="#reference-L4894">7</a></sup>

>  <uniprotId>  (200) 
P11802|Q00534|P08684|Q06520|P02768|P08183|Q9UNQ0|O15245

>  <MW>  (200) 
447.2

>  <HBA>  (200) 
9.0

>  <HBD>  (200) 
2.0

>  <NRB>  (200) 
5.0

>  <TPSA>  (200) 
105.0

>  <LogP>  (200) 
3.0

>  <RoF>  (200) 
0.0

>  <Melting point>  (200) 
263-266 ÂºC

>  <Targets>  (200) 
CDK4; CDK6

>  <Kinase families>  (200) 
CMGC

>  <FDA_approved>  (200) 
Y

$$$$
Osimertinib
     RDKit          2D

 37 40  0  0  0  0  0  0  0  0999 V2000
    8.3580   -2.5010    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3024   -1.4353    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.8198   -1.6629    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1451   -0.3232    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2108    0.7324    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5441    0.0451    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8060    0.8560    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7346    2.3543    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4013    3.0417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1394    2.2307    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6647   -0.0815    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1339    1.3214    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6534    1.5631    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7039    0.4018    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.2348   -1.0011    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7152   -1.2427    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.2853   -2.1623    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1951   -1.9206    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7260   -0.5177    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2064   -0.2760    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1559   -1.4372    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6250   -2.8401    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1446   -3.0818    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6137   -4.4847    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5632   -5.6459    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6363   -1.1955    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5858   -2.3568    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1672    0.2074    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6476    0.4491    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.1785    1.8520    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -9.6589    2.0937    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2290    3.0132    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7373    1.1269    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7878    2.2881    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3074    2.0464    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3186    3.6910    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3691    4.8523    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
  4 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 15 17  1  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  1  0
 21 26  1  0
 26 27  1  0
 26 28  1  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
 30 32  1  0
 20 33  1  0
 33 34  1  0
 34 35  2  0
 34 36  1  0
 36 37  2  0
  6  2  1  0
 10  5  1  0
 16 11  1  0
 23 18  1  0
M  END
>  <BrandName>  (201) 
Tagrisso

>  <Applicants>  (201) 
Astrazeneca

>  <CHEMBL_ID>  (201) 
CHEMBL3353410

>  <Canonical_Smiles>  (201) 
Cn1cc(c2c1cccc2)c3ccnc(n3)Nc4cc(c(cc4OC)N(C)CCN(C)C)NC(=O)C=C

>  <Chirality>  (201) 
Achiral Molecule

>  <First_Approval>  (201) 
2015

>  <Phase>  (201) 
4.0

>  <SC_Patent>  (201) 
US-8946235-B2

>  <Synonyms>  (201) 
AZD-9291 | AZD-9291 FREE BASE | AZD9291 | OSIMERTINIB | TAGRISSO

>  <Withdrawn>  (201) 


>  <Indications>  (201) 
Osimertinib is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA- approved test, who have progressed on or after EGFR-TKI therapy.

>  <Type>  (201) 
1

>  <targets_id>  (201) 
P00533

>  <inchi>  (201) 
InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)

>  <stdInchikey>  (201) 
DUYJMQONPNNFPI-UHFFFAOYSA-N

>  <csid>  (201) 
31042598

>  <Links>  (201) 
|http://www.chemspider.com/Chemical-Structure.31042598.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3353410|http://pubchem.ncbi.nlm.nih.gov/compound/71496458|http://www.drugbank.ca/drugs/DB09330| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=YY3|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/YY3|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7719|http://zinc15.docking.org/substances/ZINC000098023177|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=3C06JJ0Z2O|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50029668

>  <LinkName>  (201) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (201) 
'YY3'

>  <pdbID>  (201) 
4zau 6jwl 6jx0 6jx4 6jxt 6lud

>  <indicationG2P>  (201) 
None

>  <indicationDB>  (201) 
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. </p><p>Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.

>  <uniprotId>  (201) 
P00533|P08684|P05177|P08183|Q9UNQ0

>  <MW>  (201) 
499.3

>  <HBA>  (201) 
8.0

>  <HBD>  (201) 
2.0

>  <NRB>  (201) 
10.0

>  <TPSA>  (201) 
87.6

>  <LogP>  (201) 
4.5

>  <RoF>  (201) 
0.0

>  <Melting point>  (201) 


>  <Targets>  (201) 
EGFR

>  <Kinase families>  (201) 
Tyr

>  <FDA_approved>  (201) 
Y

$$$$
Ponatinib
     RDKit          2D

 39 43  0  0  0  0  0  0  0  0999 V2000
    5.6633   -3.4199    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1859   -3.1607    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2227   -4.3106    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7453   -4.0514    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2310   -2.6423    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1942   -1.4924    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6717   -1.7516    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6349   -0.6017    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5981    0.5482    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5613    1.6981    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1971    3.1532    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4685    3.9492    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.6184    2.9860    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0577    1.5947    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.9822    0.4135    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.4674    0.6235    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.0281    2.0148    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1036    3.1960    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2464   -2.3831    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2096   -3.5330    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7606   -0.9740    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2381   -0.7148    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7523    0.6943    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2297    0.9535    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1929   -0.1964    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6787   -1.6055    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2013   -1.8647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6419   -2.7553    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6051   -3.9052    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4920   -3.7185    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7918   -1.7921    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6704    0.0629    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1846    1.4720    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2214    2.6218    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7356    4.0309    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.2131    4.2902    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -9.1763    3.1403    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.6620    1.7312    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7273    5.6993    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  3  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
  5 19  1  0
 19 20  2  0
 19 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 26 28  1  0
 28 29  1  0
 28 30  1  0
 28 31  1  0
 25 32  1  0
 32 33  1  0
 33 34  1  0
 34 35  1  0
 35 36  1  0
 36 37  1  0
 37 38  1  0
 36 39  1  0
  7  2  1  0
 14 10  1  0
 18 13  1  0
 27 22  1  0
 38 33  1  0
M  END
>  <BrandName>  (202) 
Iclusig

>  <Applicants>  (202) 
Ariad Pharmaceuticals

>  <CHEMBL_ID>  (202) 
CHEMBL1171837

>  <Canonical_Smiles>  (202) 
Cc1ccc(cc1C#Cc2cnc3n2nccc3)C(=O)Nc4ccc(c(c4)C(F)(F)F)CN5CCN(CC5)C

>  <Chirality>  (202) 
Achiral Molecule

>  <First_Approval>  (202) 
2012

>  <Phase>  (202) 
4.0

>  <SC_Patent>  (202) 
US-8114874-B2

>  <Synonyms>  (202) 
AP-24534 | AP24534 | ICLUSIG | PONATINIB

>  <Withdrawn>  (202) 
|Study NCT01888562 in nan was Withdrawn during N/A because Could not obtain an IDE on the FGFR2 assay

>  <Indications>  (202) 
Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.

>  <Type>  (202) 
2

>  <targets_id>  (202) 
P00519|P11274|P10721|P07949|Q02763|P36888|P11362|P21802|P22607|P22455|P06239|P12931|P07948|P35968|P16234

>  <inchi>  (202) 
InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)

>  <stdInchikey>  (202) 
PHXJVRSECIGDHY-UHFFFAOYSA-N

>  <csid>  (202) 
24747381

>  <Links>  (202) 
|http://www.chemspider.com/Chemical-Structure.24747381.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1171837|http://pubchem.ncbi.nlm.nih.gov/compound/24826799|http://www.drugbank.ca/drugs/DB08901| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=0LI|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/0LI|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5890|http://zinc15.docking.org/substances/ZINC36701290|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=4340891KFS|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50322535

>  <LinkName>  (202) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (202) 
'0LI'

>  <pdbID>  (202) 
3ik3 3oxz 3zos 4c8b 4qrc 4tyj 4u0i 4uxq 4v01 4v04 6eg9 6p3d 6tu9

>  <indicationG2P>  (202) 
None

>  <indicationDB>  (202) 
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.

>  <uniprotId>  (202) 
P00519|P11274|P10721|P07949|Q02763|P36888|P11362|P21802|P22607|P22455|P06239|P12931|P07948|P35968|P16234|P08684|P10632|P10635|P20815|P08183|Q9UNQ0

>  <MW>  (202) 
532.2

>  <HBA>  (202) 
6.0

>  <HBD>  (202) 
1.0

>  <NRB>  (202) 
4.0

>  <TPSA>  (202) 
65.8

>  <LogP>  (202) 
4.5

>  <RoF>  (202) 
1.0

>  <Melting point>  (202) 


>  <Targets>  (202) 
ABL1; BCR; KIT; RET; TEK; FLT3; FGFR1; FGFR2; FGFR3; FGFR4; LCK; SRC; LYN; KDR; PDGFRA

>  <Kinase families>  (202) 
Tyr<br>Atypical

>  <FDA_approved>  (202) 
Y

$$$$
Upadacitinib
     RDKit          2D

 27 30  0  0  0  0  0  0  0  0999 V2000
    0.6514    3.0309    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1685    1.6228    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2077    0.4710    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2889    0.5712    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8468   -0.8212    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6949   -1.7820    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5748   -0.9834    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9673   -1.5413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3344   -2.9957    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8310   -3.0959    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.3889   -1.7035    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2370   -0.7427    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.4932    0.7353    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5662    1.9146    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4014    3.1606    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8445    2.7513    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.9012    1.2524    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0531    0.2916    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.7969   -1.1864    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3012   -1.1883    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7104   -2.6314    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3463   -0.1123    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8007   -0.4795    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8458    0.5965    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.8909    1.6725    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9218   -0.4486    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7698    1.6416    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  3  2  1  1
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  1
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  2  0
  5 20  1  0
 20 21  2  0
 20 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 24 26  1  0
 24 27  1  0
  7  3  1  0
 12  8  1  0
 19 11  1  0
 17 13  2  0
M  END
>  <BrandName>  (203) 
Rinvoq

>  <Applicants>  (203) 
Abbvie

>  <CHEMBL_ID>  (203) 
CHEMBL3622821

>  <Canonical_Smiles>  (203) 
CC[C@@H]1CN(C[C@@H]1c2cnc3n2c4cc[nH]c4nc3)C(=O)NCC(F)(F)F

>  <Chirality>  (203) 
Single Stereoisomer

>  <First_Approval>  (203) 
2019

>  <Phase>  (203) 
4.0

>  <SC_Patent>  (203) 
US-8962629-B2

>  <Synonyms>  (203) 
ABT-494 | RINVOQ | UPADACITINIB

>  <Withdrawn>  (203) 
|Study NCT04666675 in nan was Withdrawn during Phase 3 because Strategic considerations

>  <Indications>  (203) 
On august 2019, FDA approved fedratinib to treat adults with moderately to severely active rheumatoid arthritis

>  <Type>  (203) 
nan

>  <targets_id>  (203) 
P23458

>  <inchi>  (203) 
InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1

>  <stdInchikey>  (203) 
WYQFJHHDOKWSHR-MNOVXSKESA-N

>  <csid>  (203) 
44210449

>  <Links>  (203) 
|http://www.chemspider.com/Chemical-Structure.44210449.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3622821|http://pubchem.ncbi.nlm.nih.gov/compound/58557659|http://www.drugbank.ca/drugs/DB15091|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9246|http://zinc15.docking.org/substances/ZINC000147180128|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=4RA0KN46E0

>  <LinkName>  (203) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (203) 


>  <pdbID>  (203) 


>  <indicationG2P>  (203) 
None

>  <indicationDB>  (203) 
Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019. (PubMed ID 31692920)" href="#reference-A189165">4</a></sup> Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Rivellese F, Lobasso A, Barbieri L, Liccardo B, de Paulis A, Rossi FW: Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors. Curr Med Chem. 2019;26(16):2823-2843. doi: 10.2174/0929867325666180209145243. (PubMed ID 29424301)" href="#reference-A189171">6</a></sup> The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O&#39;Shea JJ: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017 Dec 28;17(1):78. doi: 10.1038/nrd.2017.267. (PubMed ID 29282366)" href="#reference-A189168">5</a></sup> To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and <a href="https://go.drugbank.com/drugs/DB14845">filgotinib</a>, were developed.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019. (PubMed ID 31692920)" href="#reference-A189165">4</a></sup></p><p>The FDA approved Upadacitinib in August 2019 for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Rinvoq (upadacitinib) extended-release tablets, for oral use" href="#reference-L10896">9</a></sup> In December 2019, it was additionally approved by the European Commission for the same indication in patients with inadequate response or intolerance to one or more DMARDs and can be used as monotherapy or in combination with methotrexate.<sup class="text-reference-group"><a class="reference-popover-link" data-content="AbbVie Receives European Commission Approval of RINVOQâ¢ (upadacitinib) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis" href="#reference-L10899">10</a></sup> Upadacitinib is marketed under the brand name RINVOQâ¢ for oral administration.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Rinvoq (upadacitinib) extended-release tablets, for oral use" href="#reference-L10896">9</a></sup> It is currently being investigated in several clinical trials assessing its therapeutic effectiveness in other inflammatory diseases, such as psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and atopic dermatitis.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019. (PubMed ID 31692920)" href="#reference-A189165">4</a></sup>

>  <uniprotId>  (203) 
P23458|P08684|P10635|P08183|Q9UNQ0|Q9Y6L6

>  <MW>  (203) 
380.2

>  <HBA>  (203) 
4.0

>  <HBD>  (203) 
2.0

>  <NRB>  (203) 
3.0

>  <TPSA>  (203) 
78.3

>  <LogP>  (203) 
2.9

>  <RoF>  (203) 
0.0

>  <Melting point>  (203) 
16-19

>  <Targets>  (203) 
JAK1

>  <Kinase families>  (203) 
Tyr

>  <FDA_approved>  (203) 
Y

$$$$
Fedratinib
     RDKit          2D

 37 40  0  0  0  0  0  0  0  0999 V2000
    3.6403   -5.6667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7459   -4.4625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2558   -4.6350    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3615   -3.4308    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.9571   -2.0541    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4472   -1.8817    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.3416   -3.0858    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8316   -2.9134    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.4273   -1.5367    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9173   -1.3643    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5130    0.0124    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6186    1.2166    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1286    1.0441    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5329   -0.3325    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2342    2.2483    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    5.4384    3.1427    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.0300    1.3539    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.3398    3.4525    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.9354    4.8292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5588    5.4248    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3121    4.2335    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5311    6.2058    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0627   -0.8499    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4273   -1.0224    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0230   -2.3991    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5130   -2.5715    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4074   -1.3673    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8118    0.0093    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3217    0.1818    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8975   -1.5398    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7919   -0.3356    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.2819   -0.5081    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.1763    0.6961    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7278    2.1275    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.9505    2.9964    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.1547    2.1020    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.6762    0.6803    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 13 15  1  0
 15 16  2  0
 15 17  2  0
 15 18  1  0
 18 19  1  0
 19 20  1  0
 19 21  1  0
 19 22  1  0
  5 23  1  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 27 30  1  0
 30 31  1  0
 31 32  1  0
 32 33  1  0
 33 34  1  0
 34 35  1  0
 35 36  1  0
 36 37  1  0
  7  2  1  0
 14  9  1  0
 29 24  1  0
 37 33  1  0
M  END
>  <BrandName>  (204) 
Inrebic

>  <Applicants>  (204) 
Sanofi

>  <CHEMBL_ID>  (204) 
CHEMBL1287853

>  <Canonical_Smiles>  (204) 
Cc1cnc(nc1Nc2cccc(c2)S(=O)(=O)NC(C)(C)C)Nc3ccc(cc3)OCCN4CCCC4

>  <Chirality>  (204) 
Achiral Molecule

>  <First_Approval>  (204) 
2019

>  <Phase>  (204) 
4.0

>  <SC_Patent>  (204) 
US-7528143-B2

>  <Synonyms>  (204) 
FEDRATINIB | SAR-302503 | SAR302503 | TG-101348 | TG101348

>  <Withdrawn>  (204) 


>  <Indications>  (204) 
On august 2019, FDA approved fedratinib to treat adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis

>  <Type>  (204) 
nan

>  <targets_id>  (204) 
O60674|P36888|O60885

>  <inchi>  (204) 
InChI=1S/C27H36N6O3S/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31)

>  <stdInchikey>  (204) 
JOOXLOJCABQBSG-UHFFFAOYSA-N

>  <csid>  (204) 
17626393

>  <Links>  (204) 
|http://www.chemspider.com/Chemical-Structure.17626393.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1287853|http://pubchem.ncbi.nlm.nih.gov/compound/16722836|http://www.drugbank.ca/drugs/DB12500| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=2TA|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/2TA|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5716|http://zinc15.docking.org/substances/ZINC000019862646|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6L1XP550I6|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50332294

>  <LinkName>  (204) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (204) 
'2TA'

>  <pdbID>  (204) 
4ogj 4ps5 6vne

>  <indicationG2P>  (204) 
None

>  <indicationDB>  (204) 
Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Jamieson C, Hasserjian R, Gotlib J, Cortes J, Stone R, Talpaz M, Thiele J, Rodig S, Pozdnyakova O: Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. J Transl Med. 2015 Sep 10;13:294. doi: 10.1186/s12967-015-0644-4. (PubMed ID 26357842)" href="#reference-A183176">2</a>,<a class="reference-popover-link" data-content="FDA Approved Drug Products: Fedratinib Oral Capsules" href="#reference-L8090">7</a></sup> It is an anilinopyrimidine derivative.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Roskoski R Jr: Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res. 2016 Sep;111:784-803. doi: 10.1016/j.phrs.2016.07.038. Epub 2016 Jul 26. (PubMed ID 27473820)" href="#reference-A183188">6</a></sup></p><p>Fedratinib was granted FDA approval on August 16, 2019.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Fedratinib Oral Capsules" href="#reference-L8090">7</a></sup>

>  <uniprotId>  (204) 
O60674|P36888|P23458|P08684|P33261|P31513|P10635|P08183|Q9UNQ0|Q9Y6L6|Q9NPD5|P09086|Q96FL8|Q86VL8

>  <MW>  (204) 
524.3

>  <HBA>  (204) 
8.0

>  <HBD>  (204) 
3.0

>  <NRB>  (204) 
10.0

>  <TPSA>  (204) 
108.5

>  <LogP>  (204) 
4.8

>  <RoF>  (204) 
1.0

>  <Melting point>  (204) 


>  <Targets>  (204) 
JAK2; FLT3; BRD4

>  <Kinase families>  (204) 
Tyr<br>(*)

>  <FDA_approved>  (204) 
Y

$$$$
Pemigatinib
     RDKit          2D

 35 39  0  0  0  0  0  0  0  0999 V2000
    0.1591   -3.8085    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6192   -2.5262    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1021   -1.2110    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6762    0.0713    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1758    0.0384    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1548   -1.0981    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5382   -0.5182    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4141    0.9767    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9541    1.3207    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2328    2.6358    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7331    2.6687    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0452    1.3864    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5448    1.4193    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3231    0.1370    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.6018   -1.1781    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3801   -2.4604    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.8228    0.1699    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6011   -1.1124    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1007   -1.0795    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8220    0.2357    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0437    1.5180    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5441    1.4851    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7658    2.7674    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    6.7651    2.8331    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.2647    2.8660    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8790   -2.3618    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.3786   -2.3289    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8797   -2.4275    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8205   -1.2965    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1356   -0.5751    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1685    0.9245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4837    1.6459    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.7660    0.8676    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -9.7331   -0.6321    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4179   -1.3534    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  2  0
 14 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 21 24  1  0
 24 25  1  0
 19 26  1  0
 26 27  1  0
 18 28  1  0
  7 29  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 32 33  1  0
 33 34  1  0
 34 35  1  0
 15  3  1  0
 12  4  1  0
  9  5  1  0
 22 17  1  0
 35 30  1  0
M  END
>  <BrandName>  (205) 
Pemazyre

>  <Applicants>  (205) 
Incyte Corporation

>  <CHEMBL_ID>  (205) 
CHEMBL4297522

>  <Canonical_Smiles>  (205) 
CCN1c2c3cc([nH]c3ncc2CN(C1=O)c4c(c(cc(c4F)OC)OC)F)CN5CCOCC5

>  <Chirality>  (205) 
Achiral Molecule

>  <First_Approval>  (205) 
2020

>  <Phase>  (205) 
4.0

>  <SC_Patent>  (205) 
US-9611267-B2

>  <Synonyms>  (205) 
INCB054828 | PEMAZYRE | PEMIGATINIB

>  <Withdrawn>  (205) 


>  <Indications>  (205) 
On April 2020, FDA approved pemigatinib to treat certain patients with cholangiocarcinoma, a rare form of cancer that forms in bile ducts.

>  <Type>  (205) 
nan

>  <targets_id>  (205) 
nan

>  <inchi>  (205) 
InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)

>  <stdInchikey>  (205) 
HCDMJFOHIXMBOV-UHFFFAOYSA-N

>  <csid>  (205) 
68007304

>  <Links>  (205) 
|http://www.chemspider.com/Chemical-Structure.68007304.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297522|http://pubchem.ncbi.nlm.nih.gov/compound/86705695|http://www.drugbank.ca/drugs/DB15102|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9767|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=Y6BX7BL23K|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=301310

>  <LinkName>  (205) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB

>  <lig_pdbID>  (205) 


>  <pdbID>  (205) 


>  <indicationG2P>  (205) 
None

>  <indicationDB>  (205) 
Pemigatinib is a small molecule kinase inhibitor with antitumour activity. It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Casadei C, Dizman N, Schepisi G, Cursano MC, Basso U, Santini D, Pal SK, De Giorgi U: Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. Ther Adv Med Oncol. 2019 Nov 25;11:1758835919890285. doi: 10.1177/1758835919890285. eCollection 2019. (PubMed ID 31803255)" href="#reference-A193719">1</a></sup> FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast, ovary, prostate, endometrium, lung, and stomach.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Roskoski R Jr: The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacol Res. 2020 Jan;151:104567. doi: 10.1016/j.phrs.2019.104567. Epub 2019 Nov 23. (PubMed ID 31770593)" href="#reference-A198984">4</a></sup> Deregulated FGFR signalling pathway can lead the development of oncogenes and tumour-promoting physiological processes, such as cancer cell proliferation, enhanced angiogenesis, and evasion of cell death.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Liu PCC, Koblish H, Wu L, Bowman K, Diamond S, DiMatteo D, Zhang Y, Hansbury M, Rupar M, Wen X, Collier P, Feldman P, Klabe R, Burke KA, Soloviev M, Gardiner C, He X, Volgina A, Covington M, Ruggeri B, Wynn R, Burn TC, Scherle P, Yeleswaram S, Yao W, Huber R, Hollis G: INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models. PLoS One. 2020 Apr 21;15(4):e0231877. doi: 10.1371/journal.pone.0231877. eCollection 2020. (PubMed ID 32315352)" href="#reference-A193716">2</a></sup></p><p>In April 2020, pemigatinib was approved by the FDA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously treated adult patients with a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an FDA-approved test.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Resources for Information | Approved Drugs: FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion" href="#reference-L13068">6</a></sup> Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Blechacz B: Cholangiocarcinoma: Current Knowledge and New Developments. Gut Liver. 2017 Jan 15;11(1):13-26. doi: 10.5009/gnl15568. (PubMed ID 27928095)" href="#reference-A198963">3</a></sup> This malignancy accounts for 15% to 20% of primary hepatobiliary malignancies, which account for 13% of overall cancer-related global mortality.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Blechacz B: Cholangiocarcinoma: Current Knowledge and New Developments. Gut Liver. 2017 Jan 15;11(1):13-26. doi: 10.5009/gnl15568. (PubMed ID 27928095)" href="#reference-A198963">3</a></sup> With increasing research on the pathogenesis of cholangiocarcinoma and potential therapeutic targets for anticancer drug treatment, recent studies show that up to 45% of patients with intrahepatic cholangiocarcinoma exhibited gene rearrangements resulting in oncogenic fibroblast growth factor 2 (FGFR2) fusion proteins.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Blechacz B: Cholangiocarcinoma: Current Knowledge and New Developments. Gut Liver. 2017 Jan 15;11(1):13-26. doi: 10.5009/gnl15568. (PubMed ID 27928095)" href="#reference-A198963">3</a></sup> The FDA-approved indication for pemigatinib was granted under accelerated approval based on the overall response rate and duration of response in pre-marketing clinical trials. Pemigatinib is marketed under the brand name Pemazyre, and it is available as oral tablets.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: PEMAZYRE (pemigatinib) tablets, for oral use" href="#reference-L13050">5</a></sup>

>  <uniprotId>  (205) 
P11362|P21802|P22607|P22455|P08684|P08183|Q9UNQ0|O15244|Q96FL8

>  <MW>  (205) 
487.2

>  <HBA>  (205) 
6.0

>  <HBD>  (205) 
1.0

>  <NRB>  (205) 
6.0

>  <TPSA>  (205) 
83.2

>  <LogP>  (205) 
3.7

>  <RoF>  (205) 
0.0

>  <Melting point>  (205) 


>  <Targets>  (205) 
nan

>  <Kinase families>  (205) 


>  <FDA_approved>  (205) 
Y

$$$$
Fostamatinib
     RDKit          2D

 40 43  0  0  0  0  0  0  0  0999 V2000
   -7.5685   -3.7323    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2302   -2.2710    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4121   -0.7821    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7924   -0.1951    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2135    0.1199    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8331   -0.4670    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6513   -1.9560    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2709   -2.5429    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0724   -1.6409    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2542   -0.1520    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6346    0.4350    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0557    0.7500    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.3247    0.1630    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5066   -1.3259    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8869   -1.9128    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0855   -1.0108    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.9036    0.4781    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5232    1.0650    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.1021    1.3801    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.4825    0.7931    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6644   -0.6958    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0448   -1.2828    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2433   -0.3808    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0614    1.1082    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6810    1.6951    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2599    2.0101    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.0780    3.4991    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.6237   -0.9677    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.8222   -0.0657    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2266   -2.7717    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.0281   -3.6737    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6920   -2.2279    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8498   -2.8579    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3954    1.6088    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1969    2.5108    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3788    3.9998    0.0000 P   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8899    4.1817    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8677    3.8179    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5607    5.4887    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7281   -2.1916    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  3  5  1  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 10 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 17 19  1  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 24 26  1  0
 26 27  1  0
 23 28  1  0
 28 29  1  0
 22 30  1  0
 30 31  1  0
 14 32  1  0
  7 33  1  0
  5 34  1  0
 34 35  1  0
 35 36  1  0
 36 37  2  0
 36 38  1  0
 36 39  1  0
  2 40  1  0
 33  2  1  0
 11  6  1  0
 18 13  1  0
 25 20  1  0
M  END
>  <BrandName>  (206) 
Tavalisse

>  <Applicants>  (206) 
Rigel Pharmaceuticals

>  <CHEMBL_ID>  (206) 
CHEMBL2103830

>  <Canonical_Smiles>  (206) 
CC1(C(=O)N(c2c(ccc(n2)Nc3c(cnc(n3)Nc4cc(c(c(c4)OC)OC)OC)F)O1)COP(=O)(O)O)C

>  <Chirality>  (206) 
Achiral Molecule

>  <First_Approval>  (206) 
2018

>  <Phase>  (206) 
4.0

>  <SC_Patent>  (206) 
US-7449458-B2

>  <Synonyms>  (206) 
FOSTAMATINIB | R-788 | R-788 FREE ACID | R-935788 | R-935788 FREE ACID | R788 FREE ACID | R935788 FREE ACID

>  <Withdrawn>  (206) 


>  <Indications>  (206) 
Indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to a previous treatment

>  <Type>  (206) 
nan

>  <targets_id>  (206) 
P43405

>  <inchi>  (206) 
InChI=1S/C23H26FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29)

>  <stdInchikey>  (206) 
GKDRMWXFWHEQQT-UHFFFAOYSA-N

>  <csid>  (206) 
9846198

>  <Links>  (206) 
|http://www.chemspider.com/Chemical-Structure.9846198.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103830|http://pubchem.ncbi.nlm.nih.gov/compound/11671467|http://www.drugbank.ca/drugs/DB12010| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=2RC|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/2RC|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7796|http://zinc15.docking.org/substances/ZINC000043131420|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=SQ8A3S5101|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50431381

>  <LinkName>  (206) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (206) 
'2RC'

>  <pdbID>  (206) 
4o75

>  <indicationG2P>  (206) 
None

>  <indicationDB>  (206) 
Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018 under the trade name Tavalisse for use in ITP <sup class="text-reference-group"><a class="reference-popover-link" data-content="Fostamatinib FDA Approval" href="#reference-L2644">8</a>,<a class="reference-popover-link" data-content="Official drug label" href="#label-reference">Label</a></sup>. Fostamatinib has also been granted orphan drug status by the FDA <sup class="text-reference-group"><a class="reference-popover-link" data-content="Fostamatinib FDA Approval" href="#reference-L2644">8</a></sup>.

>  <uniprotId>  (206) 
P43405|P0DMS8|Q99870|O00519|Q99808|P22309|O76074|P09917|P25774|P07711|P00519|P62344|P9WI81|Q9UK32|P29597|Q8NI60|P23458|P08581|Q8IY84|Q9P289|P17612|Q9Y6E0|Q13188|P42680|Q9BYT3|Q8TDR2|Q9NRP7|Q15208|Q9Y2H1|Q9UEW8|Q7L7X3|Q9UL54|Q9H2K8|Q9UHD2|Q02763|Q15569|P36897|P37173|P35590|Q9UKI8|Q86UE8|Q9UKE5|Q13470|Q07912|Q59H18|Q9BXA7|P33981|P42681|Q06418|O75385|Q8IYT8|Q6PHR2|P30291|P07947|Q56UN5|Q9NYL2|P43403|Q2M2I8|P42684|Q04771|P36896|Q96D53|Q9UM73|Q8NFD2|O14965|Q96GD4|Q9UQB9|P30530|P51451|Q9NSY1|O00238|Q13873|P51813|P15056|Q06187|Q14012|Q8IU85|Q96NX5|Q9UQM7|Q13554|Q13557|Q13555|Q8N5S9|Q96RR4|O14936|P07498|P06493|Q6DT37|P11802|Q00532|Q92772|O14757|O96017|O14578|P49759|P49760|P49761|Q9HAZ1|P07333|P41240|P48729|P68400|P19784|P53355|Q9UIK4|O43293|O15075|Q8N568|Q9C098|Q08345|Q16832|Q13627|Q9Y463|P00533|Q9BQI3|P19525|Q9P2K8|P21709|P29317|P29320|P54764|P54756|Q9UF33|Q15375|P29322|P54762|P29323|P54760|O15197|P04626|Q15303|O75460|P16591|P07332|P11362|P21802|P22607|P09769|P17948|P36888|P35916|P42345|P42685|P06241|O14976|P49840|P49841|P08631|Q9H2X6|Q9H422|Q9UPZ9|O14920|Q14164|P06213|P14616|P51617|Q9Y616|Q9NWZ3|Q08881|O60674|P52333|P35968|Q9Y2K2|P10721|O95835|P06239|P53667|P53671|Q5S007|P29376|P07948|P36507|P46734|Q13163|P52564|Q13233|Q02779|Q16584|Q12852|O43283|Q6ZN16|Q9Y2U5|Q99759|Q9Y6R4|O95382|P80192|Q92918|Q12851|Q8IVH8|O95819|Q9Y4K4|P53779|O15264|Q16539|Q8TD08|P31152|Q13164|P45984|Q8IW41|Q9P0L2|Q7KZI7|P27448|Q96L34|Q7Z460|Q9Y2H9|P42679|Q14680|Q12866|Q8N4C8|Q9BUB5|Q9HBH9|Q04912|O15146|Q15746|Q9H1R3|Q32MK0|Q86YV6|Q8NEV4|Q96PY6|Q8NG66|P51955|P51956|P51957|Q6P3R8|Q8TD19|P04629|Q16620|Q16288|O60285|Q9H093|O95747|Q13153|Q13177|O75914|O96013|Q9NQU5|Q9P286|Q00536|Q00537|P16234|P09619|O15530|Q96Q40|Q16816|Q9UBF8|O00750|O75747|O00329|P48736|P11309|Q86V86|P78356|Q8TBX8|Q99640|Q16512|Q16513|P53350|Q9NYY3|Q9H4B4|O00444|Q13131|Q13131|P54646|Q9Y478|O43741|P54619|Q9UGJ0|Q9UGI9|P22694|Q05655|Q02156|P05129|P41743|Q04759|Q15139|Q13237|Q13523|Q05397|Q14289|Q13882|P04049|P07949|Q9BRS2|Q9BVS4|O14730|Q13546|O43353|P57078|O75116|P08922|Q15418|P51812|Q52WX2|P0C264|Q96BR1|P57059|Q9H0K1|Q9H2G2|Q9NRH2|P12931|Q9H3Y6|O94804|O75716|Q9UEE5|O94768|Q8WU08|P08684|O60656

>  <MW>  (206) 
580.1

>  <HBA>  (206) 
12.0

>  <HBD>  (206) 
4.0

>  <NRB>  (206) 
10.0

>  <TPSA>  (206) 
186.7

>  <LogP>  (206) 
3.1

>  <RoF>  (206) 
2.0

>  <Melting point>  (206) 


>  <Targets>  (206) 
SYK

>  <Kinase families>  (206) 
Tyr

>  <FDA_approved>  (206) 
Y

$$$$
Regorafenib
     RDKit          2D

 33 35  0  0  0  0  0  0  0  0999 V2000
  -11.0440   -0.5921    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.5577   -0.3895    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.6391   -1.5753    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.2067   -2.9637    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1529   -1.3726    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5852    0.0158    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0990    0.2185    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1804   -0.9673    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7480   -2.3558    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2342   -2.5584    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5314    1.6070    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0451    1.8096    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1265    0.6238    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6403    0.8265    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0726    2.2149    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9913    3.4007    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4775    3.1981    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4236    4.7892    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    1.4136    2.4176    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.3322    1.2318    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7646   -0.1567    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.8185    1.4344    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.7371    0.2486    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1695   -1.1398    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0881   -2.3256    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5744   -2.1230    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1420   -0.7345    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2234    0.4513    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6282   -0.5319    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1145   -0.3292    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    8.4256    0.9544    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    8.8309   -2.0181    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    7.4930   -3.3088    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  3  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
  7 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 16 18  1  0
 15 19  1  0
 19 20  1  0
 20 21  2  0
 20 22  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 27 29  1  0
 29 30  1  0
 29 31  1  0
 29 32  1  0
 26 33  1  0
 10  5  1  0
 17 12  1  0
 28 23  1  0
M  END
>  <BrandName>  (207) 
Stivarga

>  <Applicants>  (207) 
Bayer

>  <CHEMBL_ID>  (207) 
CHEMBL1946170

>  <Canonical_Smiles>  (207) 
CNC(=O)c1cc(ccn1)Oc2ccc(c(c2)F)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl

>  <Chirality>  (207) 
Achiral Molecule

>  <First_Approval>  (207) 
2012

>  <Phase>  (207) 
4.0

>  <SC_Patent>  (207) 
US-7351834-B1

>  <Synonyms>  (207) 
BAY 73-4506 | BAY 73-4506 MONOHYDRATE | BAY-73-4506 | BAY-734506 | REGORAFENIB | STIVARGA

>  <Withdrawn>  (207) 


>  <Indications>  (207) 
Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.

>  <Type>  (207) 
2

>  <targets_id>  (207) 
P17948|P35968|P35916|P10721|P16234|P09619|P11362|P21802|Q02763|Q16832|P04629|P29317|P04049|P15056|Q15759|P42685|P00519|P07949

>  <inchi>  (207) 
InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)

>  <stdInchikey>  (207) 
FNHKPVJBJVTLMP-UHFFFAOYSA-N

>  <csid>  (207) 
9342697

>  <Links>  (207) 
|http://www.chemspider.com/Chemical-Structure.9342697.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1946170|http://pubchem.ncbi.nlm.nih.gov/compound/11167602|http://www.drugbank.ca/drugs/DB08896|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5891|http://zinc15.docking.org/substances/ZINC06745272|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=24T2A1DOYB|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50363397

>  <LinkName>  (207) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (207) 


>  <pdbID>  (207) 


>  <indicationG2P>  (207) 
None

>  <indicationDB>  (207) 
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.

>  <uniprotId>  (207) 
P17948|P35968|P35916|P10721|P16234|P09619|P11362|P21802|Q02763|Q16832|P04629|P29317|P04049|P15056|Q15759|P42685|P00519|P07949

>  <MW>  (207) 
482.1

>  <HBA>  (207) 
4.0

>  <HBD>  (207) 
3.0

>  <NRB>  (207) 
5.0

>  <TPSA>  (207) 
92.3

>  <LogP>  (207) 
5.7

>  <RoF>  (207) 
1.0

>  <Melting point>  (207) 


>  <Targets>  (207) 
FLT1; KDR; FLT4; KIT; PDGFRA; PDGFRB; FGFR1; FGFR2; TEK; DDR2; NTRK1; EPHA2; RAF1; BRAF; MAPK11; FRK; ABL1; RET

>  <Kinase families>  (207) 
CMGC<br>Tyr<br>TKL

>  <FDA_approved>  (207) 
Y

$$$$
Abemaciclib
     RDKit          2D

 37 41  0  0  0  0  0  0  0  0999 V2000
   -3.0503    5.7123    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4857    5.2767    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8262    3.8159    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7313    2.7906    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0718    1.3297    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5071    0.8942    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6020    1.9195    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2615    3.3803    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8476   -0.5666    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7528   -1.5919    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0932   -3.0528    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9984   -4.0781    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5630   -3.6425    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2225   -2.1817    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3174   -1.1564    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4681   -4.6678    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0327   -4.2323    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0622   -5.2576    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.4975   -4.8220    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8380   -3.3612    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7431   -2.3359    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3078   -2.7714    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0836   -0.8750    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5190   -0.4395    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8595    1.0213    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7646    2.0466    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3292    1.6111    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9887    0.1503    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2343    2.6364    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    3.4014    3.4048    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.8898    3.2188    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1729    1.7458    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.5311    1.1090    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6587   -0.3855    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7616    1.9668    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9151    4.3137    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2734   -2.9256    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  6  9  1  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 13 16  1  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 21 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 27 29  1  0
 26 30  1  0
 30 31  2  0
 31 32  1  0
 32 33  1  0
 33 34  1  0
 33 35  1  0
 31 36  1  0
 20 37  1  0
  8  3  1  0
 15 10  1  0
 22 17  1  0
 28 23  1  0
 32 25  1  0
M  END
>  <BrandName>  (208) 
Verzenio;Verzenios

>  <Applicants>  (208) 
Eli Lilly

>  <CHEMBL_ID>  (208) 
CHEMBL3301610

>  <Canonical_Smiles>  (208) 
CCN1CCN(CC1)Cc2ccc(nc2)Nc3ncc(c(n3)c4cc5c(c(c4)F)nc(n5C(C)C)C)F

>  <Chirality>  (208) 
Achiral Molecule

>  <First_Approval>  (208) 
2017

>  <Phase>  (208) 
4.0

>  <SC_Patent>  (208) 
US-7855211-B2

>  <Synonyms>  (208) 
ABEMACICLIB | LY-2835219 | LY2835219 | VERZENIO | VERZENIOS

>  <Withdrawn>  (208) 
|Study NCT04220892 in United States was Withdrawn during Early Phase 1 because One of the study drugs will no longer be supplied by manufacturer and the pembrolizumab +    abemaciclib study arm is removed due to toxicity seen in other trials|Study NCT03846583 in nan was Withdrawn during Phase 1 because Study halted prematurely, prior to enrollment of first participant

>  <Indications>  (208) 
On September 28, 2017, the Food and Drug Administration approved abemaciclib (VERZENIO, Eli Lilly and Company) in combination with fulvestrant for women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. In addition, abemaciclib was approved as monotherapy for  women and men with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.

>  <Type>  (208) 
1

>  <targets_id>  (208) 
P11802|Q00534

>  <inchi>  (208) 
InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)

>  <stdInchikey>  (208) 
UZWDCWONPYILKI-UHFFFAOYSA-N

>  <csid>  (208) 
29340700

>  <Links>  (208) 
|http://www.chemspider.com/Chemical-Structure.29340700.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3301610|http://pubchem.ncbi.nlm.nih.gov/compound/46220502|http://www.drugbank.ca/drugs/DB12001| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=6ZV|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6ZV|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7382|http://zinc15.docking.org/substances/ZINC000072318121|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=60UAB198HK|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50110183

>  <LinkName>  (208) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (208) 
'6ZV'

>  <pdbID>  (208) 
5l2s

>  <indicationG2P>  (208) 
None

>  <indicationDB>  (208) 
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed after unsuccessful endocrine therapy. It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with <a href="https://go.drugbank.com/drugs/DB00947">Fulvestrant</a>. Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma.

>  <uniprotId>  (208) 
P11802|Q00534|P08684|P05177|P20813|P10632|P11712|P10635

>  <MW>  (208) 
506.3

>  <HBA>  (208) 
8.0

>  <HBD>  (208) 
1.0

>  <NRB>  (208) 
7.0

>  <TPSA>  (208) 
75.0

>  <LogP>  (208) 
4.9

>  <RoF>  (208) 
1.0

>  <Melting point>  (208) 


>  <Targets>  (208) 
CDK4; CDK6

>  <Kinase families>  (208) 
CMGC

>  <FDA_approved>  (208) 
Y

$$$$
Lenvatinib
     RDKit          2D

 30 33  0  0  0  0  0  0  0  0999 V2000
    8.5254   -0.5212    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5041    0.5774    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.0420    0.2421    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6013   -1.1916    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1392   -1.5269    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1179   -0.4283    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5586    1.0055    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0207    1.3407    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4614    2.7745    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4400    3.8731    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.9234    3.1097    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.6558   -0.7635    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2151   -2.1973    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2364   -3.2959    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6985   -2.9607    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.6345    0.3351    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8276   -0.0001    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8489    1.0984    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3110    0.7632    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7517   -0.6706    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7304   -1.7692    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2683   -1.4339    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1711   -3.2029    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -5.2138   -1.0058    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2351    0.0928    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7944    1.5266    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6972   -0.2424    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7185    0.8561    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.1523    1.2969    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.0537    2.3182    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
  9 11  1  0
  6 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 12 16  1  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 21 23  1  0
 20 24  1  0
 24 25  1  0
 25 26  2  0
 25 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  1  0
  8  3  1  0
 15  5  1  0
 22 17  1  0
 30 28  1  0
M  END
>  <BrandName>  (209) 
Kisplyx;Lenvima

>  <Applicants>  (209) 
Eisai

>  <CHEMBL_ID>  (209) 
CHEMBL1289601

>  <Canonical_Smiles>  (209) 
COc1cc2c(cc1C(=O)N)c(ccn2)Oc3ccc(c(c3)Cl)NC(=O)NC4CC4

>  <Chirality>  (209) 
Achiral Molecule

>  <First_Approval>  (209) 
2015

>  <Phase>  (209) 
4.0

>  <SC_Patent>  (209) 
US-7253286-B2

>  <Synonyms>  (209) 
E-7080 | ER-203492-00 | KISPLYX | LENVATINIB | LENVIMA

>  <Withdrawn>  (209) 
|Study NCT02846766 in United States was Withdrawn during Phase 2 because Unable to execute a contract agreement with the drug manufacturer|Study NCT03005015 in Switzerland was Withdrawn during Phase 2 because supporting company (Eisai) withdrew their interest|Study NCT03801499 in China was Withdrawn during Phase 2 because Protocol modification|Study NCT03746249 in China was Withdrawn during Phase 2 because No participants enrolled|Study NCT03803254 in China was Withdrawn during Phase 2 because No participants enrolled|Study NCT03919383 in China was Withdrawn during Phase 2 because No participants enrolled|Study NCT03744247 in China was Withdrawn during Phase 3 because No paritcipants enrolled|Study NCT03791918 in China was Withdrawn during Phase 3 because No participants enrolled|Study NCT04044651 in China was Withdrawn during Phase 2/Phase 3 because Bristol-Myers Squibb company terminated this study|Study NCT03775707 in China was Withdrawn during Phase 2 because Protocol modification

>  <Indications>  (209) 
Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.

>  <Type>  (209) 
1.5

>  <targets_id>  (209) 
P17948|P35968|P35916|P11362|P21802|P22607|P22455|P10721

>  <inchi>  (209) 
InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)

>  <stdInchikey>  (209) 
WOSKHXYHFSIKNG-UHFFFAOYSA-N

>  <csid>  (209) 
7999567

>  <Links>  (209) 
|http://www.chemspider.com/Chemical-Structure.7999567.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1289601|http://pubchem.ncbi.nlm.nih.gov/compound/9823820|http://www.drugbank.ca/drugs/DB09078| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=LEV|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/LEV|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7426|http://zinc15.docking.org/substances/ZINC03816292|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=EE083865G2|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50331094

>  <LinkName>  (209) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (209) 
'LEV'

>  <pdbID>  (209) 
3wzd 5zv2

>  <indicationG2P>  (209) 
None

>  <indicationDB>  (209) 
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRÎ±), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers.</p><p>Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib.

>  <uniprotId>  (209) 
P17948|P35968|P35916|P11362|P21802|P22607|P22455|P16234|P07949|P10721|P08684|Q06278|P10632|P11712|P05177|P20813|P33261|P10635

>  <MW>  (209) 
426.1

>  <HBA>  (209) 
5.0

>  <HBD>  (209) 
3.0

>  <NRB>  (209) 
6.0

>  <TPSA>  (209) 
115.6

>  <LogP>  (209) 
4.1

>  <RoF>  (209) 
0.0

>  <Melting point>  (209) 


>  <Targets>  (209) 
FLT1; KDR; FLT4; FGFR1; FGFR2; FGFR3; FGFR4; KIT

>  <Kinase families>  (209) 
Tyr

>  <FDA_approved>  (209) 
Y

$$$$
Vandetanib
     RDKit          2D

 30 33  0  0  0  0  0  0  0  0999 V2000
   10.1222    0.1160    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6352   -0.0807    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.0620   -1.4669    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5750   -1.6636    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6611   -0.4741    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2342    0.9121    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7213    1.1088    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1740   -0.6708    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2601    0.5186    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.7731    0.3219    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1999   -1.0643    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2871   -1.2610    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2010   -0.0715    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6278    1.3147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8592    1.5114    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4324    2.8976    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.9194    3.0943    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6880   -0.2682    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2612   -1.6544    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3473   -2.8439    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8603   -2.6472    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6019    0.9212    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0890    0.7245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0029    1.9140    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4899    1.7172    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.0631    0.3311    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1492   -0.8584    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6621   -0.6617    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7482   -1.8511    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -9.5501    0.1344    0.0000 Br  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  5  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  1  0
 13 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 18 22  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 26 30  1  0
  7  2  1  0
 15 10  1  0
 21 12  1  0
 28 23  1  0
M  END
>  <BrandName>  (210) 
Caprelsa;Zactima

>  <Applicants>  (210) 
Ipr Pharmaceuticals

>  <CHEMBL_ID>  (210) 
CHEMBL24828

>  <Canonical_Smiles>  (210) 
CN1CCC(CC1)COc2cc3c(cc2OC)c(ncn3)Nc4ccc(cc4F)Br

>  <Chirality>  (210) 
Achiral Molecule

>  <First_Approval>  (210) 
2011

>  <Phase>  (210) 
4.0

>  <SC_Patent>  (210) 
US-7173038-B1

>  <Synonyms>  (210) 
CAPRELSA | GNF-PF-2188 | VANDETANIB | ZACTIMA | ZD-64 | ZD-6474 | ZD6474

>  <Withdrawn>  (210) 


>  <Indications>  (210) 
Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.

>  <Type>  (210) 
1.5

>  <targets_id>  (210) 
P15692|P00533|Q13882|Q02763|P07949

>  <inchi>  (210) 
InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)

>  <stdInchikey>  (210) 
UHTHHESEBZOYNR-UHFFFAOYSA-N

>  <csid>  (210) 
2338979

>  <Links>  (210) 
|http://www.chemspider.com/Chemical-Structure.2338979.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL24828|http://pubchem.ncbi.nlm.nih.gov/compound/3081361|http://www.drugbank.ca/drugs/DB08764| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=ZD6|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/ZD6|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5717|http://zinc15.docking.org/substances/ZINC000053683345|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=YO460OQ37K|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=21

>  <LinkName>  (210) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (210) 
'ZD6'

>  <pdbID>  (210) 
2ivu

>  <indicationG2P>  (210) 
None

>  <indicationDB>  (210) 
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.</p><p>On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.

>  <uniprotId>  (210) 
P15692|P00533|Q13882|Q02763|P07949|Q01740|P31513|P08684|P02763|P02768|P33527|Q9UNQ0|O15244|P08183

>  <MW>  (210) 
474.1

>  <HBA>  (210) 
6.0

>  <HBD>  (210) 
1.0

>  <NRB>  (210) 
6.0

>  <TPSA>  (210) 
59.5

>  <LogP>  (210) 
5.0

>  <RoF>  (210) 
1.0

>  <Melting point>  (210) 


>  <Targets>  (210) 
VEGFA; EGFR; PTK6; TEK; RET

>  <Kinase families>  (210) 
Tyr<br>(*)

>  <FDA_approved>  (210) 
Y

$$$$
Vemurafenib
     RDKit          2D

 33 36  0  0  0  0  0  0  0  0999 V2000
  -10.0263   -0.0831    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.5337   -0.2316    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9160   -1.5985    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4234   -1.7470    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2749   -0.2544    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5719   -3.2397    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9308   -1.8955    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0558   -0.6772    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6735    0.6898    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7986    1.9082    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3059    1.7596    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6883    0.3927    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5632   -0.8257    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9455   -2.1926    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1956    0.2442    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4221   -1.1227    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.6793    1.4626    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2079    2.8866    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4165    3.7750    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6349    2.9000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1793    1.4709    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1891    0.3618    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6546    0.6817    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1102    2.1109    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1004    3.2200    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.6645   -0.4274    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2089   -1.8565    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2187   -2.9657    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6842   -2.6457    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1398   -1.2165    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1299   -0.1074    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6941   -3.7548    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -1.4310    2.9780    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  4  6  2  0
  4  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 12 15  1  0
 15 16  2  0
 15 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 23 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 29 32  1  0
 11 33  1  0
 13  8  1  0
 21 17  1  0
 25 20  1  0
 31 26  1  0
M  END
>  <BrandName>  (211) 
Zelboraf

>  <Applicants>  (211) 
Hoffmann-La Roche

>  <CHEMBL_ID>  (211) 
CHEMBL1229517

>  <Canonical_Smiles>  (211) 
CCCS(=O)(=O)Nc1ccc(c(c1F)C(=O)c2c[nH]c3c2cc(cn3)c4ccc(cc4)Cl)F

>  <Chirality>  (211) 
Achiral Molecule

>  <First_Approval>  (211) 
2011

>  <Phase>  (211) 
4.0

>  <SC_Patent>  (211) 
US-7504509-B2

>  <Synonyms>  (211) 
PLX-4032 | PLX4032 | RG 7204 | RG-7204 | RO 5185426 | RO-51-85426 | RO-5185426 | VEMURAFENIB | ZELBORAF

>  <Withdrawn>  (211) 
|Study NCT02145910 in nan was Withdrawn during Phase 1 because Study was never opened to accrual There is no clinical benefit to patients|Study NCT02427893 in United States was Withdrawn during Phase 3 because no patients were enrolled|Study NCT03005639 in United States was Withdrawn during Phase 2 because Sponsor has decided to close study|Study NCT01843738 in United States was Withdrawn during Phase 1 because Competing Trials

>  <Indications>  (211) 
Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E.

>  <Type>  (211) 
1.5

>  <targets_id>  (211) 
P15056

>  <inchi>  (211) 
InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)

>  <stdInchikey>  (211) 
GPXBXXGIAQBQNI-UHFFFAOYSA-N

>  <csid>  (211) 
24747352

>  <Links>  (211) 
|http://www.chemspider.com/Chemical-Structure.24747352.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1229517|http://pubchem.ncbi.nlm.nih.gov/compound/42611257|http://www.drugbank.ca/drugs/DB08881| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=032|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/032|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5893|http://zinc15.docking.org/substances/ZINC000052509366|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=207SMY3FQT|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50396483

>  <LinkName>  (211) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (211) 
'032'

>  <pdbID>  (211) 
3og7 4rzv 5hes

>  <indicationG2P>  (211) 
None

>  <indicationDB>  (211) 
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Kim G, McKee AE, Ning YM, Hazarika M, Theoret M, Johnson JR, Xu QC, Tang S, Sridhara R, Jiang X, He K, Roscoe D, McGuinn WD, Helms WS, Russell AM, Miksinski SP, Zirkelbach JF, Earp J, Liu Q, Ibrahim A, Justice R, Pazdur R: FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Clin Cancer Res. 2014 Oct 1;20(19):4994-5000. doi: 10.1158/1078-0432.CCR-14-0776. Epub 2014 Aug 5. (PubMed ID 25096067)" href="#reference-A31269">2</a></sup> It exerts its function by binding to the ATP-binding domain of the mutant BRAF.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Luke JJ, Hodi FS: Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma. Clin Cancer Res. 2012 Jan 1;18(1):9-14. doi: 10.1158/1078-0432.CCR-11-2197. Epub  2011 Nov 14. (PubMed ID 22083257)" href="#reference-A31270">3</a></sup> Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. <sup class="text-reference-group"><a class="reference-popover-link" data-content="Roche news" href="#reference-L1012">8</a></sup>

>  <uniprotId>  (211) 
P15056|P05177|P10635|P08684|P11712|P10632|P20813|P02768|P02763

>  <MW>  (211) 
489.1

>  <HBA>  (211) 
4.0

>  <HBD>  (211) 
2.0

>  <NRB>  (211) 
7.0

>  <TPSA>  (211) 
91.9

>  <LogP>  (211) 
5.5

>  <RoF>  (211) 
1.0

>  <Melting point>  (211) 
272Â°C

>  <Targets>  (211) 
BRAF

>  <Kinase families>  (211) 
TKL

>  <FDA_approved>  (211) 
Y

$$$$
Larotrectinib
     RDKit          2D

 31 35  0  0  0  0  0  0  0  0999 V2000
    6.6807    1.5444    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1368    0.1154    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1274   -0.9941    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6618   -0.6747    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2056    0.7543    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2151    1.8638    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7589    3.2928    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    3.6524   -1.7842    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9567   -3.2530    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6538   -3.9963    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5442   -2.9869    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1614   -1.6197    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.4181   -0.3168    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1748    0.9783    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4315    2.2812    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0684    2.2890    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8251    0.9938    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0819   -0.3091    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2907    1.3133    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4398    2.8058    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0664    3.4088    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4106    0.3153    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8348    0.7862    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1391    2.2550    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9547   -0.2117    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8056   -1.7043    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1790   -2.3073    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.1770   -1.1874    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4203    0.1077    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.6695   -1.3365    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.5836   -2.4231    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  8  4  1  1
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 17 19  2  0
 19 20  1  0
 20 21  2  0
 19 22  1  0
 22 23  1  0
 23 24  2  0
 23 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
 28 29  1  0
 28 30  1  6
  3 31  1  0
  6  1  1  0
 12  8  1  0
 18 13  2  0
 21 16  1  0
 29 25  1  0
M  END
>  <BrandName>  (212) 
Vitrakvi

>  <Applicants>  (212) 
Array BioPharma

>  <CHEMBL_ID>  (212) 
CHEMBL3889654

>  <Canonical_Smiles>  (212) 
c1cc(c(cc1F)[C@H]2CCCN2c3ccn4c(n3)c(cn4)NC(=O)N5CC[C@@H](C5)O)F

>  <Chirality>  (212) 
Single Stereoisomer

>  <First_Approval>  (212) 
2018

>  <Phase>  (212) 
4.0

>  <SC_Patent>  (212) 
US-8513263-B2

>  <Synonyms>  (212) 
ARRY-470 | BAY-2757556 | BAY2757556 | LAROTRECTINIB | LOXO-101

>  <Withdrawn>  (212) 


>  <Indications>  (212) 
On november 26, 2018, the FDA approved larotrectinib to treat patients whose cancers have a specific genetic feature (biomarker)

>  <Type>  (212) 
nan

>  <targets_id>  (212) 
P04629|Q16620|Q16288

>  <inchi>  (212) 
InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)/t14-,18+/m0/s1

>  <stdInchikey>  (212) 
NYNZQNWKBKUAII-KBXCAEBGSA-N

>  <csid>  (212) 
44210503

>  <Links>  (212) 
|http://www.chemspider.com/Chemical-Structure.44210503.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3889654|http://pubchem.ncbi.nlm.nih.gov/compound/46188928|http://www.drugbank.ca/drugs/DB14723|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8909|http://zinc15.docking.org/substances/ZINC000118399834|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=PF9462I9HX|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=136597

>  <LinkName>  (212) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (212) 


>  <pdbID>  (212) 


>  <indicationG2P>  (212) 
None

>  <indicationDB>  (212) 
Larotrectinib is an orally administered tropomyosin receptor kinase (Trk) inhibitor with demonstrated antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.</p><p>Originally discovered by Array BioPharma, the agent was ultimately licensed to Loxo Oncology in 2013. Larotrectinib is another example of innovative new cancer therapy medications that target key, specific genetic biomarker drivers of cancer rather than particular types of tumors <sup class="text-reference-group"><a class="reference-popover-link" data-content="Larotrectinib FDA Approval Press Release" href="#reference-L4847">6</a></sup>.

>  <uniprotId>  (212) 
P04629|Q16620|Q16288

>  <MW>  (212) 
428.2

>  <HBA>  (212) 
6.0

>  <HBD>  (212) 
2.0

>  <NRB>  (212) 
3.0

>  <TPSA>  (212) 
86.0

>  <LogP>  (212) 
2.9

>  <RoF>  (212) 
0.0

>  <Melting point>  (212) 


>  <Targets>  (212) 
NTRK1; NTRK2; NTRK3

>  <Kinase families>  (212) 
Tyr

>  <FDA_approved>  (212) 
Y

$$$$
Flumatinib
     RDKit          2D

 41 45  0  0  0  0  0  0  0  0999 V2000
   -4.4877   -5.2701    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3225   -4.3254    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5580   -2.8440    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3929   -1.8993    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9922   -2.4360    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7567   -3.9174    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9218   -4.8621    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.1730   -1.4913    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.5736   -2.0281    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8092   -3.5094    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.7388   -1.0834    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1395   -1.6201    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3046   -0.6754    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0691    0.8060    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6684    1.3427    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5033    0.3980    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4329    2.8241    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1973    4.3055    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    1.9515    2.5885    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    4.9143    3.0596    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    6.2343    1.7507    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6350    1.2139    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.8705   -0.2675    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2712   -0.8042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.4363    0.1405    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.2008    1.6219    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8001    2.1586    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.8370   -0.3962    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9587   -2.3073    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1943   -0.8259    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0291    0.1188    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2647    1.6002    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6653    2.1369    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8305    1.1922    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5950   -0.2892    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.2312    1.7289    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4667    3.2103    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.8674    3.7470    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.0326    2.8024    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.7970    1.3210    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -9.3963    0.7843    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  5  8  1  0
  8  9  1  0
  9 10  2  0
  9 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 15 17  1  0
 17 18  1  0
 17 19  1  0
 17 20  1  0
 14 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 25 28  1  0
  3 29  1  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 32 33  2  0
 33 34  1  0
 34 35  2  0
 34 36  1  0
 36 37  2  0
 37 38  1  0
 38 39  2  0
 39 40  1  0
 40 41  2  0
  7  2  1  0
 16 11  1  0
 27 22  1  0
 35 30  1  0
 41 36  1  0
M  END
>  <BrandName>  (213) 


>  <Applicants>  (213) 
Jiangsu Hengrui Medicine

>  <CHEMBL_ID>  (213) 
CHEMBL3545413

>  <Canonical_Smiles>  (213) 
Cc1c(cc(cn1)NC(=O)c2ccc(c(c2)C(F)(F)F)CN3CCN(CC3)C)Nc4nccc(n4)c5cccnc5

>  <Chirality>  (213) 
Achiral Molecule

>  <First_Approval>  (213) 
nan

>  <Phase>  (213) 
4.0

>  <SC_Patent>  (213) 
None

>  <Synonyms>  (213) 
FLUMATINIB | HH-GV678 | HHGV-678

>  <Withdrawn>  (213) 


>  <Indications>  (213) 
nan

>  <Type>  (213) 
nan

>  <targets_id>  (213) 
P11274|P00519|P09619|P10721

>  <inchi>  (213) 
InChI=1S/C29H29F3N8O/c1-19-26(38-28-34-9-7-25(37-28)21-4-3-8-33-16-21)15-23(17-35-19)36-27(41)20-5-6-22(24(14-20)29(30,31)32)18-40-12-10-39(2)11-13-40/h3-9,14-17H,10-13,18H2,1-2H3,(H,36,41)(H,34,37,38)

>  <stdInchikey>  (213) 
BJCJYEYYYGBROF-UHFFFAOYSA-N

>  <csid>  (213) 
25069687

>  <Links>  (213) 
|http://www.chemspider.com/Chemical-Structure.25069687.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545413|http://pubchem.ncbi.nlm.nih.gov/compound/46848036|http://www.drugbank.ca/drugs/DB11904|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9913|http://zinc15.docking.org/substances/ZINC000068244727|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=R4009Y24AI

>  <LinkName>  (213) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (213) 


>  <pdbID>  (213) 


>  <indicationG2P>  (213) 
None

>  <indicationDB>  (213) 


>  <uniprotId>  (213) 


>  <MW>  (213) 
562.2

>  <HBA>  (213) 
8.0

>  <HBD>  (213) 
2.0

>  <NRB>  (213) 
7.0

>  <TPSA>  (213) 
99.2

>  <LogP>  (213) 
5.0

>  <RoF>  (213) 
2.0

>  <Melting point>  (213) 


>  <Targets>  (213) 
BCR; ABL1; PDGFRB; KIT

>  <Kinase families>  (213) 
Tyr<br>Atypical

>  <FDA_approved>  (213) 
N

$$$$
Lapatinib
     RDKit          2D

 40 44  0  0  0  0  0  0  0  0999 V2000
   -6.4375    7.6486    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0015    6.2134    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4367    5.7774    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5663    6.6494    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5655    4.7782    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5904    3.6830    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1544    2.2477    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1794    1.1525    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7434   -0.2827    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6482   -1.4791    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7901   -2.7093    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3548   -2.2733    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3260   -0.7736    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1585   -3.1782    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3439   -4.6667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1476   -5.5715    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7658   -4.9879    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5803   -3.4994    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7767   -2.5945    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1985   -2.9158    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9978   -3.8206    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.8123   -5.3091    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5695   -5.8927    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0131   -1.4273    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.3687   -0.8436    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5650   -1.7485    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9468   -1.1648    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1323    0.3236    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9360    1.2285    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5542    0.6449    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1214    2.7170    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    5.5141    0.9073    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.7104    0.0024    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0922    0.5861    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2886   -0.3188    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.6704    0.2648    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.8558    1.7533    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.6595    2.6582    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2777    2.0746    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8449    4.1467    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  2  4  2  0
  2  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 12 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 18 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 20 24  1  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 29 31  1  0
 28 32  1  0
 32 33  1  0
 33 34  1  0
 34 35  2  0
 35 36  1  0
 36 37  2  0
 37 38  1  0
 38 39  2  0
 38 40  1  0
 13  9  1  0
 19 14  1  0
 23 17  1  0
 30 25  1  0
 39 34  1  0
M  END
>  <BrandName>  (214) 
Tykerb;Tyverb

>  <Applicants>  (214) 
GlaxoSmithKline

>  <CHEMBL_ID>  (214) 
CHEMBL554

>  <Canonical_Smiles>  (214) 
CS(=O)(=O)CCNCc1ccc(o1)c2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5cccc(c5)F

>  <Chirality>  (214) 
Achiral Molecule

>  <First_Approval>  (214) 
2007

>  <Phase>  (214) 
4.0

>  <SC_Patent>  (214) 
US-6713485-B2

>  <Synonyms>  (214) 
GSK-572016 | GW-2016 | GW-572016 | GW-572016X | GW572016 | LAPATINIB | TYVERB

>  <Withdrawn>  (214) 
|Study NCT00513253 in United States was Withdrawn during Phase 1 because It was determined not to be needed based on the clinical development plan of Tykerb|Study NCT01005641 in Italy was Withdrawn during Phase 2 because Study not started for administrative reasons|Study NCT01985893 in Germany was Withdrawn during Phase 2 because Due to missing patient recruitment, the financial support was stopped|Study NCT00682279 in United States was Withdrawn during Phase 1 because Cancelled before enrollment|Study NCT01205217 in Spain was Withdrawn during Phase 2 because Data presented at SABCS 2010 showing that dual blockade is superior to monotherapy|Study NCT01700010 in United States was Withdrawn during Phase 2 because Funding issues

>  <Indications>  (214) 
Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma.

>  <Type>  (214) 
1.5

>  <targets_id>  (214) 
P00533|P04626

>  <inchi>  (214) 
InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)

>  <stdInchikey>  (214) 
BCFGMOOMADDAQU-UHFFFAOYSA-N

>  <csid>  (214) 
181006

>  <Links>  (214) 
|http://www.chemspider.com/Chemical-Structure.181006.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL554|http://pubchem.ncbi.nlm.nih.gov/compound/208908|http://www.drugbank.ca/drugs/DB02584| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=FMM|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/FMM|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5692|http://zinc15.docking.org/substances/ZINC000001550477|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=0VUA21238F|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=5445

>  <LinkName>  (214) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (214) 
'FMM'

>  <pdbID>  (214) 
1xkk 3bbt

>  <indicationG2P>  (214) 
None

>  <indicationDB>  (214) 
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug Capecitabine. Lapatinib is human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.

>  <uniprotId>  (214) 
P00533|P04626|P08684|P20815|P10632|P33261|P08183|Q03518

>  <MW>  (214) 
580.1

>  <HBA>  (214) 
8.0

>  <HBD>  (214) 
2.0

>  <NRB>  (214) 
11.0

>  <TPSA>  (214) 
106.4

>  <LogP>  (214) 
6.1

>  <RoF>  (214) 
2.0

>  <Melting point>  (214) 


>  <Targets>  (214) 
EGFR; ERBB2

>  <Kinase families>  (214) 
Tyr

>  <FDA_approved>  (214) 
Y

$$$$
Imatinib
     RDKit          2D

 37 41  0  0  0  0  0  0  0  0999 V2000
   -7.7450    1.8017    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2611    2.0209    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7090    3.4156    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2251    3.6347    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2933    2.4592    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8455    1.0645    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3294    0.8454    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8815   -0.5493    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9497   -1.7248    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5019   -3.1195    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5701   -4.2950    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0862   -4.0758    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5341   -2.6811    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4658   -1.5056    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0502   -2.4620    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1184   -3.6375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3655   -3.4183    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9176   -2.0236    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9859   -0.8481    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4980   -1.0673    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8094    2.6784    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8777    1.5029    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4298    0.1082    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.6062    1.7221    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5380    0.5466    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0219    0.7658    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5740    2.1604    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6423    3.3360    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1584    3.1168    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0579    2.3796    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9897    1.2041    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.4376   -0.1906    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3693   -1.3661    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8532   -1.1469    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.4054    0.2478    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4736    1.4233    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7850   -2.3224    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 13 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
  5 21  1  0
 21 22  1  0
 22 23  2  0
 22 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 27 30  1  0
 30 31  1  0
 31 32  1  0
 32 33  1  0
 33 34  1  0
 34 35  1  0
 35 36  1  0
 34 37  1  0
  7  2  1  0
 14  9  1  0
 20 15  1  0
 29 24  1  0
 36 31  1  0
M  END
>  <BrandName>  (215) 
Gleevec

>  <Applicants>  (215) 
Novartis

>  <CHEMBL_ID>  (215) 
CHEMBL941

>  <Canonical_Smiles>  (215) 
Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)NC(=O)c4ccc(cc4)CN5CCN(CC5)C

>  <Chirality>  (215) 
Achiral Molecule

>  <First_Approval>  (215) 
2001

>  <Phase>  (215) 
4.0

>  <SC_Patent>  (215) 
US-6958335-B2

>  <Synonyms>  (215) 
GLEEVEC | IMATINIB | STI-571

>  <Withdrawn>  (215) 
|Study NCT01188889 in United States was Withdrawn during Phase 1/Phase 2 because Unable to obtain sufficient funding|Study NCT02812693 in nan was Withdrawn during Phase 1/Phase 2 because poor accrual|Study NCT00403156 in United States was Withdrawn during Phase 1 because Lack of recruitment|Study NCT00594555 in United States was Withdrawn during Phase 2 because Principal Investigator resigned position with the University of Cincinnati, closing study at    this site will reopen study in new position|Study NCT03688568 in United States was Withdrawn during Phase 2 because Enrollment not feasible|Study NCT02268435 in nan was Withdrawn during Phase 1 because Dovitinib Production stopped|Study NCT02538926 in United States was Withdrawn during Phase 2 because Drugs unavailable|Study NCT00324077 in United States was Withdrawn during Phase 1 because Insufficient Enrollment|Study NCT01011998 in United States was Withdrawn during Phase 2 because Withdrawn due to lack of accrual per Center DSMP, with PI concurrence|Study NCT02129166 in nan was Withdrawn during Phase 1 because PI resigned

>  <Indications>  (215) 
For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).

>  <Type>  (215) 
2

>  <targets_id>  (215) 
P10721|P07949|P04629|P07333|P16234|Q08345|P00519|P09619

>  <inchi>  (215) 
InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)

>  <stdInchikey>  (215) 
KTUFNOKKBVMGRW-UHFFFAOYSA-N

>  <csid>  (215) 
5101

>  <Links>  (215) 
|http://www.chemspider.com/Chemical-Structure.5101.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL941|http://pubchem.ncbi.nlm.nih.gov/compound/5291|http://www.drugbank.ca/drugs/DB03261| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=STI|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/STI|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687|http://zinc15.docking.org/substances/ZINC19632618|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=BKJ8M8G5HI|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13530

>  <LinkName>  (215) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (215) 
'STI'

>  <pdbID>  (215) 
1iep 1opj 1t46 1xbb 2hyy 2oiq 2pl0 3fw1 3gvu 3hec 3k5v 3ms9 3mss 3oez 3pyy 4bkj 4csv 4r7i 5mqt 6hd4 6hd6 6jol 6ktn 6npe 6npu 6npv 6vxh

>  <indicationG2P>  (215) 
None

>  <indicationDB>  (215) 
Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.</p><p>It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.

>  <uniprotId>  (215) 
P11274|P10721|O43519|P04629|P07333|P16234|Q08345|P00519|P09619|P08684|P20815|P24462|P05177|P11712|P10635|P33261|P23219|P10632|P02768|P02763

>  <MW>  (215) 
493.3

>  <HBA>  (215) 
7.0

>  <HBD>  (215) 
2.0

>  <NRB>  (215) 
7.0

>  <TPSA>  (215) 
86.3

>  <LogP>  (215) 
4.6

>  <RoF>  (215) 
0.0

>  <Melting point>  (215) 
226Â°C (mesylate salt)

>  <Targets>  (215) 
KIT; RET; NTRK1; CSF1R; PDGFRA; DDR1; ABL1; PDGFRB

>  <Kinase families>  (215) 
Tyr

>  <FDA_approved>  (215) 
Y

$$$$
Idelalisib
     RDKit          2D

 31 35  0  0  0  0  0  0  0  0999 V2000
   -2.3225    2.1148    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9021    1.6326    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6095    0.1615    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8109   -0.3207    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1035   -1.7919    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.5239   -2.2741    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8166   -3.7452    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2369   -4.2274    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3647   -3.2384    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0721   -1.7672    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6517   -1.2851    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3591    0.1861    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4868    1.1751    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.9387    0.6683    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.6461    2.1395    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7738    3.1285    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4812    4.5997    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0608    5.0818    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0670    4.0928    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2257    2.6216    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1999   -0.7782    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7372   -0.8276    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1576   -0.3454    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2854   -1.3344    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7058   -0.8522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6033   -2.0541    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7376   -3.2791    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3050   -2.8343    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9984    0.6190    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8707    1.6080    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4503    1.1258    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  3  2  1  1
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 10 21  1  0
  3 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  1  0
 27 28  2  0
 25 29  1  0
 29 30  2  0
 30 31  1  0
 14  4  1  0
 11  6  1  0
 20 15  1  0
 31 23  2  0
 28 24  1  0
M  END
>  <BrandName>  (216) 
Zydelig

>  <Applicants>  (216) 
Gilead Sciences

>  <CHEMBL_ID>  (216) 
CHEMBL2216870

>  <Canonical_Smiles>  (216) 
CC[C@@H](c1nc2cccc(c2c(=O)n1c3ccccc3)F)Nc4c5c([nH]cn5)ncn4

>  <Chirality>  (216) 
Single Stereoisomer

>  <First_Approval>  (216) 
2014

>  <Phase>  (216) 
4.0

>  <SC_Patent>  (216) 
US-6800620-B2

>  <Synonyms>  (216) 
CAL-101 | GS-1101 | GS-11CAL-101 | IDELALISIB | ZYDELIG

>  <Withdrawn>  (216) 
|Study NCT02662296 in United States was Withdrawn during Phase 2 because Low enrollment

>  <Indications>  (216) 
Idelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.

>  <Type>  (216) 
1

>  <targets_id>  (216) 
O00329

>  <inchi>  (216) 
InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1

>  <stdInchikey>  (216) 
IFSDAJWBUCMOAH-HNNXBMFYSA-N

>  <csid>  (216) 
9800565

>  <Links>  (216) 
|http://www.chemspider.com/Chemical-Structure.9800565.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2216870|http://pubchem.ncbi.nlm.nih.gov/compound/11625818|http://www.drugbank.ca/drugs/DB09054| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=40L|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/40L|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6741|http://zinc15.docking.org/substances/ZINC13986658|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=YG57I8T5M0|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50403068

>  <LinkName>  (216) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (216) 
'40L'

>  <pdbID>  (216) 
4xe0

>  <indicationG2P>  (216) 
None

>  <indicationDB>  (216) 
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110Î´, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110Î± and p110Î², p110Î´ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.

>  <uniprotId>  (216) 
O00329

>  <MW>  (216) 
415.2

>  <HBA>  (216) 
7.0

>  <HBD>  (216) 
2.0

>  <NRB>  (216) 
5.0

>  <TPSA>  (216) 
101.4

>  <LogP>  (216) 
3.8

>  <RoF>  (216) 
0.0

>  <Melting point>  (216) 


>  <Targets>  (216) 
PIK3CD

>  <Kinase families>  (216) 
Atypical

>  <FDA_approved>  (216) 
Y

$$$$
Icotinib
     RDKit          2D

 29 32  0  0  0  0  0  0  0  0999 V2000
   -8.3777   -1.7918    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3938   -0.6596    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4099    0.4726    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8984    1.8908    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9145    3.0230    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4420    2.7370    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9534    1.3188    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9374    0.1866    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4810    1.0328    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9924   -0.3855    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5199   -0.6715    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4640    0.4607    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9365    0.1747    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4250   -1.2435    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4411   -2.3757    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0314   -2.0897    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0153   -3.2219    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4878   -2.9359    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9763   -1.5177    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.5572   -2.2274    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.0297   -2.5134    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4479   -2.0249    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4319   -0.8927    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.7179    0.5798    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2293    1.9980    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0971    2.9819    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.6246    3.2679    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2064    2.7794    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2225    1.6472    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  3  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  7  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 14 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
 28 29  1  0
  8  3  1  0
 19 10  2  0
 16 11  1  0
 29 13  1  0
M  END
>  <BrandName>  (217) 


>  <Applicants>  (217) 
Zhejiang Beta Pharma

>  <CHEMBL_ID>  (217) 
CHEMBL2087361

>  <Canonical_Smiles>  (217) 
C#Cc1cccc(c1)Nc2c3cc4c(cc3ncn2)OCCOCCOCCO4

>  <Chirality>  (217) 
Achiral Molecule

>  <First_Approval>  (217) 
2011

>  <Phase>  (217) 
4.0

>  <SC_Patent>  (217) 
None

>  <Synonyms>  (217) 
BPI-2009H | ICOTINIB

>  <Withdrawn>  (217) 


>  <Indications>  (217) 
Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)âtyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.

>  <Type>  (217) 
nan

>  <targets_id>  (217) 
P00533

>  <inchi>  (217) 
InChI=1S/C22H21N3O4/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20/h1,3-5,12-15H,6-11H2,(H,23,24,25)

>  <stdInchikey>  (217) 
QQLKULDARVNMAL-UHFFFAOYSA-N

>  <csid>  (217) 
10762174

>  <Links>  (217) 
|http://www.chemspider.com/Chemical-Structure.10762174.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2087361|http://pubchem.ncbi.nlm.nih.gov/compound/22024915|http://www.drugbank.ca/drugs/DB11737|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7641|http://zinc15.docking.org/substances/ZINC000043207566|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=9G6U5L461Q|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50391089

>  <LinkName>  (217) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (217) 


>  <pdbID>  (217) 


>  <indicationG2P>  (217) 
None

>  <indicationDB>  (217) 
Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a âMay Proceedâ from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC).

>  <uniprotId>  (217) 
P00533|P08684|P05177|P20815

>  <MW>  (217) 
391.2

>  <HBA>  (217) 
7.0

>  <HBD>  (217) 
1.0

>  <NRB>  (217) 
2.0

>  <TPSA>  (217) 
74.7

>  <LogP>  (217) 
3.2

>  <RoF>  (217) 
0.0

>  <Melting point>  (217) 


>  <Targets>  (217) 
EGFR

>  <Kinase families>  (217) 
Tyr

>  <FDA_approved>  (217) 
N

$$$$
Ibrutinib
     RDKit          2D

 33 37  0  0  0  0  0  0  0  0999 V2000
    6.5906    5.7184    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5339    4.2194    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2074    3.5191    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9376    4.3176    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.1507    2.0201    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.4205    1.2216    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3638   -0.2773    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0373   -0.9777    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7676   -0.1792    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8243    1.3198    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4411   -0.8795    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.2280   -2.3643    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7501   -2.6205    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0497   -1.2940    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0948   -0.2181    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4351   -1.0810    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9930    0.3114    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4777    0.5245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4047   -0.6549    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8468   -2.0473    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3620   -2.2603    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8894   -0.4418    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4473    0.9506    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5204    2.1299    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0783    3.5223    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5631    3.7354    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4900    2.5561    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9321    1.1637    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2330   -4.0285    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1938   -5.1804    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6718   -4.9242    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1889   -3.5162    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2450   -4.2847    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  3  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
  9 11  1  1
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 14 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 19 22  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 13 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  2  0
 29 33  1  0
 10  5  1  0
 15 11  1  0
 32 12  1  0
 21 16  1  0
 28 23  1  0
M  END
>  <BrandName>  (218) 
Imbruvica

>  <Applicants>  (218) 
Pharmacyclics

>  <CHEMBL_ID>  (218) 
CHEMBL1873475

>  <Canonical_Smiles>  (218) 
C=CC(=O)N1CCC[C@H](C1)n2c3c(c(n2)c4ccc(cc4)Oc5ccccc5)c(ncn3)N

>  <Chirality>  (218) 
Single Stereoisomer

>  <First_Approval>  (218) 
2013

>  <Phase>  (218) 
4.0

>  <SC_Patent>  (218) 
US-7514444-B2

>  <Synonyms>  (218) 
CRA-032765 | IBRUTINIB | IMBRUVICA | PC-32765 | PCI 32765 | PCI-32765 | PCI-32765-00

>  <Withdrawn>  (218) 
|Study NCT02914327 in United States was Withdrawn during Phase 1 because Lack of enrollment|Study NCT02815059 in United States was Withdrawn during Phase 1 because Termination of Investigator Initiated Studies using Ibrutinib|Study NCT02662296 in United States was Withdrawn during Phase 2 because Low enrollment|Study NCT04043845 in nan was Withdrawn during Phase 1 because Business development reasons|Study NCT02677948 in United States was Withdrawn during Phase 1/Phase 2 because FDA has placed all trials involving Pacritinib on Full Clinical Hold

>  <Indications>  (218) 
Ibrutinib was approved by the FDA for the treatment of mantle cell lymphoma, and later in February 2014 for the treatment of chronic lymphocytic leukemia

>  <Type>  (218) 
1.5

>  <targets_id>  (218) 
Q06187

>  <inchi>  (218) 
InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1

>  <stdInchikey>  (218) 
XYFPWWZEPKGCCK-GOSISDBHSA-N

>  <csid>  (218) 
26637187

>  <Links>  (218) 
|http://www.chemspider.com/Chemical-Structure.26637187.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1873475|http://pubchem.ncbi.nlm.nih.gov/compound/24821094|http://www.drugbank.ca/drugs/DB09053| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=1E8|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/1E8|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6912|http://zinc15.docking.org/substances/ZINC35328014|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=1X70OSD4VX|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50357312

>  <LinkName>  (218) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (218) 
'1E8'

>  <pdbID>  (218) 
4ifg 4rz7 5p9i 5yu9 6l8l 6yg2 6yz4

>  <indicationG2P>  (218) 
None

>  <indicationDB>  (218) 
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton&#39;s tyrosine kinase. It is designated as a targeted covalent drug and it presents a very promising activity in B cell malignancies.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Berglof A, Hamasy A, Meinke S, Palma M, Krstic A, Mansson R, Kimby E, Osterborg A, Smith CI: Targets for Ibrutinib Beyond B Cell Malignancies. Scand J Immunol. 2015 Sep;82(3):208-17. doi: 10.1111/sji.12333. (PubMed ID 26111359)" href="#reference-A32299">4</a></sup> Ibrutinib was developed by Pharmacyclics Inc and in November 2013 was FDA-approved for the treatment of mantle cell lymphoma. Later, in February 2014, ibrutinib was approved for the treatment of chronic lymphocytic leukemia and it is also indicated for the treatment of patients with WaldenstrÃ¶m&#39;s Macroglobulinemia.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approved drugs" href="#reference-L1926">13</a></sup> Ibrutinib has also been approved by the EMA for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Berglof A, Hamasy A, Meinke S, Palma M, Krstic A, Mansson R, Kimby E, Osterborg A, Smith CI: Targets for Ibrutinib Beyond B Cell Malignancies. Scand J Immunol. 2015 Sep;82(3):208-17. doi: 10.1111/sji.12333. (PubMed ID 26111359)" href="#reference-A32299">4</a></sup> Ibrutinib was approved for use in chronic graft versus host disease in August 2017 <sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA: Ibrutinib cGVHD approval" href="#reference-L937">12</a></sup>.

>  <uniprotId>  (218) 
Q06187|P08684|P20815|P10635|P02768|P02763|P19652

>  <MW>  (218) 
440.2

>  <HBA>  (218) 
7.0

>  <HBD>  (218) 
1.0

>  <NRB>  (218) 
5.0

>  <TPSA>  (218) 
99.2

>  <LogP>  (218) 
4.2

>  <RoF>  (218) 
0.0

>  <Melting point>  (218) 
149-158ÂºC

>  <Targets>  (218) 
BTK

>  <Kinase families>  (218) 
Tyr

>  <FDA_approved>  (218) 
Y

$$$$
Gefitinib
     RDKit          2D

 31 34  0  0  0  0  0  0  0  0999 V2000
   -1.3428    6.3344    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6883    4.8748    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5969    3.8457    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8399    4.2764    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9313    3.2473    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5858    1.7876    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1489    1.3570    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9424    2.3861    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3793    1.9554    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7248    0.4958    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1616    0.0651    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5071   -1.3945    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9440   -1.8252    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0353   -0.7961    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4722   -1.2268    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.8177   -2.6864    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.7263   -3.7155    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2895   -3.2848    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6772    0.7586    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1140    1.1892    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.4595    2.6489    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3682    3.6779    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.3317   -0.7011    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.4230   -1.7301    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0775   -3.1898    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1689   -4.2188    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6058   -3.7882    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9513   -2.3285    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8599   -1.2995    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3881   -1.8979    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    6.6971   -4.8172    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
  6 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 19 23  1  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 28 30  1  0
 27 31  1  0
  8  3  1  0
 22  5  1  0
 18 13  1  0
 29 24  1  0
M  END
>  <BrandName>  (219) 
Iressa

>  <Applicants>  (219) 
Astrazeneca

>  <CHEMBL_ID>  (219) 
CHEMBL939

>  <Canonical_Smiles>  (219) 
COc1cc2c(cc1OCCCN3CCOCC3)c(ncn2)Nc4ccc(c(c4)Cl)F

>  <Chirality>  (219) 
Achiral Molecule

>  <First_Approval>  (219) 
2003

>  <Phase>  (219) 
4.0

>  <SC_Patent>  (219) 
None

>  <Synonyms>  (219) 
GEFITINIB | IRESSA | ZD-1839 | ZD1839

>  <Withdrawn>  (219) 
|Study NCT00098462 in nan was Withdrawn during Phase 1/Phase 2 because Withdrawn as study never opened|Study NCT03529084 in nan was Withdrawn during Phase 3 because Decision by Sponsor not to continue with the trial|Study NCT00048087 in United States was Withdrawn during Phase 2 because Slow accrual|Study NCT00268255 in nan was Withdrawn during Phase 1/Phase 2 because Study never moved forward with accrual

>  <Indications>  (219) 
For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.

>  <Type>  (219) 
1.5

>  <targets_id>  (219) 
P00533

>  <inchi>  (219) 
InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)

>  <stdInchikey>  (219) 
XGALLCVXEZPNRQ-UHFFFAOYSA-N

>  <csid>  (219) 
110217

>  <Links>  (219) 
|http://www.chemspider.com/Chemical-Structure.110217.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL939|http://pubchem.ncbi.nlm.nih.gov/compound/123631|http://www.drugbank.ca/drugs/DB07998| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=IRE|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/IRE|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4941|http://zinc15.docking.org/substances/ZINC19632614|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=S65743JHBS|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=5447

>  <LinkName>  (219) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (219) 
'IRE'

>  <pdbID>  (219) 
2ito 2ity 2itz 3ug2 4i22 4wkq 5y7z 5y80

>  <indicationG2P>  (219) 
None

>  <indicationDB>  (219) 
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.

>  <uniprotId>  (219) 
P00533|P08684|P10635|P20815|P04798|P11712|P33261|P02768|P02763

>  <MW>  (219) 
446.2

>  <HBA>  (219) 
7.0

>  <HBD>  (219) 
1.0

>  <NRB>  (219) 
8.0

>  <TPSA>  (219) 
68.7

>  <LogP>  (219) 
4.3

>  <RoF>  (219) 
0.0

>  <Melting point>  (219) 


>  <Targets>  (219) 
EGFR

>  <Kinase families>  (219) 
Tyr

>  <FDA_approved>  (219) 
Y

$$$$
Dabrafenib
     RDKit          2D

 35 38  0  0  0  0  0  0  0  0999 V2000
   -6.2980    2.8387    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0085    3.6050    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7190    4.3713    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7748    4.8945    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2422    2.3155    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7486    2.1775    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4183    0.7143    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7078   -0.0520    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8350    0.9376    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8458   -1.5456    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6213   -2.4120    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7593   -3.9056    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1219   -4.5329    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3464   -3.6666    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2084   -2.1729    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7089   -4.2939    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0404    0.1214    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8649   -1.3682    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5130   -1.9611    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7154   -1.0642    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5398    0.4255    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1619    1.0183    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0136    2.5080    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    2.7422    1.3224    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.1200    0.7295    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    3.5272   -0.6484    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.7129    2.1074    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.4979    0.1367    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6735   -1.3530    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0513   -1.9458    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2537   -1.0489    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0781    0.4407    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7003    1.0336    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5247    2.5233    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    4.4711   -2.2499    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  2  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  8 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 14 16  1  0
  7 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 21 24  1  0
 24 25  1  0
 25 26  2  0
 25 27  2  0
 25 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 32 33  2  0
 33 34  1  0
 29 35  1  0
  9  5  1  0
 15 10  1  0
 22 17  1  0
 33 28  1  0
M  END
>  <BrandName>  (220) 
Tafinlar

>  <Applicants>  (220) 
GlaxoSmithKline

>  <CHEMBL_ID>  (220) 
CHEMBL2028663

>  <Canonical_Smiles>  (220) 
CC(C)(C)c1nc(c(s1)c2ccnc(n2)N)c3cccc(c3F)NS(=O)(=O)c4c(cccc4F)F

>  <Chirality>  (220) 
Achiral Molecule

>  <First_Approval>  (220) 
2013

>  <Phase>  (220) 
4.0

>  <SC_Patent>  (220) 
US-7994185-B2

>  <Synonyms>  (220) 
DABRAFENIB | GSK-2118436 | GSK-2118436A | GSK2118436 | GSK2118436A | TAFINLAR

>  <Withdrawn>  (220) 
|Study NCT02357732 in nan was Withdrawn during Phase 1 because PI decided not to proceed|Study NCT03972046 in United States was Withdrawn during Phase 2 because Principal investigator leaving study site; no replacement PI will be sought|Study NCT02915666 in United States was Withdrawn during Phase 1 because No subjects consented for enrollment on this study|Study NCT02672358 in nan was Withdrawn during Phase 2 because Company Decision|Study NCT02447939 in nan was Withdrawn during Phase 1 because Change in strategy|Study NCT03794297 in United States was Withdrawn during Phase 2 because Inadequate accrual rate

>  <Indications>  (220) 
Dabrafenib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.

>  <Type>  (220) 
1.5

>  <targets_id>  (220) 
P15056|P04049|P57059|Q8NG66|P53667

>  <inchi>  (220) 
InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)

>  <stdInchikey>  (220) 
BFSMGDJOXZAERB-UHFFFAOYSA-N

>  <csid>  (220) 
25948204

>  <Links>  (220) 
|http://www.chemspider.com/Chemical-Structure.25948204.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2028663|http://pubchem.ncbi.nlm.nih.gov/compound/44462760|http://www.drugbank.ca/drugs/DB08912| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=P06|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/P06|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6494|http://zinc15.docking.org/substances/ZINC000068153186|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=QGP4HA4G1B|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50428286

>  <LinkName>  (220) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (220) 
'P06'

>  <pdbID>  (220) 
4xv2 5csw 5hie 6hj2 6v2u

>  <indicationG2P>  (220) 
None

>  <indicationDB>  (220) 
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013 for the treatment of melanoma <sup class="text-reference-group"><a class="reference-popover-link" data-content="Cancer. gov Dabrafenib" href="#reference-L2718">7</a></sup>.</p><p>In May 2018, Tafinlar (dabrafenib) and Mekinist (<a href="https://go.drugbank.com/drugs/DB08911">Trametinib</a>) in combination have been approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene <sup class="text-reference-group"><a class="reference-popover-link" data-content="Novartis receives FDA approval of TafinlarÂ® + MekinistÂ® for adjuvant treatment of BRAF V600-mutant melanoma" href="#reference-L2714">5</a></sup>.

>  <uniprotId>  (220) 
P15056|P04049|P57059|Q8NG66|P53667|P08684|P10632|P20813|P11712|P33261|P05177|P08183|Q9UNQ0|Q9Y6L6|Q9NPD5|Q4U2R8|Q8TCC7

>  <MW>  (220) 
519.1

>  <HBA>  (220) 
7.0

>  <HBD>  (220) 
2.0

>  <NRB>  (220) 
5.0

>  <TPSA>  (220) 
110.9

>  <LogP>  (220) 
5.4

>  <RoF>  (220) 
2.0

>  <Melting point>  (220) 


>  <Targets>  (220) 
BRAF; RAF1; SIK1; NEK11; LIMK1

>  <Kinase families>  (220) 
NEK<br>TKL<br>CAMK

>  <FDA_approved>  (220) 
Y

$$$$
Zanubrutinib
     RDKit          2D

 35 39  0  0  0  0  0  0  0  0999 V2000
   -7.3301    5.3998    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4261    4.2029    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0106    2.8215    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4993    2.6370    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1066    1.6245    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6180    1.8090    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7139    0.6120    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2985   -0.7694    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7871   -0.9539    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6912    0.2431    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3945   -1.9664    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9790   -3.3478    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0750   -4.5447    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5864   -4.3603    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0018   -2.9789    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9059   -1.7819    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0468   -0.5522    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.3881   -0.9892    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4159   -2.4890    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6456   -3.3480    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5165   -4.8424    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.0044   -2.7126    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.5851   -0.0852    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9665   -0.6698    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1634    0.2343    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9790    1.7229    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5976    2.3075    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4006    1.4034    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1759    2.6269    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.5573    2.0424    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7418    0.5538    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1232   -0.0308    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3201    0.8732    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1357    2.3618    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7543    2.9464    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  3  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
  8 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  1  0
 20 21  2  0
 20 22  1  0
 18 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 26 29  1  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 32 33  2  0
 33 34  1  0
 34 35  2  0
 10  5  1  0
 16 11  1  0
 19 15  2  0
 28 23  1  0
 35 30  1  0
M  END
>  <BrandName>  (221) 
Brukinsa

>  <Applicants>  (221) 
BeiGene

>  <CHEMBL_ID>  (221) 
CHEMBL3936761

>  <Canonical_Smiles>  (221) 
C=CC(=O)N1CCC(CC1)C2CCNc3n2nc(c3C(=O)N)c4ccc(cc4)Oc5ccccc5

>  <Chirality>  (221) 
Single Stereoisomer

>  <First_Approval>  (221) 
2019

>  <Phase>  (221) 
4.0

>  <SC_Patent>  (221) 
US-9447106-B2

>  <Synonyms>  (221) 


>  <Withdrawn>  (221) 


>  <Indications>  (221) 
Zanubrutinib (BGB-3111) is a potent, selective and and irreversible BTK inhibitor that is being investigated for clinical utility in the treatment of hematological cancers, such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL) [<a href='javascript:callRef("ReferenceDisplayForward?referenceId=34570,34571&displayId=1,2", 960, 600)' title="1. Robak P, Robak T. (2017) Expert Opin Investig Drugs. 26 (11): 1249-1265; 2. Thompson PA, Burger JA. (2018) Expert Opin Investig Drugs. 27 (1): 31-42">1-2</a>].

>  <Type>  (221) 
nan

>  <targets_id>  (221) 
nan

>  <inchi>  (221) 
InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)

>  <stdInchikey>  (221) 
RNOAOAWBMHREKO-UHFFFAOYSA-N

>  <csid>  (221) 
60600294

>  <Links>  (221) 
|http://www.chemspider.com/Chemical-Structure.60600294.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3973435|http://pubchem.ncbi.nlm.nih.gov/compound/135905454|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=249900

>  <LinkName>  (221) 
|ChemSpider|ChEMBL|PubChem|BindingDB

>  <lig_pdbID>  (221) 


>  <pdbID>  (221) 


>  <indicationG2P>  (221) 


>  <indicationDB>  (221) 


>  <uniprotId>  (221) 


>  <MW>  (221) 
471.2

>  <HBA>  (221) 
6.0

>  <HBD>  (221) 
2.0

>  <NRB>  (221) 
6.0

>  <TPSA>  (221) 
102.5

>  <LogP>  (221) 
4.2

>  <RoF>  (221) 
0.0

>  <Melting point>  (221) 


>  <Targets>  (221) 
nan

>  <Kinase families>  (221) 


>  <FDA_approved>  (221) 
Y

$$$$
Nintedanib
     RDKit          2D

 40 44  0  0  0  0  0  0  0  0999 V2000
   -9.4367   -4.6012    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7902   -3.2477    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -9.6391   -2.0110    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.9925   -0.6575    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4971   -0.5407    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6482   -1.7774    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2947   -3.1309    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8505    0.8128    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3551    0.9296    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5062   -0.3071    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7086    2.2831    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5574    3.5198    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2131    2.3999    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3642    1.1633    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8688    1.2801    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2222    2.6336    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0711    3.8703    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5666    3.7534    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2732    2.7504    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.1221    1.5137    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6176    1.6306    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5911    0.4894    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3944   -0.9977    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5839   -1.9115    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9701   -1.3383    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1667    0.1488    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9772    1.0626    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8604    2.5581    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.4020    2.9091    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8288    4.2952    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.1596   -2.2521    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.5457   -1.6789    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.9629   -3.7392    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.1524   -4.6530    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4756    0.1602    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0199    0.0434    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6664   -1.3101    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1825   -2.5468    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6779   -2.4300    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3245   -1.0764    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  5  8  1  0
  8  9  1  0
  9 10  2  0
  9 11  1  0
 11 12  1  0
 11 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 16 19  1  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  1  0
 29 30  2  0
 25 31  1  0
 31 32  2  0
 31 33  1  0
 33 34  1  0
 20 35  1  0
 35 36  2  0
 36 37  1  0
 37 38  2  0
 38 39  1  0
 39 40  2  0
  7  2  1  0
 18 13  1  0
 21 29  1  0
 27 22  1  0
 40 35  1  0
M  END
>  <BrandName>  (222) 
Ofev;Vargatef

>  <Applicants>  (222) 
Boehringer Ingelheim

>  <CHEMBL_ID>  (222) 
CHEMBL502835

>  <Canonical_Smiles>  (222) 
CN1CCN(CC1)CC(=O)N(C)c2ccc(cc2)N/C(=C\3/c4ccc(cc4NC3=O)C(=O)OC)/c5ccccc5

>  <Chirality>  (222) 
Achiral Molecule

>  <First_Approval>  (222) 
2014

>  <Phase>  (222) 
4.0

>  <SC_Patent>  (222) 
US-6762180-B1

>  <Synonyms>  (222) 
BIBF 1120 | BIBF-1120 | BIBF1120 | INTEDANIB | NINTEDANIB | OFEV | VARGATEF

>  <Withdrawn>  (222) 
|Study NCT03361319 in nan was Withdrawn during Phase 1/Phase 2 because Withdrawal of financial support from funder

>  <Indications>  (222) 
Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

>  <Type>  (222) 
1

>  <targets_id>  (222) 
P17948|P35968|P35916|P11362|P21802|P22607|P36888|P06239|P07948|P12931

>  <inchi>  (222) 
InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-

>  <stdInchikey>  (222) 
XZXHXSATPCNXJR-ZIADKAODSA-N

>  <csid>  (222) 
7985471

>  <Links>  (222) 
|http://www.chemspider.com/Chemical-Structure.7985471.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL502835|http://pubchem.ncbi.nlm.nih.gov/compound/9809715|http://www.drugbank.ca/drugs/DB09079| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=XIN|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/XIN|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5936|http://zinc15.docking.org/substances/ZINC000100014909|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=G6HRD2P839|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50026612

>  <LinkName>  (222) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (222) 
'XIN'

>  <pdbID>  (222) 
3c7q 5maf 5te0 6nec

>  <indicationG2P>  (222) 
None

>  <indicationDB>  (222) 
Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drugs: Nintedanib" href="#reference-L8453">8</a>,<a class="reference-popover-link" data-content="EMA Approved Drugs: Nintedanib" href="#reference-L8459">9</a></sup> It was first approved for use in the United States in 2014.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drugs: Nintedanib" href="#reference-L8453">8</a></sup> Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being <a href="https://go.drugbank.com/drugs/DB04951">Pirfenidone</a>) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Richeldi L, Collard HR, Jones MG: Idiopathic pulmonary fibrosis. Lancet. 2017 May 13;389(10082):1941-1952. doi: 10.1016/S0140-6736(17)30866-8. Epub 2017 Mar 30. (PubMed ID 28365056)" href="#reference-A185237">6</a></sup> As a chemotherapeutic agent for NSCLC, nintedanib, in combination with <a href="https://go.drugbank.com/drugs/DB01248">Docetaxel</a>, is reserved for patients who have tried and failed first-line chemotherapeutic options.<sup class="text-reference-group"><a class="reference-popover-link" data-content="EMA Approved Drugs: Nintedanib" href="#reference-L8459">9</a></sup>

>  <uniprotId>  (222) 
P17948|P35968|P35916|P16234|P09619|P11362|P21802|P22607|P36888|P06239|P07948|P12931|P22309|Q9HAW7|Q9HAW9|Q9HAW8|P08684|P02768|P08183|O15245|Q9UNQ0

>  <MW>  (222) 
539.3

>  <HBA>  (222) 
7.0

>  <HBD>  (222) 
2.0

>  <NRB>  (222) 
7.0

>  <TPSA>  (222) 
94.2

>  <LogP>  (222) 
3.6

>  <RoF>  (222) 
1.0

>  <Melting point>  (222) 


>  <Targets>  (222) 
FLT1; KDR; FLT4; FGFR1; FGFR2; FGFR3; FLT3; LCK; LYN; SRC

>  <Kinase families>  (222) 
Tyr

>  <FDA_approved>  (222) 
Y

$$$$
Tepotinib
     RDKit          2D

 37 41  0  0  0  0  0  0  0  0999 V2000
   12.8705   -2.6323    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.4297   -2.2149    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.3478   -3.2539    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.9071   -2.8365    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5482   -1.3800    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.6301   -0.3410    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.0708   -0.7584    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1075   -0.9626    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7486    0.4938    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.3078    0.9112    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9490    2.3677    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5082    2.7851    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.4263    1.7461    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7852    0.2896    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.2260   -0.1278    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9856    2.1635    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6267    3.6199    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8140    4.0374    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8959    2.9983    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5370    1.5419    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0963    1.1245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6189    0.5029    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0597    0.9203    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4185    2.3767    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3367    3.4158    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8593    2.7942    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9412    1.7551    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5823    0.2987    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1415   -0.1187    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6642   -0.7403    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.1049   -0.3229    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.1868   -1.3619    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.8279   -2.8183    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3871   -3.2358    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3053   -2.1967    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.0283   -4.6922    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6694   -6.1486    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  5  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 13 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 20 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  2  0
 24 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 28 30  1  0
 30 31  2  0
 31 32  1  0
 32 33  2  0
 33 34  1  0
 34 35  2  0
 34 36  1  0
 36 37  3  0
  7  2  1  0
 15 10  1  0
 21 16  1  0
 29 23  1  0
 35 30  1  0
M  END
>  <BrandName>  (223) 


>  <Applicants>  (223) 
Merck

>  <CHEMBL_ID>  (223) 
CHEMBL3402762

>  <Canonical_Smiles>  (223) 
CN1CCC(CC1)COc2cnc(nc2)c3cccc(c3)Cn4c(=O)ccc(n4)c5cccc(c5)C#N

>  <Chirality>  (223) 
Achiral Molecule

>  <First_Approval>  (223) 
2021

>  <Phase>  (223) 
4.0

>  <SC_Patent>  (223) 
None

>  <Synonyms>  (223) 
EMD 1214063 | EMD-1214063 | EMD1214063 | MSC-2156119 | MSC-2156119J | MSC2156119 | TEPOTINIB

>  <Withdrawn>  (223) 


>  <Indications>  (223) 
On February 2021, FDA approved tepotinib to treat non-small cell lung cancer

>  <Type>  (223) 
1

>  <targets_id>  (223) 
P08581

>  <inchi>  (223) 
InChI=1S/C29H28N6O2/c1-34-12-10-21(11-13-34)20-37-26-17-31-29(32-18-26)25-7-3-5-23(15-25)19-35-28(36)9-8-27(33-35)24-6-2-4-22(14-24)16-30/h2-9,14-15,17-18,21H,10-13,19-20H2,1H3

>  <stdInchikey>  (223) 
AHYMHWXQRWRBKT-UHFFFAOYSA-N

>  <csid>  (223) 
28637823

>  <Links>  (223) 
|http://www.chemspider.com/Chemical-Structure.28637823.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3402762|http://pubchem.ncbi.nlm.nih.gov/compound/25171648|http://www.drugbank.ca/drugs/DB15133| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=3E8|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/3E8|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8293|http://zinc15.docking.org/substances/ZINC000043202335|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=1IJV77EI07|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50065457

>  <LinkName>  (223) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (223) 
'3E8'

>  <pdbID>  (223) 
4r1v

>  <indicationG2P>  (223) 
None

>  <indicationDB>  (223) 
Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Markham A: Tepotinib: First Approval. Drugs. 2020 Jun;80(8):829-833. doi: 10.1007/s40265-020-01317-9. (PubMed ID 32361823)" href="#reference-A228058">6</a></sup> It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma,<sup class="text-reference-group"><a class="reference-popover-link" data-content="Scorsone K, Zhang L, Woodfield SE, Hicks J, Zage PE: The novel kinase inhibitor EMD1214063 is effective against neuroblastoma. Invest New Drugs. 2014 Oct;32(5):815-24. doi: 10.1007/s10637-014-0107-4. Epub 2014 May 16. (PubMed ID 24832869)" href="#reference-A228053">5</a></sup> gastric cancers,<sup class="text-reference-group"><a class="reference-popover-link" data-content="Sohn SH, Sul HJ, Kim B, Kim BJ, Kim HS, Zang DY: Tepotinib Inhibits the Epithelial-Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing GSK3beta, E-Cadherin, and Mucin 5AC and 6 Levels. Int J Mol Sci. 2020 Aug 21;21(17). pii: ijms21176027. doi: 10.3390/ijms21176027. (PubMed ID 32825724)" href="#reference-A228033">2</a></sup> non-small cell lung cancer, and hepatocellular carcinoma.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Markham A: Tepotinib: First Approval. Drugs. 2020 Jun;80(8):829-833. doi: 10.1007/s40265-020-01317-9. (PubMed ID 32361823)" href="#reference-A228058">6</a></sup> MET is a desirable target in the treatment of certain solid tumors as it appears to play a critical role, both directly and indirectly, in the growth and proliferation of tumors in which it is overexpressed and/or mutated.</p><p>Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with <em>MET</em> alterations, and was subsequently granted accelerated approval by the US FDA in February 2021, under the brand name Tepmetko, for the treatment of adult patients with metastatic NSCLC and <em>MET</em> exon 14 skipping alterations.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Tepmetko (tepotinib) tablets for oral use" href="#reference-L31443">7</a>,<a class="reference-popover-link" data-content="PR Newswire: FDA Approves TEPMETKOÂ® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations" href="#reference-L31473">9</a></sup> It is the first oral MET-targeted tyrosine kinase inhibitor to allow for once-daily dosing,<sup class="text-reference-group"><a class="reference-popover-link" data-content="PR Newswire: FDA Approves TEPMETKOÂ® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations" href="#reference-L31473">9</a></sup> an advantage that may aid in easing the pill burden often associated with chemotherapeutic regimens.

>  <uniprotId>  (223) 
P08581|Q9Y2I1|P49286|P08684|P10632|P02768|P02763|P08183|Q9UNQ0

>  <MW>  (223) 
492.2

>  <HBA>  (223) 
8.0

>  <HBD>  (223) 
0.0

>  <NRB>  (223) 
7.0

>  <TPSA>  (223) 
96.9

>  <LogP>  (223) 
4.0

>  <RoF>  (223) 
0.0

>  <Melting point>  (223) 


>  <Targets>  (223) 
MET

>  <Kinase families>  (223) 
Tyr

>  <FDA_approved>  (223) 
Y

$$$$
Nilotinib
     RDKit          2D

 39 43  0  0  0  0  0  0  0  0999 V2000
    5.6804   -4.6621    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3180   -4.0345    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0933   -4.9006    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7309   -4.2729    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5932   -2.7793    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8180   -1.9132    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1803   -2.5408    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4051   -1.6748    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.2674   -0.1811    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4921    0.6849    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.3545    2.1786    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9921    2.8062    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7674    1.9402    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9050    0.4465    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.4050    2.5678    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2673    4.0615    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9050    4.6891    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3198    3.8230    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1821    2.3294    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.1803    1.7017    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2308   -2.1516    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9939   -3.0177    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0932   -0.6580    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2692   -0.0303    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4069    1.4633    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7692    2.0909    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9940    1.2249    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8563   -0.2688    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4939   -0.8964    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0810   -1.1348    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1003   -2.6347    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5327   -3.0799    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3987   -1.8552    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5016   -0.6530    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0145   -4.5004    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9069    3.5846    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0445    5.0783    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4006    3.4470    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4132    3.7223    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 13 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
  5 21  1  0
 21 22  2  0
 21 23  1  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 28 30  1  0
 30 31  1  0
 31 32  2  0
 32 33  1  0
 33 34  2  0
 32 35  1  0
 26 36  1  0
 36 37  1  0
 36 38  1  0
 36 39  1  0
  7  2  1  0
 14  9  1  0
 20 15  1  0
 29 24  1  0
 34 30  1  0
M  END
>  <BrandName>  (224) 
Tasigna

>  <Applicants>  (224) 
Novartis

>  <CHEMBL_ID>  (224) 
CHEMBL255863

>  <Canonical_Smiles>  (224) 
Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)C(=O)Nc4cc(cc(c4)n5cc(nc5)C)C(F)(F)F

>  <Chirality>  (224) 
Achiral Molecule

>  <First_Approval>  (224) 
2007

>  <Phase>  (224) 
4.0

>  <SC_Patent>  (224) 
US-7169791-B2

>  <Synonyms>  (224) 
AMN 107 | AMN-107 | AMN107 | NILOTINIB | TASIGNA

>  <Withdrawn>  (224) 
|Study NCT02973711 in United States was Withdrawn during Phase 1/Phase 2 because lack of funding

>  <Indications>  (224) 
For the potential treatment of various leukemias, including chronic myeloid leukemia (CML).

>  <Type>  (224) 
2

>  <targets_id>  (224) 
P00519|P10721

>  <inchi>  (224) 
InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)

>  <stdInchikey>  (224) 
HHZIURLSWUIHRB-UHFFFAOYSA-N

>  <csid>  (224) 
559260

>  <Links>  (224) 
|http://www.chemspider.com/Chemical-Structure.559260.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL255863|http://pubchem.ncbi.nlm.nih.gov/compound/644241|http://www.drugbank.ca/drugs/DB04868| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=NIL|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/NIL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5697|http://zinc15.docking.org/substances/ZINC06716957|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=F41401512X|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50237710

>  <LinkName>  (224) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (224) 
'NIL'

>  <pdbID>  (224) 
3cs9 3gp0 5mo4

>  <indicationG2P>  (224) 
None

>  <indicationDB>  (224) 
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.

>  <uniprotId>  (224) 
P00519|P10721|P08684|P10632|P11712|P10635|P20813|P08183|Q9UNQ0|P22309|Q9Y6L6

>  <MW>  (224) 
529.2

>  <HBA>  (224) 
7.0

>  <HBD>  (224) 
2.0

>  <NRB>  (224) 
6.0

>  <TPSA>  (224) 
97.6

>  <LogP>  (224) 
6.4

>  <RoF>  (224) 
2.0

>  <Melting point>  (224) 


>  <Targets>  (224) 
ABL1; KIT

>  <Kinase families>  (224) 
Tyr

>  <FDA_approved>  (224) 
Y

$$$$
Alpelisib
     RDKit          2D

 30 32  0  0  0  0  0  0  0  0999 V2000
    1.1304   -5.0113    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2568   -3.7919    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7299   -2.3684    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4777   -1.4787    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6971   -2.3522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2431   -3.7819    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1206   -1.8792    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4226   -0.4099    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3012    0.5863    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8461    0.0632    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0655   -0.8104    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2731    0.0794    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8000    1.5028    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3001    1.4928    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4103    2.7004    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9196    2.5336    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0112    4.0748    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.1595   -1.9145    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2675   -2.9256    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6972   -2.4716    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0188   -1.0065    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.9109    0.0046    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4812   -0.4494    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2325    1.4697    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7674    1.7914    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6976    1.1480    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5542    2.9348    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8759    4.3999    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    3.0891    3.2565    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    6.0193    2.6131    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  1  0
  5  6  2  0
  5  7  1  0
  7  8  1  0
  8  9  2  0
  8 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  1
 15 16  2  0
 15 17  1  0
  3 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 22 24  1  0
 24 25  1  0
 24 26  1  0
 24 27  1  0
 27 28  1  0
 27 29  1  0
 27 30  1  0
  6  2  1  0
 14 10  1  0
 23 18  1  0
M  END
>  <BrandName>  (225) 
Piqray

>  <Applicants>  (225) 
Novartis

>  <CHEMBL_ID>  (225) 
CHEMBL2396661

>  <Canonical_Smiles>  (225) 
Cc1c(sc(n1)NC(=O)N2CCC[C@H]2C(=O)N)c3ccnc(c3)C(C)(C)C(F)(F)F

>  <Chirality>  (225) 
Single Stereoisomer

>  <First_Approval>  (225) 
2019

>  <Phase>  (225) 
4.0

>  <SC_Patent>  (225) 
US-8227462-B2

>  <Synonyms>  (225) 
ALPELISIB | BYL-719 | NVP-BYL719 | PIQRAY

>  <Withdrawn>  (225) 


>  <Indications>  (225) 
On may 2019, FDA approved alpelisib to treat breast cancer

>  <Type>  (225) 
nan

>  <targets_id>  (225) 
P42336

>  <inchi>  (225) 
InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1

>  <stdInchikey>  (225) 
STUWGJZDJHPWGZ-LBPRGKRZSA-N

>  <csid>  (225) 
28424123

>  <Links>  (225) 
|http://www.chemspider.com/Chemical-Structure.28424123.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2396661|http://pubchem.ncbi.nlm.nih.gov/compound/56649450|http://www.drugbank.ca/drugs/DB12015| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=1LT|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/1LT|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7955|http://zinc15.docking.org/substances/ZINC000068198368|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=08W5N2C97Q|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50436459

>  <LinkName>  (225) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (225) 
'1LT'

>  <pdbID>  (225) 
4jps

>  <indicationG2P>  (225) 
None

>  <indicationDB>  (225) 
Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110Î± <sup class="text-reference-group"><a class="reference-popover-link" data-content="Rodon J, Curigliano G, Delord JP, Harb W, Azaro A, Han Y, Wilke C, Donnet V, Sellami D, Beck T: A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors. Oncotarget. 2018 Aug 3;9(60):31709-31718. doi: 10.18632/oncotarget.25854. eCollection 2018 Aug 3. (PubMed ID 30167089)" href="#reference-A179203">2</a></sup>, which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Yang X, Zhang X, Huang M, Song K, Li X, Huang M, Meng L, Zhang J: New Insights into PI3K Inhibitor Design using X-ray Structures of PI3Kalpha Complexed with a Potent Lead Compound. Sci Rep. 2017 Nov 6;7(1):14572. doi: 10.1038/s41598-017-15260-5. (PubMed ID 29109464)" href="#reference-A179209">3</a></sup> </p><p>There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as <a href="https://go.drugbank.com/drugs/DB09054">idelalisib</a> used for chronic lymphocytic leukemia (CLL).<sup class="text-reference-group"><a class="reference-popover-link" data-content="Yang X, Zhang X, Huang M, Song K, Li X, Huang M, Meng L, Zhang J: New Insights into PI3K Inhibitor Design using X-ray Structures of PI3Kalpha Complexed with a Potent Lead Compound. Sci Rep. 2017 Nov 6;7(1):14572. doi: 10.1038/s41598-017-15260-5. (PubMed ID 29109464)" href="#reference-A179209">3</a></sup> Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with <a href="https://go.drugbank.com/drugs/DB00947">fulvestrant</a> for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer <sup class="text-reference-group"><a class="reference-popover-link" data-content="Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O&#39;Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D&#39;Andrea AD, Winer E, Wulf GM, Matulonis UA: Olaparib and alpha-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019 Apr;20(4):570-580. doi: 10.1016/S1470-2045(18)30905-7. Epub 2019 Mar 14. (PubMed ID 30880072)" href="#reference-A179200">1</a></sup> and colorectal cancer <sup class="text-reference-group"><a class="reference-popover-link" data-content="Rodon J, Curigliano G, Delord JP, Harb W, Azaro A, Han Y, Wilke C, Donnet V, Sellami D, Beck T: A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors. Oncotarget. 2018 Aug 3;9(60):31709-31718. doi: 10.18632/oncotarget.25854. eCollection 2018 Aug 3. (PubMed ID 30167089)" href="#reference-A179203">2</a></sup>, are under ongoing investigations.</p><p>Alpelisib was granted FDA approval on 24 May 2019.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Piqray (alpelisib) tablet" href="#reference-L6652">7</a></sup>

>  <uniprotId>  (225) 
P42336|P08684|P11712|P10632|P33261|Q9UNQ0|P08183

>  <MW>  (225) 
441.1

>  <HBA>  (225) 
5.0

>  <HBD>  (225) 
2.0

>  <NRB>  (225) 
4.0

>  <TPSA>  (225) 
101.2

>  <LogP>  (225) 
3.8

>  <RoF>  (225) 
0.0

>  <Melting point>  (225) 


>  <Targets>  (225) 
PIK3CA

>  <Kinase families>  (225) 
Atypical

>  <FDA_approved>  (225) 
Y

$$$$
Anlotinib
     RDKit          2D

 30 34  0  0  0  0  0  0  0  0999 V2000
   -9.5022    1.0614    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.0623    0.6413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8760    1.5593    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6363    0.7148    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0564   -0.7251    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5558   -0.7706    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0194   -1.8090    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5623   -1.4528    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1422   -0.0128    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1792    1.0710    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7591    2.5109    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6851    0.3433    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6481   -0.7405    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0682   -2.1804    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0312   -3.2643    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4259   -2.9081    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.8460   -1.4681    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8090   -0.3843    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2291    1.0557    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6862    1.4118    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7232    0.3280    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3031   -1.1120    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1803    0.6842    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.2173   -0.3996    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6744   -0.0435    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1654   -0.2072    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2782   -1.4166    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5767    1.4533    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.1063    2.8518    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.5634    3.2079    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  5  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
  9 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 21 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 25 28  1  0
 20 29  1  0
 29 30  1  0
  6  2  1  0
 10  4  1  0
 18 13  1  0
 22 17  1  0
 27 25  1  0
M  END
>  <BrandName>  (226) 


>  <Applicants>  (226) 
Advenchen Laboratories

>  <CHEMBL_ID>  (226) 
nan

>  <Canonical_Smiles>  (226) 
Cc1cc2c([nH]1)ccc(c2F)Oc3ccnc4c3cc(c(c4)OCC5(CC5)N)OC

>  <Chirality>  (226) 
nan

>  <First_Approval>  (226) 
nan

>  <Phase>  (226) 
4.0

>  <SC_Patent>  (226) 
nan

>  <Synonyms>  (226) 


>  <Withdrawn>  (226) 


>  <Indications>  (226) 
Anlotinib (AL3818) is a non-selective inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor type 2 (VEGFR-2, FLT1) and type 3 (VEGFR-3, FLT4). It is being investigated for antineoplastic and anti-angiogenic potential. The dihydrochloride has PubChem CID: 57380530. Preparation and crystallisation of AL3818 is described in patent WO2016179123.

>  <Type>  (226) 
nan

>  <targets_id>  (226) 
P35968|P35916

>  <inchi>  (226) 
InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3

>  <stdInchikey>  (226) 
KSMZEXLVHXZPEF-UHFFFAOYSA-N

>  <csid>  (226) 
45743493

>  <Links>  (226) 
|http://www.chemspider.com/Chemical-Structure.45743493.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4303201|http://pubchem.ncbi.nlm.nih.gov/compound/25017411|http://www.drugbank.ca/drugs/DB11885|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9601|http://zinc15.docking.org/substances/ZINC000117924202|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=GKF8S4C432

>  <LinkName>  (226) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (226) 


>  <pdbID>  (226) 


>  <indicationG2P>  (226) 
None

>  <indicationDB>  (226) 


>  <uniprotId>  (226) 


>  <MW>  (226) 
407.2

>  <HBA>  (226) 
5.0

>  <HBD>  (226) 
2.0

>  <NRB>  (226) 
6.0

>  <TPSA>  (226) 
82.4

>  <LogP>  (226) 
4.8

>  <RoF>  (226) 
0.0

>  <Melting point>  (226) 


>  <Targets>  (226) 
KDR; FLT4

>  <Kinase families>  (226) 
Tyr

>  <FDA_approved>  (226) 
N

$$$$
Apatinib
     RDKit          2D

 30 33  0  0  0  0  0  0  0  0999 V2000
   -5.6805   -2.6420    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5900   -1.1448    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4995    0.3525    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9980    0.2860    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5243    1.6906    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3511    2.6252    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0997    1.7982    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0199    0.1060    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4935   -1.2986    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0139   -1.5451    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0607   -0.3870    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5870    1.0176    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0666    1.2641    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4190   -0.6335    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.9453   -2.0381    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0080   -3.1963    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.4249   -2.2846    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9512   -3.6893    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4308   -3.9358    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3841   -2.7776    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8578   -1.3730    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.3782   -1.1265    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8518    0.2781    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.8051    1.4363    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2847    1.1898    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2380    2.3479    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.7117    3.7525    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2321    3.9990    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2788    2.8409    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7992    3.0874    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  3  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  3  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 11 14  1  0
 14 15  1  0
 15 16  2  0
 15 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
  7  3  1  0
 13  8  1  0
 22 17  1  0
 29 24  1  0
M  END
>  <BrandName>  (227) 


>  <Applicants>  (227) 
Bukwang Pharmaceutical

>  <CHEMBL_ID>  (227) 
nan

>  <Canonical_Smiles>  (227) 
N#CC1(CCCC1)c1ccc(cc1)NC(=O)c1cccnc1Nc1cnccc1C

>  <Chirality>  (227) 
nan

>  <First_Approval>  (227) 
2014

>  <Phase>  (227) 
4.0

>  <SC_Patent>  (227) 
nan

>  <Synonyms>  (227) 
S-1||SHR-1210|APATINIB 500MG|ALBUMIN PACLITAXEL|CRYOABLATION|SPA|VP-16|H20140103|NAVELBINE+AITAN|AITAN|EMOZOLOMIDE|OXALIPLATIN|APATINIB|ARM A|APATINIB 750MG|CARBOPLATIN|5-FLUOROURACIL|PEMETREXED|APATINIB GROUP|YEW|ATAN|ARGET THERAPY|APATINIBMESYLATE|PACLITAXOL|PLATINU|REATMENT GROUP|DOCETAXEL|EGAFUR|S1|APATINIB MESYLAS|XELOX|AI TAN|NO.|YN968D1|APATINIB MESYLATE|STUDY DRUG|APATINIB TABLETS|ESYLATE APATINIB|EMOZOLOMIDEï¼TMZï¼|IE CHEMOTHERAPY|YN968D1,(AITANÂ®|CAPECITABINE

>  <Withdrawn>  (227) 
|Study NCT03104335 in China was Withdrawn during Phase 2 because Not enough patients|Study NCT04682249 in China was Withdrawn during Phase 2 because no patients enrolled|Study NCT03228043 in China was Withdrawn during N/A because It's not possible to complete in our hospital

>  <Indications>  (227) 
Apatinib mesylate is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. The free-base form is also known as Rivoceranib. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.

>  <Type>  (227) 
nan

>  <targets_id>  (227) 
P35968

>  <inchi>  (227) 
InChI=1S/C24H23N5O/c1-17-10-14-26-15-21(17)29-22-20(5-4-13-27-22)23(30)28-19-8-6-18(7-9-19)24(16-25)11-2-3-12-24/h4-10,13-15H,2-3,11-12H2,1H3,(H,27,29)(H,28,30)

>  <stdInchikey>  (227) 
MGZNERAVOCFMCU-UHFFFAOYSA-N

>  <csid>  (227) 
34980756

>  <Links>  (227) 
|http://www.chemspider.com/Chemical-Structure.34980756.html|http://pubchem.ncbi.nlm.nih.gov/compound/66577012|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7648|http://zinc15.docking.org/substances/ZINC000083291412

>  <LinkName>  (227) 
|ChemSpider|PubChem|Guide to Pharmacology|ZINC

>  <lig_pdbID>  (227) 


>  <pdbID>  (227) 


>  <indicationG2P>  (227) 
None

>  <indicationDB>  (227) 


>  <uniprotId>  (227) 


>  <MW>  (227) 
397.2

>  <HBA>  (227) 
5.0

>  <HBD>  (227) 
2.0

>  <NRB>  (227) 
5.0

>  <TPSA>  (227) 
90.7

>  <LogP>  (227) 
5.1

>  <RoF>  (227) 
1.0

>  <Melting point>  (227) 


>  <Targets>  (227) 
KDR

>  <Kinase families>  (227) 
Tyr

>  <FDA_approved>  (227) 
N

$$$$
Avapritinib
     RDKit          2D

 37 42  0  0  0  0  0  0  0  0999 V2000
    5.4243    3.6324    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1066    2.2966    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7889    0.9608    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9732   -0.2981    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6555   -1.6339    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1536   -1.7109    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.9693   -0.4521    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2869    0.8837    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8359   -3.0467    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    4.7708    1.6143    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5120    2.4300    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1761    1.7476    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0991    0.2496    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3579   -0.5661    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.6938    0.1162    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7633   -0.4327    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4955    0.3830    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8314   -0.2993    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9084   -1.7973    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6495   -2.6130    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6863   -1.9307    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2442   -2.4797    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5030   -1.6639    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7391   -0.1827    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2209    0.0505    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9006   -1.2867    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8388   -2.3463    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9159   -3.8443    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6570   -4.6600    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3212   -3.9777    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9032    1.3863    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3850    1.6195    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.6211    3.1008    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2853    3.7831    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2236    2.7235    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0521    5.2649    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4424    2.9789    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  6
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  6  9  1  0
  2 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 13 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  1  0
 19 22  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 25 31  1  0
 31 32  1  0
 32 33  2  0
 33 34  1  0
 34 35  1  0
 34 36  1  0
  2 37  1  0
  8  3  1  0
 15 10  1  0
 21 16  1  0
 30 22  2  0
 27 23  1  0
 35 31  2  0
M  END
>  <BrandName>  (228) 
Ayvakit

>  <Applicants>  (228) 
Blueprint Medicines

>  <CHEMBL_ID>  (228) 
CHEMBL4204794

>  <Canonical_Smiles>  (228) 
C[C@](c1ccc(cc1)F)(c2cnc(nc2)N3CCN(CC3)c4c5cc(cn5ncn4)c6cnn(c6)C)N

>  <Chirality>  (228) 
Single Stereoisomer

>  <First_Approval>  (228) 
2020

>  <Phase>  (228) 
4.0

>  <SC_Patent>  (228) 
US-9200002-B2

>  <Synonyms>  (228) 
70C366 | AVAPRITINIB | AYVAKIT | BLU-285 | C-366 | X-720776 | X720776

>  <Withdrawn>  (228) 


>  <Indications>  (228) 
On January 2020 FDA approved avapritinib to treat adults with unresectable or metastatic gastrointestinal stromal tumor (GIST)

>  <Type>  (228) 
nan

>  <targets_id>  (228) 
nan

>  <inchi>  (228) 
InChI=1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1

>  <stdInchikey>  (228) 
DWYRIWUZIJHQKQ-SANMLTNESA-N

>  <csid>  (228) 
58828673

>  <Links>  (228) 
|http://www.chemspider.com/Chemical-Structure.58828673.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4204794|http://pubchem.ncbi.nlm.nih.gov/compound/118023034|http://www.drugbank.ca/drugs/DB15233|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10368|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=513P80B4YJ

>  <LinkName>  (228) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS

>  <lig_pdbID>  (228) 


>  <pdbID>  (228) 


>  <indicationG2P>  (228) 
None

>  <indicationDB>  (228) 
Avapritinib, or BLU-285,<sup class="text-reference-group"><a class="reference-popover-link" data-content="Wu CP, Lusvarghi S, Wang JC, Hsiao SH, Huang YH, Hung TH, Ambudkar SV: Avapritinib: A Selective Inhibitor of KIT and PDGFRalpha that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines. Mol Pharm. 2019 Jul 1;16(7):3040-3052. doi: 10.1021/acs.molpharmaceut.9b00274. Epub 2019 Jun 4. (PubMed ID 31117741)" href="#reference-A189327">1</a></sup> is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Mazzocca A, Napolitano A, Silletta M, Spalato Ceruso M, Santini D, Tonini G, Vincenzi B: New frontiers in the medical management of gastrointestinal stromal tumours. Ther Adv Med Oncol. 2019 May 17;11:1758835919841946. doi: 10.1177/1758835919841946. eCollection 2019. (PubMed ID 31205499)" href="#reference-A189339">2</a>,<a class="reference-popover-link" data-content="FDA Approved Drug Products: Avapritinib Oral Tablets" href="#reference-L11136">3</a></sup> It is one of the first medications available for the treatment of multidrug resistant cancers.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Wu CP, Lusvarghi S, Wang JC, Hsiao SH, Huang YH, Hung TH, Ambudkar SV: Avapritinib: A Selective Inhibitor of KIT and PDGFRalpha that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines. Mol Pharm. 2019 Jul 1;16(7):3040-3052. doi: 10.1021/acs.molpharmaceut.9b00274. Epub 2019 Jun 4. (PubMed ID 31117741)" href="#reference-A189327">1</a></sup> Avapritinib shares a similar mechanism with <a href="https://go.drugbank.com/drugs/DB14840">ripretinib</a>.</p><p>Avapritinib was granted FDA approval on 9 January 2020.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Avapritinib Oral Tablets" href="#reference-L11136">3</a></sup>

>  <uniprotId>  (228) 
P10721|P08684|P11712|P08183|Q9UNQ0

>  <MW>  (228) 
498.2

>  <HBA>  (228) 
10.0

>  <HBD>  (228) 
1.0

>  <NRB>  (228) 
5.0

>  <TPSA>  (228) 
106.3

>  <LogP>  (228) 
2.6

>  <RoF>  (228) 
0.0

>  <Melting point>  (228) 


>  <Targets>  (228) 
nan

>  <Kinase families>  (228) 


>  <FDA_approved>  (228) 
Y

$$$$
Axitinib
     RDKit          2D

 28 31  0  0  0  0  0  0  0  0999 V2000
   -8.0028   -3.1808    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5451   -1.7524    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0792   -1.4345    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0710   -2.5451    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6215   -0.0061    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6297    1.1046    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1720    2.5330    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7061    2.8509    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6978    1.7403    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1555    0.3118    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1473   -0.7988    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6814   -0.4810    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6731   -1.5916    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7928   -1.2737    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2505    0.1547    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2423    1.2653    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2237    0.9475    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9870    2.5674    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.4554    2.2616    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6183    0.7704    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9204    0.0257    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2164    0.7810    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5185    0.0363    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5246   -1.4637    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8267   -2.2084    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1226   -1.4531    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1165    0.0469    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8144    0.7916    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  3  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 16 18  1  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 10  5  1  0
 17 12  1  0
 20 15  1  0
 28 23  1  0
M  END
>  <BrandName>  (229) 
Inlyta

>  <Applicants>  (229) 
Pfizer

>  <CHEMBL_ID>  (229) 
CHEMBL1289926

>  <Canonical_Smiles>  (229) 
CNC(=O)c1ccccc1Sc2ccc3c(c2)[nH]nc3/C=C/c4ccccn4

>  <Chirality>  (229) 
Achiral Molecule

>  <First_Approval>  (229) 
2012

>  <Phase>  (229) 
4.0

>  <SC_Patent>  (229) 
US-6534524-B1

>  <Synonyms>  (229) 
AG-013736 | AG-13736 | AXITINIB | INLYTA

>  <Withdrawn>  (229) 
|Study NCT01441388 in nan was Withdrawn during Phase 1 because Business/Operational issues|Study NCT03275558 in Singapore was Withdrawn during Phase 1 because Study halted prior to enrollment of first participant (It has been determined on 2018 May 15    that the NCT03275558 study will be stopped by sponsor decision)|Study NCT04197219 in nan was Withdrawn during Phase 2 because PI is leaving institution

>  <Indications>  (229) 
Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.

>  <Type>  (229) 
2

>  <targets_id>  (229) 
P17948|P35968|P35916

>  <inchi>  (229) 
InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+

>  <stdInchikey>  (229) 
RITAVMQDGBJQJZ-FMIVXFBMSA-N

>  <csid>  (229) 
4953153

>  <Links>  (229) 
|http://www.chemspider.com/Chemical-Structure.4953153.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1289926|http://pubchem.ncbi.nlm.nih.gov/compound/6450551|http://www.drugbank.ca/drugs/DB06626| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=AXI|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/AXI|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5659|http://zinc15.docking.org/substances/ZINC03816287|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=C9LVQ0YUXG|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=25117

>  <LinkName>  (229) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (229) 
'AXI'

>  <pdbID>  (229) 
4ag8 4agc 4twp 4wa9

>  <indicationG2P>  (229) 
None

>  <indicationDB>  (229) 
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).<sup class="text-reference-group"><a class="reference-popover-link" data-content="DRUG NAME: Axitinib - BC Cancer" href="#reference-L6676">7</a></sup> Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.<sup class="text-reference-group"><a class="reference-popover-link" data-content="DRUG NAME: Axitinib - BC Cancer" href="#reference-L6676">7</a></sup> Axitinib is an indazole derivative.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Gross-Goupil M, Francois L, Quivy A, Ravaud A: Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. Clin Med Insights Oncol. 2013 Oct 29;7:269-77. doi: 10.4137/CMO.S10594. (PubMed ID 24250243)" href="#reference-A179398">6</a></sup> It is most commonly marketed under the name InlytaÂ® and is available in oral formulations.

>  <uniprotId>  (229) 
P17948|P35968|P35916|P08684|P20815|P05177|P33261|P22309|P08183|Q9Y6L6

>  <MW>  (229) 
386.1

>  <HBA>  (229) 
4.0

>  <HBD>  (229) 
2.0

>  <NRB>  (229) 
5.0

>  <TPSA>  (229) 
70.7

>  <LogP>  (229) 
4.6

>  <RoF>  (229) 
0.0

>  <Melting point>  (229) 


>  <Targets>  (229) 
FLT1; KDR; FLT4

>  <Kinase families>  (229) 
Tyr

>  <FDA_approved>  (229) 
Y

$$$$
Binimetinib
     RDKit          2D

 27 29  0  0  0  0  0  0  0  0999 V2000
    5.7549   -2.6046    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0068   -1.3044    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.6189    0.0650    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5056    1.0703    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.2055    0.3222    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5152   -1.1455    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3991   -2.1476    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9731   -1.6820    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6634   -0.2143    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7796    0.7878    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4698    2.2555    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7625    0.2513    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0722    1.7190    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0439    2.7211    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2658    4.1887    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6917    4.6543    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8079    3.6522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4982    2.1846    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6143    1.1825    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0015    6.1220    0.0000 Br  0  0  0  0  0  0  0  0  0  0  0  0
   -0.1430   -2.6840    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1667   -4.1517    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5689   -2.2184    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6851   -3.2205    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1110   -2.7549    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2272   -3.7570    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6531   -3.2914    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
  9 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 16 20  1  0
  8 21  1  0
 21 22  2  0
 21 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
  6  2  1  0
 10  5  1  0
 18 13  1  0
M  END
>  <BrandName>  (230) 
Mektovi

>  <Applicants>  (230) 
Novartis

>  <CHEMBL_ID>  (230) 
CHEMBL3187723

>  <Canonical_Smiles>  (230) 
Cn1cnc2c1cc(c(c2F)Nc3ccc(cc3F)Br)C(=O)NOCCO

>  <Chirality>  (230) 
Achiral Molecule

>  <First_Approval>  (230) 
2018

>  <Phase>  (230) 
4.0

>  <SC_Patent>  (230) 
US-7777050-B2

>  <Synonyms>  (230) 
ARRY 438162 | ARRY-162 | ARRY-438162 | BINIMETINIB | MEK-162 | MEK162 | MEKTOVI | NVP-MEK162

>  <Withdrawn>  (230) 
|Study NCT02263898 in United States was Withdrawn during Phase 2 because closed without enrollment

>  <Indications>  (230) 
On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

>  <Type>  (230) 
nan

>  <targets_id>  (230) 
Q02750

>  <inchi>  (230) 
InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)

>  <stdInchikey>  (230) 
ACWZRVQXLIRSDF-UHFFFAOYSA-N

>  <csid>  (230) 
8463660

>  <Links>  (230) 
|http://www.chemspider.com/Chemical-Structure.8463660.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3187723|http://pubchem.ncbi.nlm.nih.gov/compound/10288191|http://www.drugbank.ca/drugs/DB11967| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=QO7|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/QO7|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7921|http://zinc15.docking.org/substances/ZINC000038460704|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=181R97MR71

>  <LinkName>  (230) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (230) 
'QO7'

>  <pdbID>  (230) 
6v2x

>  <indicationG2P>  (230) 
None

>  <indicationDB>  (230) 
Binimetinib, also known as <em>Mektovi</em>, is a potent is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with <a href="https://go.drugbank.com/drugs/DB11718">Encorafenib</a> <sup class="text-reference-group"><a class="reference-popover-link" data-content="Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A: A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br J Cancer. 2017 Feb 28;116(5):575-583. doi: 10.1038/bjc.2017.10. Epub 2017 Feb 2. (PubMed ID 28152546)" href="#reference-A34275">4</a></sup>,<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations" href="#reference-L3335">8</a></sup>.</p><p>On June 27, 2018, the Food and Drug Administration approved the combination of <a href="https://go.drugbank.com/drugs/DB11718">Encorafenib</a> and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test <sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations" href="#reference-L3335">8</a></sup>.

>  <uniprotId>  (230) 
P05231|P01375|P01584|Q13233|P36507|P22309|P05177|P33261

>  <MW>  (230) 
440.0

>  <HBA>  (230) 
6.0

>  <HBD>  (230) 
3.0

>  <NRB>  (230) 
6.0

>  <TPSA>  (230) 
88.4

>  <LogP>  (230) 
3.0

>  <RoF>  (230) 
0.0

>  <Melting point>  (230) 


>  <Targets>  (230) 
MAP2K1

>  <Kinase families>  (230) 
STE

>  <FDA_approved>  (230) 
Y

$$$$
Bosutinib
     RDKit          2D

 36 39  0  0  0  0  0  0  0  0999 V2000
  -12.5897   -0.0020    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.1128   -0.2640    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  -10.1474    0.8841    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.6705    0.6220    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.1589   -0.7880    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -9.1243   -1.9361    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.6013   -1.6741    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6820   -1.0501    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7166    0.0980    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2397   -0.1640    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2743    0.9840    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7973    0.7220    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2858   -0.6881    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1911   -0.9501    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1565    0.1979    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6450    1.6080    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8320    1.8700    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3435    3.2801    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3781    4.4282    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6335   -0.0641    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1450   -1.4742    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1796   -2.6222    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7027   -2.3602    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.6219   -1.7362    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0989   -1.9982    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.5989    1.0840    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.0758    0.8219    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5873   -0.5881    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0643   -0.8502    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0297    0.2979    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5181    1.7080    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0412    1.9700    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5296    3.3801    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    9.5066    0.0359    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    7.5758   -2.2602    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.0528   -2.5223    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  5  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  1  0
 15 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 21 24  1  0
 24 25  3  0
 20 26  1  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  2  0
 32 33  1  0
 30 34  1  0
 29 35  1  0
 35 36  1  0
  7  2  1  0
 17 12  1  0
 23 14  1  0
 32 27  1  0
M  END
>  <BrandName>  (231) 
Bosulif

>  <Applicants>  (231) 
Wyeth

>  <CHEMBL_ID>  (231) 
CHEMBL288441

>  <Canonical_Smiles>  (231) 
CN1CCN(CC1)CCCOc2cc3c(cc2OC)c(c(cn3)C#N)Nc4cc(c(cc4Cl)Cl)OC

>  <Chirality>  (231) 
Achiral Molecule

>  <First_Approval>  (231) 
2012

>  <Phase>  (231) 
4.0

>  <SC_Patent>  (231) 
US-7417148-B2

>  <Synonyms>  (231) 
BOSULIF | BOSUTINIB | BOSUTINIB MONOHYDRATE | SK-606 | SKI-606

>  <Withdrawn>  (231) 


>  <Indications>  (231) 
Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.

>  <Type>  (231) 
1

>  <targets_id>  (231) 
P11274|P00519|P07948|P08631|P12931|P24941|Q02750|P36507|Q9Y2U5|Q13555

>  <inchi>  (231) 
InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)

>  <stdInchikey>  (231) 
UBPYILGKFZZVDX-UHFFFAOYSA-N

>  <csid>  (231) 
4486102

>  <Links>  (231) 
|http://www.chemspider.com/Chemical-Structure.4486102.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL288441|http://pubchem.ncbi.nlm.nih.gov/compound/5328940|http://www.drugbank.ca/drugs/DB06616| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=DB8|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/DB8|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5710|http://zinc15.docking.org/substances/ZINC000022448983|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=5018V4AEZ0|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=4552

>  <LinkName>  (231) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (231) 
'DB8'

>  <pdbID>  (231) 
3soa 3ue4 4mxo 4mxx 4mxy 4mxz 4qmn 5ajq 5i9x 5vc3 5vcy 6fdy 6op9

>  <indicationG2P>  (231) 
None

>  <indicationDB>  (231) 
Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012.

>  <uniprotId>  (231) 
P11274|P00519|P07948|P08631|P12931|P24941|Q02750|P36507|Q9Y2U5|Q13555|P08684|P10632|P08183

>  <MW>  (231) 
529.2

>  <HBA>  (231) 
8.0

>  <HBD>  (231) 
1.0

>  <NRB>  (231) 
9.0

>  <TPSA>  (231) 
82.9

>  <LogP>  (231) 
5.2

>  <RoF>  (231) 
2.0

>  <Melting point>  (231) 


>  <Targets>  (231) 
BCR; ABL1; LYN; HCK; SRC; CDK2; MAP2K1; MAP2K2; MAP3K2; CAMK2G

>  <Kinase families>  (231) 
Tyr<br>Atypical<br>CMGC<br>CAMK<br>STE

>  <FDA_approved>  (231) 
Y

$$$$
Brigatinib
     RDKit          2D

 40 44  0  0  0  0  0  0  0  0999 V2000
  -13.2331   -0.7910    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.7428   -0.6209    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  -11.1449    0.7548    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.6546    0.9248    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7622   -0.2808    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -9.3600   -1.6565    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.8504   -1.8266    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2718   -0.1107    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3794   -1.3164    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8891   -1.1463    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2912    0.2294    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1836    1.4350    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6740    1.2650    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8009    0.3995    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9084   -0.8061    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4181   -0.6361    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1798    0.7396    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7126    1.9453    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2030    1.7752    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1148    3.3209    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0072    4.5266    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6701    0.9097    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.5626   -0.2959    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9647   -1.6716    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.8571   -2.8773    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3475   -2.7072    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9454   -1.3315    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0529   -0.1259    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.4357   -1.1614    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.0336    0.2143    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1411    1.4199    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7390    2.7956    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2293    2.9657    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1218    1.7601    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5239    0.3844    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4163   -0.8213    0.0000 P   0  0  0  0  0  0  0  0  0  0  0  0
   10.3088   -2.0269    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.2107   -1.7137    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.6220    0.0712    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2399   -3.9128    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  5  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 11 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 18 20  1  0
 20 21  1  0
 17 22  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 27 29  1  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 32 33  2  0
 33 34  1  0
 34 35  2  0
 35 36  1  0
 36 37  2  0
 36 38  1  0
 36 39  1  0
 26 40  1  0
  7  2  1  0
 13  8  1  0
 19 14  1  0
 28 23  1  0
 35 30  1  0
M  END
>  <BrandName>  (232) 
Alunbrig

>  <Applicants>  (232) 
Ariad Pharmaceuticals

>  <CHEMBL_ID>  (232) 
CHEMBL3545311

>  <Canonical_Smiles>  (232) 
CN1CCN(CC1)C2CCN(CC2)c3ccc(c(c3)OC)Nc4ncc(c(n4)Nc5ccccc5P(=O)(C)C)Cl

>  <Chirality>  (232) 
Achiral Molecule

>  <First_Approval>  (232) 
2017

>  <Phase>  (232) 
4.0

>  <SC_Patent>  (232) 
US-9012462-B2

>  <Synonyms>  (232) 
ALUNBRIG | AP-26113 | AP26113 | BRIGATINIB

>  <Withdrawn>  (232) 


>  <Indications>  (232) 
The anaplastic lymphoma kinase positive, metastatic non-small cell lung cancer (ALK+ NSCLC), represents only 3-5% of the NSCLC cancer cases, but the ALK mutation, overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy target. The ALK-related cases of NSCLC are associated with the presence of the fusion gene EML4-ALK which fused the ALK protein with the echinoderm microtubule-associated protein like-4 whose original function is the correct formation of microtubules. The presence of the aberrant fusion protein results in abnormal signaling that provokes increased cell growth, proliferation and survival. Crizotinib is indicated for the treatment of such cases but the presence of ALK kinase domain mutations confer resistance to the treatment. Thus, brigatinib is indicated for the treatment of patients with ALK+ NSCLC with intolerance to Crizotinib.

>  <Type>  (232) 
1

>  <targets_id>  (232) 
Q9UM73|P00533

>  <inchi>  (232) 
InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)

>  <stdInchikey>  (232) 
AILRADAXUVEEIR-UHFFFAOYSA-N

>  <csid>  (232) 
34982928

>  <Links>  (232) 
|http://www.chemspider.com/Chemical-Structure.34982928.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545311|http://pubchem.ncbi.nlm.nih.gov/compound/68165256|http://www.drugbank.ca/drugs/DB12267| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=6GY|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6GY|http://zinc15.docking.org/substances/ZINC000148723177|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=HYW8DB273J|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50185140

>  <LinkName>  (232) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (232) 
'6GY'

>  <pdbID>  (232) 
6mx8 7aem

>  <indicationG2P>  (232) 


>  <indicationDB>  (232) 
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Ceccon M, Mologni L, Bisson W, Scapozza L, Gambacorti-Passerini C: Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. Mol Cancer Res. 2013 Feb;11(2):122-32. doi: 10.1158/1541-7786.MCR-12-0569. Epub 2012 Dec 13. (PubMed ID 23239810)" href="#reference-A31311">1</a></sup> It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Iragavarapu C, Mustafa M, Akinleye A, Furqan M, Mittal V, Cang S, Liu D: Novel ALK inhibitors in clinical use and development. J Hematol Oncol. 2015 Feb 27;8:17. doi: 10.1186/s13045-015-0122-8. (PubMed ID 25888090)" href="#reference-A31313">2</a></sup> Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA News and Events" href="#reference-L1026">9</a></sup>

>  <uniprotId>  (232) 
Q9UM73|P00533|P00519|P08069|P36888|P06213|P08581|Q15303|P04626|P10632|P08684|P08684|Q9HB55|P20815|P24462|Q2M3G0|Q9UNQ0|O15245|Q96FL8|Q86VL8

>  <MW>  (232) 
583.3

>  <HBA>  (232) 
9.0

>  <HBD>  (232) 
2.0

>  <NRB>  (232) 
8.0

>  <TPSA>  (232) 
85.9

>  <LogP>  (232) 
5.1

>  <RoF>  (232) 
2.0

>  <Melting point>  (232) 


>  <Targets>  (232) 
ALK; EGFR

>  <Kinase families>  (232) 
Tyr

>  <FDA_approved>  (232) 
Y

$$$$
Cabozantinib
     RDKit          2D

 37 41  0  0  0  0  0  0  0  0999 V2000
   -9.8401   -1.8981    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3423   -1.9781    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5240   -0.7209    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0262   -0.8009    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2079    0.4563    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7101    0.3763    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8918    1.6334    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5715    2.9706    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0693    3.0506    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8876    1.7935    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3854    1.8735    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.2037    0.6163    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.7015    0.6963    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  -10.3812    2.0335    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0304   -0.9609    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5326   -1.0410    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8529   -2.3782    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6449   -2.4582    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4632   -1.2010    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7835    0.1362    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7143    0.2162    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9610   -1.2810    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.6407   -2.6182    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8224   -3.8754    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.1385   -2.6982    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5187   -3.2857    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3198   -4.1872    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4774   -1.2370    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3814   -0.2129    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.9123   -0.7999    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.2512    0.6613    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6861    1.0984    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0250    2.5596    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9290    3.5837    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4941    3.1466    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1552    1.6854    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2679    5.0449    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  1  0
  6 15  1  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 19 22  1  0
 22 23  1  0
 23 24  2  0
 23 25  1  0
 25 26  1  0
 26 27  1  0
 25 28  1  0
 28 29  2  0
 28 30  1  0
 30 31  1  0
 31 32  2  0
 32 33  1  0
 33 34  2  0
 34 35  1  0
 35 36  2  0
 34 37  1  0
 12  3  1  0
 10  5  1  0
 21 16  1  0
 27 25  1  0
 36 31  1  0
M  END
>  <BrandName>  (233) 
Cabometyx;Cometriq

>  <Applicants>  (233) 
Exelixis

>  <CHEMBL_ID>  (233) 
CHEMBL2105717

>  <Canonical_Smiles>  (233) 
COc1cc2c(ccnc2cc1OC)Oc3ccc(cc3)NC(=O)C4(CC4)C(=O)Nc5ccc(cc5)F

>  <Chirality>  (233) 
Achiral Molecule

>  <First_Approval>  (233) 
2012

>  <Phase>  (233) 
4.0

>  <SC_Patent>  (233) 
US-7579473-B2

>  <Synonyms>  (233) 
BMS-907351 | BMS-907351 FREE BASE | CABOMETYX | CABOZANTINIB | COMETRIQ | XL-184 | XL-184 FREE BASE | XL184

>  <Withdrawn>  (233) 
|Study NCT04149275 in United States was Withdrawn during Phase 2 because Funding withdrawn by sponsor

>  <Indications>  (233) 
For the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

>  <Type>  (233) 
2

>  <targets_id>  (233) 
P08581|P35968|P07949

>  <inchi>  (233) 
InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)

>  <stdInchikey>  (233) 
ONIQOQHATWINJY-UHFFFAOYSA-N

>  <csid>  (233) 
25948202

>  <Links>  (233) 
|http://www.chemspider.com/Chemical-Structure.25948202.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2105717|http://pubchem.ncbi.nlm.nih.gov/compound/25102847|http://www.drugbank.ca/drugs/DB08875|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5887|http://zinc15.docking.org/substances/ZINC000070466416|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=1C39JW444G|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50021574

>  <LinkName>  (233) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (233) 


>  <pdbID>  (233) 


>  <indicationG2P>  (233) 
None

>  <indicationDB>  (233) 
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Cometriq (cabozantinib) oral capsules" href="#reference-L15123">6</a></sup> In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Cabometyx (cabozantinib) oral tablets" href="#reference-L15128">7</a>,<a class="reference-popover-link" data-content="Health Canada Product Monograph: Cabometyx (cabozantinib) oral tablets" href="#reference-L15133">8</a></sup>

>  <uniprotId>  (233) 
P08581|P35968|P07949|P08684|P11712|P10632

>  <MW>  (233) 
501.2

>  <HBA>  (233) 
6.0

>  <HBD>  (233) 
2.0

>  <NRB>  (233) 
8.0

>  <TPSA>  (233) 
98.8

>  <LogP>  (233) 
5.5

>  <RoF>  (233) 
2.0

>  <Melting point>  (233) 


>  <Targets>  (233) 
MET; KDR; RET

>  <Kinase families>  (233) 
Tyr

>  <FDA_approved>  (233) 
Y

$$$$
Capmatinib
     RDKit          2D

 31 35  0  0  0  0  0  0  0  0999 V2000
   -9.8107   -1.9666    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.5721   -1.1204    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2200   -1.7700    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1065   -3.2657    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9815   -0.9239    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0949    0.5718    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8564    1.4180    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5043    0.7684    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3908   -0.7273    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6294   -1.5734    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5159   -3.0691    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2657    1.6145    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3792    3.1102    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1406    3.9564    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.2114    3.3068    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5988    3.8769    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.5698    2.7336    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7825    1.4568    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3249    1.8111    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9137    0.9650    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.3526    0.0694    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8392   -0.1306    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7557    1.0569    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2423    0.8569    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8124   -0.5305    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8959   -1.7180    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4093   -1.5180    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4661   -3.1054    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9527   -3.3054    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8692   -2.1179    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2990   -0.7305    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  3  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
  8 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  1  0
 18 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 26 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 10  5  1  0
 20 12  2  0
 19 15  1  0
 27 22  1  0
 31 25  1  0
M  END
>  <BrandName>  (234) 


>  <Applicants>  (234) 
Novartis

>  <CHEMBL_ID>  (234) 
CHEMBL3188267

>  <Canonical_Smiles>  (234) 
CNC(=O)c1ccc(cc1F)c2cnc3ncc(n3n2)Cc4ccc5c(c4)cccn5

>  <Chirality>  (234) 
Achiral Molecule

>  <First_Approval>  (234) 
2020

>  <Phase>  (234) 
4.0

>  <SC_Patent>  (234) 
US-7767675-B2

>  <Synonyms>  (234) 
CAPMATINIB | INC-280 | INC280 | INCB-28060 | INCB-28060 FREE BASE | NVP-INC280 | NVP-INC280-NX | NYP-INC280-NX

>  <Withdrawn>  (234) 


>  <Indications>  (234) 
On may 2020 FDA approved capmatinib to treat patients with non small cell lung cancer

>  <Type>  (234) 
nan

>  <targets_id>  (234) 
P08581

>  <inchi>  (234) 
InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)

>  <stdInchikey>  (234) 
LIOLIMKSCNQPLV-UHFFFAOYSA-N

>  <csid>  (234) 
25069712

>  <Links>  (234) 
|http://www.chemspider.com/Chemical-Structure.25069712.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3188267|http://pubchem.ncbi.nlm.nih.gov/compound/25145656|http://www.drugbank.ca/drugs/DB11791|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7904|http://zinc15.docking.org/substances/ZINC000043195321|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=TY34L4F9OZ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50146167

>  <LinkName>  (234) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (234) 


>  <pdbID>  (234) 


>  <indicationG2P>  (234) 
None

>  <indicationDB>  (234) 
Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Kim S, Kim TM, Kim DW, Kim S, Kim M, Ahn YO, Keam B, Heo DS: Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib. Cancer Res Treat. 2019 Jul;51(3):951-962. doi: 10.4143/crt.2018.052. Epub 2018 Oct 10. (PubMed ID 30309221)" href="#reference-A199122">2</a></sup> Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many types of cancer, and leads to overactivation of multiple downstream signaling pathways such as STAT3, PI3K/ATK, and RAS/MAPK.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Kim S, Kim TM, Kim DW, Kim S, Kim M, Ahn YO, Keam B, Heo DS: Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib. Cancer Res Treat. 2019 Jul;51(3):951-962. doi: 10.4143/crt.2018.052. Epub 2018 Oct 10. (PubMed ID 30309221)" href="#reference-A199122">2</a></sup> Mutations in <em>MET</em> have been detected in non-small cell lung cancer (NSCLC), and the prevalence of <em>MET</em> amplification in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-naive patients with NSCLC has been reported to be 1.4% - 21%.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Kim S, Kim TM, Kim DW, Kim S, Kim M, Ahn YO, Keam B, Heo DS: Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib. Cancer Res Treat. 2019 Jul;51(3):951-962. doi: 10.4143/crt.2018.052. Epub 2018 Oct 10. (PubMed ID 30309221)" href="#reference-A199122">2</a></sup> This co-occurrence has made c-Met a desirable target in the treatment of NSCLC.</p><p>Manufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020,<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approvals and Databases: FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer" href="#reference-L13380">4</a></sup> for the treatment of NSCLC in patients whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Tabrecta (capmatinib) oral tablets" href="#reference-L13347">3</a></sup> The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same day.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approvals and Databases: FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer" href="#reference-L13380">4</a></sup> As this indication was granted under an accelerated approval, its continued approval is contingent upon verification of capmatinib&#39;s benefit in confirmatory trials.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Tabrecta (capmatinib) oral tablets" href="#reference-L13347">3</a></sup>

>  <uniprotId>  (234) 
P08581|P08684|Q06278|P05177|P08183|Q96FL8|Q86VL8|Q9UNQ0

>  <MW>  (234) 
412.1

>  <HBA>  (234) 
6.0

>  <HBD>  (234) 
1.0

>  <NRB>  (234) 
4.0

>  <TPSA>  (234) 
85.1

>  <LogP>  (234) 
3.4

>  <RoF>  (234) 
0.0

>  <Melting point>  (234) 


>  <Targets>  (234) 
MET

>  <Kinase families>  (234) 
Tyr

>  <FDA_approved>  (234) 
Y

$$$$
Baricitinib
     RDKit          2D

 26 29  0  0  0  0  0  0  0  0999 V2000
    7.0516    1.1972    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4880   -0.1929    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0023   -0.3998    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    4.7954    1.0859    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.2092   -1.8854    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.5166   -0.6066    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.3198    0.2976    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4156   -0.8992    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6124   -1.8035    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3198    0.2976    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8084    0.1129    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2975    0.2939    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.2188    0.0050    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2162   -0.4317    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0750    0.7981    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1708    1.9949    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2469    1.5048    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5748    0.8262    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3490   -0.4586    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9122   -1.8936    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1420   -2.7524    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3388   -1.8482    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8487   -0.4305    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5743    0.8823    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8001    2.1671    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3003    2.1390    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  3  5  2  0
  3  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  8 10  1  0
 10 11  1  0
 11 12  3  0
  8 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 15 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
  9  6  1  0
 17 13  1  0
 26 18  1  0
 23 19  1  0
M  END
>  <BrandName>  (235) 
Olumiant

>  <Applicants>  (235) 
Eli Lilly

>  <CHEMBL_ID>  (235) 
CHEMBL2105759

>  <Canonical_Smiles>  (235) 
CCS(=O)(=O)N1CC(C1)(CC#N)n2cc(cn2)c3c4cc[nH]c4ncn3

>  <Chirality>  (235) 
Achiral Molecule

>  <First_Approval>  (235) 
2017

>  <Phase>  (235) 
4.0

>  <SC_Patent>  (235) 
US-8158616-B2

>  <Synonyms>  (235) 
BARICITINIB | INCB-028050 | INCB-28050 | INCB028050 | LY-3009104 | LY3009104 | OLUMIANT

>  <Withdrawn>  (235) 


>  <Indications>  (235) 
Indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs as monotherapy or in combination with methotrexate.

>  <Type>  (235) 
1

>  <targets_id>  (235) 
P23458|O60674

>  <inchi>  (235) 
InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)

>  <stdInchikey>  (235) 
XUZMWHLSFXCVMG-UHFFFAOYSA-N

>  <csid>  (235) 
26373084

>  <Links>  (235) 
|http://www.chemspider.com/Chemical-Structure.26373084.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2105759|http://pubchem.ncbi.nlm.nih.gov/compound/44205240|http://www.drugbank.ca/drugs/DB11817| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=3JW|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/3JW|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7792|http://zinc15.docking.org/substances/ZINC000073069247|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=ISP4442I3Y|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50021656

>  <LinkName>  (235) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (235) 
'3JW'

>  <pdbID>  (235) 
4w9x 6vn8

>  <indicationG2P>  (235) 
None

>  <indicationDB>  (235) 
Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway signalling that is frequently over-activated in autoimmune disorders such as rheumatoid arthritis. By blocking the actions of JAK1/2, baricitinib disrupts the activation of downstream signalling molecules and proinflammatory mediators. </p><p>Rheumatoid arthritis is a progressive autoimmune disease commonly associated with discomfort, diasability, and joint damage. Throughout disease progression, the disease may further lead to joint erosions and deformities, causing premature mortality, functional impairment, and reduced quality of life <sup class="text-reference-group"><a class="reference-popover-link" data-content="Ni H, Moe S, Myint KT, Htet A: Oral janus kinase inhibitor for the treatment of rheumatoid arthritis: tofacitinib. ISRN Rheumatol. 2013 Jul 21;2013:357904. doi: 10.1155/2013/357904. eCollection 2013. (PubMed ID 23970975)" href="#reference-A31386">3</a></sup>. While there are several disease modifying antirheumatic drugs (DMARDs) available for treatment, patients often experience inadequate threapeutic resposes to these drugs. In animal models of inflammatory arthritis, baricitinib was shown to have significant anti-inflammatory effects, but also led to preservation of cartilage and bone, with no detectable suppression of humoral immunity or adverse hematologic effects <sup class="text-reference-group"><a class="reference-popover-link" data-content="Kuriya B, Cohen MD, Keystone E: Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential. Ther Adv Musculoskelet Dis. 2017 Feb;9(2):37-44. doi: 10.1177/1759720X16687481. Epub 2017 Jan 23. (PubMed ID 28255337)" href="#reference-A31382">1</a></sup>.</p><p>In the EU, baricitinib was approved in February of 2017 as a second-line orally administered treatment for moderate to severe active rheumatoid arthritis in adults, either as a monotherapy or when combined with methotrexate. It is marketed under the trade name Olumiant.</p><p>Baricitinib in combination with <a href="https://go.drugbank.com/drugs/DB14761">remdesivir</a> for the treatment of COVID-19, was granted an FDA Emergency Use Authorization on 19 November 2020.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA: Emergency Use Authorization for Baricitinib in Combination with Remdesivir for COVID-19" href="#reference-L22619">5</a></sup>

>  <uniprotId>  (235) 
P23458|O60674|Q14289|P52333

>  <MW>  (235) 
371.1

>  <HBA>  (235) 
7.0

>  <HBD>  (235) 
1.0

>  <NRB>  (235) 
5.0

>  <TPSA>  (235) 
120.6

>  <LogP>  (235) 
1.1

>  <RoF>  (235) 
0.0

>  <Melting point>  (235) 


>  <Targets>  (235) 
JAK1; JAK2

>  <Kinase families>  (235) 
Tyr

>  <FDA_approved>  (235) 
Y

$$$$
Cobimetinib
     RDKit          2D

 30 33  0  0  0  0  0  0  0  0999 V2000
   -6.1573    0.1522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6426    1.5715    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6561    2.7015    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1843    2.4121    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6990    0.9928    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6855   -0.1371    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2271    0.7035    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7418   -0.7159    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7283   -1.8458    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2430   -3.2651    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7712   -3.5545    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2153   -2.4245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2700   -1.0052    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7165    0.1247    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2312    1.5441    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.1883   -0.1646    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.0245   -1.4100    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2698   -0.5738    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4337    0.6715    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1059   -1.8192    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.5152    0.2623    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8619   -0.3981    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.1073    0.4380    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0058    1.9346    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6591    2.5950    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4137    1.7589    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2295   -4.3951    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2002   -1.5565    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1978    3.5421    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -8.1145    1.8609    0.0000 I   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  5  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 14 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 18 20  1  0
 21 18  1  6
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 10 27  1  0
  9 28  1  0
  4 29  1  0
  2 30  1  0
  6  1  1  0
 13  8  1  0
 19 16  1  0
 26 21  1  0
M  END
>  <BrandName>  (236) 
Cotellic

>  <Applicants>  (236) 
Hoffmann-La Roche

>  <CHEMBL_ID>  (236) 
CHEMBL2146883

>  <Canonical_Smiles>  (236) 
c1c(cc(c(c1)Nc2c(c(ccc2C(=O)N3C[C@@](C3)(O)[C@H]4NCCCC4)F)F)F)I

>  <Chirality>  (236) 
Single Stereoisomer

>  <First_Approval>  (236) 
2015

>  <Phase>  (236) 
4.0

>  <SC_Patent>  (236) 
US-7803839-B2

>  <Synonyms>  (236) 
COBIMETINIB | COTELLIC | GDC-0623 | GDC-0973 | RG 7420 | RG-7420 | RG-7421 | RG7420 | XL-518

>  <Withdrawn>  (236) 
|Study NCT02427893 in United States was Withdrawn during Phase 3 because no patients were enrolled|Study NCT03005639 in United States was Withdrawn during Phase 2 because Sponsor has decided to close study

>  <Indications>  (236) 
For the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Cobimetinib is used in combination with vemurafenib, a BRAF inhibitor.

>  <Type>  (236) 
3

>  <targets_id>  (236) 
Q02750

>  <inchi>  (236) 
InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1

>  <stdInchikey>  (236) 
BSMCAPRUBJMWDF-KRWDZBQOSA-N

>  <csid>  (236) 
17349374

>  <Links>  (236) 
|http://www.chemspider.com/Chemical-Structure.17349374.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2146883|http://pubchem.ncbi.nlm.nih.gov/compound/16222096|http://www.drugbank.ca/drugs/DB05239| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=EUI|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/EUI|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7626|http://zinc15.docking.org/substances/ZINC000060325170|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=ER29L26N1X|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50391802

>  <LinkName>  (236) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (236) 
'EUI'

>  <pdbID>  (236) 
4an2 4lmn 6v2z 7juy

>  <indicationG2P>  (236) 
None

>  <indicationDB>  (236) 
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.

>  <uniprotId>  (236) 
Q02750|P08684|P08183|Q9Y6L6|Q9NPD5|Q9UNQ0|P08183

>  <MW>  (236) 
531.1

>  <HBA>  (236) 
4.0

>  <HBD>  (236) 
3.0

>  <NRB>  (236) 
4.0

>  <TPSA>  (236) 
64.6

>  <LogP>  (236) 
3.8

>  <RoF>  (236) 
1.0

>  <Melting point>  (236) 


>  <Targets>  (236) 
MAP2K1

>  <Kinase families>  (236) 
STE

>  <FDA_approved>  (236) 
Y

$$$$
Copanlisib
     RDKit          2D

 35 39  0  0  0  0  0  0  0  0999 V2000
    1.7522    2.2553    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5259    1.3914    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.6609   -0.1025    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0222   -0.7326    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1572   -2.2265    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9309   -3.0903    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4304   -2.4603    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5653   -0.9664    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9266   -0.3363    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1529   -1.2002    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0179   -2.6941    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6566   -3.3241    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8352   -4.8135    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3068   -5.1039    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0378   -3.7940    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5141   -0.5701    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6491    0.9238    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4228    1.7877    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0104    1.5539    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1454    3.0478    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5066    3.6778    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7329    2.8140    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.5979    1.3201    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2367    0.6900    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.0942    3.4441    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.2485    0.1313    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.6097   -0.4988    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8360    0.3651    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1973   -0.2650    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4235    0.5989    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.7848   -0.0312    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.0111    0.8327    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.8761    2.3266    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.5148    2.9566    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2886    2.0928    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  1  0
 10 16  1  0
 16 17  1  0
 17 18  2  0
 17 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 22 25  1  0
  4 26  1  0
 26 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 32 33  1  0
 33 34  1  0
 34 35  1  0
  8  3  1  0
 12  7  1  0
 15 11  1  0
 24 19  1  0
 35 30  1  0
M  END
>  <BrandName>  (237) 
Aliqopa

>  <Applicants>  (237) 
Bayer

>  <CHEMBL_ID>  (237) 
CHEMBL3218576

>  <Canonical_Smiles>  (237) 
COc1c(ccc2c1N=C(N3C2=NCC3)NC(=O)c4cnc(nc4)N)OCCCN5CCOCC5

>  <Chirality>  (237) 
Achiral Molecule

>  <First_Approval>  (237) 
2017

>  <Phase>  (237) 
4.0

>  <SC_Patent>  (237) 
US-7511041-B2

>  <Synonyms>  (237) 
BAY 80-6946 | BAY-80-6946 | BAY80-6946 | COPANLISIB

>  <Withdrawn>  (237) 
|Study NCT03377101 in nan was Withdrawn during Phase 2 because change in study design|Study NCT04233697 in nan was Withdrawn during Phase 1 because Investigator left institution

>  <Indications>  (237) 
Indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.

>  <Type>  (237) 
1

>  <targets_id>  (237) 
P42336|P42338

>  <inchi>  (237) 
InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32)

>  <stdInchikey>  (237) 
PZBCKZWLPGJMAO-UHFFFAOYSA-N

>  <csid>  (237) 
25069683

>  <Links>  (237) 
|http://www.chemspider.com/Chemical-Structure.25069683.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3218576|http://pubchem.ncbi.nlm.nih.gov/compound/24989044|http://www.drugbank.ca/drugs/DB12483| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=6E2|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6E2|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7875|http://zinc15.docking.org/substances/ZINC000068247389|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=WI6V529FZ9|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50204093

>  <LinkName>  (237) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (237) 
'6E2'

>  <pdbID>  (237) 
5g2n

>  <indicationG2P>  (237) 
None

>  <indicationDB>  (237) 
Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K/Phosphatidylinositol-4,5-bisphosphate 3-kinase/phosphatidylinositide 3-kinase) inhibitor that was first developed by Bayer Healthcare Pharmaceuticals, Inc. The drug targets the enzyme that plays a role in regulating cell growth and survival. Copanlisib was granted accelerated approval on September 14, 2017 under the market name Aliqopa for the treatment of adult patients with relapsed follicular lymphoma and a treatment history of at least two prior systemic therapies. Follicular lymphoma is a slow-growing type of non-Hodgkin lymphoma that is caused by unregulated proliferation and growth of lymphocytes. The active ingredient in Aliquopa intravenous therapy is copanlisib dihydrochloride.

>  <uniprotId>  (237) 
P42336|O00329

>  <MW>  (237) 
480.2

>  <HBA>  (237) 
11.0

>  <HBD>  (237) 
2.0

>  <NRB>  (237) 
7.0

>  <TPSA>  (237) 
139.8

>  <LogP>  (237) 
0.7

>  <RoF>  (237) 
1.0

>  <Melting point>  (237) 


>  <Targets>  (237) 
PIK3CA; PIK3CB

>  <Kinase families>  (237) 
Atypical

>  <FDA_approved>  (237) 
Y

$$$$
Umbralisib
     RDKit          2D

 42 47  0  0  0  0  0  0  0  0999 V2000
    2.6522    2.4495    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7439    1.2558    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3235   -0.1277    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8115   -0.3175    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3911   -1.7010    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8790   -1.8907    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.4828   -2.8947    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0624   -4.2782    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1541   -5.4719    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6662   -5.2821    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0865   -3.8986    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9948   -2.7049    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4152   -1.3214    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.7337   -6.8554    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    4.7198    0.8762    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1401    2.2597    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0485    3.4535    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5364    3.2637    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1160    1.8802    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2077    0.6865    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6040    1.6904    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    0.2559    1.4455    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4651    2.7609    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9389    2.4815    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1287    0.9936    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7722    0.3533    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4440    0.2725    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7261    1.0511    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0414    0.3300    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0746   -1.1696    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7925   -1.9482    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4772   -1.2271    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8257   -3.4478    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3899   -1.8907    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -8.6720   -1.1122    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.9874   -1.8332    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.6389    0.3875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9177    3.6182    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4227    5.0342    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9489    5.3135    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0298    4.1768    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3914    3.3389    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  1
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  5  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
  9 14  1  0
  4 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 19 21  1  0
  2 22  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 25 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  2  0
 31 33  1  0
 30 34  1  0
 34 35  1  0
 35 36  1  0
 35 37  1  0
 24 38  1  0
 38 39  2  0
 39 40  1  0
 40 41  2  0
 38 42  1  0
 13  3  1  0
 12  7  1  0
 20 15  1  0
 26 22  1  0
 41 23  1  0
 32 27  1  0
M  END
>  <BrandName>  (238) 


>  <Applicants>  (238) 
TG Therapeutics

>  <CHEMBL_ID>  (238) 
CHEMBL3948730

>  <Canonical_Smiles>  (238) 
C[C@@H](c1c(c(=O)c2cc(ccc2o1)F)c3cccc(c3)F)n4c5c(c(n4)c6ccc(c(c6)F)OC(C)C)c(ncn5)N

>  <Chirality>  (238) 
Single Stereoisomer

>  <First_Approval>  (238) 
2021

>  <Phase>  (238) 
4.0

>  <SC_Patent>  (238) 
None

>  <Synonyms>  (238) 
RP-5264 | RP5264 | TGR 1202 | TGR-1202 BASE | TGR-1202 FREE BASE | UMBRALISIB

>  <Withdrawn>  (238) 


>  <Indications>  (238) 
On February 2021, FDA approved umbralisib for the treatment of certain patients with marginal zone lymphoma and follicular lymphoma

>  <Type>  (238) 
nan

>  <targets_id>  (238) 
nan

>  <inchi>  (238) 
InChI=1S/C31H24F3N5O3/c1-15(2)41-24-9-7-18(12-22(24)34)27-26-30(35)36-14-37-31(26)39(38-27)16(3)29-25(17-5-4-6-19(32)11-17)28(40)21-13-20(33)8-10-23(21)42-29/h4-16H,1-3H3,(H2,35,36,37)/t16-/m0/s1

>  <stdInchikey>  (238) 
IUVCFHHAEHNCFT-INIZCTEOSA-N

>  <csid>  (238) 
34979945

>  <Links>  (238) 
|http://www.chemspider.com/Chemical-Structure.34979945.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3948730|http://pubchem.ncbi.nlm.nih.gov/compound/72950888|http://www.drugbank.ca/drugs/DB14989|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8916|http://zinc15.docking.org/substances/ZINC000141831516|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=38073MQB2A|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=184556

>  <LinkName>  (238) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (238) 


>  <pdbID>  (238) 


>  <indicationG2P>  (238) 
None

>  <indicationDB>  (238) 
Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with <a href="https://go.drugbank.com/drugs/DB00073">rituximab</a> (an anti-CD20 drug), either alone or in combination with chemotherapy. Unfortunately, many patients experience a relapse or develop resistance to these drugs. Treatment options then become limited, and alternate treatments for the lymphoma are required to control disease progression.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Burris HA 3rd, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Savona MR, O&#39;Connor OA: Umbralisib, a novel PI3Kdelta and casein kinase-1epsilon inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018 Apr;19(4):486-496. doi: 10.1016/S1470-2045(18)30082-2. Epub 2018 Feb 20. (PubMed ID 29475723)" href="#reference-A229363">1</a></sup> Follicular lymphoma is also treated with rituximab and other chemotherapeutic agents, but may show similar progression.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Freedman A, Jacobsen E: Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020 Mar;95(3):316-327. doi: 10.1002/ajh.25696. Epub 2019 Dec 22. (PubMed ID 31814159)" href="#reference-A229668">5</a></sup></p><p>On February 5, 2021, the Food and Drug Administration granted accelerated approval to umbralisib, a kinase inhibitor for PI3K-delta and casein kinase CK1-epsilon, based on promising results from clinical trials. It is marketed as Ukoniq by TG Therapeutics and is approved for treating relapsing and refractory marginal cell lymphoma and follicular lymphoma in adults.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA: FDA grants accelerated approval to umbralisib for marginal zone lymphoma and follicular lymphoma" href="#reference-L31863">6</a></sup> Umbralisib inhibits casein kinase, a primary regulator of protein translation, kinase-1Îµ, distinguishing it from other lymphoma treatments and offering a promising therapy for patients experiencing relapsing or refractory disease.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Burris HA 3rd, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Savona MR, O&#39;Connor OA: Umbralisib, a novel PI3Kdelta and casein kinase-1epsilon inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018 Apr;19(4):486-496. doi: 10.1016/S1470-2045(18)30082-2. Epub 2018 Feb 20. (PubMed ID 29475723)" href="#reference-A229363">1</a></sup> Continued approval may depend on confirmation of efficacy in clinical trials.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: UKONIQ (umbralisib) tablets, for oral use" href="#reference-L31878">7</a></sup>

>  <uniprotId>  (238) 
P49674|O00329|P00519|P11712|P05177|P08684|O00329|P49674|P00519|P08183

>  <MW>  (238) 
571.2

>  <HBA>  (238) 
8.0

>  <HBD>  (238) 
1.0

>  <NRB>  (238) 
6.0

>  <TPSA>  (238) 
109.1

>  <LogP>  (238) 
6.7

>  <RoF>  (238) 
2.0

>  <Melting point>  (238) 


>  <Targets>  (238) 
nan

>  <Kinase families>  (238) 


>  <FDA_approved>  (238) 
Y

$$$$
Trilaciclib
     RDKit          2D

 33 38  0  0  0  0  0  0  0  0999 V2000
   10.7857   -0.9565    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3243   -0.6187    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.3010   -1.7154    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8395   -1.3775    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4014    0.0570    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.4247    1.1538    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8862    0.8159    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9399    0.3949    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5018    1.8295    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0403    2.1673    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0170    1.0706    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4551   -0.3640    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.9166   -0.7018    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5556    1.4085    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4678    0.3118    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0296   -1.1228    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0530   -2.2196    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5144   -1.8817    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7434   -2.7417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9411   -1.8386    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4523   -0.4205    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9525   -0.4471    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9292    0.6496    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4361    0.7119    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9635    0.9976    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4748    2.4158    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4585    3.5481    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9310    3.2623    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4198    1.8442    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9086    0.4261    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3974   -0.9921    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4136   -2.1244    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9024   -3.5425    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  5  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 11 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  1  0
 22 23  2  0
 21 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
 28 29  1  0
 24 30  1  0
 30 31  1  0
 31 32  1  0
 32 33  2  0
  7  2  1  0
 13  8  1  0
 23 15  1  0
 22 18  1  0
 32 20  1  0
 29 24  1  0
M  END
>  <BrandName>  (239) 


>  <Applicants>  (239) 
G1 Therapeutics

>  <CHEMBL_ID>  (239) 
CHEMBL3894860

>  <Canonical_Smiles>  (239) 
CN1CCN(CC1)c2ccc(nc2)Nc3ncc4cc5n(c4n3)C6(CCCCC6)CNC5=O

>  <Chirality>  (239) 
Achiral Molecule

>  <First_Approval>  (239) 
2021

>  <Phase>  (239) 
4.0

>  <SC_Patent>  (239) 
None

>  <Synonyms>  (239) 
G1T28 | TRILACICLIB

>  <Withdrawn>  (239) 


>  <Indications>  (239) 
On February 2021, FDA approved trilaciclib to mitigate chemotherapy-induced myelosuppression in adult patients with small cell lung cancer

>  <Type>  (239) 
nan

>  <targets_id>  (239) 
P11802|Q00534

>  <inchi>  (239) 
InChI=1S/C24H30N8O/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29)

>  <stdInchikey>  (239) 
PDGKHKMBHVFCMG-UHFFFAOYSA-N

>  <csid>  (239) 
58825997

>  <Links>  (239) 
|http://www.chemspider.com/Chemical-Structure.58825997.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3894860|http://pubchem.ncbi.nlm.nih.gov/compound/68029831|http://www.drugbank.ca/drugs/DB15442|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9626|http://zinc15.docking.org/substances/ZINC000143683854|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=U6072DO9XG|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=253928

>  <LinkName>  (239) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (239) 


>  <pdbID>  (239) 


>  <indicationG2P>  (239) 
None

>  <indicationDB>  (239) 
Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Cosela (Trilaciclib) Intravenous Injection" href="#reference-L31828">5</a></sup> CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Peters G: The D-type cyclins and their role in tumorigenesis. J Cell Sci Suppl. 1994;18:89-96. doi: 10.1242/jcs.1994.supplement_18.13. (PubMed ID 7883799)" href="#reference-A229323">3</a></sup> Trilaciclib was first described in the literature in 2016.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Bisi JE, Sorrentino JA, Roberts PJ, Tavares FX, Strum JC: Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. Mol Cancer Ther. 2016 May;15(5):783-93. doi: 10.1158/1535-7163.MCT-15-0775. Epub 2016 Jan 29. (PubMed ID 26826116)" href="#reference-A229313">1</a></sup></p><p>Trilaciclib was granted FDA approval on 12 February 2021.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA News Release: FDA Approves Drug to Reduce Bone Marrow Suppression Caused by Chemotherapy" href="#reference-L31823">4</a></sup>

>  <uniprotId>  (239) 
P11802|Q00534|P50750|P24941|Q00535|P50613|P05177|O15244|Q96FL8|Q86VL8|Q9UNQ0|P08183

>  <MW>  (239) 
446.3

>  <HBA>  (239) 
8.0

>  <HBD>  (239) 
2.0

>  <NRB>  (239) 
3.0

>  <TPSA>  (239) 
91.2

>  <LogP>  (239) 
2.7

>  <RoF>  (239) 
0.0

>  <Melting point>  (239) 


>  <Targets>  (239) 
CDK4; CDK6

>  <Kinase families>  (239) 
CMGC

>  <FDA_approved>  (239) 
Y

$$$$
Alectinib
     RDKit          2D

 36 41  0  0  0  0  0  0  0  0999 V2000
   -3.4743   -2.8643    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0023   -3.1529    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0165   -2.0223    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4555   -2.3109    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4414   -1.1803    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9552    0.2387    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5168    0.5272    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5026   -0.6033    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9746   -0.3148    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4607    1.1043    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9327    1.3928    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9186    0.2622    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4325   -1.1568    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9605   -1.4453    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3906    0.5508    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.8767    1.9698    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.3487    2.2583    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.3346    1.1278    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -9.8484   -0.2913    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3764   -0.5798    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9411    1.3692    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4131    1.0807    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8992   -0.3383    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3990   -0.3145    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4203   -1.4131    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8824   -1.0780    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3232    0.3558    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3019    1.4544    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8398    1.1193    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6124    1.9816    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.7853    0.6909    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.2474    1.0261    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.9134   -1.4688    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3995   -2.8879    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.4808    2.7688    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6566    2.1438    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 12 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
  6 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 27 31  1  0
 31 32  3  0
 23 33  1  0
 33 34  2  0
 21 35  1  0
 21 36  1  0
  8  3  1  0
 33  5  1  0
 14  9  1  0
 20 15  1  0
 30 22  1  0
 29 24  1  0
M  END
>  <BrandName>  (240) 
Alecensa

>  <Applicants>  (240) 
Hoffmann-La Roche

>  <CHEMBL_ID>  (240) 
CHEMBL1738797

>  <Canonical_Smiles>  (240) 
CCc1cc2c(cc1N3CCC(CC3)N4CCOCC4)C(c5c(c6ccc(cc6[nH]5)C#N)C2=O)(C)C

>  <Chirality>  (240) 
Achiral Molecule

>  <First_Approval>  (240) 
2015

>  <Phase>  (240) 
4.0

>  <SC_Patent>  (240) 
US-9126931-B2

>  <Synonyms>  (240) 
AF-802 | AF802 | ALECENSA | ALECTINIB | CH-5424802 | CH5424802 | RO-5424802 | RO5424802

>  <Withdrawn>  (240) 


>  <Indications>  (240) 
Alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

>  <Type>  (240) 
1

>  <targets_id>  (240) 
Q9UM73

>  <inchi>  (240) 
InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3

>  <stdInchikey>  (240) 
KDGFLJKFZUIJMX-UHFFFAOYSA-N

>  <csid>  (240) 
26326738

>  <Links>  (240) 
|http://www.chemspider.com/Chemical-Structure.26326738.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1738797|http://pubchem.ncbi.nlm.nih.gov/compound/49806720|http://www.drugbank.ca/drugs/DB11363| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=EMH|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/EMH|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7739|http://zinc15.docking.org/substances/ZINC000066166864|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=LIJ4CT1Z3Y|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50362781

>  <LinkName>  (240) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (240) 
'EMH'

>  <pdbID>  (240) 
3aox 5xv7

>  <indicationG2P>  (240) 
None

>  <indicationDB>  (240) 
Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability. </p><p>Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance.

>  <uniprotId>  (240) 
Q9UM73

>  <MW>  (240) 
482.3

>  <HBA>  (240) 
5.0

>  <HBD>  (240) 
1.0

>  <NRB>  (240) 
3.0

>  <TPSA>  (240) 
72.4

>  <LogP>  (240) 
4.8

>  <RoF>  (240) 
0.0

>  <Melting point>  (240) 


>  <Targets>  (240) 
ALK

>  <Kinase families>  (240) 
Tyr

>  <FDA_approved>  (240) 
Y

$$$$
Ribociclib
     RDKit          2D

 32 36  0  0  0  0  0  0  0  0999 V2000
   -8.3251   -1.2153    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8748   -0.8324    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4813    0.6151    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8181   -1.8969    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2116   -3.3444    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3678   -1.5140    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2055   -2.4623    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9445   -1.6500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4971   -2.0435    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5675   -0.9867    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.1846    0.4636    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2629    0.8571    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3274   -0.1997    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8251   -0.1157    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6374    1.1453    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1351    1.2294    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5180    2.6797    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2570    3.4920    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0947    2.5437    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2491    1.5203    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.6966    1.1268    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0795   -0.3235    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5269   -0.7171    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5915    0.3397    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2086    1.7900    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7611    2.1835    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.0389   -0.0539    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.4218   -1.5042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8693   -1.8977    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9338   -0.8410    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.5509    0.6093    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1035    1.0029    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  4  5  2  0
  4  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 11 20  1  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 24 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 14  6  1  0
 13  8  1  0
 19 15  1  0
 26 21  1  0
 32 27  1  0
M  END
>  <BrandName>  (241) 
Kisqali

>  <Applicants>  (241) 
Novartis

>  <CHEMBL_ID>  (241) 
CHEMBL3545110

>  <Canonical_Smiles>  (241) 
CN(C)C(=O)c1cc2cnc(nc2n1C3CCCC3)Nc4ccc(cn4)N5CCNCC5

>  <Chirality>  (241) 
Achiral Molecule

>  <First_Approval>  (241) 
2017

>  <Phase>  (241) 
4.0

>  <SC_Patent>  (241) 
US-8324225-B2

>  <Synonyms>  (241) 
LEE-011 | LEE-011A | LEE011 | LEE011A | NVP-LEE011 | RIBOCICLIB

>  <Withdrawn>  (241) 


>  <Indications>  (241) 
Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably.

>  <Type>  (241) 
1

>  <targets_id>  (241) 
P11802|Q00534

>  <inchi>  (241) 
InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)

>  <stdInchikey>  (241) 
RHXHGRAEPCAFML-UHFFFAOYSA-N

>  <csid>  (241) 
30798107

>  <Links>  (241) 
|http://www.chemspider.com/Chemical-Structure.30798107.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545110|http://pubchem.ncbi.nlm.nih.gov/compound/44631912|http://www.drugbank.ca/drugs/DB11730| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=6ZZ|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6ZZ|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7383|http://zinc15.docking.org/substances/ZINC000072316335|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=TK8ERE8P56|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=148264

>  <LinkName>  (241) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (241) 
'6ZZ'

>  <pdbID>  (241) 
5l2t

>  <indicationG2P>  (241) 
None

>  <indicationDB>  (241) 
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali.

>  <uniprotId>  (241) 
P11802|Q00534|P08684

>  <MW>  (241) 
434.3

>  <HBA>  (241) 
8.0

>  <HBD>  (241) 
2.0

>  <NRB>  (241) 
5.0

>  <TPSA>  (241) 
91.2

>  <LogP>  (241) 
2.8

>  <RoF>  (241) 
0.0

>  <Melting point>  (241) 


>  <Targets>  (241) 
CDK4; CDK6

>  <Kinase families>  (241) 
CMGC

>  <FDA_approved>  (241) 
Y

$$$$
Afatinib
     RDKit          2D

 34 37  0  0  0  0  0  0  0  0999 V2000
   -0.8173    9.1747    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3575    7.7469    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.1089    7.4313    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3640    6.6348    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9042    5.2070    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9108    4.0949    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4509    2.6671    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0155    2.3515    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4575    1.5550    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9977    0.1273    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5313   -0.1884    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0714   -1.6162    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0780   -2.7283    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5444   -2.4126    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0042   -0.9849    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4706   -0.6692    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4772   -1.7813    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1691   -3.2494    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4701   -3.9960    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5822   -2.9894    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9686   -1.6207    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6181   -4.1561    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.8483   -4.4717    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8548   -3.3596    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.3950   -1.9318    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4016   -0.8197    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.8680   -1.1354    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3278   -2.5631    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7942   -2.8788    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8008   -1.7667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3410   -0.3389    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8746   -0.0232    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3475    0.7732    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    8.2672   -2.0823    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  7  9  1  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 17 16  1  1
 17 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  1  0
 13 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  2  0
 31 33  1  0
 30 34  1  0
 15 10  1  0
 25 12  1  0
 21 17  1  0
 32 27  1  0
M  END
>  <BrandName>  (242) 
Gilotrif;Giotrif

>  <Applicants>  (242) 
Boehringer Ingelheim

>  <CHEMBL_ID>  (242) 
CHEMBL1173655

>  <Canonical_Smiles>  (242) 
CN(C)C/C=C/C(=O)Nc1cc2c(cc1O[C@H]3CCOC3)ncnc2Nc4ccc(c(c4)Cl)F

>  <Chirality>  (242) 
Single Stereoisomer

>  <First_Approval>  (242) 
2013

>  <Phase>  (242) 
4.0

>  <SC_Patent>  (242) 
US-RE43431-E1

>  <Synonyms>  (242) 
AFATINIB | BIBW-2992 | BIBW2992 | GILOTRIF | GIOTRIF

>  <Withdrawn>  (242) 
|Study NCT02274012 in nan was Withdrawn during Phase 2 because Former PI left institution and had plans to continue at another institution|Study NCT01480141 in United States was Withdrawn during Phase 2 because PI left MUSC, no patient enrollments|Study NCT02876081 in France was Withdrawn during Phase 2 because medical decision|Study NCT03652233 in nan was Withdrawn during Phase 1 because Low accrual

>  <Indications>  (242) 
Afatinib is a kinase inhibitor indicated for the first-line treatment of patient with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.

>  <Type>  (242) 
1

>  <targets_id>  (242) 
P00533|P04626|Q15303

>  <inchi>  (242) 
InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1

>  <stdInchikey>  (242) 
ULXXDDBFHOBEHA-CWDCEQMOSA-N

>  <csid>  (242) 
8360155

>  <Links>  (242) 
|http://www.chemspider.com/Chemical-Structure.8360155.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1173655|http://pubchem.ncbi.nlm.nih.gov/compound/10184653|http://www.drugbank.ca/drugs/DB08916| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=0WM|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/0WM|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5667|http://zinc15.docking.org/substances/ZINC03976838|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=41UD74L59M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50322823

>  <LinkName>  (242) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (242) 
'0WM'

>  <pdbID>  (242) 
4g5j

>  <indicationG2P>  (242) 
None

>  <indicationDB>  (242) 
Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim&#39;s brand name Gilotrif <sup class="text-reference-group"><a class="reference-popover-link" data-content="Official drug label" href="#label-reference">Label</a></sup>. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test <sup class="text-reference-group"><a class="reference-popover-link" data-content="Boehringer Ingelheim: FDA approves new indication for GilotrifÂ® in EGFR mutation-positive NSCLC" href="#reference-L2939">4</a></sup>. Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim <sup class="text-reference-group"><a class="reference-popover-link" data-content="Boehringer Ingelheim: FDA approves new indication for GilotrifÂ® in EGFR mutation-positive NSCLC" href="#reference-L2939">4</a></sup>.

>  <uniprotId>  (242) 
P00533|P04626|Q15303

>  <MW>  (242) 
485.2

>  <HBA>  (242) 
7.0

>  <HBD>  (242) 
2.0

>  <NRB>  (242) 
8.0

>  <TPSA>  (242) 
88.6

>  <LogP>  (242) 
4.4

>  <RoF>  (242) 
0.0

>  <Melting point>  (242) 


>  <Targets>  (242) 
EGFR; ERBB2; ERBB4

>  <Kinase families>  (242) 
Tyr

>  <FDA_approved>  (242) 
Y

$$$$
Ceritinib
     RDKit          2D

 38 41  0  0  0  0  0  0  0  0999 V2000
    5.7267   -3.2197    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7768   -2.0588    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2965   -2.3010    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3465   -1.1402    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8769    0.2629    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3572    0.5052    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3071   -0.6557    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7874   -0.4134    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7374   -1.5743    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2177   -1.3321    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7481    0.0711    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.7981    1.2319    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3178    0.9897    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9269    1.4238    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.4573    2.8269    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5074    3.9878    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9376    3.0692    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8662   -1.3824    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0837   -0.2215    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4466    1.1816    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5033    2.3424    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9836    2.1002    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5140    0.6971    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5641   -0.4638    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9943    0.4548    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5247   -0.9483    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5747   -2.1091    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1051   -3.5122    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5854   -3.7545    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5353   -2.5936    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.0050   -1.1905    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9549   -0.0297    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7941    0.9203    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -8.1158   -0.9796    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9049    1.1312    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.3852    0.8890    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3745    2.5343    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9336    3.2611    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
  5 14  1  0
 14 15  1  0
 15 16  1  0
 15 17  1  0
  4 18  1  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 23 25  1  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 32 33  2  0
 32 34  2  0
 32 35  1  0
 35 36  1  0
 35 37  1  0
 22 38  1  0
  7  2  1  0
 13  8  1  0
 24 19  1  0
 31 26  1  0
M  END
>  <BrandName>  (243) 
Zykadia

>  <Applicants>  (243) 
Novartis

>  <CHEMBL_ID>  (243) 
CHEMBL2403108

>  <Canonical_Smiles>  (243) 
Cc1cc(c(cc1C2CCNCC2)OC(C)C)Nc3ncc(c(n3)Nc4ccccc4S(=O)(=O)C(C)C)Cl

>  <Chirality>  (243) 
Achiral Molecule

>  <First_Approval>  (243) 
2014

>  <Phase>  (243) 
4.0

>  <SC_Patent>  (243) 
US-7153964-B2

>  <Synonyms>  (243) 
CERITINIB | LDK-378 | LDK378 | NVP-LDK-378-NX | NVP-LDK378-NX | ZYKADIA

>  <Withdrawn>  (243) 
|Study NCT02729961 in United States was Withdrawn during Phase 1/Phase 2 because Administrative closure|Study NCT02343679 in United States was Withdrawn during Phase 2 because No accrual due to rarity of disease|Study NCT02289144 in United States was Withdrawn during Phase 2 because study was on hold for protocol redesign; decided to not move forward with study

>  <Indications>  (243) 
Ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

>  <Type>  (243) 
1

>  <targets_id>  (243) 
Q9UM73

>  <inchi>  (243) 
InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)

>  <stdInchikey>  (243) 
VERWOWGGCGHDQE-UHFFFAOYSA-N

>  <csid>  (243) 
29315053

>  <Links>  (243) 
|http://www.chemspider.com/Chemical-Structure.29315053.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2403108|http://pubchem.ncbi.nlm.nih.gov/compound/57379345|http://www.drugbank.ca/drugs/DB09063| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=4MK|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/4MK|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7397|http://zinc15.docking.org/substances/ZINC000096272772|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=K418KG2GET|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50436850

>  <LinkName>  (243) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (243) 
'4MK'

>  <pdbID>  (243) 
4mkc

>  <indicationG2P>  (243) 
None

>  <indicationDB>  (243) 
Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy. About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype. Ceritinib exerts its therapeutic effect by inhibiting autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells. Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key &quot;gatekeeper&quot; residues of the enzyme. This occurrence led to development of novel second-generation ALK inhibitors such as ceritinib to overcome crizotinib resistance. The FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status.

>  <uniprotId>  (243) 
Q9UM73|P11712|P08684

>  <MW>  (243) 
557.2

>  <HBA>  (243) 
8.0

>  <HBD>  (243) 
3.0

>  <NRB>  (243) 
9.0

>  <TPSA>  (243) 
105.2

>  <LogP>  (243) 
6.4

>  <RoF>  (243) 
2.0

>  <Melting point>  (243) 


>  <Targets>  (243) 
ALK

>  <Kinase families>  (243) 
Tyr

>  <FDA_approved>  (243) 
Y

$$$$
Ripretinib
     RDKit          2D

 33 36  0  0  0  0  0  0  0  0999 V2000
    5.7613   -2.4270    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4439   -0.9609    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0156   -0.5027    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.6983    0.9633    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8093    1.9712    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4919    3.4372    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0636    3.8954    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.9526    2.8876    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2700    1.4215    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1590    0.4137    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4764   -1.0524    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9047   -1.5106    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2220   -2.9766    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.3654   -2.0602    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0629   -1.6020    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1739   -2.6099    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8565   -4.0759    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4282   -4.5341    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6828   -3.5263    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1111   -3.9845    0.0000 Br  0  0  0  0  0  0  0  0  0  0  0  0
   -2.9675   -5.0838    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6022   -2.1517    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9195   -0.6857    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8085    0.3222    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3478   -0.2275    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6652    1.2386    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5542    2.2464    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8715    3.7125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2999    4.1707    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4108    3.1628    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0935    1.6968    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6029    4.4451    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.0312    3.9869    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 11 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 17 21  1  0
 16 22  1  0
 22 23  1  0
 23 24  2  0
 23 25  1  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
  6 32  1  0
 32 33  1  0
 12  3  1  0
  9  4  1  0
 19 14  1  0
 31 26  1  0
M  END
>  <BrandName>  (244) 
Qinlock

>  <Applicants>  (244) 
Deciphera Pharmaceuticals

>  <CHEMBL_ID>  (244) 
CHEMBL4216467

>  <Canonical_Smiles>  (244) 
CCn1c2cc(ncc2cc(c1=O)c3cc(c(cc3Br)F)NC(=O)Nc4ccccc4)NC

>  <Chirality>  (244) 
Achiral Molecule

>  <First_Approval>  (244) 
2020

>  <Phase>  (244) 
4.0

>  <SC_Patent>  (244) 
US-8188113-B2

>  <Synonyms>  (244) 
DCC-2618 | QINLOCK | RIPRETINIB

>  <Withdrawn>  (244) 


>  <Indications>  (244) 
Ripretinib (DCC-2618) is an orally bioavailable, potent pan-KIT and PDGFR&alpha; kinase inhibitor being developed by Dicephera Pharmaceuticals.  It is in clinical development for the treatment of  malignancies that are driven by KIT and/or PDGFR&alpha;, for example gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Ripretinib has activity across a broad range of resistance mutations in its target kinases, that emerge in response to imatinib treatment. Ripretinib binds to the 'switch pocket' of KIT, a domain that regulates the enzyme's catalytic conformation. Compounds that act in this way are often referred to as switch control inhibitors.

>  <Type>  (244) 
nan

>  <targets_id>  (244) 
nan

>  <inchi>  (244) 
InChI=1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33)

>  <stdInchikey>  (244) 
CEFJVGZHQAGLHS-UHFFFAOYSA-N

>  <csid>  (244) 
67886378

>  <Links>  (244) 
|http://www.chemspider.com/Chemical-Structure.67886378.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4216467|http://pubchem.ncbi.nlm.nih.gov/compound/71584930|http://www.drugbank.ca/drugs/DB14840|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9175|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=9XW757O13D

>  <LinkName>  (244) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS

>  <lig_pdbID>  (244) 


>  <pdbID>  (244) 


>  <indicationG2P>  (244) 
None

>  <indicationDB>  (244) 
Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as <a href="https://go.drugbank.com/drugs/DB01268">sunitinib</a> and <a href="https://go.drugbank.com/drugs/DB00619">imatinib</a>. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: QINLOCK (ripretinib) tablets, for oral use" href="#reference-L13769">7</a></sup> </p><p>It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approves First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors" href="#reference-L13778">8</a></sup>

>  <uniprotId>  (244) 
P10721|P09619|Q02763|P35968|P15056|P16234|P10632|P10721|P16234|P08684|P10635|P05181|P02768|P02763|P19652|P08183|Q9UNQ0|Q96FL8

>  <MW>  (244) 
509.1

>  <HBA>  (244) 
5.0

>  <HBD>  (244) 
3.0

>  <NRB>  (244) 
5.0

>  <TPSA>  (244) 
88.0

>  <LogP>  (244) 
5.7

>  <RoF>  (244) 
2.0

>  <Melting point>  (244) 


>  <Targets>  (244) 
nan

>  <Kinase families>  (244) 


>  <FDA_approved>  (244) 
Y

$$$$
Netarsudil
     RDKit          2D

 34 37  0  0  0  0  0  0  0  0999 V2000
   -8.1992    4.8387    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5923    3.4670    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1008    3.3068    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4939    1.9351    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3783    0.7235    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.8697    0.8837    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4767    2.2555    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7542   -0.3278    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7713   -0.6482    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6558   -1.8597    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2799   -0.8084    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6730   -2.1801    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1815   -2.3403    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5746   -3.7120    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0831   -3.8722    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8013   -2.6607    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1943   -1.2890    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2971   -1.1288    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2927   -2.8209    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8997   -4.1926    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0153   -5.4041    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.1772   -1.6094    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5702   -0.2376    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.6686   -1.7696    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.5530   -0.5580    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0445   -0.7182    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9289    0.4933    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3219    1.8650    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2064    3.0765    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5994    4.4482    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.1080    4.6084    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2235    3.3969    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8305    2.0252    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9461    0.8137    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  6  8  1  0
  5  9  1  0
  9 10  2  0
  9 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 16 19  1  0
 19 20  1  6
 20 21  1  0
 19 22  1  0
 22 23  2  0
 22 24  1  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  2  0
 32 33  1  0
 33 34  2  0
  7  2  1  0
 18 13  1  0
 34 25  1  0
 33 28  1  0
M  END
>  <BrandName>  (245) 
Rhopressa

>  <Applicants>  (245) 
Aerie Pharmaceutical

>  <CHEMBL_ID>  (245) 
CHEMBL4594250

>  <Canonical_Smiles>  (245) 
Cc1ccc(c(c1)C)C(=O)OCc2ccc(cc2)[C@@H](CN)C(=O)Nc3ccc4cnccc4c3

>  <Chirality>  (245) 
Single Stereoisomer

>  <First_Approval>  (245) 
2017

>  <Phase>  (245) 
4.0

>  <SC_Patent>  (245) 
US-8394826-B2

>  <Synonyms>  (245) 
AR-11324 FREE BASE | AR-13324 | NETARSUDIL

>  <Withdrawn>  (245) 


>  <Indications>  (245) 
On december 18, 2017, the FDA approved netarsudil to treat glaucoma or ocular hypertension

>  <Type>  (245) 
nan

>  <targets_id>  (245) 
nan

>  <inchi>  (245) 
InChI=1S/C28H27N3O3/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24/h3-14,16,26H,15,17,29H2,1-2H3,(H,31,32)/t26-/m1/s1

>  <stdInchikey>  (245) 
OURRXQUGYQRVML-AREMUKBSSA-N

>  <csid>  (245) 
34980598

>  <Links>  (245) 
|http://www.chemspider.com/Chemical-Structure.34980598.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4594250|http://pubchem.ncbi.nlm.nih.gov/compound/66599893|http://www.drugbank.ca/drugs/DB13931|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9322|http://zinc15.docking.org/substances/ZINC000113149554|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=W6I5QDT7QI

>  <LinkName>  (245) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS

>  <lig_pdbID>  (245) 


>  <pdbID>  (245) 


>  <indicationG2P>  (245) 
None

>  <indicationDB>  (245) 
A Rho kinase inhibitor with norepinephrine transport inhibitory activity that reduces production of aqueous</p><p>As of December 18, 2017 the FDA approved Aerie Pharmaceutical&#39;s Rhopressa (netarsudil ophthalmic solution) 0.02% for the indication of reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Acting as both a rho kinase inhibitor and a norepinephrine transport inhibitor, Netarsudil is a novel glaucoma medication in that it specifically targets the conventional trabecular pathway of aqueous humour outflow to act as an inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral pathway that many other glaucoma medications demonstrate.

>  <uniprotId>  (245) 
Q13464|O75116|P23975

>  <MW>  (245) 
453.2

>  <HBA>  (245) 
5.0

>  <HBD>  (245) 
2.0

>  <NRB>  (245) 
7.0

>  <TPSA>  (245) 
94.3

>  <LogP>  (245) 
4.9

>  <RoF>  (245) 
0.0

>  <Melting point>  (245) 


>  <Targets>  (245) 
nan

>  <Kinase families>  (245) 


>  <FDA_approved>  (245) 
Y

$$$$
Neratinib
     RDKit          2D

 40 43  0  0  0  0  0  0  0  0999 V2000
    0.1440   -6.2854    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9188   -5.2269    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5335   -3.7772    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5963   -2.7187    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0444   -3.1098    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1072   -2.0513    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7219   -0.6016    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2738   -0.2105    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2110   -1.2690    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2371   -0.8779    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.2999   -1.9364    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9146   -3.3861    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.7480   -1.5453    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8108   -2.6038    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2589   -2.2126    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3217   -3.2712    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.7698   -2.8800    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9364   -4.7208    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7847    0.4569    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2328    0.0658    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6181   -1.3839    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.5553   -2.4424    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2956    1.1243    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3584    2.1828    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3994    1.9066    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9513    2.2977    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8885    1.2392    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4404    1.6303    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0550    3.0800    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1178    4.1385    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5659    3.7474    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7325    5.5882    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    1.3931    3.4711    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.4559    2.4126    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9040    2.8037    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9667    1.7452    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4149    2.1364    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8002    3.5860    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7374    4.6446    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2893    4.2534    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  1  0
 11 12  2  0
 11 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 16 18  1  0
  7 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 20 23  1  0
 23 24  3  0
 19 25  1  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 30 32  1  0
 29 33  1  0
 33 34  1  0
 34 35  1  0
 35 36  2  0
 36 37  1  0
 37 38  2  0
 38 39  1  0
 39 40  2  0
  9  4  1  0
 22  6  1  0
 31 26  1  0
 40 35  1  0
M  END
>  <BrandName>  (246) 
Nerlynx

>  <Applicants>  (246) 
Puma Biotechnology

>  <CHEMBL_ID>  (246) 
CHEMBL180022

>  <Canonical_Smiles>  (246) 
CCOc1cc2c(cc1NC(=O)/C=C/CN(C)C)c(c(cn2)C#N)Nc3ccc(c(c3)Cl)OCc4ccccn4

>  <Chirality>  (246) 
Achiral Molecule

>  <First_Approval>  (246) 
2017

>  <Phase>  (246) 
4.0

>  <SC_Patent>  (246) 
US-7399865-B2

>  <Synonyms>  (246) 
CDP-820 | HKI-272 | NERATINIB | WAY-179272

>  <Withdrawn>  (246) 


>  <Indications>  (246) 
For use as an extended adjuvant treatment in adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy

>  <Type>  (246) 
nan

>  <targets_id>  (246) 
P04626|P00533

>  <inchi>  (246) 
InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+

>  <stdInchikey>  (246) 
JWNPDZNEKVCWMY-VQHVLOKHSA-N

>  <csid>  (246) 
8091392

>  <Links>  (246) 
|http://www.chemspider.com/Chemical-Structure.8091392.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL180022|http://pubchem.ncbi.nlm.nih.gov/compound/9915743|http://www.drugbank.ca/drugs/DB11828|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5686|http://zinc15.docking.org/substances/ZINC000003916214|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=JJH94R3PWB|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50161957

>  <LinkName>  (246) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (246) 


>  <pdbID>  (246) 


>  <indicationG2P>  (246) 
None

>  <indicationDB>  (246) 
Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.

>  <uniprotId>  (246) 
P00533

>  <MW>  (246) 
556.2

>  <HBA>  (246) 
8.0

>  <HBD>  (246) 
2.0

>  <NRB>  (246) 
11.0

>  <TPSA>  (246) 
112.4

>  <LogP>  (246) 
5.9

>  <RoF>  (246) 
2.0

>  <Melting point>  (246) 


>  <Targets>  (246) 
ERBB2; EGFR

>  <Kinase families>  (246) 
Tyr

>  <FDA_approved>  (246) 
Y

$$$$
Ruxolitinib
     RDKit          2D

 23 26  0  0  0  0  0  0  0  0999 V2000
    3.7938   -1.8866    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2306   -2.3176    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0845   -1.0844    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.1756    0.1088    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7599   -0.3869    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6227    0.5912    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9012    2.0651    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.3169    2.5609    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4541    1.5827    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.2070    0.0955    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7759   -1.3412    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7237   -1.3752    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2195    0.0405    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0262    0.9494    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6562    0.4716    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0012    1.9313    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4380    2.3624    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.8747    2.7935    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7479   -0.5571    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5573   -2.0450    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9135   -2.6860    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.9422   -1.5943    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2218   -0.2786    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  6 10  1  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  1  0
 13 15  1  0
 15 16  1  1
 16 17  1  0
 17 18  3  0
 15 19  1  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
  5  1  1  0
  9  4  1  0
 14 10  2  0
 23 19  1  0
M  END
>  <BrandName>  (247) 
Jakafi;Jakavi

>  <Applicants>  (247) 
Incyte Corporation

>  <CHEMBL_ID>  (247) 
CHEMBL1789941

>  <Canonical_Smiles>  (247) 
c1c[nH]c2c1c(ncn2)c3cnn(c3)[C@H](CC#N)C4CCCC4

>  <Chirality>  (247) 
Single Stereoisomer

>  <First_Approval>  (247) 
2011

>  <Phase>  (247) 
4.0

>  <SC_Patent>  (247) 
US-7598257-B2

>  <Synonyms>  (247) 
INC-424 | INC424 | INCB-018424 | INCB-18424 | INCB018424 | JAKAVI | RUXOLITINIB

>  <Withdrawn>  (247) 
|Study NCT02973711 in United States was Withdrawn during Phase 1/Phase 2 because lack of funding

>  <Indications>  (247) 
Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis. [Lexicomp] Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).

>  <Type>  (247) 
1

>  <targets_id>  (247) 
P23458|O60674

>  <inchi>  (247) 
InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1

>  <stdInchikey>  (247) 
HFNKQEVNSGCOJV-OAHLLOKOSA-N

>  <csid>  (247) 
25027389

>  <Links>  (247) 
|http://www.chemspider.com/Chemical-Structure.25027389.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1789941|http://pubchem.ncbi.nlm.nih.gov/compound/25126798|http://www.drugbank.ca/drugs/DB08877| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=RXT|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/RXT|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5688|http://zinc15.docking.org/substances/ZINC43207851|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=82S8X8XX8H|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50355501

>  <LinkName>  (247) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (247) 
'RXT'

>  <pdbID>  (247) 
4u5j 6vgl 6vnk

>  <indicationG2P>  (247) 
None

>  <indicationDB>  (247) 
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2,<sup class="text-reference-group"><a class="reference-popover-link" data-content="Becker H, Engelhardt M, von Bubnoff N, Wasch R: Ruxolitinib. Recent Results Cancer Res. 2014;201:249-57. doi: 10.1007/978-3-642-54490-3_16. (PubMed ID 24756798)" href="#reference-A229698">3</a></sup> which are tyrosine kinases involved in cytokine signalling and hematopoiesis.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Yang LP, Keating GM: Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012 Nov 12;72(16):2117-27. doi: 10.2165/11209340-000000000-00000. (PubMed ID 23061804)" href="#reference-A7450">2</a></sup> Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Ajayi S, Becker H, Reinhardt H, Engelhardt M, Zeiser R, von Bubnoff N, Wasch R: Ruxolitinib. Recent Results Cancer Res. 2018;212:119-132. doi: 10.1007/978-3-319-91439-8_6. (PubMed ID 30069628)" href="#reference-A229708">5</a></sup> Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Mughal TI, Girnius S, Rosen ST, Kumar S, Wiestner A, Abdel-Wahab O, Kiladjian JJ, Wilson WH, Van Etten RA: Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leuk Lymphoma. 2014 Sep;55(9):1968-79. doi: 10.3109/10428194.2013.863307. Epub 2014 Feb 17. (PubMed ID 24206094)" href="#reference-A229938">15</a></sup></p><p>Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA&#39;s approval in 2012.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Ajayi S, Becker H, Reinhardt H, Engelhardt M, Zeiser R, von Bubnoff N, Wasch R: Ruxolitinib. Recent Results Cancer Res. 2018;212:119-132. doi: 10.1007/978-3-319-91439-8_6. (PubMed ID 30069628)" href="#reference-A229708">5</a></sup> In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of <a href="https://go.drugbank.com/drugs/DB01005">hydroxyurea</a> and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Drugs.com: Jakafi FDA Approval History" href="#reference-L31958">19</a></sup> Available as oral tablets, ruxolitinib is commonly marketed under the trade name Jakafi. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, Huang L, Meng F, Huang L, Wang N, Zhou X, Luo H, Mao Z, Chen X, Xie J, Liu J, Cheng H, Zhao J, Huang G, Wang W, Zhou J: Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020 Jul;146(1):137-146.e3. doi: 10.1016/j.jaci.2020.05.019. Epub 2020 May 26. (PubMed ID 32470486)" href="#reference-A229713">6</a>,<a class="reference-popover-link" data-content="La Rosee F, Bremer HC, Gehrke I, Kehr A, Hochhaus A, Birndt S, Fellhauer M, Henkes M, Kumle B, Russo SG, La Rosee P: The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 2020 Jul;34(7):1805-1815. doi: 10.1038/s41375-020-0891-0. Epub 2020 Jun 9. (PubMed ID 32518419)" href="#reference-A229718">7</a></sup> However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Novartis: Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19" href="#reference-L31968">20</a></sup> Ruxolitinib was not approved as a treatment for COVID-19. The topical formulation of ruxolitinib was investigated to treat vitiligo,<sup class="text-reference-group"><a class="reference-popover-link" data-content="Rosmarin D, Pandya AG, Lebwohl M, Grimes P, Hamzavi I, Gottlieb AB, Butler K, Kuo F, Sun K, Ji T, Howell MD, Harris JE: Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020 Jul 11;396(10244):110-120. doi: 10.1016/S0140-6736(20)30609-7. (PubMed ID 32653055)" href="#reference-A229723">8</a></sup> atopic dermatitis,<sup class="text-reference-group"><a class="reference-popover-link" data-content="Kim BS, Howell MD, Sun K, Papp K, Nasir A, Kuligowski ME: Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2020 Feb;145(2):572-582. doi: 10.1016/j.jaci.2019.08.042. Epub 2019 Oct 17. (PubMed ID 31629805)" href="#reference-A229728">9</a></sup> and psoriasis,<sup class="text-reference-group"><a class="reference-popover-link" data-content="Punwani N, Scherle P, Flores R, Shi J, Liang J, Yeleswaram S, Levy R, Williams W, Gottlieb A: Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol. 2012 Oct;67(4):658-64. doi: 10.1016/j.jaad.2011.12.018. Epub 2012 Jan 24. (PubMed ID 22281165)" href="#reference-A229883">12</a></sup> where it showed promising preliminary results in improving the symptoms of inflammatory skin conditions.

>  <uniprotId>  (247) 
O60674|P23458|P52333|P29597|P08684|P11712|P02768

>  <MW>  (247) 
306.2

>  <HBA>  (247) 
5.0

>  <HBD>  (247) 
1.0

>  <NRB>  (247) 
4.0

>  <TPSA>  (247) 
83.2

>  <LogP>  (247) 
3.5

>  <RoF>  (247) 
0.0

>  <Melting point>  (247) 


>  <Targets>  (247) 
JAK1; JAK2

>  <Kinase families>  (247) 
Tyr

>  <FDA_approved>  (247) 
Y

$$$$
Selpercatinib
     RDKit          2D

 39 44  0  0  0  0  0  0  0  0999 V2000
   -3.8107   -4.9633    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6683   -3.9913    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9388   -2.5159    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3519   -2.0125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6225   -0.5371    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4800    0.4349    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7506    1.9103    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1636    2.4137    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3061    1.4416    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8931    0.9383    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7506    1.9103    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0212    3.3857    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.4342    3.8891    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5767    2.9170    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3376    1.4069    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0670   -0.0684    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6540   -0.5718    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4884    0.4002    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2179    1.8756    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1952    2.3790    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.9015   -0.1031    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0439    0.8689    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4569    0.3656    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7275   -1.1098    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5851   -2.0819    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.5430   -3.5813    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.1040   -4.0046    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2567   -2.7668    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2427   -2.7248    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7421   -2.6827    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.1721   -1.5785    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5994    1.3376    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.0124    0.8342    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1548    1.8063    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1828    2.9487    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1268    0.6638    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2972    2.7783    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0670   -0.0684    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7964   -1.5438    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 11 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 18 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  1  0
 29 30  3  0
 28 31  2  0
 23 32  1  0
 32 33  1  0
 33 34  1  0
 34 35  1  0
 34 36  1  0
 34 37  1  0
  6 38  1  0
 38 39  2  0
 39  3  1  0
 13  8  1  0
 20 15  1  0
 31 21  1  0
 14  9  1  0
 31 25  1  0
M  END
>  <BrandName>  (248) 
Retevmo

>  <Applicants>  (248) 
Loxo Oncology

>  <CHEMBL_ID>  (248) 
CHEMBL4559134

>  <Canonical_Smiles>  (248) 
COC1C=CC(CN2C3CN(CC2C3)C2C=CC(=CN=2)C2=CC(=CN3N=CC(C#N)=C32)OCC(C)(C)O)=CN=1

>  <Chirality>  (248) 
Achiral Molecule

>  <First_Approval>  (248) 
2020

>  <Phase>  (248) 
4.0

>  <SC_Patent>  (248) 
US-10112942-B2

>  <Synonyms>  (248) 
LOXO-292 | LY-3527723 | LY3527723 | RETEVMO | SELPERCATINIB

>  <Withdrawn>  (248) 


>  <Indications>  (248) 
On May 2020 FDA approved selpercatinib to treat lung and thyroid cancers.

>  <Type>  (248) 
nan

>  <targets_id>  (248) 
nan

>  <inchi>  (248) 
InChI=1S/C29H31N7O3/c1-29(2,37)18-39-24-9-25(28-21(10-30)13-33-36(28)17-24)20-5-6-26(31-12-20)34-15-22-8-23(16-34)35(22)14-19-4-7-27(38-3)32-11-19/h4-7,9,11-13,17,22-23,37H,8,14-16,18H2,1-3H3

>  <stdInchikey>  (248) 
XIIOFHFUYBLOLW-UHFFFAOYSA-N

>  <csid>  (248) 
72379991

>  <Links>  (248) 
|http://www.chemspider.com/Chemical-Structure.72379991.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4559134|http://pubchem.ncbi.nlm.nih.gov/compound/134436906|http://www.drugbank.ca/drugs/DB15685|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10318|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=296429

>  <LinkName>  (248) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|BindingDB

>  <lig_pdbID>  (248) 


>  <pdbID>  (248) 


>  <indicationG2P>  (248) 
None

>  <indicationDB>  (248) 
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F: State-of-the-Art Strategies for Targeting RET-Dependent Cancers. J Clin Oncol. 2020 Apr 10;38(11):1209-1221. doi: 10.1200/JCO.19.02551. Epub 2020 Feb 21. (PubMed ID 32083997)" href="#reference-A202055">4</a>,<a class="reference-popover-link" data-content="Solomon BJ, Tan L, Lin JJ, Wong SQ, Hollizeck S, Ebata K, Tuch BB, Yoda S, Gainor JF, Sequist LV, Oxnard GR, Gautschi O, Drilon A, Subbiah V, Khoo C, Zhu EY, Nguyen M, Henry D, Condroski KR, Kolakowski GR, Gomez E, Ballard J, Metcalf AT, Blake JF, Dawson SJ, Blosser W, Stancato LF, Brandhuber BJ, Andrews S, Robinson BG, Rothenberg SM: RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. J Thorac Oncol. 2020 Apr;15(4):541-549. doi: 10.1016/j.jtho.2020.01.006. Epub 2020 Jan 24. (PubMed ID 31988000)" href="#reference-A202052">3</a>,<a class="reference-popover-link" data-content="FDA Approved Drug Products: Retevmo (selpercatinib) capsules" href="#reference-L13604">7</a></sup> Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including <a href="https://go.drugbank.com/drugs/DB08875">cabozantinib</a>, <a href="https://go.drugbank.com/drugs/DB08901">ponatinib</a>, <a href="https://go.drugbank.com/drugs/DB00398">sorafenib</a>, <a href="https://go.drugbank.com/drugs/DB01268">sunitinib</a>, and <a href="https://go.drugbank.com/drugs/DB05294">vandetanib</a>, have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Russo A, Lopes AR, McCusker MG, Garrigues SG, Ricciardi GR, Arensmeyer KE, Scilla KA, Mehra R, Rolfo C: New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1). Curr Oncol Rep. 2020 Apr 16;22(5):48. doi: 10.1007/s11912-020-00909-8. (PubMed ID 32296961)" href="#reference-A202049">2</a>,<a class="reference-popover-link" data-content="Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F: State-of-the-Art Strategies for Targeting RET-Dependent Cancers. J Clin Oncol. 2020 Apr 10;38(11):1209-1221. doi: 10.1200/JCO.19.02551. Epub 2020 Feb 21. (PubMed ID 32083997)" href="#reference-A202055">4</a>,<a class="reference-popover-link" data-content="Solomon BJ, Tan L, Lin JJ, Wong SQ, Hollizeck S, Ebata K, Tuch BB, Yoda S, Gainor JF, Sequist LV, Oxnard GR, Gautschi O, Drilon A, Subbiah V, Khoo C, Zhu EY, Nguyen M, Henry D, Condroski KR, Kolakowski GR, Gomez E, Ballard J, Metcalf AT, Blake JF, Dawson SJ, Blosser W, Stancato LF, Brandhuber BJ, Andrews S, Robinson BG, Rothenberg SM: RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. J Thorac Oncol. 2020 Apr;15(4):541-549. doi: 10.1016/j.jtho.2020.01.006. Epub 2020 Jan 24. (PubMed ID 31988000)" href="#reference-A202052">3</a>,<a class="reference-popover-link" data-content="FDA Approved Drug Products: Retevmo (selpercatinib) capsules" href="#reference-L13604">7</a></sup></p><p>Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMOâ¢ by Loxo Oncology Inc.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: Retevmo (selpercatinib) capsules" href="#reference-L13604">7</a></sup>

>  <uniprotId>  (248) 
P07949|P17948|P35916|P11362|P21802|P22607|P08684|P10632|P08684|Q9HB55|P20815|P24462|P08183|Q9UNQ0|Q96FL8

>  <MW>  (248) 
525.2

>  <HBA>  (248) 
10.0

>  <HBD>  (248) 
1.0

>  <NRB>  (248) 
8.0

>  <TPSA>  (248) 
112.0

>  <LogP>  (248) 
3.3

>  <RoF>  (248) 
1.0

>  <Melting point>  (248) 


>  <Targets>  (248) 
nan

>  <Kinase families>  (248) 


>  <FDA_approved>  (248) 
Y

$$$$
Selumetinib
     RDKit          2D

 27 29  0  0  0  0  0  0  0  0999 V2000
    5.7549   -2.6046    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0068   -1.3044    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.6189    0.0650    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5056    1.0703    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.2055    0.3222    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5152   -1.1455    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3991   -2.1476    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9731   -1.6820    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6634   -0.2143    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7796    0.7878    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4698    2.2555    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7625    0.2513    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0722    1.7190    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0439    2.7211    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2658    4.1887    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6917    4.6543    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8079    3.6522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4982    2.1846    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6143    1.1825    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -2.0015    6.1220    0.0000 Br  0  0  0  0  0  0  0  0  0  0  0  0
   -0.1430   -2.6840    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1667   -4.1517    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5689   -2.2184    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6851   -3.2205    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1110   -2.7549    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2272   -3.7570    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.6531   -3.2914    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
  9 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 16 20  1  0
  8 21  1  0
 21 22  2  0
 21 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
  6  2  1  0
 10  5  1  0
 18 13  1  0
M  END
>  <BrandName>  (249) 


>  <Applicants>  (249) 
Astrazeneca

>  <CHEMBL_ID>  (249) 
CHEMBL1614701

>  <Canonical_Smiles>  (249) 
Cn1cnc2c1cc(c(c2F)Nc3ccc(cc3Cl)Br)C(=O)NOCCO

>  <Chirality>  (249) 
Achiral Molecule

>  <First_Approval>  (249) 
2020

>  <Phase>  (249) 
4.0

>  <SC_Patent>  (249) 
US-7425637-B2

>  <Synonyms>  (249) 
ARRY-142886 | ARRY-886 | AZD-6244 | AZD6244 | SELUMETINIB

>  <Withdrawn>  (249) 
|Study NCT03109301 in nan was Withdrawn during Phase 2 because slow accrual

>  <Indications>  (249) 
On April 2020 FDA approved selumetinib to treat neurofibromatosis type 1, a genetic disorder of the nervous system causing tumors to grow on nerves.

>  <Type>  (249) 
3

>  <targets_id>  (249) 
Q02750|P36507

>  <inchi>  (249) 
InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)

>  <stdInchikey>  (249) 
CYOHGALHFOKKQC-UHFFFAOYSA-N

>  <csid>  (249) 
8303141

>  <Links>  (249) 
|http://www.chemspider.com/Chemical-Structure.8303141.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1614701|http://pubchem.ncbi.nlm.nih.gov/compound/10127622|http://www.drugbank.ca/drugs/DB11689| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=3EW|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/3EW|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5665|http://zinc15.docking.org/substances/ZINC31773258|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=6UH91I579U|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50355497

>  <LinkName>  (249) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (249) 
'3EW'

>  <pdbID>  (249) 
4u7z 6v32 7jut 7juz

>  <indicationG2P>  (249) 
None

>  <indicationDB>  (249) 
Activation of the Raf-MEK-ERK signaling pathway is known to be implemented in several types of malignancies, thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Ciombor KK, Bekaii-Saab T: Selumetinib for the treatment of cancer. Expert Opin Investig Drugs. 2015 Jan;24(1):111-123. doi: 10.1517/13543784.2015.982275. Epub 2014 Nov 11. (PubMed ID 25385055)" href="#reference-A193611">6</a></sup>Results from clinical trials investigating earlier developed MEK inhibitors were underwhelming.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Ciombor KK, Bekaii-Saab T: Selumetinib for the treatment of cancer. Expert Opin Investig Drugs. 2015 Jan;24(1):111-123. doi: 10.1517/13543784.2015.982275. Epub 2014 Nov 11. (PubMed ID 25385055)" href="#reference-A193611">6</a></sup> However, selumetinib demonstrated impressive efficacy and tolerability in Phase I trials, leading to its continued investigation for the treatment of various types of tumors in Phase II trials.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Ciombor KK, Bekaii-Saab T: Selumetinib for the treatment of cancer. Expert Opin Investig Drugs. 2015 Jan;24(1):111-123. doi: 10.1517/13543784.2015.982275. Epub 2014 Nov 11. (PubMed ID 25385055)" href="#reference-A193611">6</a></sup></p><p>Currently, the novel MEK 1 / 2 inhibitor, selumetinib, is approved solely for the treatment of Neurofibromatosis type 1 (NF-1) in a limited age group. NF-1 is considered rare with an estimated incidence of 1/3000 individuals.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Tchernev G, Chokoeva AA, Patterson JW, Bakardzhiev I, Wollina U, Tana C: Plexiform Neurofibroma: A Case Report. Medicine (Baltimore). 2016 Feb;95(6):e2663. doi: 10.1097/MD.0000000000002663. (PubMed ID 26871793)" href="#reference-A193608">5</a></sup> It is a genetic, autosomal dominant condition resulting from mutations of the NF1 gene, which can lead to various complications including the development of multiple tumors in the nervous system.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC: Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943. (PubMed ID 28029918)" href="#reference-A193533">3</a>,<a class="reference-popover-link" data-content="Tchernev G, Chokoeva AA, Patterson JW, Bakardzhiev I, Wollina U, Tana C: Plexiform Neurofibroma: A Case Report. Medicine (Baltimore). 2016 Feb;95(6):e2663. doi: 10.1097/MD.0000000000002663. (PubMed ID 26871793)" href="#reference-A193608">5</a></sup> Some patients with this disorder develop plexiform neurofibromas (PN); however, this is considered to be relatively uncommon compared to other variants of NF-1.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Tchernev G, Chokoeva AA, Patterson JW, Bakardzhiev I, Wollina U, Tana C: Plexiform Neurofibroma: A Case Report. Medicine (Baltimore). 2016 Feb;95(6):e2663. doi: 10.1097/MD.0000000000002663. (PubMed ID 26871793)" href="#reference-A193608">5</a></sup> Luckily, the use of selumetinib in patients with NF-1 has shown efficacy in shrinking associated tumors and is linked to other positive clinical outcomes.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC: Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943. (PubMed ID 28029918)" href="#reference-A193533">3</a></sup>

>  <uniprotId>  (249) 
Q02750|P36507|P33261|P08684|P11712|P05177|P10632|P05181|P20815|P22309|P35503|P02768|P02763|P19652|P08183|Q9UNQ0

>  <MW>  (249) 
456.0

>  <HBA>  (249) 
6.0

>  <HBD>  (249) 
3.0

>  <NRB>  (249) 
6.0

>  <TPSA>  (249) 
88.4

>  <LogP>  (249) 
3.5

>  <RoF>  (249) 
0.0

>  <Melting point>  (249) 


>  <Targets>  (249) 
MAP2K1; MAP2K2

>  <Kinase families>  (249) 
STE

>  <FDA_approved>  (249) 
Y

$$$$
Sorafenib
     RDKit          2D

 32 34  0  0  0  0  0  0  0  0999 V2000
  -11.0580   -0.4218    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.5714   -0.2220    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.6550   -1.4095    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.2252   -2.7969    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1684   -1.2096    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5982    0.1778    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1115    0.3777    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1951   -0.8098    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7653   -2.1972    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2520   -2.3971    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5413    1.7651    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0547    1.9650    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1383    0.7775    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6517    0.9773    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0815    2.3647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9979    3.5523    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4845    3.3524    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4052    2.5646    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.3216    1.3771    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7514   -0.0103    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.8082    1.5770    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.7246    0.3895    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1544   -0.9979    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0708   -2.1854    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5574   -1.9855    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1276   -0.5981    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2112    0.5894    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6143   -0.3983    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1009   -0.1984    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    8.4144    1.0884    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    8.8142   -1.8849    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    7.4739   -3.1730    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  3  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
  7 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 15 18  1  0
 18 19  1  0
 19 20  2  0
 19 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 26 28  1  0
 28 29  1  0
 28 30  1  0
 28 31  1  0
 25 32  1  0
 10  5  1  0
 17 12  1  0
 27 22  1  0
M  END
>  <BrandName>  (250) 
Nexavar

>  <Applicants>  (250) 
Bayer

>  <CHEMBL_ID>  (250) 
CHEMBL1336

>  <Canonical_Smiles>  (250) 
CNC(=O)c1cc(ccn1)Oc2ccc(cc2)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl

>  <Chirality>  (250) 
Achiral Molecule

>  <First_Approval>  (250) 
2005

>  <Phase>  (250) 
4.0

>  <SC_Patent>  (250) 
US-7235576-B1

>  <Synonyms>  (250) 
BAY 43-9006 | BAY-43-9006 | NEXAVAR | SORAFENIB

>  <Withdrawn>  (250) 
|Study NCT01441388 in nan was Withdrawn during Phase 1 because Business/Operational issues|Study NCT02227914 in United States was Withdrawn during Phase 1/Phase 2 because Study stopped due to administrative reasons|Study NCT02989870 in United States was Withdrawn during Phase 1 because No Interest Investigator was unable to enroll any participants on study|Study NCT02599090 in nan was Withdrawn during Phase 2 because Multi phase study did not progress to Phase II Phase I registered as NCT00734526|Study NCT00627835 in Canada was Withdrawn during Phase 1 because Site decided not to open this study|Study NCT02908165 in United States was Withdrawn during Phase 2 because A future study will be taking place using the same patient population|Study NCT01736878 in Germany was Withdrawn during Phase 2 because Study was withdrawn due to unanticipated hassle in patient recruitment|Study NCT02129322 in China was Withdrawn during Phase 2 because patients not enrolled|Study NCT02691780 in Korea, Republic of was Withdrawn during N/A because not enrolled|Study NCT03563170 in United States was Withdrawn during Phase 1/Phase 2 because Enrollment not initiated|Study NCT03780634 in China was Withdrawn during Phase 2 because No participants enrolled|Study NCT01851408 in nan was Withdrawn during Phase 2 because No progression of Phase 1 trial to Phase 2|Study NCT01801163 in United States was Withdrawn during Phase 1 because Trial had no patients accrued while open|Study NCT02747537 in nan was Withdrawn during Phase 2 because Could not recruit participants for the study|Study NCT02288507 in United States was Withdrawn during Phase 1 because Closed due to no accrual|Study NCT00808145 in United States was Withdrawn during Phase 2 because Lack of enrollment, many screen failures and non eligible study participants|Study NCT02406508 in United States was Withdrawn during Phase 2 because No enrollment in the study|Study NCT00547443 in United States was Withdrawn during Phase 1/Phase 2 because Withdrawn as the sponsor has stopped the drug for NSCLC population|Study NCT01618253 in United States was Withdrawn during Phase 1 because Closed due to poor accrual

>  <Indications>  (250) 
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.

>  <Type>  (250) 
2

>  <targets_id>  (250) 
P15056|P04049|P35916|P35968|P36888|P09619|P10721|P11362|P07949|P17948

>  <inchi>  (250) 
InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)

>  <stdInchikey>  (250) 
MLDQJTXFUGDVEO-UHFFFAOYSA-N

>  <csid>  (250) 
187440

>  <Links>  (250) 
|http://www.chemspider.com/Chemical-Structure.187440.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1336|http://pubchem.ncbi.nlm.nih.gov/compound/216239|http://www.drugbank.ca/drugs/DB07438| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=BAX|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/BAX|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5711|http://zinc15.docking.org/substances/ZINC01493878|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=9ZOQ3TZI87|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16673

>  <LinkName>  (250) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (250) 
'BAX'

>  <pdbID>  (250) 
1uwh 1uwj 3gcs 3heg 3rgf 3wze 4asd 5hi2

>  <indicationG2P>  (250) 
None

>  <indicationDB>  (250) 
Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received &quot;Fast Track&quot; designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials.Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 &amp; 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway.

>  <uniprotId>  (250) 
P15056|P04049|P35916|P35968|P36888|P09619|P10721|P11362|P07949|P17948|P11712|P20815|P24462|P08684|P20813|P10632|P05177|P33261|P10635|O60656|P22309

>  <MW>  (250) 
464.1

>  <HBA>  (250) 
4.0

>  <HBD>  (250) 
3.0

>  <NRB>  (250) 
5.0

>  <TPSA>  (250) 
92.3

>  <LogP>  (250) 
5.5

>  <RoF>  (250) 
1.0

>  <Melting point>  (250) 
205.6 Â°C

>  <Targets>  (250) 
BRAF; RAF1; FLT4; KDR; FLT3; PDGFRB; KIT; FGFR1; RET; FLT1

>  <Kinase families>  (250) 
TKL<br>Tyr

>  <FDA_approved>  (250) 
Y

$$$$
Sunitinib
     RDKit          2D

 29 31  0  0  0  0  0  0  0  0999 V2000
  -10.2315    0.8288    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.8053    1.2934    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.6898    0.2905    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.0006   -1.1769    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.4268   -1.6415    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2635    0.7551    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1481   -0.2477    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.7218    0.2168    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6064   -0.7860    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9171   -2.2535    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1801   -0.3214    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0341   -1.2022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2469   -0.3196    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7823    1.1066    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7177    1.1055    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6003    2.3184    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6738   -0.7821    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7878    0.2225    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2553   -0.0883    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0062   -1.3868    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5062   -1.3856    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2553   -0.0860    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5043    1.2124    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0043    1.2113    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9998    2.3253    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.6299    1.7141    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3303    2.4632    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.2572   -2.6841    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    0.0352   -2.7022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  3  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
  9 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 13 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  1  0
 26 27  2  0
 21 28  1  0
 12 29  1  0
 15 11  2  0
 18 26  1  0
 24 19  1  0
M  END
>  <BrandName>  (251) 
Sutent

>  <Applicants>  (251) 
Cp Pharmaceuticals

>  <CHEMBL_ID>  (251) 
CHEMBL535

>  <Canonical_Smiles>  (251) 
CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)F)C

>  <Chirality>  (251) 
Achiral Molecule

>  <First_Approval>  (251) 
2006

>  <Phase>  (251) 
4.0

>  <SC_Patent>  (251) 
US-6573293-B2

>  <Synonyms>  (251) 
SU-011248 | SU-11248 | SU011248 | SUNITINIB | SUTENT

>  <Withdrawn>  (251) 
|Study NCT00748163 in nan was Withdrawn during Phase 2 because Study has been abandoned for lack of available funding|Study NCT01441388 in nan was Withdrawn during Phase 1 because Business/Operational issues|Study NCT00556205 in nan was Withdrawn during Phase 2 because Toxicity of combination from other trials|Study NCT00936832 in France was Withdrawn during Phase 2 because because the sunitinib showed futility in anotehr trial|Study NCT02400385 in United States was Withdrawn during Phase 2 because With recent advances in immunotherapy scientific question not significant|Study NCT01070186 in nan was Withdrawn during Phase 2 because No participants were enrolled|Study NCT03323710 in Poland was Withdrawn during Phase 2 because Poor patient recruitment|Study NCT03035630 in United States was Withdrawn during Phase 2 because Principal investigator left lead institution and efforts to open the protocol at another    institution were not successful|Study NCT03275558 in Singapore was Withdrawn during Phase 1 because Study halted prior to enrollment of first participant (It has been determined on 2018 May 15    that the NCT03275558 study will be stopped by sponsor decision)|Study NCT00521092 in nan was Withdrawn during Phase 2 because No participants enrolled

>  <Indications>  (251) 
For the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.

>  <Type>  (251) 
1

>  <targets_id>  (251) 
P09619|P17948|P10721|P35968|P35916|P36888|P07333|P16234

>  <inchi>  (251) 
InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-

>  <stdInchikey>  (251) 
WINHZLLDWRZWRT-ATVHPVEESA-N

>  <csid>  (251) 
4486264

>  <Links>  (251) 
|http://www.chemspider.com/Chemical-Structure.4486264.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL535|http://pubchem.ncbi.nlm.nih.gov/compound/5329102|http://www.drugbank.ca/drugs/DB07417| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=B49|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/B49|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5713|http://zinc15.docking.org/substances/ZINC000003964325|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=V99T50803M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=4814

>  <LinkName>  (251) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (251) 
'B49'

>  <pdbID>  (251) 
2y7j 3g0e 3g0f 3miy 3ti1 4agd 4ks8 4qmz 6jok 6m11 6nfy 6nfz 6ng0 6v0x

>  <indicationG2P>  (251) 
None

>  <indicationDB>  (251) 
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.

>  <uniprotId>  (251) 
P09619|P17948|P10721|P35968|P35916|P36888|P07333|P16234|P20815|P24462|P08684|O15439|P08183|Q92887|Q9UNQ0

>  <MW>  (251) 
398.2

>  <HBA>  (251) 
3.0

>  <HBD>  (251) 
3.0

>  <NRB>  (251) 
7.0

>  <TPSA>  (251) 
77.2

>  <LogP>  (251) 
3.3

>  <RoF>  (251) 
0.0

>  <Melting point>  (251) 


>  <Targets>  (251) 
PDGFRB; FLT1; KIT; KDR; FLT4; FLT3; CSF1R; PDGFRA

>  <Kinase families>  (251) 
Tyr

>  <FDA_approved>  (251) 
Y

$$$$
Midostaurin
     RDKit          2D

 43 51  0  0  0  0  0  0  0  0999 V2000
    1.0953   -2.7367    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2511   -1.4969    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7547   -1.5053    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6004   -0.2665    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9504    1.0854    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4547    1.1983    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0019   -0.1983    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9784    1.6413    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3982    3.0814    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6089    4.3569    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3190    5.6783    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8183    5.7240    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6075    4.4485    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8975    3.1271    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4043    1.7154    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2183    0.7971    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3313   -0.6987    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2323   -1.7196    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8636   -3.0802    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2749   -4.4599    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1753   -5.6595    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6645   -5.4796    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2532   -4.0999    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3528   -2.9003    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6418   -1.4284    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8692   -0.4304    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7562    1.0653    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1438    1.6350    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4986    3.0924    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1144    0.4913    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3266   -0.7852    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0962   -0.3794    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.7462   -1.7313    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9419    0.8594    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2919    2.2112    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.4376    0.7464    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0877   -0.6054    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5834   -0.7184    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4291    0.5205    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7791    1.8723    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2833    1.9853    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4048   -2.8572    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.5590   -4.0960    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  6
  2  3  1  0
  3  4  1  0
  4  5  1  0
  6  5  1  1
  6  7  1  0
  6  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 28 30  1  0
 30 31  1  0
  4 32  1  1
 32 33  1  0
 32 34  1  0
 34 35  2  0
 34 36  1  0
 36 37  2  0
 37 38  1  0
 38 39  2  0
 39 40  1  0
 40 41  2  0
  3 42  1  1
 42 43  1  0
  7  2  1  0
 18  2  1  0
 16  8  1  0
 14  9  1  0
 27 15  1  0
 25 17  2  0
 24 19  1  0
 31 26  1  0
 41 36  1  0
M  END
>  <BrandName>  (252) 
Rydapt

>  <Applicants>  (252) 
Novartis Pharmaceuticals Corp

>  <CHEMBL_ID>  (252) 
CHEMBL608533

>  <Canonical_Smiles>  (252) 
C[C@@]12[C@@H]([C@@H](C[C@@H](O1)n3c4ccccc4c5c3c6n2c7ccccc7c6c8c5C(=O)NC8)N(C)C(=O)c9ccccc9)OC

>  <Chirality>  (252) 
Single Stereoisomer

>  <First_Approval>  (252) 
2017

>  <Phase>  (252) 
4.0

>  <SC_Patent>  (252) 
US-7973031-B2

>  <Synonyms>  (252) 
CGP 41251 | CGP-41251 | MIDOSTAURIN | NVP-PKC412 | PKC 412 | PKC-412 | RYDAPT

>  <Withdrawn>  (252) 
|Study NCT03207334 in United States was Withdrawn during Phase 2 because Insufficient funding|Study NCT02723435 in nan was Withdrawn during Phase 2 because Logistical and administrative issues|Study NCT03760445 in nan was Withdrawn during Phase 1/Phase 2 because It was determined that the study design may not be optimal given the changing AML treatment    landscape

>  <Indications>  (252) 
On april 28 , 2017, the FDA approved midostaurin to  treat acute myeloid leukemia

>  <Type>  (252) 
nan

>  <targets_id>  (252) 
nan

>  <inchi>  (252) 
InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1

>  <stdInchikey>  (252) 
BMGQWWVMWDBQGC-IIFHNQTCSA-N

>  <csid>  (252) 
8005258

>  <Links>  (252) 
|http://www.chemspider.com/Chemical-Structure.8005258.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL608533|http://pubchem.ncbi.nlm.nih.gov/compound/9829523|http://www.drugbank.ca/drugs/DB06595| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=2K2|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/2K2|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5702|http://zinc15.docking.org/substances/ZINC000100013130|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=ID912S5VON|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50326053

>  <LinkName>  (252) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (252) 
'2K2'

>  <pdbID>  (252) 
4nct

>  <indicationG2P>  (252) 
None

>  <indicationDB>  (252) 
Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors <sup class="text-reference-group"><a class="reference-popover-link" data-content="Gallogly MM, Lazarus HM: Midostaurin: an emerging treatment for acute myeloid leukemia patients. J Blood Med. 2016 Apr 19;7:73-83. doi: 10.2147/JBM.S100283. eCollection 2016. (PubMed ID 27186148)" href="#reference-A19108">4</a></sup>. It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.

>  <uniprotId>  (252) 
P17252|P35968|P10721|P16234|P09619|P36888|P08684|Q9HB55|P20815|P24462|P05177|P20813|P10632|P11712|P33261|P10635|P05181|P08684|P20815|P24462|Q9HB55

>  <MW>  (252) 
570.2

>  <HBA>  (252) 
6.0

>  <HBD>  (252) 
1.0

>  <NRB>  (252) 
3.0

>  <TPSA>  (252) 
77.7

>  <LogP>  (252) 
5.9

>  <RoF>  (252) 
2.0

>  <Melting point>  (252) 
235-260

>  <Targets>  (252) 
nan

>  <Kinase families>  (252) 


>  <FDA_approved>  (252) 
Y

$$$$
Lorlatinib
     RDKit          2D

 30 33  0  0  0  0  0  0  0  0999 V2000
    3.4946   -2.8833    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3844   -1.8746    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0713   -0.5411    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4048   -1.2281    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6664   -0.4167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5946    1.0816    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2611    1.7685    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9995    0.9571    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1881    2.2188    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1967    3.3290    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.8546    2.9057    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6436    2.8338    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9053    2.0225    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5922    0.6890    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0727    0.9302    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3007    2.4128    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9612    3.0878    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6342    3.0997    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1380   -0.1257    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2034   -1.1816    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5203   -0.8093    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7090   -2.0709    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3755   -2.7578    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6060   -3.6665    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0718   -3.3481    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5290   -1.9195    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1488   -5.0952    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.1228   -2.6860    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.1730    4.3715    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9999   -1.1036    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  1
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
  9 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  1  0
 16 18  1  0
 15 19  1  0
 19 20  3  0
 14 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 24 27  1  0
 23 28  1  0
 11 29  1  0
  5 30  1  0
 28  2  1  0
  8  3  1  0
 17 13  2  0
 26 21  2  0
M  END
>  <BrandName>  (253) 
Lorbrena

>  <Applicants>  (253) 
Pfizer

>  <CHEMBL_ID>  (253) 
CHEMBL3286830

>  <Canonical_Smiles>  (253) 
C[C@@H]1c2cc(ccc2C(=O)N(Cc3c(c(n(n3)C)C#N)-c4cc(c(nc4)N)O1)C)F

>  <Chirality>  (253) 
Single Stereoisomer

>  <First_Approval>  (253) 
2018

>  <Phase>  (253) 
4.0

>  <SC_Patent>  (253) 
US-8680111-B2

>  <Synonyms>  (253) 
LORBRENA | LORLATINIB | PF-06463922

>  <Withdrawn>  (253) 


>  <Indications>  (253) 
On november 2, 2018, the FDA approved lorlatinib to treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer

>  <Type>  (253) 
1

>  <targets_id>  (253) 
Q9UM73|P08922

>  <inchi>  (253) 
InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1

>  <stdInchikey>  (253) 
IIXWYSCJSQVBQM-LLVKDONJSA-N

>  <csid>  (253) 
32813339

>  <Links>  (253) 
|http://www.chemspider.com/Chemical-Structure.32813339.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3286830|http://pubchem.ncbi.nlm.nih.gov/compound/71731823|http://www.drugbank.ca/drugs/DB12130| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=5P8|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/5P8|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7476|http://zinc15.docking.org/substances/ZINC000098208524|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=OSP71S83EU|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50018830

>  <LinkName>  (253) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (253) 
'5P8'

>  <pdbID>  (253) 
4cli 4clj 4uxl 5a9u 5aa8 5aa9

>  <indicationG2P>  (253) 
None

>  <indicationDB>  (253) 
Lorlatinib has been used in trials studying the basic science and treatment of Non-small Cell Lung Cancer and anaplastic lymphoma kinase (ALK)-positive Non-Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC. Despite initial responses from the use of various ALK inhibitors, however, it is virtually almost guaranteed that all patients with the condition in question will develop tumour progression or resistance to the current therapy in use <sup class="text-reference-group"><a class="reference-popover-link" data-content="Waqar SN, Morgensztern D: Lorlatinib: a new-generation drug for ALK-positive NSCLC. Lancet Oncol. 2018 Dec;19(12):1555-1557. doi: 10.1016/S1470-2045(18)30789-7. Epub 2018 Nov 6. (PubMed ID 30413381)" href="#reference-A40086">9</a></sup>.</p><p>Considered a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic NSCLC, lorlatinib&#39;s most optimal place in the treatment sequence of this condition has most recently been identified with its latest approval by the US FDA in November of 2018 for the indication of treating those patients&#39; disease which has progressed even after the use of first and second-generation TKIs like crizotinib, alectinib, or ceritinib <sup class="text-reference-group"><a class="reference-popover-link" data-content="Drugs.com: FDA Approves Lorbrena" href="#reference-L4848">10</a>,<a class="reference-popover-link" data-content="Official drug label" href="#label-reference">Label</a></sup>. Loratinib&#39;s ability to move past the blood-brain barrier facilitates its ability to treat progressive or worsening brain metastases as well <sup class="text-reference-group"><a class="reference-popover-link" data-content="Drugs.com: FDA Approves Lorbrena" href="#reference-L4848">10</a>,<a class="reference-popover-link" data-content="Collier TL, Maresca KP, Normandin MD, Richardson P, McCarthy TJ, Liang SH, Waterhouse RN, Vasdev N: Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET. Mol Imaging. 2017 Jan-Dec;16:1536012117736669. doi: 10.1177/1536012117736669. (PubMed ID 29067878)" href="#reference-A40078">5</a></sup>.

>  <uniprotId>  (253) 
Q9UM73

>  <MW>  (253) 
406.2

>  <HBA>  (253) 
7.0

>  <HBD>  (253) 
1.0

>  <NRB>  (253) 
0.0

>  <TPSA>  (253) 
110.1

>  <LogP>  (253) 
2.8

>  <RoF>  (253) 
0.0

>  <Melting point>  (253) 


>  <Targets>  (253) 
ALK; ROS1

>  <Kinase families>  (253) 
Tyr

>  <FDA_approved>  (253) 
Y

$$$$
Tivozanib
     RDKit          2D

 32 35  0  0  0  0  0  0  0  0999 V2000
  -11.2699    1.0431    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.7776    0.8912    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.0234   -0.4054    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.5572   -0.0887    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4053    1.4035    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7776    2.0092    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4392   -1.0888    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0142   -0.6206    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7071    0.8476    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8962   -1.6207    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4711   -1.1525    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3531   -2.1526    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0719   -1.6844    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3790   -0.2162    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7390    0.7839    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1640    0.3157    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2820    1.3158    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    1.8041    0.2520    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.9221   -0.7480    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6150   -2.2163    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7330   -3.2163    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1580   -2.7482    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.4651   -1.2799    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3471   -0.2799    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6542    1.1884    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0793    1.6565    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1973    0.6565    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8902   -0.8118    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6223    1.1246    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.7403    0.1246    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3864    3.1248    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.8114    3.5929    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  4  7  1  0
  7  8  1  0
  8  9  2  0
  8 10  1  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 14 18  1  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 27 29  1  0
 29 30  1  0
 26 31  1  0
 31 32  1  0
  6  2  1  0
 16 11  1  0
 24 19  1  0
 28 23  1  0
M  END
>  <BrandName>  (254) 
Fotivda

>  <Applicants>  (254) 
Aveo Pharmaceuticals

>  <CHEMBL_ID>  (254) 
CHEMBL1289494

>  <Canonical_Smiles>  (254) 
Cc1cc(no1)NC(=O)Nc2ccc(cc2Cl)Oc3ccnc4c3cc(c(c4)OC)OC

>  <Chirality>  (254) 
Achiral Molecule

>  <First_Approval>  (254) 
2021

>  <Phase>  (254) 
4.0

>  <SC_Patent>  (254) 
None

>  <Synonyms>  (254) 
ASP-4130 | AV-951 | FOTIVDA | KIL-8951 | KIL8951 | KRN-951 | TIVOZANIB

>  <Withdrawn>  (254) 
|Study NCT01728181 in nan was Withdrawn during Phase 1/Phase 2 because Stopped before approval due to ineffective drug

>  <Indications>  (254) 
On March 2021, FDA approved tivozanib to treat patients with renal cell carcinoma

>  <Type>  (254) 
2

>  <targets_id>  (254) 
P17948|P35968|P35916

>  <inchi>  (254) 
InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)

>  <stdInchikey>  (254) 
SPMVMDHWKHCIDT-UHFFFAOYSA-N

>  <csid>  (254) 
8087481

>  <Links>  (254) 
|http://www.chemspider.com/Chemical-Structure.8087481.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1289494|http://pubchem.ncbi.nlm.nih.gov/compound/9911830|http://www.drugbank.ca/drugs/DB11800| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=AV9|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/AV9|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6058|http://zinc15.docking.org/substances/ZINC01489430|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=172030934T|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50331095

>  <LinkName>  (254) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (254) 
'AV9'

>  <pdbID>  (254) 
4ase

>  <indicationG2P>  (254) 
None

>  <indicationDB>  (254) 
Renal cell carcinoma (RCC) is responsible for 3% of cancer cases<sup class="text-reference-group"><a class="reference-popover-link" data-content="Pallagani L, Choudhary GR, Himanshu P, Madduri VKS, Singh M, Gupta P, Shrivastava N, Baid G, Meenakshi R, Aasma N, Pareek P, Sanjeev M: Epidemiology and Clinicopathological Profile of Renal Cell Carcinoma: A Review from Tertiary Care Referral Centre. J Kidney Cancer VHL. 2021 Jan 20;8(1):1-6. doi: 10.15586/jkcvhl.2021.154. eCollection 2021. (PubMed ID 33552876)" href="#reference-A231314">2</a></sup> and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Cancer.org: Key Statistics About Kidney Cancer" href="#reference-L32529">10</a></sup> Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapies. It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: FOTIVDA (tivozanib) capsules, for oral use" href="#reference-L32524">9</a></sup>

>  <uniprotId>  (254) 
P17948|P35968|P35916|P10721|P09619|P36888|P16234|Q13882|Q02763|P11362|P08581|P08684|P02768|P08183|Q9UNQ0

>  <MW>  (254) 
454.1

>  <HBA>  (254) 
7.0

>  <HBD>  (254) 
2.0

>  <NRB>  (254) 
6.0

>  <TPSA>  (254) 
107.7

>  <LogP>  (254) 
5.6

>  <RoF>  (254) 
1.0

>  <Melting point>  (254) 


>  <Targets>  (254) 
FLT1; KDR; FLT4

>  <Kinase families>  (254) 
Tyr

>  <FDA_approved>  (254) 
Y

$$$$
Tofacitinib
     RDKit          2D

 23 25  0  0  0  0  0  0  0  0999 V2000
    1.2305   -4.2699    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2250   -3.1568    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2417   -3.4711    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2473   -2.3581    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7861   -0.9307    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3194   -0.6164    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6861   -1.7295    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1528   -1.4151    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.1584   -2.5282    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6139    0.0122    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6084    1.1252    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1084    1.1227    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3575    2.5485    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8545    3.4323    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0695    2.5526    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5362    2.8669    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.5418    1.7539    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0806    0.3265    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7917    0.1823    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3306    1.6097    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2584   -0.1320    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2640    0.9810    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2695    2.0941    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  6
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  6
  8  9  1  0
  8 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
  5 19  1  0
 19 20  2  0
 19 21  1  0
 21 22  1  0
 22 23  3  0
  7  2  1  0
 18 10  1  0
 15 11  1  0
M  END
>  <BrandName>  (255) 
Xeljanz

>  <Applicants>  (255) 
Pfizer

>  <CHEMBL_ID>  (255) 
CHEMBL221959

>  <Canonical_Smiles>  (255) 
C[C@@H]1CCN(C[C@@H]1N(C)c2c3cc[nH]c3ncn2)C(=O)CC#N

>  <Chirality>  (255) 
Single Stereoisomer

>  <First_Approval>  (255) 
2012

>  <Phase>  (255) 
4.0

>  <SC_Patent>  (255) 
US-6956041-B2

>  <Synonyms>  (255) 
550 | CP 690550 | CP- 690 550 | CP-690 | CP-690,550 | CP-690,550 FREE BASE | CP-690-550 | CP-690550 | CP-690550 FREE BASE | CP690,550 | CP690550 | TASOCITINIB | TOFACITINIB

>  <Withdrawn>  (255) 
|Study NCT04412252 in United States was Withdrawn during Phase 2 because Due to the pursuit of other SARS-CoV-2-related research including alternative trials with    tofacitinib, this trial was canceled prior to subject enrollment

>  <Indications>  (255) 
For the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy. It may also be used as an adjunct to methotrexate therapy, or other non-biologic disease-modifying antirheumatic drugs (DMARDS), when methotrexate alone is not sufficient. Tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections, and as a treatment for psoriasis, ulcerative colitis, and ankylosing spondylitis. It is not to be initiated in patients with a history of chronic or recurrent infections, or in the presence of active infection, even if localized, due to reports of serious and sometimes fatal infections (commonly pneumonia, herpes zoster and urinary tract infections). Use of tofacitinib is also discouraged in those who have been, or are likely to be, exposed to TB. An increased likelihood of exposure may be encountered by traveling to certain areas. In addition, tofacitinib is not to be used in patients with severe hepatic impairment, or low hemoglobin (less than 9g/dL). Cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation, and in the elderly who are more susceptible to infection.

>  <Type>  (255) 
1

>  <targets_id>  (255) 
P23458|O60674|P52333|P29597

>  <inchi>  (255) 
InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1

>  <stdInchikey>  (255) 
UJLAWZDWDVHWOW-YPMHNXCESA-N

>  <csid>  (255) 
8102425

>  <Links>  (255) 
|http://www.chemspider.com/Chemical-Structure.8102425.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL221959|http://pubchem.ncbi.nlm.nih.gov/compound/9926791|http://www.drugbank.ca/drugs/DB08895| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=MI1|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/MI1|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5677|http://zinc15.docking.org/substances/ZINC03818808|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=87LA6FU830|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50193995

>  <LinkName>  (255) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (255) 
'MI1'

>  <pdbID>  (255) 
3eyg 3fup 3lxk 3lxn 4oti

>  <indicationG2P>  (255) 
None

>  <indicationDB>  (255) 
Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate.Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer.

>  <uniprotId>  (255) 
P23458|O60674|P52333|P29597|P08684|P33261

>  <MW>  (255) 
312.2

>  <HBA>  (255) 
5.0

>  <HBD>  (255) 
1.0

>  <NRB>  (255) 
3.0

>  <TPSA>  (255) 
88.9

>  <LogP>  (255) 
1.5

>  <RoF>  (255) 
0.0

>  <Melting point>  (255) 


>  <Targets>  (255) 
JAK1; JAK2; JAK3; TYK2

>  <Kinase families>  (255) 
Tyr

>  <FDA_approved>  (255) 
Y

$$$$
Dacomitinib
     RDKit          2D

 33 36  0  0  0  0  0  0  0  0999 V2000
   -2.4626    3.7377    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1170    2.2781    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6802    1.8475    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4111    2.8767    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8480    2.4461    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1936    0.9865    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1023   -0.0426    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3346    0.3879    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4259   -0.6412    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8627   -0.2107    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2083    1.2490    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9540   -1.2398    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3909   -0.8093    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4822   -1.8384    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.9191   -1.4079    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.2647    0.0518    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.7016    0.4823    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.7929   -0.5468    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.4473   -2.0065    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.0104   -2.4370    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6305    0.5560    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7218    1.5851    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.3762    3.0447    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9393    3.4752    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.9761   -0.9037    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.4130   -1.3342    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7586   -2.7939    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1955   -3.2244    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2868   -2.1953    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9412   -0.7356    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5043   -0.3051    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0325    0.2935    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    9.7237   -2.6258    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  1  0
 10 11  2  0
 10 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
  6 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 21 25  1  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 30 32  1  0
 29 33  1  0
  8  3  1  0
 24  5  1  0
 20 15  1  0
 31 26  1  0
M  END
>  <BrandName>  (256) 
Vizimpro

>  <Applicants>  (256) 
Pfizer

>  <CHEMBL_ID>  (256) 
CHEMBL2110732

>  <Canonical_Smiles>  (256) 
COc1cc2c(cc1NC(=O)/C=C/CN3CCCCC3)c(ncn2)Nc4ccc(c(c4)Cl)F

>  <Chirality>  (256) 
Achiral Molecule

>  <First_Approval>  (256) 
2018

>  <Phase>  (256) 
4.0

>  <SC_Patent>  (256) 
US-7772243-B2

>  <Synonyms>  (256) 
DACOMITINIB | DACOMITINIB HYDRATE | PF-00299804

>  <Withdrawn>  (256) 


>  <Indications>  (256) 
On october 27, 2018, the FDA approved dacomitinib to treat metastatic non-small-cell lung cancer

>  <Type>  (256) 
1

>  <targets_id>  (256) 
P00533

>  <inchi>  (256) 
InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+

>  <stdInchikey>  (256) 
LVXJQMNHJWSHET-AATRIKPKSA-N

>  <csid>  (256) 
9685914

>  <Links>  (256) 
|http://www.chemspider.com/Chemical-Structure.9685914.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2110732|http://pubchem.ncbi.nlm.nih.gov/compound/11511120|http://www.drugbank.ca/drugs/DB11963| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=1C9|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/1C9|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7422|http://zinc15.docking.org/substances/ZINC000072266312|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=2XJX250C20|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=112499

>  <LinkName>  (256) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (256) 
'1C9'

>  <pdbID>  (256) 
4i23 4i24

>  <indicationG2P>  (256) 
None

>  <indicationDB>  (256) 
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Brzezniak C, Carter CA, Giaccone G: Dacomitinib, a new therapy for the treatment of non-small cell lung cancer. Expert Opin Pharmacother. 2013 Feb;14(2):247-53. doi: 10.1517/14656566.2013.758714. Epub 2013 Jan 7. (PubMed ID 23294134)" href="#reference-A40009">2</a></sup></p><p>Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approval" href="#reference-L4810">14</a></sup> Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model<sup class="text-reference-group"><a class="reference-popover-link" data-content="Momeny M, Zarrinrad G, Moghaddaskho F, Poursheikhani A, Sankanian G, Zaghal A, Mirshahvaladi S, Esmaeili F, Eyvani H, Barghi F, Sabourinejad Z, Alishahi Z, Yousefi H, Ghasemi R, Dardaei L, Bashash D, Chahardouli B, Dehpour AR, Tavakkoly-Bazzaz J, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH: Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells. Sci Rep. 2017 Jun 23;7(1):4204. doi: 10.1038/s41598-017-04147-0. (PubMed ID 28646172)" href="#reference-A39624">1</a></sup>, although further investigations are needed.

>  <uniprotId>  (256) 
P00533|P10635|P08684|P11712|P22309

>  <MW>  (256) 
469.2

>  <HBA>  (256) 
6.0

>  <HBD>  (256) 
2.0

>  <NRB>  (256) 
7.0

>  <TPSA>  (256) 
79.4

>  <LogP>  (256) 
5.2

>  <RoF>  (256) 
1.0

>  <Melting point>  (256) 
184-187 ÂºC

>  <Targets>  (256) 
EGFR

>  <Kinase families>  (256) 
Tyr

>  <FDA_approved>  (256) 
Y

$$$$
Gilteritinib
     RDKit          2D

 40 44  0  0  0  0  0  0  0  0999 V2000
    6.9789   -3.4293    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4421   -2.0026    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4382   -0.8881    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9711   -1.2002    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9672   -0.0857    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.4304    1.3410    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8976    1.6532    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9015    0.5386    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.3609    3.0798    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3570    4.1944    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.8280    3.3920    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.4265    2.4555    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.9594    2.1434    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9555    3.2579    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5117    2.9458    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9750    1.5191    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0289    0.4046    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4961    0.7167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4343   -1.0221    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9015   -1.3342    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4421    1.2070    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4460    2.3215    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9132    2.0094    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3765    0.5827    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3725   -0.5318    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9054   -0.2197    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.8436    0.2706    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.8475    1.3851    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.3147    1.0730    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.7779   -0.3537    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.7740   -1.4682    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.3069   -1.1561    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -11.2451   -0.6659    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5078   -2.6269    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.0406   -2.9390    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0367   -1.8245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5696   -2.1366    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1063   -3.5633    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.1102   -4.6778    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5774   -4.3657    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  7  9  1  0
  9 10  2  0
  9 11  1  0
  6 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 17 19  1  0
 19 20  1  0
 16 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 24 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 30 33  1  0
  4 34  1  0
 34 35  1  0
 35 36  1  0
 36 37  1  0
 37 38  1  0
 38 39  1  0
 39 40  1  0
  8  3  1  0
 18 13  1  0
 26 21  1  0
 32 27  1  0
 40 35  1  0
M  END
>  <BrandName>  (257) 
Xospata

>  <Applicants>  (257) 
Astellas Pharma

>  <CHEMBL_ID>  (257) 
CHEMBL3301622

>  <Canonical_Smiles>  (257) 
CCc1c(nc(c(n1)C(=O)N)Nc2ccc(c(c2)OC)N3CCC(CC3)N4CCN(CC4)C)NC5CCOCC5

>  <Chirality>  (257) 
Achiral Molecule

>  <First_Approval>  (257) 
2018

>  <Phase>  (257) 
4.0

>  <SC_Patent>  (257) 
US-8969336-B2

>  <Synonyms>  (257) 
ASP-2215 | ASP2215 | GILTERITINIB

>  <Withdrawn>  (257) 


>  <Indications>  (257) 
On november 28, 2018, the FDA approved gilteritinib to treat patients who have relapsed or refractory acute myeloid leukemia (AML)

>  <Type>  (257) 
nan

>  <targets_id>  (257) 
P36888|P30530|Q9UM73

>  <inchi>  (257) 
InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)

>  <stdInchikey>  (257) 
GYQYAJJFPNQOOW-UHFFFAOYSA-N

>  <csid>  (257) 
32055842

>  <Links>  (257) 
|http://www.chemspider.com/Chemical-Structure.32055842.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3301622|http://pubchem.ncbi.nlm.nih.gov/compound/49803313|http://www.drugbank.ca/drugs/DB12141| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=C6F|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/C6F|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8708|http://zinc15.docking.org/substances/ZINC000113476229|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=66D92MGC8M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=144315

>  <LinkName>  (257) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (257) 
'C6F'

>  <pdbID>  (257) 
6jqr 7ab1

>  <indicationG2P>  (257) 
None

>  <indicationDB>  (257) 
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Stone RM: What FLT3 inhibitor holds the greatest promise? Best Pract Res Clin Haematol. 2018 Dec;31(4):401-404. doi: 10.1016/j.beha.2018.09.008. Epub 2018 Sep 20. (PubMed ID 30466756)" href="#reference-A40036">1</a></sup> It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Lee LY, Hernandez D, Rajkhowa T, Smith SC, Raman JR, Nguyen B, Small D, Levis M: Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood. 2017 Jan 12;129(2):257-260. doi: 10.1182/blood-2016-10-745133. Epub 2016 Dec 1. (PubMed ID 27908881)" href="#reference-A40044">5</a></sup> Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA news" href="#reference-L4830">7</a></sup>

>  <uniprotId>  (257) 
P36888|P08908|P28222|P28221|P28566|P30939|P28223|P41595|P28335|P46098|O95264|Q8WXA8|Q70Z44|A5X5Y0|Q13639|P50406|P34969|P30530|Q9UM73|P08684|P02768|P08183|Q96FL8|Q9UNQ0|O15245

>  <MW>  (257) 
552.4

>  <HBA>  (257) 
10.0

>  <HBD>  (257) 
3.0

>  <NRB>  (257) 
9.0

>  <TPSA>  (257) 
121.1

>  <LogP>  (257) 
2.7

>  <RoF>  (257) 
1.0

>  <Melting point>  (257) 


>  <Targets>  (257) 
FLT3; AXL; ALK

>  <Kinase families>  (257) 
Tyr

>  <FDA_approved>  (257) 
Y

$$$$
Crizotinib
     RDKit          2D

 30 33  0  0  0  0  0  0  0  0999 V2000
    1.1739    0.6682    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5352    0.0383    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7614    0.9022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1227    0.2723    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3490    1.1362    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2139    2.6301    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8526    3.2601    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6263    2.3961    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2650    3.0261    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    4.7175    4.7540    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    5.2578   -1.2216    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    2.6703   -1.4556    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.4441   -2.3196    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0828   -1.6896    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1434   -2.5535    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0083   -4.0474    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3530   -4.6774    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.5792   -3.8135    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9405   -4.4434    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5047   -1.9236    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8145   -2.6546    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9145   -1.6348    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2846   -0.2735    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7952   -0.4520    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.0156    1.0363    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2468    2.3243    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9778    3.6341    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4777    3.6559    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.2465    2.3679    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.5155    1.0581    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  6
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  7 10  1  0
  4 11  1  0
  2 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 15 20  1  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  1  0
 23 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  1  0
  8  3  1  0
 18 13  1  0
 24 20  2  0
 30 25  1  0
M  END
>  <BrandName>  (258) 
Xalkori

>  <Applicants>  (258) 
Pfizer

>  <CHEMBL_ID>  (258) 
CHEMBL601719

>  <Canonical_Smiles>  (258) 
C[C@H](c1c(ccc(c1Cl)F)Cl)Oc2cc(cnc2N)c3cnn(c3)C4CCNCC4

>  <Chirality>  (258) 
Single Stereoisomer

>  <First_Approval>  (258) 
2011

>  <Phase>  (258) 
4.0

>  <SC_Patent>  (258) 
US-7230098-B2

>  <Synonyms>  (258) 
CRIZOTINIB | PF-02341066 | PF-2341066 | XALKORI

>  <Withdrawn>  (258) 
|Study NCT01441388 in nan was Withdrawn during Phase 1 because Business/Operational issues

>  <Indications>  (258) 
Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.

>  <Type>  (258) 
1

>  <targets_id>  (258) 
Q9UM73|P08581

>  <inchi>  (258) 
InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1

>  <stdInchikey>  (258) 
KTEIFNKAUNYNJU-GFCCVEGCSA-N

>  <csid>  (258) 
9801307

>  <Links>  (258) 
|http://www.chemspider.com/Chemical-Structure.9801307.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL601719|http://pubchem.ncbi.nlm.nih.gov/compound/11626560|http://www.drugbank.ca/drugs/DB08865| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=VGH|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/VGH|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4903|http://zinc15.docking.org/substances/ZINC000035902489|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=53AH36668S|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50306682

>  <LinkName>  (258) 
|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (258) 
'VGH'

>  <pdbID>  (258) 
2wgj 2xp2 2yfx 3zbf 4anq 4ans 4c9w 5aaa 5aab 5aac 6imz

>  <indicationG2P>  (258) 
None

>  <indicationDB>  (258) 
Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular&#39;s Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.

>  <uniprotId>  (258) 
Q9UM73|P08581|P08684|P20815|P20813|P08684|Q9HB55|P20815|P24462|P08183

>  <MW>  (258) 
449.1

>  <HBA>  (258) 
6.0

>  <HBD>  (258) 
2.0

>  <NRB>  (258) 
5.0

>  <TPSA>  (258) 
78.0

>  <LogP>  (258) 
5.0

>  <RoF>  (258) 
1.0

>  <Melting point>  (258) 


>  <Targets>  (258) 
ALK; MET

>  <Kinase families>  (258) 
Tyr

>  <FDA_approved>  (258) 
Y

$$$$
Acalabrutinib
     RDKit          2D

 35 39  0  0  0  0  0  0  0  0999 V2000
    6.3038   -6.4041    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7158   -5.0242    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1277   -3.6443    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5396   -2.2644    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0505   -2.0837    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.4406   -1.0652    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.9404   -1.0892    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4267    0.3298    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2275    1.2308    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0000    0.3687    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5810    0.8550    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3535   -0.0071    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.1543    0.8938    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6406    2.3128    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1404    2.2888    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.9111    3.5757    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1820    4.8866    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6822    4.9106    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.9115    3.6237    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5883    3.6477    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2796    0.4532    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3781    1.4746    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8119    1.0340    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1472   -0.4280    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0487   -1.4494    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6149   -1.0088    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.5810   -0.8686    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9164   -2.3307    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6795    0.1528    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.1134   -0.2878    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.2119    0.7336    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.6457    0.2930    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.9810   -1.1691    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.8825   -2.1905    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.4487   -1.7499    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  3  0
  3  4  1  0
  4  5  2  0
  4  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  1  6
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 13 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 24 27  1  0
 27 28  2  0
 27 29  1  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 32 33  2  0
 33 34  1  0
 34 35  2  0
 10  6  1  0
 15 11  1  0
 19 14  1  0
 26 21  1  0
 35 30  1  0
M  END
>  <BrandName>  (259) 
Calquence

>  <Applicants>  (259) 
Astrazeneca

>  <CHEMBL_ID>  (259) 
CHEMBL3707348

>  <Canonical_Smiles>  (259) 
CC#CC(=O)N1CCC[C@H]1c2nc(c3n2ccnc3N)c4ccc(cc4)C(=O)Nc5ccccn5

>  <Chirality>  (259) 
Single Stereoisomer

>  <First_Approval>  (259) 
2017

>  <Phase>  (259) 
4.0

>  <SC_Patent>  (259) 
US-7459554-B2

>  <Synonyms>  (259) 
ACALABRUTINIB | ACP-196 | CALQUENCE

>  <Withdrawn>  (259) 


>  <Indications>  (259) 
Acalabrutinib is currently indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy

>  <Type>  (259) 
nan

>  <targets_id>  (259) 
Q06187

>  <inchi>  (259) 
InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1

>  <stdInchikey>  (259) 
WDENQIQQYWYTPO-IBGZPJMESA-N

>  <csid>  (259) 
36764951

>  <Links>  (259) 
|http://www.chemspider.com/Chemical-Structure.36764951.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3707348|http://pubchem.ncbi.nlm.nih.gov/compound/71226662|http://www.drugbank.ca/drugs/DB11703|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8912|http://zinc15.docking.org/substances/ZINC000208774715|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=I42748ELQW|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50175583

>  <LinkName>  (259) 
|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB

>  <lig_pdbID>  (259) 


>  <pdbID>  (259) 


>  <indicationG2P>  (259) 
None

>  <indicationDB>  (259) 
To date, acalabrutinib has been used in trials studying the treatment of B-All, Myelofibrosis, Ovarian Cancer, Multiple Myeloma, and Hodgkin Lymphoma, among others.</p><p>As of October 31, 2017 the FDA approved Astra Zeneca&#39;s orally administered Calquence (acalabrutinib). This Bruton Tyrosine Kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and in adult patients with Mantle Cell Lymphoma (MCL) who have already received at least one prior therapy.</p><p>Also known as ACP-196, acalabrutinib is also considered a second generation BTK inhibitor because it was rationally designed to be more potent and selective than ibrutinib, theoretically expected to demonstrate fewer adverse effects owing to minimized bystander effects on targets other than BTK.</p><p>Nevertheless, acalabrutinib was approved under the FDA&#39;s accelerated approval pathway, which is based upon overall response rate and faciliates earlier approval of medicines that treat serious conditions or/and that fill an unmet medical need based on a surrogate endpoint. Continued approval for acalabrutinib&#39;s currently accepted indication may subsequently be contingent upon ongoing verification and description of clinical benefit in confimatory trials.</p><p>Furthermore, the FDA granted this medication Priority Review and Breakthrough Therapy designations. It also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases. At this time, more than 35 clinical trials across 40 countries with more than 2500 patients are underway or have been completed with regards to further research into better understanding and expanding the therapeutic uses of acalabrutinib <sup class="text-reference-group"><a class="reference-popover-link" data-content="Astra Zeneca Press Release: US FDA Approves Astrazeneca&#39;s Calquence for Adult Patients with Previously-Treated Mantle Cell Lymphoma" href="#reference-L1009">5</a></sup>.

>  <uniprotId>  (259) 
Q06187|P08684|P20815|P08684|Q9HB55|P20815|P24462|P02768|P02763|P19652

>  <MW>  (259) 
465.2

>  <HBA>  (259) 
7.0

>  <HBD>  (259) 
2.0

>  <NRB>  (259) 
4.0

>  <TPSA>  (259) 
118.5

>  <LogP>  (259) 
3.3

>  <RoF>  (259) 
0.0

>  <Melting point>  (259) 


>  <Targets>  (259) 
BTK

>  <Kinase families>  (259) 
Tyr

>  <FDA_approved>  (259) 
Y

$$$$
Pralsetinib
     RDKit          2D

 39 43  0  0  0  0  0  0  0  0999 V2000
  -10.4618    3.3494    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.9041    1.9569    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.7029    0.6873    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -9.7422   -0.4647    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.3497    0.0929    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4498    1.5896    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0801   -0.7058    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7535   -0.0057    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4839   -0.8044    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1573   -0.1042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1004    1.3947    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3700    2.1934    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6966    1.4933    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3131    3.6924    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8876   -0.9030    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9446   -2.4019    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6749   -3.2007    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6516   -2.5005    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7086   -1.0016    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5611   -0.2028    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1108   -3.9285    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.1037   -5.0401    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1377   -2.2963    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7038   -0.9072    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.0576   -3.4811    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.5436   -3.2769    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1097   -1.8878    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5958   -1.6836    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1619   -0.2945    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.2420    0.8903    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.7560    0.6861    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1898   -0.7030    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8082    2.2794    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.0172    3.5539    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.9849    4.7000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3739    4.1338    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2647    2.6378    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.6484    4.9248    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    5.4635   -4.4617    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  5  7  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 12 14  1  0
 15 10  1  6
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 18 21  1  1
 21 22  1  0
 18 23  1  0
 23 24  2  0
 23 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 31  1  0
 31 32  2  0
 30 33  1  0
 33 34  1  0
 34 35  2  0
 35 36  1  0
 36 37  2  0
 36 38  1  0
 26 39  1  6
  6  2  2  0
 13  8  1  0
 20 15  1  0
 32 27  1  0
 37 33  1  0
M  END
>  <BrandName>  (260) 


>  <Applicants>  (260) 
Blueprint Medicines

>  <CHEMBL_ID>  (260) 
CHEMBL4582651

>  <Canonical_Smiles>  (260) 
Cc1[nH]nc(c1)Nc2nc(nc(c2)C)[C@H]3CC[C@@](CC3)(OC)C(=O)N[C@H](c4cnc(cc4)n5ncc(c5)F)C

>  <Chirality>  (260) 
Single Stereoisomer

>  <First_Approval>  (260) 
2020

>  <Phase>  (260) 
4.0

>  <SC_Patent>  (260) 
None

>  <Synonyms>  (260) 
BLU-667|X-581238|GAVRETO (US|BLU123244|BLU-123244|X581238

>  <Withdrawn>  (260) 


>  <Indications>  (260) 
Pralsetinib, also known as BLU-667, is a highly potent, selective, next generation RET inhibitor. BLU-667 is a potent and selective inhibitor of RET mutations, fusions, and predicted resistant mutants. RET fusions are key drivers of multiple cancers, including lung and thyroid cancer, and our research suggests that RET also plays a key role in some colon and breast cancers. By simultaneously targeting the primary driver and predicted resistant mutants that render cancer cells insensitive to treatment with currently approved drugs

>  <Type>  (260) 
nan

>  <targets_id>  (260) 
nan

>  <inchi>  (260) 
InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19-,27-/m0/s1

>  <stdInchikey>  (260) 
GBLBJPZSROAGMF-BATDWUPUSA-N

>  <csid>  (260) 
71060332

>  <Links>  (260) 
|http://www.chemspider.com/Chemical-Structure.71060332.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297597|http://www.drugbank.ca/drugs/DB15822| http://www.rcsb.org/pdb/ligand/ligandsummary.do?hetId=Q4J|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/Q4J|http://fdasis.nlm.nih.gov/srs/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=fdasrs&actionHandle=default&nextPage=jsp/srs/ResultScreen.jsp&TXTSUPERLISTID=1WPE73O1WV

>  <LinkName>  (260) 
|ChemSpider|ChEMBL|DrugBank|RCSB|PDBe|FDA SRS

>  <lig_pdbID>  (260) 
'Q4J'

>  <pdbID>  (260) 
7ju5

>  <indicationG2P>  (260) 


>  <indicationDB>  (260) 
Pralsetinib, similar to the previously approved <a href="https://go.drugbank.com/drugs/DB15685">selpercatinib</a>, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F: State-of-the-Art Strategies for Targeting RET-Dependent Cancers. J Clin Oncol. 2020 Apr 10;38(11):1209-1221. doi: 10.1200/JCO.19.02551. Epub 2020 Feb 21. (PubMed ID 32083997)" href="#reference-A202055">3</a>,<a class="reference-popover-link" data-content="Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK: Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov. 2018 Jul;8(7):836-849. doi: 10.1158/2159-8290.CD-18-0338. Epub 2018 Apr 15. (PubMed ID 29657135)" href="#reference-A219751">5</a>,<a class="reference-popover-link" data-content="FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules" href="#reference-L15986">9</a></sup> Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including <a href="https://go.drugbank.com/drugs/DB08875">cabozantinib</a>, <a href="https://go.drugbank.com/drugs/DB08901">ponatinib</a>, <a href="https://go.drugbank.com/drugs/DB00398">sorafenib</a>, <a href="https://go.drugbank.com/drugs/DB01268">sunitinib</a>, and <a href="https://go.drugbank.com/drugs/DB05294">vandetanib</a>, have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F: State-of-the-Art Strategies for Targeting RET-Dependent Cancers. J Clin Oncol. 2020 Apr 10;38(11):1209-1221. doi: 10.1200/JCO.19.02551. Epub 2020 Feb 21. (PubMed ID 32083997)" href="#reference-A202055">3</a></sup> Pralsetinib (BLU-667) and <a href="https://go.drugbank.com/drugs/DB15685">selpercatinib</a> (LOXO-292) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Russo A, Lopes AR, McCusker MG, Garrigues SG, Ricciardi GR, Arensmeyer KE, Scilla KA, Mehra R, Rolfo C: New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1). Curr Oncol Rep. 2020 Apr 16;22(5):48. doi: 10.1007/s11912-020-00909-8. (PubMed ID 32296961)" href="#reference-A202049">1</a>,<a class="reference-popover-link" data-content="Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F: State-of-the-Art Strategies for Targeting RET-Dependent Cancers. J Clin Oncol. 2020 Apr 10;38(11):1209-1221. doi: 10.1200/JCO.19.02551. Epub 2020 Feb 21. (PubMed ID 32083997)" href="#reference-A202055">3</a>,<a class="reference-popover-link" data-content="FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules" href="#reference-L15986">9</a></sup></p><p>Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment of metastatic RET-fusion positive non-small cell lung cancer. It is currently marketed under the brand name GAVRETOâ¢ by Blueprint Medicines.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules" href="#reference-L15986">9</a></sup>

>  <uniprotId>  (260) 
P07949|Q08345|Q16288|P36888|P23458|O60674|P04629|P35968|P09619|P11362|P21802|P08684|P20815|P10635|P05177|P10632|P11712|P08183|Q9UNQ0|Q9Y6L6|Q9NPD5|Q4U2R8|Q96FL8|Q86VL8|O95342

>  <MW>  (260) 
533.3

>  <HBA>  (260) 
9.0

>  <HBD>  (260) 
3.0

>  <NRB>  (260) 
8.0

>  <TPSA>  (260) 
135.5

>  <LogP>  (260) 
4.2

>  <RoF>  (260) 
1.0

>  <Melting point>  (260) 


>  <Targets>  (260) 
nan

>  <Kinase families>  (260) 


>  <FDA_approved>  (260) 
Y

$$$$
